
<html lang="en"     class="pb-page"  data-request-id="87cb6b07-c9e2-47ec-b7b5-26e311fcaa2f"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";article:article:10.1021/acs.jmedchem.0c02265;requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;issue:issue:10.1021/jmcmar.2021.64.issue-12;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Recent Advances in the Development of Sigma Receptor Ligands as Cytotoxic Agents: A Medicinal Chemistry Perspective" /></meta><meta name="dc.Creator" content="Antonino N.  Fallica" /></meta><meta name="dc.Creator" content="Valeria  Pittalà" /></meta><meta name="dc.Creator" content="Maria N.  Modica" /></meta><meta name="dc.Creator" content="Loredana  Salerno" /></meta><meta name="dc.Creator" content="Giuseppe  Romeo" /></meta><meta name="dc.Creator" content="Agostino  Marrazzo" /></meta><meta name="dc.Creator" content="Mohamed A.  Helal" /></meta><meta name="dc.Creator" content="Sebastiano  Intagliata" /></meta><meta name="dc.Description" content="Since their discovery as distinct receptor proteins, the specific physiopathological role of sigma receptors (σRs) has been deeply investigated. It has been reported that these proteins, classified..." /></meta><meta name="Description" content="Since their discovery as distinct receptor proteins, the specific physiopathological role of sigma receptors (σRs) has been deeply investigated. It has been reported that these proteins, classified..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="June 2, 2021" /></meta><meta name="dc.Type" content="review-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.0c02265" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2021 The Authors. Published by American Chemical Society" /></meta><meta name="citation_fulltext_world_readable" content=""/></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c02265" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.0c02265" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c02265" /></link>
        
    
    

<title>Recent Advances in the Development of Sigma Receptor Ligands as Cytotoxic Agents: A Medicinal Chemistry Perspective | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.0c02265" /></meta><meta property="og:title" content="Recent Advances in the Development of Sigma Receptor Ligands as Cytotoxic Agents: A Medicinal Chemistry Perspective" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/large/jm0c02265_0031.jpeg" /></meta><meta property="og:description" content="Since their discovery as distinct receptor proteins, the specific physiopathological role of sigma receptors (σRs) has been deeply investigated. It has been reported that these proteins, classified into two subtypes indicated as σ1 and σ2, might play a pivotal role in cancer growth, cell proliferation, and tumor aggressiveness. As a result, the development of selective σR ligands with potential antitumor properties attracted significant attention as an emerging theme in cancer research. This perspective deals with the recent advances of σR ligands as novel cytotoxic agents, covering articles published between 2010 and 2020. An up-to-date description of the medicinal chemistry of selective σ1R and σ2R ligands with antiproliferative and cytotoxic activities has been provided, including major pharmacophore models and comprehensive structure–activity relationships for each main class of σR ligands." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.0c02265"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c02265">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.0c02265&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.0c02265&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.0c02265&amp;href=/doi/10.1021/acs.jmedchem.0c02265" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2021</span><span class="cit-fg-volume">, 64</span><span class="cit-fg-issue">, 12</span><span class="cit-fg-pageRange">, 7926-7962</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/64/12" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.0c02055" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Perspective</span><a href="/doi/10.1021/acs.jmedchem.1c00100" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Recent Advances in the Development of Sigma Receptor Ligands as Cytotoxic Agents: A Medicinal Chemistry Perspective</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Antonino N. Fallica</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Antonino N. Fallica</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Drug and Health Sciences, University of Catania, Viale A. Doria 6, 95125 Catania, Italy</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Antonino+N.++Fallica">Antonino N. Fallica</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath1">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Valeria Pittalà</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Valeria Pittalà</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Drug and Health Sciences, University of Catania, Viale A. Doria 6, 95125 Catania, Italy</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Valeria++Pittal%C3%A0">Valeria Pittalà</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath2">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0003-1856-0308" title="Orcid link">https://orcid.org/0000-0003-1856-0308</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Maria N. Modica</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Maria N. Modica</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Drug and Health Sciences, University of Catania, Viale A. Doria 6, 95125 Catania, Italy</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Maria+N.++Modica">Maria N. Modica</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath3">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0002-6350-931X" title="Orcid link">https://orcid.org/0000-0002-6350-931X</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Loredana Salerno</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Loredana Salerno</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Drug and Health Sciences, University of Catania, Viale A. Doria 6, 95125 Catania, Italy</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Loredana++Salerno">Loredana Salerno</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath4">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0001-6458-3717" title="Orcid link">https://orcid.org/0000-0001-6458-3717</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Giuseppe Romeo</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Giuseppe Romeo</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Drug and Health Sciences, University of Catania, Viale A. Doria 6, 95125 Catania, Italy</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Giuseppe++Romeo">Giuseppe Romeo</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath5">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0003-2160-4164" title="Orcid link">https://orcid.org/0000-0003-2160-4164</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Agostino Marrazzo</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Agostino Marrazzo</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Drug and Health Sciences, University of Catania, Viale A. Doria 6, 95125 Catania, Italy</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Agostino++Marrazzo">Agostino Marrazzo</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath6">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0002-8728-8857" title="Orcid link">https://orcid.org/0000-0002-8728-8857</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Mohamed A. Helal</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Mohamed A. Helal</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">University of Science and Technology, Biomedical Sciences Program, Zewail City of Science and Technology, October Gardens, sixth of October, Giza 12578, Egypt</div><div class="loa-info-affiliations-info">Medicinal Chemistry Department, Faculty of Pharmacy, Suez Canal University, Ismailia 41522, Egypt</div></div><span class="conrtib-corresp"><strong>*</strong>Phone: +20-120-112-2213. Email: <a href="/cdn-cgi/l/email-protection#c6abaea3aaa7aa86bca3b1a7afaaa5afb2bfe8a3a2b3e8a3a1"><span class="__cf_email__" data-cfemail="b0ddd8d5dcd1dcf0cad5c7d1d9dcd3d9c4c99ed5d4c59ed5d7">[email protected]</span></a></span><span class="conrtib-corresp"></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Mohamed+A.++Helal">Mohamed A. Helal</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath7">View Biography</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Sebastiano Intagliata</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Sebastiano Intagliata</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Drug and Health Sciences, University of Catania, Viale A. Doria 6, 95125 Catania, Italy</div></div><span class="conrtib-corresp"><strong>*</strong>Phone: +39-095-738-4053. Email: <a href="/cdn-cgi/l/email-protection#c9bae7a0a7bda8aea5a0a8bda889bca7a0aabde7a0bd"><span class="__cf_email__" data-cfemail="cfbce1a6a1bbaea8a3a6aebbae8fbaa1a6acbbe1a6bb">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Sebastiano++Intagliata">Sebastiano Intagliata</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath8">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0002-0201-1745" title="Orcid link">https://orcid.org/0000-0002-0201-1745</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c02265&amp;href=/doi/10.1021%2Facs.jmedchem.0c02265" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2021</span></span><span class="cit-volume">, 64</span><span class="cit-issue">, 12</span><span class="cit-pageRange">, 7926–7962</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">June 2, 2021</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>31 December 2020</li><li><span class="item_label"><b>Published</b> online</span>2 June 2021</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 24 June 2021</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.0c02265" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c02265</a></div><div class="article_header-article-copyright"><strong>Copyright © 2021 The Authors. Published by American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/page/rightslinkno.jsp">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"><a href="https://acsopenscience.org/open-access/licensing-options/"><img src="/pb-assets/images/programsLogos/OA_Icons_Ac-1612971054130.svg" alt="ACS AuthorChoice" /></img><span>ACS AuthorChoice</span></a><span class="article_header-cc-by"><a href="https://creativecommons.org/licenses/by/4.0/"><img src="/pb-assets/images/licensesLogos/OA_Icons_cc-1612971093887.svg" alt="CC: Creative Commons" /></img><span><strong>CC: </strong>Creative Commons</span></a><a href="https://creativecommons.org/licenses/by/4.0/"><img src="/pb-assets/images/licensesLogos/OA_Icons_by-1612971093257.svg" alt="BY: Credit must be given to the creator" /></img><span><strong>BY: </strong>Credit must be given to the creator</span></a></span></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.0c02265"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">2353</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val">-</div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.0c02265" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Recent Advances in the Development of Sigma Receptor Ligands as Cytotoxic Agents: A Medicinal Chemistry Perspective&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Antonino&quot;,&quot;last_name&quot;:&quot;N. Fallica&quot;},{&quot;first_name&quot;:&quot;Valeria&quot;,&quot;last_name&quot;:&quot;Pittalà&quot;},{&quot;first_name&quot;:&quot;Maria&quot;,&quot;last_name&quot;:&quot;N. Modica&quot;},{&quot;first_name&quot;:&quot;Loredana&quot;,&quot;last_name&quot;:&quot;Salerno&quot;},{&quot;first_name&quot;:&quot;Giuseppe&quot;,&quot;last_name&quot;:&quot;Romeo&quot;},{&quot;first_name&quot;:&quot;Agostino&quot;,&quot;last_name&quot;:&quot;Marrazzo&quot;},{&quot;first_name&quot;:&quot;Mohamed&quot;,&quot;last_name&quot;:&quot;A. Helal&quot;},{&quot;first_name&quot;:&quot;Sebastiano&quot;,&quot;last_name&quot;:&quot;Intagliata&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2021&quot;,&quot;month&quot;:&quot;06&quot;,&quot;day&quot;:&quot;02&quot;,&quot;issue&quot;:&quot;12&quot;,&quot;volume&quot;:&quot;64&quot;,&quot;pages&quot;:&quot;7926-7962&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.0c02265&quot;},&quot;abstract&quot;:&quot;Since their discovery as distinct receptor proteins, the specific physiopathological role of sigma receptors (σRs) has been deeply investigated. It has been reported that these proteins, classified into two subtypes indicated as σ1 and σ2, might play a pivotal role in cancer growth, cell proliferation, and tumor aggressiveness. As a result, the development of selective σR ligands with potential antitumor properties attracted significant attention as an emerging theme in cancer research. This perspective deals with the recent advances of σR ligands as novel cytotoxic agents, covering articles published between 2010 and 2020. An up-to-date description of the medicinal chemistry of selective σ1R and σ2R ligands with antiproliferative and cytotoxic activities has been provided, including major pharmacophore models and comprehensive structure–activity relationships for each main class of σR ligands.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c02265&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c02265" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c02265&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c02265" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c02265&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c02265" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c02265&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c02265&amp;href=/doi/10.1021/acs.jmedchem.0c02265" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.0c02265" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.0c02265" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (7 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c02265&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.0c02265%26sid%3Dliteratum%253Aachs%26pmid%3D34076441%26genre%3Darticle%26aulast%3DFallica%26date%3D2021%26atitle%3DRecent%2BAdvances%2Bin%2Bthe%2BDevelopment%2Bof%2BSigma%2BReceptor%2BLigands%2Bas%2BCytotoxic%2BAgents%253A%2BA%2BMedicinal%2BChemistry%2BPerspective%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D64%26issue%3D12%26spage%3D7926%26epage%3D7962%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=290663" title="Pharmacophores">Pharmacophores</a>,</li><li><a href="/action/doSearch?ConceptID=292366" title="Ligands">Ligands</a>,</li><li><a href="/action/doSearch?ConceptID=290896" title="Cells">Cells</a>,</li><li><a href="/action/doSearch?ConceptID=290808" title="Toxicity">Toxicity</a>,</li><li><a href="/action/doSearch?ConceptID=292186" title="Receptors">Receptors</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/64/12" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/jmcmar.2021.64.issue-12/20210624/jmcmar.2021.64.issue-12.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/medium/jm0c02265_0031.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/large/jm0c02265_0031.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02265&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Since their discovery as distinct receptor proteins, the specific physiopathological role of sigma receptors (σRs) has been deeply investigated. It has been reported that these proteins, classified into two subtypes indicated as σ<sub>1</sub> and σ<sub>2</sub>, might play a pivotal role in cancer growth, cell proliferation, and tumor aggressiveness. As a result, the development of selective σR ligands with potential antitumor properties attracted significant attention as an emerging theme in cancer research. This perspective deals with the recent advances of σR ligands as novel cytotoxic agents, covering articles published between 2010 and 2020. An up-to-date description of the medicinal chemistry of selective σ<sub>1</sub>R and σ<sub>2</sub>R ligands with antiproliferative and cytotoxic activities has been provided, including major pharmacophore models and comprehensive structure–activity relationships for each main class of σR ligands.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">1.  Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_37783" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_37783" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Cancer is a severe health concern, and it is the second leading cause of death globally.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> According to a World Health Organization report (2020), the global cancer burden is significant and increasing, with an estimated 9.6 million deaths worldwide from cancer in 2018. About 300,000 new cases per year have been diagnosed among children aged 0–19 years, while the calculated total annual cost of cancer in 2010 was more than US $1 trillion worldwide. Usually, treatment options include chemotherapy, radiotherapy, and surgery. Frequently, the toxicity of large doses of chemotherapy and the lack of effectiveness in certain tumors make surgery and radiotherapy the preferred options. By definition, anticancer drugs target rapidly multiplying cells, leading to variable toxicities to the gastrointestinal tract, bone marrow, hair follicles, and gonads. Hematological toxicity manifests as acute cytopenia due to the cytotoxic effect on the hematopoietic precursor cells. The gastrointestinal toxicity, nausea, vomiting, and anorexia is usually a physiological reflex to remove toxic substances from the gastrointestinal tract. Nausea is a widespread side effect among chemotherapeutic agents and entails 5-HT<sub>3</sub> antagonists such as ondansetron in several situations. Another common toxicity is hair follicle damage which represents both physiological and psychological burdens for the patients. Alopecia usually develops due to the cytotoxic effect of the drug on the rapidly dividing hair follicles. Finally, neurotoxicity can occur with drugs that cross the blood–brain barrier, such as vincristine, 5-fluorouracil, thiotepa, and cisplatin. Some other agents can cause peripheral neuropathy, such as paclitaxel and carboplatin. Besides, several factors may affect the effectiveness of the chemotherapy regimen, including early intracellular drug inactivation, overexpression of drug efflux pumps, low drug uptake, or dysregulation of specific intracellular signaling pathways targeted by the therapeutic drugs. Despite the striking results obtained by tumor immunotherapy and nanomedicine,<a onclick="showRef(event, 'ref2 ref3'); return false;" href="javascript:void(0);" class="ref ref2 ref3">(2,3)</a> several issues still need to be overcome. These factors emphasize the need to identify and validate alternative biological targets mainly detectable in tumor cells and develop novel anticancer agents with enhanced efficacy, safety profile, and compliance.<a onclick="showRef(event, 'ref4 ref5'); return false;" href="javascript:void(0);" class="ref ref4 ref5">(4,5)</a></div><div class="NLM_p">Sigma receptors (σRs) are considered promising targets for treating different heterogeneous medical conditions, including cancer.<a onclick="showRef(event, 'ref6 ref7 ref8'); return false;" href="javascript:void(0);" class="ref ref6 ref7 ref8">(6−8)</a> The history of σRs began in the early 1970s when Martin et al. proposed the involvement of a subtype of the opioid receptor family, named the “σ-opioid” receptors, in the psychotomimetic effects caused by the putative opioid agonist <i>N</i>-allylnormetazocine derivative (±)-SKF-10,047 in the spinal dog model.<a onclick="showRef(event, 'ref9 ref10'); return false;" href="javascript:void(0);" class="ref ref9 ref10">(9,10)</a> However, later on, the binding site within this protein, whose gene sequence was cloned by Su and colleagues,<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> was unresponsive to naloxone and naltrexone, suggesting the distinction of this type of protein from opioid receptors. In the following years, SKF-10,047 was found to interact with many biological targets, adding confusion about the classification of σRs.<a onclick="showRef(event, 'ref12 ref13'); return false;" href="javascript:void(0);" class="ref ref12 ref13">(12,13)</a> Further studies on this compound determined that it could not be completely displaced from its receptor using selective opioid ligands, indicating that it was bound to another distinct receptor. More specifically, racemic SKF-10,047 has the ability to produce algesia and psychotomimetic effects in humans. The analgesic effect is believed to be mediated through the action of (−)-SKF-10,047 on the μ and <i>k</i> opioid receptors. Conversely, it was found that (+)-SKF-10,047 binds with very low affinity to both opioid receptors, and its pharmacological action is mediated through a different site.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> This other site has since been designated as the σR.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> Further studies proved that σRs are a non-opioid, non-GPCR transmembrane protein expressed mainly in the endoplasmic reticulum (ER) membrane and physically associated with the mitochondria.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> σRs act as chaperone proteins that interfere with ion-channels and GPCR receptors activity modulating several physiological pathways through ER stress and control of intracellular Ca<sup>2+</sup> homeostasis.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> Ultimately, σRs have been classified into two subtypes, σ<sub>1</sub> and σ<sub>2</sub> receptors, depending on their biological actions, distribution, sizes, and other factors.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a></div><div class="NLM_p">It was only in 1996 that the gene sequence of σ<sub>1</sub>R has been cloned by Hanner et al.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> and was found to be expressed in various tissues inside and outside the CNS. The σ<sub>1</sub>R subtype has been cloned from many species, including mice, rats, guinea pigs, and humans. It is a 223 amino acid protein with a molecular weight of about 24 kDa. σ<sub>1</sub>Rs are widely distributed in several tissues, and they are present in the brain, spinal cord, and peripheral nerves.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> A breakthrough occurred in 2016 with the publication of the three-dimensional (3D) crystal structure of the human σ<sub>1</sub>R by Schmidt and co-workers.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> The reported structures showed a trimeric architecture formed by the association of three identical protomers possessing a single transmembrane domain (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>A).<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> So far, five different crystal structures of the σ<sub>1</sub>R in complex with historical σ<sub>1</sub>R ligands (i.e., (+)-pentazocine, haloperidol, NE-100, PD144418, and 4-IBP) have been reported,<a onclick="showRef(event, 'ref20 ref21'); return false;" href="javascript:void(0);" class="ref ref20 ref21">(20,21)</a> which have revealed a preserved ligand’s binding mode with high similarity shared by different chemical classes. Notably, the ligand-binding site is deeply located inside the large β-barrel region where ligands are accommodated in a very hydrophobic pocket entirely occluded from solvent molecules.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/medium/jm0c02265_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/large/jm0c02265_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. (A) Cartoon representation of the σ<sub>1</sub>R crystal structure (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5HK1">5HK1</a>); each color outlines a distinguished σ<sub>1</sub>R protomer which forms the σ<sub>1</sub>R trimer. (B) 2D and 3D representation of protein–ligand interactions of the σ<sub>1</sub>R with PD144418 (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5HK1">5HK1</a>). The ionic bond between the basic nitrogen of PD144418 and the Glu172 amino acid residue is shown as a dashed yellow line.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/large/jm0c02265_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02265&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Analysis of the protein–ligand contacts outlines a major ionic bond involving the basic nitrogen of the σ<sub>1</sub>R ligand (e.g., PD144418, <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>B) and the Glu172 amino acid residue as well as multiple hydrophobic interactions with bulky hydrophobic residues (i.e., Val84, Trp89, Met93, Tyr103) that shape the internal edge of the binding pocket.</div><div class="NLM_p">Growing evidence implicates the σ<sub>1</sub>R in various neurological disorders such as depression, anxiety, schizophrenia, and Alzheimer’s disease.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> Recent studies suggest that σ<sub>1</sub>R modulators possess the therapeutic potential to treat drug abuse.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> Interestingly, recent studies have investigated the repurposing of σ<sub>1</sub>R ligands for interfering with the early stages of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) replication. This approach was inspired by the colocalization of σ<sub>1</sub>R with the viral replicase protein in the ER membrane and its interaction with the nonstructural SARS-CoV-2 protein Nsp6.<a onclick="showRef(event, 'ref24 ref25'); return false;" href="javascript:void(0);" class="ref ref24 ref25">(24,25)</a> Nowadays, the oncogenic role of σ<sub>1</sub>Rs has not been fully elucidated. It is known that this protein is overexpressed in a wide number of cancer cell lines and σ<sub>1</sub>Rs fully functional activity is required for proper growth, proliferation, migration, and survival of cancer cells. The use of σ<sub>1</sub>R negative modulators, often considered as “σ<sub>1</sub>R antagonists”, or σ<sub>1</sub> gene silencing through the application of RNAi hamper tumor cell growth and survival.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> Contrarily, the overexpression of σ<sub>1</sub>Rs through recombinant techniques or the σ<sub>1</sub>Rs positive modulation exerted by selective small molecules, often considered as “σ<sub>1</sub>R agonists”, causes opposite effects.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a></div><div class="NLM_p">Unlike the σ<sub>1</sub>R, up to now, the crystal structure of the σ<sub>2</sub>R is still unknown. The difficulty of its isolation and purification is mainly due to its distribution in the lipid environment and its low abundance in the prepared mammalian membranes.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> The genetic identity of the σ<sub>2</sub>R was revealed recently in 2017 when Alon et al. used classical affinity purification approaches to isolate the σ<sub>2</sub>R binding site and characterized it as the (ER)-resident membrane protein, transmembrane protein 97 (TMEM97), with a molecular weight of about 18–21.5 kDa (frequently referred to as σ<sub>2</sub>R/TMEM97).<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> In 2011, Xu and co-workers reported that progesterone membrane binding component-1 (PGRMC1) could bind to σ<sub>2</sub>R, altering the pharmacological properties of its ligands.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> More recently Mach and collaborators from the University of Pennsylvania, using a gene-editing approach, demonstrated that TMEM97 and PGRMC1 could form a ternary complex with the low density lipoprotein (LDL) receptor leading to a much-increased LDL internalization.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> This observation, confirmed by confocal microscopy and radioligand binding studies, indicated the involvement of σ<sub>2</sub>R/TMEM97 in lipoprotein trafficking and could rationalize the upregulation of σ<sub>2</sub>Rs in certain types of cancer cells.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a></div><div class="NLM_p">The recent discovery of the identity of the σ<sub>2</sub>R rationalizes the search for small molecules with potential neuroprotective,<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> antinociceptive,<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> and antiproliferative effects.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> Concerning the role of σ<sub>2</sub>Rs in the context of cancer, different pharmacological studies have proved that the σ<sub>2</sub>R is overexpressed in cancer cells, and its abundance is correlated with the proliferative status of certain tumors.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> Furthermore, in addition to the diagnostic imaging application, σ<sub>2</sub>R ligands have shown cytotoxic effects in tumor cells <i>in vitro</i> and <i>in vivo</i>.<a onclick="showRef(event, 'ref33 ref34 ref35 ref36'); return false;" href="javascript:void(0);" class="ref ref33 ref34 ref35 ref36">(33−36)</a> A better elucidation of the implication of σ<sub>2</sub>Rs in tumor cell death was reported in 2019 by Zeng and co-workers, which conducted CRISPR/Cas9 studies to assess the cytotoxic properties of σ<sub>2</sub>R ligands in TMEM97 knockout (KO), PGRMC1 KO, or TMEM97/PGRMC1 double KO cell lines.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> Results showed that induction of cell death by σ<sub>2</sub>R ligands was not hampered, suggesting that the cytotoxic effects are not directly mediated by TMEM97 or PGRMC1, thus questioning the exact cytotoxic mechanism exerted by σ<sub>2</sub>R ligands.</div><div class="NLM_p">Following the differentiation of the two σR subtypes, tremendous efforts were directed toward developing selective ligands for each subtype. (+)-Pentazocine (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>), the first σ<sub>1</sub>R selective ligand, exhibited 500-fold selectivity (σ<sub>2</sub><i>K</i><sub>i</sub>/σ<sub>1</sub><i>K</i><sub>i</sub>) over the σ<sub>2</sub>R receptor.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> Also, the 1,2,4-triazole derivative E-5842 (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>) showed a <i>K</i><sub>i</sub> value of 4 nM for the σ<sub>1</sub>R and 55-fold selectivity.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> Later, a dipropylamine derivative named NE-100 (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>) was reported to have a high affinity for the σ<sub>1</sub>R and moderate selectivity over the σ<sub>2</sub>R.<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> Haloperidol (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>) is a butyrophenone derivative belonging to the drug class of neuroleptics, mainly acting as a D<sub>2</sub> antagonist. For many years, haloperidol has been used as a reference σ<sub>1</sub>R antagonist, and it represents a classic σR ligand prototype. Its antagonist profile toward the σ<sub>1</sub>R was discovered more than 20 years ago, along with its <i>in vitro</i> and <i>in vivo</i> anticancer properties toward several cancer types.<a onclick="showRef(event, 'ref41 ref42 ref43 ref44 ref45 ref46 ref47'); return false;" href="javascript:void(0);" class="ref ref41 ref42 ref43 ref44 ref45 ref46 ref47">(41−47)</a> In 2011, Schläger et al. reported a series of spirocyclic pyranopyrazoles with high σ<sub>1</sub>R affinity and selectivity toward the σ<sub>2</sub>R, α<sub>1</sub>, α<sub>2</sub>, 5-HT<sub>1A</sub>R, and the 5-HT-transporter.<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> Two chemically and pharmacologically distinct high-affinity σ<sub>1</sub>R ligands named 4-IBP (agonist or inverse agonist) and PD144418 (antagonist) were used to obtain the above-mentioned first crystal structures of the human σ<sub>1</sub>R (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>).<a onclick="showRef(event, 'ref49 ref50'); return false;" href="javascript:void(0);" class="ref ref49 ref50">(49,50)</a></div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/medium/jm0c02265_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/large/jm0c02265_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Selected historic and representative σR ligands.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/large/jm0c02265_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02265&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Compound CB-184 (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>) was the first reported highly selective σ<sub>2</sub>R ligand back in 1995 by Bowen and co-workers.<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a> This compound was followed by several other σ<sub>2</sub>R ligands belonging to diverse chemical classes (discussed in more detail in <a class="ref internalNav" href="#sec3_2" aria-label="Section 3.2">Section 3.2</a>), including the indole alkaloid ibogaine<a onclick="showRef(event, 'ref52 ref53'); return false;" href="javascript:void(0);" class="ref ref52 ref53">(52,53)</a> and the granatane derivative WC-59.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a> Most of the reported σ<sub>2</sub>R ligands discovered to date were developed for their cytotoxicity properties toward several cancer cell lines;<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> however, the most recently reported methanobenzazocine derivative UKH-1114<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a> and the 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline derivative CM398<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a> (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>) showed an exquisite σ<sub>2</sub>R selectivity and demonstrated to produce antinociceptive effects <i>in vivo</i>.</div><div class="NLM_p">To date, a few σR ligands have entered clinical trials to treat different diseases, including neurodegenerative diseases, mental disorders, and pain management. Among them, MR309 (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>) has been the first selective σ<sub>1</sub>R antagonist to reach phase II clinical trials for the treatment of oxaliplatin-induced neuropathic pain, and it represents a potential first-in-class analgesic. The randomized, double-blind, placebo-controlled study started in patients with colorectal cancer receiving FOLFOX, aimed to assess the efficacy of MR309 in ameliorating oxaliplatin-induced peripheral neuropathy (OXAIPN). Interestingly, discontinuous MR309 administration resulted in a potential neuroprotective role for chronic cumulative OXAIPN, with a reasonable safety profile.<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a></div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/medium/jm0c02265_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/large/jm0c02265_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. σRs ligands in clinical trials.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/large/jm0c02265_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02265&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The radio-tracer [<sup>18</sup>F]FTC-146 (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>), which is the most selective σ<sub>1</sub>R ligand known to date (>146,000-fold selectivity over the σ<sub>2</sub>R and >10,000-fold selectivity over 59 different targets), is currently in phase I clinical trials as a first-in-class diagnostic agent for positron emission tomography–magnetic resonance imaging (PET–MRI) to detect sites of nerve damage in patients with neuropathic pain.<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> The nonradiolabeled analog, named CM304 and acting as σ<sub>1</sub>R antagonist, showed a low pharmacokinetic profile with a short <i>in vivo</i> half-life (115 min) and undesirable clearance (Cl = 33 mL/min/kg)<a onclick="showRef(event, 'ref59 ref60'); return false;" href="javascript:void(0);" class="ref ref59 ref60">(59,60)</a> which did not allow the compound to move into clinical research, even though it showed efficacy in multiple preclinical mice models of pain.<a onclick="showRef(event, 'ref61 ref62'); return false;" href="javascript:void(0);" class="ref ref61 ref62">(61,62)</a></div><div class="NLM_p">The tetrahydrofuran derivative ANAVEX2-73 (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>), acting as a mixed muscarinic receptor/σ<sub>1</sub>R ligand, is currently in phase II clinical evaluation to treat patients with mild to moderate Alzheimer’s disease.<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a> Similarly, T-817MA, a high-affinity σ<sub>1</sub>R agonist with neuroprotective properties in rats,<a onclick="showRef(event, 'ref64'); return false;" href="javascript:void(0);" class="ref ref64">(64)</a> reached phase II clinic studies for the same medical condition, while cutamesine (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>), another selective σ<sub>1</sub>R agonist,<a onclick="showRef(event, 'ref65'); return false;" href="javascript:void(0);" class="ref ref65">(65)</a> has been evaluated in phase II studies in patients for recovery enhancement after acute ischemic stroke.<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a></div><div class="NLM_p">Concerning clinical candidates targeting the σ<sub>2</sub>R subtype, two different antagonists, roluperidone and CT1812 (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>), entered phase II and phase I clinical trials to establish their efficacy and safety in the treatment of schizophrenia and Alzheimer’s disease, respectively.<a onclick="showRef(event, 'ref67 ref68'); return false;" href="javascript:void(0);" class="ref ref67 ref68">(67,68)</a> Interestingly, none of the σR ligands with intrinsic cytotoxicity properties discovered so far are in clinical trials to treat cancer, likely due to the inconsistent data concerning the efficacy of σRs ligands on preclinical <i>in vivo</i> models. This situation was aggravated by the unavailability of the genetic data of the σ<sub>2</sub>R subtype until its cloning in 2017. Usually, full characterization of the molecular target is required to link the chemical probe-target engagement to the functional pharmacology before launching a full drug discovery program. Indeed, the precise role of σRs in cancer biology has not yet been entirely clarified. However, the involvement of σRs in the induction or inhibition of apoptosis, cell growth, proliferation, and tumor progression paved the way for developing small molecules that could be exploited in novel anticancer therapies. The cytotoxic or antiproliferative properties of σR modulators are exerted by interfering with both σ<sub>1</sub> and σ<sub>2</sub> receptors. In particular, inhibition of the σ<sub>1</sub>R or induction of the σ<sub>2</sub>R activities seems to lead to tumor growth inhibition.<a onclick="showRef(event, 'ref69'); return false;" href="javascript:void(0);" class="ref ref69">(69)</a> Specifically, it has been observed that σ<sub>1</sub>R negative modulators cause a caspase-dependent induction of apoptosis, whereas σ<sub>2</sub>R positive modulators mediate a caspase-independent induction of programmed cell death,<a onclick="showRef(event, 'ref70 ref71 ref72'); return false;" href="javascript:void(0);" class="ref ref70 ref71 ref72">(70−72)</a> even though this aspect could not be considered as a rule of thumb because of some exceptions. Generally, a reliable <i>in vitro</i> protocol useful to distinguish between the agonist or antagonist properties of σ<sub>1</sub>R and σ<sub>2</sub>R ligands has not been established yet, mostly due to a lack of known endogenous ligands which does not allow to compare the molecular effect of a tested compound at the level of the receptor. Despite this fact, the apoptotic mechanism of induction employed by σR modulators has been previously used as a judgment parameter to establish the functional activity of σ<sub>2</sub>R ligands, as described by Zeng et al. in 2014.<a onclick="showRef(event, 'ref73'); return false;" href="javascript:void(0);" class="ref ref73">(73)</a> However, based on the recent finding reported from the same research group, nowadays it is known that this approach of σR ligands characterization is not suitable.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a></div><div class="NLM_p">Nevertheless, the selective overexpression of σR in cancer cells makes it an attractive target for developing useful diagnostic agents, such as the σ<sub>2</sub>R molecular probe named <sup>18</sup>F-ISO-1 (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>), that has been assessed in clinical trials to evaluate the safety and feasibility of imaging tumor proliferation by PET in patients with diagnosed malignant tumors.<a onclick="showRef(event, 'ref74 ref75'); return false;" href="javascript:void(0);" class="ref ref74 ref75">(74,75)</a> Regarding this aspect, several comprehensive review articles dealing with the development of σR radiotracers to diagnose cancer have been recently published;<a onclick="showRef(event, 'ref76 ref77 ref78'); return false;" href="javascript:void(0);" class="ref ref76 ref77 ref78">(76−78)</a> thus, we will not discuss this further. Alternatively, discovering novel anticancer agents that can potentially treat certain tumors with a more selective cytotoxic profile would significantly advance global health.</div><div class="NLM_p last">Based on these premises, this perspective highlights state of the art development of σR ligands with potential anticancer activity, mainly covering articles published between 2010 and 2020. In particular, in this work, the literature search has been conducted using SciFinder and PubMed online databases and choosing “sigma receptors, sigma-1 ligands, sigma-2 ligands, cancer, cytotoxicity, anticancer agents” as keywords. After a cross-match searching process, only significant research articles strictly related to this perspective’s topics have been selected. First, we will briefly overview the most significant σR pharmacophore models reported to date to provide detailed information about essential chemical features required for ligands binding at σRs. Second, the most recently reported σR ligands with antiproliferative and cytotoxic activities will be covered, particularly selective σ<sub>1</sub>R and σ<sub>2</sub>R ligands. Extensive structure–affinity relationships (SAfiRs) and structure–activity relationships (SARs) regarding the main classes of σR ligands will be discussed and summarized in each section. Finally, a comprehensive medicinal chemistry perspective on the past, present, and future of σR ligands as a new potential generation of cytotoxic agents will be provided.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">2.  Pharmacophore Models for σR Ligands</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_23342" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_23342" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">There is a large number of reported σR ligands in literature with no clear SAfiRs or SARs. As mentioned earlier, the crystal structure of σ<sub>1</sub>R was released in 2016. Also, the 3D structure of σ<sub>2</sub>R is not yet available for structure-based design. Hence, most of the rational<a onclick="showRef(event, 'ref57 ref79'); return false;" href="javascript:void(0);" class="ref ref57 ref79">(57,79)</a> design attempts of σR ligands were ligand-based modeling. The main issue that hindered the development of pharmacophore models for σRs is the structural diversity of the reported ligands. The first model was reported by Gilligan et al. in 1992 with four pharmacophore elements for σ<sub>1</sub>R binding, namely, a basic nitrogen atom, two hydrophobic groups, and an H-bonding center midway between the basic N and the distal hydrophobic site (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>A).<a onclick="showRef(event, 'ref80'); return false;" href="javascript:void(0);" class="ref ref80">(80)</a> It is worth noting that this first model was not ideal for database mining since it only explained the binding characteristic of one class of compounds.</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/medium/jm0c02265_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/large/jm0c02265_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. (A) The proposed pharmacophore model by Gilligan et al. (B) Glennon’s pharmacophore model.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/large/jm0c02265_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02265&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Following that early attempt by Gilligan, several ligand-based models for σ<sub>1</sub>R or σ<sub>2</sub>R ligands have been reported. These models and their applications will be discussed in the following section. The second prominent attempt was reported by Glennon and co-workers in 1998. They developed a comparative molecular field analysis (CoMFA) model based on the binding data of 64 benzonorbornane derivatives to σ<sub>1</sub>R. The model showed a good correlation coefficient (<i>R</i><sup>2</sup> = 0.989) and predictive ability (<i>Q</i><sup>2</sup> = 0.732) and supported the proposal of Gilligan. The Glennon model comprises a central basic nitrogen flanked by two hydrophobic/aromatic moieties, one of them is significantly larger than the other (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>B). Also, the hydrophobic groups are not located at equal distances from the basic core. The smaller is 2.5–3.9 Å, while the larger group is proposed to be 6–10 Å away from the basic nitrogen (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>B). One of the early trials to address the diversity of σ<sub>1</sub>R ligands in the developed pharmacophore was reported by Jung and co-workers in 2004. This model includes two aromatic rings, a carbon centroid, the basic nitrogen, and a hydrogen bond close to the basic nitrogen (not shown). In 2009, Glennon reported a CoMFA model for σ<sub>2</sub>R based on a series of cyclohexylpiperazines. This model showed a similar arrangement to previously reported σ<sub>1</sub>R models with a correlation coefficient of 0.95 and a cross-validated one of 0.73.<a onclick="showRef(event, 'ref81'); return false;" href="javascript:void(0);" class="ref ref81">(81)</a></div><div class="NLM_p">Vio et al. used Catalyst software and the HypoGen algorithm to prepare a common-feature pharmacophore for a series of benzo[<i>d</i>]oxazolone with high affinity to the σ<sub>1</sub>R.<a onclick="showRef(event, 'ref82'); return false;" href="javascript:void(0);" class="ref ref82">(82)</a> Although the model was based on different compound series, it was in perfect agreement with Glennon’s previous model with very similar distances and features, including two aromatic rings (HYAr), one hydrophobic (HY), one hydrogen-bond-acceptor group (HBA), and one positive ionizable (PI) feature (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>A).</div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/medium/jm0c02265_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/large/jm0c02265_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. 3D pharmacophore models for σ<sub>1</sub>R: (A) Pharmacophore mapping of compound <b>A</b> in 3D models derived by Vio et al. (B) Pharmacophore mapping of compound <b>B</b> in 3D models derived by Meyer et al. (C) Pharmacophore mapping of PD144418 in 3D models derived by ESTEVE. Color coded as follows: PI (red), HYAr or HYD (light blue), HY (pink), HBA (light green), excluded volumes (gray). Adapted with permission from refs <a onclick="showRef(event, 'ref82 ref83'); return false;" href="javascript:void(0);" class="ref ref82 ref83">(82and83)</a>. Copyright 2009 and 2012 American Chemical Society.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/large/jm0c02265_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02265&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The same research group has also reported another pharmacophore model for σ<sub>2</sub>R ligands based on benzo[<i>d</i>]oxazolone derivatives (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>A).<a onclick="showRef(event, 'ref84'); return false;" href="javascript:void(0);" class="ref ref84">(84)</a> The latter exhibited a very similar arrangement to that of the σ<sub>1</sub>R previously developed by the same group and the one developed by Glennon. Nevertheless, compared to Glennon’s pharmacophore, the distance between the primary hydrophobic region and the basic nitrogen is significantly shorter (4.96 Å).<a onclick="showRef(event, 'ref84'); return false;" href="javascript:void(0);" class="ref ref84">(84)</a></div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/medium/jm0c02265_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/large/jm0c02265_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. 3D pharmacophore models for σ<sub>2</sub>R: (A) Pharmacophore mapping of compound <b>C</b> in 3D models derived by Vio et al. (B) Pharmacophore mapping of compound <b>D</b> in 3D models derived by Iyamu et al. Color coded as follows: PI (red), HYAr or HYD (light blue), HY (pink), HBA (light green), excluded volumes (gray).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/large/jm0c02265_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02265&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In 2012, Meyer et al. reported a σ<sub>1</sub>R ligands pharmacophore based on a novel series of spirocyclic thiophenes also using the Catalyst software (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>B).<a onclick="showRef(event, 'ref83'); return false;" href="javascript:void(0);" class="ref ref83">(83)</a> This model is comprised of the same five features described by Vio et al. with the positive ionizable feature located 4.36 and 9.77 Å away from the two hydrophobic features. Recently, in 2019, scientists from the ESTEVE pharmaceutical company developed a σ<sub>1</sub>R pharmacophore based on the published crystal structure (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5HK1">5HK1</a>) of the receptor (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>C).<a onclick="showRef(event, 'ref85'); return false;" href="javascript:void(0);" class="ref ref85">(85)</a> This model was compared to the previously mentioned pharmacophores and has been validated using a large database of 25,000 compounds with known σ<sub>1</sub>R affinity. Researchers have used the receptor–ligand pharmacophore generator job implemented in the Discovery Studio software which identifies all the critical ligand–protein interactions and then places exclusion volumes to account for any steric considerations. This model identified Glu172 as the positive ionizable group site while placing the two hydrophobic features within the space defined by residues Tyr103, Leu105, Leu95, Tyr206, Leu182, and Ala185 and confined by helices α4 and α5. This ESTEVE pharmacophore outperformed previously published models and, according to the authors, showed better results than molecular docking. On the other hand, the most recent σ<sub>2</sub>R ligands pharmacophore was published in 2019 by scientists from Northwestern University.<a onclick="showRef(event, 'ref86'); return false;" href="javascript:void(0);" class="ref ref86">(86)</a> They developed a series of tetrahydroindazoles and used the obtained SAR data to build the model using the PHASE module as implemented in the Schrödinger software suite. This pharmacophore model consists of one PI group, one HYAr ring, and three HY moieties (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>B). Although the distances were not reported, the arrangement showed an equal disposition between the basic nitrogen and two hydrophobic groups.</div><div class="NLM_p">Generally speaking, the development of σ<sub>1</sub>R ligands depended mainly on ligand-based design, especially on the general pharmacophoric features suggested by Glennon and co-workers.<a onclick="showRef(event, 'ref87 ref88'); return false;" href="javascript:void(0);" class="ref ref87 ref88">(87,88)</a> Despite the availability of the σ<sub>1</sub>R crystal structure since 2016, several studies still depend on the general sigma pharmacophore for the design of novel ligands. This approach has been successful and led to the discovery of several high affinity ligands.<a onclick="showRef(event, 'ref82 ref85 ref89'); return false;" href="javascript:void(0);" class="ref ref82 ref85 ref89">(82,85,89)</a> Moreover, some of the reported pharmacophore models addressed the σR subtype selectivity and highlighted the feature required for binding at each subtype. However, to date, we believe that selectivity against other CNS receptors has not been adequately addressed using ligand-based design methods. Noteworthy, Greenfield et al. recently provided a good example of a high-throughput structure-based computational docking approach as an effective method for the discovery of new selective σ<sub>1</sub>R ligands (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>).<a onclick="showRef(event, 'ref90'); return false;" href="javascript:void(0);" class="ref ref90">(90)</a> The platform has been developed performing an iterative process of molecular docking experiments with increased precision levels through screening a library of 6 million compounds.</div><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/medium/jm0c02265_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/large/jm0c02265_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Schematized representation of the high-throughput structure-based computational docking approach for the discovery of new σ<sub>1</sub>R ligands proposed by Greenfield et al. Adapted with permission from ref <a onclick="showRef(event, 'ref90'); return false;" href="javascript:void(0);" class="ref ref90">(90)</a>. Copyright 2020 American Chemical Society.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/large/jm0c02265_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02265&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">It should be emphasized that most of the known σR ligands possess heterogeneous structures and can adopt several binding conformations targeting any of the σR subtypes. Developing a 3D QSAR model covering diverse ligands adapting various binding modes is challenging. Also, the binding site of the crystallized σ<sub>1</sub>R is flexible, elongated, and can bind large diverse molecules.<a onclick="showRef(event, 'ref20 ref21'); return false;" href="javascript:void(0);" class="ref ref20 ref21">(20,21)</a> Docking into such flexible sites is difficult and could give a high percentage of “false positives”. Therefore, we generally recommend using a combined ligand-based (pharmacophore or QSAR) and structure-based (homology modeling and docking) approach. A combination of drug design methods should better predict the activity and eliminate more of the “false positives”.<a onclick="showRef(event, 'ref91'); return false;" href="javascript:void(0);" class="ref ref91">(91)</a></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i4">3.  σR Ligands with Cytotoxic Effects</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_20380" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_20380" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5">3.1.  Selective σ<sub>1</sub>R Ligands</h3><div class="NLM_p">Over the years, several selective σ<sub>1</sub>R ligands whose antiproliferative properties have been corroborated by several studies have been reported. <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a> shows chemical structures and σRs binding profiles of a few examples of such σ<sub>1</sub>R ligands.</div><figure id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/medium/jm0c02265_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/large/jm0c02265_0008.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Representative structures of antiproliferative σ<sub>1</sub>R ligands with their σRs binding profile.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/large/jm0c02265_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02265&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Rimcazole binds to σRs, serotonin transporter, and with higher affinity to the dopamine transporter.<a onclick="showRef(event, 'ref92'); return false;" href="javascript:void(0);" class="ref ref92">(92)</a> It was initially evaluated for the treatment of schizophrenia and later for its anticancer activity. Specifically, the antiproliferative effects exerted by rimcazole are counterbalanced by the σ<sub>1</sub>R agonist (+)-SKF-10047; thus, rimcazole has been classified as a putative σ<sub>1</sub>R antagonist.<a onclick="showRef(event, 'ref69'); return false;" href="javascript:void(0);" class="ref ref69">(69)</a> Moreover, rimcazole demonstrated to inhibit cell proliferation on xenografted models of hormone-sensitive and insensitive breast cancer cell lines.<a onclick="showRef(event, 'ref70 ref93'); return false;" href="javascript:void(0);" class="ref ref70 ref93">(70,93)</a> Particularly, completion of its anticancer activity seems to require the HIF-1α induction (mediator of apoptosis)<a onclick="showRef(event, 'ref94'); return false;" href="javascript:void(0);" class="ref ref94">(94)</a> or the presence of the p53 protein.<a onclick="showRef(event, 'ref69'); return false;" href="javascript:void(0);" class="ref ref69">(69)</a> Despite these preclinical results, rimcazole was never fully considered a potential candidate for anticancer therapy because of its off-target effects related to the interference with dopamine neurotransmission. IPAG, initially synthesized as a possible radiotracer, is a potent tumor suppressor and autophagy inducer.<a onclick="showRef(event, 'ref95'); return false;" href="javascript:void(0);" class="ref ref95">(95)</a> Also, its ability to induce an unfolded protein response has been reported in several carcinomas, including pancreas and prostate cancers.<a onclick="showRef(event, 'ref95'); return false;" href="javascript:void(0);" class="ref ref95">(95)</a> SR31747A is a selective σ<sub>1</sub>R antagonist whose antiproliferative activity is associated with immune-modulatory effects in different cancer cell lines with tumor growth inhibition values ranging from 40% to 60% based on the tumor cell lines tested.<a onclick="showRef(event, 'ref96 ref97'); return false;" href="javascript:void(0);" class="ref ref96 ref97">(96,97)</a> Finally, the arylalkylethylenediamines BD1047 and BD1063 represent two putative σ<sub>1</sub>R antagonists devoid of cytotoxic properties, although they can induce an altered cell morphology. In general, BD1047 has shown better antitumor effects when compared to its piperazine derivative BD1063.<a onclick="showRef(event, 'ref70 ref10'); return false;" href="javascript:void(0);" class="ref ref70 ref10">(70,10)</a></div><div id="sec3_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i6" class="anchor-spacer"></div><h4 class="article-section__title" id="_i6">3.1.1.  <i>N</i>,<i>N</i>-Dialkyl and <i>N</i>-Alkyl-<i>N</i>-aralkyl Fenpropimorph Derivatives</h4><div class="NLM_p">Despite its amino acid sequence similarity with the yeast C8–C7 isomerase, in 1996, the Glossman research group proved that σ<sub>1</sub>R is devoid of any sterol isomerase activity.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> Later, the same team found that fenpropimorph (an agricultural fungicide whose mechanism of action implies disruption of ergosterol biosynthesis pathways) had a high affinity for σ<sub>1</sub>Rs (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>). In 2007, Ramachandran and colleagues purified a recombinant guinea pig σ<sub>1</sub>R and identified two regions, named steroid binding domain-like I and steroid binding domain-like II, that can serve as additional σ<sub>1</sub>R binding sites.<a onclick="showRef(event, 'ref98 ref99 ref100'); return false;" href="javascript:void(0);" class="ref ref98 ref99 ref100">(98−100)</a> Interestingly, these regions share a high similarity with that of the sterol binding domains of the yeast sterol C8–C7 isomerase. The fenpropimorph’s chemical structure consists of an aryl ring linked through an alkyl spacer to a nitrogen atom incorporated in a morpholine ring. Considering that the pharmacophore of σ<sub>1</sub>R ligands and the chemical scaffold of fenpropimorph are superimposable, in 2010, Hajipour and co-workers reported the synthesis of <i>N</i>,<i>N</i>-dialkyl and <i>N</i>-alkyl-<i>N</i>-aralkyl fenpropimorph-derived compounds as σR ligands with cytotoxic properties.<a onclick="showRef(event, 'ref101'); return false;" href="javascript:void(0);" class="ref ref101">(101)</a> Among all the tested compounds, <b>1</b>–<b>3</b> and <b>5</b> exhibited high affinity for the σ<sub>1</sub>R subtype with <i>K</i><sub>i</sub> values in the nanomolar range. On the contrary, compounds <b>4</b> and <b>6</b> displayed a slight preference for the σ<sub>2</sub>R subtype (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>), even with σ<sub>2</sub><i>K</i><sub>i</sub> values in the high nanomolar or micromolar range.</div><figure id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/medium/jm0c02265_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/large/jm0c02265_0009.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. <i>N</i>,<i>N</i>-Dialkyl and <i>N</i>-alkyl-<i>N</i>-aralkyl fenpropimorph-derived compounds <b>1</b>–<b>6</b> and their σRs binding profile.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/large/jm0c02265_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02265&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">SARs were defined for this series of compounds. In general, compounds with a nitro substituent on the phenyl ring were more potent than the corresponding fluorinated derivatives. Compound <b>1</b> was about 59-fold more potent than compound <b>2</b>, whereas compound <b>5</b> was 400-fold more potent than its fluorinated analog <b>4</b>. The authors suggested that the electron-withdrawing properties of the nitro group presumably enhanced the binding with the σ<sub>1</sub>R. Interestingly, when a fluorine atom is present (e.g., compound <b>4</b>), the binding properties changed in favor of the σ<sub>2</sub>R subtype. The authors also reported the importance of the free lone pair of the nitrogen atom on the alkyl chain, which was necessary for the binding with the σ<sub>1</sub>R, according to Glennon et al.<a onclick="showRef(event, 'ref102'); return false;" href="javascript:void(0);" class="ref ref102">(102)</a> Indeed, the amide derivative of compounds <b>2</b> (not shown) did not have any affinity for the σ<sub>1</sub>R. Compounds <b>1</b>–<b>6</b> were tested for their cytotoxic properties against a broad panel of tumor cell lines (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>).</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. IC<sub>50</sub> Values of Compounds <b>1</b>–<b>6</b> on a Selected Panel of Cancer Cell Lines</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="10" align="center">IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">Compd.</th><th class="colsep0 rowsep0" align="center">NCI-H460</th><th class="colsep0 rowsep0" align="center">H1299</th><th class="colsep0 rowsep0" align="center">SKOV-3</th><th class="colsep0 rowsep0" align="center">DU145</th><th class="colsep0 rowsep0" align="center">MCF7</th><th class="colsep0 rowsep0" align="center">MCF10A</th><th class="colsep0 rowsep0" align="center">MB-MDA-231</th><th class="colsep0 rowsep0" align="center">SF268</th><th class="colsep0 rowsep0" align="center">HT-29</th><th class="colsep0 rowsep0" align="center">HCT-15</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1</b></td><td class="colsep0 rowsep0" align="center">40.52</td><td class="colsep0 rowsep0" align="center">>100</td><td class="colsep0 rowsep0" align="center">27.85</td><td class="colsep0 rowsep0" align="center">32.67</td><td class="colsep0 rowsep0" align="center">22.36</td><td class="colsep0 rowsep0" align="center">>100</td><td class="colsep0 rowsep0" align="center">57.12</td><td class="colsep0 rowsep0" align="center">>100</td><td class="colsep0 rowsep0" align="center">>100</td><td class="colsep0 rowsep0" align="center">>100</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2</b></td><td class="colsep0 rowsep0" align="center">>100</td><td class="colsep0 rowsep0" align="center">>100</td><td class="colsep0 rowsep0" align="center">56.18</td><td class="colsep0 rowsep0" align="center">>100</td><td class="colsep0 rowsep0" align="center">>100</td><td class="colsep0 rowsep0" align="center">>100</td><td class="colsep0 rowsep0" align="center">>100</td><td class="colsep0 rowsep0" align="center">>100</td><td class="colsep0 rowsep0" align="center">>100</td><td class="colsep0 rowsep0" align="center">>100</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>3</b></td><td class="colsep0 rowsep0" align="center">>100</td><td class="colsep0 rowsep0" align="center">>100</td><td class="colsep0 rowsep0" align="center">>100</td><td class="colsep0 rowsep0" align="center">>100</td><td class="colsep0 rowsep0" align="center">>100</td><td class="colsep0 rowsep0" align="center">>100</td><td class="colsep0 rowsep0" align="center">>100</td><td class="colsep0 rowsep0" align="center">>100</td><td class="colsep0 rowsep0" align="center">>100</td><td class="colsep0 rowsep0" align="center">>100</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4</b></td><td class="colsep0 rowsep0" align="center">44.77</td><td class="colsep0 rowsep0" align="center">>100</td><td class="colsep0 rowsep0" align="center">20.15</td><td class="colsep0 rowsep0" align="center">>100</td><td class="colsep0 rowsep0" align="center">41.34</td><td class="colsep0 rowsep0" align="center">>100</td><td class="colsep0 rowsep0" align="center">68.12</td><td class="colsep0 rowsep0" align="center">>100</td><td class="colsep0 rowsep0" align="center">>100</td><td class="colsep0 rowsep0" align="center">>100</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5</b></td><td class="colsep0 rowsep0" align="center">>100</td><td class="colsep0 rowsep0" align="center">>100</td><td class="colsep0 rowsep0" align="center">>100</td><td class="colsep0 rowsep0" align="center">>100</td><td class="colsep0 rowsep0" align="center">88.1</td><td class="colsep0 rowsep0" align="center">>100</td><td class="colsep0 rowsep0" align="center">>100</td><td class="colsep0 rowsep0" align="center">>100</td><td class="colsep0 rowsep0" align="center">>100</td><td class="colsep0 rowsep0" align="center">>100</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6</b></td><td class="colsep0 rowsep0" align="center">40.32</td><td class="colsep0 rowsep0" align="center">90.81</td><td class="colsep0 rowsep0" align="center">>100</td><td class="colsep0 rowsep0" align="center">13.06</td><td class="colsep0 rowsep0" align="center">16.75</td><td class="colsep0 rowsep0" align="center">88.63</td><td class="colsep0 rowsep0" align="center">21.60</td><td class="colsep0 rowsep0" align="center">38.8</td><td class="colsep0 rowsep0" align="center">36.42</td><td class="colsep0 rowsep0" align="center">54.12</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">Data from ref <a onclick="showRef(event, 'ref101'); return false;" href="javascript:void(0);" class="ref ref101">(101)</a>.</p></div></div></div><div class="NLM_p last">Compound <b>1</b> showed activity against NCI-H460, SKOV-3, DU145, MCF7, and MB-MDA-231 cancer cell lines. On the other hand, compound <b>2</b>, which differs from <b>1</b> only for the fluorine atom, was active only against SKOV-3 with an IC<sub>50</sub> value of 56.18 μM. Compound <b>5</b> demonstrated moderate activity against the MCF7 cancer cell line with an IC<sub>50</sub> value of 88.1 μM. Interestingly, an opposite trend was observed for compound <b>4</b>, the fluorine derivative of <b>5</b>. In fact, the former was found to be active on NCI-H460, SKOV-3, MCF7, and MB-MDA-231 tumor cell lines. The better affinity of compound <b>4</b> for the σ<sub>2</sub>R subtype with respect to the σ<sub>1</sub>R seems to explain this behavior. Indeed, the σ<sub>2</sub>R subtype is overexpressed in different cancer cell lines, and the authors, at the time of the publication, were not able to explain if the cytotoxic activity was due only to the involvement of the σ<sub>2</sub>R or both receptors. Compound <b>3</b> showed to be devoid of any cytotoxic activity in all the tested cell lines. Finally, compound <b>6</b> showed no specific cytotoxicity in all the selected cancer cell lines, except for SKOV-3.</div></div><div id="sec3_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i8" class="anchor-spacer"></div><h4 class="article-section__title" id="_i8">3.1.2.  Spirocyclic Piperidine Derivatives</h4><div id="sec3_1_2_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i9" class="anchor-spacer"></div><h5 class="article-section__title" id="_i9">3.1.2.1.  Spipethiane Derivatives</h5><div class="NLM_p">In 2010, Piergentili et al. discovered novel highly potent and cytotoxic σ<sub>1</sub>R ligands with a putative antagonistic profile whose chemical structure was based on the spipethiane scaffold (σ<sub>1</sub> p<i>K</i><sub>i</sub> = 9.23, σ<sub>2</sub> p<i>K</i><sub>i</sub> = 6.40, <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>),<a onclick="showRef(event, 'ref103'); return false;" href="javascript:void(0);" class="ref ref103">(103)</a> a spiro compound identified as a σR ligand by the same research group in 1998. Bioisosteric substitutions of the sulfur in position 1 and the methylene group in position 3 of spipethiane were performed to expand the SARs of this class of compounds (general structure A, compounds <b>7</b>–<b>11</b>, <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>). In addition, a smaller second set of compounds was obtained by deleting the spiro carbon and separating the two hydrophobic portions of the molecule through a carbon–carbon single bond (general structure B, compounds <b>12</b>–<b>15</b>, <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>). Moreover, insertion of a carbonyl function in position 4 and homologation at the nitrogen atom of the piperidine ring was also considered. Based on σ<sub>1</sub> and σ<sub>2</sub> radioligand binding assays performed, respectively, on Jurkat cells and rat cerebral cortex membranes using [<sup>3</sup>H]-pentazocine and [<sup>3</sup>H]1,3-di(2-tolyl)guanidine ([<sup>3</sup>H]DTG) as labels, SARs were built up. Almost all the novel compounds of the two series had higher σ<sub>1</sub>R affinity values than the lead spipethiane. Bioisosteric substitution of the sulfur atom with oxygen or with a methylene group did not alter the σ<sub>1</sub>R affinity even if a slight increase of affinity was considerable for the σ<sub>2</sub>R (compounds <b>7</b>–<b>8</b>) with a consequent decrease of σ<sub>1</sub><i>K</i><sub>i</sub>/σ<sub>2</sub><i>K</i><sub>i</sub> selectivity ratio (calculated as the antilogarithm of the difference between p<i>K</i><sub>i</sub> at σ<sub>1</sub> and σ<sub>2</sub> receptors). Better results were obtained with compounds <b>9</b> and <b>10</b>, where the methylene group of spipethiane in position 3 was substituted with an oxygen atom. Interestingly, replacement of the methylene group in position 4 with a ketone functional group afforded the best compounds in terms of σ<sub>1</sub>R affinity. The best result was obtained with compound <b>14</b>, also characterized by the absence of the spiro carbon that links the thiochromane ring to the benzylpiperidine moiety. This compound possessed a σ<sub>1</sub> p<i>K</i><sub>i</sub> of 10.28 (σ<sub>1</sub><i>K</i><sub>i</sub>/σ<sub>2</sub><i>K</i><sub>i</sub> = 29,512), and it represented the best σ<sub>1</sub>R ligand reported in the literature at the time of the publication. The high affinity of <b>14</b> was explained by hypothesizing that its more flexible structure allowed better interactions with the σ<sub>1</sub>R binding site. However, an increase in flexibility is not always a rule of thumb to be applied to develop selective σ<sub>1</sub>R antagonists. Indeed, compound <b>15</b>, which is the compound <b>13</b> homologous at the nitrogen atom of the piperazine ring, had a lower σ<sub>1</sub> p<i>K</i><sub>i</sub> = 9.96 and a σ<sub>2</sub> p<i>K</i><sub>i</sub> = 8.08. Therefore, it seemed that the elongation of the alkyl chain in this class of compounds ameliorated the σ<sub>2</sub>R affinity and caused a drastic loss of σ<sub>1</sub><i>K</i><sub>i</sub>/σ<sub>2</sub><i>K</i><sub>i</sub> selectivity ratio.</div><figure id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/medium/jm0c02265_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/large/jm0c02265_0010.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Spipethiane and general structure of spipethiane derivatives <b>7</b>–<b>11</b> and <b>12</b>–<b>15</b> with their σRs binding profile.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/large/jm0c02265_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02265&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">The spipethiane derivatives <b>7</b>–<b>15</b> were tested on MCF-7 and MCF-7/ADR cancer cell lines to evaluate their antitumor properties. The two cancer cell lines were chosen on the basis of their differential expression of σRs; in particular, the high overexpression of σ<sub>1</sub>R subtype characterizes the latter.<a onclick="showRef(event, 'ref104'); return false;" href="javascript:void(0);" class="ref ref104">(104)</a> The authors proved that all the novel compounds possessed cytostatic properties in the MCF-7/ADR cancer cell line with the best GI<sub>50</sub> values obtained with compounds <b>11</b> and <b>13</b> (10.0 μM and 7.7 μM, respectively), whereas no growth inhibition was observed in the MCF-7 cancer cell line. Also, an analysis of the ability to interfere with the cell cycle by comparing the spipethiane and compounds <b>13</b> and <b>14</b>, which possessed the best σ<sub>1</sub><i>K</i><sub>i</sub>/σ<sub>2</sub><i>K</i><sub>i</sub> selectivity ratio, was made. Specifically, compounds <b>13</b> and <b>14</b> increased the number of cells in the G<sub>0</sub>/G<sub>1</sub> phase and decreased the number of cells in the S phase in the MCF-7/ADR cell line; the same trend was not observed in MCF-7 breast cancer cells. Contrariwise, spipethiane was not able to affect the cell cycle. The capability of compounds <b>13</b> and <b>14</b> to induce apoptosis was also described. Indeed, MCF-7 and MCF-7/ADR cancer cell lines were stained with annexin V-FITC to evaluate the expression of phosphatidylserine on the outer layer of the cell membrane, which represents a typical feature of cells in apoptosis. Flow cytometry analysis highlighted phosphatidylserine expression only in MCF-7/ADR cells treated with compounds <b>13</b> and <b>14</b>. Finally, the functional activity of compound <b>14</b> was validated using the tail-flick assay. σ<sub>1</sub>Rs are highly expressed in the dorsal horn of the spinal cord,<a onclick="showRef(event, 'ref105'); return false;" href="javascript:void(0);" class="ref ref105">(105)</a> and it has been demonstrated that they can modulate opioid analgesia.<a onclick="showRef(event, 'ref106'); return false;" href="javascript:void(0);" class="ref ref106">(106)</a> In addition, KO of the σ<sub>1</sub>R gene (<i>SIGMAR1</i>) determines pain-attenuated phenotype in mice, supporting the modulatory role of σ<sub>1</sub>Rs in different types of pain (e.g., neuropathic, inflammatory, visceral).<a onclick="showRef(event, 'ref107'); return false;" href="javascript:void(0);" class="ref ref107">(107)</a> Therefore, σ<sub>1</sub>R ligands mimicking this condition are considered putative σ<sub>1</sub>R antagonists or negative modulators. Treatment of CD-1 mice only with <b>14</b> did not induce any analgesic effect, whereas pretreatment with morphine and subsequent administration of <b>14</b> enhanced the analgesic effect of morphine itself. Altogether, these results were consistent with previously reported findings on σ<sub>1</sub>R antagonist (i.e., BD1047)<a onclick="showRef(event, 'ref106'); return false;" href="javascript:void(0);" class="ref ref106">(106)</a> and proved the putative σ<sub>1</sub>R antagonist profile of compound <b>14</b>. In our opinion, the combination of structural elements, σRs binding profile, and intrinsic activity makes spipethiane derivatives an exciting class of compounds that might be further developed as cytotoxic agents helpful in those cancer cell lines whose aggressiveness is related to the overexpression of σ<sub>1</sub>Rs.</div></div><div id="sec3_1_2_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i10" class="anchor-spacer"></div><h5 class="article-section__title" id="_i10">3.1.2.2.  Spirocyclic Thienopyran and Thienofuran Derivatives</h5><div class="NLM_p">In the search for selective σ<sub>1</sub>R ligands, molecules with a spirocyclic piperidine scaffold gained much attention over the last decades. With this in mind, the synthesis of spirotetralins, spiro-joined benzofuran, isobenzofuran, and benzopyran piperidine derivatives were described, along with their affinities toward the two σR subtypes.<a onclick="showRef(event, 'ref108 ref109 ref110'); return false;" href="javascript:void(0);" class="ref ref108 ref109 ref110">(108−110)</a> Bioisosteric substitution of the benzene ring of spiro-joined benzofuran and benzopyran piperidine derivatives with a thiophene ring gave highly potent and selective σ<sub>1</sub>R ligands. Compounds <b>16</b>–<b>21</b> were identified as the most interesting compounds belonging to this series (<a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>). The main differences between these spiro-piperidines are (i) the presence of an aryl moiety linked to the α-position of the thiophene ring; (ii) the size of the oxygenated ring; and (iii) the nature of the substituent linked to such ring. Among the non-arylated lactones, a thieno[3,4-<i>c</i>]furan-3-one scaffold (<b>16</b>) showed the best results in terms of σ<sub>1</sub>R affinity when compared to the pyranone ring (not shown). Arylation of <b>16</b> in the 4′-position of the thiophene ring (on the same side of the lactone functional group) with rings possessing electron-withdrawing or electron-donating groups was tolerated. Despite a slight increase of the σ<sub>1</sub>R affinity of such compounds, the non-arylated compound <b>16</b> still possessed a better σ<sub>2</sub><i>K</i><sub>i</sub>/σ<sub>1</sub><i>K</i><sub>i</sub> selectivity ratio, so that additional derivatives of <b>16</b> substituted in the 4′-position have not been investigated. On the contrary, arylation at the 6′-position of the thiophene ring of <b>16</b>, or at both 4′- and 6′-positions, caused loss of affinity for the σ<sub>1</sub>R. Regarding the acetalic spiropiperidines with a thienopyran moiety (<b>17</b>–<b>19</b>), the sulfur position influenced the σ<sub>1</sub>R affinity. Indeed, the regioisomer <b>19</b> with a thieno[2,3-<i>c</i>]pyran moiety was about 6-fold and 8.5-fold less potent than regioisomers <b>17,18</b> (σ<sub>1</sub><i>K</i><sub>i</sub> = 1.9 nM for <b>19</b> vs σ<sub>1</sub><i>K</i><sub>i</sub> = 0.32 nM and 0.22 nM for <b>17</b> and <b>18</b>, respectively). α-Arylation of compound <b>17</b> with a thieno[3,2-<i>c</i>]pyran moiety led to compounds whose σ<sub>1</sub>R affinity is from 17- to 500-fold higher than those of the parent compound <b>17</b>.<a onclick="showRef(event, 'ref83'); return false;" href="javascript:void(0);" class="ref ref83">(83)</a> On the contrary, α-arylation of compound <b>18</b> (on the same side of the acetalic function) and α-arylation of compound <b>19</b> were tolerated. For derivatives of compound <b>18</b>, both electron-rich and electron-poor phenyl rings as well as naphthyl rings were tolerated. However, a bulky biphenyl moiety was not tolerated. Interesting results have been obtained by insertion of a <i>p</i>-cyanophenyl substituent on the thiophene ring of compound <b>18</b>. This derivative (compound <b>20</b>) displayed a σ<sub>1</sub><i>K</i><sub>i</sub> value of 0.25 nM, which is perfectly comparable with the σ<sub>1</sub><i>K</i><sub>i</sub> value obtained for compound <b>18</b> (0.22 nM). Meyer et al., who designed and synthesized these molecules, explained this aspect by a possible interaction of the additional aryl moiety with a hydrophobic pocket within the σ<sub>1</sub>R protein that is not accessible for the non-arylated parent compounds. In light of the σ<sub>1</sub>R values, it is clear that the spirocyclic scaffold was responsible for the high affinity for the σ<sub>1</sub>R. In contrast, the aryl moiety allows only additional hydrophobic interactions useful for better binding with the receptor.<a onclick="showRef(event, 'ref111'); return false;" href="javascript:void(0);" class="ref ref111">(111)</a> Aryl derivatives of <b>19</b> only tolerated unsubstituted or electron-poor aryl substituents (<b>21</b>, σ<sub>1</sub><i>K</i><sub>i</sub> = 16 nM).<a onclick="showRef(event, 'ref112'); return false;" href="javascript:void(0);" class="ref ref112">(112)</a> In order to establish the selectivity over other receptors, the affinities of compounds <b>16</b>–<b>21</b> toward the phencyclidine binding site and the ifenprodil binding site of the NMDA receptor (GluN2B) were assessed. Results showed affinity values exceeding 500 nM and selectivity for the σ<sub>1</sub>R, except for compound <b>20</b>, which displayed a <i>K</i><sub>i</sub> = 91 nM for the GluN2B.<a onclick="showRef(event, 'ref113'); return false;" href="javascript:void(0);" class="ref ref113">(113)</a> Recently, pharmacological characterization of compounds <b>16</b>–<b>21</b> has been performed.<a onclick="showRef(event, 'ref113'); return false;" href="javascript:void(0);" class="ref ref113">(113)</a> Non-arylated compounds <b>16</b>–<b>19</b> did not display affinities for the serotoninergic 5-HT<sub>1A</sub> receptor, the adrenergic α<sub>1A</sub> and α<sub>2A</sub> receptors, and the serotonin transporter (SERT). Compounds <b>16</b>, <b>20</b>, and <b>21</b> displayed a negligible affinity for opioid receptors, whereas compound <b>18</b> showed a moderate affinity for κ-opioid receptor (KOR) and δ-opioid receptor (DOR).</div><figure id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/medium/jm0c02265_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/large/jm0c02265_0011.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Structures of selected spiropiperidines with a thienofuran and thienopyran scaffold (<b>16</b>–<b>21</b>) and their σRs binding profile.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/large/jm0c02265_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02265&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">The σ<sub>1</sub>R functional activity of spirocyclic piperidines <b>16</b>–<b>21</b> was investigated by merging the information acquired from these compounds’ effect on the induced Ca<sup>2+</sup> influx mediated by voltage-gated channels in retinal ganglion cells and the capsaicin assay. In the first test, a non-arylated and an arylated compounds (<b>18</b> and <b>20</b>) were used. The KCl-induced Ca<sup>2+</sup> influx through the L-type voltage-regulated Ca<sup>2+</sup> channel was inhibited in the presence of a σ<sub>1</sub>R agonist. On the contrary, σ<sub>1</sub>R antagonists had the opposite effect. Both compounds did not inhibit the KCl-induced Ca<sup>2+</sup> influx, whereas they could reverse the inhibition mediated by the σ<sub>1</sub>R agonist opipramol, suggesting a σ<sub>1</sub>R antagonist profile. The putative σ<sub>1</sub>R antagonist properties were further confirmed with an <i>in vivo</i> capsaicin assay, in which compounds <b>18</b>, <b>19</b>, and <b>21</b> exhibited antiallodynic effects and a prolonged response latency after mechanical stimulation of the right hind paw of mice previously injected with capsaicin. The antiproliferative properties of these compounds were studied in A427 (nonsmall-cell lung cancer), LCLC-103H (large-cell lung cancer), 5637 (bladder cancer), and DAN-G (pancreatic cancer) cell lines with an <i>in vitro</i> crystal violet staining assay. The A427 and 5637 cancer cell lines were the most sensitive to spirocyclic compounds <b>16</b>–<b>20</b>. Spiropiperidines <b>20</b> and <b>21</b> were the most potent toward the A427 cell line, with IC<sub>50</sub> values of 2.6 μM and 5.9 μM, respectively. Considering that the IC<sub>50</sub> values obtained for the A427 cell line were similar to those obtained with the σ<sub>1</sub>R antagonist haloperidol, the authors assumed that the antiproliferative effect of these compounds was mediated by interference with the activity of σ<sub>1</sub>Rs. In addition, the antiproliferative properties of <b>20</b> were partially reversed when the σ<sub>1</sub>R agonist (+)-pentazocine was added. By contrast, results obtained in the bladder cell line (IC<sub>50</sub> = 5.5 μM and 9.1 μM for <b>20</b> and <b>21</b>, respectively) seemed to be not related to the interference with σ<sub>1</sub>R. Indeed, (+)-pentazocine exhibited cytotoxic properties on this cell line. In general, compound <b>20</b> displayed an unselective cytotoxic effect on all the explored cancer cell lines with the highest value of cytotoxicity (65%) detected for the A427 cell line with the lactate dehydrogenase (LDH) assay. In general, spirocyclic piperidines seemed to act as σ<sub>1</sub>R antagonists with cytotoxic properties. Thus, we suggest that this chemical scaffold may be further exploited by structural simplification or bioisosteric replacements.<a onclick="showRef(event, 'ref114'); return false;" href="javascript:void(0);" class="ref ref114">(114)</a></div></div></div><div id="sec3_1_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i11" class="anchor-spacer"></div><h4 class="article-section__title" id="_i11">3.1.3.  Bicyclic Piperazine Derivatives</h4><div id="sec3_1_3_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i12" class="anchor-spacer"></div><h5 class="article-section__title" id="_i12">3.1.3.1.  7,9-Diazabicyclo[4.2.2]decane Derivatives</h5><div class="NLM_p">The ethylenediamine moiety has been proven to represent a sufficient chemical substructure that allows a high affinity for the σRs. Indeed, almost 30 years ago, it was discovered that the <i>cis</i>-isomers of U50,488 (compound (±)-<b>22</b>, <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>), a selective KOR agonist, possessed a moderate affinity for the σ<sub>1</sub>R.<a onclick="showRef(event, 'ref115'); return false;" href="javascript:void(0);" class="ref ref115">(115)</a> Reduction of the amide functional group led to the enantiomeric cyclohexandiamine derivatives of U50,488 (compound (±)-<b>23</b>, <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>), both containing the ethylenediamine moiety and with high affinity for the σ<sub>1</sub>R.<a onclick="showRef(event, 'ref116'); return false;" href="javascript:void(0);" class="ref ref116">(116)</a> Removal of the cyclohexane ring afforded the ethylenediamine <b>24</b> (<a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>) with σ<sub>1</sub><i>K</i><sub>i</sub> and σ<sub>2</sub><i>K</i><sub>i</sub> of 2.1 nM and 8.1 nM, respectively.<a onclick="showRef(event, 'ref117'); return false;" href="javascript:void(0);" class="ref ref117">(117)</a></div><figure id="fig12" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/medium/jm0c02265_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/large/jm0c02265_0012.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Historically relevant ethylenediamine <b>22</b>–<b>24</b> with their σRs binding profile. The ethylenediamine structure is highlighted in light blue.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/large/jm0c02265_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02265&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Compound <b>24</b> was used as the lead compound for the discovery of novel σR ligands.<a onclick="showRef(event, 'ref118 ref119'); return false;" href="javascript:void(0);" class="ref ref118 ref119">(118,119)</a> To expand the SARs of this class of compounds, the ethylenediamine moiety has been included in a conformationally restricted structure, such as the piperazine ring. Specifically, piperazine derivatives were substituted at both nitrogen atoms with hydrophobic substituents to establish a proper binding with the σR protein.<a onclick="showRef(event, 'ref120 ref121'); return false;" href="javascript:void(0);" class="ref ref120 ref121">(120,121)</a> The general structure of these compounds is depicted in <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>. Among the synthesized compounds, a <i>p</i>-methoxybenzyl moiety and a benzyl moiety (compound <b>25</b>, <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>) led to a σ<sub>1</sub><i>K</i><sub>i</sub> value of 0.47 nM. In 2004 and 2012, the discovery of chiral and flexible (piperazin-2-yl)alkanol derivatives with a good affinity toward the σ<sub>1</sub>R was reported (general structure in <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>).<a onclick="showRef(event, 'ref122 ref123'); return false;" href="javascript:void(0);" class="ref ref122 ref123">(122,123)</a> The best compounds possessed once again a <i>p</i>-methoxybenzyl moiety and a benzyl moiety linked to the piperazine nitrogen atoms. The methanol side chain (compound <b>26</b>, <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>) afforded the best results in terms of σ<sub>1</sub>R affinity (σ<sub>1</sub><i>K</i><sub>i</sub> = 12.4 nM), whereas the ethanol side chain (compound <b>27</b>, <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>) afforded a slightly reduced σ<sub>1</sub><i>K</i><sub>i</sub> value (20 nM vs 12.4 nM) but a higher selectivity ratio (σ<sub>2</sub><i>K</i><sub>i</sub>/σ<sub>1</sub><i>K</i><sub>i</sub> > 50). On the other hand, the side chain elongation to three carbon atoms (compound <b>28</b>, <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>) caused a considerable reduction of affinity (σ<sub>1</sub><i>K</i><sub>i</sub> = 188 nM).</div><figure id="fig13" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/medium/jm0c02265_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/large/jm0c02265_0013.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. General structures of piperazine derivatives and structures of compounds <b>25</b>–<b>28</b> with σRs binding profile.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/large/jm0c02265_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02265&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">With the purpose of defining a 3D pharmacophore model that takes into consideration the appropriate spatial orientation of the pharmacophoric elements of a σ<sub>1</sub>R ligand, a useful strategy is represented by the structural constriction of such elements in a blocked conformation, such as bicyclic structures. With respect to the Glennon pharmacophore model for σ<sub>1</sub>R ligands, the (piperazin-2-yl)alkanol moiety was incorporated in bicyclic frameworks, giving rise to different classes of compounds with a moderate-to-high affinity toward the σ<sub>1</sub>R (general structure in <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a></a>).<a onclick="showRef(event, 'ref124 ref125 ref126 ref127 ref128 ref129'); return false;" href="javascript:void(0);" class="ref ref124 ref125 ref126 ref127 ref128 ref129">(124−129)</a> SARs were described for these derivatives. In general, lipophilic substituents at both nitrogen atoms were required for a proper binding with the σ<sub>1</sub>R. The R<sub>2</sub> group could be an allyl substituent if the carbon atom linked to R<sub>3</sub> was unsubstituted; otherwise, this unsaturated moiety was not tolerated. In all other cases, R<sub>2</sub> could be a benzyl, propyl, or dimethylallyl moiety. The R<sub>3</sub> substituent could be a benzyloxy group if the bridge was made of four carbon atoms. By contrast, if the benzyloxy group was present, a smaller bridge led to a lower affinity. Thus, a benzylidene moiety was allowed. Besides, R<sub>3</sub> could be a hydroxy group or a carbonyl function only if R<sub>2</sub> corresponded to a benzyl moiety. Substituents that decreased the basicity of the nitrogen atom linked to R<sub>2</sub>, for example, phenyl or benzoyl, were not tolerated. Finally, bridge annulation with a quinoline or an indole ring or its participation in the formation of spirocycles caused a loss of affinity. In 2007, the synthesis of constrained derivatives of (piperazin-2-yl)propanols possessing a 6,8-diazabicyclo[3.2.2]nonane scaffold and a three-carbon bridge was reported (<a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a></a>).<a onclick="showRef(event, 'ref130'); return false;" href="javascript:void(0);" class="ref ref130">(130)</a> Among these derivatives, enantiomeric alcohols <b>29</b> and <b>30</b> (<a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a></a>) gave the best results in terms of activity and selectivity. Interestingly, compound <b>29</b> was about 30-fold more potent than its corresponding flexible piperazine <b>28</b>. The diastereoisomeric alcohols of <b>29</b> and <b>30</b> (not shown) were about 20-fold less potent (6.5 nM vs 125 nM for compound <b>29</b> and its diastereoisomer, 7.5 nM vs 118 nM for compound <b>30</b> and its diastereoisomer), suggesting that the orientation of the alcoholic function at the 2-position was somehow crucial to establish a proper interaction with a HBA present in the binding site of the σ<sub>1</sub>R. Also, the authors observed that the alcoholic function of compounds <b>29</b> and <b>30</b> had a similar spatial orientation of the alcoholic group of compound <b>26</b>.</div><figure id="fig14" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/medium/jm0c02265_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/large/jm0c02265_0014.jpeg" id="gr14" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. General structure of bicyclic piperazines, chemical structures of 6,8-diazabicyclo[3.2.2]nonanes <b>29</b> and <b>30</b>, and 7,9-diazabicyclo[4.2.2]decane derivatives <b>31</b>–<b>37</b> with their σRs binding profile.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/large/jm0c02265_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02265&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In 2010, Sunnam and co-workers, as a continuation of the work previously described, expanded the carbon bridge of 6,8-diazabicyclo[3.2.2]nonanes from three to four carbon atoms, affording 7,9-diazabicyclo[4.2.2]decane derivatives (compounds <b>31</b>–<b>37</b>, <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a></a>). The authors investigated if ring homologation and modification of the alcoholic function at the 2-position or its complete deletion could affect the activity of this novel class of compounds. Correctly, the homologous compound <b>29</b> (alcohol <b>31</b>, <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a></a>) had only a moderate affinity toward the σ<sub>1</sub>R, whereas the affinity for the σ<sub>2</sub>R fell in the micromolar range. Etherification of the alcoholic function of <b>31</b> led to alkyl ethers <b>32</b>–<b>34</b>. Except for <b>34</b>, which possessed a branched isopentyl moiety (σ<sub>1</sub><i>K</i><sub>i</sub> = 123 nM), ethers <b>32</b> and <b>33</b> displayed a worse affinity for the σ<sub>1</sub>R when compared with compound <b>31</b>. Elongation of the alkyl chain or insertion of an aromatic ring led to ethers with very low affinity for the σ<sub>1</sub>R (not shown). Also, the authors performed similar structural modifications for the diastereoisomeric alcohols and ethers of <b>31</b>–<b>34</b>. It was reported that the σ<sub>1</sub>R affinities of such diastereoisomers fell in the micromolar range, emphasizing that in the postulated bioactive conformation, the substituent in position 2 must possess the same spatial orientation observed for compounds <b>29</b> and <b>31</b>. Removal of the oxygen atom led to alkane <b>35</b> with a σ<sub>1</sub>R affinity comparable to <b>31</b> (253 nM vs 298 nM, respectively).<a onclick="showRef(event, 'ref131'); return false;" href="javascript:void(0);" class="ref ref131">(131)</a></div><div class="NLM_p">Moreover, insertion of a double bond between carbons in positions 2 and 3 on the carbon bridge afforded compound <b>36</b>, representing the best compound of this series in terms of σ<sub>1</sub>R affinity. Indeed, compound <b>36</b> was about 40-fold more potent than <b>31</b> (7.5 nM vs 298 nM, respectively). Unfortunately, compound <b>36</b> also displayed the best <i>K</i><sub>i</sub> value for the σ<sub>2</sub>R for this class of compounds (184 nM). Insertion of a fluorine atom at the 2-position of the double bond led to compound <b>37</b> whose σ<sub>1</sub>R affinity was once again comparable with those of compound <b>31</b>. SARs were outlined for this class of novel compounds. Comparing the results obtained from the 6,8-diazabicyclo[3.2.2]nonane series and the 7,9-diazabicyclo[4.2.2]decane series, it seemed that homologation of the carbon bridge did not represent a valuable strategy for a better σ<sub>1</sub>R binding. Furthermore, the presence of a substituent at the 2-position of the 7,9-diazabicyclo[4.2.2]decane scaffold was not necessary for the affinity, although stereochemistry represented a factor that must be taken into consideration when such substituents were present. The presence of unsaturation could justify the best result obtained with compound <b>36</b>. Indeed, the shorter length of the double bond reduces the bridge size and its flexibility, so that the steric demand of the unsaturated four-carbon bridge and the three-carbon bridge becomes similar with a consequently improved interaction with the σ<sub>1</sub>R (<b>29</b>, <b>30</b> and <b>36</b>). To summarize, enlargement of the bridge size to four atoms in piperazine bicyclic derivatives did not bring a striking beneficial effect for σ<sub>1</sub>R binding unless an unsubstituted double bond was present.</div><div class="NLM_p last">Cytotoxic properties of compounds <b>35</b> and <b>36</b> were evaluated in a panel of six human tumor cell lines, including A427 (small-cell lung cancer), 5637 (bladder cancer), RT-4 (bladder cancer), LCLC-103H (large-cell lung cancer), MCF-7 (breast cancer), and DAN-G (pancreas cancer). While no cytotoxic activity was observed for RT-4, LCLC-103H, or DAN-G cancer cell lines, good results were obtained mainly with A427 and 5637 cell lines. Specifically, after 96 h of exposure, compound <b>36</b> displayed an IC<sub>50</sub> value of 13 μM for the 5637 cancer cell line and an IC<sub>50</sub> value of 10 μM for the A427 cancer cell line. Interestingly, the A427 cell line was susceptible to haloperidol, a well-known σ<sub>1</sub>R antagonist, so that the authors hypothesized that compound <b>36</b> could act as a σ<sub>1</sub>R antagonist, explaining its antiproliferative activity. However, the same assumption cannot be made for the 5637 cell line, which is insensitive to haloperidol. For these reasons, in our opinion, the assumption of functional activity based on the simple comparison of the biological effect with a reference compound, like haloperidol, is misleading. For this reason, the precise mechanism of cytotoxicity should be investigated more in detail to establish if the cytotoxic properties of compound <b>36</b> depend on the selective interaction and inhibition of the σ<sub>1</sub>R.</div></div><div id="sec3_1_3_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i13" class="anchor-spacer"></div><h5 class="article-section__title" id="_i13">3.1.3.2.  2,5-Diazabicyclo[2.2.2]octane Derivatives</h5><div class="NLM_p">In 2016, Weber et al. reported the synthesis of 2,5-diazabicyclo[2.2.2]octane derivatives.<a onclick="showRef(event, 'ref132'); return false;" href="javascript:void(0);" class="ref ref132">(132)</a> These compounds were designed for the same purposes previously discussed for the 7,9-diazabicyclo[4.2.2]decane series. The authors hypothesized that if rigidification of <b>28</b> into compound <b>29</b> afforded a 30-fold improvement of the σ<sub>1</sub><i>K</i><sub>i</sub> affinity value, then similar results should also be achieved by rigidification of the flexible (piperazin-2-yl)-ethanol structure (general structure in <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>) into the 2,5-diazabicyclo[2.2.2]octane scaffold (i.e., <b>38</b>–<b>43</b>, <b>ent-38</b>–<b>43</b>, <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a></a>). The best results in terms of σ<sub>1</sub>R binding (calculated in animal and human myeloma cell lines) were obtained when a cyclohexylmethyl moiety was linked to one nitrogen atom of the bicyclic piperazine (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>).</div><figure id="fig15" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/medium/jm0c02265_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/large/jm0c02265_0015.jpeg" id="gr15" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 15. General structure of 2,5-diazabicyclo[2.2.2]octane derivatives <b>38</b>–<b>43</b> and <b>ent-38</b>–<b>43</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/large/jm0c02265_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02265&amp;id=fig15"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. σ<sub>1</sub>R Binding Profile of Compounds <b>38</b>–<b>43</b> and <b>ent-38</b>–<b>43</b></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">Compd.</th><th class="colsep0 rowsep0" align="center">σ<sub>1</sub><i>K</i><sub>i</sub> [nM]<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a> (guinea pig brain)</th><th class="colsep0 rowsep0" align="center">σ<sub>2</sub><i>K</i><sub>i</sub> [nM]<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a> (rat liver)</th><th class="colsep0 rowsep0" align="center">σ<sub>1</sub><i>K</i><sub>i</sub> [nM]<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a> (human RPMI 8226 cell line)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>38</b></td><td class="colsep0 rowsep0" align="center">4.8</td><td class="colsep0 rowsep0" align="center">36</td><td class="colsep0 rowsep0" align="center">3.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>ent-38</b></td><td class="colsep0 rowsep0" align="center">23</td><td class="colsep0 rowsep0" align="center">197</td><td class="colsep0 rowsep0" align="center">2.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>39</b></td><td class="colsep0 rowsep0" align="center">6.9</td><td class="colsep0 rowsep0" align="center">60</td><td class="colsep0 rowsep0" align="center">2.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>ent-39</b></td><td class="colsep0 rowsep0" align="center">5.7</td><td class="colsep0 rowsep0" align="center">501</td><td class="colsep0 rowsep0" align="center">1.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>40</b></td><td class="colsep0 rowsep0" align="center">8.0</td><td class="colsep0 rowsep0" align="center">51</td><td class="colsep0 rowsep0" align="center">13</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>ent-40</b></td><td class="colsep0 rowsep0" align="center">14</td><td class="colsep0 rowsep0" align="center">40</td><td class="colsep0 rowsep0" align="center">38</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>41</b></td><td class="colsep0 rowsep0" align="center">7.1</td><td class="colsep0 rowsep0" align="center">157</td><td class="colsep0 rowsep0" align="center">7.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>ent-41</b></td><td class="colsep0 rowsep0" align="center">0.50</td><td class="colsep0 rowsep0" align="center">116</td><td class="colsep0 rowsep0" align="center">6.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>42</b></td><td class="colsep0 rowsep0" align="center">8.7</td><td class="colsep0 rowsep0" align="center">20</td><td class="colsep0 rowsep0" align="center">27</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>ent-42</b></td><td class="colsep0 rowsep0" align="center">11</td><td class="colsep0 rowsep0" align="center">202</td><td class="colsep0 rowsep0" align="center">27</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>43</b></td><td class="colsep0 rowsep0" align="center">23</td><td class="colsep0 rowsep0" align="center">334</td><td class="colsep0 rowsep0" align="center">73</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>ent-43</b></td><td class="colsep0 rowsep0" align="center">11</td><td class="colsep0 rowsep0" align="center">593</td><td class="colsep0 rowsep0" align="center">24</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">Data from ref <a onclick="showRef(event, 'ref132'); return false;" href="javascript:void(0);" class="ref ref132">(132)</a>.</p></div></div></div><div class="NLM_p">Almost all compounds displayed a σ<sub>1</sub><i>K</i><sub>i</sub> value <20 nM in guinea pig homogenate, except <b>ent-38</b> and <b>43</b>. In general, <i>N</i>-benzyl derivatives <b>38</b>, <b>ent-38</b>, <b>39</b>, and <b>ent-39</b> unveiled better σ<sub>1</sub><i>K</i><sub>i</sub> values for the 1-naphtylmethyl and biphenylmethyl derivatives <b>40</b>–<b>43</b> and <b>ent-40</b>–<b>43</b> in both animal and human radioligand binding assays (σ<sub>1</sub><i>K</i><sub>i</sub> RPMI 8226 cell line <3.0 nM). Interestingly, the 1<i>S</i>,4<i>R</i>,7<i>S</i> configuration ensured the best σ<sub>2</sub><i>K</i><sub>i</sub>/σ<sub>1</sub><i>K</i><sub>i</sub> selectivity ratio (90-fold for <b>ent-39</b>, 230-fold for <b>ent-41</b>, and 55-fold for <b>ent-43</b>). Among all compounds, the naphtylmethyl derivative <b>ent-41</b> showed the best affinity toward the σ<sub>1</sub>R (σ<sub>1</sub><i>K</i><sub>i</sub> guinea pig brain = 0.50 nM). Generally, stereochemistry seemed to not represent a relevant factor for proper binding to the σ<sub>1</sub>R. Surprisingly, structure rigidification did not significantly improve the σ<sub>1</sub><i>K</i><sub>i</sub> values for this class of compounds. Indeed, the authors compared the <i>K</i><sub>i</sub> values of these novel bicyclic piperazines with those of their parent hydroxyethyl piperazines and saw that they were more or less superimposable.</div><div class="NLM_p">Molecular modeling studies were performed in order to explain these unexpected results. For both classes of compounds, binding free energy values were calculated and compared. Results showed that rigidification of the flexible hydroxyethyl piperazine structure into the 2,5-diazabicyclo[2.2.2]octane scaffold determined a slightly favorable increase of the entropic binding component value. The enthalpic–entropic compensation observed for the 2,5-diazabicyclo[2.2.2]octane class of compounds determined binding free energy values perfectly comparable with the binding free energy values calculated for their parent hydroxyethyl piperazines. In addition, these studies also highlighted the binding determinants of bicyclic piperazine derivatives as follows: (i) the cyclohexyl methyl moiety is buried in a hydrophobic pocket of the receptor; (ii) the aromatic portion of the molecule is involved in the formation of π–π and π-cation interactions; (iii) the nitrogen atom linked to the aryl methyl moiety establishes a salt bridge bond with the carboxylic residue of Asp126; and (iv) the hydroxy group assumes the role of a HBA (<a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig16" id="" class=" internalNav">16</a></a>).</div><figure id="fig16" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 16</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/medium/jm0c02265_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/large/jm0c02265_0016.jpeg" id="gr16" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 16. (A) 2D schematic representation of the identified interactions between compound <b>42</b> and the main amino acid residues. (B) 3D protein–ligand binding interactions of compound <b>42</b> with the σ<sub>1</sub>R homology model. Color-coded as follows: PI (red), HYAr or HYD (light blue), HY (pink), HBA (light green), π-interactions (Arg119 and Tyr120, cyan), salt bridge (Asp126, red), hydrophobic interactions (Ile128, Phe133, Tyr173, and Leu186, purple), and hydrogen bond (Thr181, green). Adapted with permission from ref <a onclick="showRef(event, 'ref132'); return false;" href="javascript:void(0);" class="ref ref132">(132)</a>. Copyright 2016 American Chemical Society.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/large/jm0c02265_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02265&amp;id=fig16"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Cytotoxicity studies on 2,5-diazabicyclo[2.2.2]octanes <b>38</b>–<b>43</b> and <b>ent-38</b>–<b>43</b> were performed using the crystal violet assay in seven cancer cell lines: 5637 and RT-4 (bladder cancer), DAN-G (pancreatic cancer), MCF-7 (breast cancer), A427 (small-cell lung cancer), and LCLC-103H (large-cell lung cancer). Compounds <b>40</b> and <b>41</b> displayed unselective growth inhibition, whereas the 5637 cell line was slightly sensitive to compounds <b>ent-38</b>, <b>39</b>, <b>ent-41</b>, and <b>42</b>. Except for unselective cytotoxic compounds <b>40</b> and <b>41</b>, the other bicyclic piperazines exhibited potent IC<sub>50</sub> values ranging from 1.6 to 4.3 μM for the A427 cell line. The higher susceptibility of A427 cells can be attributed to their overexpression of σ<sub>1</sub>Rs,<a onclick="showRef(event, 'ref130'); return false;" href="javascript:void(0);" class="ref ref130">(130)</a> as previously stated for spiropiperidines <b>16</b>–<b>21</b>. In depth studies on double-stained A427 cells with annexin V-FITC and propidium iodide were made to investigate apoptosis induction by compounds <b>ent-38</b> and <b>ent-40</b>–<b>42</b>. After 24 h, the biphenylmethyl compound <b>ent-42</b> caused the appearance of about 40% of early apoptotic cells. On the other hand, all other tested compounds induced apoptosis only after 48 h. Considering that the induced growth inhibition effect mediated by these compounds on A427 cells was similar to that of haloperidol, the authors assumed that 2,5-diazabicyclo[2.2.2]octanes acted as σ<sub>1</sub>R antagonists. However, we would like to stress that as a good practice in defining the putative functional role of new σR ligands, additional <i>in vivo</i> studies (e.g., formalin mice assay) are needed to validate such generalizations.</div></div></div></div><div id="sec3_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15">3.2.  Selective σ<sub>2</sub>R Ligands</h3><div class="NLM_p">To date, the development of truly selective σ<sub>2</sub>R ligands has been challenging due to the vast and heterogeneous range of structures that can fit into the σ<sub>2</sub>R binding site. These chemical classes include conformationally restricted amines (e.g., benzomorphan-7-one, granatane, and methanobenzazocine derivatives), indole analogs compounds (e.g., siramesine-related derivatives),<a onclick="showRef(event, 'ref133'); return false;" href="javascript:void(0);" class="ref ref133">(133)</a> and cycloalkyl amines with a flexible alkyl linker (e.g., <i>N</i>-cyclohexylpiperazine, <i>N</i>-(4-fluorophenyl)piperazine, and 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline derivatives).<a onclick="showRef(event, 'ref134 ref135 ref136'); return false;" href="javascript:void(0);" class="ref ref134 ref135 ref136">(134−136)</a> A few examples of such representative structures are depicted in <a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">17</a></a>. Concerning their cytotoxicity properties, siramesine showed to induce cell death through a p53- and caspase-independent apoptotic pathway.<a onclick="showRef(event, 'ref72'); return false;" href="javascript:void(0);" class="ref ref72">(72)</a> On the other hand, the dose-dependent effect exerted by the tropane derivative RHM-138 was mediated by caspase-dependent apoptosis.<a onclick="showRef(event, 'ref137'); return false;" href="javascript:void(0);" class="ref ref137">(137)</a> The highly selective granatane derivative WC-26 and the cyclohexylpiperazine derivative PB28 enhanced the cytotoxicity of existing anticancer drugs, such as doxorubicin, by increasing the intracellular reactive oxygen species (ROS) or decreasing the expression of the P-glycoprotein (P-gp), respectively.<a onclick="showRef(event, 'ref138 ref139'); return false;" href="javascript:void(0);" class="ref ref138 ref139">(138,139)</a> Finally, benzamide derivative RHM-1 did not induce cytotoxicity and caspase-3 activation. However, due to the favorable binding profile, it was radiolabeled and further developed as a PET tracer for cancer diagnosis.<a onclick="showRef(event, 'ref140'); return false;" href="javascript:void(0);" class="ref ref140">(140)</a></div><figure id="fig17" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Figure 17</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/medium/jm0c02265_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/large/jm0c02265_0017.jpeg" id="gr17" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 17. Representative structures for different chemical classes of σ<sub>2</sub>R ligands.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/large/jm0c02265_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02265&amp;id=fig17"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div id="sec3_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i16" class="anchor-spacer"></div><h4 class="article-section__title" id="_i16">3.2.1.  Conformationally Restricted Amines: Selective Granatane Derivatives</h4><div class="NLM_p">The σRs’ ability to bind tropane-based molecules, including cocaine,<a onclick="showRef(event, 'ref141'); return false;" href="javascript:void(0);" class="ref ref141">(141)</a> drove much of the early interest in the development of this class and structurally related compounds such as granatane derivatives.<a onclick="showRef(event, 'ref138 ref142 ref143'); return false;" href="javascript:void(0);" class="ref ref138 ref142 ref143">(138,142,143)</a> In 2010, Hornick et al. evaluated the capability of a novel granatane-based σ<sub>2</sub>R ligand to induce apoptosis and augment standard chemotherapy in pancreas cancer.<a onclick="showRef(event, 'ref144'); return false;" href="javascript:void(0);" class="ref ref144">(144)</a> SW-43, bearing a 9-azabicyclo[3.3.1]nonan-3α-yl ring with an aminoalkyl extension, showed a higher effect on tumor cell viability when compared to the structural related analog SV-119 (<a data-tab="pane-pcw-Figures" href="#fig18" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig18" id="" class=" internalNav">18</a></a>), even though a loss of σ<sub>2</sub>R affinity and selectivity occurred. Indeed, shortening the length of the aminoalkyl chain from 10 (SW-43) to 6 (SV-119) carbons increased the σ<sub>1</sub><i>K</i><sub>i</sub>/σ<sub>2</sub><i>K</i><sub>i</sub> selectivity ratio significantly (19 vs 273).<a onclick="showRef(event, 'ref143'); return false;" href="javascript:void(0);" class="ref ref143">(143)</a> However, the higher lipophilicity of SW-43 might have helped to enhance the membrane diffusion into the cell.<a onclick="showRef(event, 'ref144'); return false;" href="javascript:void(0);" class="ref ref144">(144)</a> Moreover, the <i>in vivo</i> antitumor effects of the commercially available siramesine were also compared with that of the two granatane-based compounds. Thus, σ<sub>2</sub>R ligands treatment decreased tumor volume to the same extent as gemcitabine, while the combination of compound SW-43 with gemcitabine resulted in a superior effect in the stabilization of tumor volume than other tested compounds.<a onclick="showRef(event, 'ref144'); return false;" href="javascript:void(0);" class="ref ref144">(144)</a></div><figure id="fig18" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Figure 18</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/medium/jm0c02265_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/large/jm0c02265_0018.jpeg" id="gr18" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 18. Chemical structure and σRs binding profile of selective <i>N</i>-substituted 9-azabicyclo[3.3.1]nonan-3α-yl phenylcarbamate derivatives and conjugated derivative SW III-123.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/large/jm0c02265_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02265&amp;id=fig18"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The primary amine function of compound SW-43 was successively condensed with 4-chloro-7-nitrobenzo-2-oxa-1,3-diazole or 5-(dimethylamino)naphthalene-1-sulfonyl chloride (<a data-tab="pane-pcw-Figures" href="#fig18" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig18" id="" class=" internalNav">18</a></a>), which acted as fluorophores, to develop novel fluorescent σ<sub>2</sub>R selective ligands SW-120 and SW-116 for imaging of cell proliferation.<a onclick="showRef(event, 'ref145'); return false;" href="javascript:void(0);" class="ref ref145">(145)</a> SAR analysis on granatane analogs suggested that a broad range of <i>N</i>-substitutions of the 9-azabicyclo[3.3.1]nonane was highly tolerated. Indeed, the introduction of extraordinarily long and large substituents (e.g., ω-amino groups and substituted benzo-fused heterocycles) did not affect σ<sub>2</sub>R affinity and selectivity significantly (WC-26 vs SV-119), while the <i>N</i>-substitution bearing an additional nitrogen atom located at least five carbon units apart led to increased affinity for the σ<sub>2</sub>R. Finally, the presence of aryl groups on the <i>N</i>-substituent was not essential for both affinity and selectivity for the σ<sub>2</sub>R (SW-43), although it was permitted.</div><div class="NLM_p last">In a follow-up study, the structure of SW-43 was conjugated with that of a second mitochondria-derived activator of caspase (SMAC) compound to develop an innovative class of tumor-targeting drug delivery agents for treating ovarian cancer.<a onclick="showRef(event, 'ref146'); return false;" href="javascript:void(0);" class="ref ref146">(146)</a> As a result, the new hybrid compound named SW III-123 (<a data-tab="pane-pcw-Figures" href="#fig18" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig18" id="" class=" internalNav">18</a></a>) retained a sufficient σ<sub>2</sub>R affinity to allow the successful delivery of the SMAC compound into ovarian cancer cells. The finding was supported by the potent cytotoxic effect of the new compound toward different human ovarian cancer cell lines (i.e., SKOV-3, CaOV-3, and BG-1) after 24 h treatment, which was not due to synergistic effects of the two molecules since their combination produced less cytotoxicity than the conjugated compound.<a onclick="showRef(event, 'ref146'); return false;" href="javascript:void(0);" class="ref ref146">(146)</a> The strategy proposed by Zeng et al. was an interesting attempt; however, a significant limitation is the absence of either improved cytotoxic effect or synergism between the simultaneous modulation of the two targets. From our perspective, a different conjugation strategy (e.g., not cleavable vs cleavable linker) of the two active small molecules might be beneficial to overcome this issue. Therefore, as a future investigation, we suggest applying the mutual prodrugs approach to develop novel conjugates with bivalent function, that is, to obtain the synergistic effect and develop an effective drug delivery system. Consequently, by using selective σ<sub>2</sub>R ligands as a suitable promoiety, it might be possible to take advantage of both its antiproliferative effect (active promoiety) and tumor-targeting drug delivery properties (carrier promoiety).</div></div><div id="sec3_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i17" class="anchor-spacer"></div><h4 class="article-section__title" id="_i17">3.2.2.  Siramesine-Related Compounds: Selective Indole Derivatives</h4><div class="NLM_p">Siramesine (<a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">17</a></a>) has been reported, by Perregaard et al. in 1995, as a first selective σ<sub>2</sub>R ligand with relatively low affinity for additional off-targets, including 5-HT<sub>1A</sub>R, 5-HT<sub>2A</sub>R, D<sub>2</sub>R, and α<sub>1</sub>R.<a onclick="showRef(event, 'ref133'); return false;" href="javascript:void(0);" class="ref ref133">(133)</a> Although siramesine was initially developed as a nontoxic CNS agent with potent anxiolytic activity,<a onclick="showRef(event, 'ref147 ref148 ref149 ref150'); return false;" href="javascript:void(0);" class="ref ref147 ref148 ref149 ref150">(147−150)</a> later, it has been extensively evaluated both <i>in vitro</i> and <i>in vivo</i> for its antitumor properties and used as a reference σ<sub>2</sub>R agonist accordingly.<a onclick="showRef(event, 'ref151 ref152 ref153 ref154 ref155'); return false;" href="javascript:void(0);" class="ref ref151 ref152 ref153 ref154 ref155">(151−155)</a> Nevertheless, it has been demonstrated that siramesine-mediated cell death was likely due to the modulation of multiple molecular targets rather than through exclusively σ<sub>2</sub>Rs activation.<a onclick="showRef(event, 'ref156'); return false;" href="javascript:void(0);" class="ref ref156">(156)</a> Precisely, siramesine seemed to act as a lysosomotropic agent able to impact lysosomal membrane permeabilization and leakage, leading to increased ROS and triggering apoptosis signaling and cell death.<a onclick="showRef(event, 'ref72 ref152'); return false;" href="javascript:void(0);" class="ref ref72 ref152">(72,152)</a> More recently, the combination of siramesine and lapatinib (a dual tyrosine kinase inhibitor) was reported to induce cell death in MDA MB-231 and SKBR3 breast cancer cell lines mediating ferroptosis and autophagy through an unclear synergistic effect.<a onclick="showRef(event, 'ref157'); return false;" href="javascript:void(0);" class="ref ref157">(157)</a></div><div class="NLM_p">Since its discovery, the chemical structure of siramesine has been manipulated to obtain improved highly selective indole analogs (<a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig19" id="" class=" internalNav">19</a></a>). Mainly, modification of both the indole scaffold and the spiropiperidine moiety was carried out; thus, structural determinants for this class of σRs ligands were extensively explored.<a onclick="showRef(event, 'ref109 ref110 ref158 ref159'); return false;" href="javascript:void(0);" class="ref ref109 ref110 ref158 ref159">(109,110,158,159)</a></div><figure id="fig19" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Figure 19</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/medium/jm0c02265_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/large/jm0c02265_0019.jpeg" id="gr19" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 19. Early structural modification of siramesine and its analogs <b>44</b>–<b>48</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/large/jm0c02265_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02265&amp;id=fig19"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Earlier SAR studies on indole analogs revealed that a concurrent presence of a butyl chain as a spacer and a 4-fluorophenyl substituent at the indole ring increased the σ<sub>2</sub>R selectivity considerably.<a onclick="showRef(event, 'ref133'); return false;" href="javascript:void(0);" class="ref ref133">(133)</a> On the other hand, the arylpiperidine moiety induced higher σRs affinity than arylpiperazine (<b>45</b> vs <b>44</b>), while their replacement with a spiro[isobenzofuran-l(3<i>H</i>),4′-piperidine] resulted in a more selective compound (siramesine vs <b>44</b> and <b>45</b>). Concerning the σ<sub>1</sub><i>K</i><sub>i</sub>/σ<sub>2</sub><i>K</i><sub>i</sub> selectivity ratio, the best result was obtained by the tropane derivative <b>46</b>.</div><div class="NLM_p">A subsequent study aimed to determine the structural elements leading the σRs affinity and selectivity within the indole analogs class was performed by synthesizing spiro-joined benzofuran, isobenzofuran, and benzopyran piperidine derivatives.<a onclick="showRef(event, 'ref109'); return false;" href="javascript:void(0);" class="ref ref109">(109)</a> Accordingly, two major critical features were found: (i) larger lipophilic <i>N</i>-substituents at the spiro-joined isobenzofuran ring promoted the σ<sub>2</sub>R affinity (H < Me < Et < <i>i</i>-Pr < <i>n</i>-Pr < <i>n</i>-Bu < (CH<sub>2</sub>)<sub>4</sub>Ph); and (ii) a substituent at the benzene ring of the spiropiperidine system greatly affected the σ<sub>1</sub>R/σ<sub>2</sub>R ratio (<i>i</i>-Pr < Me < 4-CF<sub>3</sub> < 4-<i>F</i> < 7-F), as exemplified by <b>47</b>, while changing in the geometry of the spiro-system (e.g., benzofuran and benzopyran) decreased the σ<sub>2</sub>R affinity. Finally, exchanging the isobenzofuran portion of siramesine with the thioisobenzofuran moiety further increased the σ<sub>2</sub>R selectivity (siramesine vs <b>48</b>).</div><div class="NLM_p">Niso et al. described the development of novel σ<sub>2</sub>R agonists as possible antitumor agents in multidrug-resistant cancers.<a onclick="showRef(event, 'ref158'); return false;" href="javascript:void(0);" class="ref ref158">(158)</a> The newly synthesized compounds possessed different and heterogeneous scaffolds, such as 1-(4-fluorophenyl)-1<i>H</i>-indole, 1<i>H</i>-indole, 5-methoxy-1,2,3,4-tetrahydronaphthalene, and 9<i>H</i>-carbazole, which were selected based on the structure of different reference compounds, for instance, siramesine, PB28, and F281 (<a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">20</a></a>). Also, to combine the structural features probably responsible for high σ<sub>2</sub>R affinity, specific cyclic amine moieties (<a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">20</a></a>) were alternatively connected to the scaffolds forming four different series. Among the indole series, the <i>N</i>-substituted analogs were more selective for the σ<sub>2</sub>R than <i>N</i>-unsubstituted ones (<b>49</b> vs <b>50</b>). Thus, the authors suggested that the preferred σ<sub>1</sub>R affinity observed for indole analogs might be due to an additional hydrogen bond formed between the NH group belonging to the indole and the σ<sub>1</sub>R. These data were consistent with that previously reported by Perregaard et al. On the other hand, the σ<sub>1</sub>R affinity value of siramesine (<i>K</i><sub>i</sub> = 10.5 nM, <a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">20</a></a>) was found to be much higher than discovered initially, causing a tremendous reduction of the σ<sub>1</sub><i>K</i><sub>i</sub>/σ<sub>2</sub><i>K</i><sub>i</sub> selectivity ratio.<a onclick="showRef(event, 'ref158'); return false;" href="javascript:void(0);" class="ref ref158">(158)</a> For the sake of clarity, these inconsistent data are indeed most likely due to the slightly different binding protocols adopted. Similarly, PB28, originally described as a high-preferred σ<sub>2</sub>R agonist (σ<sub>1</sub><i>K</i><sub>i</sub>/σ<sub>2</sub><i>K</i><sub>i</sub> = 40), was found to possess a more significant affinity for the σ<sub>1</sub>R (σ<sub>1</sub><i>K</i><sub>i</sub> = 0.38 nM and σ<sub>2</sub><i>K</i><sub>i</sub> = 0.68 nM). Despite the σ<sub>1</sub>R/σ<sub>2</sub>R mixed profile of PB28, this cyclohexylpiperazine derivative emerged as one of the most potent putative σ<sub>1</sub>R antagonist/σ<sub>2</sub>R agonist known until today, and as we will discuss in the next section, it has been extensively studied both for its biological activity and the SAfiRs as a lead compound.<a onclick="showRef(event, 'ref160'); return false;" href="javascript:void(0);" class="ref ref160">(160)</a> Interestingly, PB28 has been recently tested for its <i>in vitro</i> anti-SARS-CoV-2 activity, and it was found to be more potent and less cardiotoxic than hydroxychloroquine, supporting further studies as a promising pan-viral candidate.<a onclick="showRef(event, 'ref161'); return false;" href="javascript:void(0);" class="ref ref161">(161)</a></div><figure id="fig20" data-index="20" class="article__inlineFigure"><h2 class="fig-label">Figure 20</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/medium/jm0c02265_0020.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/large/jm0c02265_0020.jpeg" id="gr20" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 20. General structure and σRs binding profile of siramesine-related derivatives.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/large/jm0c02265_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02265&amp;id=fig20"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Compound <b>49</b> (<a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig20" id="" class=" internalNav">20</a></a>), a siramesine analog, displayed notable σ<sub>2</sub>R selectivity over the σ<sub>1</sub>R subtype as well as significant antiproliferative activity in human breast cancer cells, either sensitive or resistant to doxorubicin (EC<sub>50</sub> = 17.8 and 21.8 μM, in MCF-7 and MCF-7/dox, respectively). Furthermore, <b>49</b> interacted with P-gp stronger than siramesine (EC<sub>50</sub> = 0.21 and 1.41 μM, respectively) and restored the antitumor activity of doxorubicin after co-administration with it, suggesting efficacy in cells with P-gp-induced resistance.<a onclick="showRef(event, 'ref158'); return false;" href="javascript:void(0);" class="ref ref158">(158)</a></div><div class="NLM_p">In 2015, Xie et al. reported the synthesis, SAfiRs, and antiproliferative activity of a series of indole-based σ<sub>2</sub>R ligands derived from siramesine.<a onclick="showRef(event, 'ref159'); return false;" href="javascript:void(0);" class="ref ref159">(159)</a> To develop new σ<sub>2</sub>R ligands and find valuable radiotracers for tumor imaging, the authors applied three different modifications to the siramesine’s structure (<b>51</b>–<b>53</b>, <a data-tab="pane-pcw-Figures" href="#fig21" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig21" id="" class=" internalNav">21</a></a>). Notably, both the spiro-joined isobenzofuran and the indole <i>N</i>-substitution regions of siramesine were explored by replacing them with different preferred σRs cyclic amines, including 5,6-dimethoxyisoindoline (<b>51</b>), 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline (<b>52</b>), 4-phenylpiperidine-4-carbonitrile (<b>53</b>), and different fluoroalkoxy-phenyl-piperazines (not shown), or with a 2-fluoroalkyl group (<b>52</b>) and a <i>N</i>-(4-iodophenyl) group (<b>53</b>), respectively. Subsequently, both portions were concurrently modified, like in <b>53</b>. SARs performed on this series were consistent with previously reported studies, confirming the critical role of both the σ<sub>2</sub>R-preferred cyclic amine motif and the <i>N</i>-(4-fluorophenyl)indole scaffold to increase the σ<sub>2</sub>R affinity and selectivity. On the other hand, a consistent discrepancy in the σ<sub>2</sub><i>K</i>i values with those reported by Niso et al. was observed for compound <b>49</b> (σ<sub>1</sub><i>K</i><sub>i</sub> = 530.8 nM and σ<sub>2</sub><i>K</i><sub>i</sub> = 49.2 nM vs σ<sub>1</sub><i>K</i><sub>i</sub> = 1,390 nM and σ<sub>2</sub><i>K</i><sub>i</sub> = 5.34 nM) which resulted in a substantial loss of subtype selectivity (σ<sub>1</sub><i>K</i><sub>i</sub>/σ<sub>2</sub><i>K</i><sub>i</sub> = 260 vs 11). Nevertheless, compounds <b>49</b> and its 5,6-dimethoxyisoindolineanalog (<b>51</b>) (σ<sub>1</sub><i>K</i><sub>i</sub> = 255.6 nM and σ<sub>2</sub><i>K</i><sub>i</sub> = 53.8 nM) were tested in the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay to evaluate their antiproliferative activity in DU145, MCF-7, and C6 cancer cells along with siramesine used as a reference compound. Both compounds showed EC<sub>50</sub> values comparable to that of siramesine in all the tested cell lines, with the highest antiproliferative activity exerted by <b>51</b> in MCF-7 cells (EC<sub>50</sub> = 17.0 μM). Moreover, cell cycle analysis using flow cytometry revealed that <b>49</b>, <b>51</b>, and siramesine induced G<sub>1</sub> phase cell cycle arrest in DU145 cells.</div><figure id="fig21" data-index="21" class="article__inlineFigure"><h2 class="fig-label">Figure 21</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/medium/jm0c02265_0021.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/large/jm0c02265_0021.jpeg" id="gr21" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 21. General structure and σRs binding profile of siramesine-related derivatives <b>51</b>, <b>52</b>, and <b>53</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/large/jm0c02265_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02265&amp;id=fig21"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Very recently, compound <b>49</b>, with other two low-affinity σ<sub>2</sub>R ligands (not shown), was reported as the first-in-class multidrug resistance-associated protein 1 (MRP1) modulator acting as a collateral sensitizer.<a onclick="showRef(event, 'ref162'); return false;" href="javascript:void(0);" class="ref ref162">(162)</a> Higher cytotoxicity effects were observed in the MRP1 overexpressing cells (i.e., MDCK/MRP1 and A549/DX) than in the wild-type counterparts, supporting the involvement of the collateral sensitivity-mediated activity. Furthermore, co-administration of <b>49</b> with cisplatin in a A549/DX xenografts model showed a significant reduction in tumor growth, while the single-agent administration did not.<a onclick="showRef(event, 'ref162'); return false;" href="javascript:void(0);" class="ref ref162">(162)</a></div></div><div id="sec3_2_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i18" class="anchor-spacer"></div><h4 class="article-section__title" id="_i18">3.2.3.  Cycloalkyl Amines with Flexible Alkyl Linker: Substituted Piperazine/Piperidine and Tetrahydroisoquinoline Derivatives</h4><div id="sec3_2_3_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i19" class="anchor-spacer"></div><h5 class="article-section__title" id="_i19">3.2.3.1.  Cyclohexylpiperazine and Cyclohexylpiperidine Analogs</h5><div class="NLM_p">Cyclohexylpiperazine derivatives represent a broad set of well-studied σRs ligands, with PB28 (<a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig17" id="" class=" internalNav">17</a></a>) being the prototype compound for this class. This tetralin-based σR-preferred ligand has been extensively investigated for its anticancer properties,<a onclick="showRef(event, 'ref36 ref41 ref163'); return false;" href="javascript:void(0);" class="ref ref36 ref41 ref163">(36,41,163)</a> and many PB28 related analogs were prepared over the past years.<a onclick="showRef(event, 'ref164'); return false;" href="javascript:void(0);" class="ref ref164">(164)</a> Particularly, specific modifications of the PB28 structure, aiming to obtain optimal log <i>P</i> and log <i>D</i> values to reduce nonspecific binding and improve cancer cells intake of new analogs, were performed.<a onclick="showRef(event, 'ref103'); return false;" href="javascript:void(0);" class="ref ref103">(103)</a> With this in mind, in 2011, Abate et al. synthesized new PB28 analogs with reduced lipophilicity by introducing a polar functional group (i.e., amine, amide, or ether group) in the propylene linker or by replacing the tetralin with a chromane nucleus (<a data-tab="pane-pcw-Figures" href="#fig22" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig22" id="" class=" internalNav">22</a></a>). In addition, pure enantiomers were obtained whenever possible, and a naphthalene ring instead of the tetralin one was used to evaluate the effect of the chirality on the σ<sub>2</sub>R affinity. Unfortunately, none of the newly less lipophilic analogs showed better affinity or selectivity than PB28. Compound <b>54</b> (<a data-tab="pane-pcw-Figures" href="#fig22" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig22" id="" class=" internalNav">22</a></a>) displayed the best binding profile through the series and suitable lipophilicity to enter tumor cells. However, <b>54</b> did not exert antiproliferative activity in SK-N-SH cells, while it showed specific activity toward the P-gp efflux pump (EC<sub>50</sub> = 8.1 μM), suggesting a few limitations in its further development as a diagnostic or therapeutic agent.</div><figure id="fig22" data-index="22" class="article__inlineFigure"><h2 class="fig-label">Figure 22</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/medium/jm0c02265_0022.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/large/jm0c02265_0022.jpeg" id="gr22" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 22. General structure of PB28 analogs with reduced lipophilicity and σRs binding profile of compound <b>54</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/large/jm0c02265_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02265&amp;id=fig22"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Interestingly, these results, along with previously reported ones from the same authors,<a onclick="showRef(event, 'ref165'); return false;" href="javascript:void(0);" class="ref ref165">(165)</a> supported the fact that lipophilicity played a pivotal role in the σ<sub>2</sub>R activity. In contrast, the enantioselectivity had only a marginal effect on receptor subtypes interactions. Based on σRs binding data and the extensive modifications performed on PB28 structure (<b>55</b>–<b>58</b> and PB221, <a data-tab="pane-pcw-Figures" href="#fig23" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig23" id="" class=" internalNav">23</a></a>), the following SAfiRs can be summarized: (i) introduction of a polar functional group either in the propylene linker or in the tetralin scaffold of PB28 reduced the σ<sub>2</sub>R affinity (PB28 vs <b>55</b> and <b>56</b>); (ii) piperazine ring replacement or opening led to decrease of the σRs affinity (PB28 vs PB221); (iii) modification of the <i>N</i>-atom connected to the cyclohexyl group (e.g., substitution, quaternization or incorporation into an amide function) mainly affected the affinity at the σ<sub>1</sub>R subtype (PB28 vs <b>57</b>); however, the presence of both basic <i>N</i>-atoms is needed for higher σ<sub>2</sub>R affinity; and (iv) a cyclohexyl group as a substituent at the piperazine ring is optimal for the σRs affinity (PB28 vs <b>58</b>).</div><figure id="fig23" data-index="23" class="article__inlineFigure"><h2 class="fig-label">Figure 23</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/medium/jm0c02265_0023.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/large/jm0c02265_0023.jpeg" id="gr23" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 23. Representative structural modification for PB28 analogs on propylene linker and tetralin scaffold (<b>55</b> and <b>56</b>), piperazine ring (PB221), basic <i>N</i>-atom (<b>57</b>), piperazine substitution (<b>58</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/large/jm0c02265_0023.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02265&amp;id=fig23"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The preclinical efficacy toward pancreatic tumor models of PB28-related compounds, including F281 and PB221, was investigated by Pati et al.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> The cytotoxic effect after 24 h exposure to the tested compounds was assessed on different human and mouse pancreatic cancer cell lines (i.e., MIAPaCa-2, BxPC3, AsPC-1, Panc-1 and Panc02, KP-2, and KCKO, respectively). Heterogeneous outcomes on cell viability were observed in a cancer cell lines manner. For example, the cytotoxic effect was more significant for specific cell lines such as Panc02, while AsPC1 and Panc-1 resulted in the most resistance among the selected cell lines. Among the tested ligands, both F281 and PB221 displayed the best <i>in vitro</i> antiproliferative profile toward the cells panel. A significant increase in caspase-3 <i>in vitro</i> activity was detected for PB221, supporting the caspase-dependent apoptotic pathway mediated by its σ<sub>2</sub>R activity. Also, a substantial increase in mitochondrial superoxide radical production was observed. On the other hand, generally, a poor match between <i>in vitro</i> and <i>in vivo</i> efficacy occurred, except for daily treatment with PB28, which produced a similar <i>in vivo</i> effect to that of gemcitabine alone. To justify these results, the authors suggested the formation of active metabolites for the most potent compounds. However, no metabolic stability studies were performed to support this speculation.</div><div class="NLM_p last">Very recently, the antitumor effect of the 4-cyclohexylpiperidine derivative PB221 on an anaplastic astrocytoma tumor model has been explored.<a onclick="showRef(event, 'ref79'); return false;" href="javascript:void(0);" class="ref ref79">(79)</a> To pursue this goal, both the murine brain tumor cell line ALTS1C1 and the murine pancreatic cell line UN-KC6141 were initially used to examine the compound’s cytotoxic properties. The IC<sub>50</sub> values of PB221 were found to be 10.61 μM and 13.13 μM for ALTS1C1 and UN-KC6141 cell lines, respectively. However, α-tocopherol (but not <i>N</i>-acetylcysteine) counteracted these effects, suggesting the involvement of mitochondrial superoxide production.<a onclick="showRef(event, 'ref79'); return false;" href="javascript:void(0);" class="ref ref79">(79)</a> Besides, <i>in vivo</i> studies performed on C57BL/6 J mice showed that PB221 delayed tumor growth up to 36% compared to the control and increased the survival time from 26 to 31 days in the orthotopic tumor model. Interestingly, PB221 was well tolerated at the tested dose (1 mg/mouse/injection), showing similar side effects to the approved drug Temozolomide.</div></div><div id="sec3_2_3_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i20" class="anchor-spacer"></div><h5 class="article-section__title" id="_i20">3.2.3.2.  <i>N</i>-(4-Fluorophenyl)piperazine Analogs</h5><div class="NLM_p">McCurdy and co-workers carried out extensive research on developing selective σ<sub>2</sub>R probes to elucidate the receptor’s functional roles in several medical conditions, including cancer.<a onclick="showRef(event, 'ref51 ref55 ref138'); return false;" href="javascript:void(0);" class="ref ref51 ref55 ref138">(51,55,138)</a><a onclick="showRef(event, 'ref112 ref166 ref167'); return false;" href="javascript:void(0);" class="ref ref112 ref166 ref167">(112,166,167)</a> Notably, in 2015, Nicholson et al. reported the pharmacological characterization of a σ<sub>2</sub>R-preferred ligand bearing the <i>N</i>-(4-fluorophenyl)piperazine as a cyclic amine moiety (CM572, <a data-tab="pane-pcw-Figures" href="#fig24" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig24" id="" class=" internalNav">24</a></a>).<a onclick="showRef(event, 'ref166'); return false;" href="javascript:void(0);" class="ref ref166">(166)</a> This new compound was initially developed within a set of isothiocyanate analogs of SN79 (<a data-tab="pane-pcw-Figures" href="#fig24" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig24" id="" class=" internalNav">24</a></a>), a well-characterized mixed σ<sub>1</sub>R/σ<sub>2</sub>R antagonist (σ<sub>1</sub><i>K</i><sub>i</sub> = 27 nM, and σ<sub>2</sub><i>K</i><sub>i</sub> = 7 nM). To obtain irreversible σ<sub>2</sub>R binding, the authors incorporated the isothiocyanate group at the 6-position of the 1,3-benzoxazol-2(3<i>H</i>)-one scaffold. Furthermore, the introduction of the 6-isothiocyanate moiety (CM572) instead of the 6-acetyl group (SN79) was detrimental for the σ<sub>1</sub>R binding, with a consequent increase of the σ<sub>2</sub>R selectivity (σ<sub>1</sub><i>K</i><sub>i</sub>/σ<sub>2</sub><i>K</i><sub>i</sub> = 685, <a data-tab="pane-pcw-Figures" href="#fig24" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig24" id="" class=" internalNav">24</a></a>). Interestingly, CM572 showed a dose-dependent calcium response in a neuroblastoma cancer cell line (SK-N-SH) at higher doses, supporting its partial agonist properties at the σ<sub>2</sub>R. Subsequently, the cytotoxicity of CM572 was evaluated against three different cancer cell lines (i.e., SK-N-SH, PANC-1, and MCF-7) as well as toward normal cells such as primary epidermal melanocytes and human mammary epithelial cells. As a result, the cytotoxic effect for CM572 was higher in cancer cells than normal cells, significantly CM572 showed to induce dose-dependent cell death (EC<sub>50</sub> = 7.6 μM) after 24 h treatment of SK-N-SH cells.<a onclick="showRef(event, 'ref166'); return false;" href="javascript:void(0);" class="ref ref166">(166)</a></div><figure id="fig24" data-index="24" class="article__inlineFigure"><h2 class="fig-label">Figure 24</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/medium/jm0c02265_0024.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/large/jm0c02265_0024.jpeg" id="gr24" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 24. Chemical structure and σRs binding profile of <i>N</i>-(4-fluorophenyl)piperazine derivatives.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/large/jm0c02265_0024.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02265&amp;id=fig24"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The same research team investigated the non-apoptotic and stimulatory effects on glycolytic cellular metabolism exerted by some of their σ<sub>2</sub>R selective ligands. In particular, based on the pharmacological characterization of compound CM764, a new metabolic regulatory function for σ<sub>2</sub>R was proposed. The novel benzoxazolone analog of SN79, which differed from the parent compound only in the amino group at 2-position of the 4-fluorophenylpiperazine moiety (<a data-tab="pane-pcw-Figures" href="#fig24" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig24" id="" class=" internalNav">24</a></a>), was initially assessed in a radioligand binding competition assay, revealing 25-fold selectivity over the σ<sub>1</sub>R with an improvement in the σ<sub>2</sub>R affinity (CM764 vs SN79). Interestingly, CM764 increased the MTT reduction in SK-N-SH neuroblastoma cells without inducing changes in cell viability or cell proliferation. In addition, the increase in MTT reduction was partially or entirely blocked by different σ<sub>2</sub>R antagonists, suggesting a σ<sub>2</sub>R-mediated mechanism. Moreover, the overall stimulatory effect included an increased level of NAD<sup>+</sup>/NADH and ATP, a reduction in ROS, and an increment of both the hypoxia-inducible factor 1α and the vascular endothelial growth factor levels. Altogether, the data suggested that σ<sub>2</sub>R ligands with different functional profiles could modulate dual cellular pathways (death vs survival).<a onclick="showRef(event, 'ref112'); return false;" href="javascript:void(0);" class="ref ref112">(112)</a></div><div class="NLM_p">In a more recent study, the divergent cytotoxic and metabolically stimulative effects of <i>N</i>-(4-fluorophenyl)piperazines were further examined.<a onclick="showRef(event, 'ref167'); return false;" href="javascript:void(0);" class="ref ref167">(167)</a> Also, the structural determinants required to design selective σ<sub>2</sub>R with predicted dual functions were analyzed. The tested series encompassed σR ligands structurally related to compounds CM572 and SN79 (included), where single-element variations at the 6-position of the 1,3-benzoxazol-2(3<i>H</i>)-one, 3-methyl-1<i>H</i>-benzimidazol-2-one, and 1,3-benzothiazol-2(3<i>H</i>)-one heterocyclic systems were applied (CM458, WA403, and WA435, <a data-tab="pane-pcw-Figures" href="#fig24" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig24" id="" class=" internalNav">24</a></a>). Compound CM458 bearing a nitro functional group at the 6-position of the benzoxazolone ring stood out for its subnanomolar affinity at the σ<sub>2</sub>R (<i>K</i><sub>i</sub> = 0.56 nM), while the 5-amino-3-methyl-benzimidazolone analog WA403 showed the best selectivity ratio (σ<sub>1</sub><i>K</i><sub>i</sub>/σ<sub>2</sub><i>K</i><sub>i</sub> = 167) among the series. Generally, an isothiocyanate group as a substituent reduced the σ<sub>1</sub>R affinity, thus increasing the σ<sub>2</sub>R selectivity (CM572 and WA435 vs SN79, <a data-tab="pane-pcw-Figures" href="#fig24" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig24" id="" class=" internalNav">24</a></a>). However, for the benzothiazolone analog WA435, the loss of σ<sub>1</sub>R affinity was less remarkable. Notably, the new SN79 analogs were at least 25-fold more selective for the σ<sub>2</sub>R than the parent compound. Concerning the divergent effects elicited by <i>N</i>-(4-fluorophenyl)piperazine analogs, the following SARs were found: (i) introduction of the 6-isothiocyanate group, regardless of heterocycle, potently induced programmed cell death most likely due to the irreversible receptor binding; (ii) substitution at the 6-position with acetyl, nitro, amino, or fluorine did not produce a significant cytotoxic effect; therefore, the presence of a highly electron-withdrawing group is not sufficient to obtain cytotoxicity; and (iii) changing in the heterocycle system was not decisive for the divergent effect. Finally, other non-isothiocyanate derivatives, including SN79, possibly acting as putative σ<sub>2</sub>R antagonists, were tagged as “neutral” since they produced neither programmed cell death nor metabolic stimulation.<a onclick="showRef(event, 'ref167'); return false;" href="javascript:void(0);" class="ref ref167">(167)</a></div><div class="NLM_p last">An interesting aspect of the SARs studies by Nicholson et al. is the proposed irreversible binding to the σ<sub>2</sub>R for the 6-isothiocyanate derivatives which is possibly responsible for their cytotoxic properties. This effect on cell viability has been examined by extensive washing of SK-N-SH neuroblastoma cells after an acute exposure with the tested compounds followed by an incubation period with fresh media. Particularly, the 6-isothiocyanate derivatives might mediate the irreversible binding via covalent bond formation with specific amino acid residues bearing a nucleophilic group (i.e., serine and cysteine) within the σ<sub>2</sub>R binding pocket. From our standpoint, an integrated approach involving the synthesis of a larger set of various properly substituted derivatives (e.g., Michael acceptors) and <i>in silico</i> molecular modeling studies might help to define the exact mechanism of the irreversible binding mode.</div></div><div id="sec3_2_3_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i21" class="anchor-spacer"></div><h5 class="article-section__title" id="_i21">3.2.3.3.  6,7-Dimethoxy-1,2,3,4-tetrahydroisoquinoline Analogs</h5><div class="NLM_p">Similar to the <i>N</i>-cyclohexylpiperazine and the <i>N</i>-(4-fluorophenyl)piperazine, the 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline moiety has been extensively used as a suitable σ<sub>2</sub>R-preferred cyclic amine fragment to develop selective σ<sub>2</sub>R ligands. To this extent, 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolinoalkyl benzamide derivatives (general structure, <a data-tab="pane-pcw-Figures" href="#fig25" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig25" id="" class=" internalNav">25</a></a>) can be considered the most representative σ<sub>2</sub>R ligands prototype, even though Mach et al. initially developed them as a set of mixed dopamine receptor D<sub>3</sub> and σ<sub>2</sub>R ligands.<a onclick="showRef(event, 'ref168'); return false;" href="javascript:void(0);" class="ref ref168">(168)</a> Indeed, since their discovery, this specific class of conformationally flexible amines showed high affinities and attractive selectivity for σ<sub>2</sub>R, making them useful chemical probes for imaging the σ<sub>2</sub>R in tumors with PET.<a onclick="showRef(event, 'ref76 ref169'); return false;" href="javascript:void(0);" class="ref ref76 ref169">(76,169)</a> A few examples of early developed 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline analogs possessing a flexible benzamide scaffold (<b>59</b>–<b>64</b>) are depicted in <a data-tab="pane-pcw-Figures" href="#fig25" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig25" id="" class=" internalNav">25</a></a>.<a onclick="showRef(event, 'ref136 ref168'); return false;" href="javascript:void(0);" class="ref ref136 ref168">(136,168)</a> SARs studies on this first set of ligands elucidated the structural features required for high σ<sub>2</sub>R affinity and selectivity. The introduction of the 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline gave superb selectivity (σ<sub>1</sub><i>K</i><sub>i</sub>/σ<sub>2</sub><i>K</i><sub>i</sub> = 1573) with a considerable reduction of binding with the dopamine receptors (<b>59</b>, <a data-tab="pane-pcw-Figures" href="#fig25" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig25" id="" class=" internalNav">25</a></a>). Alkyl chain shortening, from four to two methylene units, did not affect the σ<sub>2</sub>R affinity (<b>59</b> vs <b>60</b>). Similarly, removing the methoxy group at the 3-position of the benzamide ring did not significantly reduce the σ<sub>2</sub>R affinity nor the selectivity (<b>61</b> vs <b>59</b> and <b>60</b>). The introduction of methyl instead of bromo group was highly tolerated (<b>62</b> vs <b>61</b>). Regarding the 1,2,3,4-tetrahydroisoquinoline moiety, fusing methylene-, ethylene-, and propylenedioxy rings onto the tetrahydroisoquinoline ring was detrimental for both the affinity and selectivity at the σ<sub>2</sub>R (<b>63</b> vs <b>59</b>). Furthermore, the tetrahydroisoquinoline ring-opening led to an ultimate loss of affinity for the σ<sub>2</sub>R (<b>64</b> vs <b>59</b>).<a onclick="showRef(event, 'ref136 ref168'); return false;" href="javascript:void(0);" class="ref ref136 ref168">(136,168)</a></div><figure id="fig25" data-index="25" class="article__inlineFigure"><h2 class="fig-label">Figure 25</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/medium/jm0c02265_0025.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/large/jm0c02265_0025.jpeg" id="gr25" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 25. Chemical structure and σRs binding profile of early 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline analogs <b>59</b>–<b>64</b>, reported by Mach and co-workers.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/large/jm0c02265_0025.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02265&amp;id=fig25"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">As an extension of their previous works on selective σ<sub>2</sub>R ligands, Sun et al. synthesized a new series of 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline analogs without the benzamide moiety.<a onclick="showRef(event, 'ref170'); return false;" href="javascript:void(0);" class="ref ref170">(170)</a> In this new series, substituted benzene and quinazolin-4(3<i>H</i>)-one fragments acting as electron-deficient or electron-rich aromatic portions were linked through different alkyl length chains to the 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline moiety (general structures A and B, <a data-tab="pane-pcw-Figures" href="#fig26" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig26" id="" class=" internalNav">26</a></a>). Unlike the quinazolin-4(3<i>H</i>)-one analogs, the new 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline derivatives showed high σ<sub>2</sub>R affinities with a good selectivity ratio (<b>65</b> and <b>66</b>, <a data-tab="pane-pcw-Figures" href="#fig26" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig26" id="" class=" internalNav">26</a></a>). Specifically, the ketone reduction to the corresponding hydroxyl group was broadly tolerated without affecting the affinity and selectivity at the σ<sub>2</sub>R (<b>65</b> vs <b>66</b>). On the other hand, the introduction of an electron-deficient aromatic moiety such as the quinazoline scaffold as a hydrophobic domain led to a decrease of affinity and selectivity (e.g., <b>67</b> vs <b>65</b>). Compound <b>66</b>, possessing an excellent selectivity ratio, produced a cytotoxicity effect toward two different cancer cell lines (EC<sub>50</sub> = 12.50 μM for liver Huh-7, and EC<sub>50</sub> = 14.86 μM for esophagus KYSE-140) similar to that of cisplatin (EC<sub>50</sub> = 15.31 μM and 21.34 μM, respectively). Surprisingly, compound <b>65</b> which shows a close σRs binding profile to analog <b>66</b> did not show any effect, suggesting that the biological activity might not be σ<sub>2</sub>R mediated.</div><figure id="fig26" data-index="26" class="article__inlineFigure"><h2 class="fig-label">Figure 26</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/medium/jm0c02265_0026.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/large/jm0c02265_0026.jpeg" id="gr26" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 26. Chemical structure and σRs binding profile of 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline analogs <b>65</b>–<b>67</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/large/jm0c02265_0026.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02265&amp;id=fig26"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Very recently, Xie et al. further developed the series mentioned above by analyzing the impact of introducing additional methoxy groups to the tetrahydroisoquinoline moiety on the σRs binding profile. In particular, to increase the affinity and selectivity toward the σ<sub>2</sub>R subtypes, the electron-rich 2,3,4,5-tetramethoxytoluene scaffold was used as a hydrophobic portion (general structure, <a data-tab="pane-pcw-Figures" href="#fig27" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig27" id="" class=" internalNav">27</a></a>). The new di- and trimethoxy-substituted tetrahydroisoquinolin-2-alkylphenones showed moderate to high affinity and selectivity for the σ<sub>2</sub>R. Analog <b>68</b> (<a data-tab="pane-pcw-Figures" href="#fig27" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig27" id="" class=" internalNav">27</a></a>), bearing a five methylene linker between the phenone carbonyl portion and the 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline moiety, displayed the highest affinity and selectivity for the σ<sub>2</sub>R among all the benzamide derivatives reported so far (<b>68</b> vs <b>59</b> and <b>65</b>). Replacement of 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline moiety with 5,6,7-trimethoxy- or 6,7,8-trimethoxy-1,2,3,4-tetrahydroisoquinoline moieties led to a decrease in affinity for σ<sub>2</sub>R (<b>68</b> vs <b>69</b> and <b>70</b>). Despite the favorable σRs binding profile, no significant inhibitory effects on MCF-7 cancer cell lines were observed. Indeed, functional studies performed by measuring intracellular calcium concentration allowed their classification as putative σ<sub>2</sub>R antagonists.<a onclick="showRef(event, 'ref171'); return false;" href="javascript:void(0);" class="ref ref171">(171)</a></div><figure id="fig27" data-index="27" class="article__inlineFigure"><h2 class="fig-label">Figure 27</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/medium/jm0c02265_0027.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/large/jm0c02265_0027.jpeg" id="gr27" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 27. Chemical structure and σRs binding profile of 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline analogs <b>68</b>–<b>70</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/large/jm0c02265_0027.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02265&amp;id=fig27"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In 2011, Abate et al. combined the structural determinants (i.e., benzamide scaffold and cyclic amine moieties) of their lead compound PB28 with the highly potent and selective σ<sub>2</sub>R ligands RHM-1 to develop new potential PET radiotracers.<a onclick="showRef(event, 'ref172'); return false;" href="javascript:void(0);" class="ref ref172">(172)</a> Good results in terms of σ<sub>1</sub><i>K</i><sub>i</sub>/σ<sub>2</sub><i>K</i><sub>i</sub> selectivity ratio were obtained by 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline derivatives <b>71</b> and <b>72</b> (<a data-tab="pane-pcw-Figures" href="#fig28" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig28" id="" class=" internalNav">28</a></a>). However, the newly synthesized ligands also interacted with P-gp (e.g., EC<sub>50</sub> = 2.5 μM for <b>72</b>), hence, limiting their further development as PET agents. A similar interaction with P-gp was observed for cyclohexylpiperazine analogs <b>73</b> and <b>74</b> (<a data-tab="pane-pcw-Figures" href="#fig28" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig28" id="" class=" internalNav">28</a></a>), which also showed higher binding at the σ<sub>1</sub>R with a parallel loss of σ<sub>2</sub>R selectivity. These results are consistent with recent σ<sub>1</sub>R molecular models developed by Niso et al.<a onclick="showRef(event, 'ref173'); return false;" href="javascript:void(0);" class="ref ref173">(173)</a> which showed that the two methoxy substituents belonging to the tetrahydroisoquinoline ring might be placed in a sterically hindered region within the secondary hydrophobic domain of the σ<sub>1</sub>R binding pocket.</div><figure id="fig28" data-index="28" class="article__inlineFigure"><h2 class="fig-label">Figure 28</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/medium/jm0c02265_0028.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/large/jm0c02265_0028.jpeg" id="gr28" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 28. Chemical structure and σRs binding profile of compounds <b>71</b>–<b>75</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/large/jm0c02265_0028.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02265&amp;id=fig28"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Interestingly, an intramolecular hydrogen bond between the 2-methoxy substituent and the <i>N</i>-atom of the benzamide group was proposed (general structure, <a data-tab="pane-pcw-Figures" href="#fig28" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig28" id="" class=" internalNav">28</a></a>), suggesting a bicyclic-like active conformation for this set of derivatives.<a onclick="showRef(event, 'ref172'); return false;" href="javascript:void(0);" class="ref ref172">(172)</a> Indeed, this hypothesis was corroborated by the σRs binding profile of the 3,4-dihydroisoquinolin-1(2<i>H</i>)-one derivative <b>75</b> (<a data-tab="pane-pcw-Figures" href="#fig28" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig28" id="" class=" internalNav">28</a></a>), in which the above-mentioned intramolecular bond has been mimicked by a rigid ring.<a onclick="showRef(event, 'ref172'); return false;" href="javascript:void(0);" class="ref ref172">(172)</a></div><div class="NLM_p">Therefore, in a subsequent study, Niso et al. further investigated the role of bicyclic-preferred conformation proposed for flexible benzamides as a suitable hydrophobic portion to target the σ<sub>2</sub>R.<a onclick="showRef(event, 'ref174'); return false;" href="javascript:void(0);" class="ref ref174">(174)</a> The authors synthesized 3,4-dihydroquinolin-(1<i>H</i>)2-one and 1,2,3,4-tetrahydroquinoline derivatives along with flexible anilide and aniline analogs linked to the 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolinoalkyl portion. Also, considering the good σRs binding profile and the appropriate lipophilicity showed by previously developed substituted 3,4-dihydroisoquinolin(2<i>H</i>)1-one derivatives (<b>76</b> and <b>77</b>, <a data-tab="pane-pcw-Figures" href="#fig29" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig29" id="" class=" internalNav">29</a></a>),<a onclick="showRef(event, 'ref175'); return false;" href="javascript:void(0);" class="ref ref175">(175)</a> the introduction of a 5-methoxy or 6-fluoro group in the new scaffolds was examined. Binding studies showed that 3,4-dihydroquinolin-(1<i>H</i>)2-one (<b>78</b>) and 1,2,3,4-tetrahydroquinoline (<b>79</b>) derivatives exhibited excellent affinity and selectivity for the σ<sub>2</sub>R, while the corresponding anilide (<b>80</b>) and aniline (<b>81</b>) analogs generally had a worse σRs binding profile (<a data-tab="pane-pcw-Figures" href="#fig29" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig29" id="" class=" internalNav">29</a></a>). Notably, anilide derivatives showed a lower binding for the σ<sub>2</sub>R than the corresponding anilines, probably due to the lack of partial rigidification that might occur in anilines because of the lone pair conjugation of the <i>N</i>-atom with the benzene ring with a resulting resembling bicyclic framework.<a onclick="showRef(event, 'ref174'); return false;" href="javascript:void(0);" class="ref ref174">(174)</a> These data confirmed that a rigid bicyclic structure as a hydrophobic moiety was optimal for both affinity and selectivity for the σ<sub>2</sub>R. Surprisingly, none of the compounds exerted antiproliferative activity in human breast adenocarcinoma MCF-7 cells. However, since the modest interaction with the P-gp (EC<sub>50</sub> = 2.13 μM), appropriate lipophilicity (clogP = 3.94), and the presence of easily radiolabeling functions (i.e., 3-methoxy groups) of <b>79</b>, the authors suggested its further development as a possible PET radiotracer.</div><figure id="fig29" data-index="29" class="article__inlineFigure"><h2 class="fig-label">Figure 29</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/medium/jm0c02265_0029.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/large/jm0c02265_0029.jpeg" id="gr29" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 29. Chemical structure and σRs binding profile of compounds <b>76</b>–<b>81</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/large/jm0c02265_0029.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02265&amp;id=fig29"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_2_3_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i22" class="anchor-spacer"></div><h5 class="article-section__title" id="_i22">3.2.3.4.  3-Alkoxyisoxazole Analogs</h5><div class="NLM_p">Very recently, small molecules characterized by the presence of the 3-alkoxyisoxazole moiety have been designed and evaluated for their potential binding properties toward the σRs.<a onclick="showRef(event, 'ref176'); return false;" href="javascript:void(0);" class="ref ref176">(176)</a> This chemical scaffold was identified from the superimposition of the pharmacophoric elements required for a righteous binding to both σ<sub>1</sub> and α4β2 nicotinic receptors.<a onclick="showRef(event, 'ref177'); return false;" href="javascript:void(0);" class="ref ref177">(177)</a> Compound <b>82</b> (<a data-tab="pane-pcw-Figures" href="#fig30" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig30" id="" class=" internalNav">30</a></a>) was detected as a σ<sub>1</sub>R ligand with high affinity and selectivity over the σ<sub>2</sub>R subtype. Structural modifications of compound <b>82</b> were conducted to switch selectivity toward the σ<sub>2</sub>R and find potential anticancer compounds. The general structure of the developed 3-alkoxyisoxazole derivatives of <b>82</b> is depicted in <a data-tab="pane-pcw-Figures" href="#fig30" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig30" id="" class=" internalNav">30</a></a>. Insertion of electron-withdrawing substituents (fluorine, chlorine, trifluoromethyl) on the aryloxymethyl group linked to the 5-position of the isoxazole ring led to increased affinity values for the σ<sub>2</sub>R subtype. Particularly, <i>meta</i>-fluorine and <i>meta</i>-trifluoromethyl substitutions were preferred concerning substitutions in <i>ortho</i> and <i>para</i> positions. The trifluoromethyl substitution was more effective with a 15-fold increased σ<sub>2</sub><i>K</i><sub>i</sub> (data not shown) with respect to <b>82</b>. On the contrary, electron-donating substituents such as a methoxy group had minor effects on the affinity with only a 2-fold increased affinity for the σ<sub>2</sub>R. To further evaluate halogen substituents’ effects, double substitutions were performed, and optimal results were achieved with 3,4-dichloro-substituted aryl rings (compound <b>83</b>), with an increment of affinity of 28-fold compared to <b>82</b> (46.5 nM vs 1312 nM, respectively). N-methylation of the pyrrolidine ring of <b>82</b> slightly ameliorated the affinity for the σ<sub>2</sub>R, whereas replacement of the 2-pyrrolidine ring with its 3-pyrrolidine isomer led to a 2-fold improvement of σ<sub>2</sub><i>K</i><sub>i</sub> values and a substantial reduction of σ<sub>1</sub>R affinity for <b>82</b> (data not shown). Retention of the electron-withdrawing substituents on the aromatic ring and insertion of a bulky aminoalkyl chain on the <i>N</i>-atom of 2-pyrrolidine gave compounds <b>84</b>–<b>86</b>, with an ameliorant of σ<sub>2</sub><i>K</i><sub>i</sub> values from 4.5- to 6.0-fold when compared to compound <b>83</b>. Specifically, the best σ<sub>2</sub><i>K</i><sub>i</sub> value for compounds with general structure A (<a data-tab="pane-pcw-Figures" href="#fig30" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig30" id="" class=" internalNav">30</a></a>) was obtained when the alkyl chain was made of four carbon atoms (compound <b>86</b>, σ<sub>2</sub><i>K</i><sub>i</sub> = 7.92 nM). Derivatives <b>87</b>–<b>90</b> (general structure B, <a data-tab="pane-pcw-Figures" href="#fig30" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig30" id="" class=" internalNav">30</a></a>) were obtained by removing the pyrrolidine ring in favor of cycloalkylaminoethoxy moieties. Better results were obtained with unsubstituted six-membered rings. Indeed, the authors pointed out that smaller rings favor stronger interactions with the σ<sub>1</sub>R. On the other hand, more oversized rings increase the σ<sub>2</sub> affinity and selectivity (compare <b>87</b> vs <b>82</b>). These results indicated that steric bulk plays an important role in the proper binding to the σ<sub>2</sub>R for this class of compounds. Starting from <b>87</b> (σ<sub>2</sub><i>K</i><sub>i</sub> = 22.8 nM), favorable substitutions on the aromatic ring were repeated (i.e., insertion of electron-withdrawing substituents) in order to further validate the results previously discussed. As expected, insertion of a 3-trifluoromethyl group or a 3,4-dichloro substitution on <b>87</b> determined a strong increase of affinity for the σ<sub>2</sub>R getting one-digit values ranging from 1.81 nM (compound <b>88</b>) to 2.53 nM (compound <b>89</b>), while methylation of the nitrogen atom of the cycloalkylaminoethoxy group slightly reduced the affinity (compound <b>90</b>, 4.44 nM).</div><figure id="fig30" data-index="30" class="article__inlineFigure"><h2 class="fig-label">Figure 30</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/medium/jm0c02265_0030.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/large/jm0c02265_0030.jpeg" id="gr30" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 30. Chemical structures of 3-alkoxyisoxazoles <b>82</b>–<b>90</b> and their σRs binding profile.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/large/jm0c02265_0030.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02265&amp;id=fig30"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Compounds <b>82</b>–<b>90</b> were tested on two osteosarcoma cancer cell lines (143B and MOS-J cells). Despite their strong σ<sub>2</sub>R affinity, compounds <b>88</b>–<b>90</b> did not show significant cytotoxic properties as well as compounds <b>82</b>–<b>83</b> and <b>87</b>. Interestingly, the bulkier derivatives <b>84</b>–<b>86</b> displayed cytotoxicity in both cell lines, strengthening the previously discussed steric bulk hypothesis. In particular, in the crystal violet assay, compound <b>86</b> exhibited IC<sub>50</sub> values of 0.89 μM and 0.71 μM for 143B and MOS-J cell lines. Compared with siramesine (IC<sub>50</sub> = 1.81 μM and 2.01 μM for 143B and MOS-J), compound <b>86</b> possessed more potent cytotoxic properties. Cytotoxicity measured on healthy cells (human immortalized keratinocytes HaCaT and human normal embryonic liver cells LO2) revealed IC<sub>50</sub> values of 6.47 μM and >10 μM, respectively. Compound <b>86</b> also caused inhibition of colony formation of osteosarcoma 143B cells and interference with the cell cycle reducing the number of cells in the S and G<sub>2</sub>M phases and blocking cells in the G<sub>0</sub>G<sub>1</sub> phase. Cancer cell death induction was confirmed by the annexin V assay, where 33.4% of osteosarcoma cells started apoptosis when a concentration of 5 μM of <b>86</b> was applied. These results did not exclude an eventual involvement of σ<sub>1</sub>Rs in the cytotoxic properties of this class of compounds. Nevertheless, the 3-alkoxyisoxazole chemical scaffold could be further exploited to design novel σ<sub>2</sub>R ligands with augmented anticancer properties.</div></div></div></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i23">4.  Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_87167" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_87167" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">σRs represent a unique class of proteins involved in many physiopathological and pathological roles. Several immunohistochemical and radioligand binding assay studies revealed that both receptor subtypes are overexpressed in several cancer cell lines, suggesting a potential role of these proteins in cancer progression and tumor invasiveness. Moreover, the pharmacological modulation of σRs through small molecules has been proved to be a promising approach for developing novel therapeutics. However, although several studies supported the search for novel compounds targeting σRs to treat cancer, no compounds have reached the clinical phase yet. One of the reasons for this might be related to the heterogeneous and promiscuous biological effects exerted by certain σR ligands in preclinical studies, which are also related to the inconclusive evidence about the molecular role of the σRs in the etiopathogenesis and pathogenesis of cancer. Thus, there is still a need to answer crucial questions concerning the role and the involvement of σRs in tumor biology to reveal the real potential and benefit of the clinical use of σRs ligands in cancer chemotherapy. Indeed, an unambiguous characterization of the biological target is essential to link its perturbation to functional pharmacology. Moreover, several potent ligands, of both σRs subtypes, showed poor pharmacokinetic profiles. This fact hinders their clinical utilization as drugs and allows their use merely as diagnostic or pharmacological tools such as radioligand probes for PET scanning. We believe that this problem could be dealt with using the following strategies: (i) optimizing the ADME properties and the off-target effects, such as hERG binding, during the early stages of drug design; (ii) using computational techniques when available, such as QSAR and toxicity prediction machine learning methods, to estimate the potential adverse effects of the drug candidates; and (iii) repurposing of certain Food and Drug Administration approved CNS drugs which, by definition, have well-established pharmacokinetic and safety profiles. The drug repurposing approach is especially useful in the case of σRs ligands because they already share some pharmacophoric features with other ligands of certain CNS targets such as the opioid and dopamine receptors, which is exemplified by the affinity of pentazocine and haloperidol, respectively, to the σRs.</div><div class="NLM_p">As extensively described in this perspective, tremendous efforts to discover selective σR ligands with antiproliferative properties have been made by medicinal chemists in the last 10 years. These efforts led to the identification of various chemical prototypes; therefore, for a comprehensive overview, a summary of this information has been collected in <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Summary of Chemical Classification, Cancer Cell Lines, and Assays Used for the Biological Evaluation of the Most Representative σR Ligands</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col /></col><col /></col><col /></col><col /></col><col /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">Compound</th><th class="colsep0 rowsep0" align="center">Chemotype</th><th class="colsep0 rowsep0" align="center">Cell line</th><th class="colsep0 rowsep0" align="center">Biological test</th><th class="colsep0 rowsep0" align="center">Reference</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="5">σ<sub>1</sub>R Ligands</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0"><b>1</b></td><td class="colsep0 rowsep0" rowspan="3" valign="middle"><i>N</i>,<i>N</i>-dialkyl and <i>N</i>-alkyl-<i>N</i>-aralkyl fenpropimorph-derivatives</td><td class="colsep0 rowsep0">NCI-H460, DU145, MCF7, SKOV-3, MB-MDA231</td><td class="colsep0 rowsep0" rowspan="3" valign="middle">multiplex cytotoxicity assays</td><td class="colsep0 rowsep0" rowspan="3" valign="middle"><a onclick="showRef(event, 'ref101'); return false;" href="javascript:void(0);" class="ref ref101">(101)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0"><b>2</b></td><td class="colsep0 rowsep0">SKOV-3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0"><b>5</b></td><td class="colsep0 rowsep0">MCF-7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0"><b>13</b>, <b>14</b></td><td class="colsep0 rowsep0">spipethiane derivatives</td><td class="colsep0 rowsep0">MCF-7/ADR</td><td class="colsep0 rowsep0">annexin V-FITC assay, tail-flick assay</td><td class="colsep0 rowsep0"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0"><b>20</b>, <b>21</b></td><td class="colsep0 rowsep0">spirocyclic thienopyran and thienofuran derivatives</td><td class="colsep0 rowsep0">A427</td><td class="colsep0 rowsep0">retinal ganglion assay, capsaicin assay, crystal violet assay, LDH assay</td><td class="colsep0 rowsep0"><a onclick="showRef(event, 'ref83 ref111 ref113 ref178'); return false;" href="javascript:void(0);" class="ref ref83 ref111 ref113 ref178">(83, 111, 113, 178)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0"><b>36</b></td><td class="colsep0 rowsep0">7,9-diazabicyclo[4.2.2]decane derivative</td><td class="colsep0 rowsep0">A427</td><td class="colsep0 rowsep0">crystal violet assay</td><td class="colsep0 rowsep0"><a onclick="showRef(event, 'ref131'); return false;" href="javascript:void(0);" class="ref ref131">(131)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0"><b>ent-38</b>, <b>40</b>, <b>ent-40</b>, <b>ent-41</b>, <b>42</b>, <b>ent-42</b></td><td class="colsep0 rowsep0" rowspan="2" valign="middle">2,5-diazabicyclo[2.2.2]octane derivatives</td><td class="colsep0 rowsep0">A427</td><td class="colsep0 rowsep0" rowspan="2" valign="middle">crystal violet assay, annexin V-FITC assay</td><td class="colsep0 rowsep0" rowspan="2"><a onclick="showRef(event, 'ref132'); return false;" href="javascript:void(0);" class="ref ref132">(132)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0"><b>ent-38</b>, <b>39</b>, <b>ent-41</b>, <b>42</b></td><td class="colsep0 rowsep0">5637</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" colspan="5">σ<sub>2</sub>R Ligands</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0"><b>SWIII-123</b></td><td class="colsep0 rowsep0">granatane derivative</td><td class="colsep0 rowsep0">SKOV-3, CaOV-3, BG-1</td><td class="colsep0 rowsep0">MTS assay</td><td class="colsep0 rowsep0"><a onclick="showRef(event, 'ref146'); return false;" href="javascript:void(0);" class="ref ref146">(146)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0"><b>49</b></td><td class="colsep0 rowsep0" rowspan="2" valign="middle">indole derivatives</td><td class="colsep0 rowsep0">MCF-7, MCF-7/dox, DU145, C6, A549/DX</td><td class="colsep0 rowsep0" rowspan="2" valign="middle">MTT assay, cell cycle analysis</td><td class="colsep0 rowsep0"><a onclick="showRef(event, 'ref158 ref159 ref162'); return false;" href="javascript:void(0);" class="ref ref158 ref159 ref162">(158, 159, 162)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0"><b>51</b></td><td class="colsep0 rowsep0">DU145, MCF-7, C6</td><td class="colsep0 rowsep0"><a onclick="showRef(event, 'ref159'); return false;" href="javascript:void(0);" class="ref ref159">(159)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0"><b>F281</b></td><td class="colsep0 rowsep0">carbazole derivative</td><td class="colsep0 rowsep0">Panc02</td><td class="colsep0 rowsep0">MTT assay</td><td class="colsep0 rowsep0"><a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0"><b>PB221</b></td><td class="colsep0 rowsep0">tetralin derivative</td><td class="colsep0 rowsep0">Panc02, ALTS1C1, UN-KC6141</td><td class="colsep0 rowsep0">MTT assay, caspase-Glo assay</td><td class="colsep0 rowsep0"><a onclick="showRef(event, 'ref36 ref79'); return false;" href="javascript:void(0);" class="ref ref36 ref79">(36, 79)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0"><b>CM572</b>, <b>CM764</b></td><td class="colsep0 rowsep0">1,3-benzoxazol-2(3<i>H</i>)-one derivatives</td><td class="colsep0 rowsep0">SK-N-SH</td><td class="colsep0 rowsep0">MTT assay</td><td class="colsep0 rowsep0"><a onclick="showRef(event, 'ref112 ref166'); return false;" href="javascript:void(0);" class="ref ref112 ref166">(112, 166)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0"><b>66</b></td><td class="colsep0 rowsep0">6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline derivative</td><td class="colsep0 rowsep0">Huh-7, KYSE-140</td><td class="colsep0 rowsep0">CCK8 assay</td><td class="colsep0 rowsep0"><a onclick="showRef(event, 'ref170'); return false;" href="javascript:void(0);" class="ref ref170">(170)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0"><b>86</b></td><td class="colsep0 rowsep0">3-alkoxyisoxazole derivative</td><td class="colsep0 rowsep0">143B, MOS-J</td><td class="colsep0 rowsep0">crystal violet assay, annexin V assay</td><td class="colsep0 rowsep0"><a onclick="showRef(event, 'ref176'); return false;" href="javascript:void(0);" class="ref ref176">(176)</a></td></tr></tbody></table></div></div><div class="NLM_p">It is worth noting that the σ<sub>2</sub>R identity has been established only recently, and no crystal structure has been reported yet. Nevertheless, a variety of new selective σ<sub>2</sub>R ligands have been recently discovered, and the specific overexpression of σ<sub>2</sub>Rs in a broad panel of cancer cell lines has been elucidated. As a result, the potential ability to pinpoint the tumor cells in an early stage of the pathology makes σ<sub>2</sub>R ligands powerful molecular tools exploitable in diagnostics and theranostics. Conversely, the study reported by Zeng et al.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> proved that the cytotoxicity exerted by some well-known σ<sub>2</sub>R ligands, including siramesine and PB28, was independent of the modulation of the σ<sub>2</sub>R. This finding corroborates the hypothesis that multiple unknown targets are likely involved in the observed cytotoxic effect mediated by σ<sub>2</sub>R ligands, making the overall scenario very intriguing. Besides, the recent identification by Abate and co-workers of σ<sub>2</sub>R ligands that promote collateral sensitivity in multidrug resistance cells further supports the hypothesis that a direct correlation between σ<sub>2</sub>Rs modulation and the observed cytotoxicity does not exist. Interestingly, collateral sensitivity is a well-studied phenomenon in cancer research.<a onclick="showRef(event, 'ref179'); return false;" href="javascript:void(0);" class="ref ref179">(179)</a> Thus, the development of new σR ligands which exploit the mechanism of the synthetic lethality to induce selective cytotoxicity is emerging as a new successful strategy in the field.<a onclick="showRef(event, 'ref162'); return false;" href="javascript:void(0);" class="ref ref162">(162)</a></div><div class="NLM_p">Despite the lack of homogeneous evidence of one-to-one correspondence between σRs modulation and cytotoxicity, the involvement of these chaperons as key players in the tumor-supportive cellular machinery has been proved. Recently, Maher et al.<a onclick="showRef(event, 'ref180'); return false;" href="javascript:void(0);" class="ref ref180">(180)</a> described the ability of σRs ligands in regulating the programmed death-ligand 1 (PD-L1) expression and activity in cancer cells, suggesting a novel therapeutic strategy acting on tumor immune microenvironments. Specifically, σ<sub>1</sub>Rs inhibition either by σ<sub>1</sub>R negative modulators or using shRNA-induced PD-L1 autophagic degradation in breast and prostate cancer cells, suggesting the possibility of combining σRs modulators with specific drugs that can induce PD-L1 degradation (e.g., gefitinib), therefore enhancing the antitumor activity.<a onclick="showRef(event, 'ref181'); return false;" href="javascript:void(0);" class="ref ref181">(181)</a> However, the effectiveness of possible drug combinations might be mitigated by undesirable drug interactions and interferences. Alternatively, polypharmacology represents a current paradigm to enhance the efficacy of new anticancer agents.<a onclick="showRef(event, 'ref182 ref183'); return false;" href="javascript:void(0);" class="ref ref182 ref183">(182,183)</a> More specifically, in this case, selected molecular entities having the ability to intercept other validated molecular targets involved in the tumor progression and aggression can be effectively combined with structural determinants belonging to σR ligands to obtain novel multitarget ligands. As an example, Mangiatordi et al.<a onclick="showRef(event, 'ref184'); return false;" href="javascript:void(0);" class="ref ref184">(184)</a> have recently described their perspective on an innovative polypharmacology approach involving the concurrent targeting of cannabinoid receptor subtype 2 (CB<sub>2</sub>R) and σRs for cancer. Particularly, taking advantage of both the common pharmacophoric elements and the anticancer activities of CB<sub>2</sub>R agonists and σRs modulators, the authors proposed the development of molecular hybrids, that is, dual CB<sub>2</sub>R/σR ligands, potentially able to modulate different cancer pathways synergistically.</div><div class="NLM_p last">We expect the interest in the development of σRs ligands to continue for the next few years as tumor diagnostic tools as well as chemotherapeutic agents, perhaps as adjuvant therapies. Moreover, the availability of the σ<sub>1</sub>R crystal structure and the potential crystallization of the σ<sub>2</sub>R in the near future would give momentum to this research field. Finally, we believe that the recent discovery of repurposing some σRs ligands for fighting the early stages of COVID-19 could draw more attention to these biological targets. Altogether, this article represents a comprehensive literature review that might help to provide a reader with a perspective on the development of potent σRs ligands as additional weapons exploitable in anticancer therapy.</div></div><div class="NLM_back"><div class="article_supporting-info" id=""></div><div class="testing" data-doi="10.1021/acs.jmedchem.0c02265" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_03465" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_03465" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mohamed A. Helal</span> - <span class="hlFld-Affiliation affiliation">University
of Science and Technology, Biomedical Sciences Program, Zewail City of Science and Technology, October Gardens, sixth of October, Giza 12578, Egypt</span>; 
    <span class="hlFld-Affiliation affiliation">Medicinal
Chemistry Department, Faculty of Pharmacy, Suez Canal University, Ismailia 41522, Egypt</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#721f1a171e131e32081705131b1e111b060b5c1716075c1715"><span class="__cf_email__" data-cfemail="f29f9a979e939eb2889785939b9e919b868bdc979687dc9795">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sebastiano Intagliata</span> - <span class="hlFld-Affiliation affiliation">Department
of Drug and Health Sciences, University
of Catania, Viale A. Doria 6, 95125 Catania, Italy</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0002-0201-1745" title="Orcid link">https://orcid.org/0000-0002-0201-1745</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#ff8cd196918b9e9893969e8b9ebf8a91969c8bd1968b"><span class="__cf_email__" data-cfemail="d2a1fcbbbca6b3b5bebbb3a6b392a7bcbbb1a6fcbba6">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Antonino N. Fallica</span> - <span class="hlFld-Affiliation affiliation">Department
of Drug and Health Sciences, University
of Catania, Viale A. Doria 6, 95125 Catania, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Valeria Pittalà</span> - <span class="hlFld-Affiliation affiliation">Department
of Drug and Health Sciences, University
of Catania, Viale A. Doria 6, 95125 Catania, Italy</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0003-1856-0308" title="Orcid link">https://orcid.org/0000-0003-1856-0308</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Maria N. Modica</span> - <span class="hlFld-Affiliation affiliation">Department
of Drug and Health Sciences, University
of Catania, Viale A. Doria 6, 95125 Catania, Italy</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0002-6350-931X" title="Orcid link">https://orcid.org/0000-0002-6350-931X</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Loredana Salerno</span> - <span class="hlFld-Affiliation affiliation">Department
of Drug and Health Sciences, University
of Catania, Viale A. Doria 6, 95125 Catania, Italy</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0001-6458-3717" title="Orcid link">https://orcid.org/0000-0001-6458-3717</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Giuseppe Romeo</span> - <span class="hlFld-Affiliation affiliation">Department
of Drug and Health Sciences, University
of Catania, Viale A. Doria 6, 95125 Catania, Italy</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0003-2160-4164" title="Orcid link">https://orcid.org/0000-0003-2160-4164</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Agostino Marrazzo</span> - <span class="hlFld-Affiliation affiliation">Department
of Drug and Health Sciences, University
of Catania, Viale A. Doria 6, 95125 Catania, Italy</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0002-8728-8857" title="Orcid link">https://orcid.org/0000-0002-8728-8857</a></span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="bio" rid="ath1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="biographies">Biographies</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_20842" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_20842" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><figure id="ath1" data-index="31" class="article__inlineFigure"><h2 class="fig-label">Antonino N. Fallica</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02265&amp;id=BIO-d7e5955-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Antonino Nicolò Fallica</b> received his M.S. in Chemistry and Pharmaceutical Technology in July 2018 from the University of Catania under the supervision of Prof. Agostino Marrazzo. He is currently pursuing his Ph.D. in Biotechnology (pharmaceutical curriculum) under the guidance of Prof. Valeria Pittalà at the University of Catania. His research interests focus on medicinal chemistry, with a particular emphasis on the design and synthesis of novel small molecules with potential antitumor properties acting as modulators of the heme oxygenase enzymatic system.</p></figure></div><div class="bio" rid="ath2"><figure id="ath2" data-index="32" class="article__inlineFigure"><h2 class="fig-label">Valeria Pittalà</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02265&amp;id=BIO-d7e5960-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Valeria Pittalá</b> attained an M.S. in Chemistry and Pharmaceutical Technologies and completed a Ph.D. in Pharmaceutical Sciences at the University of Catania (Italy). She joined Pharmacia Corporation, where she worked as a member of the Combinatorial Chemistry Group. She contributed to the discovery of the Aurora kinase inhibitor danusertib, which underwent clinical investigation, by being a co-inventor of the bicyclopyrazoles class. Subsequently, she returned to the University of Catania as a Medicinal Chemistry Assistant Professor. Pittalá has published over 90 scientific papers in peer-reviewed journals focused on structure–activity relationships for biological targets including GPCRs. She is a co-inventor of seven patents.</p></figure></div><div class="bio" rid="ath3"><figure id="ath3" data-index="33" class="article__inlineFigure"><h2 class="fig-label">Maria N. Modica</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02265&amp;id=BIO-d7e5965-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Maria N. Modica</b> graduated in Pharmacy, in 1989, at the University of Catania, discussing a thesis in medicinal chemistry. In 1994, she received a Ph.D. in pharmaceutical sciences. She has been a researcher in the Department of Drug and Health Sciences at the University of Catania since 1997. Her research topics include the design and synthesis of ligands for the 5-HT<sub>1A</sub> and 5-HT<sub>7</sub> serotonin, α<sub>1</sub>-adrenergic, and endothelin receptors and of HO-1 and NOS inhibitors. She has published 64 papers, one contribution of a volume for a book, five proceedings, and 49 congress communications.</p></figure></div><div class="bio" rid="ath4"><figure id="ath4" data-index="34" class="article__inlineFigure"><h2 class="fig-label">Loredana Salerno</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02265&amp;id=BIO-d7e5979-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Loredana Salerno</b> obtained the degree in Pharmacy in 1986 at the University of Catania and a Ph.D. in Pharmaceutical Sciences in 1993. At the Department of Drug and Health Sciences of the same university, she was appointed as a Researcher (1996) and as Associate Professor in Medicinal Chemistry (2006). She has focused her research activity on the development of ligands for serotonergic and adrenergic receptor ligands, enzymatic inhibitors of nitric oxide synthase and heme oxygenase-1 as antitumor drugs, and modified natural compounds as inducers of heme oxygenase-1 useful in stress-induced diseases. She is the author of more than 85 scientific publications in peer-reviewed journals.</p></figure></div><div class="bio" rid="ath5"><figure id="ath5" data-index="35" class="article__inlineFigure"><h2 class="fig-label">Giuseppe Romeo</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02265&amp;id=BIO-d7e5984-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Giuseppe Romeo</b> received a degree in Pharmacy (honors) at the University of Catania in 1985. At the same university, he was appointed Research Associate in Medicinal Chemistry (1991) and Associate Professor in Medicinal Chemistry in 1998 (Department of Drug Sciences). His research activity has been mainly involved in the design, synthesis, and characterization of novel heterocyclic compounds endowed with potential pharmacological activity. The main topics of his research include the development of selective ligands for the α<sub>1</sub>-adrenoceptor subtypes and for the serotonin 5-HT<sub>1A</sub> and 5-HT<sub>7</sub> receptors.</p></figure></div><div class="bio" rid="ath6"><figure id="ath6" data-index="36" class="article__inlineFigure"><h2 class="fig-label">Agostino Marrazzo</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02265&amp;id=BIO-d7e5998-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Agostino Marrazzo</b> graduated with honors in Chemistry and Pharmaceutical Technology on April 26, 1990. In May 1990, he was awarded an ENI-Ricerche scholarship working at the Department of Chemical Sciences of the University of Parma. From May 1991 to April 1992, he worked for the Italian multinational company BRACCO (chemical and pharmaceutical sector). In May 1992, he was a Research Associate in Medicinal Chemistry at the Department of Drug and Health Sciences of the University of Catania. In November 2001, he was appointed Associate Professor. His research focuses on the development of selective σRs ligands to treat neurodegenerative diseases, chronic pain, and cancer. His work has resulted in more than 90 publications.</p></figure></div><div class="bio" rid="ath7"><figure id="ath7" data-index="37" class="article__inlineFigure"><h2 class="fig-label">Mohamed A. Helal</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02265&amp;id=BIO-d7e6003-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Mohamed A. Helal</b> is currently an Associate Professor of Drug Design and Development at the University of Science and Technology, Zewail City. After graduating from the Faculty of Pharmacy, Suez Canal University, he studied Organic and Medicinal Chemistry for his masters. Five years after completing his masters, he received his Ph.D. in Medicinal Chemistry from the University of Mississippi, USA, after studying molecular modeling and drug design. Between 2010 and 2017, he was an Assistant Professor of Medicinal Chemistry at the Faculty of Pharmacy, Suez Canal University. Since 2012, he received six research grants from STDF, ASRT, and the Library of Alexandria to develop drug candidates for the treatment of several diseases. He also received a grant from the National Academy of Sciences, Washington, D.C., for teaching research ethics for Egyptians young scientists. Helal also holds two certificates in the fields of “Active Learning” and “Research Ethics” from the National Academy of Sciences (NAS) and the American Chemical Society (ACS). In 2018, he received a Fulbright Grant as a visiting scholar at the Department of Medicinal Chemistry, University of Florida. Helal has also been affiliated with some world scientific societies such as ACS, AAPS, and Rho Chi academic chapter of Mississippi.</p></figure></div><div class="bio" rid="ath8"><figure id="ath8" data-index="38" class="article__inlineFigure"><h2 class="fig-label">Sebastiano Intagliata</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02265&amp;id=BIO-d7e6008-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Sebastiano Intagliata</b> received his M.S. in Chemistry and Pharmaceutical Technology (July 2012) and his Ph.D. in Pharmaceutical Sciences (February 2016) from the University of Catania, Italy. He was a Post-Doctoral Associate at the University of Mississippi (USA, 2016), and then at the Department of Medicinal Chemistry, University of Florida (USA, 2017–2019) under the guidance of Dr. Christopher R. McCurdy. Since August 2019, he has been appointed Research Associate at the Department of Drug and Health Sciences, University of Catania. Currently his research focuses on the development of novel anticancer agents with a peculiar cytotoxic effect, such as heme oxygenase inhibitors, σR ligands, hybrids, and mutual prodrugs.</p></figure></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i33">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_88318" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_88318" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">This work was supported by PON R&I funds 2014-2020 (CUP: E66C18001320007, AIM1872330, activity 1).</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">[<sup>3</sup>H]DTG</td><td class="NLM_def"><p class="first last">[<sup>3</sup>H]1,3-di(2-tolyl)guanidine</p></td></tr><tr><td class="NLM_term">Bn</td><td class="NLM_def"><p class="first last">benzyl</p></td></tr><tr><td class="NLM_term">CB<sub>2</sub>R</td><td class="NLM_def"><p class="first last">cannabinoid receptor subtype 2</p></td></tr><tr><td class="NLM_term">Cl</td><td class="NLM_def"><p class="first last">clearance</p></td></tr><tr><td class="NLM_term">CNS</td><td class="NLM_def"><p class="first last">central nervous system</p></td></tr><tr><td class="NLM_term">CoMFA</td><td class="NLM_def"><p class="first last">comparative molecular field analysis</p></td></tr><tr><td class="NLM_term">COVID-19</td><td class="NLM_def"><p class="first last">coronavirus disease 19</p></td></tr><tr><td class="NLM_term">DOR</td><td class="NLM_def"><p class="first last">δ-opioid receptor</p></td></tr><tr><td class="NLM_term">ent-</td><td class="NLM_def"><p class="first last">enantiomer</p></td></tr><tr><td class="NLM_term">ER</td><td class="NLM_def"><p class="first last">endoplasmic reticulum</p></td></tr><tr><td class="NLM_term">Et</td><td class="NLM_def"><p class="first last">ethyl</p></td></tr><tr><td class="NLM_term">FITC</td><td class="NLM_def"><p class="first last">fluorescein isothiocyanate</p></td></tr><tr><td class="NLM_term">GPCR</td><td class="NLM_def"><p class="first last">G protein-coupled receptor</p></td></tr><tr><td class="NLM_term">HB</td><td class="NLM_def"><p class="first last">hydrogen bond</p></td></tr><tr><td class="NLM_term">HBA</td><td class="NLM_def"><p class="first last">hydrogen-bond acceptor</p></td></tr><tr><td class="NLM_term">HIF-1α</td><td class="NLM_def"><p class="first last">hypoxia-inducible factor 1α</p></td></tr><tr><td class="NLM_term">HO-1</td><td class="NLM_def"><p class="first last">heme oxygenase-1</p></td></tr><tr><td class="NLM_term">HY</td><td class="NLM_def"><p class="first last">hydrophobic</p></td></tr><tr><td class="NLM_term">HYAl</td><td class="NLM_def"><p class="first last">hydrophobic aliphatic</p></td></tr><tr><td class="NLM_term">HYAr</td><td class="NLM_def"><p class="first last">hydrophobic aromatic</p></td></tr><tr><td class="NLM_term"><i>i</i>-Pr</td><td class="NLM_def"><p class="first last">isopropyl</p></td></tr><tr><td class="NLM_term">KO</td><td class="NLM_def"><p class="first last">knockout</p></td></tr><tr><td class="NLM_term">KOR</td><td class="NLM_def"><p class="first last">κ-opioid receptor</p></td></tr><tr><td class="NLM_term">LDH</td><td class="NLM_def"><p class="first last">lactate dehydrogenase</p></td></tr><tr><td class="NLM_term">LDL</td><td class="NLM_def"><p class="first last">low density lipoprotein</p></td></tr><tr><td class="NLM_term">Me</td><td class="NLM_def"><p class="first last">methyl</p></td></tr><tr><td class="NLM_term">MRP1</td><td class="NLM_def"><p class="first last">multidrug resistance-associated protein 1</p></td></tr><tr><td class="NLM_term">MTS</td><td class="NLM_def"><p class="first last">3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium</p></td></tr><tr><td class="NLM_term">MTT</td><td class="NLM_def"><p class="first last">3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide</p></td></tr><tr><td class="NLM_term"><i>n</i>-Bu</td><td class="NLM_def"><p class="first last">normal butyl</p></td></tr><tr><td class="NLM_term">NMDA</td><td class="NLM_def"><p class="first last"><i>N</i>-methyl-<span class="smallcaps smallerCapital">d</span>-aspartate</p></td></tr><tr><td class="NLM_term"><i>n</i>-Pr</td><td class="NLM_def"><p class="first last">normal propyl</p></td></tr><tr><td class="NLM_term">Nsp6</td><td class="NLM_def"><p class="first last">nonstructural protein 6</p></td></tr><tr><td class="NLM_term">OXAIPN</td><td class="NLM_def"><p class="first last">oxaliplatin-induced peripheral neuropathy</p></td></tr><tr><td class="NLM_term">PD-L1</td><td class="NLM_def"><p class="first last">programmed death-ligand 1</p></td></tr><tr><td class="NLM_term">PET</td><td class="NLM_def"><p class="first last">positron emission tomography</p></td></tr><tr><td class="NLM_term">PET–MRI</td><td class="NLM_def"><p class="first last">positron emission tomography–magnetic resonance imaging</p></td></tr><tr><td class="NLM_term">P-gp</td><td class="NLM_def"><p class="first last">P-glycoprotein</p></td></tr><tr><td class="NLM_term">PGRMC1</td><td class="NLM_def"><p class="first last">progesterone receptor membrane component 1</p></td></tr><tr><td class="NLM_term">Ph</td><td class="NLM_def"><p class="first last">phenyl</p></td></tr><tr><td class="NLM_term">PI</td><td class="NLM_def"><p class="first last">positive ionizable</p></td></tr><tr><td class="NLM_term"><i>p</i>-Me</td><td class="NLM_def"><p class="first last"><i>para</i>-methyl</p></td></tr><tr><td class="NLM_term">QSAR</td><td class="NLM_def"><p class="first last">quantitative structure–activity relationship</p></td></tr><tr><td class="NLM_term">RNAi</td><td class="NLM_def"><p class="first last">RNA interference</p></td></tr><tr><td class="NLM_term">ROS</td><td class="NLM_def"><p class="first last">reactive oxygen species</p></td></tr><tr><td class="NLM_term">SAfiR</td><td class="NLM_def"><p class="first last">structure–affinity relationships</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structure–activity relationships</p></td></tr><tr><td class="NLM_term">SARS-CoV-2</td><td class="NLM_def"><p class="first last">severe acute respiratory syndrome coronavirus 2</p></td></tr><tr><td class="NLM_term">SERT</td><td class="NLM_def"><p class="first last">serotonin transporter</p></td></tr><tr><td class="NLM_term">shRNA</td><td class="NLM_def"><p class="first last">short hairpin RNA</p></td></tr><tr><td class="NLM_term"><i>SIGMAR1</i></td><td class="NLM_def"><p class="first last">sigma non-opioid intracellular receptor 1 gene</p></td></tr><tr><td class="NLM_term">SMAC</td><td class="NLM_def"><p class="first last">second mitochondria-derived activator of caspase</p></td></tr><tr><td class="NLM_term">TMEM97</td><td class="NLM_def"><p class="first last">transmembrane protein 97</p></td></tr><tr><td class="NLM_term">σR</td><td class="NLM_def"><p class="first last">σ receptor</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i35">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_68566" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_68566" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 184 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Heron, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, R. N.</span></span> <span> </span><span class="NLM_article-title">Changes in the Leading Cause of Death: Recent Patterns in Heart Disease and Cancer Mortality</span>. <i>NCHS data Brief.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">8</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=27598767" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A280%3ADC%252BC2szot1ektg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&pages=1-8&author=M.+Heronauthor=R.+N.+Anderson&title=Changes+in+the+Leading+Cause+of+Death%3A+Recent+Patterns+in+Heart+Disease+and+Cancer+Mortality"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Changes in the Leading Cause of Death: Recent Patterns in Heart Disease and Cancer Mortality</span></div><div class="casAuthors">Heron Melonie; Anderson Robert N</div><div class="citationInfo"><span class="NLM_cas:title">NCHS data brief</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume"></span>
        (<span class="NLM_cas:issue">254</span>),
    <span class="NLM_cas:pages">1-8</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">KEY FINDINGS:  Data from the National Vital Statistics System •Heart disease has consistently been the leading cause of death in the United States and remained so in 2014. •The gap between the number of heart disease and cancer deaths generally widened from 1950 through 1968, narrowed from 1968 through 2012, and then slightly widened again from 2012 through 2014. •The mortality burden of cancer has surpassed that of heart disease in several states.  In 2000, there were only 2 states where cancer was the leading cause of death; in 2014, there were 22. •Heart disease remained the leading cause of death for the non-Hispanic white and non-Hispanic black populations in 2014. •Cancer is now the leading cause of death for the non-Hispanic Asian or Pacific Islander and Hispanic populations.  The timing of the leading-cause crossover varied by group.  For the total U.S. population, heart disease has been the leading cause of death for decades, with cancer the second leading cause (1).  However, the ranking of these causes has varied across demographic group and geographic unit over time.  Rankings are based on the number of deaths and reflect mortality burden rather than risk of death (2).  This report highlights changes in the mortality burden of heart disease and cancer and presents findings by state, race, and Hispanic origin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTseAgqV32DDFMGsG_HTXYFfW6udTcc2eZ0f7HO0QZhhLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2szot1ektg%253D%253D&md5=830dd4c4fcf1f34497f4dc9c8ec34d10</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHeron%26aufirst%3DM.%26aulast%3DAnderson%26aufirst%3DR.%2BN.%26atitle%3DChanges%2520in%2520the%2520Leading%2520Cause%2520of%2520Death%253A%2520Recent%2520Patterns%2520in%2520Heart%2520Disease%2520and%2520Cancer%2520Mortality%26jtitle%3DNCHS%2520data%2520Brief.%26date%3D2016%26spage%3D1%26epage%3D8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chidambaram, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manavalan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kathiresan, K.</span></span> <span> </span><span class="NLM_article-title">Nanotherapeutics to overcome conventional cancer chemotherapy limitations</span>. <i>J. Pharm. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">67</span>– <span class="NLM_lpage">77</span>, <span class="refDoi"> DOI: 10.18433/J30C7D</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.18433%2FJ30C7D" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=21501554" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A280%3ADC%252BC3MvksF2juw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2011&pages=67-77&author=M.+Chidambaramauthor=R.+Manavalanauthor=K.+Kathiresan&title=Nanotherapeutics+to+overcome+conventional+cancer+chemotherapy+limitations&doi=10.18433%2FJ30C7D"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Nanotherapeutics to overcome conventional cancer chemotherapy limitations</span></div><div class="casAuthors">Chidambaram Moorthi; Manavalan R; Kathiresan K</div><div class="citationInfo"><span class="NLM_cas:title">Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">67-77</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Cancer is one of the major causes of death worldwide and chemotherapy is a major therapeutic approach for the treatment which may be used alone or combined with other forms of therapy.  However, conventional chemotherapy suffers lack of aqueous solubility, lack of selectivity and multidrug resistance.  Nanotherapeutics is rapidly progressing aimed to solve several limitations of conventional drug delivery systems.  Nonspecific target of cancer chemotherapy leads to damage rapidly proliferating normal cells and can be significantly reduced through folate and transferrin mediated nanotherapeutics which are aimed to target cancerous cells.  Multidrug resistance is challenge in cancer chemotherapy which can be significantly reversed by solid lipid nanoparticles, polymeric nanoparticles, mesoporous silica nanoparticles, nanoparticulated chemosensitizer, nanoparticluated poloxamer and magnetic nanoparticles.  Hydrophobic nature of chemotherapeutics leads to poor aqueous solubility and low bioavailability which can be overcome by nanocrystals, albumin based nanoparticles, liposomal formulation, polymeric micelles, cyclodextrin and chitosan based nanoparticles.  This review focuses the role of nanotherapeutics to overcome lack of selectivity, multidrug resistance and lack of aqueous solubility of conventional cancer chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQb9xNNgG2B7xFwe7cAcrfPfW6udTcc2eZJJ-ybOATCQLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3MvksF2juw%253D%253D&md5=afab976d9f9335614563ad4883cd7d13</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.18433%2FJ30C7D&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18433%252FJ30C7D%26sid%3Dliteratum%253Aachs%26aulast%3DChidambaram%26aufirst%3DM.%26aulast%3DManavalan%26aufirst%3DR.%26aulast%3DKathiresan%26aufirst%3DK.%26atitle%3DNanotherapeutics%2520to%2520overcome%2520conventional%2520cancer%2520chemotherapy%2520limitations%26jtitle%3DJ.%2520Pharm.%2520Pharm.%2520Sci.%26date%3D2011%26volume%3D14%26spage%3D67%26epage%3D77%26doi%3D10.18433%2FJ30C7D" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vanneman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dranoff, G.</span></span> <span> </span><span class="NLM_article-title">Combining immunotherapy and targeted therapies in cancer treatment</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">237</span>– <span class="NLM_lpage">251</span>, <span class="refDoi"> DOI: 10.1038/nrc3237</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1038%2Fnrc3237" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=22437869" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BC38XksVehtrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2012&pages=237-251&author=M.+Vannemanauthor=G.+Dranoff&title=Combining+immunotherapy+and+targeted+therapies+in+cancer+treatment&doi=10.1038%2Fnrc3237"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Combining immunotherapy and targeted therapies in cancer treatment</span></div><div class="casAuthors">Vanneman, Matthew; Dranoff, Glenn</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">237-251</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  During the past two decades, the paradigm for cancer treatment has evolved from relatively nonspecific cytotoxic agents to selective, mechanism-based therapeutics.  Cancer chemotherapies were initially identified through screens for compds. that killed rapidly dividing cells.  These drugs remain the backbone of current treatment, but they are limited by a narrow therapeutic index, significant toxicities and frequently acquired resistance.  More recently, an improved understanding of cancer pathogenesis has given rise to new treatment options, including targeted agents and cancer immunotherapy.  Targeted approaches aim to inhibit mol. pathways that are crucial for tumor growth and maintenance; whereas, immunotherapy endeavors to stimulate a host immune response that effectuates long-lived tumor destruction.  Targeted therapies and cytotoxic agents also modulate immune responses, which raises the possibility that these treatment strategies might be effectively combined with immunotherapy to improve clin. outcomes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXt9BTvySH7rVg90H21EOLACvtfcHk0ljxwYNhkXKrDA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XksVehtrg%253D&md5=e1ed968896a11cea34456010a72fca57</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fnrc3237&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc3237%26sid%3Dliteratum%253Aachs%26aulast%3DVanneman%26aufirst%3DM.%26aulast%3DDranoff%26aufirst%3DG.%26atitle%3DCombining%2520immunotherapy%2520and%2520targeted%2520therapies%2520in%2520cancer%2520treatment%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2012%26volume%3D12%26spage%3D237%26epage%3D251%26doi%3D10.1038%2Fnrc3237" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kunick, C.</span></span> <span> </span><span class="NLM_article-title">Novel molecular targets in cancer chemotherapy waiting for discovery</span>. <i>Curr. Med. Chem.: Anti-Cancer Agents</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">421</span>– <span class="NLM_lpage">423</span>, <span class="refDoi"> DOI: 10.2174/1568011043352858</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.2174%2F1568011043352858" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=15379696" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BD2cXntVertbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2004&pages=421-423&author=C.+Kunick&title=Novel+molecular+targets+in+cancer+chemotherapy+waiting+for+discovery&doi=10.2174%2F1568011043352858"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Novel molecular targets in cancer chemotherapy waiting for discovery</span></div><div class="casAuthors">Kunick, Conrad</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry: Anti-Cancer Agents</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">421-423</span>CODEN:
                <span class="NLM_cas:coden">CMCACI</span>;
        ISSN:<span class="NLM_cas:issn">1568-0118</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Despite a no. of advances in the past decades the medicinal cancer therapy is hampered by problems of severe unwanted side effects and the development of resistances.  Many established anti-cancer drugs are directed toward targets that are not specific for cancer but are essential biochem. mols. in living cells.  Because cancer cells do not only carry one but multiple genetic alterations which are more characteristic for the individual patient than for the tumor entity, an individualized medicinal approach could improve the success of a tumor therapy.  A prerequisite for personalized tumor therapies is an upgrade of the array of anticancer drugs directed to different mol. targets.  Therefore, a systematic search for anticancer drug targets should constitute a research priority.  The database of fingerprints of new chem. entities generated in the National Cancer Institute's Anticancer Drug Screening is a rich source of novel targets which might be uncovered by the interdisciplinary application of methods from bioinformatics, biochem., chem., tumor biol., and related sciences.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq0V-ryJFjEG7Vg90H21EOLACvtfcHk0ljxwYNhkXKrDA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXntVertbw%253D&md5=5b11e88a896c1126944fd5e15853d08e</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.2174%2F1568011043352858&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568011043352858%26sid%3Dliteratum%253Aachs%26aulast%3DKunick%26aufirst%3DC.%26atitle%3DNovel%2520molecular%2520targets%2520in%2520cancer%2520chemotherapy%2520waiting%2520for%2520discovery%26jtitle%3DCurr.%2520Med.%2520Chem.%253A%2520Anti-Cancer%2520Agents%26date%3D2004%26volume%3D4%26spage%3D421%26epage%3D423%26doi%3D10.2174%2F1568011043352858" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, H.-Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, D.-H.</span></span> <span> </span><span class="NLM_article-title">Editorial: Novel Targets and Biomarkers in Solid Tumors</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">828</span>, <span class="refDoi"> DOI: 10.3389/fphar.2019.00828</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.3389%2Ffphar.2019.00828" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=31417402" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BB3cXksFSiur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=828&author=Z.+Shiauthor=H.-Q.+Guoauthor=P.+A.+Cohenauthor=D.-H.+Yang&title=Editorial%3A+Novel+Targets+and+Biomarkers+in+Solid+Tumors&doi=10.3389%2Ffphar.2019.00828"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Editorial: novel targets and biomarkers in solid tumors</span></div><div class="casAuthors">Shi, Zhi; Guo, Hui-Qin; Cohen, Pascale A.; Yang, Dong-Hua</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Pharmacology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">828</span>CODEN:
                <span class="NLM_cas:coden">FPRHAU</span>;
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">Our aim was to generate a collaborative discussion contributing to the future direction of pharmaceutical drug development and therapeutic options.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKHN6FNcSRfrVg90H21EOLACvtfcHk0ljxwYNhkXKrDA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXksFSiur4%253D&md5=34686f468132f386e48bc2d6266ce755</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2019.00828&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2019.00828%26sid%3Dliteratum%253Aachs%26aulast%3DShi%26aufirst%3DZ.%26aulast%3DGuo%26aufirst%3DH.-Q.%26aulast%3DCohen%26aufirst%3DP.%2BA.%26aulast%3DYang%26aufirst%3DD.-H.%26atitle%3DEditorial%253A%2520Novel%2520Targets%2520and%2520Biomarkers%2520in%2520Solid%2520Tumors%26jtitle%3DFront.%2520Pharmacol.%26date%3D2019%26volume%3D10%26spage%3D828%26doi%3D10.3389%2Ffphar.2019.00828" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Oyer, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanders, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, F. J.</span></span> <span> </span><span class="NLM_article-title">Small-Molecule Modulators of Sigma1 and Sigma2/TMEM97 in the Context of Cancer: Foundational Concepts and Emerging Themes</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1141</span>, <span class="refDoi"> DOI: 10.3389/fphar.2019.01141</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.3389%2Ffphar.2019.01141" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=31695608" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BB3cXpvVeqsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=1141&author=H.+M.+Oyerauthor=C.+M.+Sandersauthor=F.+J.+Kim&title=Small-Molecule+Modulators+of+Sigma1+and+Sigma2%2FTMEM97+in+the+Context+of+Cancer%3A+Foundational+Concepts+and+Emerging+Themes&doi=10.3389%2Ffphar.2019.01141"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Small-molecule modulators of Sigma1 and Sigma2/TMEM97 in the context of cancer: foundational concepts and emerging themes</span></div><div class="casAuthors">Oyer, Halley M.; Sanders, Christina M.; Kim, Felix J.</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Pharmacology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1141</span>CODEN:
                <span class="NLM_cas:coden">FPRHAU</span>;
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">A review.  There are two known subtypes of the so-called sigma receptors, Sigma1 and Sigma2.  Sigma1 (encoded by the SIGMAR1 gene and also known as Sigma-1 receptor, S1R) is a unique pharmacol. regulated integral membrane chaperone or scaffolding protein that allosterically modulates the activity of its assocd. proteins.  Sigma2, recently identified as transmembrane protein 97 (TMEM97), is an integral membrane protein implicated in cellular cholesterol homeostasis.  A no. of publications over the past two decades have suggested a role for both sigma proteins in tumor biol.  Although there is currently no clin. used anti-cancer drug that targets Sigma1 or Sigma2/TMEM97, a growing body of evidence supports the potential of small-mol. compds. with affinity for these proteins, putative sigma ligands, as therapeutic agents to treat cancer.  In preclin. models, these compds. have been reported to inhibit cancer cell proliferation, survival, adhesion, and migration; furthermore, they have been demonstrated to suppress tumor growth, to alleviate cancer-assocd. pain, and to exert immunomodulatory properties.  Here, we will address the known knowns and the known unknowns of Sigma1 and Sigma2/TMEM97 ligand actions in the context of cancer.  This review will highlight key discoveries and published evidence in support of a role for sigma proteins in cancer and will discuss several fundamental questions regarding the physiol. roles of sigma proteins in cancer and sigma ligand mechanism of action.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSrAyrTeGahrVg90H21EOLACvtfcHk0lgUr9UD91NMEg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXpvVeqsbY%253D&md5=af4db128dd079492a68d665068414c93</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2019.01141&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2019.01141%26sid%3Dliteratum%253Aachs%26aulast%3DOyer%26aufirst%3DH.%2BM.%26aulast%3DSanders%26aufirst%3DC.%2BM.%26aulast%3DKim%26aufirst%3DF.%2BJ.%26atitle%3DSmall-Molecule%2520Modulators%2520of%2520Sigma1%2520and%2520Sigma2%252FTMEM97%2520in%2520the%2520Context%2520of%2520Cancer%253A%2520Foundational%2520Concepts%2520and%2520Emerging%2520Themes%26jtitle%3DFront.%2520Pharmacol.%26date%3D2019%26volume%3D10%26spage%3D1141%26doi%3D10.3389%2Ffphar.2019.01141" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Izzo, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colom-Cadena, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riad, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abate, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cahill, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spires-Jones, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowen, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mach, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Catalano, S. M.</span></span> <span> </span><span class="NLM_article-title">Proceedings from the Fourth International Symposium on σ-2 Receptors: Role in Health and Disease</span>. <i>eNeuro</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">ENEURO.0317-20.2020</span>, <span class="refDoi"> DOI: 10.1523/ENEURO.0317-20.2020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1523%2FENEURO.0317-20.2020" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2020&pages=ENEURO.0317-20.2020&author=N.+J.+Izzoauthor=M.+Colom-Cadenaauthor=A.+A.+Riadauthor=J.+Xuauthor=M.+Singhauthor=C.+Abateauthor=M.+A.+Cahillauthor=T.+L.+Spires-Jonesauthor=W.+D.+Bowenauthor=R.+H.+Machauthor=S.+M.+Catalano&title=Proceedings+from+the+Fourth+International+Symposium+on+%CF%83-2+Receptors%3A+Role+in+Health+and+Disease&doi=10.1523%2FENEURO.0317-20.2020"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1523%2FENEURO.0317-20.2020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1523%252FENEURO.0317-20.2020%26sid%3Dliteratum%253Aachs%26aulast%3DIzzo%26aufirst%3DN.%2BJ.%26aulast%3DColom-Cadena%26aufirst%3DM.%26aulast%3DRiad%26aufirst%3DA.%2BA.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DSingh%26aufirst%3DM.%26aulast%3DAbate%26aufirst%3DC.%26aulast%3DCahill%26aufirst%3DM.%2BA.%26aulast%3DSpires-Jones%26aufirst%3DT.%2BL.%26aulast%3DBowen%26aufirst%3DW.%2BD.%26aulast%3DMach%26aufirst%3DR.%2BH.%26aulast%3DCatalano%26aufirst%3DS.%2BM.%26atitle%3DProceedings%2520from%2520the%2520Fourth%2520International%2520Symposium%2520on%2520%25CF%2583-2%2520Receptors%253A%2520Role%2520in%2520Health%2520and%2520Disease%26jtitle%3DeNeuro%26date%3D2020%26volume%3D7%26spage%3DENEURO.0317-20.2020%26doi%3D10.1523%2FENEURO.0317-20.2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kruse, A. C.</span></span> <span> </span><span class="NLM_article-title">The Molecular Function of σ Receptors: Past, Present, and Future</span>. <i>Trends Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">636</span>– <span class="NLM_lpage">654</span>, <span class="refDoi"> DOI: 10.1016/j.tips.2019.07.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1016%2Fj.tips.2019.07.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=31387763" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsVeqs7bJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2019&pages=636-654&author=H.+R.+Schmidtauthor=A.+C.+Kruse&title=The+Molecular+Function+of+%CF%83+Receptors%3A+Past%2C+Present%2C+and+Future&doi=10.1016%2Fj.tips.2019.07.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">The Molecular Function of σ Receptors: Past, Present, and Future</span></div><div class="casAuthors">Schmidt, Hayden R.; Kruse, Andrew C.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Pharmacological Sciences</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">636-654</span>CODEN:
                <span class="NLM_cas:coden">TPHSDY</span>;
        ISSN:<span class="NLM_cas:issn">0165-6147</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The σ1 and σ2 receptors are enigmatic proteins that have attracted attention for decades due to the chem. diversity and therapeutic potential of their ligands.  However, despite ongoing clin. trials with σ receptor ligands for multiple conditions, relatively little is known regarding the mol. function of these receptors.  In this review, we revisit past research on σ receptors and discuss the interpretation of these data in light of recent developments.  We provide a synthesis of emerging structural and genetic data on the σ1 receptor and discuss the recent cloning of the σ2 receptor.  Finally, we discuss the major questions that remain in the study of σ receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonQzGSQdFecbVg90H21EOLACvtfcHk0lgUr9UD91NMEg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsVeqs7bJ&md5=03896ad7b332beb873ad3fbc32c96423</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2019.07.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2019.07.006%26sid%3Dliteratum%253Aachs%26aulast%3DSchmidt%26aufirst%3DH.%2BR.%26aulast%3DKruse%26aufirst%3DA.%2BC.%26atitle%3DThe%2520Molecular%2520Function%2520of%2520%25CF%2583%2520Receptors%253A%2520Past%252C%2520Present%252C%2520and%2520Future%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2019%26volume%3D40%26spage%3D636%26epage%3D654%26doi%3D10.1016%2Fj.tips.2019.07.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Su, T. P.</span></span> <span> </span><span class="NLM_article-title">Psychotomimetic opioid binding: specific binding of [3H]SKF-10047 to etorphine-inaccessible sites in guinea-pig brain</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1981</span>,  <span class="NLM_volume"><i>75</i></span>,  <span class="NLM_fpage">81</span>– <span class="NLM_lpage">82</span>, <span class="refDoi"> DOI: 10.1016/0014-2999(81)90352-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1016%2F0014-2999%2881%2990352-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=6274661" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADyaL38XksFyisQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=1981&pages=81-82&author=T.+P.+Su&title=Psychotomimetic+opioid+binding%3A+specific+binding+of+%5B3H%5DSKF-10047+to+etorphine-inaccessible+sites+in+guinea-pig+brain&doi=10.1016%2F0014-2999%2881%2990352-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Psychotomimetic opioid binding:  specific binding of [3H]SKF-10047 to etorphine-inaccessible sites in guinea pig brain</span></div><div class="casAuthors">Su, Tsung Ping</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">1981</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">81-2</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    </div><div class="casAbstract">At 0.1-250 μM, etorphine (I)  [14521-96-1] consistently exhibited a max. (∼82%) inhibition of specific SKF 10047 (II)  [14198-28-8] binding in guinea pig brain homogenates indicating that I binding also occurs at sites which are inaccessible to I.  The binding of II to I-inaccessible sites was saturable and heat-sensitive, and represented ∼70% of total binding.  Opioids which are not traditional morphine-like drugs and several non-opioid drugs were potent inhibitors of the binding.  The binding exhibited stereospecificity, which is the reverse of that for a μ-receptor.  Thus, II binds to a class of I-inaccessible sites which are not μ-receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_2Ld2NXzbq7Vg90H21EOLACvtfcHk0lgjvh8h81Ie_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL38XksFyisQ%253D%253D&md5=e098b702f8a81c78a592c80b8702d880</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2F0014-2999%2881%2990352-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0014-2999%252881%252990352-6%26sid%3Dliteratum%253Aachs%26aulast%3DSu%26aufirst%3DT.%2BP.%26atitle%3DPsychotomimetic%2520opioid%2520binding%253A%2520specific%2520binding%2520of%2520%255B3H%255DSKF-10047%2520to%2520etorphine-inaccessible%2520sites%2520in%2520guinea-pig%2520brain%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D1981%26volume%3D75%26spage%3D81%26epage%3D82%26doi%3D10.1016%2F0014-2999%2881%2990352-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Martin, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eades, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huppler, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilbert, P. E.</span></span> <span> </span><span class="NLM_article-title">The effects of morphine- and nalorphine- like drugs in the nondependent and morphine-dependent chronic spinal dog</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">1976</span>,  <span class="NLM_volume"><i>197</i></span>,  <span class="NLM_fpage">517</span>– <span class="NLM_lpage">532</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=945347" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADyaE28XltlOhurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=197&publication_year=1976&pages=517-532&author=W.+R.+Martinauthor=C.+G.+Eadesauthor=J.+A.+Thompsonauthor=R.+E.+Hupplerauthor=P.+E.+Gilbert&title=The+effects+of+morphine-+and+nalorphine-+like+drugs+in+the+nondependent+and+morphine-dependent+chronic+spinal+dog"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">The effects of morphine- and nalorphine-like drugs in the nondependent and morphine-dependent chronic spinal dog</span></div><div class="casAuthors">Martin, W. R.; Eades, C. G.; Thompson, J. A.; Huppler, R. E.; Gilbert, P. E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">1976</span>),
    <span class="NLM_cas:volume">197</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">517-32</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    </div><div class="casAbstract">Three different syndromes produced by congeners of morphine sulfate (I sulfate) [64-31-3] were identified in the nondependent chronic spinal dog.  These syndromes were attributed to interaction of agonists with three distinguishable receptors (μ, κ and σ).  I was the prototype agonist for the μ receptor, ketocyclazocine lactate [59985-33-0] for the κ receptor and SKF-10,047 lactate [59985-34-1] for the σ receptor.  The I syndrome (μ) in the dog was characterized by miosis, bradycardia, hypothermia, a general depression of the nociceptive responses and indifferences to environmental stimuli.  Ketocyclazocine (κ) constricted pupils, depressed the flexor reflex and produced sedation but did not markedly alter pulse rate or the skin twitch reflex.  SKF-10,047 (σ) caused mydriasis, tachypnea, tachycardia and mania.  The effects of these three drugs was antagonized by the pure antagonist naltrexone-HCl, indicating that they are agonists.  Further, chronic administration of I, ketocyclazocine and SKF-10,047 induced tolerance to their agonistic effects.  I suppressed abstinence in I-dependent dogs while ketocyclazocine did not.  Ketocyclazocine at best pptd. only a liminal abstinence syndrome in the I-dependent dog, indicating that it had little affinity for the I receptor.  Ketocyclazocine thus appears to be a selective agonist at the κ receptor.  Buprenorphine-HCl [53152-21-9] was a partial agonist of the μ type which both suppressed and pptd. abstinence in the I-dependent dog while I and d-propoxyphene-HCl [1639-60-7] were stronger agonists.  Apomorphine-HCl [314-19-2] and SKF-10,047 produced similar pharmacol. effects suggesting that σ activity may involve a dopaminergic mechanism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6rgyf41iRTbVg90H21EOLACvtfcHk0lgjvh8h81Ie_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE28XltlOhurw%253D&md5=ca7c637f336ac9ecc2c3bb040dbcdbee</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMartin%26aufirst%3DW.%2BR.%26aulast%3DEades%26aufirst%3DC.%2BG.%26aulast%3DThompson%26aufirst%3DJ.%2BA.%26aulast%3DHuppler%26aufirst%3DR.%2BE.%26aulast%3DGilbert%26aufirst%3DP.%2BE.%26atitle%3DThe%2520effects%2520of%2520morphine-%2520and%2520nalorphine-%2520like%2520drugs%2520in%2520the%2520nondependent%2520and%2520morphine-dependent%2520chronic%2520spinal%2520dog%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D1976%26volume%3D197%26spage%3D517%26epage%3D532" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hayashi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, T. P.</span></span> <span> </span><span class="NLM_article-title">Sigma-1 receptors (sigma(1) binding sites) form raft-like microdomains and target lipid droplets on the endoplasmic reticulum: roles in endoplasmic reticulum lipid compartmentalization and export</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>306</i></span>,  <span class="NLM_fpage">718</span>– <span class="NLM_lpage">725</span>, <span class="refDoi"> DOI: 10.1124/jpet.103.051284</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1124%2Fjpet.103.051284" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=12730355" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BD3sXlslGlu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=306&publication_year=2003&pages=718-725&author=T.+Hayashiauthor=T.+P.+Su&title=Sigma-1+receptors+%28sigma%281%29+binding+sites%29+form+raft-like+microdomains+and+target+lipid+droplets+on+the+endoplasmic+reticulum%3A+roles+in+endoplasmic+reticulum+lipid+compartmentalization+and+export&doi=10.1124%2Fjpet.103.051284"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">σ-1 Receptors (σ1 binding sites) form raft-like microdomains and target lipid droplets on the endoplasmic reticulum: Roles in endoplasmic reticulum lipid compartmentalization and export</span></div><div class="casAuthors">Hayashi, Teruo; Su, Tsung-Ping</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">306</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">718-725</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The brain σ-1 receptors can bind neurosteroids and psychotropic drugs, including neuroleptics and cocaine and are implicated in schizophrenia, depression, and drug dependence.  In this study, we found that σ-1 receptors specifically target lipid storage sites (lipid droplets) on the endoplasmic reticulum by forming a distinct class of lipid microdomains.  Both endogenously expressing σ-1 receptors and transfected C-terminally enhanced yellow fluorescent protein (EYFP)-tagged σ-1 receptors (Sig-1R-EYFP) target unique "ring-like" structures assocd. with endoplasmic reticulum reticular networks in NG108-15 cells.  The ring-like structures contain neutral lipids and are enlarged by the oleate treatment, indicating that they are endoplasmic reticulum-assocd. lipid droplets (ER-LDs).  σ-1 Receptors colocalize with caveolin-2, a cholesterol-binding protein in lipid rafts on the ER-LDs, but not with adipocyte differentiation-related protein (ADRP), a cytosolic lipid droplet (c-LD)-specific protein.  When the double-arginine ER retention signal on the N terminus of σ-1 receptors is truncated, σ-1 receptors no longer exist on ER-LDs, but predominantly target c-LDs, which contain ADRP.  σ-1 Receptors on ER-LDs form detergent-resistant raft-like lipid microdomains, the buoyancy of which is different from that of plasma membrane lipid rafts.  (+)-Pentazocine causes σ-1 receptors to disappear from the microdomains.  N-Terminally EYFP-tagged σ-1 receptors (EYFP-Sig-1R) failed to target ER-LDs.  EYFP-Sig-1R-transfected cells showed an unrestricted distribution of neutral lipids all over the endoplasmic reticulum network, decreases in c-LDs and cholesterol in plasma membranes, and the bulbous aggregation of endoplasmic reticulum.  Thus, σ-1 receptors are unique endoplasmic reticulum proteins that regulate the compartmentalization of lipids on the endoplasmic reticulum and their export from the endoplasmic reticulum to plasma membrane and c-LDs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqucsqmLw2q4rVg90H21EOLACvtfcHk0lgjvh8h81Ie_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXlslGlu7s%253D&md5=d2ae26871c09e84930a0643ddfa0d768</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1124%2Fjpet.103.051284&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.103.051284%26sid%3Dliteratum%253Aachs%26aulast%3DHayashi%26aufirst%3DT.%26aulast%3DSu%26aufirst%3DT.%2BP.%26atitle%3DSigma-1%2520receptors%2520%2528sigma%25281%2529%2520binding%2520sites%2529%2520form%2520raft-like%2520microdomains%2520and%2520target%2520lipid%2520droplets%2520on%2520the%2520endoplasmic%2520reticulum%253A%2520roles%2520in%2520endoplasmic%2520reticulum%2520lipid%2520compartmentalization%2520and%2520export%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2003%26volume%3D306%26spage%3D718%26epage%3D725%26doi%3D10.1124%2Fjpet.103.051284" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Itzhak, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stein, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kassim, C. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cristante, D.</span></span> <span> </span><span class="NLM_article-title">Binding of sigma-ligands to C57BL/6 mouse brain membranes: effects of monoamine oxidase inhibitors and subcellular distribution studies suggest the existence of sigma-receptor subtypes</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">1991</span>,  <span class="NLM_volume"><i>257</i></span>,  <span class="NLM_fpage">141</span>– <span class="NLM_lpage">148</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1850463" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADyaK3MXksVWkuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=257&publication_year=1991&pages=141-148&author=Y.+Itzhakauthor=I.+Steinauthor=S.+H.+Zhangauthor=C.+O.+Kassimauthor=D.+Cristante&title=Binding+of+sigma-ligands+to+C57BL%2F6+mouse+brain+membranes%3A+effects+of+monoamine+oxidase+inhibitors+and+subcellular+distribution+studies+suggest+the+existence+of+sigma-receptor+subtypes"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Binding of σ-ligands to C57BL/6 mouse brain membranes:  effects of monoamine oxidase inhibitors and subcellular distribution studies suggest the existence of σ-receptor subtypes</span></div><div class="casAuthors">Itzhak, Yossef; Stein, Ira; Zhang, She Hui; Kassim, Claude O.; Cristante, Daniela</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">257</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">141-8</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    </div><div class="casAbstract">Preliminary studies indicated that certain monoamine oxidase (MAO) inhibitors display high affinity for the σ-binding sites labeled with (+)[3H]-3-(3-hydroxyphenyl)-N-1-(propyl)piperidine [(+)[3H]-3-PPP] in C57BL/6 mouse brain (Itzhak, Y., and Kassim, 1990).  In the present study, the drug specificity and the subcellular distribution of (+)[3H]-3-PPP, (+)[3H]-N-allylnormetazocine [(+)[3H]SKF 10047] and [3H]1,3-di-O-tolyl-guanidine ([3H]DTG) binding sites in C57BL/6 mouse brain were investigated, and the properties of clorgyline interaction with the (+)-3-PPP/σ-binding site(s) were examd.  (+)[3H]-3-PPP binding, but not [3H]DTG binding, is inhibited by low concns. (nM) of the dextrorotatory (+)-isomers of SKF 10047, 3-PPP and deprenyl and the type A MAO inhibitor, clorgyline.  The haloperidol-sensitive/(+)[3H]SKF 10047 binding sites display virtually identical sensitivity towards the MAO inhibitors as (+)-3-PPP binding sites.  These observations suggest a distinction between [3H]DTG and (+)[3H]-3-PPP/(+)[3H]SKF 10047 binding sites in the mouse brain.  Clorgyline interaction with (+)-3-PPP/δ-sites is competitive and reversible unlike the interaction of clorgyline with MAO-A.  The σ-ligands tested do not inhibit MAO activity and bind to sites that are apparently distinct from the MAO binding sites labeled with [3H]-N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.  However, the mitochondrial fraction of the mouse brain that expresses MAO activity and high d. of [3H]-N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine binding sites also comprises high d. of (+)-3-PPP/(+)SKF 10047 binding sites.  These findings suggest that clorgyline-sensitive/σ-binding sites may coexist with MAO in the mitochondrial fraction of mouse brain.  High d. of DTG binding sites is present in the microsomal fraction of the mouse brain, which also constitutes high d. of (+)-3-PPP/(+)SKF 10047 binding sites.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-Wd-Eay8LY7Vg90H21EOLACvtfcHk0lgjvh8h81Ie_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXksVWkuro%253D&md5=729e135b8075cb9bfc08b7700a1f79a3</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DItzhak%26aufirst%3DY.%26aulast%3DStein%26aufirst%3DI.%26aulast%3DZhang%26aufirst%3DS.%2BH.%26aulast%3DKassim%26aufirst%3DC.%2BO.%26aulast%3DCristante%26aufirst%3DD.%26atitle%3DBinding%2520of%2520sigma-ligands%2520to%2520C57BL%252F6%2520mouse%2520brain%2520membranes%253A%2520effects%2520of%2520monoamine%2520oxidase%2520inhibitors%2520and%2520subcellular%2520distribution%2520studies%2520suggest%2520the%2520existence%2520of%2520sigma-receptor%2520subtypes%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D1991%26volume%3D257%26spage%3D141%26epage%3D148" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Iwamoto, E. T.</span></span> <span> </span><span class="NLM_article-title">Pharmacologic effects of N-allylnormetazocine (SKF-10047)</span>. <i>NIDA Res. Monogr.</i> <span class="NLM_year" style="font-weight: bold;">1981</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">82</span>– <span class="NLM_lpage">88</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=6783955" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A280%3ADyaL3M7ntlShtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=1981&pages=82-88&author=E.+T.+Iwamoto&title=Pharmacologic+effects+of+N-allylnormetazocine+%28SKF-10047%29"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacologic effects of N-allylnormetazocine (SKF-10047)</span></div><div class="casAuthors">Iwamoto E T</div><div class="citationInfo"><span class="NLM_cas:title">NIDA research monograph</span>
        (<span class="NLM_cas:date">1981</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">82-8</span>
        ISSN:<span class="NLM_cas:issn">1046-9516</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSvDQTl2-0_KFm8bhe6roZYfW6udTcc2eZCW2APy1C-Qrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaL3M7ntlShtg%253D%253D&md5=c5bad204462d5ce6c9a4220721678145</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DIwamoto%26aufirst%3DE.%2BT.%26atitle%3DPharmacologic%2520effects%2520of%2520N-allylnormetazocine%2520%2528SKF-10047%2529%26jtitle%3DNIDA%2520Res.%2520Monogr.%26date%3D1981%26volume%3D34%26spage%3D82%26epage%3D88" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tam, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cook, L.</span></span> <span> </span><span class="NLM_article-title">Sigma opiates and certain antipsychotic drugs mutually inhibit (+)-[3H] SKF 10,047 and [3H]haloperidol binding in guinea pig brain membranes</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">1984</span>,  <span class="NLM_volume"><i>81</i></span>,  <span class="NLM_fpage">5618</span>– <span class="NLM_lpage">5621</span>, <span class="refDoi"> DOI: 10.1073/pnas.81.17.5618</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1073%2Fpnas.81.17.5618" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=6147851" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADyaL2cXmtVCiu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=81&publication_year=1984&pages=5618-5621&author=S.+W.+Tamauthor=L.+Cook&title=Sigma+opiates+and+certain+antipsychotic+drugs+mutually+inhibit+%28%2B%29-%5B3H%5D+SKF+10%2C047+and+%5B3H%5Dhaloperidol+binding+in+guinea+pig+brain+membranes&doi=10.1073%2Fpnas.81.17.5618"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">σ Opiates and certain antipsychotic drugs mutually inhibit (+)-[3H]SKF 10,047 and [3H]haloperidol binding in guinea pig brain membranes</span></div><div class="casAuthors">Tam, S. William; Cook, Leonard</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1984</span>),
    <span class="NLM_cas:volume">81</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">5618-21</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    </div><div class="casAbstract">The relationship between binding of antipsychotic drugs and σ psychotomimetic opiates to binding sites for the σ agonist 3H-labeled (+)-SKF 10,047  [58640-82-7] and to dopamine D2 sites was investigated.  In guinea pig brain membranes, (+)-[3H]SKF 10,047 bound to a single class of sites with a Kd of 4 × 10-8M and a Bmax of 333 fmol/mg of protein.  This binding was different from μ, κ, or δ opiate receptor binding.  It was inhibited by opiates that produce psychotomimetic activities but not by opiates that lack such activities.  Some antipsychotic drugs inhibited (+)-[3H]SKF 10,047 binding with high to moderate affinities in the following order of potency: haloperidol  [52-86-8] > perphenazine  [58-39-9] > fluphenazine  [69-23-8] > acetophenazine  [2751-68-0] > trifluoperazine  [117-89-5] > molindone  [7416-34-4] ≥ pimozide  [2062-78-4] ≥ thioridazine  [50-52-2] ≥ chlorpromazine  [50-53-3] ≥ triflupromazine  [146-54-3].  However, there were other antipsychotic drugs such as spiperone  [749-02-0] and clozapine  [5786-21-0] that showed low affinity for the (+)-[3H]SKF 10,047 binding sites.  Affinities of antipsychotic drugs for (+)-[3H]SKF 10,047 binding sites did not correlate with those for [3H]spiperone (dopamine D2) sites.  [3H]-Haloperidol binding in whole brain membranes was also inhibited by the σ opiates pentazocine  [359-83-1], cyclazocine  [3572-80-3], and (+)-SKF 10,047.  In the striatum, about half of the saturable [3H]haloperidol binding was to [3H]spiperone (D2) sites and the other half was to sites similar to (+)-[3H]SKF 10,047 binding sites.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3J2yT0mD-vLVg90H21EOLACvtfcHk0lhjgjT4K1HJ3Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2cXmtVCiu7w%253D&md5=bdb8459ffe1755e96b9cba9d63186817</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1073%2Fpnas.81.17.5618&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.81.17.5618%26sid%3Dliteratum%253Aachs%26aulast%3DTam%26aufirst%3DS.%2BW.%26aulast%3DCook%26aufirst%3DL.%26atitle%3DSigma%2520opiates%2520and%2520certain%2520antipsychotic%2520drugs%2520mutually%2520inhibit%2520%2528%252B%2529-%255B3H%255D%2520SKF%252010%252C047%2520and%2520%255B3H%255Dhaloperidol%2520binding%2520in%2520guinea%2520pig%2520brain%2520membranes%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1984%26volume%3D81%26spage%3D5618%26epage%3D5621%26doi%3D10.1073%2Fpnas.81.17.5618" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Navarro, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beltrán, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavas, M.</span></span> <span> </span><span class="NLM_article-title">Effects of (+) SKF 10,047, a sigma-1 receptor agonist, on anxiety, tested in two laboratory models in mice</span>. <i>Psicothema</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">427</span>– <span class="NLM_lpage">430</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=22748735" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A280%3ADC%252BC38jmt1entw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2012&pages=427-430&author=J.+F.+Navarroauthor=D.+Beltr%C3%A1nauthor=M.+Cavas&title=Effects+of+%28%2B%29+SKF+10%2C047%2C+a+sigma-1+receptor+agonist%2C+on+anxiety%2C+tested+in+two+laboratory+models+in+mice"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of (+) SKF 10,047, a sigma-1 receptor agonist, on anxiety,tested in two laboratory models in mice</span></div><div class="casAuthors">Navarro Jose Francisco; Beltran David; Cavas Maria</div><div class="citationInfo"><span class="NLM_cas:title">Psicothema</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">427-30</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Recently, sigma-1 receptor modulators have been considered drugs with an interesting therapeutic potential for the treatment of anxiety.  However, there is no clear information in preclinical studies about the possible effects of sigma-1 ligands on anxiety in experimental animal models.  Therefore, the present study examined the effects of (+)SKF 10,047 (2-8 mg/kg, ip), a sigma-1 agonist, on anxiety, tested in two classical laboratory models (social interaction test and elevated plus maze). (+)SKF 10,047 (8 mg/kg) produced a significant decrease of social investigation in the "social interaction test", whereas in the "elevated plus maze", the drug (4 and 8 mg/kg) provoked a significant reduction in the number of entries into open arms, as well as in the time spent in this area, as compared with the control group, without affecting motor activity.  Overall, these findings indicate that (+)SKF 10,047 exhibits an anxiogenic-like profile in mice.  It is suggested that anxiogenic effects of this sigma-1 ligand could be related to its potent ability to modulate diverse neurotransmitter systems involved in anxiety regulation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ-5aBXYB9pjhgd2Wuil24tfW6udTcc2eZCW2APy1C-Qrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38jmt1entw%253D%253D&md5=5b0d245b7f4afce7c6fdd1d612a5439d</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNavarro%26aufirst%3DJ.%2BF.%26aulast%3DBeltr%25C3%25A1n%26aufirst%3DD.%26aulast%3DCavas%26aufirst%3DM.%26atitle%3DEffects%2520of%2520%2528%252B%2529%2520SKF%252010%252C047%252C%2520a%2520sigma-1%2520receptor%2520agonist%252C%2520on%2520anxiety%252C%2520tested%2520in%2520two%2520laboratory%2520models%2520in%2520mice%26jtitle%3DPsicothema%26date%3D2012%26volume%3D24%26spage%3D427%26epage%3D430" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hayashi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujimoto, M.</span></span> <span> </span><span class="NLM_article-title">Detergent-resistant microdomains determine the localization of sigma-1 receptors to the endoplasmic reticulum-mitochondria junction</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>77</i></span>,  <span class="NLM_fpage">517</span>– <span class="NLM_lpage">528</span>, <span class="refDoi"> DOI: 10.1124/mol.109.062539</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1124%2Fmol.109.062539" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=20053954" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BC3cXkvVyktbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2010&pages=517-528&author=T.+Hayashiauthor=M.+Fujimoto&title=Detergent-resistant+microdomains+determine+the+localization+of+sigma-1+receptors+to+the+endoplasmic+reticulum-mitochondria+junction&doi=10.1124%2Fmol.109.062539"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Detergent-resistant microdomains determine the localization of σ-1 receptors to the endoplasmic reticulum-mitochondria junction</span></div><div class="casAuthors">Hayashi, Teruo; Fujimoto, Michiko</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">517-528</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">σ-1 Receptors (Sig-1Rs) that bind diverse synthetic and endogenous compds. have been implicated in the pathophysiol. of several human diseases such as drug addiction, depression, neurodegenerative disorders, pain-related disorders, and cancer.  Sig-1Rs were identified recently as novel ligand-operated mol. chaperones.  Although Sig-1Rs are predominantly expressed at endoplasmic reticulum (ER) subdomains apposing mitochondria [i.e., the mitochondria-assocd. ER membrane (MAM)], they dynamically change the cellular distribution, thus regulating both MAM-specific and plasma membrane proteins.  However, what dets. the location of Sig-1R at the MAM and how the receptor translocation is initiated is unknown.  Here we report that the detergent-resistant membranes (DRMs) play an important role in anchoring Sig-1Rs to the MAM.  The MAM, which is highly capable of accumulating ceramides, is enriched with both cholesterol and simple sphingolipids, thus forming Triton X-114-resistant DRMs.  Sig-1Rs assoc. with MAM-derived DRMs but not with those from microsomes.  A lipid overlay assay found that solubilized Sig-1Rs preferentially assoc. with simple sphingolipids such as ceramides.  Disrupting DRMs by lowering cholesterol or inhibiting de novo synthesis of ceramides at the ER largely decreases Sig-1R at DRMs and causes translocation of Sig-1R from the MAM to ER cisternae.  These findings suggest that the MAM, bearing cholesterol and ceramide-enriched microdomains at the ER, may use the microdomains to anchor Sig-1Rs to the location; thus, it serves to stage Sig-1R at ER-mitochondria junctions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZYY_eReHQzbVg90H21EOLACvtfcHk0lgKnXNrlcP5qw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXkvVyktbY%253D&md5=f36cef4c5a43f799cf7fbdef27bb968f</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1124%2Fmol.109.062539&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.109.062539%26sid%3Dliteratum%253Aachs%26aulast%3DHayashi%26aufirst%3DT.%26aulast%3DFujimoto%26aufirst%3DM.%26atitle%3DDetergent-resistant%2520microdomains%2520determine%2520the%2520localization%2520of%2520sigma-1%2520receptors%2520to%2520the%2520endoplasmic%2520reticulum-mitochondria%2520junction%26jtitle%3DMol.%2520Pharmacol.%26date%3D2010%26volume%3D77%26spage%3D517%26epage%3D528%26doi%3D10.1124%2Fmol.109.062539" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, T.</span></span> <span> </span><span class="NLM_article-title">The Roles of Intracellular Chaperone Proteins, Sigma Receptors, in Parkinson’s Disease (PD) and Major Depressive Disorder (MDD)</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">528</span>, <span class="refDoi"> DOI: 10.3389/fphar.2019.00528</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.3389%2Ffphar.2019.00528" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=31178723" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A280%3ADC%252BB3M3kslaqtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=528&author=K.+Yangauthor=C.+Wangauthor=T.+Sun&title=The+Roles+of+Intracellular+Chaperone+Proteins%2C+Sigma+Receptors%2C+in+Parkinson%E2%80%99s+Disease+%28PD%29+and+Major+Depressive+Disorder+%28MDD%29&doi=10.3389%2Ffphar.2019.00528"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">The Roles of Intracellular Chaperone Proteins, Sigma Receptors, in Parkinson's Disease (PD) and Major Depressive Disorder (MDD)</span></div><div class="casAuthors">Yang Kai; Wang Changcai; Sun Taolei; Sun Taolei</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in pharmacology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">528</span>
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    </div><div class="casAbstract">Sigma receptors, including Sigma-1 receptors and Sigma-2 receptors, are highly expressed in the CNS.  They are intracellular chaperone proteins.  Sigma-1 receptors localize mainly at the mitochondria-associated endoplasmic reticulum (ER) membrane (MAM).  Upon stimulation, they translocate from MAM to plasma membrane (PM) and nucleus, where they interact with many proteins and ion channels.  Sigma-1 receptor could interact with itself to form oligomers, its oligomerization states affect its ability to interact with client proteins including ion channels and BiP.  Sigma-1 receptor shows high affinity for many unrelated and structurally diverse ligands, but the mechanism for this diverse drug receptor interaction remains unknown.  Sigma-1 receptors also directly bind many proteins including G protein-coupled receptors (GPCRs) and ion channels.  In recent years, significant progress has been made in our understanding of roles of the Sigma-1 receptors in normal and pathological conditions, but more studies are still required for the Sigma-2 receptors.  The physiological roles of Sigma-1 receptors in the CNS are discussed.  They can modulate the activity of many ion channels including voltage-dependent ion channels including Ca(2+), Na(+), K(+) channels and NMDAR, thus affecting neuronal excitability and synaptic activity.  They are also involved in synaptic plasticity and learning and memory.  Moreover, the activation of Sigma receptors protects neurons from death via the modulation of ER stress, neuroinflammation, and Ca(2+) homeostasis.  Evidences about the involvement of Sigma-1 receptors in Parkinson's disease (PD) and Major Depressive Disorder (MDD) are also presented, indicating Sigma-1 receptors might be promising targets for pharmacologically treating PD and MDD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTX1yhwJRUF1HT4ugvCDgnZfW6udTcc2eYBMrq0qdkf_Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3M3kslaqtw%253D%253D&md5=fdec2ea27cf307a82d5a574da02b4f37</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2019.00528&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2019.00528%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DK.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DSun%26aufirst%3DT.%26atitle%3DThe%2520Roles%2520of%2520Intracellular%2520Chaperone%2520Proteins%252C%2520Sigma%2520Receptors%252C%2520in%2520Parkinson%25E2%2580%2599s%2520Disease%2520%2528PD%2529%2520and%2520Major%2520Depressive%2520Disorder%2520%2528MDD%2529%26jtitle%3DFront.%2520Pharmacol.%26date%3D2019%26volume%3D10%26spage%3D528%26doi%3D10.3389%2Ffphar.2019.00528" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hanner, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moebius, F. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flandorfer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knaus, H. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Striessnig, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kempner, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glossmann, H.</span></span> <span> </span><span class="NLM_article-title">Purification, molecular cloning, and expression of the mammalian sigma1-binding site</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>93</i></span>,  <span class="NLM_fpage">8072</span>– <span class="NLM_lpage">8077</span>, <span class="refDoi"> DOI: 10.1073/pnas.93.15.8072</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1073%2Fpnas.93.15.8072" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=8755605" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADyaK28XksFSqsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=1996&pages=8072-8077&author=M.+Hannerauthor=F.+F.+Moebiusauthor=A.+Flandorferauthor=H.+G.+Knausauthor=J.+Striessnigauthor=E.+Kempnerauthor=H.+Glossmann&title=Purification%2C+molecular+cloning%2C+and+expression+of+the+mammalian+sigma1-binding+site&doi=10.1073%2Fpnas.93.15.8072"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Purification, molecular cloning, and expression of the mammalian sigma1-binding site</span></div><div class="casAuthors">Hanner, Markus; Moebius, Fabian F.; Flandorfer, Astrid; Knaus, Hans-Guenther; Striessnig, Joerg; Kempner, Ellis; Glossman, Hartmut</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">93</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">8072-8077</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Sigma-ligands comprise several chem. unrelated drugs such as haloperidol, pentazocine, and ditolylguanidine, which bind to a family of low mol. mass proteins in the endoplasmic reticulum.  These so-called sigma-receptors are believed to mediate various pharmacol. effects of sigma-ligands by as yet unknown mechanisms.  Based on their opposite enantioselectivity for benzomorphans and different mol. masses, two subtypes are differentiated.  We purified the sigma1-binding site as a single 30-kDa protein from guinea pig liver employing the benzomorphan (+)[3H]pentazocine and the aryladize (-)[3H]azidopamil as specific probes.  The purified (+)[3H]pentazocine-binding protein retained its high affinity for haloperidol, pentazocine, and ditolylguanidine.  Partial amino acid sequence obtained after trypsinolysis revealed no homol. to known proteins.  Radiation inactivation of the pentazocine-labeled sigma1-binding site yielded a mol. mass of 24 kDa.  The corresponding cDNA was cloned using degenerate oligonucleotides and cDNA library screening.  Its open reading frame encoded a 25.3-kDa protein with at least one putative transmembrane segment.  The protein expressed in yeast cells transformed with the cDNA showed the pharmacol. characteristics of the brain and liver sigma1-binding site.  The deduced amino acid sequence was structurally unrelated to known mammalian proteins but it shared homol. with fungal proteins involved in sterol synthesis.  Northern blots showed high densities of the sigma1-binding site mRNA in sterol-producing tissues.  This is also in agreement with the known ability of sigma1-binding sites to interact with steroids, such as progesterone.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3kp2l6ZPKdrVg90H21EOLACvtfcHk0lgKnXNrlcP5qw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XksFSqsr8%253D&md5=01c7d3bbab83dd5d18531845213bf267</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1073%2Fpnas.93.15.8072&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.93.15.8072%26sid%3Dliteratum%253Aachs%26aulast%3DHanner%26aufirst%3DM.%26aulast%3DMoebius%26aufirst%3DF.%2BF.%26aulast%3DFlandorfer%26aufirst%3DA.%26aulast%3DKnaus%26aufirst%3DH.%2BG.%26aulast%3DStriessnig%26aufirst%3DJ.%26aulast%3DKempner%26aufirst%3DE.%26aulast%3DGlossmann%26aufirst%3DH.%26atitle%3DPurification%252C%2520molecular%2520cloning%252C%2520and%2520expression%2520of%2520the%2520mammalian%2520sigma1-binding%2520site%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1996%26volume%3D93%26spage%3D8072%26epage%3D8077%26doi%3D10.1073%2Fpnas.93.15.8072" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Quirion, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowen, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Itzhak, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Junien, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Musacchio, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rothman, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tam, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, D. P.</span></span> <span> </span><span class="NLM_article-title">A proposal for the classification of sigma binding sites</span>. <i>Trends Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">1992</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">85</span>– <span class="NLM_lpage">86</span>, <span class="refDoi"> DOI: 10.1016/0165-6147(92)90030-A</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1016%2F0165-6147%2892%2990030-A" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1315463" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A280%3ADyaK383ksFGrsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=1992&pages=85-86&author=R.+Quirionauthor=W.+D.+Bowenauthor=Y.+Itzhakauthor=J.+L.+Junienauthor=J.+M.+Musacchioauthor=R.+B.+Rothmanauthor=T.+P.+Suauthor=S.+W.+Tamauthor=D.+P.+Taylor&title=A+proposal+for+the+classification+of+sigma+binding+sites&doi=10.1016%2F0165-6147%2892%2990030-A"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">A proposal for the classification of sigma binding sites</span></div><div class="casAuthors">Quirion R; Bowen W D; Itzhak Y; Junien J L; Musacchio J M; Rothman R B; Su T P; Tam S W; Taylor D P</div><div class="citationInfo"><span class="NLM_cas:title">Trends in pharmacological sciences</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">85-6</span>
        ISSN:<span class="NLM_cas:issn">0165-6147</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR9QiJWG_oOy3p3bfzSLaX5fW6udTcc2ea3eXzDVaaOzbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK383ksFGrsQ%253D%253D&md5=bdbde1d04c3c3e627e4ff512102ddf5d</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2F0165-6147%2892%2990030-A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0165-6147%252892%252990030-A%26sid%3Dliteratum%253Aachs%26aulast%3DQuirion%26aufirst%3DR.%26aulast%3DBowen%26aufirst%3DW.%2BD.%26aulast%3DItzhak%26aufirst%3DY.%26aulast%3DJunien%26aufirst%3DJ.%2BL.%26aulast%3DMusacchio%26aufirst%3DJ.%2BM.%26aulast%3DRothman%26aufirst%3DR.%2BB.%26aulast%3DSu%26aufirst%3DT.%2BP.%26aulast%3DTam%26aufirst%3DS.%2BW.%26aulast%3DTaylor%26aufirst%3DD.%2BP.%26atitle%3DA%2520proposal%2520for%2520the%2520classification%2520of%2520sigma%2520binding%2520sites%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D1992%26volume%3D13%26spage%3D85%26epage%3D86%26doi%3D10.1016%2F0165-6147%2892%2990030-A" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gurpinar, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koehl, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manglik, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kruse, A. C.</span></span> <span> </span><span class="NLM_article-title">Crystal structure of the human σ1 receptor</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>532</i></span>,  <span class="NLM_fpage">527</span>– <span class="NLM_lpage">530</span>, <span class="refDoi"> DOI: 10.1038/nature17391</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1038%2Fnature17391" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=27042935" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BC28Xlsl2gt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=532&publication_year=2016&pages=527-530&author=H.+R.+Schmidtauthor=S.+Zhengauthor=E.+Gurpinarauthor=A.+Koehlauthor=A.+Manglikauthor=A.+C.+Kruse&title=Crystal+structure+of+the+human+%CF%831+receptor&doi=10.1038%2Fnature17391"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structure of the human σ1 receptor</span></div><div class="casAuthors">Schmidt, Hayden R.; Zheng, Sanduo; Gurpinar, Esin; Koehl, Antoine; Manglik, Aashish; Kruse, Andrew C.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">532</span>
        (<span class="NLM_cas:issue">7600</span>),
    <span class="NLM_cas:pages">527-530</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The human σ1 receptor is an enigmatic endoplasmic reticulum (ER)-resident transmembrane protein implicated in a variety of disorders including depression, drug addiction, and neuropathic pain.  Recently, an addnl. connection to amyotrophic lateral sclerosis has emerged from studies of human genetics and mouse models.  Unlike many transmembrane receptors that belong to large, extensively studied families such as G-protein-coupled receptors or ligand-gated ion channels, the σ1 receptor is an evolutionary isolate with no discernible similarity to any other human protein.  Despite its increasingly clear importance in human physiol. and disease, the mol. architecture of the σ1 receptor and its regulation by drug-like compds. remain poorly defined.  Here, the authors report crystal structures of the human σ1 receptor in complex with 2 chem. divergent ligands, PD 144418 and 4-(N-benzylpiperidin-4-yl)-4-iodobenzamide (4-IBP).  The structures revealed a trimeric architecture with a single transmembrane domain in each protomer.  The C-terminal domain of the receptor showed an extensive flat, hydrophobic membrane-proximal surface, suggesting an intimate assocn. with the cytosolic surface of the ER membrane in cells.  This domain included a cupin-like β-barrel with the ligand-binding site buried at its center.  This large, hydrophobic ligand-binding cavity showed remarkable plasticity in ligand recognition, binding the 2 ligands in similar positions despite dissimilar chem. structures.  Taken together, these results revealed the overall architecture, oligomerization state, and mol. basis for ligand recognition by this important but poorly understood protein.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokQBAf03Pml7Vg90H21EOLACvtfcHk0lifyiNLYShPrA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xlsl2gt7o%253D&md5=fb6df7814060fbd05ba41261ad1061f5</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1038%2Fnature17391&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature17391%26sid%3Dliteratum%253Aachs%26aulast%3DSchmidt%26aufirst%3DH.%2BR.%26aulast%3DZheng%26aufirst%3DS.%26aulast%3DGurpinar%26aufirst%3DE.%26aulast%3DKoehl%26aufirst%3DA.%26aulast%3DManglik%26aufirst%3DA.%26aulast%3DKruse%26aufirst%3DA.%2BC.%26atitle%3DCrystal%2520structure%2520of%2520the%2520human%2520%25CF%25831%2520receptor%26jtitle%3DNature%26date%3D2016%26volume%3D532%26spage%3D527%26epage%3D530%26doi%3D10.1038%2Fnature17391" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Betz, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dror, R. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kruse, A. C.</span></span> <span> </span><span class="NLM_article-title">Structural basis for σ(1) receptor ligand recognition</span>. <i>Nat. Struct. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">981</span>– <span class="NLM_lpage">987</span>, <span class="refDoi"> DOI: 10.1038/s41594-018-0137-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1038%2Fs41594-018-0137-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=30291362" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvVOjsbvM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2018&pages=981-987&author=H.+R.+Schmidtauthor=R.+M.+Betzauthor=R.+O.+Drorauthor=A.+C.+Kruse&title=Structural+basis+for+%CF%83%281%29+receptor+ligand+recognition&doi=10.1038%2Fs41594-018-0137-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Structural basis for σ1 receptor ligand recognition</span></div><div class="casAuthors">Schmidt, Hayden R.; Betz, Robin M.; Dror, Ron O.; Kruse, Andrew C.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Structural & Molecular Biology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">981-987</span>CODEN:
                <span class="NLM_cas:coden">NSMBCU</span>;
        ISSN:<span class="NLM_cas:issn">1545-9993</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">The s1 receptor is a poorly understood membrane protein expressed throughout the human body.  Ligands targeting the s1 receptor are in clin. trials for treatment of Alzheimer's disease, ischemic stroke, and neuropathic pain.  However, relatively little is known regarding the s1 receptor's mol. function.  Here, we present crystal structures of human s1 receptor bound to the antagonists haloperidol and NE-100, and the agonist (+)-pentazocine, at crystallog. resolns. of 3.1 Å, 2.9 Å, and 3.1 Å, resp.  These structures reveal a unique binding pose for the agonist.  The structures and accompanying mol. dynamics (MD) simulations identify agonist-induced structural rearrangements in the receptor.  Addnl., we show that ligand binding to s1 is a multistep process that is rate limited by receptor conformational change.  We used MD simulations to reconstruct a ligand binding pathway involving two major conformational changes.  These data provide a framework for understanding the mol. basis for s1 agonism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQ2dgVTV70vbVg90H21EOLACvtfcHk0lifyiNLYShPrA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvVOjsbvM&md5=d12d12aecbd89684824975977ec03e4b</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1038%2Fs41594-018-0137-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41594-018-0137-2%26sid%3Dliteratum%253Aachs%26aulast%3DSchmidt%26aufirst%3DH.%2BR.%26aulast%3DBetz%26aufirst%3DR.%2BM.%26aulast%3DDror%26aufirst%3DR.%2BO.%26aulast%3DKruse%26aufirst%3DA.%2BC.%26atitle%3DStructural%2520basis%2520for%2520%25CF%2583%25281%2529%2520receptor%2520ligand%2520recognition%26jtitle%3DNat.%2520Struct.%2520Mol.%2520Biol.%26date%3D2018%26volume%3D25%26spage%3D981%26epage%3D987%26doi%3D10.1038%2Fs41594-018-0137-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ryskamp, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korban, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhemkov, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kraskovskaya, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bezprozvanny, I.</span></span> <span> </span><span class="NLM_article-title">Neuronal Sigma-1 Receptors: Signaling Functions and Protective Roles in Neurodegenerative Diseases</span>. <i>Front. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">862</span>, <span class="refDoi"> DOI: 10.3389/fnins.2019.00862</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.3389%2Ffnins.2019.00862" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=31551669" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A280%3ADC%252BB3MnhvVWjsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2019&pages=862&author=D.+A.+Ryskampauthor=S.+Korbanauthor=V.+Zhemkovauthor=N.+Kraskovskayaauthor=I.+Bezprozvanny&title=Neuronal+Sigma-1+Receptors%3A+Signaling+Functions+and+Protective+Roles+in+Neurodegenerative+Diseases&doi=10.3389%2Ffnins.2019.00862"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Neuronal Sigma-1 Receptors: Signaling Functions and Protective Roles in Neurodegenerative Diseases</span></div><div class="casAuthors">Ryskamp Daniel A; Zhemkov Vladimir; Bezprozvanny Ilya; Korban Svetlana; Kraskovskaya Nina; Bezprozvanny Ilya</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in neuroscience</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">862</span>
        ISSN:<span class="NLM_cas:issn">1662-4548</span>.
    </div><div class="casAbstract">Sigma-1 receptor (S1R) is a multi-functional, ligand-operated protein situated in endoplasmic reticulum (ER) membranes and changes in its function and/or expression have been associated with various neurological disorders including amyotrophic lateral sclerosis/frontotemporal dementia, Alzheimer's (AD) and Huntington's diseases (HD).  S1R agonists are broadly neuroprotective and this is achieved through a diversity of S1R-mediated signaling functions that are generally pro-survival and anti-apoptotic; yet, relatively little is known regarding the exact mechanisms of receptor functioning at the molecular level.  This review summarizes therapeutically relevant mechanisms by which S1R modulates neurophysiology and implements neuroprotective functions in neurodegenerative diseases.  These mechanisms are diverse due to the fact that S1R can bind to and modulate a large range of client proteins, including many ion channels in both ER and plasma membranes.  We summarize the effect of S1R on its interaction partners and consider some of the cell type- and disease-specific aspects of these actions.  Besides direct protein interactions in the endoplasmic reticulum, S1R is likely to function at the cellular/interorganellar level by altering the activity of several plasmalemmal ion channels through control of trafficking, which may help to reduce excitotoxicity.  Moreover, S1R is situated in lipid rafts where it binds cholesterol and regulates lipid and protein trafficking and calcium flux at the mitochondrial-associated membrane (MAM) domain.  This may have important implications for MAM stability and function in neurodegenerative diseases as well as cellular bioenergetics.  We also summarize the structural and biochemical features of S1R proposed to underlie its activity.  In conclusion, S1R is incredibly versatile in its ability to foster neuronal homeostasis in the context of several neurodegenerative disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTnXmondofHvmyYR5VtavbzfW6udTcc2eaQEXuu_Uzkl7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MnhvVWjsA%253D%253D&md5=b8a65774a44e82a94e5049247c993883</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.3389%2Ffnins.2019.00862&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffnins.2019.00862%26sid%3Dliteratum%253Aachs%26aulast%3DRyskamp%26aufirst%3DD.%2BA.%26aulast%3DKorban%26aufirst%3DS.%26aulast%3DZhemkov%26aufirst%3DV.%26aulast%3DKraskovskaya%26aufirst%3DN.%26aulast%3DBezprozvanny%26aufirst%3DI.%26atitle%3DNeuronal%2520Sigma-1%2520Receptors%253A%2520Signaling%2520Functions%2520and%2520Protective%2520Roles%2520in%2520Neurodegenerative%2520Diseases%26jtitle%3DFront.%2520Neurosci.%26date%3D2019%26volume%3D13%26spage%3D862%26doi%3D10.3389%2Ffnins.2019.00862" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Katz, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hiranita, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kopajtic, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rice, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mesangeau, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narayanan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abdelazeem, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCurdy, C. R.</span></span> <span> </span><span class="NLM_article-title">Blockade of Cocaine or σ Receptor Agonist Self Administration by Subtype-Selective σ Receptor Antagonists</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>358</i></span>,  <span class="NLM_fpage">109</span>– <span class="NLM_lpage">124</span>, <span class="refDoi"> DOI: 10.1124/jpet.116.232728</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1124%2Fjpet.116.232728" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=27189970" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsFOhsLnK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=358&publication_year=2016&pages=109-124&author=J.+L.+Katzauthor=T.+Hiranitaauthor=T.+A.+Kopajticauthor=K.+C.+Riceauthor=C.+Mesangeauauthor=S.+Narayananauthor=A.+H.+Abdelazeemauthor=C.+R.+McCurdy&title=Blockade+of+Cocaine+or+%CF%83+Receptor+Agonist+Self+Administration+by+Subtype-Selective+%CF%83+Receptor+Antagonists&doi=10.1124%2Fjpet.116.232728"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Blockade of cocaine or σ receptor agonist self administration by subtype-selective σ receptor antagonists</span></div><div class="casAuthors">Katz, Jonathan L.; Hiranita, Takato; Kopajtic, Theresa A.; Rice, Kenner C.; Mesangeau, Christophe; Narayanan, Sanju; Abdelazeem, Ahmed H.; McCurdy, Christopher R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">358</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">109-124</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The identification of sigma receptor (σR) subtypes has been based on radioligand binding and, despite progress with σ1R cellular function, less is known about σR subtype functions in vivo.  Recent findings that cocaine self administration experience will trigger σR agonist self administration was used in this study to assess the in vivo receptor subtype specificity of the agonists (1)-pentazocine, PRE-084 [2-(4-morpholinethyl) 1-phenylcyclohexanecarboxylate hydrochloride], and 1,3-di-o-tolylguanidine (DTG) and several novel putative σR antagonists.  Radioligand binding studies detd. in vitro σR selectivity of the novel compds., which were subsequently studied for self administration and antagonism of cocaine, (1)-pentazocine, PRE-084, or DTG self administration.  Across the dose ranges studied, none of the novel compds. were self administered, nor did they alter cocaine self administration.  All compds. blocked DTG self administration, with a subset also blocking (1)-pentazocine and PRE-084 self administration.  The most selective of the compds. in binding σ1Rs blocked cocaine self administration when combined with a dopamine transport inhibitor, either methylphenidate or nomifensine.  These drug combinations did not decrease rates of responding maintained by food reinforcement.  In contrast, the most selective of the compds. in binding σ2Rs had no effect on cocaine self administration in combination with either dopamine transport inhibitor.  Thus, these results identify subtype-specific in vivo antagonists, and the utility of σR agonist substitution for cocaine self administration as an assay capable of distinguishing σR subtype selectivity in vivo.  These results further suggest that effectiveness of dual σR antagonism and dopamine transport inhibition in blocking cocaine self administration is specific for σ1Rs and further support this dual targeting approach to development of cocaine antagonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqz4jCUfp7CsLVg90H21EOLACvtfcHk0lj4L-CPKwk3lQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsFOhsLnK&md5=721dfe4db5a272382b8c6a50b1dda748</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1124%2Fjpet.116.232728&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.116.232728%26sid%3Dliteratum%253Aachs%26aulast%3DKatz%26aufirst%3DJ.%2BL.%26aulast%3DHiranita%26aufirst%3DT.%26aulast%3DKopajtic%26aufirst%3DT.%2BA.%26aulast%3DRice%26aufirst%3DK.%2BC.%26aulast%3DMesangeau%26aufirst%3DC.%26aulast%3DNarayanan%26aufirst%3DS.%26aulast%3DAbdelazeem%26aufirst%3DA.%2BH.%26aulast%3DMcCurdy%26aufirst%3DC.%2BR.%26atitle%3DBlockade%2520of%2520Cocaine%2520or%2520%25CF%2583%2520Receptor%2520Agonist%2520Self%2520Administration%2520by%2520Subtype-Selective%2520%25CF%2583%2520Receptor%2520Antagonists%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2016%26volume%3D358%26spage%3D109%26epage%3D124%26doi%3D10.1124%2Fjpet.116.232728" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jang, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bouhaddou, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obernier, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Meara, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rezelj, V. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, J. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swaney, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tummino, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hüttenhain, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaake, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richards, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tutuncuoglu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foussard, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Batra, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haas, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Modak, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haas, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polacco, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Braberg, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fabius, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eckhardt, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soucheray, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bennett, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cakir, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGregor, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roesch, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vallet, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mac Kain, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miorin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreno, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naing, Z. Z. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirby, I. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melnyk, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chorba, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lou, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrio-Hernandez, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Memon, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hernandez-Armenta, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathy, C. J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perica, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pilla, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganesan, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saltzberg, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rakesh, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenthal, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calviello, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venkataramanan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liboy-Lugo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wankowicz, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bohn, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Safari, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ugur, F. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koh, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savar, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tran, Q. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shengjuler, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fletcher, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Neal, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, J. C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Broadhurst, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klippsten, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharp, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wenzell, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuzuoglu-Ozturk, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trenker, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavero, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hiatt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rathore, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Subramanian, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noack, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hubert, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stroud, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frankel, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenberg, O. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verba, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agard, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ott, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emerman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jura, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Zastrow, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verdin, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashworth, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">d’Enfert, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mukherjee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malik, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujimori, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ideker, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Craik, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Floor, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fraser, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gross, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sali, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruggero, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taunton, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kortemme, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beltrao, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vignuzzi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">García-Sastre, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shokat, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shoichet, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krogan, N. J.</span></span> <span> </span><span class="NLM_article-title">A SARS-CoV-2 protein interaction map reveals targets for drug repurposing</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>583</i></span>,  <span class="NLM_fpage">459</span>– <span class="NLM_lpage">468</span>, <span class="refDoi"> DOI: 10.1038/s41586-020-2286-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1038%2Fs41586-020-2286-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=32353859" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtlCqtbrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=583&publication_year=2020&pages=459-468&author=D.+E.+Gordonauthor=G.+M.+Jangauthor=M.+Bouhaddouauthor=J.+Xuauthor=K.+Obernierauthor=K.+M.+Whiteauthor=M.+J.+O%E2%80%99Mearaauthor=V.+V.+Rezeljauthor=J.+Z.+Guoauthor=D.+L.+Swaneyauthor=T.+A.+Tumminoauthor=R.+H%C3%BCttenhainauthor=R.+M.+Kaakeauthor=A.+L.+Richardsauthor=B.+Tutuncuogluauthor=H.+Foussardauthor=J.+Batraauthor=K.+Haasauthor=M.+Modakauthor=M.+Kimauthor=P.+Haasauthor=B.+J.+Polaccoauthor=H.+Brabergauthor=J.+M.+Fabiusauthor=M.+Eckhardtauthor=M.+Soucherayauthor=M.+J.+Bennettauthor=M.+Cakirauthor=M.+J.+McGregorauthor=Q.+Liauthor=B.+Meyerauthor=F.+Roeschauthor=T.+Valletauthor=A.+Mac+Kainauthor=L.+Miorinauthor=E.+Morenoauthor=Z.+Z.+C.+Naingauthor=Y.+Zhouauthor=S.+Pengauthor=Y.+Shiauthor=Z.+Zhangauthor=W.+Shenauthor=I.+T.+Kirbyauthor=J.+E.+Melnykauthor=J.+S.+Chorbaauthor=K.+Louauthor=S.+A.+Daiauthor=I.+Barrio-Hernandezauthor=D.+Memonauthor=C.+Hernandez-Armentaauthor=J.+Lyuauthor=C.+J.+P.+Mathyauthor=T.+Pericaauthor=K.+B.+Pillaauthor=S.+J.+Ganesanauthor=D.+J.+Saltzbergauthor=R.+Rakeshauthor=X.+Liuauthor=S.+B.+Rosenthalauthor=L.+Calvielloauthor=S.+Venkataramananauthor=J.+Liboy-Lugoauthor=Y.+Linauthor=X.+P.+Huangauthor=Y.+Liuauthor=S.+A.+Wankowiczauthor=M.+Bohnauthor=M.+Safariauthor=F.+S.+Ugurauthor=C.+Kohauthor=N.+S.+Savarauthor=Q.+D.+Tranauthor=D.+Shengjulerauthor=S.+J.+Fletcherauthor=M.+C.+O%E2%80%99Nealauthor=Y.+Caiauthor=J.+C.+J.+Changauthor=D.+J.+Broadhurstauthor=S.+Klippstenauthor=P.+P.+Sharpauthor=N.+A.+Wenzellauthor=D.+Kuzuoglu-Ozturkauthor=H.+Y.+Wangauthor=R.+Trenkerauthor=J.+M.+Youngauthor=D.+A.+Caveroauthor=J.+Hiattauthor=T.+L.+Rothauthor=U.+Rathoreauthor=A.+Subramanianauthor=J.+Noackauthor=M.+Hubertauthor=R.+M.+Stroudauthor=A.+D.+Frankelauthor=O.+S.+Rosenbergauthor=K.+A.+Verbaauthor=D.+A.+Agardauthor=M.+Ottauthor=M.+Emermanauthor=N.+Juraauthor=M.+von+Zastrowauthor=E.+Verdinauthor=A.+Ashworthauthor=O.+Schwartzauthor=C.+d%E2%80%99Enfertauthor=S.+Mukherjeeauthor=M.+Jacobsonauthor=H.+S.+Malikauthor=D.+G.+Fujimoriauthor=T.+Idekerauthor=C.+S.+Craikauthor=S.+N.+Floorauthor=J.+S.+Fraserauthor=J.+D.+Grossauthor=A.+Saliauthor=B.+L.+Rothauthor=D.+Ruggeroauthor=J.+Tauntonauthor=T.+Kortemmeauthor=P.+Beltraoauthor=M.+Vignuzziauthor=A.+Garc%C3%ADa-Sastreauthor=K.+M.+Shokatauthor=B.+K.+Shoichetauthor=N.+J.+Krogan&title=A+SARS-CoV-2+protein+interaction+map+reveals+targets+for+drug+repurposing&doi=10.1038%2Fs41586-020-2286-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">A SARS-CoV-2 protein interaction map reveals targets for drug repurposing</span></div><div class="casAuthors">Gordon, David E.; Jang, Gwendolyn M.; Bouhaddou, Mehdi; Xu, Jiewei; Obernier, Kirsten; White, Kris M.; O'Meara, Matthew J.; Rezelj, Veronica V.; Guo, Jeffrey Z.; Swaney, Danielle L.; Tummino, Tia A.; Huttenhain, Ruth; Kaake, Robyn M.; Richards, Alicia L.; Tutuncuoglu, Beril; Foussard, Helene; Batra, Jyoti; Haas, Kelsey; Modak, Maya; Kim, Minkyu; Haas, Paige; Polacco, Benjamin J.; Braberg, Hannes; Fabius, Jacqueline M.; Eckhardt, Manon; Soucheray, Margaret; Bennett, Melanie J.; Cakir, Merve; McGregor, Michael J.; Li, Qiongyu; Meyer, Bjoern; Roesch, Ferdinand; Vallet, Thomas; Mac Kain, Alice; Miorin, Lisa; Moreno, Elena; Naing, Zun Zar Chi; Zhou, Yuan; Peng, Shiming; Shi, Ying; Zhang, Ziyang; Shen, Wenqi; Kirby, Ilsa T.; Melnyk, James E.; Chorba, John S.; Lou, Kevin; Dai, Shizhong A.; Barrio-Hernandez, Inigo; Memon, Danish; Hernandez-Armenta, Claudia; Lyu, Jiankun; Mathy, Christopher J. P.; Perica, Tina; Pilla, Kala Bharath; Ganesan, Sai J.; Saltzberg, Daniel J.; Rakesh, Ramachandran; Liu, Xi; Rosenthal, Sara B.; Calviello, Lorenzo; Venkataramanan, Srivats; Liboy-Lugo, Jose; Lin, Yizhu; Huang, Xi-Ping; Liu, YongFeng; Wankowicz, Stephanie A.; Bohn, Markus; Safari, Maliheh; Ugur, Fatima S.; Koh, Cassandra; Savar, Nastaran Sadat; Tran, Quang Dinh; Shengjuler, Djoshkun; Fletcher, Sabrina J.; O'Neal, Michael C.; Cai, Yiming; Chang, Jason C. J.; Broadhurst, David J.; Klippsten, Saker; Sharp, Phillip P.; Wenzell, Nicole A.; Kuzuoglu-Ozturk, Duygu; Wang, Hao-Yuan; Trenker, Raphael; Young, Janet M.; Cavero, Devin A.; Hiatt, Joseph; Roth, Theodore L.; Rathore, Ujjwal; Subramanian, Advait; Noack, Julia; Hubert, Mathieu; Stroud, Robert M.; Frankel, Alan D.; Rosenberg, Oren S.; Verba, Kliment A.; Agard, David A.; Ott, Melanie; Emerman, Michael; Jura, Natalia; von Zastrow, Mark; Verdin, Eric; Ashworth, Alan; Schwartz, Olivier; d'Enfert, Christophe; Mukherjee, Shaeri; Jacobson, Matt; Malik, Harmit S.; Fujimori, Danica G.; Ideker, Trey; Craik, Charles S.; Floor, Stephen N.; Fraser, James S.; Gross, John D.; Sali, Andrej; Roth, Bryan L.; Ruggero, Davide; Taunton, Jack; Kortemme, Tanja; Beltrao, Pedro; Vignuzzi, Marco; Garcia-Sastre, Adolfo; Shokat, Kevan M.; Shoichet, Brian K.; Krogan, Nevan J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">583</span>
        (<span class="NLM_cas:issue">7816</span>),
    <span class="NLM_cas:pages">459-468</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Abstr.: A newly described coronavirus named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is the causative agent of coronavirus disease 2019 (COVID-19), has infected over 2.3 million people, led to the death of more than 160,000 individuals and caused worldwide social and economic disruption1,2.  There are no antiviral drugs with proven clin. efficacy for the treatment of COVID-19, nor are there any vaccines that prevent infection with SARS-CoV-2, and efforts to develop drugs and vaccines are hampered by the limited knowledge of the mol. details of how SARS-CoV-2 infects cells.  Here we cloned, tagged and expressed 26 of the 29 SARS-CoV-2 proteins in human cells and identified the human proteins that phys. assocd. with each of the SARS-CoV-2 proteins using affinity-purifn. mass spectrometry, identifying 332 high-confidence protein-protein interactions between SARS-CoV-2 and human proteins.  Among these, we identify 66 druggable human proteins or host factors targeted by 69 compds. (of which, 29 drugs are approved by the US Food and Drug Administration, 12 are in clin. trials and 28 are preclin. compds.).  We screened a subset of these in multiple viral assays and found two sets of pharmacol. agents that displayed antiviral activity: inhibitors of mRNA translation and predicted regulators of the sigma-1 and sigma-2 receptors.  Further studies of these host-factor-targeting agents, including their combination with drugs that directly target viral enzymes, could lead to a therapeutic regimen to treat COVID-19.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDvJUIvi-Ws7Vg90H21EOLACvtfcHk0lgXUDm7in3X0Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtlCqtbrI&md5=ce8b172ae73aacd3b3d8bb64877f4435</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1038%2Fs41586-020-2286-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41586-020-2286-9%26sid%3Dliteratum%253Aachs%26aulast%3DGordon%26aufirst%3DD.%2BE.%26aulast%3DJang%26aufirst%3DG.%2BM.%26aulast%3DBouhaddou%26aufirst%3DM.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DObernier%26aufirst%3DK.%26aulast%3DWhite%26aufirst%3DK.%2BM.%26aulast%3DO%25E2%2580%2599Meara%26aufirst%3DM.%2BJ.%26aulast%3DRezelj%26aufirst%3DV.%2BV.%26aulast%3DGuo%26aufirst%3DJ.%2BZ.%26aulast%3DSwaney%26aufirst%3DD.%2BL.%26aulast%3DTummino%26aufirst%3DT.%2BA.%26aulast%3DH%25C3%25BCttenhain%26aufirst%3DR.%26aulast%3DKaake%26aufirst%3DR.%2BM.%26aulast%3DRichards%26aufirst%3DA.%2BL.%26aulast%3DTutuncuoglu%26aufirst%3DB.%26aulast%3DFoussard%26aufirst%3DH.%26aulast%3DBatra%26aufirst%3DJ.%26aulast%3DHaas%26aufirst%3DK.%26aulast%3DModak%26aufirst%3DM.%26aulast%3DKim%26aufirst%3DM.%26aulast%3DHaas%26aufirst%3DP.%26aulast%3DPolacco%26aufirst%3DB.%2BJ.%26aulast%3DBraberg%26aufirst%3DH.%26aulast%3DFabius%26aufirst%3DJ.%2BM.%26aulast%3DEckhardt%26aufirst%3DM.%26aulast%3DSoucheray%26aufirst%3DM.%26aulast%3DBennett%26aufirst%3DM.%2BJ.%26aulast%3DCakir%26aufirst%3DM.%26aulast%3DMcGregor%26aufirst%3DM.%2BJ.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DMeyer%26aufirst%3DB.%26aulast%3DRoesch%26aufirst%3DF.%26aulast%3DVallet%26aufirst%3DT.%26aulast%3DMac%2BKain%26aufirst%3DA.%26aulast%3DMiorin%26aufirst%3DL.%26aulast%3DMoreno%26aufirst%3DE.%26aulast%3DNaing%26aufirst%3DZ.%2BZ.%2BC.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DPeng%26aufirst%3DS.%26aulast%3DShi%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DShen%26aufirst%3DW.%26aulast%3DKirby%26aufirst%3DI.%2BT.%26aulast%3DMelnyk%26aufirst%3DJ.%2BE.%26aulast%3DChorba%26aufirst%3DJ.%2BS.%26aulast%3DLou%26aufirst%3DK.%26aulast%3DDai%26aufirst%3DS.%2BA.%26aulast%3DBarrio-Hernandez%26aufirst%3DI.%26aulast%3DMemon%26aufirst%3DD.%26aulast%3DHernandez-Armenta%26aufirst%3DC.%26aulast%3DLyu%26aufirst%3DJ.%26aulast%3DMathy%26aufirst%3DC.%2BJ.%2BP.%26aulast%3DPerica%26aufirst%3DT.%26aulast%3DPilla%26aufirst%3DK.%2BB.%26aulast%3DGanesan%26aufirst%3DS.%2BJ.%26aulast%3DSaltzberg%26aufirst%3DD.%2BJ.%26aulast%3DRakesh%26aufirst%3DR.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DRosenthal%26aufirst%3DS.%2BB.%26aulast%3DCalviello%26aufirst%3DL.%26aulast%3DVenkataramanan%26aufirst%3DS.%26aulast%3DLiboy-Lugo%26aufirst%3DJ.%26aulast%3DLin%26aufirst%3DY.%26aulast%3DHuang%26aufirst%3DX.%2BP.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DWankowicz%26aufirst%3DS.%2BA.%26aulast%3DBohn%26aufirst%3DM.%26aulast%3DSafari%26aufirst%3DM.%26aulast%3DUgur%26aufirst%3DF.%2BS.%26aulast%3DKoh%26aufirst%3DC.%26aulast%3DSavar%26aufirst%3DN.%2BS.%26aulast%3DTran%26aufirst%3DQ.%2BD.%26aulast%3DShengjuler%26aufirst%3DD.%26aulast%3DFletcher%26aufirst%3DS.%2BJ.%26aulast%3DO%25E2%2580%2599Neal%26aufirst%3DM.%2BC.%26aulast%3DCai%26aufirst%3DY.%26aulast%3DChang%26aufirst%3DJ.%2BC.%2BJ.%26aulast%3DBroadhurst%26aufirst%3DD.%2BJ.%26aulast%3DKlippsten%26aufirst%3DS.%26aulast%3DSharp%26aufirst%3DP.%2BP.%26aulast%3DWenzell%26aufirst%3DN.%2BA.%26aulast%3DKuzuoglu-Ozturk%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DH.%2BY.%26aulast%3DTrenker%26aufirst%3DR.%26aulast%3DYoung%26aufirst%3DJ.%2BM.%26aulast%3DCavero%26aufirst%3DD.%2BA.%26aulast%3DHiatt%26aufirst%3DJ.%26aulast%3DRoth%26aufirst%3DT.%2BL.%26aulast%3DRathore%26aufirst%3DU.%26aulast%3DSubramanian%26aufirst%3DA.%26aulast%3DNoack%26aufirst%3DJ.%26aulast%3DHubert%26aufirst%3DM.%26aulast%3DStroud%26aufirst%3DR.%2BM.%26aulast%3DFrankel%26aufirst%3DA.%2BD.%26aulast%3DRosenberg%26aufirst%3DO.%2BS.%26aulast%3DVerba%26aufirst%3DK.%2BA.%26aulast%3DAgard%26aufirst%3DD.%2BA.%26aulast%3DOtt%26aufirst%3DM.%26aulast%3DEmerman%26aufirst%3DM.%26aulast%3DJura%26aufirst%3DN.%26aulast%3Dvon%2BZastrow%26aufirst%3DM.%26aulast%3DVerdin%26aufirst%3DE.%26aulast%3DAshworth%26aufirst%3DA.%26aulast%3DSchwartz%26aufirst%3DO.%26aulast%3Dd%25E2%2580%2599Enfert%26aufirst%3DC.%26aulast%3DMukherjee%26aufirst%3DS.%26aulast%3DJacobson%26aufirst%3DM.%26aulast%3DMalik%26aufirst%3DH.%2BS.%26aulast%3DFujimori%26aufirst%3DD.%2BG.%26aulast%3DIdeker%26aufirst%3DT.%26aulast%3DCraik%26aufirst%3DC.%2BS.%26aulast%3DFloor%26aufirst%3DS.%2BN.%26aulast%3DFraser%26aufirst%3DJ.%2BS.%26aulast%3DGross%26aufirst%3DJ.%2BD.%26aulast%3DSali%26aufirst%3DA.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26aulast%3DRuggero%26aufirst%3DD.%26aulast%3DTaunton%26aufirst%3DJ.%26aulast%3DKortemme%26aufirst%3DT.%26aulast%3DBeltrao%26aufirst%3DP.%26aulast%3DVignuzzi%26aufirst%3DM.%26aulast%3DGarc%25C3%25ADa-Sastre%26aufirst%3DA.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26aulast%3DShoichet%26aufirst%3DB.%2BK.%26aulast%3DKrogan%26aufirst%3DN.%2BJ.%26atitle%3DA%2520SARS-CoV-2%2520protein%2520interaction%2520map%2520reveals%2520targets%2520for%2520drug%2520repurposing%26jtitle%3DNature%26date%3D2020%26volume%3D583%26spage%3D459%26epage%3D468%26doi%3D10.1038%2Fs41586-020-2286-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vela, J. M.</span></span> <span> </span><span class="NLM_article-title">Repurposing Sigma-1 Receptor Ligands for COVID-19 Therapy?</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">582310</span>, <span class="refDoi"> DOI: 10.3389/fphar.2020.582310</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.3389%2Ffphar.2020.582310" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=33364957" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BB3MXjsl2isb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2020&pages=582310&author=J.+M.+Vela&title=Repurposing+Sigma-1+Receptor+Ligands+for+COVID-19+Therapy%3F&doi=10.3389%2Ffphar.2020.582310"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Repurposing sigma-1 receptor ligands for COVID-19 therapy?</span></div><div class="casAuthors">Vela, Jose Miguel</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Pharmacology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">582310</span>CODEN:
                <span class="NLM_cas:coden">FPRHAU</span>;
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">Outbreaks of emerging infections, such as COVID-19 pandemic esp., confront health professionals with the unique challenge of treating patients.  With no time to discover new drugs, repurposing of approved drugs or in clin. development is likely the only soln.  Replication of coronaviruses (CoVs) occurs in a modified membranous compartment derived from the endoplasmic reticulum (ER), causes host cell ER stress and activates pathways to facilitate adaptation of the host cell machinery to viral needs.  Accordingly, modulation of ER remodeling and ER stress response might be pivotal in elucidating CoVhost interactions and provide a rationale for new therapeutic, host-based antiviral approaches.  The sigma-1 receptor (Sig-1R) is a ligand-operated, ER membranebound chaperone that acts as an upstream modulator of ER stress and thus a candidate host protein for host-based repurposing approaches to treat COVID-19 patients.  Sig-1R ligands are frequently identified in in vitro drug repurposing screens aiming to identify antiviral compds. against CoVs, including severe acute respiratory syndrome CoV-2 (SARS-CoV-2).  Sig-1R regulates key mechanisms of the adaptive host cell stress response and takes part in early steps of viral replication.  It is enriched in lipid rafts and detergent-resistant ER membranes, where it colocalizes with viral replicase proteins.  Indeed, the non-structural SARS-CoV-2 protein Nsp6 interacts with Sig-1R.  The activity of Sig-1R ligands against COVID-19 remains to be specifically assessed in clin. trials.  This review provides a rationale for targeting Sig-1R as a host-based drug repurposing approach to treat COVID-19 patients.  Evidence gained using Sig-1R ligands in unbiased in vitro antiviral drug screens and the potential mechanisms underlying the modulatory effect of Sig-1R on the host cell response are discussed.  Targeting Sig-1R is not expected to reduce dramatically established viral replication, but it might interfere with early steps of virus-induced host cell reprogramming, aid to slow down the course of infection, prevent the aggravation of the disease and/or allow a time window to mature a protective immune response.  Sig-1R-based medicines could provide benefit not only as early intervention, preventive but also as adjuvant therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpah9yXKMk0xLVg90H21EOLACvtfcHk0lgXUDm7in3X0Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3MXjsl2isb4%253D&md5=d1cd496f4e4deb2da04626d7de035c04</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2020.582310&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2020.582310%26sid%3Dliteratum%253Aachs%26aulast%3DVela%26aufirst%3DJ.%2BM.%26atitle%3DRepurposing%2520Sigma-1%2520Receptor%2520Ligands%2520for%2520COVID-19%2520Therapy%253F%26jtitle%3DFront.%2520Pharmacol.%26date%3D2020%26volume%3D11%26spage%3D582310%26doi%3D10.3389%2Ffphar.2020.582310" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sahn, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kruse, A. C.</span></span> <span> </span><span class="NLM_article-title">Identification of the gene that codes for the σ</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>114</i></span>,  <span class="NLM_fpage">7160</span>– <span class="NLM_lpage">7165</span>, <span class="refDoi"> DOI: 10.1073/pnas.1705154114</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1073%2Fpnas.1705154114" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=28559337" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BC2sXovVSisrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2017&pages=7160-7165&author=A.+Alonauthor=H.+R.+Schmidtauthor=M.+D.+Woodauthor=J.+J.+Sahnauthor=S.+F.+Martinauthor=A.+C.+Kruse&title=Identification+of+the+gene+that+codes+for+the+%CF%83&doi=10.1073%2Fpnas.1705154114"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of the gene that codes for the σ2 receptor</span></div><div class="casAuthors">Alon, Assaf; Schmidt, Hayden R.; Wood, Michael D.; Sahn, James J.; Martin, Stephen F.; Kruse, Andrew C.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">114</span>
        (<span class="NLM_cas:issue">27</span>),
    <span class="NLM_cas:pages">7160-7165</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The σ2 receptor is an enigmatic protein that has attracted significant attention because of its involvement in diseases as diverse as cancer and neurol. disorders.  Unlike virtually all other receptors of medical interest, it has eluded mol. cloning since its discovery, and the gene that codes for the receptor remains unknown, precluding the use of modern biol. methods to study its function.  Using a chem. biol. approach, we purified the σ2 receptor from tissue, revealing its identity as TMEM97, an endoplasmic reticulum-resident transmembrane protein that regulates the sterol transporter NPC1.  We show that TMEM97 possesses the full suite of mol. properties that define the σ2 receptor, and we identify Asp29 and Asp56 as essential for ligand recognition.  Cloning the σ2 receptor resolves a longstanding mystery and will enable therapeutic targeting of this potential drug target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqsoAS9Q6KtY7Vg90H21EOLACvtfcHk0lgdbDQ0Xhua2g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXovVSisrw%253D&md5=71d3c246ebe6ac84c33980b97cb9889c</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1705154114&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1705154114%26sid%3Dliteratum%253Aachs%26aulast%3DAlon%26aufirst%3DA.%26aulast%3DSchmidt%26aufirst%3DH.%2BR.%26aulast%3DWood%26aufirst%3DM.%2BD.%26aulast%3DSahn%26aufirst%3DJ.%2BJ.%26aulast%3DMartin%26aufirst%3DS.%2BF.%26aulast%3DKruse%26aufirst%3DA.%2BC.%26atitle%3DIdentification%2520of%2520the%2520gene%2520that%2520codes%2520for%2520the%2520%25CF%2583%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2017%26volume%3D114%26spage%3D7160%26epage%3D7165%26doi%3D10.1073%2Fpnas.1705154114" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rothfuss, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vangveravong, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnston, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spitzer, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hotchkiss, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hawkins, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wheeler, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mach, R. H.</span></span> <span> </span><span class="NLM_article-title">Identification of the PGRMC1 protein complex as the putative sigma-2 receptor binding site</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">380</span>, <span class="refDoi"> DOI: 10.1038/ncomms1386</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1038%2Fncomms1386" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=21730960" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A280%3ADC%252BC3MnlvVKgtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2011&pages=380&author=J.+Xuauthor=C.+Zengauthor=W.+Chuauthor=F.+Panauthor=J.+M.+Rothfussauthor=F.+Zhangauthor=Z.+Tuauthor=D.+Zhouauthor=D.+Zengauthor=S.+Vangveravongauthor=F.+Johnstonauthor=D.+Spitzerauthor=K.+C.+Changauthor=R.+S.+Hotchkissauthor=W.+G.+Hawkinsauthor=K.+T.+Wheelerauthor=R.+H.+Mach&title=Identification+of+the+PGRMC1+protein+complex+as+the+putative+sigma-2+receptor+binding+site&doi=10.1038%2Fncomms1386"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of the PGRMC1 protein complex as the putative sigma-2 receptor binding site</span></div><div class="casAuthors">Xu Jinbin; Zeng Chenbo; Chu Wenhua; Pan Fenghui; Rothfuss Justin M; Zhang Fanjie; Tu Zhude; Zhou Dong; Zeng Dexing; Vangveravong Suwanna; Johnston Fabian; Spitzer Dirk; Chang Katherine C; Hotchkiss Richard S; Hawkins William G; Wheeler Kenneth T; Mach Robert H</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">380</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The sigma-2 receptor, whose gene remains to be cloned, has been validated as a biomarker for tumour cell proliferation.  Here we report the use of a novel photoaffinity probe, WC-21, to identify the sigma-2 receptor-binding site.  WC-21, a sigma-2 ligand containing both a photoactive azide moiety and a fluorescein isothiocyanate group, irreversibly labels sigma-2 receptors in rat liver; the membrane-bound protein was identified as PGRMC1 (progesterone receptor membrane component 1).  Immunocytochemistry reveals that both PGRMC1 and SW120, a fluorescent sigma-2 receptor ligand, colocalize with molecular markers of the endoplasmic reticulum and mitochondria in HeLa cells.  Overexpression and knockdown of the PGRMC1 protein results in an increase and a decrease in binding of a sigma-2 selective radioligand, respectively.  The identification of the putative sigma-2 receptor-binding site as PGRMC1 should stimulate the development of unique imaging agents and cancer therapeutics that target the sigma-2 receptor/PGRMC1 complex.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRKpNfsa0DIvIJKJbLTgsvCfW6udTcc2eZKLLgOtYnoqLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3MnlvVKgtQ%253D%253D&md5=46675c07c87eccab091f8a8ec0f12db6</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1038%2Fncomms1386&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms1386%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DZeng%26aufirst%3DC.%26aulast%3DChu%26aufirst%3DW.%26aulast%3DPan%26aufirst%3DF.%26aulast%3DRothfuss%26aufirst%3DJ.%2BM.%26aulast%3DZhang%26aufirst%3DF.%26aulast%3DTu%26aufirst%3DZ.%26aulast%3DZhou%26aufirst%3DD.%26aulast%3DZeng%26aufirst%3DD.%26aulast%3DVangveravong%26aufirst%3DS.%26aulast%3DJohnston%26aufirst%3DF.%26aulast%3DSpitzer%26aufirst%3DD.%26aulast%3DChang%26aufirst%3DK.%2BC.%26aulast%3DHotchkiss%26aufirst%3DR.%2BS.%26aulast%3DHawkins%26aufirst%3DW.%2BG.%26aulast%3DWheeler%26aufirst%3DK.%2BT.%26aulast%3DMach%26aufirst%3DR.%2BH.%26atitle%3DIdentification%2520of%2520the%2520PGRMC1%2520protein%2520complex%2520as%2520the%2520putative%2520sigma-2%2520receptor%2520binding%2520site%26jtitle%3DNat.%2520Commun.%26date%3D2011%26volume%3D2%26spage%3D380%26doi%3D10.1038%2Fncomms1386" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Riad, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weng, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winters, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Makvandi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metz, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mach, R. H.</span></span> <span> </span><span class="NLM_article-title">Sigma-2 Receptor/TMEM97 and PGRMC-1 Increase the Rate of Internalization of LDL by LDL Receptor through the Formation of a Ternary Complex</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">16845</span>, <span class="refDoi"> DOI: 10.1038/s41598-018-35430-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1038%2Fs41598-018-35430-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=30443021" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A280%3ADC%252BB3crhsVKktg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2018&pages=16845&author=A.+Riadauthor=C.+Zengauthor=C.+C.+Wengauthor=H.+Wintersauthor=K.+Xuauthor=M.+Makvandiauthor=T.+Metzauthor=S.+Carlinauthor=R.+H.+Mach&title=Sigma-2+Receptor%2FTMEM97+and+PGRMC-1+Increase+the+Rate+of+Internalization+of+LDL+by+LDL+Receptor+through+the+Formation+of+a+Ternary+Complex&doi=10.1038%2Fs41598-018-35430-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Sigma-2 Receptor/TMEM97 and PGRMC-1 Increase the Rate of Internalization of LDL by LDL Receptor through the Formation of a Ternary Complex</span></div><div class="casAuthors">Riad Aladdin; Zeng Chenbo; Weng Chi-Chang; Winters Harrison; Xu Kuiying; Makvandi Mehran; Metz Tyler; Carlin Sean; Mach Robert H</div><div class="citationInfo"><span class="NLM_cas:title">Scientific reports</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">16845</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">CRISPR/Cas gene studies were conducted in HeLa cells where either PGRMC1, TMEM97 or both proteins were removed via gene editing.  A series of radioligand binding studies, confocal microscopy studies, and internalization of radiolabeled or fluorescently tagged LDL particles were then conducted in these cells.  The results indicate that PGRMC1 knockout (KO) did not reduce the density of binding sites for the sigma-2 receptor (σ2R) radioligands, [(125)I]RHM-4 or [(3)H]DTG, but a reduction in the receptor affinity of both radioligands was observed.  TMEM97 KO resulted in a complete loss of binding of [(125)I]RHM-4 and a significant reduction in binding of [(3)H]DTG.  TMEM97 KO and PGRMC1 KO resulted in an equal reduction in the rate of uptake of fluorescently-tagged or (3)H-labeled LDL, and knocking out both proteins did not result in a further rate of reduction of LDL uptake.  Confocal microscopy and Proximity Ligation Assay studies indicated a clear co-localization of LDLR, PGRMC1 and TMEM97.  These data indicate that the formation of a ternary complex of LDLR-PGRMC1-TMEM97 is necessary for the rapid internalization of LDL by LDLR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTJbdh-iRrqnedfST00W0BcfW6udTcc2eZKLLgOtYnoqLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3crhsVKktg%253D%253D&md5=b042e5184b567292abe352343f434486</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1038%2Fs41598-018-35430-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41598-018-35430-3%26sid%3Dliteratum%253Aachs%26aulast%3DRiad%26aufirst%3DA.%26aulast%3DZeng%26aufirst%3DC.%26aulast%3DWeng%26aufirst%3DC.%2BC.%26aulast%3DWinters%26aufirst%3DH.%26aulast%3DXu%26aufirst%3DK.%26aulast%3DMakvandi%26aufirst%3DM.%26aulast%3DMetz%26aufirst%3DT.%26aulast%3DCarlin%26aufirst%3DS.%26aulast%3DMach%26aufirst%3DR.%2BH.%26atitle%3DSigma-2%2520Receptor%252FTMEM97%2520and%2520PGRMC-1%2520Increase%2520the%2520Rate%2520of%2520Internalization%2520of%2520LDL%2520by%2520LDL%2520Receptor%2520through%2520the%2520Formation%2520of%2520a%2520Ternary%2520Complex%26jtitle%3DSci.%2520Rep.%26date%3D2018%26volume%3D8%26spage%3D16845%26doi%3D10.1038%2Fs41598-018-35430-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kargbo, R. B.</span></span> <span> </span><span class="NLM_article-title">Sigma-1 and Sigma-2 Receptor Modulators as Potential Therapeutics for Alzheimer’s Disease</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2021</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">178</span>– <span class="NLM_lpage">179</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.1c00002</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.1c00002" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BB3MXhvVWrs7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2021&pages=178-179&author=R.+B.+Kargbo&title=Sigma-1+and+Sigma-2+Receptor+Modulators+as+Potential+Therapeutics+for+Alzheimer%E2%80%99s+Disease&doi=10.1021%2Facsmedchemlett.1c00002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Sigma-1 and Sigma-2 Receptor Modulators as Potential Therapeutics for Alzheimer's Disease</span></div><div class="casAuthors">Kargbo, Robert B.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2021</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">178-179</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKheuSFPPDoLVg90H21EOLACvtfcHk0lgYTyawAkxWhQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3MXhvVWrs7o%253D&md5=6c751a49db3193a37628ffa4acc81726</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.1c00002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.1c00002%26sid%3Dliteratum%253Aachs%26aulast%3DKargbo%26aufirst%3DR.%2BB.%26atitle%3DSigma-1%2520and%2520Sigma-2%2520Receptor%2520Modulators%2520as%2520Potential%2520Therapeutics%2520for%2520Alzheimer%25E2%2580%2599s%2520Disease%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2021%26volume%3D12%26spage%3D178%26epage%3D179%26doi%3D10.1021%2Facsmedchemlett.1c00002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sánchez-Blázquez, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortés-Montero, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodríguez-Muñoz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merlos, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garzón-Niño, J.</span></span> <span> </span><span class="NLM_article-title">The Sigma 2 receptor promotes and the Sigma 1 receptor inhibits mu-opioid receptor-mediated antinociception</span>. <i>Mol. Brain</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">150</span>, <span class="refDoi"> DOI: 10.1186/s13041-020-00676-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1186%2Fs13041-020-00676-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=33176836" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BB3cXitlygtL3K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2020&pages=150&author=P.+S%C3%A1nchez-Bl%C3%A1zquezauthor=E.+Cort%C3%A9s-Monteroauthor=M.+Rodr%C3%ADguez-Mu%C3%B1ozauthor=M.+Merlosauthor=J.+Garz%C3%B3n-Ni%C3%B1o&title=The+Sigma+2+receptor+promotes+and+the+Sigma+1+receptor+inhibits+mu-opioid+receptor-mediated+antinociception&doi=10.1186%2Fs13041-020-00676-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">The Sigma 2 receptor promotes and the Sigma 1 receptor inhibits mu-opioid receptor-mediated antinociception</span></div><div class="casAuthors">Sanchez-Blazquez, Pilar; Cortes-Montero, Elsa; Rodriguez-Munoz, Maria; Merlos, Manuel; Garzon-Nino, Javier</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Brain</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">150</span>CODEN:
                <span class="NLM_cas:coden">MBORAO</span>;
        ISSN:<span class="NLM_cas:issn">1756-6606</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">The Sigma-1 receptor (σ1R) has emerged as an interesting pharmacol. target because it inhibits analgesia mediated by mu-opioid receptors (MOR), and also facilitates the development of neuropathic pain.  Based on these findings, the recent cloning of the Sigma-2 receptor (σ2R) led us to investigate its potential role as a regulator of opioid analgesia and of pain hypersensitivity in σ2R knockout mice.  In contrast to σ1R deficient mice, σ2R knockout mice developed mech. allodynia following establishment of chronic constriction injury-induced neuropathic pain, which was alleviated by the σ1R antagonist S1RA.  The analgesic effects of morphine, [D-Ala, N-MePhe, Gly-ol]-encephalin (DAMGO) and β-endorphin increased in σ1R-/- mice and diminished in σ2R-/- mice.  The analgesic effect of morphine was increased in σ2R-/- mice by treatment with S1RA.  However, σ2R-/- mice and wild-type mice exhibited comparable antinociceptive responses to the delta receptor agonist [D-Pen2,5]-encephalin (DPDPE), the cannabinoid type 1 receptor agonist WIN55,212-2 and the α2-adrenergic receptor agonist clonidine.  Therefore, while σR1 inhibits and σ2R facilitates MOR-mediated analgesia these receptors exchange their roles when regulating neuropathic pain perception.  Our study may help identify new pharmacol. targets for diminishing pain perception and improving opioid detoxification therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2GokgU9eshrVg90H21EOLACvtfcHk0lgYTyawAkxWhQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXitlygtL3K&md5=bcbcb76385f92a3b398a005bc12600d4</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1186%2Fs13041-020-00676-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13041-020-00676-4%26sid%3Dliteratum%253Aachs%26aulast%3DS%25C3%25A1nchez-Bl%25C3%25A1zquez%26aufirst%3DP.%26aulast%3DCort%25C3%25A9s-Montero%26aufirst%3DE.%26aulast%3DRodr%25C3%25ADguez-Mu%25C3%25B1oz%26aufirst%3DM.%26aulast%3DMerlos%26aufirst%3DM.%26aulast%3DGarz%25C3%25B3n-Ni%25C3%25B1o%26aufirst%3DJ.%26atitle%3DThe%2520Sigma%25202%2520receptor%2520promotes%2520and%2520the%2520Sigma%25201%2520receptor%2520inhibits%2520mu-opioid%2520receptor-mediated%2520antinociception%26jtitle%3DMol.%2520Brain%26date%3D2020%26volume%3D13%26spage%3D150%26doi%3D10.1186%2Fs13041-020-00676-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schmit, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michiels, C.</span></span> <span> </span><span class="NLM_article-title">TMEM Proteins in Cancer: A Review</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1345</span>, <span class="refDoi"> DOI: 10.3389/fphar.2018.01345</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.3389%2Ffphar.2018.01345" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=30574087" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BC1MXht1OlurvF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=1345&author=K.+Schmitauthor=C.+Michiels&title=TMEM+Proteins+in+Cancer%3A+A+Review&doi=10.3389%2Ffphar.2018.01345"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">TMEM proteins in cancer: a review</span></div><div class="casAuthors">Schmit, Kathleen; Michiels, Carine</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Pharmacology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1345</span>CODEN:
                <span class="NLM_cas:coden">FPRHAU</span>;
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">A review.  A transmembrane protein (TMEM) is a type of protein that spans biol. membranes.  Many of them extend through the lipid bilayer of the plasma membrane but others are located to the membrane of organelles.  The TMEM family gathers proteins of mostly unknown functions.  Many studies showed that TMEM expression can be down- or up-regulated in tumor tissues compared to adjacent healthy tissues.  Indeed, some TMEMs such as TMEM48 or TMEM97 are defined as potential prognostic biomarkers for lung cancer.  Furthermore, exptl. evidence suggests that TMEM proteins can be described as tumor suppressors or oncogenes.  TMEMs, such as TMEM45A and TMEM205, have also been implicated in tumor progression and invasion but also in chemoresistance.  Thus, a better characterization of these proteins could help to better understand their implication in cancer and to allow the development of improved therapy strategies in the future.  This review gives an overview of the implication of TMEM proteins in cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQ4DXcuh3IG7Vg90H21EOLACvtfcHk0lgYTyawAkxWhQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXht1OlurvF&md5=a7b274b43919962695b219cba0ef6ea9</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2018.01345&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2018.01345%26sid%3Dliteratum%253Aachs%26aulast%3DSchmit%26aufirst%3DK.%26aulast%3DMichiels%26aufirst%3DC.%26atitle%3DTMEM%2520Proteins%2520in%2520Cancer%253A%2520A%2520Review%26jtitle%3DFront.%2520Pharmacol.%26date%3D2018%26volume%3D9%26spage%3D1345%26doi%3D10.3389%2Ffphar.2018.01345" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vilner, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">John, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowen, W. D.</span></span> <span> </span><span class="NLM_article-title">Sigma-1 and sigma-2 receptors are expressed in a wide variety of human and rodent tumor cell lines</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">408</span>– <span class="NLM_lpage">413</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=7812973" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADyaK2MXjtFyjtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=1995&pages=408-413&author=B.+J.+Vilnerauthor=C.+S.+Johnauthor=W.+D.+Bowen&title=Sigma-1+and+sigma-2+receptors+are+expressed+in+a+wide+variety+of+human+and+rodent+tumor+cell+lines"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Sigma-1 and sigma-2 receptors are expressed in a wide variety of human and rodent tumor cell lines</span></div><div class="casAuthors">Vilner, Bertold J.; John, Christy S.; Bowen, Wayne D.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">408-13</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Thirteen tumor-derived cell lines of human and nonhuman origin and from various tissues were examd. for the presence and d. of sigma-1 and sigma-2 receptors.  Sigma-1 receptors of a crude membrane fraction were labeled using [3H](+)-pentazocine, and sigma-2 receptors were labeled with [3H]1,3-di-o-tolylguanidine ([3H]DTG); in the presence or absence of dextrallorphan.  [3H](+)-Pentazocine-binding sites were heterogeneous.  In rodent cell lines (e.g., C6 glioma, NIE-115 neuroblastoma, and NG108-15 neuroblastoma × glioma hybrid), human T47D breast ductal carcinoma, human NCI-H727 lung carcinoid, and human A375 melanoma, [3H](+)-pentazocine bound to high- and low-affinity sites with Kd1 = 0.67-7.0 nM, Bmax 1 = 25.5-108 fmol/mg protein, Kd2 = 127-600 nM, and Bmax2 = 942-5431 fmol/mg protein.  However, [3H](+)-pentazocine bound to a single site in other cell lines.  In human U-138MG glioblastoma, SK-N-sh neuroblastoma, and LNCaP.FGC prostate, Kd=28-61nM and Bmax-1411 fmol/mg protein.  The sigma-1-like nature of [3H](+)-pentazocine-binding sites was confirmed by competition studies which revealed high affinity for haloperidol and enantioselectivity for (+)-pentazocine over (-)-pentazocine.  Interestingly, human MCF-7 breast adenocarcinoma showed little or no specific binding of [3H](+)-pentazocine, suggesting the absence of sigma-1 receptors in this cell line.  All cell lines examd. expressed a high d. of sigma-2 receptors with Kd values for [3H]DTG ranging from 20 to 101 nM and Bmax values of 491 to 7324 fmol/mg protein.  Competition studies indicated possible heterogeneity of sigma-2 receptors.  While sites labeled by [3H]DTG in all cell lines tested exhibited affinity for haloperidol and approx. 10-fold lower affinity for (-)-pentazocine compared with the rodent cell lines.  The high d. of sigma-1 and sigma-2 binding sites in these cell lines suggests important cellular functions in cancer, as well as potential diagnostic utility for tumor-imaging agents which target sigma sites.  These cell lines may be useful as model systems in which to study the functions of sigma sites in normal tissues, as well as their possible role in tumor biol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomx5dT2-5Hz7Vg90H21EOLACvtfcHk0lgdvNW6IC3FuQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXjtFyjtr8%253D&md5=80276a71555fdb08d76ae39b73d1cbe1</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DVilner%26aufirst%3DB.%2BJ.%26aulast%3DJohn%26aufirst%3DC.%2BS.%26aulast%3DBowen%26aufirst%3DW.%2BD.%26atitle%3DSigma-1%2520and%2520sigma-2%2520receptors%2520are%2520expressed%2520in%2520a%2520wide%2520variety%2520of%2520human%2520and%2520rodent%2520tumor%2520cell%2520lines%26jtitle%3DCancer%2520Res.%26date%3D1995%26volume%3D55%26spage%3D408%26epage%3D413" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Collina, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bignardi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rui, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rossi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaggeri, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zamagni, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortesi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tesei, A.</span></span> <span> </span><span class="NLM_article-title">Are sigma modulators an effective opportunity for cancer treatment? A patent overview (1996–2016)</span>. <i>Expert Opin. Ther. Pat.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">565</span>– <span class="NLM_lpage">578</span>, <span class="refDoi"> DOI: 10.1080/13543776.2017.1276569</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1080%2F13543776.2017.1276569" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=28051882" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BC2sXpsFOjtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2017&pages=565-578&author=S.+Collinaauthor=E.+Bignardiauthor=M.+Ruiauthor=D.+Rossiauthor=R.+Gaggeriauthor=A.+Zamagniauthor=M.+Cortesiauthor=A.+Tesei&title=Are+sigma+modulators+an+effective+opportunity+for+cancer+treatment%3F+A+patent+overview+%281996%E2%80%932016%29&doi=10.1080%2F13543776.2017.1276569"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Are sigma modulators an effective opportunity for cancer treatment? A patent overview (1996-2016)</span></div><div class="casAuthors">Collina, Simona; Bignardi, Emanuele; Rui, Marta; Rossi, Daniela; Gaggeri, Raffaella; Zamagni, Alice; Cortesi, Michela; Tesei, Anna</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">565-578</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Although several mol. targets against cancer have been identified, there is a continuous need for new therapeutic strategies.  Sigma Receptors (SRs) overexpression has been recently assocd. with different cancer conditions.  Therefore, novel anticancer agents targeting SRs may increase the specificity of therapies, overcoming some of the common drawbacks of conventional chemotherapy.  The present review focuses on patent documents disclosing SR modulators with possible application in cancer therapy and diagnosis.  The anal. reviews patents of the last two decades (1996-2016); patents were grouped according to target subtypes (S1R, S2R, pan-SRs) and relevant Applicants.  The literature was searched through Espacenet, ISI Web, PatentScope and PubMed databases.  The no. of patents related to SRs and cancer has increased in the last twenty years, confirming the importance of this receptor family as valuable target against neoplasias.  Despite their short history in the cancer scenario, many SR modulators are at pre-clin. stage and one is undergoing a phase II clin. trial.  SRs ligands may represent a powerful source of innovative antitumor therapeutics.  Further investigation is needed for validating SR modulators as anti-cancer drugs.  We strongly hope that this review could stimulate the interest of both Academia and pharmaceutical companies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqcMac8vpx9c7Vg90H21EOLACvtfcHk0lgdvNW6IC3FuQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXpsFOjtg%253D%253D&md5=081e1a949ad2185865e73ff32955ce29</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1080%2F13543776.2017.1276569&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F13543776.2017.1276569%26sid%3Dliteratum%253Aachs%26aulast%3DCollina%26aufirst%3DS.%26aulast%3DBignardi%26aufirst%3DE.%26aulast%3DRui%26aufirst%3DM.%26aulast%3DRossi%26aufirst%3DD.%26aulast%3DGaggeri%26aufirst%3DR.%26aulast%3DZamagni%26aufirst%3DA.%26aulast%3DCortesi%26aufirst%3DM.%26aulast%3DTesei%26aufirst%3DA.%26atitle%3DAre%2520sigma%2520modulators%2520an%2520effective%2520opportunity%2520for%2520cancer%2520treatment%253F%2520A%2520patent%2520overview%2520%25281996%25E2%2580%25932016%2529%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2017%26volume%3D27%26spage%3D565%26epage%3D578%26doi%3D10.1080%2F13543776.2017.1276569" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Georgiadis, M. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karoutzou, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foscolos, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papanastasiou, I.</span></span> <span> </span><span class="NLM_article-title">Sigma Receptor (σR) Ligands with Antiproliferative and Anticancer Activity</span>. <i>Molecules</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">1408</span>, <span class="refDoi"> DOI: 10.3390/molecules22091408</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.3390%2Fmolecules22091408" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhslWgt73J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2017&pages=1408&author=M.+O.+Georgiadisauthor=O.+Karoutzouauthor=A.+S.+Foscolosauthor=I.+Papanastasiou&title=Sigma+Receptor+%28%CF%83R%29+Ligands+with+Antiproliferative+and+Anticancer+Activity&doi=10.3390%2Fmolecules22091408"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Sigma receptor (σR) ligands with antiproliferative and anticancer activity</span></div><div class="casAuthors">Georgiadis, Markos-Orestis; Karoutzou, Olga; Foscolos, Angeliki-Sofia; Papanastasiou, Ioannis</div><div class="citationInfo"><span class="NLM_cas:title">Molecules</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1408/1-1408/18</span>CODEN:
                <span class="NLM_cas:coden">MOLEFW</span>;
        ISSN:<span class="NLM_cas:issn">1420-3049</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Sigma receptor (σR) ligands have proven to be useful as cancer diagnostics and anticancer therapeutics and their ligands have been developed as mol. probes in oncol.  Moreover, various σR ligands generate cancer cell death in vitro and in vivo.  These σR ligands have exhibited promising results against numerous human and rodent cancers and are investigated under preclin. and clin. study trials, indicating a new category of drugs in cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomgqdswubm2LVg90H21EOLACvtfcHk0lgdvNW6IC3FuQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhslWgt73J&md5=9a651a3d8f09047f6685eea198b3a9fe</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.3390%2Fmolecules22091408&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmolecules22091408%26sid%3Dliteratum%253Aachs%26aulast%3DGeorgiadis%26aufirst%3DM.%2BO.%26aulast%3DKaroutzou%26aufirst%3DO.%26aulast%3DFoscolos%26aufirst%3DA.%2BS.%26aulast%3DPapanastasiou%26aufirst%3DI.%26atitle%3DSigma%2520Receptor%2520%2528%25CF%2583R%2529%2520Ligands%2520with%2520Antiproliferative%2520and%2520Anticancer%2520Activity%26jtitle%3DMolecules%26date%3D2017%26volume%3D22%26spage%3D1408%26doi%3D10.3390%2Fmolecules22091408" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Berardi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abate, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferorelli, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Robertis, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leopoldo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colabufo, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niso, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perrone, R.</span></span> <span> </span><span class="NLM_article-title">Novel 4-(4-aryl)cyclohexyl-1-(2-pyridyl)piperazines as Delta(8)-Delta(7) sterol isomerase (emopamil binding protein) selective ligands with antiproliferative activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">7523</span>– <span class="NLM_lpage">7531</span>, <span class="refDoi"> DOI: 10.1021/jm800965b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm800965b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVWks77N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=7523-7531&author=F.+Berardiauthor=C.+Abateauthor=S.+Ferorelliauthor=A.+F.+de+Robertisauthor=M.+Leopoldoauthor=N.+A.+Colabufoauthor=M.+Nisoauthor=R.+Perrone&title=Novel+4-%284-aryl%29cyclohexyl-1-%282-pyridyl%29piperazines+as+Delta%288%29-Delta%287%29+sterol+isomerase+%28emopamil+binding+protein%29+selective+ligands+with+antiproliferative+activity&doi=10.1021%2Fjm800965b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Novel 4-(4-Aryl)cyclohexyl-1-(2-pyridyl)piperazines as Δ8-Δ7 Sterol Isomerase (Emopamil Binding Protein) Selective Ligands with Antiproliferative Activity</span></div><div class="casAuthors">Berardi, Francesco; Abate, Carmen; Ferorelli, Savina; de Robertis, Anna F.; Leopoldo, Marcello; Colabufo, Nicola A.; Niso, Mauro; Perrone, Roberto</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">7523-7531</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">To find Δ8-Δ7 sterol isomerase (EBP) selective ligands, various arylpiperazines previously studied and structurally related to some σ receptors ligands were preliminarily screened.  Consequently, a novel series of 2- or 2,6-disubstituted (CH3, CH3O, Cl, F) cis- and trans-4-(4-aryl)cyclohexyl-1-(2-pyridyl)piperazines was developed.  Radioreceptor binding assays evidenced cis-19, cis-30 and cis-33 as new ligands with nanomolar affinity toward EBP site and a good selectivity relative to EBP-related σ receptors.  The most selective 2,6-dimethoxy deriv. (cis-33) demonstrated the highest potency (EC50 = 12.9 μM) and efficacy (70%) in inhibiting proliferation of human prostate cancer PC-3 cell line.  Among the ref. compds., σ2 agonist 36 (PB28) reached the max. efficacy (100%), suggesting the contribution of the σ2 receptor to the antiproliferative activity.  This novel class of EBP inhibitors represents a valuable tool for investigating the last steps of cholesterol biosynthesis and related pathologies, as well as a starting point for developing new anticancer drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqM-0fpVS1nMLVg90H21EOLACvtfcHk0ljxvOxi4-R1tg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVWks77N&md5=4f65b6b9418fa3a6dff7d9400017d7a1</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1021%2Fjm800965b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm800965b%26sid%3Dliteratum%253Aachs%26aulast%3DBerardi%26aufirst%3DF.%26aulast%3DAbate%26aufirst%3DC.%26aulast%3DFerorelli%26aufirst%3DS.%26aulast%3Dde%2BRobertis%26aufirst%3DA.%2BF.%26aulast%3DLeopoldo%26aufirst%3DM.%26aulast%3DColabufo%26aufirst%3DN.%2BA.%26aulast%3DNiso%26aufirst%3DM.%26aulast%3DPerrone%26aufirst%3DR.%26atitle%3DNovel%25204-%25284-aryl%2529cyclohexyl-1-%25282-pyridyl%2529piperazines%2520as%2520Delta%25288%2529-Delta%25287%2529%2520sterol%2520isomerase%2520%2528emopamil%2520binding%2520protein%2529%2520selective%2520ligands%2520with%2520antiproliferative%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D7523%26epage%3D7531%26doi%3D10.1021%2Fjm800965b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pati, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hornick, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niso, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berardi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spitzer, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abate, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hawkins, W.</span></span> <span> </span><span class="NLM_article-title">Sigma-2 receptor agonist derivatives of 1-Cyclohexyl-4-[3-(5-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)propyl]piperazine (PB28) induce cell death via mitochondrial superoxide production and caspase activation in pancreatic cancer</span>. <i>BMC Cancer</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">51</span>, <span class="refDoi"> DOI: 10.1186/s12885-016-3040-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1186%2Fs12885-016-3040-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=28086830" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BC1cXjs12mtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2017&pages=51&author=M.+L.+Patiauthor=J.+R.+Hornickauthor=M.+Nisoauthor=F.+Berardiauthor=D.+Spitzerauthor=C.+Abateauthor=W.+Hawkins&title=Sigma-2+receptor+agonist+derivatives+of+1-Cyclohexyl-4-%5B3-%285-methoxy-1%2C2%2C3%2C4-tetrahydronaphthalen-1-yl%29propyl%5Dpiperazine+%28PB28%29+induce+cell+death+via+mitochondrial+superoxide+production+and+caspase+activation+in+pancreatic+cancer&doi=10.1186%2Fs12885-016-3040-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Sigma-2 receptor agonist derivatives of 1-Cyclohexyl-4-[3-(5-methoxy-1,2,3,4- tetrahydronaphthalen-1-yl)propyl]piperazine (PB28) induce cell death via mitochondrial superoxide production and caspase activation in pancreatic cancer</span></div><div class="casAuthors">Pati, Maria Laura; Hornick, John R.; Niso, Mauro; Berardi, Francesco; Spitzer, Dirk; Abate, Carmen; Hawkins, William</div><div class="citationInfo"><span class="NLM_cas:title">BMC Cancer</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">51/1-51/12</span>CODEN:
                <span class="NLM_cas:coden">BCMACL</span>;
        ISSN:<span class="NLM_cas:issn">1471-2407</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Despite considerable efforts by scientific research, pancreatic cancer is the fourth leading cause of cancer related mortalities.  Sigma-2 receptors, which are overexpressed in several tumors, represent promising targets for triggering selective pancreatic cancer cells death.  We selected five differently structured high-affinity sigma-2 ligands (PB28, PB183, PB221, F281 and PB282) to study how they affect the viability of diverse pancreatic cancer cells (human cell lines BxPC3, AsPC1, Mia PaCa-2, and Panc1 and mouse Panc-02, KCKO and KP-02) and how this is reflected in vivo in a tumor model.  Important cytotoxicity was shown by the compds. in the aggressive Panc02 cells, where cytotoxic activity was caspase-3 independent for four of the five compds.  However, both cytotoxicity and caspase-3 activation involved generation of Reactive Oxygen Species (ROS), which could be partially reverted by the lipid antioxidant a-tocopherol, but not by the hydrophilic N-acetylcysteine (NAC) indicating crucial differences in the intracellular sites exposed to oxidative stress induced by sigma-2 receptor ligands.  Importantly, all the compds. strongly increased the prodn. of mitochondrial superoxide radicals except for PB282.  Despite a poor match between in vitro and the in vivo efficacy, daily treatment of C57BL/6 mice bearing Panc02 tumors resulted in promising effects with PB28 and PB282 which were similar compared to the current std.-of-care chemotherapeutic gemcitabine without showing signs of systemic toxicities.  Overall, this study identified differential sensitivities of pancreatic cancer cells to structurally diverse sigma-2 receptor ligands.  Of note, we identified the mitochondrial superoxide pathway as a previously unrecognized sigma-2 receptor-activated process, which encourages further studies on sigma-2 ligand-mediated cancer cell death for the targeted treatment of pancreatic tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokTrvVNhfXn7Vg90H21EOLACvtfcHk0ljxvOxi4-R1tg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXjs12mtbo%253D&md5=f8dce42ee93876e672a4d0705d8dc890</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1186%2Fs12885-016-3040-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12885-016-3040-4%26sid%3Dliteratum%253Aachs%26aulast%3DPati%26aufirst%3DM.%2BL.%26aulast%3DHornick%26aufirst%3DJ.%2BR.%26aulast%3DNiso%26aufirst%3DM.%26aulast%3DBerardi%26aufirst%3DF.%26aulast%3DSpitzer%26aufirst%3DD.%26aulast%3DAbate%26aufirst%3DC.%26aulast%3DHawkins%26aufirst%3DW.%26atitle%3DSigma-2%2520receptor%2520agonist%2520derivatives%2520of%25201-Cyclohexyl-4-%255B3-%25285-methoxy-1%252C2%252C3%252C4-tetrahydronaphthalen-1-yl%2529propyl%255Dpiperazine%2520%2528PB28%2529%2520induce%2520cell%2520death%2520via%2520mitochondrial%2520superoxide%2520production%2520and%2520caspase%2520activation%2520in%2520pancreatic%2520cancer%26jtitle%3DBMC%2520Cancer%26date%3D2017%26volume%3D17%26spage%3D51%26doi%3D10.1186%2Fs12885-016-3040-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weng, C.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puentes, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riad, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Makvandi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hawkins, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mach, R. H.</span></span> <span> </span><span class="NLM_article-title">TMEM97 and PGRMC1 do not mediate sigma-2 ligand-induced cell death</span>. <i>Cell Death Discovery</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">58</span>, <span class="refDoi"> DOI: 10.1038/s41420-019-0141-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1038%2Fs41420-019-0141-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=30701090" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A280%3ADC%252BB3cjntF2jtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2019&pages=58&author=C.+Zengauthor=C.-C.+Wengauthor=M.+E.+Schneiderauthor=L.+Puentesauthor=A.+Riadauthor=K.+Xuauthor=M.+Makvandiauthor=L.+Jinauthor=W.+G.+Hawkinsauthor=R.+H.+Mach&title=TMEM97+and+PGRMC1+do+not+mediate+sigma-2+ligand-induced+cell+death&doi=10.1038%2Fs41420-019-0141-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">TMEM97 and PGRMC1 do not mediate sigma-2 ligand-induced cell death</span></div><div class="casAuthors">Zeng Chenbo; Weng Chi-Chang; Schneider Mark E Jr; Puentes Laura; Riad Aladdin; Xu Kuiying; Makvandi Mehran; Mach Robert H; Jin Linda; Hawkins William G</div><div class="citationInfo"><span class="NLM_cas:title">Cell death discovery</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">58</span>
        ISSN:<span class="NLM_cas:issn">2058-7716</span>.
    </div><div class="casAbstract">Sigma-2 receptors have been implicated in both tumor proliferation and neurodegenerative diseases.  Recently the sigma-2 receptor was identified as transmembrane protein 97 (TMEM97).  Progesterone receptor membrane component 1 (PGRMC1) was also recently reported to form a complex with TMEM97 and the low density lipoprotein (LDL) receptor, and this trimeric complex is responsible for the rapid internalization of LDL.  Sigma-2 receptor ligands with various structures have been shown to induce cell death in cancer cells.  In the current study, we examined the role of TMEM97 and PGRMC1 in mediating sigma-2 ligand-induced cell death.  Cell viability and caspase-3 assays were performed in control, TMEM97 knockout (KO), PGRMC1 KO, and TMEM97/PGRMC1 double KO cell lines treated with several sigma-2 ligands.  The data showed that knockout of TMEM97, PGRMC1, or both did not affect the concentrations of sigma-2 ligands that induced 50% of cell death (EC50), suggesting that cytotoxic effects of these compounds are not mediated by TMEM97 or PGRMC1.  Sigma-1 receptor ligands, (+)-pentazocine and NE-100, did not block sigma-2 ligand cytotoxicity, suggesting that sigma-1 receptor was not responsible for sigma-2 ligand cytotoxicity.  We also examined whether the alternative, residual binding site (RBS) of 1,3-Di-o-tolylguanidine (DTG) could be responsible for sigma-2 ligand cytotoxicity.  Our data showed that the binding affinities (Ki) of sigma-2 ligands on the DTG RBS did not correlate with the cytotoxicity potency (EC50) of these ligands, suggesting that the DTG RBS was not fully responsible for sigma-2 ligand cytotoxicity.  In addition, we showed that knocking out TMEM97, PGRMC1, or both reduced the initial internalization rate of a sigma-2 fluorescent ligand, SW120.  However, concentrations of internalized SW120 became identical later in the control and knockout cells.  These data suggest that the initial internalization process of sigma-2 ligands does not appear to mediate the cell-killing effect of sigma-2 ligands.  In summary, we have provided evidence that sigma-2 receptor/TMEM97 and PGRMC1 do not mediate sigma-2 ligand cytotoxicity.  Our work will facilitate elucidating mechanisms of sigma-2 ligand cytotoxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRfU8tat7Clh0EksK8CslK8fW6udTcc2eZNmHS_zmmBiLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cjntF2jtA%253D%253D&md5=72af79dc6b0bc2995f8be565d15e1a7f</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1038%2Fs41420-019-0141-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41420-019-0141-2%26sid%3Dliteratum%253Aachs%26aulast%3DZeng%26aufirst%3DC.%26aulast%3DWeng%26aufirst%3DC.-C.%26aulast%3DSchneider%26aufirst%3DM.%2BE.%26aulast%3DPuentes%26aufirst%3DL.%26aulast%3DRiad%26aufirst%3DA.%26aulast%3DXu%26aufirst%3DK.%26aulast%3DMakvandi%26aufirst%3DM.%26aulast%3DJin%26aufirst%3DL.%26aulast%3DHawkins%26aufirst%3DW.%2BG.%26aulast%3DMach%26aufirst%3DR.%2BH.%26atitle%3DTMEM97%2520and%2520PGRMC1%2520do%2520not%2520mediate%2520sigma-2%2520ligand-induced%2520cell%2520death%26jtitle%3DCell%2520Death%2520Discovery%26date%3D2019%26volume%3D5%26spage%3D58%26doi%3D10.1038%2Fs41420-019-0141-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ha, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liou, G. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonsalvez, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bollinger, K. E.</span></span> <span> </span><span class="NLM_article-title">Sigma receptor ligand, (+)-pentazocine, suppresses inflammatory responses of retinal microglia</span>. <i>Invest. Ophthalmol. Visual Sci.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">3375</span>– <span class="NLM_lpage">3384</span>, <span class="refDoi"> DOI: 10.1167/iovs.13-12823</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1167%2Fiovs.13-12823" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=24812552" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVSqur7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2014&pages=3375-3384&author=J.+Zhaoauthor=Y.+Haauthor=G.+I.+Liouauthor=G.+B.+Gonsalvezauthor=S.+B.+Smithauthor=K.+E.+Bollinger&title=Sigma+receptor+ligand%2C+%28%2B%29-pentazocine%2C+suppresses+inflammatory+responses+of+retinal+microglia&doi=10.1167%2Fiovs.13-12823"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Sigma receptor ligand, (+)-pentazocine, suppresses inflammatory responses of retinal microglia</span></div><div class="casAuthors">Zhao, Jing; Ha, Yonju; Liou, Gregory I.; Gonsalvez, Graydon B.; Smith, Sylvia B.; Bollinger, Kathryn E.</div><div class="citationInfo"><span class="NLM_cas:title">Investigative Ophthalmology & Visual Science</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">3375-3384</span>CODEN:
                <span class="NLM_cas:coden">IOVSDA</span>;
        ISSN:<span class="NLM_cas:issn">1552-5783</span>.
    
            (<span class="NLM_cas:orgname">Association for Research in Vision and Ophthalmology</span>)
        </div><div class="casAbstract">PURPOSE. To evaluate the effects of the σ 1 receptor (σR1) agonist, (+)-pentazocine, on lipopolysaccharide (LPS)-induced inflammatory changes in retinal microglia cells.  METHODS. Retinal microglia cells were isolated from Sprague-Dawley rat pups.  Cells were treated with LPS with or without (+)-pentazocine and with or without the σR1 antagonist BD1063.  Morphol. changes were assayed.  Cell viability was assessed by using MTT assay.  Supernatant levels of tumor necrosis factor α (TNF-α), interleukin 10, (IL-10), monocyte chemoattractant protein-1 (MCP-1), and nitric oxide (NO) were detd.  Reactive oxygen species (ROS) formation was assayed, and levels of mitogen-activated protein kinases (MAPKs) were analyzed by using Western blot.  RESULTS. The σR1 protein was expressed in retinal microglia.  Incubation with LPS and/or (+)- pentazocine did not alter cell viability or σR1 protein levels.  Incubation with LPS for 24 h induced a marked change in microglial morphol. and a significant increase in secreted levels of TNF-α, IL-10, MCP-1, and NO.  Pretreatment with (+)-pentazocine inhibited the LPS-induced morphol. changes.  Release of TNF-α, IL-10, MCP-1, and NO was reduced with (+)- pentazocine.  Intracellular ROS formation was suppressed with (+)-pentazocine.  Phosphorylation of extracellular signal-regulated kinase (ERK) and c-Jun N-terminal kinase (JNK) was reduced in the presence of (+)-pentazocine.  The σR1 antagonist BD1063 blocked the (+)-pentazocine-mediated inhibition of LPS-induced morphol. changes.  In addn., BD1063 treatment blocked (+)-pentazocine-mediated suppression of LPS-induced TNF-α, IL-10, MCP-1, NO, and intracellular ROS release.  CONCLUSIONS. Treatment with (+)-pentazocine suppressed inflammatory responses of retinal microglia and inhibited LPS-induced activation of ERK/JNK MAPK.  In neurodegenerative disease, (+)-pentazocine may exert neuroprotective effects through manipulation of microglia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqkRG40_9ttkrVg90H21EOLACvtfcHk0ljCVZ0HGrGk0Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVSqur7E&md5=5921c39790ee8b4a8beead13ea3d3ee3</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1167%2Fiovs.13-12823&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1167%252Fiovs.13-12823%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DJ.%26aulast%3DHa%26aufirst%3DY.%26aulast%3DLiou%26aufirst%3DG.%2BI.%26aulast%3DGonsalvez%26aufirst%3DG.%2BB.%26aulast%3DSmith%26aufirst%3DS.%2BB.%26aulast%3DBollinger%26aufirst%3DK.%2BE.%26atitle%3DSigma%2520receptor%2520ligand%252C%2520%2528%252B%2529-pentazocine%252C%2520suppresses%2520inflammatory%2520responses%2520of%2520retinal%2520microglia%26jtitle%3DInvest.%2520Ophthalmol.%2520Visual%2520Sci.%26date%3D2014%26volume%3D55%26spage%3D3375%26epage%3D3384%26doi%3D10.1167%2Fiovs.13-12823" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bai, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.</span></span> <span> </span><span class="NLM_article-title">Haloperidol, a sigma receptor 1 antagonist, promotes ferroptosis in hepatocellular carcinoma cells</span>. <i>Biochem. Biophys. Res. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>491</i></span>,  <span class="NLM_fpage">919</span>– <span class="NLM_lpage">925</span>, <span class="refDoi"> DOI: 10.1016/j.bbrc.2017.07.136</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1016%2Fj.bbrc.2017.07.136" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=28756230" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht1GisbrK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=491&publication_year=2017&pages=919-925&author=T.+Baiauthor=S.+Wangauthor=Y.+Zhaoauthor=R.+Zhuauthor=W.+Wangauthor=Y.+Sun&title=Haloperidol%2C+a+sigma+receptor+1+antagonist%2C+promotes+ferroptosis+in+hepatocellular+carcinoma+cells&doi=10.1016%2Fj.bbrc.2017.07.136"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Haloperidol, a sigma receptor 1 antagonist, promotes ferroptosis in hepatocellular carcinoma cells</span></div><div class="casAuthors">Bai, Tao; Wang, Shuai; Zhao, Yipu; Zhu, Rongtao; Wang, Weijie; Sun, Yuling</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical and Biophysical Research Communications</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">491</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">919-925</span>CODEN:
                <span class="NLM_cas:coden">BBRCA9</span>;
        ISSN:<span class="NLM_cas:issn">0006-291X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Ferroptosis is a novel form of cell death, which is characterized by accumulation of reactive oxygen species (ROS).  Sigma 1 receptor (S1R) has been suggested to function in oxidative stress metab.  Both erastin and sorafenib significantly induced S1R protein expression.  Haloperidol strongly promoted erastin- and sorafenib-induced cell death, which was blocked by ferrostatin-1 but not ZVAD-FMK or necrosulfonamide.  During ferroptosis, haloperidol substantially increased the cellular levels of Fe2+, GSH and lipid peroxidn.  Furthermore, several ferroptosis-related protein targets were up-regulated in the absence of haloperidol.  Thus, Our study identified an assocn. between haloperidol and ferroptosis for the first time.  Our analyses of a combination of drugs may provide a novel strategy of hepatocellular carcinoma (HCC) therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbCPPfWoO81rVg90H21EOLACvtfcHk0ljCVZ0HGrGk0Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht1GisbrK&md5=29e2b7138c4e91f542b771ba8bc3244c</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1016%2Fj.bbrc.2017.07.136&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbrc.2017.07.136%26sid%3Dliteratum%253Aachs%26aulast%3DBai%26aufirst%3DT.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DZhu%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DSun%26aufirst%3DY.%26atitle%3DHaloperidol%252C%2520a%2520sigma%2520receptor%25201%2520antagonist%252C%2520promotes%2520ferroptosis%2520in%2520hepatocellular%2520carcinoma%2520cells%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D2017%26volume%3D491%26spage%3D919%26epage%3D925%26doi%3D10.1016%2Fj.bbrc.2017.07.136" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, X. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, X. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, H. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X. Y.</span></span> <span> </span><span class="NLM_article-title">Sigma-1 receptor agonist increases axon outgrowth of hippocampal neurons via voltage-gated calcium ions channels</span>. <i>CNS Neurosci. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">930</span>– <span class="NLM_lpage">939</span>, <span class="refDoi"> DOI: 10.1111/cns.12768</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1111%2Fcns.12768" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=28990373" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhslyhsr7O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2017&pages=930-939&author=D.+Liauthor=S.+Z.+Zhangauthor=Y.+H.+Yaoauthor=Y.+Xiangauthor=X.+Y.+Maauthor=X.+L.+Weiauthor=H.+T.+Yanauthor=X.+Y.+Liu&title=Sigma-1+receptor+agonist+increases+axon+outgrowth+of+hippocampal+neurons+via+voltage-gated+calcium+ions+channels&doi=10.1111%2Fcns.12768"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Sigma-1 receptor agonist increases axon outgrowth of hippocampal neurons via voltage-gated calcium ions channels</span></div><div class="casAuthors">Li, Dong; Zhang, Shu-Zhuo; Yao, Yu-Hong; Xiang, Yun; Ma, Xiao-Yun; Wei, Xiao-Li; Yan, Hai-Tao; Liu, Xiao-Yan</div><div class="citationInfo"><span class="NLM_cas:title">CNS Neuroscience & Therapeutics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">930-939</span>CODEN:
                <span class="NLM_cas:coden">CNTNAB</span>;
        ISSN:<span class="NLM_cas:issn">1755-5930</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Summary : Introduction : Sigma-1 receptors (Sig-1Rs) are unique endoplasmic reticulum proteins that have been implicated in both neurodegenerative and ischemic diseases, such as Alzheimer's disease and stroke.  Accumulating evidence has suggested that Sig-1R plays a role in neuroprotection and axon outgrowth.  The underlying mechanisms of Sig-1R-mediated neuroprotection have been well elucidated.  However, the mechanisms underlying the effects of Sig-1R on axon outgrowth are not fully understood.  Methods : To clarify this issue, we utilized immunofluorescence to compare the axon lengths of cultured naive hippocampal neurons before and after the application of the Sig-1R agonist, SA4503.  Then, electrophysiol. and immunofluorescence were used to examine voltage-gated calcium ion channel (VGCCs) currents in the cell membranes and growth cones.  Results : We found that Sig-1R activation dramatically enhanced the axonal length of the naive hippocampal neurons.  Application of the Sig-1R antagonist NE100 and gene knockdown techniques both demonstrated the effects of Sig-1R.  The growth-promoting effect of SA4503 was accompanied by the inhibition of voltage-gated Ca2+ influx and was recapitulated by incubating the neurons with the L-type, N-type, and P/Q-type VGCC blockers, nimodipine, MVIIA and ω-agatoxin IVA, resp.  This effect was unrelated to glial cells.  The application of SA4503 transformed the growth cone morphologies from complicated to simple, which favored axon outgrowth.  Conclusion : Sig-1R activation can enhance axon outgrowth and may have a substantial influence on neurogenesis and neurodegenerative diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqmWsTwTP6fLVg90H21EOLACvtfcHk0ljCVZ0HGrGk0Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhslyhsr7O&md5=2adffff3d75ec0ae3325b47b275caa25</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1111%2Fcns.12768&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fcns.12768%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DD.%26aulast%3DZhang%26aufirst%3DS.%2BZ.%26aulast%3DYao%26aufirst%3DY.%2BH.%26aulast%3DXiang%26aufirst%3DY.%26aulast%3DMa%26aufirst%3DX.%2BY.%26aulast%3DWei%26aufirst%3DX.%2BL.%26aulast%3DYan%26aufirst%3DH.%2BT.%26aulast%3DLiu%26aufirst%3DX.%2BY.%26atitle%3DSigma-1%2520receptor%2520agonist%2520increases%2520axon%2520outgrowth%2520of%2520hippocampal%2520neurons%2520via%2520voltage-gated%2520calcium%2520ions%2520channels%26jtitle%3DCNS%2520Neurosci.%2520Ther.%26date%3D2017%26volume%3D23%26spage%3D930%26epage%3D939%26doi%3D10.1111%2Fcns.12768" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Colabufo, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berardi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Contino, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niso, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abate, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perrone, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tortorella, V.</span></span> <span> </span><span class="NLM_article-title">Antiproliferative and cytotoxic effects of some sigma2 agonists and sigma1 antagonists in tumour cell lines</span>. <i>Naunyn-Schmiedeberg's Arch. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>370</i></span>,  <span class="NLM_fpage">106</span>– <span class="NLM_lpage">113</span>, <span class="refDoi"> DOI: 10.1007/s00210-004-0961-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1007%2Fs00210-004-0961-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=15322732" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BD2cXoslyrtrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=370&publication_year=2004&pages=106-113&author=N.+A.+Colabufoauthor=F.+Berardiauthor=M.+Continoauthor=M.+Nisoauthor=C.+Abateauthor=R.+Perroneauthor=V.+Tortorella&title=Antiproliferative+and+cytotoxic+effects+of+some+sigma2+agonists+and+sigma1+antagonists+in+tumour+cell+lines&doi=10.1007%2Fs00210-004-0961-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Antiproliferative and cytotoxic effects of some σ2 agonists and σ1 antagonists in tumour cell lines</span></div><div class="casAuthors">Colabufo, Nicola Antonio; Berardi, Francesco; Contino, Marialessandra; Niso, Mauro; Abate, Carmen; Perrone, Roberto; Tortorella, Vincenzo</div><div class="citationInfo"><span class="NLM_cas:title">Naunyn-Schmiedeberg's Archives of Pharmacology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">370</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">106-113</span>CODEN:
                <span class="NLM_cas:coden">NSAPCC</span>;
        ISSN:<span class="NLM_cas:issn">0028-1298</span>.
    
            (<span class="NLM_cas:orgname">Springer GmbH</span>)
        </div><div class="casAbstract">To establish the activity of σ ligands at σ1 and σ2 receptor, we chose two tumor cell lines, the human SK-N-SH neuroblastoma and the rat C6 glioma lines, which express σ2 receptors at a high d. and σ1 receptors in their high-affinity or low-affinity state.  We tested the σ2 receptor agonist PB28 and the σ2 antagonist AC927, and (+)-pentazocine and NE100 as agonist and antagonist, resp., at σ1 receptors, with regard to antiproliferative and cytotoxic effects.  In addn., 1,3-di (2-tolyl)guanidine (DTG) and haloperidol were tested as ref. compds. displaying nearly equipotent σ affinity (σ2>σ1 and σ1>σ2, resp.).  In both SK-N-SH and C6 cells, PB28 and NE100 displayed the most potent results both in antiproliferative and cytotoxic assay while AC927 and (+)-pentazocine were inactive in both assays.  The cytotoxic and antiproliferative effects of DTG and haloperidol reflected their σ1 antagonist activity and σ2 agonist activity.  Moreover, our results in the tumor cell lines correlated well with those for σ2 activity found previously in a functional assay in the guinea-pig bladder.  These findings establish a new model for evaluating both σ2 and σ1 receptor activity of σ ligands, which could be useful for developing new ligands having mixed σ2 agonist/σ1 antagonist activity as potential antineoplastic agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrs66SL4M6j97Vg90H21EOLACvtfcHk0ljq9cBSTv2Fjg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXoslyrtrg%253D&md5=3adb421f453f96086fd45096dc49366c</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1007%2Fs00210-004-0961-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00210-004-0961-2%26sid%3Dliteratum%253Aachs%26aulast%3DColabufo%26aufirst%3DN.%2BA.%26aulast%3DBerardi%26aufirst%3DF.%26aulast%3DContino%26aufirst%3DM.%26aulast%3DNiso%26aufirst%3DM.%26aulast%3DAbate%26aufirst%3DC.%26aulast%3DPerrone%26aufirst%3DR.%26aulast%3DTortorella%26aufirst%3DV.%26atitle%3DAntiproliferative%2520and%2520cytotoxic%2520effects%2520of%2520some%2520sigma2%2520agonists%2520and%2520sigma1%2520antagonists%2520in%2520tumour%2520cell%2520lines%26jtitle%3DNaunyn-Schmiedeberg%2527s%2520Arch.%2520Pharmacol.%26date%3D2004%26volume%3D370%26spage%3D106%26epage%3D113%26doi%3D10.1007%2Fs00210-004-0961-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vilner, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowen, W. D.</span></span> <span> </span><span class="NLM_article-title">Sigma receptor-active neuroleptics are cytotoxic to C6 glioma cells in culture</span>. <i>Eur. J. Pharmacol., Mol. Pharmacol. Sect.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>244</i></span>,  <span class="NLM_fpage">199</span>– <span class="NLM_lpage">201</span>, <span class="refDoi"> DOI: 10.1016/0922-4106(93)90029-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1016%2F0922-4106%2893%2990029-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=8094338" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADyaK3sXhtl2ksLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=244&publication_year=1993&pages=199-201&author=B.+J.+Vilnerauthor=W.+D.+Bowen&title=Sigma+receptor-active+neuroleptics+are+cytotoxic+to+C6+glioma+cells+in+culture&doi=10.1016%2F0922-4106%2893%2990029-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">σ Receptor-active neuroleptics are cytotoxic to C6 glioma cells in culture</span></div><div class="casAuthors">Vilner, Bertold J.; Bowen, Wayne D.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology, Molecular Pharmacology Section</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">244</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">199-201</span>CODEN:
                <span class="NLM_cas:coden">EJPPET</span>;
        ISSN:<span class="NLM_cas:issn">0922-4106</span>.
    </div><div class="casAbstract">When exposed to neuroleptics (100 μM), C6 glioma cells exhibited marked changes in cell morphol., accompanied by cessation of cell division and ultimately cell death.  The degree of activity generally correlated with binding affinity at σ sites: fluphenazine = perphenazine = haloperidol = reduced haloperidol > pimozide = spiperone » (-)-sulpiride.  σ-Inactive compds. (100 μM) which block dopamine, serotonin, phencyclidine, muscarinic receptor and adrenoceptors showed no effect.  These results may suggest a role of σ binding sites in maintenance of cell viability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2v7cjcUdcf7Vg90H21EOLACvtfcHk0ljq9cBSTv2Fjg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXhtl2ksLw%253D&md5=bcb055ae2d3807d99d74d07443cda16e</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1016%2F0922-4106%2893%2990029-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0922-4106%252893%252990029-9%26sid%3Dliteratum%253Aachs%26aulast%3DVilner%26aufirst%3DB.%2BJ.%26aulast%3DBowen%26aufirst%3DW.%2BD.%26atitle%3DSigma%2520receptor-active%2520neuroleptics%2520are%2520cytotoxic%2520to%2520C6%2520glioma%2520cells%2520in%2520culture%26jtitle%3DEur.%2520J.%2520Pharmacol.%252C%2520Mol.%2520Pharmacol.%2520Sect.%26date%3D1993%26volume%3D244%26spage%3D199%26epage%3D201%26doi%3D10.1016%2F0922-4106%2893%2990029-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vilner, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Costa, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowen, W. D.</span></span> <span> </span><span class="NLM_article-title">Cytotoxic effects of sigma ligands: sigma receptor-mediated alterations in cellular morphology and viability</span>. <i>J. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">117</span>– <span class="NLM_lpage">134</span>, <span class="refDoi"> DOI: 10.1523/JNEUROSCI.15-01-00117.1995</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1523%2FJNEUROSCI.15-01-00117.1995" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=7823122" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADyaK2MXjtFejtLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=1995&pages=117-134&author=B.+J.+Vilnerauthor=B.+R.+de+Costaauthor=W.+D.+Bowen&title=Cytotoxic+effects+of+sigma+ligands%3A+sigma+receptor-mediated+alterations+in+cellular+morphology+and+viability&doi=10.1523%2FJNEUROSCI.15-01-00117.1995"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Cytotoxic effects of sigma ligands: sigma receptor-mediated alterations in cellular morphology and viability</span></div><div class="casAuthors">Vilner, Bertold J.; de Costa, Brian R.; Bowen, Wayne D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">1, Pt. 1</span>),
    <span class="NLM_cas:pages">117-34</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-6474</span>.
    
            (<span class="NLM_cas:orgname">Society for Neuroscience</span>)
        </div><div class="casAbstract">The morphol. effects of several neuroleptics as well as other novel and prototypic sigma ligands were examd. by addn. to cultures of C6 glioma cells.  Sigma ligands caused loss of processes, assumption of spherical shape, and cessation of cell division.  The time course and magnitude of this effect were dependent on the concn. of sigma ligand.  Continued exposure to sigma compds. ultimately resulted in cell death.  However, the morphol. effect was reversible when sigma ligand was removed shortly after rounding.  The potency of compds. to produce these effects generally correlated with binding affinity at sigma receptors of C6 glioma cells membranes labeled with [3H](+)-pentazocine.  At a concn. of 100 μM, haloperidol, reduced haloperidol, fluphenazine, perphenazine, trifluoperazine, BD737, LR172, BE1008, and SH344 produced significant effects in 3-6 h of exposure.  Other compds., such as trifluoperidol, thioridazine, and (-)-butaclamol, produced significant effects by 24 h of exposure.  Despite the requirement of micromolar concns. of ligand (some compds. were effective at 30 μm), the effect showed a remarkable specificity for compds. exhibiting sigma receptor binding affinity.  Neuroleptics lacking potent sigma affinity [e.g., (-)-sulpiride, (+)-butaclamol, and clozapine] and other compds. that lack significant sigma affinity but that are agonists or antagonists at dopamine, serotonin, adrenergic, glutamate, phencyclidine, GABA, opiate, or muscarinic cholinergic receptors were without effect on cellular morphol. at concns. up to 300 μM over a period of 72 h.  Likewise, blockers and activators of Na+, K+, and Ca2+ channels and a monoamine oxidase inhibitor devoid of sigma affinity were without effect.  Interestingly, 1,3-di-o-tolylguanidine (DTG), (+)-3-(3-hydroxyphenyl)-N-(1-propyl)piperidine [(+)-3-PPP], (+)-pentazocine, (+)-cyclazocine, and other sigma-active benzomorphans and morphinans appeared inactive in up to 72 h of culture.  However, these compds. interacted synergistically with a subeffective dose of BD737 (30 μM) to produce effects usually in 6 h or less.  Also, the pH of the culture medium had a profound effect on the activity of sigma compds.  Increasing the pH from the normal range of 7.2-7.4 to pH 8.3-8.5 shifted the dose curves (30, 100, 300 μM) for all sigma compds. to the left.  Under these conditions, DTG,(+)-3-PPP, and benzomorphans produced effects in 24 h or less.  Decreasing the medium pH to 6.5-6.7 markedly reduced the activity of all sigma ligands, producing significant protection from cytotoxic effects.  Importantly, compds. that lacked sigma binding affinity showed neither synergism with 30 μM MD737 nor an increase in activity at higher pH.  These results confirm the sigma receptor specificity of this effect.  Sigma ligands had similar effects on other cells of neuronal and non-neuronal origin, including SK-N-SH and SH-SY5Y neuroblastomas, NCB-20 hybridoma, NG 108-15 neuroblastoma-glioma hybrid, COS-7 (kidney), MRS-5 (lung), and PC12 pheochromosome vital role in cell function and may have important implications for neurodegenerative disorders and neuroleptic treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWmjOwA6xlzLVg90H21EOLACvtfcHk0ljq9cBSTv2Fjg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXjtFejtLc%253D&md5=ec404f0a920da3fb64fb5fbc75c311e4</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1523%2FJNEUROSCI.15-01-00117.1995&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1523%252FJNEUROSCI.15-01-00117.1995%26sid%3Dliteratum%253Aachs%26aulast%3DVilner%26aufirst%3DB.%2BJ.%26aulast%3Dde%2BCosta%26aufirst%3DB.%2BR.%26aulast%3DBowen%26aufirst%3DW.%2BD.%26atitle%3DCytotoxic%2520effects%2520of%2520sigma%2520ligands%253A%2520sigma%2520receptor-mediated%2520alterations%2520in%2520cellular%2520morphology%2520and%2520viability%26jtitle%3DJ.%2520Neurosci.%26date%3D1995%26volume%3D15%26spage%3D117%26epage%3D134%26doi%3D10.1523%2FJNEUROSCI.15-01-00117.1995" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Romeo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prezzavento, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Intagliata, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pittalà, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Modica, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marrazzo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turnaturi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parenti, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiechio, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arena, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campisi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sposito, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salerno, L.</span></span> <span> </span><span class="NLM_article-title">Synthesis, in vitro and in vivo characterization of new benzoxazole and benzothiazole-based sigma receptor ligands</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>174</i></span>,  <span class="NLM_fpage">226</span>– <span class="NLM_lpage">235</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2019.04.056</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1016%2Fj.ejmech.2019.04.056" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=31042618" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BC1MXos12isLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=174&publication_year=2019&pages=226-235&author=G.+Romeoauthor=O.+Prezzaventoauthor=S.+Intagliataauthor=V.+Pittal%C3%A0author=M.+N.+Modicaauthor=A.+Marrazzoauthor=R.+Turnaturiauthor=C.+Parentiauthor=S.+Chiechioauthor=E.+Arenaauthor=A.+Campisiauthor=G.+Spositoauthor=L.+Salerno&title=Synthesis%2C+in+vitro+and+in+vivo+characterization+of+new+benzoxazole+and+benzothiazole-based+sigma+receptor+ligands&doi=10.1016%2Fj.ejmech.2019.04.056"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis, in vitro and in vivo characterization of new benzoxazole and benzothiazole-based sigma receptor ligands</span></div><div class="casAuthors">Romeo, Giuseppe; Prezzavento, Orazio; Intagliata, Sebastiano; Pittala, Valeria; Modica, Maria N.; Marrazzo, Agostino; Turnaturi, Rita; Parenti, Carmela; Chiechio, Santina; Arena, Emanuela; Campisi, Agata; Sposito, Giovanni; Salerno, Loredana</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">174</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">226-235</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A new set of 5-chlorobenzoxazole- and 5-chlorobenzothiazole-based derivs. I and II [X = O, S; n = 2, 3, 4] contg. the azepane ring as a basic moiety was designed, synthesized and evaluated through binding assays to measure their affinity and selectivity towards σ1 and σ2 receptors.  Compds. I [X = S; n = 3] and II [X = O; n = 4; X = S, n = 4], with a four units spacer between the bicyclic scaffold and the azepane ring, showed nanomolar affinity towards both receptor subtype and the best Ki values (Ki σ1 = 1.27, 2.30 and 0.78 and Ki σ2 = 7.9, 3.8 and 7.61 nM, resp.).  Evaluation of cytotoxic and apoptotic effects in MCF-7 human cancer cells was useful to assess σ2 receptor activity, while an in-vivo mice model of inflammatory pain allowed to analyze σ1 receptor pharmacol. properties.  In-vitro and in-vivo results suggested that compd. I [X = S, n = 3] was a σ1/σ2 agonist, compd. II [X = S, n = 4] a σ1 antagonist/σ2 agonist, whereas compd. II [X = O, n = 4] might act as σ1 antagonist/σ2 partial agonist.  Due to their pharmacol. profile, a potential therapeutic application in cancer of aforesaid novel σ1/σ2 receptor ligands, esp. compds. II [X = O; n = 4; X = S; n = 4], was proposed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2eACohvx7VLVg90H21EOLACvtfcHk0lhJknMpBTS8KQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXos12isLY%253D&md5=6a2ff604f935292ea9d5a0218baefa52</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2019.04.056&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2019.04.056%26sid%3Dliteratum%253Aachs%26aulast%3DRomeo%26aufirst%3DG.%26aulast%3DPrezzavento%26aufirst%3DO.%26aulast%3DIntagliata%26aufirst%3DS.%26aulast%3DPittal%25C3%25A0%26aufirst%3DV.%26aulast%3DModica%26aufirst%3DM.%2BN.%26aulast%3DMarrazzo%26aufirst%3DA.%26aulast%3DTurnaturi%26aufirst%3DR.%26aulast%3DParenti%26aufirst%3DC.%26aulast%3DChiechio%26aufirst%3DS.%26aulast%3DArena%26aufirst%3DE.%26aulast%3DCampisi%26aufirst%3DA.%26aulast%3DSposito%26aufirst%3DG.%26aulast%3DSalerno%26aufirst%3DL.%26atitle%3DSynthesis%252C%2520in%2520vitro%2520and%2520in%2520vivo%2520characterization%2520of%2520new%2520benzoxazole%2520and%2520benzothiazole-based%2520sigma%2520receptor%2520ligands%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2019%26volume%3D174%26spage%3D226%26epage%3D235%26doi%3D10.1016%2Fj.ejmech.2019.04.056" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mégalizzi, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Decaestecker, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Debeir, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spiegl-Kreinecker, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berger, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lefranc, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kast, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiss, R.</span></span> <span> </span><span class="NLM_article-title">Screening of anti-glioma effects induced by sigma-1 receptor ligands: potential new use for old anti-psychiatric medicines</span>. <i>Eur. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">2893</span>– <span class="NLM_lpage">2905</span>, <span class="refDoi"> DOI: 10.1016/j.ejca.2009.07.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1016%2Fj.ejca.2009.07.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=19679463" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtlSqsL3K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2009&pages=2893-2905&author=V.+M%C3%A9galizziauthor=C.+Decaesteckerauthor=O.+Debeirauthor=S.+Spiegl-Kreineckerauthor=W.+Bergerauthor=F.+Lefrancauthor=R.+E.+Kastauthor=R.+Kiss&title=Screening+of+anti-glioma+effects+induced+by+sigma-1+receptor+ligands%3A+potential+new+use+for+old+anti-psychiatric+medicines&doi=10.1016%2Fj.ejca.2009.07.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Screening of anti-glioma effects induced by sigma-1 receptor ligands: Potential new use for old anti-psychiatric medicines</span></div><div class="casAuthors">Megalizzi, Veronique; Decaestecker, Christine; Debeir, Olivier; Spiegl-Kreinecker, Sabine; Berger, Walter; Lefranc, Florence; Kast, Richard E.; Kiss, Robert</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Cancer</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">2893-2905</span>CODEN:
                <span class="NLM_cas:coden">EJCAEL</span>;
        ISSN:<span class="NLM_cas:issn">0959-8049</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The prognosis of glioblastoma (GBM) remains poor.  Diffuse invasion of distant brain tissue by migrating cells from the primary tumor mass has already occurred at time of diagnosis.  Anti-cancer effects of a selective sigma-1 agonist, 4-(N-benzylpiperidin-4-yl)-4-iodobenzamide (4-IBP), in glioblastoma were shown previously, leading to the present work where the effects on glioblastoma cells of 17 agonists or antagonists of sigma-1 receptors were studied, including currently marketed drugs fluvoxamine, dextromethorphan, donepezil, memantine and haloperidol.  We first showed that established GBM cell lines, primary cultures and surgical specimens express sigma-1 receptors.  In vitro analyses then focused on anti-proliferation and anti-migratory effects on human glioblastoma cell lines using quant. videomicroscopy analyses.  These cell monitoring assays revealed specific impacts on the mitotic cell process.  Using an aggressive glioma model orthotopically grafted into the brains of immunocompromised mice, we showed that combining donepezil and temozolomide gave additive benefit in terms of long survivors as compared to temozolomide or donepezil alone.  Clin. study is planned if further rodent dose-ranging studies of donepezil with temozolomide continue to show evidence of benefit in this model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoOqvYlLDZFJrVg90H21EOLACvtfcHk0lhJknMpBTS8KQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtlSqsL3K&md5=a8809714c0c9930dd8a0556061568666</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1016%2Fj.ejca.2009.07.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejca.2009.07.011%26sid%3Dliteratum%253Aachs%26aulast%3DM%25C3%25A9galizzi%26aufirst%3DV.%26aulast%3DDecaestecker%26aufirst%3DC.%26aulast%3DDebeir%26aufirst%3DO.%26aulast%3DSpiegl-Kreinecker%26aufirst%3DS.%26aulast%3DBerger%26aufirst%3DW.%26aulast%3DLefranc%26aufirst%3DF.%26aulast%3DKast%26aufirst%3DR.%2BE.%26aulast%3DKiss%26aufirst%3DR.%26atitle%3DScreening%2520of%2520anti-glioma%2520effects%2520induced%2520by%2520sigma-1%2520receptor%2520ligands%253A%2520potential%2520new%2520use%2520for%2520old%2520anti-psychiatric%2520medicines%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D2009%26volume%3D45%26spage%3D2893%26epage%3D2905%26doi%3D10.1016%2Fj.ejca.2009.07.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nordenberg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perlmutter, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lavie, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beery, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uziel, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgenstern, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fenig, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weizman, A.</span></span> <span> </span><span class="NLM_article-title">Anti-proliferative activity of haloperidol in B16 mouse and human SK-MEL-28 melanoma cell lines</span>. <i>Int. J. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">1097</span>– <span class="NLM_lpage">1103</span>, <span class="refDoi"> DOI: 10.3892/ijo.27.4.1097</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.3892%2Fijo.27.4.1097" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=16142328" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtFeisrrE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2005&pages=1097-1103&author=J.+Nordenbergauthor=I.+Perlmutterauthor=G.+Lavieauthor=E.+Beeryauthor=O.+Uzielauthor=C.+Morgensternauthor=E.+Fenigauthor=A.+Weizman&title=Anti-proliferative+activity+of+haloperidol+in+B16+mouse+and+human+SK-MEL-28+melanoma+cell+lines&doi=10.3892%2Fijo.27.4.1097"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-proliferative activity of haloperidol in B16 mouse and human SK-MEL-28 melanoma cell lines</span></div><div class="casAuthors">Nordenberg, Jardena; Perlmutter, Israela; Lavie, Gad; Beery, Einat; Uziel, Orit; Morgenstern, Chaya; Fenig, Eyal; Weizman, Abraham</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Oncology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1097-1103</span>CODEN:
                <span class="NLM_cas:coden">IJONES</span>;
        ISSN:<span class="NLM_cas:issn">1019-6439</span>.
    
            (<span class="NLM_cas:orgname">International Journal of Oncology</span>)
        </div><div class="casAbstract">Sigma receptors are present in cancer cell lines.  The aim of the present study is to evaluate the anti-tumor activity of a series of sigma 1, sigma 2 and sigma 1/2 ligands in B16 melanoma cell lines.  Proliferation, apoptosis, intracellular ATP content, cell cycle and mol. regulators were analyzed.  Cell growth was detd. using the sulforhodamine B (SRB) colorimetric cytotoxicity assay.  Apoptosis was assessed by flow cytometry and DNA fragmentation, using ELISA Cell Death assay.  ATP content was measured spectrofluorometrically and cell cycle anal. was performed by flow cytometry.  The cytoplasmic and nuclear expression of cell cycle regulatory mols., cyclin D and CDK2 (cyclin dependent kinase 2) were detd. by Western blot anal. and quantified by densitometry.  The sigma ligands in single digit micromolar concns. inhibited B16 and multidrug-resistant B16 COL/R cell growth, leading to cell death at higher concns.  The potency order was: haloperidol, reduced-haloperidol, ifenprodil tartrate, opipramol and carbetapentane citrate.  B16 COL/R cells were to some extent, less sensitive to sigma ligands.  Further studies have shown that the growth inhibitory effect of sigma ligands could be attributed to G1 arrest of the cell cycle, mediated by a marked decrease in cytoplasmic and nuclear cyclin D and CDK2 protein expression, though haloperidol induced loss of cell viability due to apoptosis.  Sigma ligands induced an early decrease in ATP content.  These data stimulated us to examine the combined anti-proliferative activity of haloperidol and the tyrosine kinase inhibitor imatinib mesylate (STI 571), on SK-MEL-28 human melanoma cells.  Preliminary expts. demonstrated a marked synergistic interaction between the two agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrfMlHU_Jhtj7Vg90H21EOLACvtfcHk0lhJknMpBTS8KQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtFeisrrE&md5=33cf7006f587d4e8bfbb538b2af1c179</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.3892%2Fijo.27.4.1097&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252Fijo.27.4.1097%26sid%3Dliteratum%253Aachs%26aulast%3DNordenberg%26aufirst%3DJ.%26aulast%3DPerlmutter%26aufirst%3DI.%26aulast%3DLavie%26aufirst%3DG.%26aulast%3DBeery%26aufirst%3DE.%26aulast%3DUziel%26aufirst%3DO.%26aulast%3DMorgenstern%26aufirst%3DC.%26aulast%3DFenig%26aufirst%3DE.%26aulast%3DWeizman%26aufirst%3DA.%26atitle%3DAnti-proliferative%2520activity%2520of%2520haloperidol%2520in%2520B16%2520mouse%2520and%2520human%2520SK-MEL-28%2520melanoma%2520cell%2520lines%26jtitle%3DInt.%2520J.%2520Oncol.%26date%3D2005%26volume%3D27%26spage%3D1097%26epage%3D1103%26doi%3D10.3892%2Fijo.27.4.1097" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moody, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leyton, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">John, C.</span></span> <span> </span><span class="NLM_article-title">Sigma ligands inhibit the growth of small cell lung cancer cells</span>. <i>Life Sci.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">1979</span>– <span class="NLM_lpage">1986</span>, <span class="refDoi"> DOI: 10.1016/S0024-3205(00)00523-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1016%2FS0024-3205%2800%2900523-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10821122" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BD3cXisFKksbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2000&pages=1979-1986&author=T.+W.+Moodyauthor=J.+Leytonauthor=C.+John&title=Sigma+ligands+inhibit+the+growth+of+small+cell+lung+cancer+cells&doi=10.1016%2FS0024-3205%2800%2900523-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Sigma ligands inhibit the growth of small cell lung cancer cells</span></div><div class="casAuthors">Moody, T. W.; Leyton, J.; John, C.</div><div class="citationInfo"><span class="NLM_cas:title">Life Sciences</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">1979-1986</span>CODEN:
                <span class="NLM_cas:coden">LIFSAK</span>;
        ISSN:<span class="NLM_cas:issn">0024-3205</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Inc.</span>)
        </div><div class="casAbstract">The effects of sigma ligands on small cell lung cancer (SCLC) cells were investigated.  125I-N-(2-(piperidino)ethyl)-2-iodobenzamide (2-IBP) bound with high affinity to SCLC cell line NCl-H209 and NCl-N417.  Specific 125I-2-IBP binding was inhibited with high affinity by infedipin, haloperidol, (2-piperidinyl-aminoethyl)-4-iodobenzamide (IPAB) and 1,3-ditolylguanidine (DTG) with IC50 values of 3, 10, 15 and 90 nM resp.  In vitro, 10μM 2-IBP, haloperidol or IPAB inhibited NCl-N417 proliferation using a MTT or clonogenic assay.  In vivo, 4 mg/kg IPAB or 2-IBP inhibited NCl-N417 xenograft proliferation.  125I-2-IBP localized to the SCLC tumors after s.c. injection.  These results suggest that sigma ligands may be utilized to localize and inhibit the proliferation of SCLC tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_KpqFXYchU7Vg90H21EOLACvtfcHk0lgWIUjjdzb2Yw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXisFKksbk%253D&md5=0f72e887b15a400ac0ef105efc1bced2</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1016%2FS0024-3205%2800%2900523-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0024-3205%252800%252900523-3%26sid%3Dliteratum%253Aachs%26aulast%3DMoody%26aufirst%3DT.%2BW.%26aulast%3DLeyton%26aufirst%3DJ.%26aulast%3DJohn%26aufirst%3DC.%26atitle%3DSigma%2520ligands%2520inhibit%2520the%2520growth%2520of%2520small%2520cell%2520lung%2520cancer%2520cells%26jtitle%3DLife%2520Sci.%26date%3D2000%26volume%3D66%26spage%3D1979%26epage%3D1986%26doi%3D10.1016%2FS0024-3205%2800%2900523-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schläger, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schepmann, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehmkuhl, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holenz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vela, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buschmann, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wünsch, B.</span></span> <span> </span><span class="NLM_article-title">Combination of two pharmacophoric systems: synthesis and pharmacological evaluation of spirocyclic pyranopyrazoles with high σ<sub>1</sub> receptor affinity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">6704</span>– <span class="NLM_lpage">6713</span>, <span class="refDoi"> DOI: 10.1021/jm200585k</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm200585k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtFygurfF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=6704-6713&author=T.+Schl%C3%A4gerauthor=D.+Schepmannauthor=K.+Lehmkuhlauthor=J.+Holenzauthor=J.+M.+Velaauthor=H.+Buschmannauthor=B.+W%C3%BCnsch&title=Combination+of+two+pharmacophoric+systems%3A+synthesis+and+pharmacological+evaluation+of+spirocyclic+pyranopyrazoles+with+high+%CF%831+receptor+affinity&doi=10.1021%2Fjm200585k"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Combination of two pharmacophoric systems: Synthesis and pharmacological evaluation of spirocyclic pyranopyrazoles with high σ1 receptor affinity</span></div><div class="casAuthors">Schlager, Torsten; Schepmann, Dirk; Lehmkuhl, Kirstin; Holenz, Jorg; Vela, Jose Miguel; Buschmann, Helmut; Wunsch, Bernhard</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">6704-6713</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The novel class of spirocyclic σ1 ligands (6',7'-dihydro-1'H-spiro[piperidine-4,4'-pyrano[4,3-c]pyrazoles]) I was designed by the combination of the potent σ1 ligands II and III(n = 0, 1) in one mol.  Thorough structure affinity relationships were derived by the variation of the substituents in position 1', 1, and 6'.  Whereas the small electron rich methylpyrazole heterocycle was less tolerated by the σ1 receptor protein, the introduction of a Ph substituent instead of the Me group led to ligands with a high σ1 affinity.  It is postulated that the addnl. Ph substituent occupies a previously unrecognized hydrophobic region of the σ1 receptor resulting in addnl. lipophilic interactions.  The spirocyclic pyranopyrazoles are very selective against the σ2 subtype, the PCP binding site of the NMDA receptor, and further targets.  Despite high σ1 affinity, the cyclohexylmethyl deriv. I(R1 = Ph, R2 = C6H11CH2, R3 = MeO) (Ki (σ1) = 0.55 nM) and the isopentenyl deriv. I(R1 = Ph, R2 = isopentenyl, R3 = MeO) (Ki (σ1) = 1.6 nM) showed only low antiallodynic activity in the capsaicin assay.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWuyeWYkUMbLVg90H21EOLACvtfcHk0lgWIUjjdzb2Yw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtFygurfF&md5=af670e6a4bc3cc2eed6ac3407dbce682</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1021%2Fjm200585k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200585k%26sid%3Dliteratum%253Aachs%26aulast%3DSchl%25C3%25A4ger%26aufirst%3DT.%26aulast%3DSchepmann%26aufirst%3DD.%26aulast%3DLehmkuhl%26aufirst%3DK.%26aulast%3DHolenz%26aufirst%3DJ.%26aulast%3DVela%26aufirst%3DJ.%2BM.%26aulast%3DBuschmann%26aufirst%3DH.%26aulast%3DW%25C3%25BCnsch%26aufirst%3DB.%26atitle%3DCombination%2520of%2520two%2520pharmacophoric%2520systems%253A%2520synthesis%2520and%2520pharmacological%2520evaluation%2520of%2520spirocyclic%2520pyranopyrazoles%2520with%2520high%2520%25CF%25831%2520receptor%2520affinity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D6704%26epage%3D6713%26doi%3D10.1021%2Fjm200585k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Akunne, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whetzel, S. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiley, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corbin, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ninteman, F. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tecle, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pei, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pugsley, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heffner, T. G.</span></span> <span> </span><span class="NLM_article-title">The pharmacology of the novel and selective sigma ligand, PD 144418</span>. <i>Neuropharmacology</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">51</span>– <span class="NLM_lpage">62</span>, <span class="refDoi"> DOI: 10.1016/S0028-3908(96)00161-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1016%2FS0028-3908%2896%2900161-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=9144641" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADyaK2sXhvF2ms7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=1997&pages=51-62&author=H.+C.+Akunneauthor=S.+Z.+Whetzelauthor=J.+N.+Wileyauthor=A.+E.+Corbinauthor=F.+W.+Nintemanauthor=H.+Tecleauthor=Y.+Peiauthor=T.+A.+Pugsleyauthor=T.+G.+Heffner&title=The+pharmacology+of+the+novel+and+selective+sigma+ligand%2C+PD+144418&doi=10.1016%2FS0028-3908%2896%2900161-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">The pharmacology of the novel and selective sigma ligand, PD 144418</span></div><div class="casAuthors">Akunne, H. C.; Whetzel, S. Z.; Wiley, J. N.; Corbin, A. E.; Ninteman, F. W.; Tecle, H.; Pei, Y.; Pugsley, T. A.; Heffner, T. G.</div><div class="citationInfo"><span class="NLM_cas:title">Neuropharmacology</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">51-62</span>CODEN:
                <span class="NLM_cas:coden">NEPHBW</span>;
        ISSN:<span class="NLM_cas:issn">0028-3908</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">The pharmacol. of PD 144418 (1-propyl-5-(3-p-tolyl-isoxazol -5-yl)-1,2,3,6-tetrahydropyridine) was characterized using neurochem., biochem. and behavioral techniques.  For sigma (σ1 and σ2, resp.) sites, PD 144418 affinities were detd. using whole guinea pig brain membranes with [3H](+)-pentazocine and neuroblastoma × glioma cell membranes using [3H]1,3-di-o-tolylguanidine (DTG) in the presence of 200 nM (+)-pentazocine.  PD 144418 exhibited an affinity for σ1 of 0.08 nM (Ki) vs. a Ki of 1377 nM for σ2 site.  Addnl. receptor binding studies indicated that PD 144418 lacked affinity for dopaminergic, adrenergic, muscarinic and a variety of other receptors.  In vitro studies indicated that PD 144418 reversed the N-methyl-D-aspartate (NMDA)-induced increase in cyclic GMP (cGMP) in rat cerebellar slices without affecting the basal levels, suggesting that σ1 sites may be important in the regulation of glutamine-induced actions.  PD 144418 potentiated the decrease in 5-hydroxytryptophan caused by haloperidol in the mesolimbic region, but by itself had no effect in 5-hydroxytrypamine (5-HT) and dopamine (DA) synthesis.  Behaviorally, similar to other σ ligands, PD 144418 antagonized mescaline-induced scratching at doses that did not alter spontaneous motor activity.  This action is suggestive of potential antipsychotic property.  It exhibited no anxiolytic and antidepressant properties in the models used.  These results show that PD 144418 is a very selective σ1 agent, devoid of any significant affinity for other receptors and that σ1 site may modulate actions in the CNS.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8tFKmm7SP57Vg90H21EOLACvtfcHk0lgWIUjjdzb2Yw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXhvF2ms7s%253D&md5=cd99a62e955ddfdd9e05b883bc0d7cfb</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1016%2FS0028-3908%2896%2900161-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0028-3908%252896%252900161-X%26sid%3Dliteratum%253Aachs%26aulast%3DAkunne%26aufirst%3DH.%2BC.%26aulast%3DWhetzel%26aufirst%3DS.%2BZ.%26aulast%3DWiley%26aufirst%3DJ.%2BN.%26aulast%3DCorbin%26aufirst%3DA.%2BE.%26aulast%3DNinteman%26aufirst%3DF.%2BW.%26aulast%3DTecle%26aufirst%3DH.%26aulast%3DPei%26aufirst%3DY.%26aulast%3DPugsley%26aufirst%3DT.%2BA.%26aulast%3DHeffner%26aufirst%3DT.%2BG.%26atitle%3DThe%2520pharmacology%2520of%2520the%2520novel%2520and%2520selective%2520sigma%2520ligand%252C%2520PD%2520144418%26jtitle%3DNeuropharmacology%26date%3D1997%26volume%3D36%26spage%3D51%26epage%3D62%26doi%3D10.1016%2FS0028-3908%2896%2900161-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">John, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vilner, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowen, W. D.</span></span> <span> </span><span class="NLM_article-title">Synthesis and characterization of [125I]-N-(N-benzylpiperidin-4-yl)-4- iodobenzamide, a new sigma receptor radiopharmaceutical: high-affinity binding to MCF-7 breast tumor cells</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">1737</span>– <span class="NLM_lpage">1739</span>, <span class="refDoi"> DOI: 10.1021/jm00038a002</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00038a002" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADyaK2cXktlGhuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=1994&pages=1737-1739&author=C.+S.+Johnauthor=B.+J.+Vilnerauthor=W.+D.+Bowen&title=Synthesis+and+characterization+of+%5B125I%5D-N-%28N-benzylpiperidin-4-yl%29-4-+iodobenzamide%2C+a+new+sigma+receptor+radiopharmaceutical%3A+high-affinity+binding+to+MCF-7+breast+tumor+cells&doi=10.1021%2Fjm00038a002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Characterization of [125I]-N-(N-Benzylpiperidin-4-yl)-4-iodobenzamide, a New σ Receptor Radiopharmaceutical: High-Affinity Binding to MCF-7 Breast Tumor Cells</span></div><div class="casAuthors">John, Christy S.; Vilner, Bertold J.; Bowen, Wayne D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1737-9</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    </div><div class="casAbstract">(N-benzylpiperidin-4-yl)-iodobenzamides I (R = 2-I, 3-I, 4-I) were prepd. and evaluated for their affinities for sigma receptors.  All three I showed high affinities for sigma-1 receptors in guinea pig brain membranes (Ki = 1.64 ± 0.15 nM, 3.02 ± 1.06 nM, 1.70 ± 0.15 nM resp.) against [3H](+)-pentazocine, a sigma-1 selective ligand.  I (R = 2-I, 4-I) showed modest affinity for sigma-2 sites (Ki = 29.6 ± 0.49 nM, 25.2 ± 1.28 nM resp.) against [3H]DTG in the presence of dextrallorphan to mask sigma-1 sites.  I (R = 4-I) had a weak affinity for D-2 dopamine receptors as found by competition with [3H](-)-sulpiride in rat brain membranes.  In order to obtain high yields (with high specific activity) of radioiodinated ligand, I (R = 4-SnBu3) was synthesized from I (R = 4-I) by a palladium catalyzed reaction with Bu3SnSnBu3.  I (R = 4-125I) was prepd. in high yields from I (R = SnBu3) using chloramine-T or hydrogen peroxide as an oxidizing agent.  The competition binding studies of I (R = 4-125I) in MCF-7 breast tumor cells with haloperidol and DTG (known sigma ligands) showed complete displacement and high affinity binding (Ki = 4.6 and 60 nM resp.) demonstrating that sigma receptors are expressed in MCF-7 breast tumor cells.  Furthermore, the Scatchard anal. of [3H]DTG binding in MCF-7 cells gave Kd of 38.2 nM and a Bmax of 3867 fmol/mg of protein.  These results demonstrate that high d. of sigma receptors are expressed in MCF-7 cells and that I (R = 4-125I) has potential for imaging breast cancer by targeting sigma sites.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqf5CdIQQi59rVg90H21EOLACvtfcHk0ljfkhKq1613BA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXktlGhuro%253D&md5=86fd60c122b8ff0d82b92c1fde361969</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1021%2Fjm00038a002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00038a002%26sid%3Dliteratum%253Aachs%26aulast%3DJohn%26aufirst%3DC.%2BS.%26aulast%3DVilner%26aufirst%3DB.%2BJ.%26aulast%3DBowen%26aufirst%3DW.%2BD.%26atitle%3DSynthesis%2520and%2520characterization%2520of%2520%255B125I%255D-N-%2528N-benzylpiperidin-4-yl%2529-4-%2520iodobenzamide%252C%2520a%2520new%2520sigma%2520receptor%2520radiopharmaceutical%253A%2520high-affinity%2520binding%2520to%2520MCF-7%2520breast%2520tumor%2520cells%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1994%26volume%3D37%26spage%3D1737%26epage%3D1739%26doi%3D10.1021%2Fjm00038a002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bowen, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertha, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vilner, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rice, K. C.</span></span> <span> </span><span class="NLM_article-title">CB-64D and CB-184: ligands with high sigma 2 receptor affinity and subtype selectivity</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>278</i></span>,  <span class="NLM_fpage">257</span>– <span class="NLM_lpage">260</span>, <span class="refDoi"> DOI: 10.1016/0014-2999(95)00176-L</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1016%2F0014-2999%2895%2900176-L" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=7589164" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADyaK2MXlvFKns70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=278&publication_year=1995&pages=257-260&author=W.+D.+Bowenauthor=C.+M.+Berthaauthor=B.+J.+Vilnerauthor=K.+C.+Rice&title=CB-64D+and+CB-184%3A+ligands+with+high+sigma+2+receptor+affinity+and+subtype+selectivity&doi=10.1016%2F0014-2999%2895%2900176-L"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">CB-64D and CB-184: ligands with high σ2 receptor affinity and subtype selectivity</span></div><div class="casAuthors">Bowen, Wayne D.; Bertha, Craig M.; Vilner, Bertold J.; Rice, Kenner C.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">278</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">257-60</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Four members of a novel class of sigma (σ) ligands were investigated for σ subtype selectivity. (-)-1S,5S- and (+)-1R,5R-(E)-8-Benzylidene-5-(3-hydroxyphenyl)-2-methylmorphan-7-one (CB-64L and CB-64D, resp.) exhibited σ1 Ki = 10.5 nM and 3063 nM; σ2 Ki = 154 nM and 16.5 nM, resp.  The corresponding 3,4-dichloro derivs., (-)-1S,5S- and (+)-1R,5R-(E)-8-(3,4-dichlorobenzylidene)-5-(3-hydroxyphenyl)-2-Me morphan-7-one (CB-182 and CB-184, resp.) were also examd.  CB-182 ((-)-isomer) showed σ1 and σ2 Ki = 27.3 nM and 35.5 nM, resp., whereas CB-184 ((+)-isomer) exhibited σ1 and σ2 Ki = 7436 nM and 13.4 nM, resp.  Thus, the two σ subtypes showed opposite enantioselectivity for these compds., with (-)>(+) at σ1 and (+)>(-) at σ2.  Importantly, CB-64D and CB-184 showed high σ2 affinity and, resp., 185-fold and 554-fold selectivity for σ2 receptors over σ1.  While high σ2 selectivity relative to σ1 was achieved with these compds., they both exhibited high affinity at mu (μ) opioid receptors (Ki = 37.6 nM and 4.5 nM, resp.).  Despite this, CB-64D and CB-184 will be useful tools for further characterization of σ2 receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpx0pBVs3KXDrVg90H21EOLACvtfcHk0ljfkhKq1613BA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXlvFKns70%253D&md5=b5497d6699586de5508e8239ad433268</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1016%2F0014-2999%2895%2900176-L&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0014-2999%252895%252900176-L%26sid%3Dliteratum%253Aachs%26aulast%3DBowen%26aufirst%3DW.%2BD.%26aulast%3DBertha%26aufirst%3DC.%2BM.%26aulast%3DVilner%26aufirst%3DB.%2BJ.%26aulast%3DRice%26aufirst%3DK.%2BC.%26atitle%3DCB-64D%2520and%2520CB-184%253A%2520ligands%2520with%2520high%2520sigma%25202%2520receptor%2520affinity%2520and%2520subtype%2520selectivity%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D1995%26volume%3D278%26spage%3D257%26epage%3D260%26doi%3D10.1016%2F0014-2999%2895%2900176-L" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mach, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Childers, S. R.</span></span> <span> </span><span class="NLM_article-title">Ibogaine possesses a selective affinity for σ2 receptors</span>. <i>Life Sci.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">PL57</span>– <span class="NLM_lpage">PL62</span>, <span class="refDoi"> DOI: 10.1016/0024-3205(95)00301-L</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1016%2F0024-3205%2895%2900301-L" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=7603301" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=1995&pages=PL57-PL62&author=R.+H.+Machauthor=C.+R.+Smithauthor=S.+R.+Childers&title=Ibogaine+possesses+a+selective+affinity+for+%CF%832+receptors&doi=10.1016%2F0024-3205%2895%2900301-L"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1016%2F0024-3205%2895%2900301-L&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0024-3205%252895%252900301-L%26sid%3Dliteratum%253Aachs%26aulast%3DMach%26aufirst%3DR.%2BH.%26aulast%3DSmith%26aufirst%3DC.%2BR.%26aulast%3DChilders%26aufirst%3DS.%2BR.%26atitle%3DIbogaine%2520possesses%2520a%2520selective%2520affinity%2520for%2520%25CF%25832%2520receptors%26jtitle%3DLife%2520Sci.%26date%3D1995%26volume%3D57%26spage%3DPL57%26epage%3DPL62%26doi%3D10.1016%2F0024-3205%2895%2900301-L" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bowen, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vilner, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertha, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuehne, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobson, A. E.</span></span> <span> </span><span class="NLM_article-title">Ibogaine and its congeners are sigma 2 receptor-selective ligands with moderate affinity</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>279</i></span>,  <span class="NLM_fpage">R1</span>– <span class="NLM_lpage">3</span>, <span class="refDoi"> DOI: 10.1016/0014-2999(95)00247-I</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1016%2F0014-2999%2895%2900247-I" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=7556375" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADyaK2MXmtVymtro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=279&publication_year=1995&pages=R1-3&author=W.+D.+Bowenauthor=B.+J.+Vilnerauthor=W.+Williamsauthor=C.+M.+Berthaauthor=M.+E.+Kuehneauthor=A.+E.+Jacobson&title=Ibogaine+and+its+congeners+are+sigma+2+receptor-selective+ligands+with+moderate+affinity&doi=10.1016%2F0014-2999%2895%2900247-I"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Ibogaine and its congeners are σ2 receptor-selective ligands with moderate affinity</span></div><div class="casAuthors">Bowen, Wayne D.; Vilner, Bertold J.; Williams, Wanda; Bertha, Craig M.; Kuehne, Martin E.; Jacobson, Arthur E.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">279</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">R1-R3</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Ibogaine (12-methoxyibogamine) exhibited moderate affinity for σ2 sites (Ki = 201 nM) and low affinity for σ1 sites (Ki = 8554 nM), thus showing 43-fold selectivity for σ2 receptors.  Tabernanthine (13-methoxyibogamine) and (±)-ibogamine had σ2 Ki = 194 nM and 137 nM, resp.  However, they showed 3- to 5-fold higher σ1 affinity compared to ibogaine, resulting in about 14-fold selectivity for σ2 sites over σ1.  A potential ibogaine metabolite, O-des-methyl-ibogaine, had markedly reduced σ2 affinity relative to ibogaine (Ki = 5,226 nM) and also lacked significant affinity for σ1 sites. (±)-Coronaridine ((±)-18-carbomethoxyibogamine) and harmaline (1-methyl-7-methoxy-3,4-dihydro-β-carboline) lacked significant affinity for either σ subtype.  Thus, σ2 receptors could play a role in the actions of ibogaine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqycw-jz291ZbVg90H21EOLACvtfcHk0li4ud9lvQHwSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXmtVymtro%253D&md5=94dd768cd7cb3b523d8031353ecadff1</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1016%2F0014-2999%2895%2900247-I&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0014-2999%252895%252900247-I%26sid%3Dliteratum%253Aachs%26aulast%3DBowen%26aufirst%3DW.%2BD.%26aulast%3DVilner%26aufirst%3DB.%2BJ.%26aulast%3DWilliams%26aufirst%3DW.%26aulast%3DBertha%26aufirst%3DC.%2BM.%26aulast%3DKuehne%26aufirst%3DM.%2BE.%26aulast%3DJacobson%26aufirst%3DA.%2BE.%26atitle%3DIbogaine%2520and%2520its%2520congeners%2520are%2520sigma%25202%2520receptor-selective%2520ligands%2520with%2520moderate%2520affinity%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D1995%26volume%3D279%26spage%3DR1%26epage%3D3%26doi%3D10.1016%2F0014-2999%2895%2900247-I" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wheeler, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mach, R. H.</span></span> <span> </span><span class="NLM_article-title">New N-substituted 9-azabicyclo[3.3.1]nonan-3alpha-yl phenylcarbamate analogs as sigma2 receptor ligands: synthesis, in vitro characterization, and evaluation as PET imaging and chemosensitization agents</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">1222</span>– <span class="NLM_lpage">1231</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2008.12.025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1016%2Fj.bmc.2008.12.025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=19119012" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtlOht7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2009&pages=1222-1231&author=W.+Chuauthor=J.+Xuauthor=D.+Zhouauthor=F.+Zhangauthor=L.+A.+Jonesauthor=K.+T.+Wheelerauthor=R.+H.+Mach&title=New+N-substituted+9-azabicyclo%5B3.3.1%5Dnonan-3alpha-yl+phenylcarbamate+analogs+as+sigma2+receptor+ligands%3A+synthesis%2C+in+vitro+characterization%2C+and+evaluation+as+PET+imaging+and+chemosensitization+agents&doi=10.1016%2Fj.bmc.2008.12.025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">New N-substituted 9-azabicyclo[3.3.1]nonan-3α-yl phenylcarbamate analogs as σ2 receptor ligands: Synthesis, in vitro characterization, and evaluation as PET imaging and chemosensitization agents</span></div><div class="casAuthors">Chu, Wenhua; Xu, Jinbin; Zhou, Dong; Zhang, Fanjie; Jones, Lynne A.; Wheeler, Kenneth T.; Mach, Robert H.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1222-1231</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A series of N-substituted 9-azabicyclo[3.3.1]nonan-3α-yl phenylcarbamate analogs were synthesized.  Among them, WC-26 and WC-59 were identified as the most potent σ2 receptor ligands (Ki = 2.58 and 0.82 nM, resp.) with high selectivity against σ1 (Ki of σ1/σ2 ratio = 557 and 2087, resp.). [18F]WC-59 was radiolabeled via a nucleophilic substitution of a mesylate precursor by [18F]fluoride, and in vitro direct binding studies of [18F]WC-59 were conducted using membrane prepns. from murine EMT-6 solid breast tumors.  The results indicate that [18F]WC-59 binds specifically to σ2 receptors in vitro (Kd = ∼2 nM).  Biodistribution studies of [18F]WC-59 in EMT-6 tumor-bearing mice indicated that the tracer was a less suitable candidate for clin. imaging studies than existing F-18 labeled σ2 receptor ligands.  The ability of WC-26 to enhance the cytotoxic effects of the chemotherapy drug, doxorubicin, was evaluated in cell culture using the mouse breast tumor EMT-6 and the human tumor MDA-MB435.  WC-26 greatly increased the ability of doxorubicin to kill these two tumor cell lines in vitro.  These results indicate that WC-26 is potentially a useful chemosensitizer for the treatment of cancer when combined with conventional chemotherapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqcNkdxZdeDmbVg90H21EOLACvtfcHk0li4ud9lvQHwSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtlOht7o%253D&md5=164a5c8a7e81d14338e3981d317d417b</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2008.12.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2008.12.025%26sid%3Dliteratum%253Aachs%26aulast%3DChu%26aufirst%3DW.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DZhou%26aufirst%3DD.%26aulast%3DZhang%26aufirst%3DF.%26aulast%3DJones%26aufirst%3DL.%2BA.%26aulast%3DWheeler%26aufirst%3DK.%2BT.%26aulast%3DMach%26aufirst%3DR.%2BH.%26atitle%3DNew%2520N-substituted%25209-azabicyclo%255B3.3.1%255Dnonan-3alpha-yl%2520phenylcarbamate%2520analogs%2520as%2520sigma2%2520receptor%2520ligands%253A%2520synthesis%252C%2520in%2520vitro%2520characterization%252C%2520and%2520evaluation%2520as%2520PET%2520imaging%2520and%2520chemosensitization%2520agents%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2009%26volume%3D17%26spage%3D1222%26epage%3D1231%26doi%3D10.1016%2Fj.bmc.2008.12.025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sahn, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mejia, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ray, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Price, T. J.</span></span> <span> </span><span class="NLM_article-title">Sigma 2 Receptor/Tmem97 Agonists Produce Long Lasting Antineuropathic Pain Effects in Mice</span>. <i>ACS Chem. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1801</span>– <span class="NLM_lpage">1811</span>, <span class="refDoi"> DOI: 10.1021/acschemneuro.7b00200</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschemneuro.7b00200" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtVCkt73I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=1801-1811&author=J.+J.+Sahnauthor=G.+L.+Mejiaauthor=P.+R.+Rayauthor=S.+F.+Martinauthor=T.+J.+Price&title=Sigma+2+Receptor%2FTmem97+Agonists+Produce+Long+Lasting+Antineuropathic+Pain+Effects+in+Mice&doi=10.1021%2Facschemneuro.7b00200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Sigma 2 Receptor/Tmem97 Agonists Produce Long Lasting Antineuropathic Pain Effects in Mice</span></div><div class="casAuthors">Sahn, James J.; Mejia, Galo L.; Ray, Pradipta R.; Martin, Stephen F.; Price, Theodore J.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1801-1811</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Neuropathic pain is an important medical problem with few effective treatments.  The sigma 1 receptor (σ1R) is a potential target for neuropathic pain therapeutics, and antagonists for this receptor are effective in preclin. models and are currently in phase II clin. trials.  Relatively little is known about the σ2R, which has recently been identified as transmembrane protein 97 (Tmem97).  The authors generated a series of σ1R and σ2R/Tmem97 agonists and antagonists and tested them for efficacy in the mouse spared nerve injury (SNI) model.  In agreement with previous reports, the authors find that σ1R ligands given intrathecally (IT) produce relief of SNI-induced mech. hypersensitivity.  The authors also find that the putative σ2R/Tmem97 agonists, DKR-1005, DKR-1051 and UKH-1114 (Ki ∼ 46 nM) lead to relief of SNI-induced mech. hypersensitivity, peaking at 48 h after dosing when given IT.  This effect is blocked by the putative σ2R/Tmem97 antagonist SAS-0132.  Systemic administration of UKH-1114 (10 mg/kg) relieves SNI-induced mech. hypersensitivity for 48 h with a peak magnitude of effect equiv. to 100 mg/kg gabapentin and without producing any motor impairment.  Finally, the authors find that the Tmem97 gene is expressed in mouse and human dorsal root ganglion (DRG) including populations of neurons that are involved in pain; however, the gene is also likely expressed in non-neuronal cells that may contribute to the obsd. behavioral effects.  The authors' results show robust anti-neuropathic pain effects of σ1R and σ2R/Tmem97 ligands, demonstrate that σ2R/Tmem97 is a novel neuropathic pain target, and identify UKH-1114 as a lead mol. for further development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrz2DAhBH9TXLVg90H21EOLACvtfcHk0li4ud9lvQHwSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtVCkt73I&md5=27d14b5ef6645a02332f051fab254f51</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1021%2Facschemneuro.7b00200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschemneuro.7b00200%26sid%3Dliteratum%253Aachs%26aulast%3DSahn%26aufirst%3DJ.%2BJ.%26aulast%3DMejia%26aufirst%3DG.%2BL.%26aulast%3DRay%26aufirst%3DP.%2BR.%26aulast%3DMartin%26aufirst%3DS.%2BF.%26aulast%3DPrice%26aufirst%3DT.%2BJ.%26atitle%3DSigma%25202%2520Receptor%252FTmem97%2520Agonists%2520Produce%2520Long%2520Lasting%2520Antineuropathic%2520Pain%2520Effects%2520in%2520Mice%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2017%26volume%3D8%26spage%3D1801%26epage%3D1811%26doi%3D10.1021%2Facschemneuro.7b00200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Intagliata, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">King, T. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mesangeau, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seminerio, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chin, F. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsumoto, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLaughlin, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avery, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCurdy, C. R.</span></span> <span> </span><span class="NLM_article-title">Discovery of a Highly Selective Sigma-2 Receptor Ligand, 1-(4-(6,7-Dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)butyl)-3-methyl-1H-benzo[d]imidazol-2(3H)-one (CM398), with Drug-Like Properties and Antinociceptive Effects In Vivo</span>. <i>AAPS J.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">94</span>, <span class="refDoi"> DOI: 10.1208/s12248-020-00472-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1208%2Fs12248-020-00472-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=32691179" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhsVaqtb3J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2020&pages=94&author=S.+Intagliataauthor=A.+Sharmaauthor=T.+I.+Kingauthor=C.+Mesangeauauthor=M.+Seminerioauthor=F.+T.+Chinauthor=L.+L.+Wilsonauthor=R.+R.+Matsumotoauthor=J.+P.+McLaughlinauthor=B.+A.+Averyauthor=C.+R.+McCurdy&title=Discovery+of+a+Highly+Selective+Sigma-2+Receptor+Ligand%2C+1-%284-%286%2C7-Dimethoxy-3%2C4-dihydroisoquinolin-2%281H%29-yl%29butyl%29-3-methyl-1H-benzo%5Bd%5Dimidazol-2%283H%29-one+%28CM398%29%2C+with+Drug-Like+Properties+and+Antinociceptive+Effects+In+Vivo&doi=10.1208%2Fs12248-020-00472-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Highly Selective Sigma-2 Receptor Ligand, 1-(4-(6,7-Dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)butyl)-3-methyl-1H-benzo[d]imidazol-2(3H)-one (CM398), with Drug-Like Properties and Antinociceptive Effects In Vivo</span></div><div class="casAuthors">Intagliata, Sebastiano; Sharma, Abhisheak; King, Tamara I.; Mesangeau, Christophe; Seminerio, Michael; Chin, Frederick T.; Wilson, Lisa L.; Matsumoto, Rae R.; McLaughlin, Jay P.; Avery, Bonnie A.; McCurdy, Christopher R.</div><div class="citationInfo"><span class="NLM_cas:title">AAPS Journal</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">94</span>CODEN:
                <span class="NLM_cas:coden">AJAOB6</span>;
        ISSN:<span class="NLM_cas:issn">1550-7416</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">The sigma-2 receptor has been cloned and identified as Tmem97, which is a transmembrane protein involved in intracellular Ca2+ regulation and cholesterol homeostasis.  Since its discovery, the sigma-2 receptor has been an extremely controversial target, and many efforts have been made to elucidate the functional role of this receptor during physiol. and pathol. conditions.  Recently, this receptor has been proposed as a potential target to treat neuropathic pain due to the ability of sigma-2 receptor agonists to relieve mech. hyperalgesia in mice model of chronic pain.  In the present work, we developed a highly selective sigma-2 receptor ligand (sigma-1/sigma-2 selectivity ratio > 1000), 1-(4-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)butyl)-3-methyl-1H- benzo[d]imidazol-2(3H)-one (CM398), with an encouraging in vitro and in vivo pharmacol. profile in rodents.  In particular, radioligand binding studies demonstrated that CM398 had preferential affinity for sigma-2 receptor compared with sigma-1 receptor and at least four other neurotransmitter receptors sites, including the norepinephrine transporter.  Following oral administration, CM398 showed rapid absorption and peak plasma concn. (Cmax) occurred within 10 min of dosing.  Moreover, the compd. showed adequate, abs. oral bioavailability of 29.0%.  Finally, CM398 showed promising anti-inflammatory analgesic effects in the formalin model of inflammatory pain in mice.  The results collected in this study provide more evidence that selective sigma-2 receptor ligands can be useful tools in the development of novel pain therapeutics and altogether, these data suggest that CM398 is a suitable lead candidate for further evaluation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopUUccVNqFTLVg90H21EOLACvtfcHk0lgJsy7_Pudz9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhsVaqtb3J&md5=91e614b3d520e9d8cc6ac195fe490220</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1208%2Fs12248-020-00472-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1208%252Fs12248-020-00472-x%26sid%3Dliteratum%253Aachs%26aulast%3DIntagliata%26aufirst%3DS.%26aulast%3DSharma%26aufirst%3DA.%26aulast%3DKing%26aufirst%3DT.%2BI.%26aulast%3DMesangeau%26aufirst%3DC.%26aulast%3DSeminerio%26aufirst%3DM.%26aulast%3DChin%26aufirst%3DF.%2BT.%26aulast%3DWilson%26aufirst%3DL.%2BL.%26aulast%3DMatsumoto%26aufirst%3DR.%2BR.%26aulast%3DMcLaughlin%26aufirst%3DJ.%2BP.%26aulast%3DAvery%26aufirst%3DB.%2BA.%26aulast%3DMcCurdy%26aufirst%3DC.%2BR.%26atitle%3DDiscovery%2520of%2520a%2520Highly%2520Selective%2520Sigma-2%2520Receptor%2520Ligand%252C%25201-%25284-%25286%252C7-Dimethoxy-3%252C4-dihydroisoquinolin-2%25281H%2529-yl%2529butyl%2529-3-methyl-1H-benzo%255Bd%255Dimidazol-2%25283H%2529-one%2520%2528CM398%2529%252C%2520with%2520Drug-Like%2520Properties%2520and%2520Antinociceptive%2520Effects%2520In%2520Vivo%26jtitle%3DAAPS%2520J.%26date%3D2020%26volume%3D22%26spage%3D94%26doi%3D10.1208%2Fs12248-020-00472-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bruna, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Videla, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Argyriou, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Velasco, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villoria, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santos, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nadal, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavaletti, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alberti, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Briani, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalofonos, H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortinovis, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sust, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaqué, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klein, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plata-Salamán, C.</span></span> <span> </span><span class="NLM_article-title">Efficacy of a Novel Sigma-1 Receptor Antagonist for Oxaliplatin-Induced Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase IIa Clinical Trial</span>. <i>Neurotherapeutics</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">178</span>– <span class="NLM_lpage">189</span>, <span class="refDoi"> DOI: 10.1007/s13311-017-0572-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1007%2Fs13311-017-0572-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=28924870" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFantb3E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2018&pages=178-189&author=J.+Brunaauthor=S.+Videlaauthor=A.+A.+Argyriouauthor=R.+Velascoauthor=J.+Villoriaauthor=C.+Santosauthor=C.+Nadalauthor=G.+Cavalettiauthor=P.+Albertiauthor=C.+Brianiauthor=H.+P.+Kalofonosauthor=D.+Cortinovisauthor=M.+Sustauthor=A.+Vaqu%C3%A9author=T.+Kleinauthor=C.+Plata-Salam%C3%A1n&title=Efficacy+of+a+Novel+Sigma-1+Receptor+Antagonist+for+Oxaliplatin-Induced+Neuropathy%3A+A+Randomized%2C+Double-Blind%2C+Placebo-Controlled+Phase+IIa+Clinical+Trial&doi=10.1007%2Fs13311-017-0572-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy of a Novel Sigma-1 Receptor Antagonist for Oxaliplatin-Induced Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase IIa Clinical Trial</span></div><div class="casAuthors">Bruna, Jordi; Videla, Sebastian; Argyriou, Andreas A.; Velasco, Roser; Villoria, Jesus; Santos, Cristina; Nadal, Cristina; Cavaletti, Guido; Alberti, Paola; Briani, Chiara; Kalofonos, Haralabos P.; Cortinovis, Diego; Sust, Mariano; Vaque, Anna; Klein, Thomas; Plata-Salaman, Carlos</div><div class="citationInfo"><span class="NLM_cas:title">Neurotherapeutics</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">178-189</span>CODEN:
                <span class="NLM_cas:coden">NEURNV</span>;
        ISSN:<span class="NLM_cas:issn">1878-7479</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">This trial assessed the efficacy of MR309 (a novel selective sigma-1 receptor ligand previously developed as E-52862) in ameliorating oxaliplatin-induced peripheral neuropathy (oxaipn).  A discontinuous regimen of MR309 (400 mg/day, 5 days per cycle) was tested in patients with colorectal cancer receiving FOLFOX in a phase II, randomized, double-blind, placebo-controlled, multicenter clin. trial.  Outcome measures included changes in 24-wk quant. measures of thermal sensitivity and total neuropathy score.  In total, 124 patients were randomized (1:1) to MR309 or placebo.  Sixty-three (50.8%) patients withdrew prematurely before completing 12 planned oxaliplatin cycles.  Premature withdrawal because of cancer progression was less frequent in the MR309 group (7.4% vs 25.0% with placebo; p = 0.054).  MR309 significantly reduced cold pain threshold temp. [mean treatment effect difference (SE) vs placebo: 5.29 (1.60)°C; p = 0.001] and suprathreshold cold stimulus-evoked pain intensity [mean treatment effect difference: 1.24 (0.57) points; p = 0.032].  Total neuropathy score, health-related quality-of-life measures, and nerve-conduction parameters changed similarly in both arms, whereas the proportion of patients with severe chronic neuropathy (National Cancer Institute Common Terminol. Criteria for Adverse Events ≥ 3) was significantly lower in the MR309 group (3.0% vs 18.2% with placebo; p = 0.046).  The total amt. of oxaliplatin delivered was greater in the active arm (1618.9 mg vs 1453.8 mg with placebo; p = 0.049).  Overall, 19.0% of patients experienced at least 1 treatment-related adverse event (25.8% and 11.9% with MR309 and placebo, resp.).  Intermittent treatment with MR309 was assocd. with reduced acute oxaipn and higher oxaliplatin exposure, and showed a potential neuroprotective role for chronic cumulative oxaipn.  Furthermore, MR309 showed an acceptable safety profile.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTkVyo1fPRe7Vg90H21EOLACvtfcHk0lgJsy7_Pudz9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFantb3E&md5=78eac14b1175a004af19c4c9a53af1be</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1007%2Fs13311-017-0572-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs13311-017-0572-5%26sid%3Dliteratum%253Aachs%26aulast%3DBruna%26aufirst%3DJ.%26aulast%3DVidela%26aufirst%3DS.%26aulast%3DArgyriou%26aufirst%3DA.%2BA.%26aulast%3DVelasco%26aufirst%3DR.%26aulast%3DVilloria%26aufirst%3DJ.%26aulast%3DSantos%26aufirst%3DC.%26aulast%3DNadal%26aufirst%3DC.%26aulast%3DCavaletti%26aufirst%3DG.%26aulast%3DAlberti%26aufirst%3DP.%26aulast%3DBriani%26aufirst%3DC.%26aulast%3DKalofonos%26aufirst%3DH.%2BP.%26aulast%3DCortinovis%26aufirst%3DD.%26aulast%3DSust%26aufirst%3DM.%26aulast%3DVaqu%25C3%25A9%26aufirst%3DA.%26aulast%3DKlein%26aufirst%3DT.%26aulast%3DPlata-Salam%25C3%25A1n%26aufirst%3DC.%26atitle%3DEfficacy%2520of%2520a%2520Novel%2520Sigma-1%2520Receptor%2520Antagonist%2520for%2520Oxaliplatin-Induced%2520Neuropathy%253A%2520A%2520Randomized%252C%2520Double-Blind%252C%2520Placebo-Controlled%2520Phase%2520IIa%2520Clinical%2520Trial%26jtitle%3DNeurotherapeutics%26date%3D2018%26volume%3D15%26spage%3D178%26epage%3D189%26doi%3D10.1007%2Fs13311-017-0572-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hjørnevik, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cipriano, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gulaka, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holley, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gandhi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoon, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mittra, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaharchuk, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gambhir, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCurdy, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chin, F. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biswal, S.</span></span> <span> </span><span class="NLM_article-title">Biodistribution and Radiation Dosimetry of (18)F-FTC-146 in Humans</span>. <i>J. Nucl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">2004</span>– <span class="NLM_lpage">2009</span>, <span class="refDoi"> DOI: 10.2967/jnumed.117.192641</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.2967%2Fjnumed.117.192641" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=28572487" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A280%3ADC%252BC1cnktVOguw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2017&pages=2004-2009&author=T.+Hj%C3%B8rnevikauthor=P.+W.+Ciprianoauthor=B.+Shenauthor=J.+H.+Parkauthor=P.+Gulakaauthor=D.+Holleyauthor=H.+Gandhiauthor=D.+Yoonauthor=E.+S.+Mittraauthor=G.+Zaharchukauthor=S.+S.+Gambhirauthor=C.+R.+McCurdyauthor=F.+T.+Chinauthor=S.+Biswal&title=Biodistribution+and+Radiation+Dosimetry+of+%2818%29F-FTC-146+in+Humans&doi=10.2967%2Fjnumed.117.192641"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Biodistribution and Radiation Dosimetry of (18)F-FTC-146 in Humans</span></div><div class="casAuthors">Hjornevik Trine; Cipriano Peter W; Shen Bin; Park Jun Hyung; Gulaka Praveen; Holley Dawn; Gandhi Harsh; Yoon Daehyun; Mittra Erik S; Zaharchuk Greg; Gambhir Sanjiv S; Chin Frederick T; Biswal Sandip; Hjornevik Trine; Hjornevik Trine; McCurdy Christopher R; McCurdy Christopher R</div><div class="citationInfo"><span class="NLM_cas:title">Journal of nuclear medicine : official publication, Society of Nuclear Medicine</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2004-2009</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The purpose of this study was to assess safety, biodistribution, and radiation dosimetry in humans for the highly selective σ-1 receptor PET agent (18)F-6-(3-fluoropropyl)-3-(2-(azepan-1-yl)ethyl)benzo[d]thiazol-2(3H)-one ((18)F-FTC-146).  Methods: Ten healthy volunteers (5 women, 5 men; age ± SD, 34.3 ± 6.5 y) were recruited, and written informed consent was obtained from all participants.  Series of whole-body PET/MRI examinations were acquired for up to 3 h after injection (357.2 ± 48.8 MBq).  Blood samples were collected, and standard vital signs (heart rate, pulse oximetry, and body temperature) were monitored at regular intervals.  Regions of interest were delineated, time-activity curves were calculated, and organ uptake and dosimetry were estimated.  Results: All subjects tolerated the PET/MRI examination well, and no adverse reactions to (18)F-FTC-146 were reported.  High accumulation of (18)F-FTC-146 was observed in σ-1 receptor-dense organs such as the pancreas and spleen, moderate uptake in the brain and myocardium, and low uptake in bone and muscle.  High uptake was also observed in the kidneys and bladder, indicating renal tracer clearance.  The effective dose of (18)F-FTC-146 was 0.0259 ± 0.0034 mSv/MBq (range, 0.0215-0.0301 mSv/MBq).  Conclusion: First-in-human studies with clinical-grade (18)F-FTC-146 were successful.  Injection of (18)F-FTC-146 is safe, and absorbed doses are acceptable.  The potential of (18)F-FTC-146 as an imaging agent for a variety of neuroinflammatory diseases is currently under investigation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRJ_SCYdyBBVOIHSmpohpd0fW6udTcc2ebDGM-JLP2307ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cnktVOguw%253D%253D&md5=00a57b42e5557e5ad6655d45188a21d1</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.2967%2Fjnumed.117.192641&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2967%252Fjnumed.117.192641%26sid%3Dliteratum%253Aachs%26aulast%3DHj%25C3%25B8rnevik%26aufirst%3DT.%26aulast%3DCipriano%26aufirst%3DP.%2BW.%26aulast%3DShen%26aufirst%3DB.%26aulast%3DPark%26aufirst%3DJ.%2BH.%26aulast%3DGulaka%26aufirst%3DP.%26aulast%3DHolley%26aufirst%3DD.%26aulast%3DGandhi%26aufirst%3DH.%26aulast%3DYoon%26aufirst%3DD.%26aulast%3DMittra%26aufirst%3DE.%2BS.%26aulast%3DZaharchuk%26aufirst%3DG.%26aulast%3DGambhir%26aufirst%3DS.%2BS.%26aulast%3DMcCurdy%26aufirst%3DC.%2BR.%26aulast%3DChin%26aufirst%3DF.%2BT.%26aulast%3DBiswal%26aufirst%3DS.%26atitle%3DBiodistribution%2520and%2520Radiation%2520Dosimetry%2520of%2520%252818%2529F-FTC-146%2520in%2520Humans%26jtitle%3DJ.%2520Nucl.%2520Med.%26date%3D2017%26volume%3D58%26spage%3D2004%26epage%3D2009%26doi%3D10.2967%2Fjnumed.117.192641" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Avery, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vuppala, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jamalapuram, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mesangeau, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chin, F. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCurdy, C. R.</span></span> <span> </span><span class="NLM_article-title">Quantification of highly selective sigma-1 receptor antagonist CM304 using liquid chromatography tandem mass spectrometry and its application to a pre-clinical pharmacokinetic study</span>. <i>Drug Test. Anal.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1236</span>– <span class="NLM_lpage">1242</span>, <span class="refDoi"> DOI: 10.1002/dta.2156</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1002%2Fdta.2156" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=28039926" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BC2sXlvVClsrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2017&pages=1236-1242&author=B.+A.+Averyauthor=P.+K.+Vuppalaauthor=S.+Jamalapuramauthor=A.+Sharmaauthor=C.+Mesangeauauthor=F.+T.+Chinauthor=C.+R.+McCurdy&title=Quantification+of+highly+selective+sigma-1+receptor+antagonist+CM304+using+liquid+chromatography+tandem+mass+spectrometry+and+its+application+to+a+pre-clinical+pharmacokinetic+study&doi=10.1002%2Fdta.2156"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Quantification of highly selective sigma-1 receptor antagonist CM304 using liquid chromatography tandem mass spectrometry and its application to a pre-clinical pharmacokinetic study</span></div><div class="casAuthors">Avery, Bonnie A.; Vuppala, Pradeep K.; Jamalapuram, Seshulatha; Sharma, Abhisheak; Mesangeau, Christophe; Chin, Frederick T.; McCurdy, Christopher R.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Testing and Analysis</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1236-1242</span>CODEN:
                <span class="NLM_cas:coden">DTARBG</span>;
        ISSN:<span class="NLM_cas:issn">1942-7603</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">An ultra-performance liq. chromatog.-tandem mass spectrometry (UPLC-MS/MS) method was developed and validated for quantification of CM304, a novel and highly selective sigma-1 receptor antagonist that has recently entered into human clin. trials.  A structural analog of CM304, SN56, was used as the internal std. (IS).  Chromatog. sepn. was achieved on an Acquity UPLC® BEH C18 (1.7 μm, 2.1 mm × 50 mm) column using a mobile phase [water:methanol (0.1%vol./vol. formic acid; 50:50, %vol./vol.)] at a flow rate of 0.2 mL/min.  Mass spectrometric detection was performed in the pos. ionization mode with multiple reaction monitoring (MRM) using m/z transitions of 337 > 238 for CM304 and 319 > 220 for the IS.  The method was found to be linear and reproducible with a regression coeff. consistently >0.99 for the calibration range of 3 to 3000 ng/mL.  The extn. recovery ranged from 91.5 to 98.4% from spiked (7.5, 300 and 2526 ng/mL) plasma quality control samples.  The precision (%RSD; 1.1 to 2.9%) and accuracy (%RE; -1.9 to 1.8%) were within acceptable limit.  The validated method was successfully applied to a single dose oral and i.v. (I.V.) pharmacokinetic study of CM304 in rats.  Following I. V. administration, the compd. exhibited adequate exposure along with high extravascular distribution and insignificant amt. of extra hepatic metab.  Copyright © 2016 John Wiley & Sons, Ltd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpxx25OJ92NuLVg90H21EOLACvtfcHk0lgWmap6ek6Wkg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXlvVClsrc%253D&md5=7b647717f8384c5222631a6926fa5e5d</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1002%2Fdta.2156&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fdta.2156%26sid%3Dliteratum%253Aachs%26aulast%3DAvery%26aufirst%3DB.%2BA.%26aulast%3DVuppala%26aufirst%3DP.%2BK.%26aulast%3DJamalapuram%26aufirst%3DS.%26aulast%3DSharma%26aufirst%3DA.%26aulast%3DMesangeau%26aufirst%3DC.%26aulast%3DChin%26aufirst%3DF.%2BT.%26aulast%3DMcCurdy%26aufirst%3DC.%2BR.%26atitle%3DQuantification%2520of%2520highly%2520selective%2520sigma-1%2520receptor%2520antagonist%2520CM304%2520using%2520liquid%2520chromatography%2520tandem%2520mass%2520spectrometry%2520and%2520its%2520application%2520to%2520a%2520pre-clinical%2520pharmacokinetic%2520study%26jtitle%3DDrug%2520Test.%2520Anal.%26date%3D2017%26volume%3D9%26spage%3D1236%26epage%3D1242%26doi%3D10.1002%2Fdta.2156" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span> <i>ClinicalTrails.gov</i>, <span class="NLM_publisher-name">NIH</span>, <span class="NLM_publisher-loc">Bethesda, MD</span>. Identifier: NCT02753101,
[18F]FTC-146 PET/MRI in Healthy Volunteers and in CRPS and Sciatica.
Available from: <a href="https://clinicaltrials.gov/ct2/show/NCT02753101?term=FTC146&amp;draw=2&amp;rank=1" class="extLink">https://clinicaltrials.gov/ct2/show/NCT02753101?term=FTC146&draw=2&rank=1</a> (accessed Feb 16, 2017).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+ClinicalTrails.gov%2C+NIH%2C+Bethesda%2C+MD.+Identifier%3A+NCT02753101%2C%0A%5B18F%5DFTC-146+PET%2FMRI+in+Healthy+Volunteers+and+in+CRPS+and+Sciatica.%0AAvailable+from%3A+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT02753101%3Fterm%3DFTC146%26draw%3D2%26rank%3D1+%28accessed+Feb+16%2C+2017%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DClinicalTrails.gov%26pub%3DNIH" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cirino, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eans, S. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medina, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mottinelli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Intagliata, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCurdy, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLaughlin, J. P.</span></span> <span> </span><span class="NLM_article-title">Characterization of Sigma 1 Receptor Antagonist CM-304 and Its Analog, AZ-66: Novel Therapeutics Against Allodynia and Induced Pain</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">678</span>, <span class="refDoi"> DOI: 10.3389/fphar.2019.00678</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.3389%2Ffphar.2019.00678" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=31258480" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BB3cXktlGqsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=678&author=T.+J.+Cirinoauthor=S.+O.+Eansauthor=J.+M.+Medinaauthor=L.+L.+Wilsonauthor=M.+Mottinelliauthor=S.+Intagliataauthor=C.+R.+McCurdyauthor=J.+P.+McLaughlin&title=Characterization+of+Sigma+1+Receptor+Antagonist+CM-304+and+Its+Analog%2C+AZ-66%3A+Novel+Therapeutics+Against+Allodynia+and+Induced+Pain&doi=10.3389%2Ffphar.2019.00678"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of sigma 1 receptor antagonist CM-304 and its analog, AZ-66: novel therapeutics against allodynia and induced pain</span></div><div class="casAuthors">Cirino, Thomas J.; Eans, Shainnel O.; Medina, Jessica M.; Wilson, Lisa L.; Mottinelli, Marco; Intagliata, Sebastiano; McCurdy, Christopher R.; McLaughlin, Jay P.</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Pharmacology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">678</span>CODEN:
                <span class="NLM_cas:coden">FPRHAU</span>;
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">Sigma-1 receptors (S1R) and sigma-2 receptors (S2R) may modulate nociception without the liabilities of opioids, offering a promising therapeutic target to treat pain.  The purpose of this study was to investigate the in vivo analgesic and anti-allodynic activity of two novel sigma receptor antagonists, the S1R-selective CM-304 and its analog the non-selective S1R/S2R antagonist AZ-66.  Inhibition of thermal, induced chem. or inflammatory pain, as well as the allodynia resulting from chronic nerve constriction injury (CCI) and cisplatin exposure as models of neuropathic pain were assessed in male mice.  Both sigma receptor antagonists dose-dependently (10-45 mg/kg, i.p.) reduced allodynia in the CCI and cisplatin neuropathic pain models, equiv. at the higher dose to the effect of the control analgesic gabapentin (50 mg/kg, i.p.), although AZ-66 demonstrated a much longer duration of action.  Both CM-304 and AZ-66 produced antinociception in the writhing test [0.48 (0.09-1.82) and 2.31 (1.02-4.81) mg/kg, i.p., resp.] equiv. to morphine [1.75 (0.31-7.55) mg/kg, i.p.].  Likewise, pretreatment (i.p.) with either sigma-receptor antagonist dose-dependently produced antinociception in the formalin paw assay of inflammatory pain.  However, CM-304 [17.5 (12.7-25.2) mg/kg, i.p.) and AZ-66 [11.6 (8.29-15.6) mg/kg, i.p.) were less efficacious than morphine [3.87 (2.85-5.18) mg/kg, i.p.] in the 55°C warm-water tail-withdrawal assay.  While AZ-66 exhibited modest sedative effects in a rotarod assay and conditioned place aversion, CM-304 did not produce significant effects in the place conditioning assay.  Overall, these results demonstrate the S1R selective antagonist CM-304 produces antinociception and anti-allodynia with fewer liabilities than established therapeutics, supporting the use of S1R antagonists as potential treatments for chronic pain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSXYurn5Us5bVg90H21EOLACvtfcHk0lgWmap6ek6Wkg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXktlGqsbY%253D&md5=f271c2c690934da285e86b94d0d86920</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2019.00678&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2019.00678%26sid%3Dliteratum%253Aachs%26aulast%3DCirino%26aufirst%3DT.%2BJ.%26aulast%3DEans%26aufirst%3DS.%2BO.%26aulast%3DMedina%26aufirst%3DJ.%2BM.%26aulast%3DWilson%26aufirst%3DL.%2BL.%26aulast%3DMottinelli%26aufirst%3DM.%26aulast%3DIntagliata%26aufirst%3DS.%26aulast%3DMcCurdy%26aufirst%3DC.%2BR.%26aulast%3DMcLaughlin%26aufirst%3DJ.%2BP.%26atitle%3DCharacterization%2520of%2520Sigma%25201%2520Receptor%2520Antagonist%2520CM-304%2520and%2520Its%2520Analog%252C%2520AZ-66%253A%2520Novel%2520Therapeutics%2520Against%2520Allodynia%2520and%2520Induced%2520Pain%26jtitle%3DFront.%2520Pharmacol.%26date%3D2019%26volume%3D10%26spage%3D678%26doi%3D10.3389%2Ffphar.2019.00678" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Popa, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamble, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanumuri, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">King, T. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berthold, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Intagliata, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCurdy, C. R.</span></span> <span> </span><span class="NLM_article-title">Bioanalytical method development and pharmacokinetics of MCI-92, a sigma-1 receptor ligand</span>. <i>J. Pharm. Biomed. Anal.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>191</i></span>,  <span class="NLM_fpage">113610</span>, <span class="refDoi"> DOI: 10.1016/j.jpba.2020.113610</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1016%2Fj.jpba.2020.113610" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=32971495" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhvV2ms7rE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=191&publication_year=2020&pages=113610&author=R.+Popaauthor=S.+H.+Kambleauthor=R.+S.+Kanumuriauthor=T.+I.+Kingauthor=E.+C.+Bertholdauthor=S.+Intagliataauthor=A.+Sharmaauthor=C.+R.+McCurdy&title=Bioanalytical+method+development+and+pharmacokinetics+of+MCI-92%2C+a+sigma-1+receptor+ligand&doi=10.1016%2Fj.jpba.2020.113610"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Bioanalytical method development and pharmacokinetics of MCI-92, a sigma-1 receptor ligand</span></div><div class="casAuthors">Popa, Raluca; Kamble, Shyam H.; Kanumuri, Raju S.; King, Tamara I.; Berthold, Erin C.; Intagliata, Sebastiano; Sharma, Abhisheak; McCurdy, Christopher R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmaceutical and Biomedical Analysis</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">191</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">113610</span>CODEN:
                <span class="NLM_cas:coden">JPBADA</span>;
        ISSN:<span class="NLM_cas:issn">0731-7085</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Sigma-1 receptors are found throughout the nervous system and play a role in regulating nociception.  They are highly expressed in nerve injury, making them a potential target for the treatment of neuropathic pain.  Although sigma-1 receptor antagonists have been shown to have anti-nociceptive and anti-allodynic effects, improved selectivity of these ligands is needed to further investigate their potential to treat neuropathic pain.  MCI-92 is a novel, selective sigma-1 receptor ligand developed to address this need.  A sensitive and rapid ultra-performance liq. chromatog. tandem mass spectrometry (UPLC-MS/MS) method was developed and validated for the quantification of MCI-92 in mouse plasma and brain homogenate.  A structural analog of the analyte, MCI-147, was used as the internal std. (IS).  The chromatog. sepn. was achieved on an Acquity UPLC BEH C18 column using a mobile phase consisting of water acidified with 0.1% vol./vol. formic acid and acetonitrile with gradient elution over 3.2 min.  The method was linear over a concn. range of 1-200 ng/mL.  Multiple reaction monitoring in the pos. ionization mode was used for the mass spectrometric quantitation using m/z transitions 369.2 > 126.0 for MCI-92 and 448.9 > 350.1 for the IS.  The method was successfully applied to the anal. of plasma and brain samples obtained in the course of oral and i.v. pharmacokinetic studies in CD-1 mice.  MCI-92 showed a high vol. of distribution (11.3 ± 0.6 L/kg) and rapid clearance (6.1 ± 0.8 L/h/kg) from systemic circulation.  The concn. of the MCI-92 was higher in the brain than in plasma throughout all terminal time points, indicating high blood-to-brain partitioning and slow brain clearance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQD73nMkm8QrVg90H21EOLACvtfcHk0lh1C60uxM_tzA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhvV2ms7rE&md5=5492bcf0f2472efc9d9ef4eb90ced605</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1016%2Fj.jpba.2020.113610&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jpba.2020.113610%26sid%3Dliteratum%253Aachs%26aulast%3DPopa%26aufirst%3DR.%26aulast%3DKamble%26aufirst%3DS.%2BH.%26aulast%3DKanumuri%26aufirst%3DR.%2BS.%26aulast%3DKing%26aufirst%3DT.%2BI.%26aulast%3DBerthold%26aufirst%3DE.%2BC.%26aulast%3DIntagliata%26aufirst%3DS.%26aulast%3DSharma%26aufirst%3DA.%26aulast%3DMcCurdy%26aufirst%3DC.%2BR.%26atitle%3DBioanalytical%2520method%2520development%2520and%2520pharmacokinetics%2520of%2520MCI-92%252C%2520a%2520sigma-1%2520receptor%2520ligand%26jtitle%3DJ.%2520Pharm.%2520Biomed.%2520Anal.%26date%3D2020%26volume%3D191%26spage%3D113610%26doi%3D10.1016%2Fj.jpba.2020.113610" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Villard, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Espallergues, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keller, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vamvakides, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maurice, T.</span></span> <span> </span><span class="NLM_article-title">Anti-amnesic and neuroprotective potentials of the mixed muscarinic receptor/sigma 1 (σ1) ligand ANAVEX2–73, a novel aminotetrahydrofuran derivative</span>. <i>J. Psychopharmacol. (London, U. K.)</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">1101</span>– <span class="NLM_lpage">1117</span>, <span class="refDoi"> DOI: 10.1177/0269881110379286</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1177%2F0269881110379286" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=20829307" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1Gkur%252FF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2011&pages=1101-1117&author=V.+Villardauthor=J.+Espallerguesauthor=E.+Kellerauthor=A.+Vamvakidesauthor=T.+Maurice&title=Anti-amnesic+and+neuroprotective+potentials+of+the+mixed+muscarinic+receptor%2Fsigma+1+%28%CF%831%29+ligand+ANAVEX2%E2%80%9373%2C+a+novel+aminotetrahydrofuran+derivative&doi=10.1177%2F0269881110379286"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-amnesic and neuroprotective potentials of the mixed muscarinic receptor/sigma1 (σ1) ligand ANAVEX2-73, a novel aminotetrahydrofuran derivative</span></div><div class="casAuthors">Villard, Vanessa; Espallergues, Julie; Keller, Emeline; Vamvakides, Alexandre; Maurice, Tangui</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Psychopharmacology (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1101-1117</span>CODEN:
                <span class="NLM_cas:coden">JOPSEQ</span>;
        ISSN:<span class="NLM_cas:issn">0269-8811</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications Ltd.</span>)
        </div><div class="casAbstract">Tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride (ANAVEX2-73) binds to muscarinic acetylcholine and sigma1 (σ1) receptors with affinities in the low micromolar range.  We characterized its anti-amnesic and neuroprotective potentials in pharmacol. and pathol. amnesia models.  Spatial working memory was evaluated using spontaneous alternation in the Y-maze and non-spatial memory using passive avoidance procedures.  ANAVEX2-73 (0.01-3.0 mg/kg i.p.) alleviated the scopolamine- and dizocilpine-induced learning impairments.  ANAVEX2-73 (300 μg/kg) also reversed the learning deficits in mice injected with Aβ25-35 peptide, a non-transgenic Alzheimer's disease model.  When the drug was injected simultaneously with Aβ25-35, 7 days before the tests, it blocked the appearance of learning impairments.  This protective activity was confirmed since ANAVEX2-73 blocked the Aβ25-35-induced oxidative stress in the hippocampus.  This effect was differentially sensitive to the muscarinic receptor antagonist scopolamine or the σ1 protein antagonist BD1047, confirming the mixed muscarinic/σ1 pharmacol. action.  Finally, its unique demethyl metabolite, ANAVEX19-144, was also effective and ANAVEX2-73 presented a longer duration of action, effective 12 h before Aβ25-35, than its related compd. ANAVEX1-41.  The neuroprotective activity of ANAVEX2-73, its mixed cholinergic/σ1 activity, its low active dose range and its long duration of action together reinforce its therapeutic potential in Alzheimer's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWVEQ6V9EfObVg90H21EOLACvtfcHk0lh1C60uxM_tzA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1Gkur%252FF&md5=4a9ed81d07ba7a7e11b72385f60d941f</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1177%2F0269881110379286&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F0269881110379286%26sid%3Dliteratum%253Aachs%26aulast%3DVillard%26aufirst%3DV.%26aulast%3DEspallergues%26aufirst%3DJ.%26aulast%3DKeller%26aufirst%3DE.%26aulast%3DVamvakides%26aufirst%3DA.%26aulast%3DMaurice%26aufirst%3DT.%26atitle%3DAnti-amnesic%2520and%2520neuroprotective%2520potentials%2520of%2520the%2520mixed%2520muscarinic%2520receptor%252Fsigma%25201%2520%2528%25CF%25831%2529%2520ligand%2520ANAVEX2%25E2%2580%259373%252C%2520a%2520novel%2520aminotetrahydrofuran%2520derivative%26jtitle%3DJ.%2520Psychopharmacol.%2520%2528London%252C%2520U.%2520K.%2529%26date%3D2011%26volume%3D25%26spage%3D1101%26epage%3D1117%26doi%3D10.1177%2F0269881110379286" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hirata, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamaguchi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takamura, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takagi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukushima, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwakami, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saitoh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakagawa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamada, T.</span></span> <span> </span><span class="NLM_article-title">A novel neurotrophic agent, T-817MA [1-{3-[2-(1-benzothiophen-5-yl) ethoxy] propyl}-3-azetidinol maleate], attenuates amyloid-beta-induced neurotoxicity and promotes neurite outgrowth in rat cultured central nervous system neurons</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>314</i></span>,  <span class="NLM_fpage">252</span>– <span class="NLM_lpage">259</span>, <span class="refDoi"> DOI: 10.1124/jpet.105.083543</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1124%2Fjpet.105.083543" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=15798005" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BD2MXmtVeju7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=314&publication_year=2005&pages=252-259&author=K.+Hirataauthor=H.+Yamaguchiauthor=Y.+Takamuraauthor=A.+Takagiauthor=T.+Fukushimaauthor=N.+Iwakamiauthor=A.+Saitohauthor=M.+Nakagawaauthor=T.+Yamada&title=A+novel+neurotrophic+agent%2C+T-817MA+%5B1-%7B3-%5B2-%281-benzothiophen-5-yl%29+ethoxy%5D+propyl%7D-3-azetidinol+maleate%5D%2C+attenuates+amyloid-beta-induced+neurotoxicity+and+promotes+neurite+outgrowth+in+rat+cultured+central+nervous+system+neurons&doi=10.1124%2Fjpet.105.083543"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">A novel neurotrophic agent, T-817MA [1-{3-[2-(1-benzothiophen-5-yl)ethoxy]propyl}-3-azetidinol maleate], attenuates amyloid-β-induced neurotoxicity and promotes neurite outgrowth in rat cultured central nervous system neurons</span></div><div class="casAuthors">Hirata, Kazunari; Yamaguchi, Hidetoshi; Takamura, Yusaku; Takagi, Akiko; Fukushima, Tetsuo; Iwakami, Noboru; Saitoh, Akihito; Nakagawa, Masaya; Yamada, Tatsuo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">314</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">252-259</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Progressive neuronal loss in Alzheimer's disease (AD) is considered to be a consequence of the neurotoxic properties of amyloid-β peptides (Aβ).  T-817MA was screened as a candidate therapeutic agent for the treatment of AD based on its neuroprotective potency against Aβ-induced neurotoxicity and its effect of enhancing axonal regeneration in the sciatic nerve axotomy model.  The neuroprotective effect of T-817MA against Aβ(1-42) or oxidative stress-induced neurotoxicity was assessed using a coculture of rat cortical neurons with glia.  T-817MA (0.1 and 1 μM) was strongly protective against Aβ(1-42)-induced (10 μM for 48 h) or H2O2-induced (100 μM for 24 h) neuronal death.  T-817MA suppressed the decrease of GSH levels induced by H2O2 exposure (30 μM for 4 h) in cortical neuron culture; therefore, T-817MA was likely to alleviate oxidative stress.  Besides the neuroprotective effect, T-817MA (0.1 and 1 μM) promoted neurite outgrowth in hippocampal slice cultures and reaggregation culture of rat cortical neurons.  T-817MA also increased the growth-assocd. protein 43 content in the reaggregation culture of cortical neurons.  These findings suggest that T-817MA exerts neuroprotective effect and promotes neurite outgrowth in rat primary cultured neurons.  Based on these neurotrophic features, T-817MA may have a potential for disease modification and be useful for patients with neurodegenerative diseases, such as AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYEzJ50bSUcbVg90H21EOLACvtfcHk0lh1C60uxM_tzA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXmtVeju7w%253D&md5=bab946365eb087fe5302b3aa91e376d3</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1124%2Fjpet.105.083543&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.105.083543%26sid%3Dliteratum%253Aachs%26aulast%3DHirata%26aufirst%3DK.%26aulast%3DYamaguchi%26aufirst%3DH.%26aulast%3DTakamura%26aufirst%3DY.%26aulast%3DTakagi%26aufirst%3DA.%26aulast%3DFukushima%26aufirst%3DT.%26aulast%3DIwakami%26aufirst%3DN.%26aulast%3DSaitoh%26aufirst%3DA.%26aulast%3DNakagawa%26aufirst%3DM.%26aulast%3DYamada%26aufirst%3DT.%26atitle%3DA%2520novel%2520neurotrophic%2520agent%252C%2520T-817MA%2520%255B1-%257B3-%255B2-%25281-benzothiophen-5-yl%2529%2520ethoxy%255D%2520propyl%257D-3-azetidinol%2520maleate%255D%252C%2520attenuates%2520amyloid-beta-induced%2520neurotoxicity%2520and%2520promotes%2520neurite%2520outgrowth%2520in%2520rat%2520cultured%2520central%2520nervous%2520system%2520neurons%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2005%26volume%3D314%26spage%3D252%26epage%3D259%26doi%3D10.1124%2Fjpet.105.083543" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Matsuno, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakazawa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okamoto, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawashima, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mita, S.</span></span> <span> </span><span class="NLM_article-title">Binding properties of SA4503, a novel and selective sigma 1 receptor agonist</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>306</i></span>,  <span class="NLM_fpage">271</span>– <span class="NLM_lpage">279</span>, <span class="refDoi"> DOI: 10.1016/0014-2999(96)00201-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1016%2F0014-2999%2896%2900201-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=8813641" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADyaK28Xktl2ntbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=306&publication_year=1996&pages=271-279&author=K.+Matsunoauthor=M.+Nakazawaauthor=K.+Okamotoauthor=Y.+Kawashimaauthor=S.+Mita&title=Binding+properties+of+SA4503%2C+a+novel+and+selective+sigma+1+receptor+agonist&doi=10.1016%2F0014-2999%2896%2900201-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Binding properties of SA4503, a novel and selective σ1 receptor agonist</span></div><div class="casAuthors">Matsuno, Kiyoshi; Nakazawa, Minako; Okamoto, Kazuyoshi; Kawashima, Yoichi; Mita, Shiro</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">306</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">271-279</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">The binding profiles of SA4503 (1-(3,4-dimethoxyphenethyl)-4-(3-phenylpropyl)piperazine dihydrochloride), a novel σ receptor ligand, to σ1 and σ2 receptor subtypes in guinea pig and rat brain membranes were evaluated.  SA4503 showed a high affinity for the σ1 receptor subtype labeled by (+)-[3H]pentazocine (IC50 = 17.4±1.9 nM), while it had about 100-fold less affinity for the σ2 receptor subtype labeled by [3H]1,3-di(2-tolyl)guanidine ([3H]DTG) in the presence of 200 nM (+)-pentazocine.  SA4503 showed little affinity for 36 other receptors, ion channels and second messenger systems.  The inhibition curves of SA4503 for (+)-[3H]pentazocine binding were shifted to the right in the presence of guanosine 5'-o-(3-thiotriphosphate)(GTPγS), as similar to those of (+)-3-(3-hydroxyphenyl)-N-(1-propyl)piperidine ((+)-3-PPP) and (+)-pentazocine, σ1 receptor agonists.  SA4503 significantly increased the KD value, but did not affect the Bmax value for specific (+)-[3H]pentazocine binding.  These results indicated that SA4503 is a potent and selective agonist for the σ1 receptor subtype in the brain.  In addn., SA4503 inhibited specific (+)-[3H]pentazocine binding in a competitive manner.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2Wso8XHzUE7Vg90H21EOLACvtfcHk0ljUR7RLUtDxPw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28Xktl2ntbs%253D&md5=587287bfffd018c8b316255cbf14a026</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1016%2F0014-2999%2896%2900201-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0014-2999%252896%252900201-4%26sid%3Dliteratum%253Aachs%26aulast%3DMatsuno%26aufirst%3DK.%26aulast%3DNakazawa%26aufirst%3DM.%26aulast%3DOkamoto%26aufirst%3DK.%26aulast%3DKawashima%26aufirst%3DY.%26aulast%3DMita%26aufirst%3DS.%26atitle%3DBinding%2520properties%2520of%2520SA4503%252C%2520a%2520novel%2520and%2520selective%2520sigma%25201%2520receptor%2520agonist%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D1996%26volume%3D306%26spage%3D271%26epage%3D279%26doi%3D10.1016%2F0014-2999%2896%2900201-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Urfer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moebius, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skoloudik, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santamarina, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sato, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mita, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muir, K. W.</span></span> <span> </span><span class="NLM_article-title">Phase II trial of the Sigma-1 receptor agonist cutamesine (SA4503) for recovery enhancement after acute ischemic stroke</span>. <i>Stroke</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">3304</span>– <span class="NLM_lpage">3310</span>, <span class="refDoi"> DOI: 10.1161/STROKEAHA.114.005835</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1161%2FSTROKEAHA.114.005835" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=25270629" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVKrtrbP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2014&pages=3304-3310&author=R.+Urferauthor=H.+J.+Moebiusauthor=D.+Skoloudikauthor=E.+Santamarinaauthor=W.+Satoauthor=S.+Mitaauthor=K.+W.+Muir&title=Phase+II+trial+of+the+Sigma-1+receptor+agonist+cutamesine+%28SA4503%29+for+recovery+enhancement+after+acute+ischemic+stroke&doi=10.1161%2FSTROKEAHA.114.005835"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Phase II Trial of the Sigma-1 Receptor Agonist Cutamesine (SA4503) for Recovery Enhancement After Acute Ischemic Stroke</span></div><div class="casAuthors">Urfer, Roman; Moebius, Hans J.; Skoloudik, David; Santamarina, Estevo; Sato, Wakao; Mita, Shiro; Muir, Keith W.</div><div class="citationInfo"><span class="NLM_cas:title">Stroke</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3304-3310</span>CODEN:
                <span class="NLM_cas:coden">SJCCA7</span>;
        ISSN:<span class="NLM_cas:issn">0039-2499</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">BACKGROUND AND PURPOSE-: The σ-1 receptor (Sig-1R) agonist cutamesine (SA4503) enhanced functional recovery after exptl. stroke with a treatment initiation window of 48 h and chronic treatment for 28 days.  We conducted a phase 2 clin. trial exploring the safety, tolerability, dose range, and functional effects of cutamesine in patients with ischemic stroke.  METHODS-: Subjects were randomized between 48 and 72 h after stroke to receive cutamesine 1 mg/d, 3 mg/d, or placebo for 28 days.  Effects on safety and function were assessed at baseline, at end of treatment (day 28), and at end of follow-up (day 56).  RESULTS-: In 60 patients, treatment with both cutamesine dosages was safe and well tolerated without significant differences in nos. of treatment emergent or serious adverse events.  No significant effect was obsd. on the primary efficacy measure (change in National Institutes of Health Stroke Scale from baseline to day 56) or modified Rankin Scale and Barthel Index scores.  Post hoc anal. of moderately and severely affected patients (baseline National Institutes of Health Stroke Scale, ≥7 and ≥10) showed greater National Institutes of Health Stroke Scale improvements in the 3 mg/d cutamesine group when compared with placebo (P=0.034 and P=0.038, resp.).  A trend toward a higher proportion being able to complete a 10m timed walk was obsd. for cutamesine-treated subjects.  CONCLUSIONS-: Cutamesine was safe and well tolerated at both dosage levels.  Although no significant effects on functional end points were seen in the population as a whole, greater improvement in National Institutes of Health Stroke Scale scores among patients with greater pretreatment deficits seen in post hoc anal. warrants further investigation.  Addnl. studies should focus on the patient population with moderate-to-severe stroke.  Clin. TRIAL REGISTRATION-: URL: http://www.clinicaltrials.gov/show/NCT00639249.  Unique identifier: NCT00639249.  The EudraCT no. is 2007-004840-60 (https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-004840-60/GB).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDEGW1pd0NnLVg90H21EOLACvtfcHk0ljUR7RLUtDxPw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVKrtrbP&md5=cdf635de1aff93573aab643921d25acf</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1161%2FSTROKEAHA.114.005835&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FSTROKEAHA.114.005835%26sid%3Dliteratum%253Aachs%26aulast%3DUrfer%26aufirst%3DR.%26aulast%3DMoebius%26aufirst%3DH.%2BJ.%26aulast%3DSkoloudik%26aufirst%3DD.%26aulast%3DSantamarina%26aufirst%3DE.%26aulast%3DSato%26aufirst%3DW.%26aulast%3DMita%26aufirst%3DS.%26aulast%3DMuir%26aufirst%3DK.%2BW.%26atitle%3DPhase%2520II%2520trial%2520of%2520the%2520Sigma-1%2520receptor%2520agonist%2520cutamesine%2520%2528SA4503%2529%2520for%2520recovery%2520enhancement%2520after%2520acute%2520ischemic%2520stroke%26jtitle%3DStroke%26date%3D2014%26volume%3D45%26spage%3D3304%26epage%3D3310%26doi%3D10.1161%2FSTROKEAHA.114.005835" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Davidson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saoud, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staner, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noel, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luthringer, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Werner, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reilly, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaffhauser, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rabinowitz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiser, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luthringer, R.</span></span> <span> </span><span class="NLM_article-title">Efficacy and Safety of MIN-101: A 12-Week Randomized, Double-Blind, Placebo-Controlled Trial of a New Drug in Development for the Treatment of Negative Symptoms in Schizophrenia</span>. <i>Am. J. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>174</i></span>,  <span class="NLM_fpage">1195</span>– <span class="NLM_lpage">1202</span>, <span class="refDoi"> DOI: 10.1176/appi.ajp.2017.17010122</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1176%2Fappi.ajp.2017.17010122" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=28750582" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A280%3ADC%252BC1cfhvVartg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=174&publication_year=2017&pages=1195-1202&author=M.+Davidsonauthor=J.+Saoudauthor=C.+Stanerauthor=N.+Noelauthor=E.+Luthringerauthor=S.+Wernerauthor=J.+Reillyauthor=J.+Y.+Schaffhauserauthor=J.+Rabinowitzauthor=M.+Weiserauthor=R.+Luthringer&title=Efficacy+and+Safety+of+MIN-101%3A+A+12-Week+Randomized%2C+Double-Blind%2C+Placebo-Controlled+Trial+of+a+New+Drug+in+Development+for+the+Treatment+of+Negative+Symptoms+in+Schizophrenia&doi=10.1176%2Fappi.ajp.2017.17010122"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and Safety of MIN-101: A 12-Week Randomized, Double-Blind, Placebo-Controlled Trial of a New Drug in Development for the Treatment of Negative Symptoms in Schizophrenia</span></div><div class="casAuthors">Davidson Michael; Saoud Jay; Staner Corinne; Noel Nadine; Luthringer Elisabeth; Werner Sandra; Reilly Joseph; Schaffhauser Jean-Yves; Rabinowitz Jonathan; Weiser Mark; Luthringer Remy</div><div class="citationInfo"><span class="NLM_cas:title">The American journal of psychiatry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">174</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1195-1202</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">OBJECTIVE:  The authors assessed the efficacy, safety, and tolerability of MIN-101, a compound with affinities for sigma-2 and 5-HT2A receptors and no direct dopamine affinities, in comparison with placebo in treating negative symptoms in stabilized patients with schizophrenia.  METHOD:  The trial enrolled 244 patients who had been symptomatically stable for at least 3 months and had scores of at least 20 on the negative subscale of the Positive and Negative Syndrome Scale (PANSS).  After at least 5 days' withdrawal from all antipsychotic medication, patients were randomly assigned to receive placebo or 32 mg/day or 64 mg/day of MIN-101 for 12 weeks.  The primary outcome measure was the PANSS negative factor score (pentagonal structure model).  Secondary outcome measures were PANSS total score and scores on the Clinical Global Impressions Scale (CGI), the Brief Negative Symptom Scale, the Brief Assessment of Cognition in Schizophrenia, and the Calgary Depression Scale for Schizophrenia.  RESULTS:  A statistically significant difference in PANSS negative factor score was observed, with lower scores for the MIN-101 32 mg/day and 64 mg/day groups compared with the placebo group (effect sizes, d=0.45 and d=0.57, respectively).  Supporting these findings were similar effects on several of the secondary outcome measures, such as the PANSS negative symptom, total, and activation factor scores, the CGI severity item, and the Brief Negative Symptom Scale.  There were no statistically significant differences in PANSS positive scale score between the MIN-101 and placebo groups.  No clinically significant changes were observed in vital signs, routine laboratory values, weight, metabolic indices, and Abnormal Involuntary Movement Scale score.  CONCLUSIONS:  MIN-101 demonstrated statistically significant efficacy in reducing negative symptoms and good tolerability in stable schizophrenia patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQJp7PYq61mjVHFYivNCdPRfW6udTcc2eZbtTc0r2RmkLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cfhvVartg%253D%253D&md5=cbc089cc56f69145a1974424b68d84f3</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1176%2Fappi.ajp.2017.17010122&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1176%252Fappi.ajp.2017.17010122%26sid%3Dliteratum%253Aachs%26aulast%3DDavidson%26aufirst%3DM.%26aulast%3DSaoud%26aufirst%3DJ.%26aulast%3DStaner%26aufirst%3DC.%26aulast%3DNoel%26aufirst%3DN.%26aulast%3DLuthringer%26aufirst%3DE.%26aulast%3DWerner%26aufirst%3DS.%26aulast%3DReilly%26aufirst%3DJ.%26aulast%3DSchaffhauser%26aufirst%3DJ.%2BY.%26aulast%3DRabinowitz%26aufirst%3DJ.%26aulast%3DWeiser%26aufirst%3DM.%26aulast%3DLuthringer%26aufirst%3DR.%26atitle%3DEfficacy%2520and%2520Safety%2520of%2520MIN-101%253A%2520A%252012-Week%2520Randomized%252C%2520Double-Blind%252C%2520Placebo-Controlled%2520Trial%2520of%2520a%2520New%2520Drug%2520in%2520Development%2520for%2520the%2520Treatment%2520of%2520Negative%2520Symptoms%2520in%2520Schizophrenia%26jtitle%3DAm.%2520J.%2520Psychiatry%26date%3D2017%26volume%3D174%26spage%3D1195%26epage%3D1202%26doi%3D10.1176%2Fappi.ajp.2017.17010122" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grundman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lickliter, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeKosky, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Izzo, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guttendorf, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Higgin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pribyl, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mozzoni, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Safferstein, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Catalano, S. M.</span></span> <span> </span><span class="NLM_article-title">A phase 1 clinical trial of the sigma-2 receptor complex allosteric antagonist CT1812, a novel therapeutic candidate for Alzheimer’s disease</span>. <i>Alzheimer’s Dementia</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">20</span>– <span class="NLM_lpage">26</span>, <span class="refDoi"> DOI: 10.1016/j.trci.2018.11.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1016%2Fj.trci.2018.11.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A280%3ADC%252BB3cjpsVyhtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2019&pages=20-26&author=M.+Grundmanauthor=R.+Morganauthor=J.+D.+Lickliterauthor=L.+S.+Schneiderauthor=S.+DeKoskyauthor=N.+J.+Izzoauthor=R.+Guttendorfauthor=M.+Higginauthor=J.+Pribylauthor=K.+Mozzoniauthor=H.+Saffersteinauthor=S.+M.+Catalano&title=A+phase+1+clinical+trial+of+the+sigma-2+receptor+complex+allosteric+antagonist+CT1812%2C+a+novel+therapeutic+candidate+for+Alzheimer%E2%80%99s+disease&doi=10.1016%2Fj.trci.2018.11.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">A phase 1 clinical trial of the sigma-2 receptor complex allosteric antagonist CT1812, a novel therapeutic candidate for Alzheimer's disease</span></div><div class="casAuthors">Grundman Michael; Grundman Michael; Morgan Roger; Lickliter Jason D; Schneider Lon S; DeKosky Steven; Izzo Nicholas J; Mozzoni Kelsie; Safferstein Hank; Catalano Susan M; Guttendorf Robert; Higgin Michelle; Pribyl Julie</div><div class="citationInfo"><span class="NLM_cas:title">Alzheimer's & dementia (New York, N. Y.)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">20-26</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Background:  Elayta (CT1812) is a novel allosteric antagonist of the sigma-2 receptor complex that prevents and displaces binding of Aβ oligomers to neurons.  By stopping a key initiating event in Alzheimer's disease, this first-in-class drug candidate mitigates downstream synaptotoxicity and restores cognitive function in aged transgenic mouse models of Alzheimer's disease.  Methods:  A phase 1, two-part single and multiple ascending dose study was conducted in 7 and 4 cohorts of healthy human subjects, respectively.  In part A, healthy, young subjects (<65 years old) received CT1812 doses ranging from 10 to 1120 mg (6:2 active to placebo [A:P] per cohort).  In part B, subjects were administered 280, 560, and 840 mg once daily for 14 days (8:2 A:P per cohort).  An elderly cohort, aged 65-75 years, was dosed at 560 mg once daily for 14 days (7:2 A:P).  Serum concentrations of CT1812 in part B were measured on day 3 and 14 and cerebrospinal fluid concentrations on day 7 or 9.  Cognitive testing was performed in the healthy elderly cohort at baseline and at day 14 of treatment.  Results:  Treatment with CT1812 was well tolerated in all cohorts.  Adverse events were mild to moderate in severity and included headache and GI tract symptoms.  Plasma concentrations of drug were dose proportional across two orders of magnitude with minimal accumulation over 14 days.  Cognitive scores in the healthy elderly cohort were similar before and after treatment.  Conclusions:  CT1812 was well tolerated with single dose administration up to 1120 mg and with multiple dose administration up to 840 mg and 560 mg in healthy young and healthy elderly subjects, respectively.  CT1812 is currently being studied in early phase 2 trials in patients with Alzheimer's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTgFoKQ-yRX76Nc3HjJRoFAfW6udTcc2eaAHHJCiAxicbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cjpsVyhtg%253D%253D&md5=58b0f34902f93608fac1f2dcd6b1573e</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1016%2Fj.trci.2018.11.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.trci.2018.11.001%26sid%3Dliteratum%253Aachs%26aulast%3DGrundman%26aufirst%3DM.%26aulast%3DMorgan%26aufirst%3DR.%26aulast%3DLickliter%26aufirst%3DJ.%2BD.%26aulast%3DSchneider%26aufirst%3DL.%2BS.%26aulast%3DDeKosky%26aufirst%3DS.%26aulast%3DIzzo%26aufirst%3DN.%2BJ.%26aulast%3DGuttendorf%26aufirst%3DR.%26aulast%3DHiggin%26aufirst%3DM.%26aulast%3DPribyl%26aufirst%3DJ.%26aulast%3DMozzoni%26aufirst%3DK.%26aulast%3DSafferstein%26aufirst%3DH.%26aulast%3DCatalano%26aufirst%3DS.%2BM.%26atitle%3DA%2520phase%25201%2520clinical%2520trial%2520of%2520the%2520sigma-2%2520receptor%2520complex%2520allosteric%2520antagonist%2520CT1812%252C%2520a%2520novel%2520therapeutic%2520candidate%2520for%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DAlzheimer%25E2%2580%2599s%2520Dementia%26date%3D2019%26volume%3D5%26spage%3D20%26epage%3D26%26doi%3D10.1016%2Fj.trci.2018.11.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref69"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref69'); return false;" data-citation="" class="refNumLink">69</a></strong><div class="NLM_citation" id="cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maher, C. M.</span></span> <span> </span><span class="NLM_article-title">Sigma1 Pharmacology in the Context of Cancer</span>. <i>Handb. Exp. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>244</i></span>,  <span class="NLM_fpage">237</span>– <span class="NLM_lpage">308</span>, <span class="refDoi"> DOI: 10.1007/164_2017_38</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1007%2F164_2017_38" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=28744586" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvFeitbvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=244&publication_year=2017&pages=237-308&author=F.+J.+Kimauthor=C.+M.+Maher&title=Sigma1+Pharmacology+in+the+Context+of+Cancer&doi=10.1007%2F164_2017_38"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Sigma1 pharmacology in the context of cancer</span></div><div class="casAuthors">Kim, Felix J.; Maher, Christina M.</div><div class="citationInfo"><span class="NLM_cas:title">Handbook of Experimental Pharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">244</span>
        (<span class="NLM_cas:issue">Sigma Proteins: Evolution of the Concept of Sigma Receptors</span>),
    <span class="NLM_cas:pages">237-308</span>CODEN:
                <span class="NLM_cas:coden">HEPHD2</span>;
        ISSN:<span class="NLM_cas:issn">1865-0325</span>.
    
            (<span class="NLM_cas:orgname">Springer GmbH</span>)
        </div><div class="casAbstract">A review.  Sigma1 (also known as sigma-1 receptor, Sig1R, s1 receptor) is a unique pharmacol. regulated integral membrane chaperone or scaffolding protein.  The majority of publications on the subject have focused on the neuropharmacol. of Sigma1.  However, a no. of publications have also suggested a role for Sigma1 in cancer.  Although there is currently no clin. used anti-cancer drug that targets Sigma1, a growing body of evidence supports the potential of Sigma1 ligands as therapeutic agents to treat cancer.  In preclin. models, compds. with affinity for Sigma1 have been reported to inhibit cancer cell proliferation and survival, cell adhesion and migration, tumor growth, to alleviate cancer-assocd. pain, and to have immunomodulatory properties.  This review will highlight that although the literature supports a role for Sigma1 in cancer, several fundamental questions regarding drug mechanism of action and the physiol. relevance of aberrant SIGMAR1 transcript and Sigma1 protein expression in certain cancers remain unanswered or only partially answered.  However, emerging lines of evidence suggest that Sigma1 is a component of the cancer cell support machinery, that it facilitates protein interaction networks, that it allosterically modulates the activity of its assocd. proteins, and that Sigma1 is a selectively multifunctional drug target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGolV7ANX6gwGLVg90H21EOLACvtfcHk0lgwwBTLghPzKQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvFeitbvI&md5=6c5d82c84dce7107d0d471a678bd6cd7</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1007%2F164_2017_38&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F164_2017_38%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DF.%2BJ.%26aulast%3DMaher%26aufirst%3DC.%2BM.%26atitle%3DSigma1%2520Pharmacology%2520in%2520the%2520Context%2520of%2520Cancer%26jtitle%3DHandb.%2520Exp.%2520Pharmacol.%26date%3D2017%26volume%3D244%26spage%3D237%26epage%3D308%26doi%3D10.1007%2F164_2017_38" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref70"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref70'); return false;" data-citation="" class="refNumLink">70</a></strong><div class="NLM_citation" id="cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Spruce, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McTavish, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Appleyard, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Neill, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howie, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watt, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLean, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leslie, N. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Safrany, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferguson, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peters, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prescott, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Box, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayes, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nutley, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raynaud, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Downes, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lambert, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eccles, S.</span></span> <span> </span><span class="NLM_article-title">Small molecule antagonists of the sigma-1 receptor cause selective release of the death program in tumor and self-reliant cells and inhibit tumor growth in vitro and in vivo</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">4875</span>– <span class="NLM_lpage">4886</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-03-3180</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1158%2F0008-5472.CAN-03-3180" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=15256458" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BD2cXls1Omtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2004&pages=4875-4886&author=B.+A.+Spruceauthor=L.+A.+Campbellauthor=N.+McTavishauthor=M.+A.+Cooperauthor=M.+V.+Appleyardauthor=M.+O%E2%80%99Neillauthor=J.+Howieauthor=J.+Samsonauthor=S.+Wattauthor=K.+Murrayauthor=D.+McLeanauthor=N.+R.+Leslieauthor=S.+T.+Safranyauthor=M.+J.+Fergusonauthor=J.+A.+Petersauthor=A.+R.+Prescottauthor=G.+Boxauthor=A.+Hayesauthor=B.+Nutleyauthor=F.+Raynaudauthor=C.+P.+Downesauthor=J.+J.+Lambertauthor=A.+M.+Thompsonauthor=S.+Eccles&title=Small+molecule+antagonists+of+the+sigma-1+receptor+cause+selective+release+of+the+death+program+in+tumor+and+self-reliant+cells+and+inhibit+tumor+growth+in+vitro+and+in+vivo&doi=10.1158%2F0008-5472.CAN-03-3180"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Small Molecule Antagonists of the σ-1 Receptor Cause Selective Release of the Death Program in Tumor and Self-Reliant Cells and Inhibit Tumor Growth in Vitro and in Vivo</span></div><div class="casAuthors">Spruce, Barbara A.; Campbell, Lorna A.; McTavish, Niall; Cooper, Michelle A.; Appleyard, M. Virginia L.; O'Neill, Mary; Howie, Jacqueline; Samson, Jayne; Watt, Stephen; Murray, Karen; McLean, Doris; Leslie, Nick R.; Safrany, Stephen T.; Ferguson, Michelle J.; Peters, John A.; Prescott, Alan R.; Box, Gary; Hayes, Angela; Nutley, Bernard; Raynaud, Florence; Downes, C. Peter; Lambert, Jeremy J.; Thompson, Alastair M.; Eccles, Suzanne</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">4875-4886</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The acquisition of resistance to apoptosis, the cell's intrinsic suicide program, is essential for cancers to arise and progress and is a major reason behind treatment failures.  We show in this article that small mol. antagonists of the σ-1 receptor inhibit tumor cell survival to reveal caspase-dependent apoptosis.  σ-Antagonist-mediated caspase activation and cell death are substantially attenuated by the prototypic -1 agonists (+)-SKF10,047 and (+)-pentazocine.  Although several normal cell types such as fibroblasts, epithelial cells, and even σ receptor-rich neurons are resistant to the apoptotic effects of σ antagonists, cells that can promote autocrine survival such as lens epithelial and microvascular endothelial cells are as susceptible as tumor cells.  Cellular susceptibility appears to correlate with differences in σ receptor coupling rather than levels of expression.  In susceptible cells only, σ antagonists evoke a rapid rise in cytosolic calcium that is inhibited by σ-1 agonists.  In at least some tumor cells, σ antagonists cause calcium-dependent activation of phospholipase C and concomitant calcium-independent inhibition of phosphatidylinositol 3'-kinase pathway signaling.  BSystemic administration of σ antagonists significantly inhibits the growth of evolving and established hormone-sensitive and hormone-insensitive mammary carcinoma xenografts, orthotopic prostate tumors, and p53-null lung carcinoma xenografts in immunocompromised mice in the absence of side effects.  Release of a σ receptor-mediated brake on apoptosis may offer a new approach to cancer treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpSCoAyVi6oLVg90H21EOLACvtfcHk0lgwwBTLghPzKQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXls1Omtr8%253D&md5=a91eaaa7754714c7113c8107ffedc965</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-03-3180&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-03-3180%26sid%3Dliteratum%253Aachs%26aulast%3DSpruce%26aufirst%3DB.%2BA.%26aulast%3DCampbell%26aufirst%3DL.%2BA.%26aulast%3DMcTavish%26aufirst%3DN.%26aulast%3DCooper%26aufirst%3DM.%2BA.%26aulast%3DAppleyard%26aufirst%3DM.%2BV.%26aulast%3DO%25E2%2580%2599Neill%26aufirst%3DM.%26aulast%3DHowie%26aufirst%3DJ.%26aulast%3DSamson%26aufirst%3DJ.%26aulast%3DWatt%26aufirst%3DS.%26aulast%3DMurray%26aufirst%3DK.%26aulast%3DMcLean%26aufirst%3DD.%26aulast%3DLeslie%26aufirst%3DN.%2BR.%26aulast%3DSafrany%26aufirst%3DS.%2BT.%26aulast%3DFerguson%26aufirst%3DM.%2BJ.%26aulast%3DPeters%26aufirst%3DJ.%2BA.%26aulast%3DPrescott%26aufirst%3DA.%2BR.%26aulast%3DBox%26aufirst%3DG.%26aulast%3DHayes%26aufirst%3DA.%26aulast%3DNutley%26aufirst%3DB.%26aulast%3DRaynaud%26aufirst%3DF.%26aulast%3DDownes%26aufirst%3DC.%2BP.%26aulast%3DLambert%26aufirst%3DJ.%2BJ.%26aulast%3DThompson%26aufirst%3DA.%2BM.%26aulast%3DEccles%26aufirst%3DS.%26atitle%3DSmall%2520molecule%2520antagonists%2520of%2520the%2520sigma-1%2520receptor%2520cause%2520selective%2520release%2520of%2520the%2520death%2520program%2520in%2520tumor%2520and%2520self-reliant%2520cells%2520and%2520inhibit%2520tumor%2520growth%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DCancer%2520Res.%26date%3D2004%26volume%3D64%26spage%3D4875%26epage%3D4886%26doi%3D10.1158%2F0008-5472.CAN-03-3180" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref71"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref71'); return false;" data-citation="" class="refNumLink">71</a></strong><div class="NLM_citation" id="cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Crawford, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowen, W. D.</span></span> <span> </span><span class="NLM_article-title">Sigma-2 receptor agonists activate a novel apoptotic pathway and potentiate antineoplastic drugs in breast tumor cell lines</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">313</span>– <span class="NLM_lpage">322</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=11782394" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BD38XntV2gug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2002&pages=313-322&author=K.+W.+Crawfordauthor=W.+D.+Bowen&title=Sigma-2+receptor+agonists+activate+a+novel+apoptotic+pathway+and+potentiate+antineoplastic+drugs+in+breast+tumor+cell+lines"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Sigma-2 receptor agonists activate a novel apoptotic pathway and potentiate antineoplastic drugs in breast tumor cell lines</span></div><div class="casAuthors">Crawford, Keith W.; Bowen, Wayne D.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">313-322</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">We have reported previously that sigma-2 receptors are expressed in high densities in a variety of tumor cell types and that various sigma ligands have cytotoxic effects.  Other investigators have demonstrated increased expression of sigma-2 receptors in rapidly proliferating tumors and the ability of some sigma ligands to inhibit proliferation.  We demonstrate here the ability of sigma-2 receptor agonists to induce cell death by a mechanism consistent with apoptosis.  In breast tumor cell lines that are sensitive (MCF-7) and resistant (MCF-7/Adr-, T47D, and SKBr3) to antineoplastic agents, incubation with the sigma-2 subtype-selective agonists CB-64D and CB-184 produced dose-dependent cytotoxicity (measured by lactate dehydrogenase release into medium).  The EC50 for this response was similar across cell lines, irresp. of p53 genotype and drug-resistance phenotype.  CB-64D and the subtype nonselective sigma-2 agonists haloperidol and reduced haloperidol induced terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling staining in MCF-7 and T47D cells, indicating that cell death occurs via apoptosis.  Apoptosis was also indicated by increases in Annexin V binding caused by CB-64D.  In MCF-7 cells, cytotoxicity and Annexin V binding induced by the antineoplastics doxorubicin and actinomycin D was partially or completely abrogated by certain specific and general inhibitors of caspases.  In contrast, caspase inhibitors had no effect on sigma-2 receptor-mediated (CB-64D and CB-184) cytotoxicity or Annexin V binding.  Marked potentiation of cytotoxicity was obsd. when a subtoxic dose of CB-184 was combined with doxorubicin or actinomycin D, both in drug-sensitive (MCF-7) and drug-resistant (MCF-7/Adr-) cell lines.  Haloperidol potentiated doxorubicin only in drug-resistant cells.  These findings suggest the involvement of a novel p53- and caspase-independent apoptotic pathway used by sigma-2 receptors, which is distinct from mechanisms used by some DNA-damaging, antineoplastic agents and other apoptotic stimuli.  These observations further suggest that sigma-2 receptors may be targets that can be therapeutically exploited in the treatment of both drug-sensitive and drug-resistant metastatic tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpEJugG63Xfy7Vg90H21EOLACvtfcHk0ljDPKfplXYZ2A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XntV2gug%253D%253D&md5=89feb1caf2fa574ba2f49aff8be7d920</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCrawford%26aufirst%3DK.%2BW.%26aulast%3DBowen%26aufirst%3DW.%2BD.%26atitle%3DSigma-2%2520receptor%2520agonists%2520activate%2520a%2520novel%2520apoptotic%2520pathway%2520and%2520potentiate%2520antineoplastic%2520drugs%2520in%2520breast%2520tumor%2520cell%2520lines%26jtitle%3DCancer%2520Res.%26date%3D2002%26volume%3D62%26spage%3D313%26epage%3D322" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref72"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref72'); return false;" data-citation="" class="refNumLink">72</a></strong><div class="NLM_citation" id="cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ostenfeld, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fehrenbacher, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Høyer-Hansen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomsen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farkas, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jäättelä, M.</span></span> <span> </span><span class="NLM_article-title">Effective tumor cell death by sigma-2 receptor ligand siramesine involves lysosomal leakage and oxidative stress</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>65</i></span>,  <span class="NLM_fpage">8975</span>– <span class="NLM_lpage">8983</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-05-0269</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1158%2F0008-5472.CAN-05-0269" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=16204071" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVKiu7rP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2005&pages=8975-8983&author=M.+S.+Ostenfeldauthor=N.+Fehrenbacherauthor=M.+H%C3%B8yer-Hansenauthor=C.+Thomsenauthor=T.+Farkasauthor=M.+J%C3%A4%C3%A4ttel%C3%A4&title=Effective+tumor+cell+death+by+sigma-2+receptor+ligand+siramesine+involves+lysosomal+leakage+and+oxidative+stress&doi=10.1158%2F0008-5472.CAN-05-0269"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Effective Tumor Cell Death by σ-2 Receptor Ligand Siramesine Involves Lysosomal Leakage and Oxidative Stress</span></div><div class="casAuthors">Ostenfeld, Marie Stampe; Fehrenbacher, Nicole; Hoyer-Hansen, Maria; Thomsen, Christian; Farkas, Thomas; Jaeaettelae, Marja</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">8975-8983</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Acquired resistance to classic caspase-mediated apoptosis is a common problem for the treatment of human cancer.  Here, we show that siramesine, a novel σ-2 receptor ligand, effectively induces caspase-independent programmed cell death in immortalized and transformed cells of various origins.  Siramesine-treated tumor cells displayed increased levels of reactive oxygen species, lysosomal membrane permeabilization, chromatin condensation, and shrinkage and detachment of cells.  Lipid antioxidants (α-tocopherol and γ-tocopherol), but not other tested antioxidants (butylated hydroxyanisol or N-acetyl cysteine), effectively inhibited siramesine-induced morphol. changes and cell death.  Cathepsin B inhibitors (CA-074-Me and R-2525) conferred similar, but less pronounced protection, whereas ectopic expression of antiapoptotic protein Bcl-2, lack of wild-type p53 as well as pharmacol. inhibitors of caspases (zVAD-fmk, DEVD-CHO, and LEHD-CHO), calpains (PD150606), and serine proteases (N-tosyl-L-phenylalanine chloromethyl ketone and pefabloc) failed to protect cells against siramesine-induced death.  Importantly, transformation of murine embryonic fibroblasts with activated c-src or v-Ha-ras oncogenes greatly sensitized them to siramesine-induced cytotoxicity.  Furthermore, p.o. administration of well-tolerated doses of siramesine had a significant antitumorigenic effect in orthotopic breast cancer and s.c. fibrosarcoma models in mice.  These results present siramesine as a promising new drug for the treatment of tumors resistant to traditional therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRyz3SkulSoLVg90H21EOLACvtfcHk0ljDPKfplXYZ2A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVKiu7rP&md5=8f3f4852a795c78230545c5bad292d8e</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-05-0269&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-05-0269%26sid%3Dliteratum%253Aachs%26aulast%3DOstenfeld%26aufirst%3DM.%2BS.%26aulast%3DFehrenbacher%26aufirst%3DN.%26aulast%3DH%25C3%25B8yer-Hansen%26aufirst%3DM.%26aulast%3DThomsen%26aufirst%3DC.%26aulast%3DFarkas%26aufirst%3DT.%26aulast%3DJ%25C3%25A4%25C3%25A4ttel%25C3%25A4%26aufirst%3DM.%26atitle%3DEffective%2520tumor%2520cell%2520death%2520by%2520sigma-2%2520receptor%2520ligand%2520siramesine%2520involves%2520lysosomal%2520leakage%2520and%2520oxidative%2520stress%26jtitle%3DCancer%2520Res.%26date%3D2005%26volume%3D65%26spage%3D8975%26epage%3D8983%26doi%3D10.1158%2F0008-5472.CAN-05-0269" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref73"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref73'); return false;" data-citation="" class="refNumLink">73</a></strong><div class="NLM_citation" id="cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rothfuss, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vangveravong, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mach, R. H.</span></span> <span> </span><span class="NLM_article-title">Functional assays to define agonists and antagonists of the sigma-2 receptor</span>. <i>Anal. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>448</i></span>,  <span class="NLM_fpage">68</span>– <span class="NLM_lpage">74</span>, <span class="refDoi"> DOI: 10.1016/j.ab.2013.12.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1016%2Fj.ab.2013.12.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=24333652" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitleltbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=448&publication_year=2014&pages=68-74&author=C.+Zengauthor=J.+M.+Rothfussauthor=J.+Zhangauthor=S.+Vangveravongauthor=W.+Chuauthor=S.+Liauthor=Z.+Tuauthor=J.+Xuauthor=R.+H.+Mach&title=Functional+assays+to+define+agonists+and+antagonists+of+the+sigma-2+receptor&doi=10.1016%2Fj.ab.2013.12.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Functional assays to define agonists and antagonists of the sigma-2 receptor</span></div><div class="casAuthors">Zeng, Chenbo; Rothfuss, Justin M.; Zhang, Jun; Vangveravong, Suwanna; Chu, Wenhua; Li, Shihong; Tu, Zhude; Xu, Jinbin; Mach, Robert H.</div><div class="citationInfo"><span class="NLM_cas:title">Analytical Biochemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">448</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">68-74</span>CODEN:
                <span class="NLM_cas:coden">ANBCA2</span>;
        ISSN:<span class="NLM_cas:issn">0003-2697</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The sigma-2 receptor has been identified as a biomarker in proliferating tumors.  To date there is no well-established functional assay for defining sigma-2 agonists and antagonists.  Many sigma-2 ligands with diverse structures have been shown to induce cell death in a variety of cancer cells by triggering caspase-dependent and independent apoptosis.  Therefore, in the current study, we used the cell viability assay and the caspase-3 activity assay to det. sigma-2 agonists and antagonists.  Three classes of sigma-2 ligands developed in our lab. were evaluated for their potency to induce cell death in two tumor cell lines, mouse breast cancer cell line EMT-6 and human melanoma cell line MDA-MB-435.  The data showed that the EC50 values of the sigma-2 ligands using the cell viability assay ranged from 11.4 μM to >200 μM, which were comparable with the EC50 values obtained using the caspase-3 assay.  Based on the cytotoxicity of a sigma-2 ligand relative to that of siramesine, a commonly accepted sigma-2 agonist, we have categorized our sigma-2 ligands into agonists, partial agonists, and antagonists.  The establishment of functional assays for defining sigma-2 agonists and antagonists will facilitate functional characterization of sigma-2 receptor ligands and sigma-2 receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFM0mxQ6ge67Vg90H21EOLACvtfcHk0lgvPorXen_ZPw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitleltbw%253D&md5=4f50b1c949dfd9ffaf07b539e109d741</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1016%2Fj.ab.2013.12.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ab.2013.12.008%26sid%3Dliteratum%253Aachs%26aulast%3DZeng%26aufirst%3DC.%26aulast%3DRothfuss%26aufirst%3DJ.%2BM.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DVangveravong%26aufirst%3DS.%26aulast%3DChu%26aufirst%3DW.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DTu%26aufirst%3DZ.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DMach%26aufirst%3DR.%2BH.%26atitle%3DFunctional%2520assays%2520to%2520define%2520agonists%2520and%2520antagonists%2520of%2520the%2520sigma-2%2520receptor%26jtitle%3DAnal.%2520Biochem.%26date%3D2014%26volume%3D448%26spage%3D68%26epage%3D74%26doi%3D10.1016%2Fj.ab.2013.12.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref74"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref74'); return false;" data-citation="" class="refNumLink">74</a></strong><div class="NLM_citation" id="cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dehdashti, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laforest, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shoghi, K. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aft, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nussenbaum, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kreisel, F. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartlett, N. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cashen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner-Johnston, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mach, R. H.</span></span> <span> </span><span class="NLM_article-title">Assessment of cellular proliferation in tumors by PET using 18F-ISO-1</span>. <i>J. Nucl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">350</span>– <span class="NLM_lpage">357</span>, <span class="refDoi"> DOI: 10.2967/jnumed.112.111948</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.2967%2Fjnumed.112.111948" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=23359657" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BC3sXltV2ksr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2013&pages=350-357&author=F.+Dehdashtiauthor=R.+Laforestauthor=F.+Gaoauthor=K.+I.+Shoghiauthor=R.+L.+Aftauthor=B.+Nussenbaumauthor=F.+H.+Kreiselauthor=N.+L.+Bartlettauthor=A.+Cashenauthor=N.+Wagner-Johnstonauthor=R.+H.+Mach&title=Assessment+of+cellular+proliferation+in+tumors+by+PET+using+18F-ISO-1&doi=10.2967%2Fjnumed.112.111948"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Assessment of cellular proliferation in tumors by PET using 18F-ISO-1</span></div><div class="casAuthors">Dehdashti, Farrokh; Laforest, Richard; Gao, Feng; Shoghi, Kooresh I.; Aft, Rebecca L.; Nussenbaum, Brian; Kreisel, Friederike H.; Bartlett, Nancy L.; Cashen, Amanda; Wagner-Johnston, Nina; Mach, Robert H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Nuclear Medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">350-357</span>CODEN:
                <span class="NLM_cas:coden">JNMEAQ</span>;
        ISSN:<span class="NLM_cas:issn">0161-5505</span>.
    
            (<span class="NLM_cas:orgname">Society of Nuclear Medicine and Molecular Imaging</span>)
        </div><div class="casAbstract">This first study in humans was designed to evaluate the safety and dosimetry of a cellular proliferative marker, N-(4-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)butyl)-2-(2-18F-fluoro-ethoxy)-5-methylbenzamide (18F-ISO-1), and evaluate the feasibility of imaging tumor proliferation by PET in patients with newly diagnosed malignant neoplasms.  Methods: Patients with biopsy-proven lymphoma, breast cancer, or head and neck cancer underwent 18F-ISO-1 PET.  Tumor 18F-ISO-1 uptake was assessed semiquant. by max. standardized uptake value, ratios of tumor to normal tissue and tumor to muscle, and relative distribution vol. ratio.  The PET results were correlated with tumor Ki-67 and mitotic index, from in vitro assays of the tumor tissue.  The biodistribution of 18F-ISO-1 and human dosimetry were evaluated.  Results: Thirty patients with primary breast cancer (n = 13), head and neck cancer (n = 10), and lymphoma (n = 7) were evaluated.  In the entire group, tumor max. standardized uptake value and tumor-to-muscle ratio correlated significantly with Ki-67 (*au = 0.27, P = 0.04, and *au = 0.38, P = 0.003, resp.), but no significant correlation was obsd. between Ki-67 and tumor-to-normal-tissue ratio (*au = 0.07, P = 0.56) or distribution vol. ratio (*au = 0.26, P = 0.14).  On the basis of whole-body PET data, the gallbladder is the dose-limiting organ, with an av. radiation dose of 0.091 mGy/MBq.  The whole-body and EDs were 0.012 mGy/MBq and 0.016 mSv/MBq, resp.  No adverse effects of 18F-ISO-1 were encountered.  Conclusion: The presence of a significant correlation between 18F-ISO-1 and Ki-67 makes this agent promising for evaluation of the proliferative status of solid tumors.  The relatively small absorbed doses to normal organs allow for the safe administration of up to 550 MBq, which is sufficient for PET imaging in clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEJzNLBiXZh7Vg90H21EOLACvtfcHk0lgvPorXen_ZPw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXltV2ksr4%253D&md5=c746f6bb256184c9e2e2dfa164be875f</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.2967%2Fjnumed.112.111948&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2967%252Fjnumed.112.111948%26sid%3Dliteratum%253Aachs%26aulast%3DDehdashti%26aufirst%3DF.%26aulast%3DLaforest%26aufirst%3DR.%26aulast%3DGao%26aufirst%3DF.%26aulast%3DShoghi%26aufirst%3DK.%2BI.%26aulast%3DAft%26aufirst%3DR.%2BL.%26aulast%3DNussenbaum%26aufirst%3DB.%26aulast%3DKreisel%26aufirst%3DF.%2BH.%26aulast%3DBartlett%26aufirst%3DN.%2BL.%26aulast%3DCashen%26aufirst%3DA.%26aulast%3DWagner-Johnston%26aufirst%3DN.%26aulast%3DMach%26aufirst%3DR.%2BH.%26atitle%3DAssessment%2520of%2520cellular%2520proliferation%2520in%2520tumors%2520by%2520PET%2520using%252018F-ISO-1%26jtitle%3DJ.%2520Nucl.%2520Med.%26date%3D2013%26volume%3D54%26spage%3D350%26epage%3D357%26doi%3D10.2967%2Fjnumed.112.111948" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref75"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref75'); return false;" data-citation="" class="refNumLink">75</a></strong><div class="NLM_citation" id="cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McDonald, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doot, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schubert, E. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tchou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pryma, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farwell, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nayak, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ziober, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feldman, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeMichele, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlin, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mach, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mankoff, D. A.</span></span> <span> </span><span class="NLM_article-title">Breast Cancer (18)F-ISO-1 Uptake as a Marker of Proliferation Status</span>. <i>J. Nucl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">665</span>– <span class="NLM_lpage">670</span>, <span class="refDoi"> DOI: 10.2967/jnumed.119.232363</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.2967%2Fjnumed.119.232363" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=31836680" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhvVOis77L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2020&pages=665-670&author=E.+S.+McDonaldauthor=R.+K.+Dootauthor=A.+J.+Youngauthor=E.+K.+Schubertauthor=J.+Tchouauthor=D.+A.+Prymaauthor=M.+D.+Farwellauthor=A.+Nayakauthor=A.+Zioberauthor=M.+D.+Feldmanauthor=A.+DeMicheleauthor=A.+S.+Clarkauthor=P.+D.+Shahauthor=H.+Leeauthor=S.+D.+Carlinauthor=R.+H.+Machauthor=D.+A.+Mankoff&title=Breast+Cancer+%2818%29F-ISO-1+Uptake+as+a+Marker+of+Proliferation+Status&doi=10.2967%2Fjnumed.119.232363"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">Breast cancer 18F-ISO-1 uptake as a marker of proliferation status</span></div><div class="casAuthors">Mcdonald, Elizabeth S.; Doot, Robert K.; Young, Anthony J.; Schubert, Erin K.; Tchou, Julia; Pryma, Daniel A.; Farwell, Michael D.; Nayak, Anupma; Ziober, Amy; Feldman, Michael D.; Demichele, Angela; Clark, Amy S.; Shah, Payal D.; Lee, Hsiaoju; Carlin, Sean D.; MacH, Robert H.; Mankoff, David A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Nuclear Medicine</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">665-671</span>CODEN:
                <span class="NLM_cas:coden">JNMEAQ</span>;
        ISSN:<span class="NLM_cas:issn">1535-5667</span>.
    
            (<span class="NLM_cas:orgname">Society of Nuclear Medicine and Molecular Imaging</span>)
        </div><div class="casAbstract">The σ 2 receptor is a potential in vivo target for measuring proliferative status in cancer.  The feasibility of using N-(4-(6,7-dimethoxy-3,4- dihydroisoquinolin-2(1 H)-yl)butyl)-2-(2-18F-fluoroethoxy)-5-methylbenzamide (18F-ISO-1) to image solid tumors in lymphoma, breast cancer, and head and neck cancer has been previously established.  Here, we report the results of the first dedicated clin. trial of 18FISO-1 in women with primary breast cancer.  Our study objective was to det. whether 18F-ISO-1 PET could provide an in vivo measure of tumor proliferative status, and we hypothesized that uptake would correlate with a tissue-based assay of proliferation, namely Ki-67 expression.  Twenty-eight women with 29 primary invasive breast cancers were prospectively enrolled in a clin. trial (NCT 02284919) between March 2015 and Jan. 2017.  Each received an injection of 278-527 MBq of 18F-ISO-1 and then underwent PET/CT imaging of the breasts 50-55 min later.  In vivo uptake of 18F-ISO-1 was quantitated by SUVmax and distribution vol. ratios and was compared with ex vivo immunohistochem. for Ki-67.  Wilcoxon rank-sum tests assessed uptake differences across Ki-67 thresholds, and Spearman correlation tested assocns. between uptake and Ki-67.  Tumor SUVmax (median, 2.0 g/mL; range, 1.3-3.3 g/mL), partial-vol.-cor. SUV max, and SUV ratios were tested against Ki-67.  Tumors stratified into the high-Ki-67 ($20%) group had SUVmax greater than the low-Ki-67 (,20%) group (P 5 0.02).  SUVmax exhibited a pos. correlation with Ki-67 across all breast cancer subtypes (ρ 5 0.46, P 5 0.01, n 5 29).  Partial-vol.-cor. SUVmax was pos. correlated with Ki-67 for invasive ductal carcinoma (ρ 5 0.51, P 5 0.02, n 5 21).  Tumor-to-normal-tissue ratios and tumor distribution vol. ratio did not correlate with Ki-67 (P . 0.05).  18F-ISO-1 uptake in breast cancer modestly correlates with an in vitro assay of proliferation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpAknHL7ikKYrVg90H21EOLACvtfcHk0lgvPorXen_ZPw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhvVOis77L&md5=b78d0f4ece45a307e173b3d56dcd60e6</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.2967%2Fjnumed.119.232363&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2967%252Fjnumed.119.232363%26sid%3Dliteratum%253Aachs%26aulast%3DMcDonald%26aufirst%3DE.%2BS.%26aulast%3DDoot%26aufirst%3DR.%2BK.%26aulast%3DYoung%26aufirst%3DA.%2BJ.%26aulast%3DSchubert%26aufirst%3DE.%2BK.%26aulast%3DTchou%26aufirst%3DJ.%26aulast%3DPryma%26aufirst%3DD.%2BA.%26aulast%3DFarwell%26aufirst%3DM.%2BD.%26aulast%3DNayak%26aufirst%3DA.%26aulast%3DZiober%26aufirst%3DA.%26aulast%3DFeldman%26aufirst%3DM.%2BD.%26aulast%3DDeMichele%26aufirst%3DA.%26aulast%3DClark%26aufirst%3DA.%2BS.%26aulast%3DShah%26aufirst%3DP.%2BD.%26aulast%3DLee%26aufirst%3DH.%26aulast%3DCarlin%26aufirst%3DS.%2BD.%26aulast%3DMach%26aufirst%3DR.%2BH.%26aulast%3DMankoff%26aufirst%3DD.%2BA.%26atitle%3DBreast%2520Cancer%2520%252818%2529F-ISO-1%2520Uptake%2520as%2520a%2520Marker%2520of%2520Proliferation%2520Status%26jtitle%3DJ.%2520Nucl.%2520Med.%26date%3D2020%26volume%3D61%26spage%3D665%26epage%3D670%26doi%3D10.2967%2Fjnumed.119.232363" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref76"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref76'); return false;" data-citation="" class="refNumLink">76</a></strong><div class="NLM_citation" id="cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riad, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mach, R. H.</span></span> <span> </span><span class="NLM_article-title">The Biological Function of Sigma-2 Receptor/TMEM97 and Its Utility in PET Imaging Studies in Cancer</span>. <i>Cancers</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">1877</span>, <span class="refDoi"> DOI: 10.3390/cancers12071877</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.3390%2Fcancers12071877" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BB3cXisFKntLfP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2020&pages=1877&author=C.+Zengauthor=A.+Riadauthor=R.+H.+Mach&title=The+Biological+Function+of+Sigma-2+Receptor%2FTMEM97+and+Its+Utility+in+PET+Imaging+Studies+in+Cancer&doi=10.3390%2Fcancers12071877"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">The biological function of sigma-2receptor/TMEM97 and its utility inPET imaging studies in cancer</span></div><div class="casAuthors">Zeng, Chenbo; Riad, Aladdin; Mach, Robert H.</div><div class="citationInfo"><span class="NLM_cas:title">Cancers</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1877</span>CODEN:
                <span class="NLM_cas:coden">CANCCT</span>;
        ISSN:<span class="NLM_cas:issn">2072-6694</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">The sigma-2 receptor was originally defined pharmacol. and recently identified as TMEM97.  TMEM97 has been validated as a biomarker of proliferative status and the radioligand of TMEM97, [18F]ISO-1, has been developed and validated as a PET imaging biomarker of proliferative status of tumors and as a predictor of the cancer therapy response. [18F]ISO-1 PET imaging should be useful to guide treatment for cancer patients.  TMEM97 is a membrane-bound protein and localizes in multiple subcellular organelles including endoplasmic reticulum and lysosomes.  TMEM97 plays distinct roles in cancer.  It is reported that TMEM97 is upregulated in some tumors but downregulated in other tumors and it is required for cell proliferation in certain tumor cells.  TMEM97 plays important roles in cholesterol homeostasis.  TMEM97 expression is regulated by cholesterol-regulating signals such as sterol depletion and SREBP expression levels.  TMEM97 regulates cholesterol trafficking processes such as low d. lipoprotein (LDL) uptake by forming complexes with PGRMC1 and low d. lipoprotein receptor (LDLR), as well as cholesterol transport out of lysosome by interacting with and regulating NPC1 protein.  Understanding mol. functions of TMEM97 in proliferation and cholesterol metab. will be important to develop strategies to diagnose and treat cancer and cholesterol disorders using a rich collection of TMEM97 radiotracers and ligands.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUb0WUMHzwTLVg90H21EOLACvtfcHk0liQ-43t0FoV8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXisFKntLfP&md5=87dd4415becc2f44bb03ac1238044095</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.3390%2Fcancers12071877&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fcancers12071877%26sid%3Dliteratum%253Aachs%26aulast%3DZeng%26aufirst%3DC.%26aulast%3DRiad%26aufirst%3DA.%26aulast%3DMach%26aufirst%3DR.%2BH.%26atitle%3DThe%2520Biological%2520Function%2520of%2520Sigma-2%2520Receptor%252FTMEM97%2520and%2520Its%2520Utility%2520in%2520PET%2520Imaging%2520Studies%2520in%2520Cancer%26jtitle%3DCancers%26date%3D2020%26volume%3D12%26spage%3D1877%26doi%3D10.3390%2Fcancers12071877" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref77"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref77'); return false;" data-citation="" class="refNumLink">77</a></strong><div class="NLM_citation" id="cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Agha, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCurdy, C. R.</span></span> <span> </span><span class="NLM_article-title">In vitro and in vivo sigma 1 receptor imaging studies in different disease states</span>. <i>RSC Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2021</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">154</span>– <span class="NLM_lpage">177</span>, <span class="refDoi"> DOI: 10.1039/D0MD00186D</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1039%2FD0MD00186D" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=34046607" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BB3cXitVSrtb3O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2021&pages=154-177&author=H.+Aghaauthor=C.+R.+McCurdy&title=In+vitro+and+in+vivo+sigma+1+receptor+imaging+studies+in+different+disease+states&doi=10.1039%2FD0MD00186D"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro and in vivo sigma 1 receptor imaging studies in different disease states</span></div><div class="casAuthors">Agha, Hebaalla; McCurdy, Christopher R.</div><div class="citationInfo"><span class="NLM_cas:title">RSC Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2021</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">154-177</span>CODEN:
                <span class="NLM_cas:coden">RMCSEZ</span>;
        ISSN:<span class="NLM_cas:issn">2632-8682</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A review.  The sigma receptor system has been classified into two distinct subtypes, sigma 1 (σ1R) and sigma 2 (σ2R).  Sigma 1 receptors (σ1Rs) are involved in many neurodegenerative diseases and different central nervous system disorders such as Alzheimer's disease, Parkinson's disease, schizophrenia, and drug addiction, and pain.  This makes them attractive targets for developing radioligands as tools to gain a better understanding of disease pathophysiol. and clin. diagnosis.  Over the years, several σ1R radioligands have been developed to image the changes in σ1R distribution and d. providing insights into their role in disease development.  Moreover, the involvement of both σ1Rs and σ2Rs with cancer make these ligands, esp. those that are σ2R selective, great tools for imaging different types of tumors.  This will discuss the principles of mol. imaging using PET and SPECT, known σ1R radioligands and their applications for labeling σ1Rs under different disease conditions.  Furthermore, this will highlight σ1R radioligands that have demonstrated considerable potential as biomarkers, and an opportunity to fulfill the ultimate goal of better healthcare outcomes and improving human health.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBJH6I2iaq9rVg90H21EOLACvtfcHk0liQ-43t0FoV8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXitVSrtb3O&md5=4b8d16ab6b72a8fef621a9b0bfc42927</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1039%2FD0MD00186D&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FD0MD00186D%26sid%3Dliteratum%253Aachs%26aulast%3DAgha%26aufirst%3DH.%26aulast%3DMcCurdy%26aufirst%3DC.%2BR.%26atitle%3DIn%2520vitro%2520and%2520in%2520vivo%2520sigma%25201%2520receptor%2520imaging%2520studies%2520in%2520different%2520disease%2520states%26jtitle%3DRSC%2520Med.%2520Chem.%26date%3D2021%26volume%3D12%26spage%3D154%26epage%3D177%26doi%3D10.1039%2FD0MD00186D" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref78"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref78'); return false;" data-citation="" class="refNumLink">78</a></strong><div class="NLM_citation" id="cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Drake, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hillmer, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, Z.</span></span> <span> </span><span class="NLM_article-title">Approaches to PET Imaging of Glioblastoma</span>. <i>Molecules</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">568</span>, <span class="refDoi"> DOI: 10.3390/molecules25030568</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.3390%2Fmolecules25030568" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BB3cXksVamu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2020&pages=568&author=L.+R.+Drakeauthor=A.+T.+Hillmerauthor=Z.+Cai&title=Approaches+to+PET+Imaging+of+Glioblastoma&doi=10.3390%2Fmolecules25030568"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Approaches to PET Imaging of Glioblastoma</span></div><div class="casAuthors">Drake, Lindsey R.; Hillmer, Ansel T.; Cai, Zhengxin</div><div class="citationInfo"><span class="NLM_cas:title">Molecules</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">568</span>CODEN:
                <span class="NLM_cas:coden">MOLEFW</span>;
        ISSN:<span class="NLM_cas:issn">1420-3049</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Glioblastoma multiforme (GBM) is the deadliest type of brain tumor, affecting approx. three in 100,000 adults annually.  Positron emission tomog. (PET) imaging provides an important non-invasive method of measuring biochem. specific targets at GBM lesions.  These powerful data can characterize tumors, predict treatment effectiveness, and monitor treatment.  This review will discuss the PET imaging agents that have already been evaluated in GBM patients so far, and new imaging targets with promise for future use.  Previously used PET imaging agents include the tracers for markers of proliferation ([11C]methionine; [18F]fluoro-ethyl- L-tyrosine, [18F]Fluorodopa,[18F]fluoro-thymidine, and [18F]clofarabine), hypoxia sensing ([18F]FMISO, [18F]FET-NIM, [18F]EF5, [18F]HX4, and [64Cu]ATSM), and ligands for inflammation.  As cancer therapeutics evolve toward personalized medicine and therapies centered on tumor biomarkers, the development of complimentary selective PET agents can dramatically enhance these efforts.  Newer biomarkers for GBM PET imaging are discussed, with some already in use for PET imaging other cancers and neurol. disorders.  These targets include Sigma 1, Sigma 2, programmed death ligand 1, poly-ADP-ribose polymerase, and isocitrate dehydrogenase.  For GBM, these imaging agents come with addnl. considerations such as blood-brain barrier penetration, quant. modeling approaches, and nonspecific binding.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGol3qcmGFKhP7Vg90H21EOLACvtfcHk0liQ-43t0FoV8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXksVamu7Y%253D&md5=b0f8beeed3ed4b7efc695c3acc38467f</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.3390%2Fmolecules25030568&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmolecules25030568%26sid%3Dliteratum%253Aachs%26aulast%3DDrake%26aufirst%3DL.%2BR.%26aulast%3DHillmer%26aufirst%3DA.%2BT.%26aulast%3DCai%26aufirst%3DZ.%26atitle%3DApproaches%2520to%2520PET%2520Imaging%2520of%2520Glioblastoma%26jtitle%3DMolecules%26date%3D2020%26volume%3D25%26spage%3D568%26doi%3D10.3390%2Fmolecules25030568" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref79"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref79'); return false;" data-citation="" class="refNumLink">79</a></strong><div class="NLM_citation" id="cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abate, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiang, C. S.</span></span> <span> </span><span class="NLM_article-title">Sigma-2 receptor/TMEM97 agonist PB221 as an alternative drug for brain tumor</span>. <i>BMC Cancer</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">473</span>, <span class="refDoi"> DOI: 10.1186/s12885-019-5700-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1186%2Fs12885-019-5700-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=31109310" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A280%3ADC%252BB3M7nvVWisw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2019&pages=473&author=C.+C.+Liuauthor=C.+F.+Yuauthor=S.+C.+Wangauthor=H.+Y.+Liauthor=C.+M.+Linauthor=H.+H.+Wangauthor=C.+Abateauthor=C.+S.+Chiang&title=Sigma-2+receptor%2FTMEM97+agonist+PB221+as+an+alternative+drug+for+brain+tumor&doi=10.1186%2Fs12885-019-5700-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">Sigma-2 receptor/TMEM97 agonist PB221 as an alternative drug for brain tumor</span></div><div class="casAuthors">Liu Chia-Chi; Li Hsueh-Yin; Lin Chiu-Min; Wang Hsia-Han; Chiang Chi-Shiun; Liu Chia-Chi; Yu Ching-Fang; Wang Shu-Chi; Abate Carmen; Chiang Chi-Shiun; Chiang Chi-Shiun</div><div class="citationInfo"><span class="NLM_cas:title">BMC cancer</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">473</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  There are limited effective drugs that can reach the brain to target brain tumors, in particular glioblastoma, which is one of the most difficult cancers to be cured from.  Because the overexpression of the sigma-2 receptor is frequently reported in glioma clinical samples and associated with poor prognosis and malignancy, we herein studied the anti-tumor effect of the sigma-2 receptor agonist PB221 (4-cyclohexyl-1-[3-(5-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)propyl]piperidine) on an anaplastic astrocytoma tumor model based on previous encouraging results in pancreatic cancer and neuroblastoma SK-N-SH cells.  METHODS:  The expression of the sigma-2 receptor, transmembrane protein 97 (TMEM97), in ALTS1C1 and UN-KC6141 cell lines was measured by RT-PCR and quantitative RT-PCR.  The binding of sigma-2 receptor fluorescent ligands PB385 (6-[5-[3-(4-cyclohexylpiperazin-1-yl)propyl]-5,6,7,8-tetrahydronaphthalen-5-yloxy]-N-(7-nitro-2,1,3-benzoxadiazol-4-yl)hexanamine) and NO1 (2-{6-[2-(3-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)propyl)-3,4-dihydroisoquinolin-1(2H)-one-5-yloxy]hexyl}-5-(dimethylamino)isoindoline-1,3-dione) was examined by flow cytometry and the fluorescent plate reader.  The antitumor activity of PB221 was initially examined in the murine brain tumor cell line ALTS1C1 and then in the murine pancreatic cell line UN-KC6141.  The potential therapeutic efficacy of PB221 for murine brain tumors was examined by in vitro migration and invasion assays and in vivo ectopic and orthotopic ALTS1C1 tumor models.  RESULTS:  The IC50 of PB221 for ALTS1C1 and UN-KC6141 cell lines was 10.61 ± 0.96 and 13.13 ± 1.15 μM, respectively.  A low dose of PB221 (1 μM) significantly repressed the migration and invasion of ALTS1C1 cells, and a high dose of PB221 (20 μM) resulted in the apoptotic cell death of ALTS1C1 cells.  These effects were reduced by the lipid antioxidant α-tocopherol, but not by the hydrophilic N-acetylcysteine, suggesting mitochondrial oxidative stress is involved.  The in vivo study revealed that PB221 effectively retarded tumor growth to 36% of the control tumor volume in the ectopic intramuscular tumor model and increased the overall survival time by 20% (from 26 to 31 days) in the orthotopic intracerebral tumor model.  CONCLUSIONS:  This study demonstrates that the sigma-2 receptor agonist PB221 has the potential to be an alternative chemotherapeutic drug for brain tumors with comparable side effects as the current standard-of-care drug, temozolomide.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRjG6m4HxP7vNbHMBt0mMIXfW6udTcc2eZq4YMZFDtOvbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3M7nvVWisw%253D%253D&md5=93bf8f0d4844d5d59039fe750b6ba33c</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1186%2Fs12885-019-5700-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12885-019-5700-7%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DC.%2BC.%26aulast%3DYu%26aufirst%3DC.%2BF.%26aulast%3DWang%26aufirst%3DS.%2BC.%26aulast%3DLi%26aufirst%3DH.%2BY.%26aulast%3DLin%26aufirst%3DC.%2BM.%26aulast%3DWang%26aufirst%3DH.%2BH.%26aulast%3DAbate%26aufirst%3DC.%26aulast%3DChiang%26aufirst%3DC.%2BS.%26atitle%3DSigma-2%2520receptor%252FTMEM97%2520agonist%2520PB221%2520as%2520an%2520alternative%2520drug%2520for%2520brain%2520tumor%26jtitle%3DBMC%2520Cancer%26date%3D2019%26volume%3D19%26spage%3D473%26doi%3D10.1186%2Fs12885-019-5700-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref80"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref80'); return false;" data-citation="" class="refNumLink">80</a></strong><div class="NLM_citation" id="cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gilligan, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cain, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christos, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cook, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drummond, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kergaye, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McElroy, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rohrbach, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, W. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tam, S. W.</span></span> <span> </span><span class="NLM_article-title">Novel piperidine sigma receptor ligands as potential antipsychotic drugs</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1992</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">4344</span>– <span class="NLM_lpage">4361</span>, <span class="refDoi"> DOI: 10.1021/jm00101a012</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00101a012" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADyaK3sXlvFGnsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=1992&pages=4344-4361&author=P.+J.+Gilliganauthor=G.+A.+Cainauthor=T.+E.+Christosauthor=L.+Cookauthor=S.+Drummondauthor=A.+L.+Johnsonauthor=A.+A.+Kergayeauthor=J.+F.+McElroyauthor=K.+W.+Rohrbachauthor=W.+K.+Schmidtauthor=S.+W.+Tam&title=Novel+piperidine+sigma+receptor+ligands+as+potential+antipsychotic+drugs&doi=10.1021%2Fjm00101a012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">Novel piperidine σ receptor ligands as potential antipsychotic drugs</span></div><div class="casAuthors">Gilligan, Paul J.; Cain, Gary A.; Christos, Thomas E.; Cook, Leonard; Drummond, Spencer; Johnson, Alexander L.; Kergaye, Ahmed A.; McElroy, John F.; Rohrbach, Kenneth W.; et al.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">4344-61</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    </div><div class="casAbstract">σ Receptor ligands represent a new class of potential antipsychotic drugs.  This paper presents the structure-activity relationships leading to novel disubstituted piperidine σ ligands, which have little or no affinity for dopamine D2 receptors.  Selectivity for σ sites over dopamine D2 or serotonin 5-HT2 receptors appears to be governed by the chem. nature of the piperidine nitrogen substituent, its distance from the basic nitrogen, and its orientation relative to the other piperidine substituent.  Several of these compds. have good oral potency in some animal models used to evaluate potential antipsychotic drugs.  The N-cyclopropylmethyl ketones and ethers I (R = cyano, F; X = CO, O) have the best in vivo potency.  I (R = cyano, F; X = CO) did not cause catalepsy in the rat, even at very high doses.  Based on the pharmacol. profiles of these σ ligands, these compds. may be effective antipsychotic drugs, which do not induce extrapyramidal side effects or tardive dyskinesia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAaGTuY9sV5rVg90H21EOLACvtfcHk0lhp1t7yiM2sew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXlvFGnsg%253D%253D&md5=0d30d6e5f7874b7cb26237b6418d7202</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1021%2Fjm00101a012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00101a012%26sid%3Dliteratum%253Aachs%26aulast%3DGilligan%26aufirst%3DP.%2BJ.%26aulast%3DCain%26aufirst%3DG.%2BA.%26aulast%3DChristos%26aufirst%3DT.%2BE.%26aulast%3DCook%26aufirst%3DL.%26aulast%3DDrummond%26aufirst%3DS.%26aulast%3DJohnson%26aufirst%3DA.%2BL.%26aulast%3DKergaye%26aufirst%3DA.%2BA.%26aulast%3DMcElroy%26aufirst%3DJ.%2BF.%26aulast%3DRohrbach%26aufirst%3DK.%2BW.%26aulast%3DSchmidt%26aufirst%3DW.%2BK.%26aulast%3DTam%26aufirst%3DS.%2BW.%26atitle%3DNovel%2520piperidine%2520sigma%2520receptor%2520ligands%2520as%2520potential%2520antipsychotic%2520drugs%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1992%26volume%3D35%26spage%3D4344%26epage%3D4361%26doi%3D10.1021%2Fjm00101a012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref81"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref81'); return false;" data-citation="" class="refNumLink">81</a></strong><div class="NLM_citation" id="cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Abate, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mosier, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berardi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glennon, R. A.</span></span> <span> </span><span class="NLM_article-title">A structure-affinity and comparative molecular field analysis of sigma-2 (sigma2) receptor ligands</span>. <i>Cent. Nerv. Syst. Agents Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">246</span>– <span class="NLM_lpage">257</span>, <span class="refDoi"> DOI: 10.2174/1871524910909030246</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.2174%2F1871524910909030246" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=20021358" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtVWnt7rK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2009&pages=246-257&author=C.+Abateauthor=P.+D.+Mosierauthor=F.+Berardiauthor=R.+A.+Glennon&title=A+structure-affinity+and+comparative+molecular+field+analysis+of+sigma-2+%28sigma2%29+receptor+ligands&doi=10.2174%2F1871524910909030246"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">A structure-affinity and comparative molecular field analysis of sigma-2 (σ2) receptor ligands</span></div><div class="casAuthors">Abate, Carmen; Mosier, Philip Daniel; Berardi, Francesco; Glennon, Richard A.</div><div class="citationInfo"><span class="NLM_cas:title">Central Nervous System Agents in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">246-257</span>CODEN:
                <span class="NLM_cas:coden">CNSAC3</span>;
        ISSN:<span class="NLM_cas:issn">1871-5249</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">Several σ1 receptor ligands with sub-nanomolar affinity and excellent selectivity have been reported, but relatively few σ2-selective ligands are known.  1-Cyclohexyl-4-[3-(5-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)propyl] piperazine (PB28; 1) has been reported by us as a high-affinity σ2 receptor ligand with significant σ2 selectivity, and several analogs of (1) now have been developed.  Among these are the class of cyclohexylpiperazines that display a good compromise between affinity/activity and selectivity for σ2 receptors.  Very little is currently known about the nature of σ2 receptors.  In the absence of structure-based receptor information, we applied a comparative mol. field anal. (CoMFA) - a three-dimensional structure-activity relationship (3D-QSAR) method - to a set of cyclohexylpiperazine σ2 ligands to develop a predictive model that might provide information about the stereoelectronic nature of the receptor binding site.  Two CoMFA models were generated from two different alignments: the first used an automated FlexS algorithm, and the second used a rationally-driven manual alignment.  Significantly better predictivity was obtained with the manual alignment (TSET: q2 = 0.73, r2 = 0.95; PSET: r2 = 0.55/0.73) than from the automated alignment (TSET: q2 = 0.69, r2 = 0.98; PSET: r2 = 0.13/0.16).  The resulting CoMFA maps account for obsd. structure-affinity relationships and suggest a possible anatomy for the σ2 receptor/cyclohexylpiperazine binding site.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNSRDXO2Ws7bVg90H21EOLACvtfcHk0lhp1t7yiM2sew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtVWnt7rK&md5=b1203a3a8343205b4439481c0ece5a8e</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.2174%2F1871524910909030246&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1871524910909030246%26sid%3Dliteratum%253Aachs%26aulast%3DAbate%26aufirst%3DC.%26aulast%3DMosier%26aufirst%3DP.%2BD.%26aulast%3DBerardi%26aufirst%3DF.%26aulast%3DGlennon%26aufirst%3DR.%2BA.%26atitle%3DA%2520structure-affinity%2520and%2520comparative%2520molecular%2520field%2520analysis%2520of%2520sigma-2%2520%2528sigma2%2529%2520receptor%2520ligands%26jtitle%3DCent.%2520Nerv.%2520Syst.%2520Agents%2520Med.%2520Chem.%26date%3D2009%26volume%3D9%26spage%3D246%26epage%3D257%26doi%3D10.2174%2F1871524910909030246" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref82"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref82'); return false;" data-citation="" class="refNumLink">82</a></strong><div class="NLM_citation" id="cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zampieri, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mamolo, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laurini, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Florio, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zanette, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fermeglia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Posocco, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paneni, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pricl, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vio, L.</span></span> <span> </span><span class="NLM_article-title">Synthesis, biological evaluation, and three-dimensional in silico pharmacophore model for sigma(1) receptor ligands based on a series of substituted benzo[d]oxazol-2(3H)-one derivatives</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">5380</span>– <span class="NLM_lpage">5393</span>, <span class="refDoi"> DOI: 10.1021/jm900366z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm900366z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BD1MXpslaht78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=5380-5393&author=D.+Zampieriauthor=M.+G.+Mamoloauthor=E.+Lauriniauthor=C.+Florioauthor=C.+Zanetteauthor=M.+Fermegliaauthor=P.+Posoccoauthor=M.+S.+Paneniauthor=S.+Priclauthor=L.+Vio&title=Synthesis%2C+biological+evaluation%2C+and+three-dimensional+in+silico+pharmacophore+model+for+sigma%281%29+receptor+ligands+based+on+a+series+of+substituted+benzo%5Bd%5Doxazol-2%283H%29-one+derivatives&doi=10.1021%2Fjm900366z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis, Biological Evaluation, and Three-Dimensional in Silico Pharmacophore Model for σ1 Receptor Ligands Based on a Series of Substituted Benzo[d]oxazol-2(3H)-one Derivatives</span></div><div class="casAuthors">Zampieri, Daniele; Mamolo, Maria Grazia; Laurini, Erik; Florio, Chiara; Zanette, Caterina; Fermeglia, Maurizio; Posocco, Paola; Paneni, Maria Silvia; Pricl, Sabrina; Vio, Luciano</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">5380-5393</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Novel benzo[d]oxazol-2(3H)-one derivs. were designed and synthesized, and their affinities against σ receptors were evaluated.  On the basis of 31 compds., a three-dimensional pharmacophore model for the σ1 receptor binding site was developed using the Catalyst 4.9 software package.  The best 3D pharmacophore hypothesis, consisting of one pos. ionizable, one hydrogen bond acceptor, two hydrophobic arom., and one hydrophobic features provided a 3D-QSAR model with a correlation coeff. of 0.89.  The best hypothesis was also validated by three independent methods, i.e., the Fisher randomization test included in the CatScramble functionality of Catalyst, the leave-one-out test, and activity prediction of an addnl. test set.  The achieved results will allow researchers to use this 3D pharmacophore model for the design and synthesis of a second generation of high affinity σ1 ligands, as well as to discover other lead compds. for this class of receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZ7dYDBRve47Vg90H21EOLACvtfcHk0lhp1t7yiM2sew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXpslaht78%253D&md5=678e879dd9b79c55fc61bfec02d3b927</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1021%2Fjm900366z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm900366z%26sid%3Dliteratum%253Aachs%26aulast%3DZampieri%26aufirst%3DD.%26aulast%3DMamolo%26aufirst%3DM.%2BG.%26aulast%3DLaurini%26aufirst%3DE.%26aulast%3DFlorio%26aufirst%3DC.%26aulast%3DZanette%26aufirst%3DC.%26aulast%3DFermeglia%26aufirst%3DM.%26aulast%3DPosocco%26aufirst%3DP.%26aulast%3DPaneni%26aufirst%3DM.%2BS.%26aulast%3DPricl%26aufirst%3DS.%26aulast%3DVio%26aufirst%3DL.%26atitle%3DSynthesis%252C%2520biological%2520evaluation%252C%2520and%2520three-dimensional%2520in%2520silico%2520pharmacophore%2520model%2520for%2520sigma%25281%2529%2520receptor%2520ligands%2520based%2520on%2520a%2520series%2520of%2520substituted%2520benzo%255Bd%255Doxazol-2%25283H%2529-one%2520derivatives%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D5380%26epage%3D5393%26doi%3D10.1021%2Fjm900366z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref83"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref83'); return false;" data-citation="" class="refNumLink">83</a></strong><div class="NLM_citation" id="cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schepmann, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yanagisawa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamaguchi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dal Col, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laurini, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Itami, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pricl, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wünsch, B.</span></span> <span> </span><span class="NLM_article-title">Pd-catalyzed direct C-H bond functionalization of spirocyclic σ1 ligands: generation of a pharmacophore model and analysis of the reverse binding mode by docking into a 3D homology model of the σ1 receptor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">8047</span>– <span class="NLM_lpage">8065</span>, <span class="refDoi"> DOI: 10.1021/jm300894h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300894h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1CisrjN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=8047-8065&author=C.+Meyerauthor=D.+Schepmannauthor=S.+Yanagisawaauthor=J.+Yamaguchiauthor=V.+Dal+Colauthor=E.+Lauriniauthor=K.+Itamiauthor=S.+Priclauthor=B.+W%C3%BCnsch&title=Pd-catalyzed+direct+C-H+bond+functionalization+of+spirocyclic+%CF%831+ligands%3A+generation+of+a+pharmacophore+model+and+analysis+of+the+reverse+binding+mode+by+docking+into+a+3D+homology+model+of+the+%CF%831+receptor&doi=10.1021%2Fjm300894h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">Pd-Catalyzed Direct C-H Bond Functionalization of Spirocyclic σ1 Ligands: Generation of a Pharmacophore Model and Analysis of the Reverse Binding Mode by Docking into a 3D Homology Model of the σ1 Receptor</span></div><div class="casAuthors">Meyer, Christina; Schepmann, Dirk; Yanagisawa, Shuichi; Yamaguchi, Junichiro; Dal Col, Valentina; Laurini, Erik; Itami, Kenichiro; Pricl, Sabrina; Wuensch, Bernhard</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">8047-8065</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">To explore the hydrophobic binding region of the σ1 receptor protein, regioisomeric spirocyclic thiophenes I (R = H) and II (R1 = R2 = H; R3 = H, MeO) were developed as versatile building blocks.  Regioselective α- and β-arylation using the catalyst systems PdCl2/bipy/Ag2CO3 and PdCl2/P[OCH(CF3)2]3/Ag2CO3 allowed the introduction of various aryl moieties at different positions in the last step of the synthesis.  The increasing σ1 affinity in the order I (R = Ph, 4-MeOC6H4, 4-NCC6H4, 4-PhC6H4) < II (R1 = Ph, 4-MeC6H4, 1-naphthyl, 3-pyridyl, etc.; R2 = H; R3 = H, MeO) < II (R1 = H; R2 = Ph, 4-MeOC6H4, 4-MeC6H4; R3 = H, MeO) indicated that the positions of the addnl. aryl moiety and the S atom in the spirocyclic thiophene systems control the σ1 affinity.  The main features of the pharmacophore model developed for this class of σ1 ligands are a pos. ionizable group, a H-bond acceptor group, two hydrophobic moieties, and one hydrophobic arom. group.  Docking of the ligands into a σ1 3D homol. model via mol. mechanics/Poisson-Boltzmann surface area calcns. led to a very good correlation between the exptl. detd. and estd. free energy of receptor binding.  These calcns. supported the hypothesis of a reverse binding mode of ligands bearing the aryl moiety at the "top" [e.g. compds. II (R1 = H; R2 = Ph, 4-MeC6H4, 4-MeOC6H4; R3 = H, MeO)] and "left" [e.g. compds. I (R = Ph, 4-MeOC6H4, etc.) and II (R1 = Ph, 4-MeC6H4, etc.; R2 = H; R3 = H, MeO)] positions, resp.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGof-c_9FzrfCbVg90H21EOLACvtfcHk0ljwQsgzbvRRtw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1CisrjN&md5=a7a89849dff3c9f177eac824df9d5f0f</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1021%2Fjm300894h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300894h%26sid%3Dliteratum%253Aachs%26aulast%3DMeyer%26aufirst%3DC.%26aulast%3DSchepmann%26aufirst%3DD.%26aulast%3DYanagisawa%26aufirst%3DS.%26aulast%3DYamaguchi%26aufirst%3DJ.%26aulast%3DDal%2BCol%26aufirst%3DV.%26aulast%3DLaurini%26aufirst%3DE.%26aulast%3DItami%26aufirst%3DK.%26aulast%3DPricl%26aufirst%3DS.%26aulast%3DW%25C3%25BCnsch%26aufirst%3DB.%26atitle%3DPd-catalyzed%2520direct%2520C-H%2520bond%2520functionalization%2520of%2520spirocyclic%2520%25CF%25831%2520ligands%253A%2520generation%2520of%2520a%2520pharmacophore%2520model%2520and%2520analysis%2520of%2520the%2520reverse%2520binding%2520mode%2520by%2520docking%2520into%2520a%25203D%2520homology%2520model%2520of%2520the%2520%25CF%25831%2520receptor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D8047%26epage%3D8065%26doi%3D10.1021%2Fjm300894h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref84"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref84'); return false;" data-citation="" class="refNumLink">84</a></strong><div class="NLM_citation" id="cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Laurini, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zampieri, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mamolo, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vio, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zanette, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Florio, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Posocco, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fermeglia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pricl, S.</span></span> <span> </span><span class="NLM_article-title">A 3D-pharmacophore model for sigma2 receptors based on a series of substituted benzo[d]oxazol-2(3H)-one derivatives</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">2954</span>– <span class="NLM_lpage">2957</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2010.03.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1016%2Fj.bmcl.2010.03.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=20347592" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BC3cXkvFCjsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=2954-2957&author=E.+Lauriniauthor=D.+Zampieriauthor=M.+G.+Mamoloauthor=L.+Vioauthor=C.+Zanetteauthor=C.+Florioauthor=P.+Posoccoauthor=M.+Fermegliaauthor=S.+Pricl&title=A+3D-pharmacophore+model+for+sigma2+receptors+based+on+a+series+of+substituted+benzo%5Bd%5Doxazol-2%283H%29-one+derivatives&doi=10.1016%2Fj.bmcl.2010.03.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">A 3D-pharmacophore model for σ2 receptors based on a series of substituted benzo[d]oxazol-2(3H)-one derivatives</span></div><div class="casAuthors">Laurini, Erik; Zampieri, Daniele; Mamolo, Maria Grazia; Vio, Luciano; Zanette, Caterina; Florio, Chiara; Posocco, Paola; Fermeglia, Maurizio; Pricl, Sabrina</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2954-2957</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">In this work we developed a 3D-pharmacophore model for σ2 receptor based on 19 benzooxazolone derivs.  The best 3D-pharmacophore hypothesis, consisting of five features: a pos. ionizable, a hydrogen bond acceptor, a hydrophobic arom., a hydrophobic aliph., and a generic hydrophobic provided a 3D-QSAR model with a correlation coeff. of 0.97 and a RMSD of 0.48.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcKZ2Af8LJdLVg90H21EOLACvtfcHk0ljwQsgzbvRRtw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXkvFCjsbw%253D&md5=c33600826462836d4d6301e85d387df0</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2010.03.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2010.03.009%26sid%3Dliteratum%253Aachs%26aulast%3DLaurini%26aufirst%3DE.%26aulast%3DZampieri%26aufirst%3DD.%26aulast%3DMamolo%26aufirst%3DM.%2BG.%26aulast%3DVio%26aufirst%3DL.%26aulast%3DZanette%26aufirst%3DC.%26aulast%3DFlorio%26aufirst%3DC.%26aulast%3DPosocco%26aufirst%3DP.%26aulast%3DFermeglia%26aufirst%3DM.%26aulast%3DPricl%26aufirst%3DS.%26atitle%3DA%25203D-pharmacophore%2520model%2520for%2520sigma2%2520receptors%2520based%2520on%2520a%2520series%2520of%2520substituted%2520benzo%255Bd%255Doxazol-2%25283H%2529-one%2520derivatives%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D2954%26epage%3D2957%26doi%3D10.1016%2Fj.bmcl.2010.03.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref85"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref85'); return false;" data-citation="" class="refNumLink">85</a></strong><div class="NLM_citation" id="cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pascual, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Almansa, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plata-Salamán, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vela, J. M.</span></span> <span> </span><span class="NLM_article-title">A New Pharmacophore Model for the Design of Sigma-1 Ligands Validated on a Large Experimental Dataset</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">519</span>, <span class="refDoi"> DOI: 10.3389/fphar.2019.00519</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.3389%2Ffphar.2019.00519" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=31214020" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BB3cXktFOnsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=519&author=R.+Pascualauthor=C.+Almansaauthor=C.+Plata-Salam%C3%A1nauthor=J.+M.+Vela&title=A+New+Pharmacophore+Model+for+the+Design+of+Sigma-1+Ligands+Validated+on+a+Large+Experimental+Dataset&doi=10.3389%2Ffphar.2019.00519"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">A new pharmacophore model for the design of sigma-1 ligands validated on a large experimental dataset</span></div><div class="casAuthors">Pascual, Rosalia; Almansa, Carmen; Plata-Salaman, Carlos; Vela, Jose Miguel</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Pharmacology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">519</span>CODEN:
                <span class="NLM_cas:coden">FPRHAU</span>;
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">The recent publication of the σ1R crystal structure is an important cornerstone for the derivation of more accurate activity prediction models.  We report here a comparative study involving a set of more than 25,000 structures from our internal database that had been screened for σ1R affinity.  Using the recently published crystal structure, 5HK1, two new pharmacophore models were generated.  The first one, 5HK1-Ph.A, was obtained by an algorithm that identifies the most important receptor-ligand interactions including vol. restrictions enforced by the at. structure of the recognition site.  The second, 5HK1-Ph.B, resulted from a manual edition of the first one by the fusion of two hydrophobic (HYD) features.  Finally, we also docked the database using a high throughput docking technique and scored the resulting poses with seven different scoring functions.  Statistical performance measures were obtained for the two models, comparing them with previously published σ1R pharmacophores (Hit Rate, sensitivity, specificity, and Receiver Operator Characteristic) and 5HK1-Ph.B emerged as the best one in discriminating between active and inactive compds., with a ROC-AUC value above 0.8 and enrichment values above 3 at different fractions of screened samples. 5HK1-Ph.B also showed better results than the direct docking, which may be due to the rigidity of the crystal structure in the docking process (i.e., feature tolerances in the pharmacophore model).  Addnl., the impact of the HYD interactions and the penalty for desolvating ligands with polar atoms may be not adequately captured by scoring functions, whereas HYD groups filling up such regions of the binding site are entailed in the pharmacophore model.  Altogether, using annotated data from a large and diverse compd. collection together with crystal structure information provides a sound basis for the generation and validation of predictive models to design new mols.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGommlNCghqBXrVg90H21EOLACvtfcHk0liUcG1CU_GC5A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXktFOnsr0%253D&md5=156ec236d1cf03779cae199e0716b497</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2019.00519&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2019.00519%26sid%3Dliteratum%253Aachs%26aulast%3DPascual%26aufirst%3DR.%26aulast%3DAlmansa%26aufirst%3DC.%26aulast%3DPlata-Salam%25C3%25A1n%26aufirst%3DC.%26aulast%3DVela%26aufirst%3DJ.%2BM.%26atitle%3DA%2520New%2520Pharmacophore%2520Model%2520for%2520the%2520Design%2520of%2520Sigma-1%2520Ligands%2520Validated%2520on%2520a%2520Large%2520Experimental%2520Dataset%26jtitle%3DFront.%2520Pharmacol.%26date%3D2019%26volume%3D10%26spage%3D519%26doi%3D10.3389%2Ffphar.2019.00519" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref86"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref86'); return false;" data-citation="" class="refNumLink">86</a></strong><div class="NLM_citation" id="cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Iyamu, I. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lv, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malik, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mishra, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schiltz, G. E.</span></span> <span> </span><span class="NLM_article-title">Development of Tetrahydroindazole-Based Potent and Selective Sigma-2 Receptor Ligands</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">1248</span>– <span class="NLM_lpage">1256</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201900203</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1002%2Fcmdc.201900203" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=31071238" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtVOns7%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2019&pages=1248-1256&author=I.+D.+Iyamuauthor=W.+Lvauthor=N.+Malikauthor=R.+K.+Mishraauthor=G.+E.+Schiltz&title=Development+of+Tetrahydroindazole-Based+Potent+and+Selective+Sigma-2+Receptor+Ligands&doi=10.1002%2Fcmdc.201900203"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">Development of Tetrahydroindazole-Based Potent and Selective Sigma-2 Receptor Ligands</span></div><div class="casAuthors">Iyamu, Iredia D.; Lv, Wei; Malik, Neha; Mishra, Rama K.; Schiltz, Gary E.</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1248-1256</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">The sigma-2 receptor has been shown to play important roles in a no. of important diseases, including central nervous system (CNS) disorders and cancer.  However, mechanisms by which sigma-2 contributes to these diseases remain unclear.  The development of new sigma-2 ligands that can be used to probe the function of this protein and potentially as drug discovery leads is therefore of great importance.  Herein we report the development of a series of tetrahydroindazole compds. that are highly potent and selective for sigma-2.  Structure-activity relationship data were used to generate a pharmacophore model that summarizes the common features present in the potent ligands.  Assays for soly. and microsomal stability showed that several members of this compd. series possess promising characteristics for further development of useful chem. probes or drug discovery leads.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrVYUrjkbc4rVg90H21EOLACvtfcHk0liUcG1CU_GC5A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtVOns7%252FI&md5=95f910086e2082c97b83a7526eb8223a</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201900203&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201900203%26sid%3Dliteratum%253Aachs%26aulast%3DIyamu%26aufirst%3DI.%2BD.%26aulast%3DLv%26aufirst%3DW.%26aulast%3DMalik%26aufirst%3DN.%26aulast%3DMishra%26aufirst%3DR.%2BK.%26aulast%3DSchiltz%26aufirst%3DG.%2BE.%26atitle%3DDevelopment%2520of%2520Tetrahydroindazole-Based%2520Potent%2520and%2520Selective%2520Sigma-2%2520Receptor%2520Ligands%26jtitle%3DChemMedChem%26date%3D2019%26volume%3D14%26spage%3D1248%26epage%3D1256%26doi%3D10.1002%2Fcmdc.201900203" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref87"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref87'); return false;" data-citation="" class="refNumLink">87</a></strong><div class="NLM_citation" id="cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Glennon, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ismaiel, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">el-Ashmawy, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Battaglia, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, J. B.</span></span> <span> </span><span class="NLM_article-title">Identification and exploitation of the sigma-opiate pharmacophore</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1991</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">1094</span>– <span class="NLM_lpage">1098</span>, <span class="refDoi"> DOI: 10.1021/jm00107a033</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00107a033" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADyaK3MXit1ynsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=1991&pages=1094-1098&author=R.+A.+Glennonauthor=J.+D.+Smithauthor=A.+M.+Ismaielauthor=M.+el-Ashmawyauthor=G.+Battagliaauthor=J.+B.+Fischer&title=Identification+and+exploitation+of+the+sigma-opiate+pharmacophore&doi=10.1021%2Fjm00107a033"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">Identification and exploitation of the σ-opiate pharmacophore</span></div><div class="casAuthors">Glennon, Richard A.; Smith, J. Doyle; Ismaiel, Abd M.; El-Ashmawy, Mahmoud; Battaglia, George; Fischer, James B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1094-8</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    </div><div class="casAbstract">Reductive alkylation of PhCH2CH(NH2)Me gave (R)- and (S)-RR1NCHMeCH2Ph [I; R = Et, Pr, Bu, CH2Ph, CHMePh, CH2CH2Ph, (CH2)3Ph, (CH2)4Ph, (CH2)5Ph, C:CHPh, CH2OPh, etc.; R1 = H, Me].  E.g., alkylation of (R)-PhCH2CH(NH2)Me with PhCH2CH2CHO gave (R)-PhCH2CH2CH2NHCHMeCH2Ph.  I were tested for their affinity to σ-receptors and their psychotomimetic activity; the structure-activity relationship was discussed.  The role of I as a component of a benzomorphan structure was studied; the presence of a 1-phenyl-2-aminopropane nucleus was sufficient for binding at the σ-site, provided that the terminal amine is not a tertiary amine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp30jRVEOn-j7Vg90H21EOLACvtfcHk0liUcG1CU_GC5A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXit1ynsbc%253D&md5=202d16f2d33e4fff57f736617d3d1377</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1021%2Fjm00107a033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00107a033%26sid%3Dliteratum%253Aachs%26aulast%3DGlennon%26aufirst%3DR.%2BA.%26aulast%3DSmith%26aufirst%3DJ.%2BD.%26aulast%3DIsmaiel%26aufirst%3DA.%2BM.%26aulast%3Del-Ashmawy%26aufirst%3DM.%26aulast%3DBattaglia%26aufirst%3DG.%26aulast%3DFischer%26aufirst%3DJ.%2BB.%26atitle%3DIdentification%2520and%2520exploitation%2520of%2520the%2520sigma-opiate%2520pharmacophore%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1991%26volume%3D34%26spage%3D1094%26epage%3D1098%26doi%3D10.1021%2Fjm00107a033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref88"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref88'); return false;" data-citation="" class="refNumLink">88</a></strong><div class="NLM_citation" id="cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Glennon, R. A.</span></span> <span> </span><span class="NLM_article-title">Pharmacophore identification for sigma-1 (sigma1) receptor binding: application of the “deconstruction-reconstruction-elaboration” approach</span>. <i>Mini-Rev. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">927</span>– <span class="NLM_lpage">940</span>, <span class="refDoi"> DOI: 10.2174/138955705774329519</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.2174%2F138955705774329519" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=16250835" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVWku7rM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2005&pages=927-940&author=R.+A.+Glennon&title=Pharmacophore+identification+for+sigma-1+%28sigma1%29+receptor+binding%3A+application+of+the+%E2%80%9Cdeconstruction-reconstruction-elaboration%E2%80%9D+approach&doi=10.2174%2F138955705774329519"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacophore identification for sigma-1 (σ1) receptor binding: Application of the deconstruction - reconstruction - elaboration approach</span></div><div class="casAuthors">Glennon, R. A.</div><div class="citationInfo"><span class="NLM_cas:title">Mini-Reviews in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">927-940</span>CODEN:
                <span class="NLM_cas:coden">MMCIAE</span>;
        ISSN:<span class="NLM_cas:issn">1389-5575</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  At least two different types of sigma σ (σ1 and σ2) receptors have been identified.  A structural feature common to high-affinity (Ki <10 nM) σ1 ligands is: C-N(R)-X-Ph; both C and Ph are assocd. with regions of bulk tolerance.  Numerous other ligands bind, but typically do so with lower affinity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGot_9JlDBLhrbVg90H21EOLACvtfcHk0liUcG1CU_GC5A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVWku7rM&md5=66ae2e51d57fa97cd3954ae90e7e3167</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.2174%2F138955705774329519&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138955705774329519%26sid%3Dliteratum%253Aachs%26aulast%3DGlennon%26aufirst%3DR.%2BA.%26atitle%3DPharmacophore%2520identification%2520for%2520sigma-1%2520%2528sigma1%2529%2520receptor%2520binding%253A%2520application%2520of%2520the%2520%25E2%2580%259Cdeconstruction-reconstruction-elaboration%25E2%2580%259D%2520approach%26jtitle%3DMini-Rev.%2520Med.%2520Chem.%26date%3D2005%26volume%3D5%26spage%3D927%26epage%3D940%26doi%3D10.2174%2F138955705774329519" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref89"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref89'); return false;" data-citation="" class="refNumLink">89</a></strong><div class="NLM_citation" id="cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Conroy, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manohar, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilkinson, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webster, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lieberman, B. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banister, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reekie, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mach, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rendina, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kassiou, M.</span></span> <span> </span><span class="NLM_article-title">A systematic exploration of the effects of flexibility and basicity on sigma (σ) receptor binding in a series of substituted diamines</span>. <i>Org. Biomol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">9388</span>– <span class="NLM_lpage">9405</span>, <span class="refDoi"> DOI: 10.1039/C6OB00615A</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1039%2FC6OB00615A" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=27714195" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsFSgurfK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2016&pages=9388-9405&author=T.+Conroyauthor=M.+Manoharauthor=Y.+Gongauthor=S.+M.+Wilkinsonauthor=M.+Websterauthor=B.+P.+Liebermanauthor=S.+D.+Banisterauthor=T.+A.+Reekieauthor=R.+H.+Machauthor=L.+M.+Rendinaauthor=M.+Kassiou&title=A+systematic+exploration+of+the+effects+of+flexibility+and+basicity+on+sigma+%28%CF%83%29+receptor+binding+in+a+series+of+substituted+diamines&doi=10.1039%2FC6OB00615A"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">A systematic exploration of the effects of flexibility and basicity on sigma (σ) receptor binding in a series of substituted diamines</span></div><div class="casAuthors">Conroy, Trent; Manohar, Madhura; Gong, Yu; Wilkinson, Shane M.; Webster, Michael; Lieberman, Brian P.; Banister, Samuel D.; Reekie, Tristan A.; Mach, Robert H.; Rendina, Louis M.; Kassiou, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Organic & Biomolecular Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">39</span>),
    <span class="NLM_cas:pages">9388-9405</span>CODEN:
                <span class="NLM_cas:coden">OBCRAK</span>;
        ISSN:<span class="NLM_cas:issn">1477-0520</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">The sigma-1 receptor (S1R) has attracted a great deal of attention as a prospective drug target due to its involvement in numerous neurol. disorders and, more recently, for its therapeutic potential in neuropathic pain.  As there was no crystal structure of this membrane-bound protein reported until 2016, ligand generation was driven by pharmacophore refinements to the general model suggested by Glennon and coworkers.  The generalized S1R pharmacophore comprises a central region where a basic amino group is preferred, flanked by two hydrophobic groups.  Guided by this pharmacophore, S1R ligands contg. piperazines, piperazinones, and ethylenediamines have been developed.  In the current work, the authors systematically deconstructed the piperazine core of a prototypic piperazine S1R ligand (vide infra) developed in the labs.  Although the authors did not improve the affinity at the S1R compared to the lead, the authors identified several features important for affinity and selectivity.  These included at least one basic nitrogen atom, conformational flexibility and, for S1R, a secondary or tertiary amine group proximal to the anisole.  Furthermore, S2R selectivity can be tailored with functional group modifications of the N-atom proximal to the anisole.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrRblD6b2r0b7Vg90H21EOLACvtfcHk0lhm1RhsAACzgw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsFSgurfK&md5=77e2e441b882243c72ac119a24e8db3d</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1039%2FC6OB00615A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC6OB00615A%26sid%3Dliteratum%253Aachs%26aulast%3DConroy%26aufirst%3DT.%26aulast%3DManohar%26aufirst%3DM.%26aulast%3DGong%26aufirst%3DY.%26aulast%3DWilkinson%26aufirst%3DS.%2BM.%26aulast%3DWebster%26aufirst%3DM.%26aulast%3DLieberman%26aufirst%3DB.%2BP.%26aulast%3DBanister%26aufirst%3DS.%2BD.%26aulast%3DReekie%26aufirst%3DT.%2BA.%26aulast%3DMach%26aufirst%3DR.%2BH.%26aulast%3DRendina%26aufirst%3DL.%2BM.%26aulast%3DKassiou%26aufirst%3DM.%26atitle%3DA%2520systematic%2520exploration%2520of%2520the%2520effects%2520of%2520flexibility%2520and%2520basicity%2520on%2520sigma%2520%2528%25CF%2583%2529%2520receptor%2520binding%2520in%2520a%2520series%2520of%2520substituted%2520diamines%26jtitle%3DOrg.%2520Biomol.%2520Chem.%26date%3D2016%26volume%3D14%26spage%3D9388%26epage%3D9405%26doi%3D10.1039%2FC6OB00615A" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref90"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref90'); return false;" data-citation="" class="refNumLink">90</a></strong><div class="NLM_citation" id="cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Greenfield, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skiba, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mandler, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sliz, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kruse, A. C.</span></span> <span> </span><span class="NLM_article-title">Virtual Screening for Ligand Discovery at the σ(1) Receptor</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">1555</span>– <span class="NLM_lpage">1561</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.9b00314</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.9b00314" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhsVGns7nF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2020&pages=1555-1561&author=D.+A.+Greenfieldauthor=H.+R.+Schmidtauthor=M.+A.+Skibaauthor=M.+D.+Mandlerauthor=J.+R.+Andersonauthor=P.+Slizauthor=A.+C.+Kruse&title=Virtual+Screening+for+Ligand+Discovery+at+the+%CF%83%281%29+Receptor&doi=10.1021%2Facsmedchemlett.9b00314"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">Virtual Screening for Ligand Discovery at the σ1 Receptor</span></div><div class="casAuthors">Greenfield, Daniel A.; Schmidt, Hayden R.; Skiba, Meredith A.; Mandler, Michael D.; Anderson, Jacob R.; Sliz, Piotr; Kruse, Andrew C.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1555-1561</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The σ1 receptor is a transmembrane protein implicated in several pathophysiol. conditions, including neurodegenerative disease, drug addiction, cancer, and pain.  However, there are no high-throughput functional assays for σ1 receptor drug discovery.  Here, we assessed high-throughput structure-based computational docking for discovery of novel ligands of the σ1 receptor.  We screened a library of over 6 million compds. using the Schr.ovrddot.odinger Glide package, followed by exptl. characterization of top-scoring candidates. 77% of tested candidates bound σ1 with high affinity (KD < 1 μM).  These include compds. with high selectivity for the σ1 receptor compared to the genetically unrelated but pharmacol. similar σ2 receptor, as well as compds. with substantial crossreactivity between the two receptors.  These results establish structure-based virtual screening as a highly effective platform for σ1 receptor ligand discovery and provide compds. to prioritize in studies of σ1 biol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqiDfUmoQaAcLVg90H21EOLACvtfcHk0lhm1RhsAACzgw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhsVGns7nF&md5=f9bb32db3e629e604044651de2147bb5</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.9b00314&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.9b00314%26sid%3Dliteratum%253Aachs%26aulast%3DGreenfield%26aufirst%3DD.%2BA.%26aulast%3DSchmidt%26aufirst%3DH.%2BR.%26aulast%3DSkiba%26aufirst%3DM.%2BA.%26aulast%3DMandler%26aufirst%3DM.%2BD.%26aulast%3DAnderson%26aufirst%3DJ.%2BR.%26aulast%3DSliz%26aufirst%3DP.%26aulast%3DKruse%26aufirst%3DA.%2BC.%26atitle%3DVirtual%2520Screening%2520for%2520Ligand%2520Discovery%2520at%2520the%2520%25CF%2583%25281%2529%2520Receptor%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2020%26volume%3D11%26spage%3D1555%26epage%3D1561%26doi%3D10.1021%2Facsmedchemlett.9b00314" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref91"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref91'); return false;" data-citation="" class="refNumLink">91</a></strong><div class="NLM_citation" id="cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">March-Vila, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinzi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sturm, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tinivella, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engkvist, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rastelli, G.</span></span> <span> </span><span class="NLM_article-title">On the Integration of In Silico Drug Design Methods for Drug Repurposing</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">298</span>, <span class="refDoi"> DOI: 10.3389/fphar.2017.00298</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.3389%2Ffphar.2017.00298" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=28588497" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvFentbbP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=298&author=E.+March-Vilaauthor=L.+Pinziauthor=N.+Sturmauthor=A.+Tinivellaauthor=O.+Engkvistauthor=H.+Chenauthor=G.+Rastelli&title=On+the+Integration+of+In+Silico+Drug+Design+Methods+for+Drug+Repurposing&doi=10.3389%2Ffphar.2017.00298"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">On the integration of in silico drug design methods for drug repurposing</span></div><div class="casAuthors">March-Vila, Eric; Pinzi, Luca; Sturm, Noe; Tinivella, Annachiara; Engkvist, Ola; Chen, Hongming; Rastelli, Giulio</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Pharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">298/1-298/7</span>CODEN:
                <span class="NLM_cas:coden">FPRHAU</span>;
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">Drug repurposing has become an important branch of drug discovery.  Several computational approaches that help to uncover new repurposing opportunities and aid the discovery process have been put forward, or adapted from previous applications.  A no. of successful examples are now available.  Overall, future developments will greatly benefit from integration of different methods, approaches and disciplines.  Steps forward in this direction are expected to help to clarify, and therefore to rationally predict, new drug-target, target-disease, and ultimately drug-disease assocns.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-SylGJO5wt7Vg90H21EOLACvtfcHk0lhm1RhsAACzgw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvFentbbP&md5=cf38db8a704a52cddbd6949caca49783</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2017.00298&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2017.00298%26sid%3Dliteratum%253Aachs%26aulast%3DMarch-Vila%26aufirst%3DE.%26aulast%3DPinzi%26aufirst%3DL.%26aulast%3DSturm%26aufirst%3DN.%26aulast%3DTinivella%26aufirst%3DA.%26aulast%3DEngkvist%26aufirst%3DO.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DRastelli%26aufirst%3DG.%26atitle%3DOn%2520the%2520Integration%2520of%2520In%2520Silico%2520Drug%2520Design%2520Methods%2520for%2520Drug%2520Repurposing%26jtitle%3DFront.%2520Pharmacol.%26date%3D2017%26volume%3D8%26spage%3D298%26doi%3D10.3389%2Ffphar.2017.00298" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref92"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref92'); return false;" data-citation="" class="refNumLink">92</a></strong><div class="NLM_citation" id="cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gilmore, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsumoto, R. R.</span></span> <span> </span><span class="NLM_article-title">Review of the pharmacological and clinical profile of rimcazole</span>. <i>CNS Drug Rev.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">22</span>, <span class="refDoi"> DOI: 10.1111/j.1527-3458.2004.tb00001.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1111%2Fj.1527-3458.2004.tb00001.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=14978511" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjtlClu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2004&pages=1-22&author=D.+L.+Gilmoreauthor=Y.+Liuauthor=R.+R.+Matsumoto&title=Review+of+the+pharmacological+and+clinical+profile+of+rimcazole&doi=10.1111%2Fj.1527-3458.2004.tb00001.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">Review of the pharmacological and clinical profile of rimcazole</span></div><div class="casAuthors">Gilmore, Deborah L.; Liu, Yun; Matsumoto, Rae R.</div><div class="citationInfo"><span class="NLM_cas:title">CNS Drug Reviews</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-22</span>CODEN:
                <span class="NLM_cas:coden">CDREFB</span>;
        ISSN:<span class="NLM_cas:issn">1080-563X</span>.
    
            (<span class="NLM_cas:orgname">Neva Press</span>)
        </div><div class="casAbstract">A review.  Rimcazole is a carbazole deriv. that acts in part as a σ receptor antagonist.  Wellcome Research Labs. introduced this compd. during the 1980s when it was hypothesized to be a novel antipsychotic with an improved side effect profile.  However, subsequent clin. trials demonstrated that rimcazole lacked efficacy in schizophrenic patients and it is now primarily used as an exptl. tool.  In addn. to its actions as a σ receptor antagonist, rimcazole also has high affinity for dopamine transporters, and in recent years it has served as a lead compd. for the development of novel dopamine transporter ligands.  Although rimcazole cannot be considered a selective ligand for σ receptors, the recent development of other selective agonists and antagonists for σ receptors have aided in clarifying the involvement of these receptors in the actions of rimcazole.  Many of the physiol. and behavioral effects of rimcazole can in fact be ascribed to its action as a σ receptor antagonist, although there are exceptions.  Rimcazole is likely to have a continued role in elucidating σ receptor function in either in vitro or in vivo systems where σ receptor-mediated effects can be studied independently of the influence of dopamine and serotonin transporters.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnDturAcy-MbVg90H21EOLACvtfcHk0li6qUPxLZnr6Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjtlClu7k%253D&md5=4acf91e4e7b49d1d74372dc095b07594</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1111%2Fj.1527-3458.2004.tb00001.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1527-3458.2004.tb00001.x%26sid%3Dliteratum%253Aachs%26aulast%3DGilmore%26aufirst%3DD.%2BL.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DMatsumoto%26aufirst%3DR.%2BR.%26atitle%3DReview%2520of%2520the%2520pharmacological%2520and%2520clinical%2520profile%2520of%2520rimcazole%26jtitle%3DCNS%2520Drug%2520Rev.%26date%3D2004%26volume%3D10%26spage%3D1%26epage%3D22%26doi%3D10.1111%2Fj.1527-3458.2004.tb00001.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref93"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref93'); return false;" data-citation="" class="refNumLink">93</a></strong><div class="NLM_citation" id="cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Happy, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dejoie, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zajac, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortez, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chakraborty, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aderemi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sauane, M.</span></span> <span> </span><span class="NLM_article-title">Sigma 1 Receptor antagonist potentiates the anti-cancer effect of p53 by regulating ER stress, ROS production, Bax levels, and caspase-3 activation</span>. <i>Biochem. Biophys. Res. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>456</i></span>,  <span class="NLM_fpage">683</span>– <span class="NLM_lpage">688</span>, <span class="refDoi"> DOI: 10.1016/j.bbrc.2014.12.029</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1016%2Fj.bbrc.2014.12.029" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=25511708" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BC2MXkslGrsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=456&publication_year=2015&pages=683-688&author=M.+Happyauthor=J.+Dejoieauthor=C.+K.+Zajacauthor=B.+Cortezauthor=K.+Chakrabortyauthor=J.+Aderemiauthor=M.+Sauane&title=Sigma+1+Receptor+antagonist+potentiates+the+anti-cancer+effect+of+p53+by+regulating+ER+stress%2C+ROS+production%2C+Bax+levels%2C+and+caspase-3+activation&doi=10.1016%2Fj.bbrc.2014.12.029"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">Sigma 1 Receptor antagonist potentiates the anti-cancer effect of p53 by regulating ER stress, ROS production, Bax levels, and caspase-3 activation</span></div><div class="casAuthors">Happy, Mireille; Dejoie, Jordan; Zajac, Cynthia K.; Cortez, Briseida; Chakraborty, Karabi; Aderemi, Joseph; Sauane, Moira</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical and Biophysical Research Communications</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">456</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">683-688</span>CODEN:
                <span class="NLM_cas:coden">BBRCA9</span>;
        ISSN:<span class="NLM_cas:issn">0006-291X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Over the last years, many improvements have been made in the treatment of breast cancer; however, novel and less toxic therapies are still needed, esp. for relapsing and chemo-resistant patients.  Here, we analyzed the therapeutic potential of p53 and Rimcazole, a Sigma 1 Receptor antagonist.  Rimcazole and p53 are being evaluated in preclin. and clin. trials, resp.  While p53 is a promising antitumor therapeutic agent, antagonists of Sigma 1 Receptor also inhibit tumor cell survival and induce apoptosis.  Our current study demonstrates for the first time the synergistic effect of p53 in combination with the Sigma 1 Receptor antagonist Rimcazole.  Furthermore, we show that shRNA knockdown of Sigma 1 Receptor in combination with p53, lead to a similar synergistic effect, and that this synergistic effect, in breast cancer growth suppression occurs independent of p53 status.  Furthermore, this combination treatment induced ER stress, p38 MAPK activation, ROS prodn., and proteins involved in apoptosis (caspases-3, Bax) in breast cancer cells.  Combining these therapeutic anti-cancer mols. provides an innovative approach for potentially treating human breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-olGz9KhR_7Vg90H21EOLACvtfcHk0li6qUPxLZnr6Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXkslGrsw%253D%253D&md5=2ead9d26d94e08d8174230536ba4db63</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1016%2Fj.bbrc.2014.12.029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbrc.2014.12.029%26sid%3Dliteratum%253Aachs%26aulast%3DHappy%26aufirst%3DM.%26aulast%3DDejoie%26aufirst%3DJ.%26aulast%3DZajac%26aufirst%3DC.%2BK.%26aulast%3DCortez%26aufirst%3DB.%26aulast%3DChakraborty%26aufirst%3DK.%26aulast%3DAderemi%26aufirst%3DJ.%26aulast%3DSauane%26aufirst%3DM.%26atitle%3DSigma%25201%2520Receptor%2520antagonist%2520potentiates%2520the%2520anti-cancer%2520effect%2520of%2520p53%2520by%2520regulating%2520ER%2520stress%252C%2520ROS%2520production%252C%2520Bax%2520levels%252C%2520and%2520caspase-3%2520activation%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D2015%26volume%3D456%26spage%3D683%26epage%3D688%26doi%3D10.1016%2Fj.bbrc.2014.12.029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref94"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref94'); return false;" data-citation="" class="refNumLink">94</a></strong><div class="NLM_citation" id="cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Achison, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boylan, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hupp, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spruce, B. A.</span></span> <span> </span><span class="NLM_article-title">HIF-1alpha contributes to tumour-selective killing by the sigma receptor antagonist rimcazole</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">1137</span>– <span class="NLM_lpage">1146</span>, <span class="refDoi"> DOI: 10.1038/sj.onc.1209890</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1038%2Fsj.onc.1209890" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=16924239" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhvF2jur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2007&pages=1137-1146&author=M.+Achisonauthor=M.+T.+Boylanauthor=T.+R.+Huppauthor=B.+A.+Spruce&title=HIF-1alpha+contributes+to+tumour-selective+killing+by+the+sigma+receptor+antagonist+rimcazole&doi=10.1038%2Fsj.onc.1209890"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">HIF-1α contributes to tumour-selective killing by the sigma receptor antagonist rimcazole</span></div><div class="casAuthors">Achison, M.; Boylan, M. T.; Hupp, T. R.; Spruce, B. A.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1137-1146</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">We have previously reported tumor-selective killing by the sigma (σ) receptor ligand rimcazole.  We now report that rimcazole elevates hypoxia inducible factor-1α (HIF-1α) protein levels under normoxic conditions in colorectal (HCT-116) and mammary carcinoma (MDA MB 231) cells but fails to induce HIF-1α in normal fibroblasts or mammary epithelial cells.  Combining the σ-1 agonist (+)-pentazocine with rimcazole substantially reduces the accumulation of HIF-1α, confirming that the effect is mediated at least partly by antagonism of σ-1 sites.  HIF-1α knockdown by RNA interference attenuates rimcazole-induced cell death in both cell types.  Thus, the induction of HIF-1α by rimcazole contributes to tumor cell killing.  In a comparison of HCT-116p53+/+ and HCT-116p53-/- cells, HIF-1α levels are consistently higher after rimcazole treatment in HCT-116p53+/+ cells.  Furthermore, although rimcazole kills HCT-116p53-/- cells, it has a more potent apoptosis-inducing effect in HCT-116p53+/+ cells.  This suggests that the presence of functional p53 protein may enhance death induction by rimcazole in part through greater induction of HIF-1α. p53 is not required, however, for the rimcazole-induced engagement of HIF-1α in proapoptotic mode as HIF-1α knockdown attenuates rimcazole-induced death to comparable extents in p53 mutant and wild-type cell systems.  Knowledge of HIF-1α involvement may assist the re-profiling of rimcazole and other σ ligands as cancer therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrD0Ge5Ue_R4LVg90H21EOLACvtfcHk0li6qUPxLZnr6Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhvF2jur0%253D&md5=58fcdc8182174be1f97d2dd9ea78279b</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1209890&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1209890%26sid%3Dliteratum%253Aachs%26aulast%3DAchison%26aufirst%3DM.%26aulast%3DBoylan%26aufirst%3DM.%2BT.%26aulast%3DHupp%26aufirst%3DT.%2BR.%26aulast%3DSpruce%26aufirst%3DB.%2BA.%26atitle%3DHIF-1alpha%2520contributes%2520to%2520tumour-selective%2520killing%2520by%2520the%2520sigma%2520receptor%2520antagonist%2520rimcazole%26jtitle%3DOncogene%26date%3D2007%26volume%3D26%26spage%3D1137%26epage%3D1146%26doi%3D10.1038%2Fsj.onc.1209890" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref95"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref95'); return false;" data-citation="" class="refNumLink">95</a></strong><div class="NLM_citation" id="cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schrock, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spino, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Longen, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stabler, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marino, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasternak, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, F. J.</span></span> <span> </span><span class="NLM_article-title">Sequential cytoprotective responses to Sigma1 ligand-induced endoplasmic reticulum stress</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>84</i></span>,  <span class="NLM_fpage">751</span>– <span class="NLM_lpage">762</span>, <span class="refDoi"> DOI: 10.1124/mol.113.087809</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1124%2Fmol.113.087809" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=24006496" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1KjtLbE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=84&publication_year=2013&pages=751-762&author=J.+M.+Schrockauthor=C.+M.+Spinoauthor=C.+G.+Longenauthor=S.+M.+Stablerauthor=J.+C.+Marinoauthor=G.+W.+Pasternakauthor=F.+J.+Kim&title=Sequential+cytoprotective+responses+to+Sigma1+ligand-induced+endoplasmic+reticulum+stress&doi=10.1124%2Fmol.113.087809"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">Sequential cytoprotective responses to Sigma1 ligand-induced endoplasmic reticulum stress</span></div><div class="casAuthors">Schrock, Joel M.; Spino, Christina M.; Longen, Charles G.; Stabler, Stacy M.; Marino, Jacqueline C.; Pasternak, Gavril W.; Kim, Felix J.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">84</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">751-762</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">1521-0111</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The Sigma1 receptor (Sigma1) is an endoplasmic reticulum (ER) integral membrane protein that is highly expressed in a no. of cancer cell lines.  Small mol. compds. targeting Sigma1 (Sigma1 ligands) inhibit cancer cell proliferation and induce apoptotic cell death in vitro and inhibit tumor growth in xenograft expts.  However, the cellular pathways activated by Sigma1 protein-ligand interaction are not well defined.  Here, we find that treatment with some Sigma1 ligands induces ER stress and activates the unfolded protein response (UPR) in a dose- and time-responsive manner in a range of adenocarcinoma cell lines.  Autophagy is engaged after extended treatment with Sigma1 ligands, which suggests that protracted UPR results in autophagy as a secondary response.  Inhibition of UPR by RNAi-mediated knockdown of inositol-requiring enzyme 1α and activating transcription factor 4 abrogates autophagosome formation, as does knockdown of essential autophagy gene products Beclin1 and autophagy protein 5.  Knockdown of Sigma1 also suppresses IPAG [1-(4-iodophenyl)-3-(2-adamantyl) guanidine] induced UPR marker and autophagosome levels, indicating that this response is indeed Sigma1-mediated.  We find that UPR activation precedes autophagosome formation and autophagy precedes apoptosis in Sigma1 ligand-treated cells.  These processes are reversible, and washout of IPAG before cell death results in a return of autophagosomes and UPR markers toward basal levels.  However, inhibition of Sigma1 ligand-induced UPR or autophagy accelerates apoptotic cell death.  Together, these data suggest that UPR and autophagy are engaged as primary and secondary cytoprotective responses, resp., to Sigma1 ligand-induced disruption of cancer cell protein homeostasis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXXCF4X7v7r7Vg90H21EOLACvtfcHk0lixzifeliEowA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1KjtLbE&md5=3f3f80e868c04d3358ceeb423beacd47</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1124%2Fmol.113.087809&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.113.087809%26sid%3Dliteratum%253Aachs%26aulast%3DSchrock%26aufirst%3DJ.%2BM.%26aulast%3DSpino%26aufirst%3DC.%2BM.%26aulast%3DLongen%26aufirst%3DC.%2BG.%26aulast%3DStabler%26aufirst%3DS.%2BM.%26aulast%3DMarino%26aufirst%3DJ.%2BC.%26aulast%3DPasternak%26aufirst%3DG.%2BW.%26aulast%3DKim%26aufirst%3DF.%2BJ.%26atitle%3DSequential%2520cytoprotective%2520responses%2520to%2520Sigma1%2520ligand-induced%2520endoplasmic%2520reticulum%2520stress%26jtitle%3DMol.%2520Pharmacol.%26date%3D2013%26volume%3D84%26spage%3D751%26epage%3D762%26doi%3D10.1124%2Fmol.113.087809" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref96"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref96'); return false;" data-citation="" class="refNumLink">96</a></strong><div class="NLM_citation" id="cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Berthois, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bourrié, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galiègue, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vidal, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carayon, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casellas, P.</span></span> <span> </span><span class="NLM_article-title">SR31747A is a sigma receptor ligand exhibiting antitumoural activity both in vitro and in vivo</span>. <i>Br. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>88</i></span>,  <span class="NLM_fpage">438</span>– <span class="NLM_lpage">446</span>, <span class="refDoi"> DOI: 10.1038/sj.bjc.6600709</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1038%2Fsj.bjc.6600709" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=12569389" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BD3sXoslKmtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=88&publication_year=2003&pages=438-446&author=Y.+Berthoisauthor=B.+Bourri%C3%A9author=S.+Gali%C3%A8gueauthor=H.+Vidalauthor=P.+Carayonauthor=P.+M.+Martinauthor=P.+Casellas&title=SR31747A+is+a+sigma+receptor+ligand+exhibiting+antitumoural+activity+both+in+vitro+and+in+vivo&doi=10.1038%2Fsj.bjc.6600709"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">SR31747A is a sigma receptor ligand exhibiting antitumoural activity both in vitro and in vivo</span></div><div class="casAuthors">Berthois, Y.; Bourrie, B.; Galiegue, S.; Vidal, H.; Carayon, P.; Martin, P. M.; Casellas, P.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">88</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">438-446</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">SR31747A is a recently described sigma receptor ligand that binds SR31747A-binding protein 1 (SR-BP) and emopamil-binding protein (EBP) (also called the sigma 1 receptor and the human sterol isomerase (HSI), resp.), and has immunoregulatory and antiproliferative activities.  To further investigate its antitumor activity and focusing on cancers, which are sensitive to the mol., we measured the proliferation of different human epithelial breast or prostate cancer cell lines following in vitro and in vivo SR31747A treatment.  Firstly, in vitro, we found that nanomolar concns. of SR31747A dramatically inhibited cell proliferation in both hormono-responsive and -unresponsive cancer cell lines.  Secondly, tumor development was significantly decreased in mice treated with SR31747A.  In an attempt to decipher the SR31747A mode of action, we found that the two binding sites may not fully account for this activity.  Indeed, while competitive expts. indicated that EBP prevails in mediating SR31747A antiproliferative activity, an anal. of the expression of both receptors indicated that the cellular sensitivity to SR31747A is not correlated with either EBP or SR-BP expression.  These data suggest that addnl. binding sites may exist.  Preliminary binding studies demonstrated that SR31747A also binds to sigma2, a protein that has not yet been cloned, but which is considered as a potential marker of the proliferative status of tumor cells.  Altogether, our data demonstrate the antitumoral activity of SR31747A both in vitro and in vivo in two different cancer models, broaden the spectrum of its binding proteins and enhance the potential for further therapeutic development of the mol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpP61EjXFMPiLVg90H21EOLACvtfcHk0lixzifeliEowA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXoslKmtQ%253D%253D&md5=c03c521472c1ae7e1a8e387c1d201fc4</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjc.6600709&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjc.6600709%26sid%3Dliteratum%253Aachs%26aulast%3DBerthois%26aufirst%3DY.%26aulast%3DBourri%25C3%25A9%26aufirst%3DB.%26aulast%3DGali%25C3%25A8gue%26aufirst%3DS.%26aulast%3DVidal%26aufirst%3DH.%26aulast%3DCarayon%26aufirst%3DP.%26aulast%3DMartin%26aufirst%3DP.%2BM.%26aulast%3DCasellas%26aufirst%3DP.%26atitle%3DSR31747A%2520is%2520a%2520sigma%2520receptor%2520ligand%2520exhibiting%2520antitumoural%2520activity%2520both%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2003%26volume%3D88%26spage%3D438%26epage%3D446%26doi%3D10.1038%2Fsj.bjc.6600709" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref97"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref97'); return false;" data-citation="" class="refNumLink">97</a></strong><div class="NLM_citation" id="cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Casellas, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galiegue, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bourrie, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrini, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jbilo, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vidal, H.</span></span> <span> </span><span class="NLM_article-title">SR31747A: a peripheral sigma ligand with potent antitumor activities</span>. <i>Anti-Cancer Drugs</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">113</span>– <span class="NLM_lpage">118</span>, <span class="refDoi"> DOI: 10.1097/00001813-200402000-00003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1097%2F00001813-200402000-00003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=15075666" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BD2cXivFaktrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2004&pages=113-118&author=P.+Casellasauthor=S.+Galiegueauthor=B.+Bourrieauthor=J.+B.+Ferriniauthor=O.+Jbiloauthor=H.+Vidal&title=SR31747A%3A+a+peripheral+sigma+ligand+with+potent+antitumor+activities&doi=10.1097%2F00001813-200402000-00003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">SR31747A: a peripheral σ ligand with potent antitumor activities</span></div><div class="casAuthors">Casellas, Pierre; Galiegue, Sylvaine; Bourrie, Bernard; Ferrini, Jean-Bernard; Jbilo, Omar; Vidal, Hubert</div><div class="citationInfo"><span class="NLM_cas:title">Anti-Cancer Drugs</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">113-118</span>CODEN:
                <span class="NLM_cas:coden">ANTDEV</span>;
        ISSN:<span class="NLM_cas:issn">0959-4973</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">A review.  SR31747A is currently being evaluated in phase IIb clin. trials for prostate cancer treatment.  The mol. is a peripheral σ ligand that binds four proteins in human cells, i.e. SRBP-1, σ-2, HSI and its relative SRBP-2.  SR31747A is a dual agent with both immunomodulatory and antiproliferative activities.  The mol. blocks proliferation of human and mouse lymphocytes, modulates the expression of pro- and anti-inflammatory cytokines, and was shown to protect animals in vivo against acute and chronic inflammatory conditions such as acute graft-vs.-host reaction, lethality induced by staphylococcal enterotoxin B and lipopolysaccharide or rheumatoid arthritis.  Besides these immunomodulatory activities, the mol. also inhibits the proliferation of various tumor cell lines in vitro in a time- and concn.-dependent manner.  In vivo, SR31747A has potent antitumoral activity as demonstrated against mammary and prostatic tumoral cell lines injected into nude mice, where both tumor incidence and growth were decreased by more than 40% following daily SR31747A treatment at 25 mg/kg i.p.  The recent literature on SR31747A in cancer is reviewed here.  We focus specifically on preclin. data obtained in vivo and on studies aimed at deciphering the mode of action of the mol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4Y06fjIaU8LVg90H21EOLACvtfcHk0lixzifeliEowA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXivFaktrg%253D&md5=3de4da66fa0c2c11575f5ed2a1181b3c</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1097%2F00001813-200402000-00003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F00001813-200402000-00003%26sid%3Dliteratum%253Aachs%26aulast%3DCasellas%26aufirst%3DP.%26aulast%3DGaliegue%26aufirst%3DS.%26aulast%3DBourrie%26aufirst%3DB.%26aulast%3DFerrini%26aufirst%3DJ.%2BB.%26aulast%3DJbilo%26aufirst%3DO.%26aulast%3DVidal%26aufirst%3DH.%26atitle%3DSR31747A%253A%2520a%2520peripheral%2520sigma%2520ligand%2520with%2520potent%2520antitumor%2520activities%26jtitle%3DAnti-Cancer%2520Drugs%26date%3D2004%26volume%3D15%26spage%3D113%26epage%3D118%26doi%3D10.1097%2F00001813-200402000-00003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref98"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref98'); return false;" data-citation="" class="refNumLink">98</a></strong><div class="NLM_citation" id="cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hajipour, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sievert, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arbabian, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruoho, A. E.</span></span> <span> </span><span class="NLM_article-title">Characterization of the cocaine binding site on the sigma-1 receptor</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">3532</span>– <span class="NLM_lpage">3542</span>, <span class="refDoi"> DOI: 10.1021/bi061727o</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi061727o" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhvF2rt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2007&pages=3532-3542&author=Y.+Chenauthor=A.+R.+Hajipourauthor=M.+K.+Sievertauthor=M.+Arbabianauthor=A.+E.+Ruoho&title=Characterization+of+the+cocaine+binding+site+on+the+sigma-1+receptor&doi=10.1021%2Fbi061727o"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of the Cocaine Binding Site on the Sigma-1 Receptor</span></div><div class="casAuthors">Chen, Yuenmu; Hajipour, Abdol R.; Sievert, Michael K.; Arbabian, Marty; Ruoho, Arnold E.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3532-3542</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The cocaine photoaffinity label 3-iodo-4-azido-cocaine ([125I]IACoc) binds to the sigma-1 receptor with an affinity that is 2-3 orders of magnitude higher than the parent compd. cocaine.  In the present study, the binding properties of several cocaine derivs. to the guinea pig liver sigma-1 receptor were detd.  The results from assessing the affinity of various derivs. of cocaine which were substituted on the Ph ring indicated that an important determinant of binding to the guinea pig sigma-1 receptor binding site may be the development of a dipole in the ring in which the π electron d. of the Ph ring is reduced.  This implies that an electron-rich source is present in the sigma-1 receptor binding site, such as the π system of an arom. ring or other electron-rich side chains, which interact with the Ph ring of cocaine.  The precise [125I]IACoc derivatization site in the guinea pig sigma-1 receptor was identified using chem. cleavage and purifn. of the resulting labeled peptides.  Cyanogen bromide cleavage of the [125I]IACoc photolabeled sigma-1 receptor followed by radio-sequencing identified Asp188, which is located in the putative steroid binding domain-like II (SBDL II) near the carboxyl terminus, as the site of [125I]IACoc insertion.  Systematic truncation of the C-terminus indicated the requirement for the last 15 amino acid residues of the receptor for [125I]IACoc photolabeling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGouSQz-3lvCbbVg90H21EOLACvtfcHk0lh_KWRgQw_7CQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhvF2rt7Y%253D&md5=64d49c672bcdb3da82000805d05aaeea</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1021%2Fbi061727o&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi061727o%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DY.%26aulast%3DHajipour%26aufirst%3DA.%2BR.%26aulast%3DSievert%26aufirst%3DM.%2BK.%26aulast%3DArbabian%26aufirst%3DM.%26aulast%3DRuoho%26aufirst%3DA.%2BE.%26atitle%3DCharacterization%2520of%2520the%2520cocaine%2520binding%2520site%2520on%2520the%2520sigma-1%2520receptor%26jtitle%3DBiochemistry%26date%3D2007%26volume%3D46%26spage%3D3532%26epage%3D3542%26doi%3D10.1021%2Fbi061727o" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref99"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref99'); return false;" data-citation="" class="refNumLink">99</a></strong><div class="NLM_citation" id="cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pal, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hajipour, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fontanilla, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramachandran, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, U. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mavlyutov, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruoho, A. E.</span></span> <span> </span><span class="NLM_article-title">Identification of regions of the sigma-1 receptor ligand binding site using a novel photoprobe</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>72</i></span>,  <span class="NLM_fpage">921</span>– <span class="NLM_lpage">933</span>, <span class="refDoi"> DOI: 10.1124/mol.107.038307</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1124%2Fmol.107.038307" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=17622576" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtFaiu7%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2007&pages=921-933&author=A.+Palauthor=A.+R.+Hajipourauthor=D.+Fontanillaauthor=S.+Ramachandranauthor=U.+B.+Chuauthor=T.+Mavlyutovauthor=A.+E.+Ruoho&title=Identification+of+regions+of+the+sigma-1+receptor+ligand+binding+site+using+a+novel+photoprobe&doi=10.1124%2Fmol.107.038307"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of regions of the σ-1 receptor ligand binding site using a novel photoprobe</span></div><div class="casAuthors">Pal, Arindam; Hajipour, Abdol R.; Fontanilla, Dominique; Ramachandran, Subramaniam; Chu, Uyen B.; Mavlyutov, Timur; Ruoho, Arnold E.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">921-933</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">σ Receptors, once considered a class of opioid receptors, are now regarded as a unique class of receptors that contain binding sites for a wide range of ligands, including the drug 1-N(2',6'-dimethylmorpholino)3-(4-t-butylpropylamine) (fenpropimorph), a yeast sterol isomerase inhibitor.  Because fenpropimorph has high-binding affinity to the σ-1 receptor, the authors have synthesized a series of fenpropimorph-like derivs. with varying Ph ring substituents and have characterized their binding affinities to the σ-1 receptor.  In addn., the authors have synthesized a carrier-free, radioiodinated fenpropimorph-like photoaffinity label, 1-N-(2',6'-dimethyl-morpholino)-3-(4-azido-3-[125I]iodo- phenyl)propane ([125I]IAF), which covalently derivatized the σ-1 receptor (25.3 kDa) in both the rat liver and guinea pig liver membranes and the σ-2 receptor (18 kDa) in rat liver membranes with high specificity.  Furthermore, after cleaving the specific [125I]AF-photolabeled σ-1 receptor in guinea pig and rat liver membranes and the pure guinea pig σ-1 receptor with EndoLys-C and cyanogen bromide, the [125I]IAF label was identified both in a peptide contg. steroid binding domain-like I (SBDLI) (amino acids 91-109) and in a peptide contg. steroid binding domain-like II (SBDLII) (amino acids 176-194).  Because a single population of binding sites (R2 = 0.992) for [125I]IAF interaction with the σ-1 receptor was identified by (+)-[3H]pentazocine competitive binding with nonradioactive [127I]IAF, it was concluded that SBDLI (amino acids 91-109) and SBDLII (amino acids 176-194) comprises, at least in part, regions of the σ-1 receptor ligand binding site(s).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzaWBnxuOtA7Vg90H21EOLACvtfcHk0lh_KWRgQw_7CQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtFaiu7%252FJ&md5=a0496b04f5f98df95eaf2402e0790c2d</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1124%2Fmol.107.038307&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.107.038307%26sid%3Dliteratum%253Aachs%26aulast%3DPal%26aufirst%3DA.%26aulast%3DHajipour%26aufirst%3DA.%2BR.%26aulast%3DFontanilla%26aufirst%3DD.%26aulast%3DRamachandran%26aufirst%3DS.%26aulast%3DChu%26aufirst%3DU.%2BB.%26aulast%3DMavlyutov%26aufirst%3DT.%26aulast%3DRuoho%26aufirst%3DA.%2BE.%26atitle%3DIdentification%2520of%2520regions%2520of%2520the%2520sigma-1%2520receptor%2520ligand%2520binding%2520site%2520using%2520a%2520novel%2520photoprobe%26jtitle%3DMol.%2520Pharmacol.%26date%3D2007%26volume%3D72%26spage%3D921%26epage%3D933%26doi%3D10.1124%2Fmol.107.038307" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref100"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref100'); return false;" data-citation="" class="refNumLink">100</a></strong><div class="NLM_citation" id="cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ramachandran, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prabhu, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruoho, A. E.</span></span> <span> </span><span class="NLM_article-title">Purification and characterization of the guinea pig sigma-1 receptor functionally expressed in Escherichia coli</span>. <i>Protein Expression Purif.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">283</span>– <span class="NLM_lpage">292</span>, <span class="refDoi"> DOI: 10.1016/j.pep.2006.07.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1016%2Fj.pep.2006.07.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=16962337" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BD28Xht1Klt7fK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2007&pages=283-292&author=S.+Ramachandranauthor=H.+Luauthor=U.+Prabhuauthor=A.+E.+Ruoho&title=Purification+and+characterization+of+the+guinea+pig+sigma-1+receptor+functionally+expressed+in+Escherichia+coli&doi=10.1016%2Fj.pep.2006.07.019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">Purification and characterization of the guinea pig sigma-1 receptor functionally expressed in Escherichia coli</span></div><div class="casAuthors">Ramachandran, Subramaniam; Lu, Hongliang; Prabhu, Usha; Ruoho, Arnold E.</div><div class="citationInfo"><span class="NLM_cas:title">Protein Expression and Purification</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">283-292</span>CODEN:
                <span class="NLM_cas:coden">PEXPEJ</span>;
        ISSN:<span class="NLM_cas:issn">1046-5928</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Sigma receptors once considered as a class of opioid receptors are now regarded as unique orphan receptors, distinguished by the ability to bind various pharmacol. agents such as the progesterone (steroid), haloperidol (anti-psychotic), and drugs of abuse such as cocaine and methamphetamine.  The sigma-1 receptor is a 223 amino acid protein, proposed to have two transmembrane segments.  The authors have developed a scheme for the purifn. of the guinea pig sigma-1 receptor following overexpression in Escherichia coli as a maltose binding protein (MBP) fusion and extn. with Triton X-100.  Affinity chromatog. using an amylose column and Ni2+ affinity column was used to purify the sigma-1 receptor.  The sigma-1 receptor purified by this method is a 26-kDa polypeptide as assessed by SDS-PAGE, binds sigma ligands with high affinity and can be specifically photoaffinity labeled with the sigma-1 receptor photoprobe, [125I]-iodoazidococaine.  Ligand binding using [3H]-(+)-pentazocine indicated that approx. half of the purified protein in Triton X-100 bound to radioligand.  The MBP-sigma-1 receptor and the sigma-1 receptor in 0.5% Triton were maximally stable for approx. two weeks at -20° in buffer contg. 30% glycerol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpodBNpteBB-rVg90H21EOLACvtfcHk0lh_KWRgQw_7CQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xht1Klt7fK&md5=f9204212cac015ca49604e6401700406</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1016%2Fj.pep.2006.07.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pep.2006.07.019%26sid%3Dliteratum%253Aachs%26aulast%3DRamachandran%26aufirst%3DS.%26aulast%3DLu%26aufirst%3DH.%26aulast%3DPrabhu%26aufirst%3DU.%26aulast%3DRuoho%26aufirst%3DA.%2BE.%26atitle%3DPurification%2520and%2520characterization%2520of%2520the%2520guinea%2520pig%2520sigma-1%2520receptor%2520functionally%2520expressed%2520in%2520Escherichia%2520coli%26jtitle%3DProtein%2520Expression%2520Purif.%26date%3D2007%26volume%3D51%26spage%3D283%26epage%3D292%26doi%3D10.1016%2Fj.pep.2006.07.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref101"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref101'); return false;" data-citation="" class="refNumLink">101</a></strong><div class="NLM_citation" id="cit101"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hajipour, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fontanilla, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, U. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arbabian, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruoho, A. E.</span></span> <span> </span><span class="NLM_article-title">Synthesis and characterization of N,N-dialkyl and N-alkyl-N-aralkyl fenpropimorph-derived compounds as high affinity ligands for sigma receptors</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">4397</span>– <span class="NLM_lpage">4404</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2010.04.078</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1016%2Fj.bmc.2010.04.078" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=20493718" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BC3cXntV2rurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2010&pages=4397-4404&author=A.+R.+Hajipourauthor=D.+Fontanillaauthor=U.+B.+Chuauthor=M.+Arbabianauthor=A.+E.+Ruoho&title=Synthesis+and+characterization+of+N%2CN-dialkyl+and+N-alkyl-N-aralkyl+fenpropimorph-derived+compounds+as+high+affinity+ligands+for+sigma+receptors&doi=10.1016%2Fj.bmc.2010.04.078"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and characterization of N,N-dialkyl and N-alkyl-N-aralkyl fenpropimorph-derived compounds as high affinity ligands for sigma receptors</span></div><div class="casAuthors">Hajipour, Abdol R.; Fontanilla, Dominique; Chu, Uyen B.; Arbabian, Marty; Ruoho, Arnold E.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">4397-4404</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The sigma-1 receptor is a unique non-opioid, non-PCP binding site that has been implicated in many different pathophysiol. conditions including psychosis, drug addiction, retinal degeneration and cancer.  Based on the structure of fenpropimorph, a high affinity (K i = 0.005 nM) sigma-1 receptor ligand and strong inhibitor of the yeast sterol isomerase (ERG2), we previously deduced a basic sigma-1 receptor pharmacophore or chem. backbone composed of a Ph ring attached to a di-substituted nitrogen atom via an alkyl chain.  Here, we report the design and synthesis of various N,N-dialkyl or N-alkyl-N-aralkyl derivs. based on this pharmacophore as well as their binding affinities to the sigma-1 receptor.  We introduce three high affinity sigma-1 receptor compds., N,N-dibutyl-3-(4-fluorophenyl)propylamine (9)(I), N,N-dibutyl-3-(4-nitrophenyl)propylamine (3)(II), and N-propyl-N'-4-aminophenylethyl-3-(4-nitrophenyl)propylamine (20)(III) with K i values of 17.7 nM, 0.36 nM, and 6 nM, resp.  In addn. to sigma receptor affinity, we show through cytotoxicity assays that growth inhibition of various tumor cell lines occurs with our high affinity N,N-dialkyl or N-alkyl-N-aralkyl derivs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQLoE6p6LHRrVg90H21EOLACvtfcHk0lg2cmvusJpV5w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXntV2rurY%253D&md5=26b58c34a1ba0337bd0f7a4258f7df00</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2010.04.078&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2010.04.078%26sid%3Dliteratum%253Aachs%26aulast%3DHajipour%26aufirst%3DA.%2BR.%26aulast%3DFontanilla%26aufirst%3DD.%26aulast%3DChu%26aufirst%3DU.%2BB.%26aulast%3DArbabian%26aufirst%3DM.%26aulast%3DRuoho%26aufirst%3DA.%2BE.%26atitle%3DSynthesis%2520and%2520characterization%2520of%2520N%252CN-dialkyl%2520and%2520N-alkyl-N-aralkyl%2520fenpropimorph-derived%2520compounds%2520as%2520high%2520affinity%2520ligands%2520for%2520sigma%2520receptors%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2010%26volume%3D18%26spage%3D4397%26epage%3D4404%26doi%3D10.1016%2Fj.bmc.2010.04.078" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref102"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref102'); return false;" data-citation="" class="refNumLink">102</a></strong><div class="NLM_citation" id="cit102"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ablordeppey, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glennon, R. A.</span></span> <span> </span><span class="NLM_article-title">Is a nitrogen atom an important pharmacophoric element in sigma ligand binding?</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">2105</span>– <span class="NLM_lpage">2111</span>, <span class="refDoi"> DOI: 10.1016/S0968-0896(00)00148-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1016%2FS0968-0896%2800%2900148-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=11003156" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BD3cXls1Cmsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2000&pages=2105-2111&author=S.+Y.+Ablordeppeyauthor=J.+B.+Fischerauthor=R.+A.+Glennon&title=Is+a+nitrogen+atom+an+important+pharmacophoric+element+in+sigma+ligand+binding%3F&doi=10.1016%2FS0968-0896%2800%2900148-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit102R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">Is a Nitrogen Atom an Important Pharmacophoric Element in Sigma Ligand Binding?</span></div><div class="casAuthors">Ablordeppey, S. Y.; Fischer, J. B.; Glennon, R. A.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2105-2111</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A lingering question in σ receptor ligand development is whether a nitrogen atom serves as an important pharmacophoric element in binding affinity.  To address this question, we have synthesized several phenylalkylpiperidines and phenylalkylpiperazines and demonstrated that removal of the N atom from a typical phenylalkylpiperidine led to little or no binding to σ receptors.  In addn., where two N atoms occur in a compd., such as with phenylalkylpiperazines, the N atom on the longer alkyl chain appears to be more important.  Thus, based on this study, the N atom is an important pharmacophoric element in the binding of phenylalkylpiperidines and phenylalkylpiperazines to σ receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqetIuRV7wqmrVg90H21EOLACvtfcHk0lg2cmvusJpV5w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXls1Cmsrs%253D&md5=b1d5bb18bb50fb4cacc63c1ad739a57b</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.1016%2FS0968-0896%2800%2900148-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0968-0896%252800%252900148-6%26sid%3Dliteratum%253Aachs%26aulast%3DAblordeppey%26aufirst%3DS.%2BY.%26aulast%3DFischer%26aufirst%3DJ.%2BB.%26aulast%3DGlennon%26aufirst%3DR.%2BA.%26atitle%3DIs%2520a%2520nitrogen%2520atom%2520an%2520important%2520pharmacophoric%2520element%2520in%2520sigma%2520ligand%2520binding%253F%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2000%26volume%3D8%26spage%3D2105%26epage%3D2111%26doi%3D10.1016%2FS0968-0896%2800%2900148-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref103"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref103'); return false;" data-citation="" class="refNumLink">103</a></strong><div class="NLM_citation" id="cit103"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Piergentili, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amantini, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Del Bello, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giannella, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mattioli, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmery, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perfumi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pigini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santoni, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tucci, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zotti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quaglia, W.</span></span> <span> </span><span class="NLM_article-title">Novel highly potent and selective sigma 1 receptor antagonists related to spipethiane</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">1261</span>– <span class="NLM_lpage">1269</span>, <span class="refDoi"> DOI: 10.1021/jm901542q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901542q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BC3cXkt1Wktg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=1261-1269&author=A.+Piergentiliauthor=C.+Amantiniauthor=F.+Del+Belloauthor=M.+Giannellaauthor=L.+Mattioliauthor=M.+Palmeryauthor=M.+Perfumiauthor=M.+Piginiauthor=G.+Santoniauthor=P.+Tucciauthor=M.+Zottiauthor=W.+Quaglia&title=Novel+highly+potent+and+selective+sigma+1+receptor+antagonists+related+to+spipethiane&doi=10.1021%2Fjm901542q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Highly Potent and Selective σ1 Receptor Antagonists Related to Spipethiane</span></div><div class="casAuthors">Piergentili, Alessandro; Amantini, Consuelo; Del Bello, Fabio; Giannella, Mario; Mattioli, Laura; Palmery, Maura; Perfumi, Marina; Pigini, Maria; Santoni, Giorgio; Tucci, Paolo; Zotti, Margherita; Quaglia, Wilma</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1261-1269</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Conservative chem. modifications of the core structure of the lead spipethiane (1) afforded novel potent σ1 ligands. σ1 affinity and σ1/σ2 selectivity proved to be favored by the introduction of polar functions (oxygen atom or carbonyl group) in position 3 or 4 (4-6) or by the elongation of the distance between the two hydrophobic portions of the mol. with the simultaneous presence of a carbonyl group in position 4 (8 and 9).  The obsd. cytostatic effect against the human breast cancer cell line MCF-7/ADR, highly expressing σ1 receptors, and not against MCF-7, as well as the enhancement of morphine analgesia highlighted the σ1 antagonist profile of this series of compds.  In particular, due to its high σ1 affinity (pKi = 10.28) and σ1/σ2 selectivity ratio (29510), compd. 9 (I) might be a novel valuable tool for σ receptor characterization and a suitable template for the rational design of potential therapeutically useful σ1 antagonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7JWhD2T1LHrVg90H21EOLACvtfcHk0lg2cmvusJpV5w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXkt1Wktg%253D%253D&md5=ab40c7eaaf8f259f9796d38d48af96a8</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1021%2Fjm901542q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901542q%26sid%3Dliteratum%253Aachs%26aulast%3DPiergentili%26aufirst%3DA.%26aulast%3DAmantini%26aufirst%3DC.%26aulast%3DDel%2BBello%26aufirst%3DF.%26aulast%3DGiannella%26aufirst%3DM.%26aulast%3DMattioli%26aufirst%3DL.%26aulast%3DPalmery%26aufirst%3DM.%26aulast%3DPerfumi%26aufirst%3DM.%26aulast%3DPigini%26aufirst%3DM.%26aulast%3DSantoni%26aufirst%3DG.%26aulast%3DTucci%26aufirst%3DP.%26aulast%3DZotti%26aufirst%3DM.%26aulast%3DQuaglia%26aufirst%3DW.%26atitle%3DNovel%2520highly%2520potent%2520and%2520selective%2520sigma%25201%2520receptor%2520antagonists%2520related%2520to%2520spipethiane%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D1261%26epage%3D1269%26doi%3D10.1021%2Fjm901542q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref104"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref104'); return false;" data-citation="" class="refNumLink">104</a></strong><div class="NLM_citation" id="cit104"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Azzariti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colabufo, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berardi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porcelli, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niso, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simone, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perrone, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paradiso, A.</span></span> <span> </span><span class="NLM_article-title">Cyclohexylpiperazine derivative PB28, a sigma2 agonist and sigma1 antagonist receptor, inhibits cell growth, modulates P-glycoprotein, and synergizes with anthracyclines in breast cancer</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">1807</span>– <span class="NLM_lpage">1816</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-05-0402</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1158%2F1535-7163.MCT-05-0402" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=16891467" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BD28XnslWksbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2006&pages=1807-1816&author=A.+Azzaritiauthor=N.+A.+Colabufoauthor=F.+Berardiauthor=L.+Porcelliauthor=M.+Nisoauthor=G.+M.+Simoneauthor=R.+Perroneauthor=A.+Paradiso&title=Cyclohexylpiperazine+derivative+PB28%2C+a+sigma2+agonist+and+sigma1+antagonist+receptor%2C+inhibits+cell+growth%2C+modulates+P-glycoprotein%2C+and+synergizes+with+anthracyclines+in+breast+cancer&doi=10.1158%2F1535-7163.MCT-05-0402"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit104R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclohexylpiperazine derivative PB28, a σ2 agonist and σ1 antagonist receptor, inhibits cell growth, modulates P-glycoprotein, and synergizes with anthracyclines in breast cancer</span></div><div class="casAuthors">Azzariti, Amalia; Colabufo, Nicola A.; Berardi, Francesco; Porcelli, Letizia; Niso, Mauro; Simone, Grazia M.; Perrone, Roberto; Paradiso, Angelo</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1807-1816</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">σ Ligands have recently been shown to have cytotoxic activity, to induce ceramide-dependent/caspase-independent apoptosis, and to down-regulate P-glycoprotein (P-gp) mRNA levels in some mouse and human models.  In this study, we verified whether a mixed σ2 agonist/σ1 antagonist, PB28, was able to have antitumor activity and to enhance anthracycline efficacy in two human breast cancer cell lines, MCF7 and MCF7 ADR, both characterized by significant σ2 receptor expression, by high and low σ1 receptor expression, and low and high P-gp expression, resp.  In both cell lines, PB28 showed high σ2 receptor affinity and low σ1 receptor affinity; furthermore, it inhibited cell growth with a clear effect at 48 h (IC50 in nanomolar range), a consistent time exposure-independent increase of G0-G1-phase fraction (of ∼20% of both cell lines) and caspase-independent apoptosis (15% increased after 1-day drug exposure).  PB28 also reduced P-gp expression in a concn.- and time-dependent manner (∼60% in MCF7 and 90% in MCF7 ADR).  We showed also a strong synergism between PB28 and doxorubicin by adopting either simultaneous or sequential schedules of the two drugs.  We suggest that this synergism could depend on PB28-induced increase of intracellular accumulation of doxorubicin (∼50% in MCF7 and 75% in MCF7 ADR by flow cytometry anal.).  In conclusion, we suggest that the σ2 agonist PB28 could be an interesting antitumor agent either in monotherapy or in combination with conventional drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPbEQT82-rDrVg90H21EOLACvtfcHk0lg2cmvusJpV5w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XnslWksbo%253D&md5=a0581c8aec111a6474b1b041d916bcf5</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-05-0402&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-05-0402%26sid%3Dliteratum%253Aachs%26aulast%3DAzzariti%26aufirst%3DA.%26aulast%3DColabufo%26aufirst%3DN.%2BA.%26aulast%3DBerardi%26aufirst%3DF.%26aulast%3DPorcelli%26aufirst%3DL.%26aulast%3DNiso%26aufirst%3DM.%26aulast%3DSimone%26aufirst%3DG.%2BM.%26aulast%3DPerrone%26aufirst%3DR.%26aulast%3DParadiso%26aufirst%3DA.%26atitle%3DCyclohexylpiperazine%2520derivative%2520PB28%252C%2520a%2520sigma2%2520agonist%2520and%2520sigma1%2520antagonist%2520receptor%252C%2520inhibits%2520cell%2520growth%252C%2520modulates%2520P-glycoprotein%252C%2520and%2520synergizes%2520with%2520anthracyclines%2520in%2520breast%2520cancer%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2006%26volume%3D5%26spage%3D1807%26epage%3D1816%26doi%3D10.1158%2F1535-7163.MCT-05-0402" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref105"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref105'); return false;" data-citation="" class="refNumLink">105</a></strong><div class="NLM_citation" id="cit105"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alonso, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phan, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guillemain, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saunier, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Legrand, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anoal, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maurice, T.</span></span> <span> </span><span class="NLM_article-title">Immunocytochemical localization of the sigma(1) receptor in the adult rat central nervous system</span>. <i>Neuroscience</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>97</i></span>,  <span class="NLM_fpage">155</span>– <span class="NLM_lpage">170</span>, <span class="refDoi"> DOI: 10.1016/S0306-4522(00)00014-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1016%2FS0306-4522%2800%2900014-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10771347" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BD3cXisFGhurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=97&publication_year=2000&pages=155-170&author=G.+Alonsoauthor=V.+Phanauthor=I.+Guillemainauthor=M.+Saunierauthor=A.+Legrandauthor=M.+Anoalauthor=T.+Maurice&title=Immunocytochemical+localization+of+the+sigma%281%29+receptor+in+the+adult+rat+central+nervous+system&doi=10.1016%2FS0306-4522%2800%2900014-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit105R"><div class="casContent"><span class="casTitleNuber">105</span><div class="casTitle"><span class="NLM_cas:atitle">Immunocytochemical localization of the sigma1 receptor in the adult rat central nervous system</span></div><div class="casAuthors">Alonso, G.; Phan, V.-L.; Guillemain, I.; Saunier, M.; Legrand, A.; Anoal, M.; Maurice, T.</div><div class="citationInfo"><span class="NLM_cas:title">Neuroscience (Oxford)</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">97</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">155-170</span>CODEN:
                <span class="NLM_cas:coden">NRSCDN</span>;
        ISSN:<span class="NLM_cas:issn">0306-4522</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">To characterize the localization of the sigma1 receptor in the adult rat central nervous system, a polyclonal antibody was raised against a 20 amino acid peptide, corresponding to the fragment 143-162 of the cloned sigma1 receptor protein.  Throughout the rostrocaudal regions of the central nervous system extending from the olfactory bulb to the spinal cord, intense to moderate immunostaining was found to be assocd. with: (i) ependymocytes bordering the entire ventricular system, and (ii) neuron-like structures located within the parenchyma.  Double fluorescence studies confirmed that, throughout the parenchyma, sigma1 receptor-immunostaining was essentially assocd. with neuronal structures immunostained for the neuronal marker βIII-tubulin.  In all rats examd., high levels of immunostaining were always assocd. with neurons located within specific regions including the granular layer of the olfactory bulb, various hypothalamic nuclei, the septum, the central gray, motor nuclei of the hindbrain and the dorsal horn of the spinal cord.  In contrast, only faint immunostaining was assocd. with neurons located in the caudate-putamen and the cerebellum.  Electron microscope studies indicated that sigma1 receptor immunostaining was mostly assocd. with neuronal perikarya and dendrites, where it was localized to the limiting plasma membrane, the membrane of mitochondria and of some cisternae of the endoplasmic reticulum.  At the level of synaptic contacts, intense immunostaining was assocd. with postsynaptic structures including the postsynaptic thickening and some polymorphous vesicles, whereas the presynaptic axons were devoid of immunostaining.  These data indicate that the sigma1 receptor antibody prepd. here, represents a promising tool for further investigating the role of σ1 receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqsAacDelSDfbVg90H21EOLACvtfcHk0lgpwroLHdFWjQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXisFGhurg%253D&md5=2df1ba6a60488364ad458069e059354d</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.1016%2FS0306-4522%2800%2900014-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0306-4522%252800%252900014-2%26sid%3Dliteratum%253Aachs%26aulast%3DAlonso%26aufirst%3DG.%26aulast%3DPhan%26aufirst%3DV.%26aulast%3DGuillemain%26aufirst%3DI.%26aulast%3DSaunier%26aufirst%3DM.%26aulast%3DLegrand%26aufirst%3DA.%26aulast%3DAnoal%26aufirst%3DM.%26aulast%3DMaurice%26aufirst%3DT.%26atitle%3DImmunocytochemical%2520localization%2520of%2520the%2520sigma%25281%2529%2520receptor%2520in%2520the%2520adult%2520rat%2520central%2520nervous%2520system%26jtitle%3DNeuroscience%26date%3D2000%26volume%3D97%26spage%3D155%26epage%3D170%26doi%3D10.1016%2FS0306-4522%2800%2900014-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref106"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref106'); return false;" data-citation="" class="refNumLink">106</a></strong><div class="NLM_citation" id="cit106"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tseng, L. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hogan, Q. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, H. E.</span></span> <span> </span><span class="NLM_article-title">(+)-Morphine attenuates the (−)-morphine-produced tail-flick inhibition via the sigma-1 receptor in the mouse spinal cord</span>. <i>Life Sci.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>89</i></span>,  <span class="NLM_fpage">875</span>– <span class="NLM_lpage">877</span>, <span class="refDoi"> DOI: 10.1016/j.lfs.2011.09.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1016%2Fj.lfs.2011.09.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=21989208" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsV2msr%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=89&publication_year=2011&pages=875-877&author=L.+F.+Tsengauthor=Q.+H.+Hoganauthor=H.+E.+Wu&title=%28%2B%29-Morphine+attenuates+the+%28%E2%88%92%29-morphine-produced+tail-flick+inhibition+via+the+sigma-1+receptor+in+the+mouse+spinal+cord&doi=10.1016%2Fj.lfs.2011.09.018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">(+)-Morphine attenuates the (-)-morphine-produced tail-flick inhibition via the sigma-1 receptor in the mouse spinal cord</span></div><div class="casAuthors">Tseng, Leon F.; Hogan, Quinn H.; Wu, Hsiang-En</div><div class="citationInfo"><span class="NLM_cas:title">Life Sciences</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">89</span>
        (<span class="NLM_cas:issue">23-24</span>),
    <span class="NLM_cas:pages">875-877</span>CODEN:
                <span class="NLM_cas:coden">LIFSAK</span>;
        ISSN:<span class="NLM_cas:issn">0024-3205</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Aims: We have previously demonstrated that pretreatment with (+)-morphine given intrathecally attenuates the intrathecal (-)-morphine-produced tail-flick inhibition.  The phenomenon has been defined as antianalgesia against (-)-morphine-produced analgesia.  Present expts. were then undertaken to det. if the antianalgesic effect induced by (+)-morphine given spinally is mediated by the stimulation of the sigma-1 receptor in the mouse spinal cord.  Main methods: Sigma-1 receptor ligands, N-[2-(3,4-Dichlorophenyl)ethyl]-N-methyl-2-(dimethylamino)ethylamine dihydrobromide (BD1047) and (+)-pentazocine were used to det. if (+)-morphine-induced antianalgesia is mediated by the stimulation of sigma-1 receptors in the mouse spinal cord.  Tail-flick test was employed to measure the nociceptive response.  All compds. were given intrathecally.  Key findings: Pretreatment with BD1047 (1-10 μg) or (+)-pentazocine (0.1-10 μg) dose-dependently reversed the attenuation of the (-)-morphine-produced tail-flick inhibition induced by (+)-morphine (10 pg).  BD1047 and (+)-pentazocine injected alone did not affect (-)-morphine-produced tail-flick inhibition.  Significance: The finding indicates that (+)-morphine attenuates the (-)-morphine-produced tail-flick inhibition via the activation of the sigma-1 receptors in the mouse spinal cord.  Sigma-1 receptors may play an important role in opioid analgesia in the mouse spinal cord.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYY2oyslQc3rVg90H21EOLACvtfcHk0lgpwroLHdFWjQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsV2msr%252FO&md5=d86f7a9043beada5e17931f17e92a866</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1016%2Fj.lfs.2011.09.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.lfs.2011.09.018%26sid%3Dliteratum%253Aachs%26aulast%3DTseng%26aufirst%3DL.%2BF.%26aulast%3DHogan%26aufirst%3DQ.%2BH.%26aulast%3DWu%26aufirst%3DH.%2BE.%26atitle%3D%2528%252B%2529-Morphine%2520attenuates%2520the%2520%2528%25E2%2588%2592%2529-morphine-produced%2520tail-flick%2520inhibition%2520via%2520the%2520sigma-1%2520receptor%2520in%2520the%2520mouse%2520spinal%2520cord%26jtitle%3DLife%2520Sci.%26date%3D2011%26volume%3D89%26spage%3D875%26epage%3D877%26doi%3D10.1016%2Fj.lfs.2011.09.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref107"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref107'); return false;" data-citation="" class="refNumLink">107</a></strong><div class="NLM_citation" id="cit107"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Merlos, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burgueño, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Portillo-Salido, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plata-Salamán, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vela, J. M.</span></span> <span> </span><span class="NLM_article-title">Pharmacological Modulation of the Sigma 1 Receptor and the Treatment of Pain</span>. <i>Adv. Exp. Med. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>964</i></span>,  <span class="NLM_fpage">85</span>– <span class="NLM_lpage">107</span>, <span class="refDoi"> DOI: 10.1007/978-3-319-50174-1_8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1007%2F978-3-319-50174-1_8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=28315267" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtFegtb7O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=964&publication_year=2017&pages=85-107&author=M.+Merlosauthor=J.+Burgue%C3%B1oauthor=E.+Portillo-Salidoauthor=C.+R.+Plata-Salam%C3%A1nauthor=J.+M.+Vela&title=Pharmacological+Modulation+of+the+Sigma+1+Receptor+and+the+Treatment+of+Pain&doi=10.1007%2F978-3-319-50174-1_8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit107R"><div class="casContent"><span class="casTitleNuber">107</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological modulation of the sigma 1 receptor and the treatment of pain</span></div><div class="casAuthors">Merlos, Manuel; Burgueno, Javier; Portillo-Salido, Enrique; Plata-Salaman, Carlos Ramon; Vela, Jose Miguel</div><div class="citationInfo"><span class="NLM_cas:title">Advances in Experimental Medicine and Biology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">964</span>
        (<span class="NLM_cas:issue">Sigma Receptors: Their Role in Disease and as Therapeutic Targets</span>),
    <span class="NLM_cas:pages">85-107</span>CODEN:
                <span class="NLM_cas:coden">AEMBAP</span>;
        ISSN:<span class="NLM_cas:issn">2214-8019</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">There is a crit. need for new analgesics acting through new mechanisms of action, which could increase the efficacy with respect to existing therapies and reduce their unwanted effects.  Current preclin. evidence supports the modulatory role of sigma-1 receptors (σ1R) in nociception, mainly based on the pain-attenuated phenotype of σ1R knockout mice and on the antinociceptive effect exerted by σ1R antagonists on pains of different etiologies. σ1R is highly expressed in different pain areas of the CNS and the periphery (particularly dorsal root ganglia), and interacts and modulates the functionality of different receptors and ion channels.  The antagonism of σ1R leads to decreased amplification of pain signaling within the spinal cord (central sensitization), but recent data also support a role at the periphery. σ1R antagonists have consistently demonstrated efficacy in neuropathic pain, but also in other types of pain including inflammatory, orofacial, visceral, and post-operative pain.  Apart from acting alone, when combined with opioids, σ1R antagonists enhance opioid analgesia but not opioid-induced unwanted effects.  Interestingly, unlike opioids, σ1R antagonists do not modify normal sensory mech. and thermal sensitivity thresholds but they exert antihypersensitive effects in sensitizing conditions, enabling the reversal of nociceptive thresholds back to normal values.  Accordingly, σ1R antagonists are not strictly analgesics; they are antiallodynic and antihyperalgesic drugs acting when the system is sensitized following prolonged noxious stimulation or persistent abnormal afferent input (e.g., secondary to nerve injury).  These are distinctive features allowing σ1R antagonists to exert a modulatory effect specifically in pathophysiol. conditions such as chronic pain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwcRJqz4BxF7Vg90H21EOLACvtfcHk0lgpwroLHdFWjQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtFegtb7O&md5=212a8fac96a772a7888762da8e70fc0d</span></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1007%2F978-3-319-50174-1_8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-3-319-50174-1_8%26sid%3Dliteratum%253Aachs%26aulast%3DMerlos%26aufirst%3DM.%26aulast%3DBurgue%25C3%25B1o%26aufirst%3DJ.%26aulast%3DPortillo-Salido%26aufirst%3DE.%26aulast%3DPlata-Salam%25C3%25A1n%26aufirst%3DC.%2BR.%26aulast%3DVela%26aufirst%3DJ.%2BM.%26atitle%3DPharmacological%2520Modulation%2520of%2520the%2520Sigma%25201%2520Receptor%2520and%2520the%2520Treatment%2520of%2520Pain%26jtitle%3DAdv.%2520Exp.%2520Med.%2520Biol.%26date%3D2017%26volume%3D964%26spage%3D85%26epage%3D107%26doi%3D10.1007%2F978-3-319-50174-1_8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref108"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref108'); return false;" data-citation="" class="refNumLink">108</a></strong><div class="NLM_citation" id="cit108"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chambers, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Billington, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knight, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Middlemiss, D. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, E. H.</span></span> <span> </span><span class="NLM_article-title">Spiropiperidines as high-affinity, selective sigma ligands</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1992</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">2033</span>– <span class="NLM_lpage">2039</span>, <span class="refDoi"> DOI: 10.1021/jm00089a013</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00089a013" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADyaK38XisFGntrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=1992&pages=2033-2039&author=M.+S.+Chambersauthor=R.+Bakerauthor=D.+C.+Billingtonauthor=A.+K.+Knightauthor=D.+N.+Middlemissauthor=E.+H.+Wong&title=Spiropiperidines+as+high-affinity%2C+selective+sigma+ligands&doi=10.1021%2Fjm00089a013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit108R"><div class="casContent"><span class="casTitleNuber">108</span><div class="casTitle"><span class="NLM_cas:atitle">Spiropiperidines as high-affinity, selective σ ligands.</span></div><div class="casAuthors">Chambers, Mark S.; Baker, Raymond; Billington, David C.; Knight, Anthony K.; Middlemiss, D. N.; Wong, Eric H. F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2033-9</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    </div><div class="casAbstract">A variety of achiral conformationally restricted spirocyclic piperidines were prepd. in an attempt to investigate the functional role of the central σ recognition site.  All compds. possessed a lipophilic N-substituent incorporating either a tetralin (I; n = 2, R = PhCH2, Bu, hexyl, 2-picolyl, cyclohexylmethyl, CH2CH:CH2, 2-furylmethyl, 2-thienylmethyl, CH2CH:CMe2, etc.), indan (I; n = 1, R = PhCH2, PhCH2CH2, CH2CH:CMe2, Bu, etc.), or benzocycloheptane skeleton (I; n = 3, R = PhCH2, Bu).  Their in vitro affinity at the σ site was assessed in radioligand displacement expts. with guinea pig cerebellum homogenates using the σ-specific radioligand N,N-di-o-[5-3H]-tolylguanidine (II).  A study of the structure-activity relationships identified the N-Bu and N-dimethylallyl substituents as the optimum groups for high affinity and selectivity at the σ site, e.g., I (n = 1, R = CH2CH:CMe2), pIC50 = 8.9 vs II and >10,000-fold selective over the dopamine D2 receptor.  Such compds. are amongst the highest affinity σ ligands reported to date, with excellent selectivity over the dopamine D2 receptor, and may serve as a useful tool for exploring the physiol. role of the σ site.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr90qP5qz7Mm7Vg90H21EOLACvtfcHk0li24508bKAF7A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK38XisFGntrg%253D&md5=1d61ff31c46c1c2febdfccd3673799da</span></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1021%2Fjm00089a013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00089a013%26sid%3Dliteratum%253Aachs%26aulast%3DChambers%26aufirst%3DM.%2BS.%26aulast%3DBaker%26aufirst%3DR.%26aulast%3DBillington%26aufirst%3DD.%2BC.%26aulast%3DKnight%26aufirst%3DA.%2BK.%26aulast%3DMiddlemiss%26aufirst%3DD.%2BN.%26aulast%3DWong%26aufirst%3DE.%2BH.%26atitle%3DSpiropiperidines%2520as%2520high-affinity%252C%2520selective%2520sigma%2520ligands%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1992%26volume%3D35%26spage%3D2033%26epage%3D2039%26doi%3D10.1021%2Fjm00089a013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref109"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref109'); return false;" data-citation="" class="refNumLink">109</a></strong><div class="NLM_citation" id="cit109"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moltzen, E. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perregaard, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meier, E.</span></span> <span> </span><span class="NLM_article-title">Sigma ligands with subnanomolar affinity and preference for the sigma 2 binding site. 2. Spiro-joined benzofuran, isobenzofuran, and benzopyran piperidines</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">2009</span>– <span class="NLM_lpage">2017</span>, <span class="refDoi"> DOI: 10.1021/jm00011a020</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00011a020" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADyaK2MXls1yqt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=1995&pages=2009-2017&author=E.+K.+Moltzenauthor=J.+Perregaardauthor=E.+Meier&title=Sigma+ligands+with+subnanomolar+affinity+and+preference+for+the+sigma+2+binding+site.+2.+Spiro-joined+benzofuran%2C+isobenzofuran%2C+and+benzopyran+piperidines&doi=10.1021%2Fjm00011a020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit109R"><div class="casContent"><span class="casTitleNuber">109</span><div class="casTitle"><span class="NLM_cas:atitle">σ Ligands with Subnanomolar Affinity and Preference for the σ2 Binding Site. 2. Spiro-Joined Benzofuran, Isobenzofuran, and Benzopyran Piperidines</span></div><div class="casAuthors">Moltzen, Ejner K.; Perregaard, Jens; Meier, Eddi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2009-17</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">MSpiro[isobenzofuran-1(3H),4'-piperidines] and the corresponding benzofuran and benzopyran derivs. were synthesized and evaluated as σ ligands.  The compds. are related to Lu 28-179 that has been demonstrated to be a selective σ2 ligand with affinity in the subnanomolar range.  The object of the study was to det. the structural factors governing σ1/σ2 affinity and selectivity within this class of compds.  The N-substituent in spiro[isobenzofuran-1(3H),4'-piperidines] is highly important, both for affinity and selectivity.  Spiropiperidines with no or small N-substituents (H, Me, Et) exert very low affinity for both σ1 and σ2 binding sites (IC50(σ1,σ2) > 100 nM), whereas medium-sized substituents (e.g., Pr, Bu, Ph(CH2)2) result in potent, but unselective compds. (IC50(σ1,σ2) = 2-5 nM).  Increasing the chain length and the lipophilicity of the N-substituent result in compds. in which high affinity for σ2 binding sites is retained and with selectivity for σ2 vs σ1 binding sites (e.g., 4-cyclohexyl-1-butyl: IC50(σ1) = 1.5 nM, IC50(σ2) = 0.07 nM).  Introduction of substituents in the benzene ring of the spiro[isobenzofuran-1(3H),4'-piperidine] ring system of Lu 28-179 mainly affects affinity for σ1 binding sites.  Compds. with substituents (F, CF3) in the 4- or 7-position of the isobenzofuran display high affinity for σ2 binding sites (IC50(σ2) = 0.5-2 nM) and very low affinity for σ1 binding sites (IC50(σ1) > 100 nM).  Compds. with substituents (F, CF3, Me) in the 5- or 6-position of the isobenzofuran exert increased affinity for σ1 binding sites (IC50(σ1) = 5-30 nM, IC50(σ2) = 0.3-7 nM), thus rendering unselective compds.  Exchanging the isobenzofuran moiety of Lu 28-179 with thioisobenzofuran, benzofuran, or benzopyran also has a pronounced effect on both affinity and selectivity for σ binding sites.  The position of the oxygen atom and the position of the spiroconnection with the 4-position of the piperidine ring were varied, and only compds. in which both the benzene ring and the heteroatom are attached directly to the piperidine ring retain high affinity and selectivity for σ2 binding sites (e.g., 3,4-dihydro-1'-[4-[1-(4-fluorophenyl)-1H-indol-3-yl]-1-butyl]spiro[1H-2-benzopyran-1,4'- piperidine]: IC50(σ1) = 53 nM, IC50(σ2) = 0.9 nM).  All other variations result either in unselective compds. or in compds. with low affinity for σ binding sites.  The data presented provide detailed information concerning structural requirements for binding to σ1 and σ2 binding sites, resp., and together with Lu 28-179, some of the compds. presented in this work belong to the most potent and selective σ2 ligands described so far.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovu0LdT7foS7Vg90H21EOLACvtfcHk0li24508bKAF7A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXls1yqt70%253D&md5=4d3db3729dd2c7ab50529eac32ac7225</span></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1021%2Fjm00011a020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00011a020%26sid%3Dliteratum%253Aachs%26aulast%3DMoltzen%26aufirst%3DE.%2BK.%26aulast%3DPerregaard%26aufirst%3DJ.%26aulast%3DMeier%26aufirst%3DE.%26atitle%3DSigma%2520ligands%2520with%2520subnanomolar%2520affinity%2520and%2520preference%2520for%2520the%2520sigma%25202%2520binding%2520site.%25202.%2520Spiro-joined%2520benzofuran%252C%2520isobenzofuran%252C%2520and%2520benzopyran%2520piperidines%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1995%26volume%3D38%26spage%3D2009%26epage%3D2017%26doi%3D10.1021%2Fjm00011a020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref110"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref110'); return false;" data-citation="" class="refNumLink">110</a></strong><div class="NLM_citation" id="cit110"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maier, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wünsch, B.</span></span> <span> </span><span class="NLM_article-title">Novel spiropiperidines as highly potent and subtype selective sigma-receptor ligands. Part 1</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">438</span>– <span class="NLM_lpage">448</span>, <span class="refDoi"> DOI: 10.1021/jm010992z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm010992z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BD3MXptFyjsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2002&pages=438-448&author=C.+A.+Maierauthor=B.+W%C3%BCnsch&title=Novel+spiropiperidines+as+highly+potent+and+subtype+selective+sigma-receptor+ligands.+Part+1&doi=10.1021%2Fjm010992z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit110R"><div class="casContent"><span class="casTitleNuber">110</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Spiropiperidines as Highly Potent and Subtype Selective σ-Receptor Ligands. Part 1</span></div><div class="casAuthors">Maier, Christoph A.; Wuensch, Bernhard</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">438-448</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of spiro[[2]benzopyran-1,4'-piperidines] and spiro[[2]benzofuran-1,4'-piperidines] of general structure I [X = (CH2)n] is prepd., and the affinity for σ1- and σ2-receptors is investigated by means of radioligand binding assays.  The synthesis of the spiropiperidines, 1'-benzyl-3-methoxy-3,4-dihydrospiro[[2]benzopyran-1,4'-piperidine] (II) and the 1'-benzyl-3-methoxy-3H-spiro[[2]benzofuran-1,4'-piperidine] (III), proceeds via bromine/lithium exchange of the bromoacetals, e.g., 2-(2-bromophenyl)acetaldehyde di-Me acetal in the case of II, addn. to N-benzylpiperidin-4-one, and subsequent cyclization.  Systematic variations of the substituent R at the nitrogen atom, the group Y in position 3, and the ring size of the oxygen heterocycle are performed.  The σ1- and σ2-receptor affinities are detd. with guinea pig brain and rat liver membrane prepns. using [3H]-labeled (+)-pentazocine and ditolylguanidine, resp.  Test results show that a benzyl residue at the piperidine nitrogen atom and a methoxy group in position 3 are advantageous for high σ1-receptor affinity.  In this series II and III are among the most potent σ1-ligands interacting in the low nanomolar range with σ1-receptors (14a, Ki = 1.29 nM; 23, Ki = 1.14 nM).  Variation of the nitrogen substituent R from benzyl to H, alkyl, Ph, or ω-phenylalkyl and the group Y from methoxy to hydroxy, carbonyl, or alkyloxy led to reduced σ1-receptor affinity.  In addn. to their high σ1-receptor affinity, the spiropiperidines II and III display excellent selectivity toward σ2-receptors (σ1/σ2 = 2708 and 1130) and several other receptor and reuptake systems.  Introduction of a polar hydroxy group in position 3 and elongation of the distance between the piperidine nitrogen atom and the Ph moiety result in ligands with considerable σ2-receptor affinity and therefore diminished σ1/σ2-receptor selectivity.  The hemiacetalic 1'-(3-phenylpropyl)-3,4-dihydrospiro[[2]benzopyran-1,4'-piperidin]-3-ol represents the most active σ2-receptor ligand in this series with a Ki value of 83.1 nM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfVYGDmsjdLLVg90H21EOLACvtfcHk0li24508bKAF7A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXptFyjsLg%253D&md5=13fb1c59fd2f82c128a18d487a6ee8b8</span></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.1021%2Fjm010992z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm010992z%26sid%3Dliteratum%253Aachs%26aulast%3DMaier%26aufirst%3DC.%2BA.%26aulast%3DW%25C3%25BCnsch%26aufirst%3DB.%26atitle%3DNovel%2520spiropiperidines%2520as%2520highly%2520potent%2520and%2520subtype%2520selective%2520sigma-receptor%2520ligands.%2520Part%25201%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2002%26volume%3D45%26spage%3D438%26epage%3D448%26doi%3D10.1021%2Fjm010992z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref111"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref111'); return false;" data-citation="" class="refNumLink">111</a></strong><div class="NLM_citation" id="cit111"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neue, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schepmann, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yanagisawa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamaguchi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Würthwein, E. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Itami, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wünsch, B.</span></span> <span> </span><span class="NLM_article-title">Exploitation of an additional hydrophobic pocket of σ1 receptors: late-stage diverse modifications of spirocyclic thiophenes by C-H bond functionalization</span>. <i>Org. Biomol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">8016</span>– <span class="NLM_lpage">8029</span>, <span class="refDoi"> DOI: 10.1039/c1ob06149f</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1039%2Fc1ob06149f" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=21986584" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVGmt7fP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2011&pages=8016-8029&author=C.+Meyerauthor=B.+Neueauthor=D.+Schepmannauthor=S.+Yanagisawaauthor=J.+Yamaguchiauthor=E.+U.+W%C3%BCrthweinauthor=K.+Itamiauthor=B.+W%C3%BCnsch&title=Exploitation+of+an+additional+hydrophobic+pocket+of+%CF%831+receptors%3A+late-stage+diverse+modifications+of+spirocyclic+thiophenes+by+C-H+bond+functionalization&doi=10.1039%2Fc1ob06149f"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit111R"><div class="casContent"><span class="casTitleNuber">111</span><div class="casTitle"><span class="NLM_cas:atitle">Exploitation of an additional hydrophobic pocket of σ1 receptors: Late-stage diverse modifications of spirocyclic thiophenes by C-H bond functionalization</span></div><div class="casAuthors">Meyer, Christina; Neue, Benedikt; Schepmann, Dirk; Yanagisawa, Shuichi; Yamaguchi, Junichiro; Wuerthwein, Ernst-Ulrich; Itami, Kenichiro; Wuensch, Bernhard</div><div class="citationInfo"><span class="NLM_cas:title">Organic & Biomolecular Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">8016-8029</span>CODEN:
                <span class="NLM_cas:coden">OBCRAK</span>;
        ISSN:<span class="NLM_cas:issn">1477-0520</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">The hypothesis that the σ1 receptor will tolerate an addnl. aryl moiety in position 1 of the spirocyclic system was based on spirocyclic pyrazole derivs., pharmacophore models of σ1 receptor ligands and DFT calcns.  The strategy of introducing the aryl residue at the final step of the synthesis allowed the prepn. of a large set of diverse ligands for the exploitation of the hydrophobic pocket of the σ1 receptor protein.  The catalyst system PdCl2/2,2'-bipyridyl/Ag2CO3 is able to introduce various aryl groups onto the α-positions of spirocyclic thiophene derivs. to afford the target aryl-appended spirocyclic thiophenes .  Although the σ1 affinity of the 1-Ph substituted spirocyclic thiophenes is slightly reduced compared with the σ1 affinity of the non-arylated compds. , both compds. represent very potent σ1 receptor ligands (3a: Ki = 4.5 nM; 4a: Ki = 1.0 nM).  This result indicates that an aryl moiety in position 1 is well tolerated by the σ1 receptor protein.  The substitution pattern of the addnl. Ph moiety has only weak effects on the σ1 affinity.  Decrease of σ1 affinity by extension of the π-system to a biphenylyl substituent (: Ki = 30 nM) indicates that the biphenylyl residue is too large for the primary hydrophobic binding pocket of the σ1 receptor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpaw7IyfcAY7Vg90H21EOLACvtfcHk0liMG_TYZZCjfA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVGmt7fP&md5=7390f878648e602f7339c987eb62fe8f</span></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1039%2Fc1ob06149f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc1ob06149f%26sid%3Dliteratum%253Aachs%26aulast%3DMeyer%26aufirst%3DC.%26aulast%3DNeue%26aufirst%3DB.%26aulast%3DSchepmann%26aufirst%3DD.%26aulast%3DYanagisawa%26aufirst%3DS.%26aulast%3DYamaguchi%26aufirst%3DJ.%26aulast%3DW%25C3%25BCrthwein%26aufirst%3DE.%2BU.%26aulast%3DItami%26aufirst%3DK.%26aulast%3DW%25C3%25BCnsch%26aufirst%3DB.%26atitle%3DExploitation%2520of%2520an%2520additional%2520hydrophobic%2520pocket%2520of%2520%25CF%25831%2520receptors%253A%2520late-stage%2520diverse%2520modifications%2520of%2520spirocyclic%2520thiophenes%2520by%2520C-H%2520bond%2520functionalization%26jtitle%3DOrg.%2520Biomol.%2520Chem.%26date%3D2011%26volume%3D9%26spage%3D8016%26epage%3D8029%26doi%3D10.1039%2Fc1ob06149f" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref112"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref112'); return false;" data-citation="" class="refNumLink">112</a></strong><div class="NLM_citation" id="cit112"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nicholson, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mesangeau, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCurdy, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowen, W. D.</span></span> <span> </span><span class="NLM_article-title">Sigma-2 Receptors Play a Role in Cellular Metabolism: Stimulation of Glycolytic Hallmarks by CM764 in Human SK-N-SH Neuroblastoma</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>356</i></span>,  <span class="NLM_fpage">232</span>– <span class="NLM_lpage">243</span>, <span class="refDoi"> DOI: 10.1124/jpet.115.228387</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1124%2Fjpet.115.228387" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=26574517" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsFGjt7zF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=356&publication_year=2016&pages=232-243&author=H.+Nicholsonauthor=C.+Mesangeauauthor=C.+R.+McCurdyauthor=W.+D.+Bowen&title=Sigma-2+Receptors+Play+a+Role+in+Cellular+Metabolism%3A+Stimulation+of+Glycolytic+Hallmarks+by+CM764+in+Human+SK-N-SH+Neuroblastoma&doi=10.1124%2Fjpet.115.228387"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit112R"><div class="casContent"><span class="casTitleNuber">112</span><div class="casTitle"><span class="NLM_cas:atitle">Sigma-2 receptors play a role in cellular metabolism: stimulation of glycolytic hallmarks by CM764 in human SK-N-SH neuroblastoma</span></div><div class="casAuthors">Nicholson, Hilary; Mesangeau, Christophe; McCurdy, Christopher R.; Bowen, Wayne D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">356</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">232-243</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Sigma-2 receptors are attractive antineoplastic targets due to their ability to induce apoptosis and their upregulation in rapidly proliferating cancer cells compared with healthy tissue.  However, this role is inconsistent with overexpression in cancer, which is typically assocd. with upregulation of prosurvival factors.  Here, we report a novel metabolic regulatory function for sigma-2 receptors.  CM764 [6-acetyl-3-(4-(4-(2-amino-4-fluorophenyl)piperazin-1-yl)butyl)benzo[d]oxazol-2(3H)-one] binds with Ki values of 86.6 ± 2.8 and 3.5 ± 0.9 nM at the sigma-1 and sigma-2 receptors, resp.  CM764 increased redn. of MTT [3-[4,5 dimethylthiazol-2-yl]-2,5 diphenyltetrazolium bromide] in human SK-N-SH neuroblastoma compared with untreated cells, an effect not due to proliferation.  This effect was attenuated by five different sigma antagonists, including CM572 [3-(4-(4-(4-fluorophenyl)piperazin-1-yl)butyl)-6-isothiocyanatobenzo[d]oxazol-2(3H)-one], which has no significant affinity for sigma-1 receptors.  This effect was also obsd. in MG-63 osteosarcoma and HEK293T cells, indicating that this function is not exclusive to neuroblastoma or to cancer cells.  CM764 produced an immediate, robust, and transient increase in cytosolic calcium, consistent with sigma-2 receptor activation.  Addnl., we obsd. an increase in the total NAD+/NADH level and the ATP level in CM764-treated SK-N-SH cells compared with untreated cells.  After only 4 h of treatment, basal levels of reactive oxygen species were reduced by 90% in cells treated with CM764 over untreated cells, and HIF1α and VEGF levels were increased after 3-24 h of treatment.  These data indicate that sigma-2 receptors may play a role in induction of glycolysis, representing a possible prosurvival function for the sigma-2 receptor that is consistent with its upregulation in cancer cells compared with healthy tissue.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtpMnc20DMxbVg90H21EOLACvtfcHk0liMG_TYZZCjfA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsFGjt7zF&md5=91ec2b962d347ff47ebfa98342ca0dca</span></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.1124%2Fjpet.115.228387&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.115.228387%26sid%3Dliteratum%253Aachs%26aulast%3DNicholson%26aufirst%3DH.%26aulast%3DMesangeau%26aufirst%3DC.%26aulast%3DMcCurdy%26aufirst%3DC.%2BR.%26aulast%3DBowen%26aufirst%3DW.%2BD.%26atitle%3DSigma-2%2520Receptors%2520Play%2520a%2520Role%2520in%2520Cellular%2520Metabolism%253A%2520Stimulation%2520of%2520Glycolytic%2520Hallmarks%2520by%2520CM764%2520in%2520Human%2520SK-N-SH%2520Neuroblastoma%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2016%26volume%3D356%26spage%3D232%26epage%3D243%26doi%3D10.1124%2Fjpet.115.228387" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref113"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref113'); return false;" data-citation="" class="refNumLink">113</a></strong><div class="NLM_citation" id="cit113"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schepmann, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neue, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westphälinger, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bracher, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lange, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bednarski, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Almansa, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedland, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Räbiger, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Düfer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wünsch, B.</span></span> <span> </span><span class="NLM_article-title">Pharmacological characterization of high-affinity σ(1) receptor ligands with spirocyclic thienopyran and thienofuran scaffold</span>. <i>J. Pharm. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>72</i></span>,  <span class="NLM_fpage">236</span>– <span class="NLM_lpage">248</span>, <span class="refDoi"> DOI: 10.1111/jphp.13196</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1111%2Fjphp.13196" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=31743446" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitFOru7vO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2020&pages=236-248&author=D.+Schepmannauthor=C.+Neueauthor=S.+Westph%C3%A4lingerauthor=C.+M%C3%BCllerauthor=F.+Bracherauthor=C.+Langeauthor=P.+Bednarskiauthor=C.+Almansaauthor=K.+Friedlandauthor=V.+R%C3%A4bigerauthor=M.+D%C3%BCferauthor=B.+W%C3%BCnsch&title=Pharmacological+characterization+of+high-affinity+%CF%83%281%29+receptor+ligands+with+spirocyclic+thienopyran+and+thienofuran+scaffold&doi=10.1111%2Fjphp.13196"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit113R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological characterization of high-affinity s1 receptor ligands with spirocyclic thienopyran and thienofuran scaffold</span></div><div class="casAuthors">Schepmann, Dirk; Neue, Christina; Westphaelinger, Stefanie; Mueller, Christoph; Bracher, Franz; Lange, Carsten; Bednarski, Patrick; Almansa, Carmen; Friedland, Kristina; Raebiger, Vivien; Duefer, Martina; Wuensch, Bernhard</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacy and Pharmacology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">236-248</span>CODEN:
                <span class="NLM_cas:coden">JPPMAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3573</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">In this study, the pharmacol. properties of six spirocyclic piperidines 1-6 showing very high s1 receptor affinity (Ki = 0.2-16 nM) were investigated.  In vitro receptor binding studies, retinal ganglion assay and in vivo capsaicin assay were used to det. the affinity, selectivity and activity.  Influence on human tumor cell growth (cell lines A427, LCLC-103H, 5637 and DAN-G) was detd. in different assays.  The effect on the ergosterol and cholesterol biosynthesis was detd. by GLC/MS anal.  Receptor binding studies demonstrated high selectivity for the s1 receptor.  The increased Ca2+ influx mediated by 2 and the analgesic activity of 1, 4, 5 and 6 confirm s1 receptor antagonistic activity.  Inhibition of human tumor cell growth further supports the s1 antagonistic effects.  Treatment of A427 tumor cells with 2 led to cell detachment and cell degrdn.  Whereas the ergosterol biosynthesis was not affected, the sterol C14-reductase, a key enzyme in the cholesterol biosynthesis, was weakly inhibited.  Due to the high selectivity, off-target effects are not expected.  The antiallodynic activity underlines the clin. potential of the spirocyclic piperidines for the treatment of neuropathic pain.  Due to the antiproliferative activity, the spirocyclic s1 antagonists represent promising antitumor agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxRwwNlSXePLVg90H21EOLACvtfcHk0liMG_TYZZCjfA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitFOru7vO&md5=408d16fe23a338e8c25f374d918c6d60</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1111%2Fjphp.13196&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fjphp.13196%26sid%3Dliteratum%253Aachs%26aulast%3DSchepmann%26aufirst%3DD.%26aulast%3DNeue%26aufirst%3DC.%26aulast%3DWestph%25C3%25A4linger%26aufirst%3DS.%26aulast%3DM%25C3%25BCller%26aufirst%3DC.%26aulast%3DBracher%26aufirst%3DF.%26aulast%3DLange%26aufirst%3DC.%26aulast%3DBednarski%26aufirst%3DP.%26aulast%3DAlmansa%26aufirst%3DC.%26aulast%3DFriedland%26aufirst%3DK.%26aulast%3DR%25C3%25A4biger%26aufirst%3DV.%26aulast%3DD%25C3%25BCfer%26aufirst%3DM.%26aulast%3DW%25C3%25BCnsch%26aufirst%3DB.%26atitle%3DPharmacological%2520characterization%2520of%2520high-affinity%2520%25CF%2583%25281%2529%2520receptor%2520ligands%2520with%2520spirocyclic%2520thienopyran%2520and%2520thienofuran%2520scaffold%26jtitle%3DJ.%2520Pharm.%2520Pharmacol.%26date%3D2020%26volume%3D72%26spage%3D236%26epage%3D248%26doi%3D10.1111%2Fjphp.13196" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref114"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref114'); return false;" data-citation="" class="refNumLink">114</a></strong><div class="NLM_citation" id="cit114"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kokornaczyk, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schepmann, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamaguchi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Itami, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laurini, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fermeglia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pricl, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wünsch, B.</span></span> <span> </span><span class="NLM_article-title">Thiazole-Based σ(1) Receptor Ligands: Diversity by Late-Stage C-H Arylation of Thiazoles, Structure-Affinity and Selectivity Relationships, and Molecular Interactions</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">1070</span>– <span class="NLM_lpage">1080</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201700166</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1002%2Fcmdc.201700166" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=28544475" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtVarsL3K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2017&pages=1070-1080&author=A.+K.+Kokornaczykauthor=D.+Schepmannauthor=J.+Yamaguchiauthor=K.+Itamiauthor=E.+Lauriniauthor=M.+Fermegliaauthor=S.+Priclauthor=B.+W%C3%BCnsch&title=Thiazole-Based+%CF%83%281%29+Receptor+Ligands%3A+Diversity+by+Late-Stage+C-H+Arylation+of+Thiazoles%2C+Structure-Affinity+and+Selectivity+Relationships%2C+and+Molecular+Interactions&doi=10.1002%2Fcmdc.201700166"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit114R"><div class="casContent"><span class="casTitleNuber">114</span><div class="casTitle"><span class="NLM_cas:atitle">Thiazole-Based σ1 Receptor Ligands: Diversity by Late-Stage C-H Arylation of Thiazoles, Structure-Affinity and Selectivity Relationships, and Mol. Interactions</span></div><div class="casAuthors">Kokornaczyk, Artur K.; Schepmann, Dirk; Yamaguchi, Junichiro; Itami, Kenichiro; Laurini, Erik; Fermeglia, Maurizio; Pricl, Sabrina; Wuensch, Bernhard</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1070-1080</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Spirocyclic thiophene derivs. represent promising σ1 ligands with high σ1 affinity and selectivity over the σ2 subtype.  To increase ligand efficiency, the thiophene ring was replaced bioisosterically by a thiazole ring, and the pyran ring was opened.  Late-stage diversification by regioselective C-H arylation of thiazoles 9 a-c resulted in a set of 53 compds. with high diversity.  This set of compds. was analyzed with respect to σ1 affinity, σ1/σ2 selectivity, lipophilicity (logD7.4), lipophilicity-cor. ligand efficiency (LELP), and mol. target interactions.  The most promising candidates were pyridyl-substituted thiazole derivs. 33 c (2-(1-benzyl-4-ethoxypiperidin-4-yl)-5-(pyridin-3-yl)thiazole) and 34 c (2-(1-benzyl-4-ethoxypiperidin-4-yl)-5-(pyridin-4-yl)thiazole), possessing low-nanomolar σ1 affinity (Ki=1.3 and 1.9 nM), high σ1/σ2 selectivity (>1500-fold), low lipophilicity (logD7.4=1.8) and very good ligand efficiency (LELP=5.5), indicating promising pharmacodynamics and pharmacokinetics.  Mol. simulation studies, including docking and deconvolution of the free binding energy into its major components, led to decreased hydrophobic stabilization of pyridyl derivs. 33 c and 34 c, which was compensated by lower desolvation energy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpH1KP3Hivs9rVg90H21EOLACvtfcHk0lgwsuiAeeIcRw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtVarsL3K&md5=5317bdafd4f74079cf90fc4d86d751fa</span></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201700166&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201700166%26sid%3Dliteratum%253Aachs%26aulast%3DKokornaczyk%26aufirst%3DA.%2BK.%26aulast%3DSchepmann%26aufirst%3DD.%26aulast%3DYamaguchi%26aufirst%3DJ.%26aulast%3DItami%26aufirst%3DK.%26aulast%3DLaurini%26aufirst%3DE.%26aulast%3DFermeglia%26aufirst%3DM.%26aulast%3DPricl%26aufirst%3DS.%26aulast%3DW%25C3%25BCnsch%26aufirst%3DB.%26atitle%3DThiazole-Based%2520%25CF%2583%25281%2529%2520Receptor%2520Ligands%253A%2520Diversity%2520by%2520Late-Stage%2520C-H%2520Arylation%2520of%2520Thiazoles%252C%2520Structure-Affinity%2520and%2520Selectivity%2520Relationships%252C%2520and%2520Molecular%2520Interactions%26jtitle%3DChemMedChem%26date%3D2017%26volume%3D12%26spage%3D1070%26epage%3D1080%26doi%3D10.1002%2Fcmdc.201700166" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref115"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref115'); return false;" data-citation="" class="refNumLink">115</a></strong><div class="NLM_citation" id="cit115"><span><span class="NLM_contrib-group"><span class="NLM_string-name">de Costa, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowen, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hellewell, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">George, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rothman, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reid, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobson, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rice, K. C.</span></span> <span> </span><span class="NLM_article-title">Alterations in the stereochemistry of the kappa-selective opioid agonist U50,488 result in high-affinity sigma ligands</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1989</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">1996</span>– <span class="NLM_lpage">2002</span>, <span class="refDoi"> DOI: 10.1021/jm00128a050</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00128a050" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADyaL1MXkvFOjsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=1989&pages=1996-2002&author=B.+R.+de+Costaauthor=W.+D.+Bowenauthor=S.+B.+Hellewellauthor=C.+Georgeauthor=R.+B.+Rothmanauthor=A.+A.+Reidauthor=J.+M.+Walkerauthor=A.+E.+Jacobsonauthor=K.+C.+Rice&title=Alterations+in+the+stereochemistry+of+the+kappa-selective+opioid+agonist+U50%2C488+result+in+high-affinity+sigma+ligands&doi=10.1021%2Fjm00128a050"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit115R"><div class="casContent"><span class="casTitleNuber">115</span><div class="casTitle"><span class="NLM_cas:atitle">Alterations in the stereochemistry of the κ-selective opioid agonist U50,488 result in high-affinity σ ligands</span></div><div class="casAuthors">De Costa, Brian R.; Bowen, Wayne D.; Hellewell, Susan B.; George, Clifford; Rothman, Richard B.; Reid, Audrey A.; Walker, J. Michael; Jacobson, Arthur E.; Rice, Kenner C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1989</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1996-2002</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    </div><div class="casAbstract">The prepn. and in vitro σ receptor activity of (1R,2S)- (I) (R = 3,4-Cl2C6H3CH2CO throughout) and (1S,2R)-cis-3,4-dichloro-N-methyl-N-(2-pyrrolidinocyclohexyl)phenylacetamide (II) are described.  I and II are prepd. from (±)-trans-2-(methylamino)cyclohexanol (III).  III is converted to (±)-cis-2-pyrrolidino-N-methylcycohexylamine [(±)-IV] in 5 steps.  ±-IV is resolved with mandelic acid and the individual enantiomers coupled with ROH to give I and II.  I, II and their corresponding optically pure trans diastereomers V and VI were compared for their binding affinities at κ opioid, σ, D2-dopamine, and phencyclidine receptors in competitive binding assays.  V shows the highest affinity for κ receptors, and moderate affinity for σ receptors.  VI has low affinity for both receptors.  In contrast, I and II show high affinity for σ receptors and negligible affinity for κ opioid receptors.  V and VI lack affinity for D2-dopamine receptors.  I and II bind only weakly to these receptors.  All the compds. lack affinity for phencyclidine receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDId1AOnJ0Z7Vg90H21EOLACvtfcHk0lgwsuiAeeIcRw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1MXkvFOjsLY%253D&md5=1cebf875652a80a4407737d52a9a43f9</span></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.1021%2Fjm00128a050&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00128a050%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BCosta%26aufirst%3DB.%2BR.%26aulast%3DBowen%26aufirst%3DW.%2BD.%26aulast%3DHellewell%26aufirst%3DS.%2BB.%26aulast%3DGeorge%26aufirst%3DC.%26aulast%3DRothman%26aufirst%3DR.%2BB.%26aulast%3DReid%26aufirst%3DA.%2BA.%26aulast%3DWalker%26aufirst%3DJ.%2BM.%26aulast%3DJacobson%26aufirst%3DA.%2BE.%26aulast%3DRice%26aufirst%3DK.%2BC.%26atitle%3DAlterations%2520in%2520the%2520stereochemistry%2520of%2520the%2520kappa-selective%2520opioid%2520agonist%2520U50%252C488%2520result%2520in%2520high-affinity%2520sigma%2520ligands%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1989%26volume%3D32%26spage%3D1996%26epage%3D2002%26doi%3D10.1021%2Fjm00128a050" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref116"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref116'); return false;" data-citation="" class="refNumLink">116</a></strong><div class="NLM_citation" id="cit116"><span><span class="NLM_contrib-group"><span class="NLM_string-name">de Costa, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rice, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowen, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thurkauf, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rothman, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Band, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobson, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Radesca, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Contreras, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daly, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iyengar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finn, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vazirani, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, J. M.</span></span> <span> </span><span class="NLM_article-title">Synthesis and evaluation of N-substituted cis-N-methyl-2-(1-pyrrolidinyl)cyclohexylamines as high affinity sigma receptor ligands. Identification of a new class of highly potent and selective sigma receptor probes</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1990</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">3100</span>– <span class="NLM_lpage">3110</span>, <span class="refDoi"> DOI: 10.1021/jm00173a030</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00173a030" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADyaK3MXitlOgtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=1990&pages=3100-3110&author=B.+R.+de+Costaauthor=K.+C.+Riceauthor=W.+D.+Bowenauthor=A.+Thurkaufauthor=R.+B.+Rothmanauthor=L.+Bandauthor=A.+E.+Jacobsonauthor=L.+Radescaauthor=P.+C.+Contrerasauthor=N.+M.+Grayauthor=I.+Dalyauthor=S.+Iyengarauthor=D.+T.+Finnauthor=S.+Vaziraniauthor=J.+M.+Walker&title=Synthesis+and+evaluation+of+N-substituted+cis-N-methyl-2-%281-pyrrolidinyl%29cyclohexylamines+as+high+affinity+sigma+receptor+ligands.+Identification+of+a+new+class+of+highly+potent+and+selective+sigma+receptor+probes&doi=10.1021%2Fjm00173a030"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit116R"><div class="casContent"><span class="casTitleNuber">116</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and evaluation of N-substituted cis-N-methyl-2-(1-pyrrolidinyl)cyclohexylamines as high affinity σ receptor ligands.  Identification of a new class of highly potent and selective σ receptor probes</span></div><div class="casAuthors">De Costa, Brian R.; Bowen, Wayne D.; Thurkauf, Andrew; Finn, Daniel T.; Vazirani, Sondra; Rothman, Richard B.; Band, Linda; Contreras, Patricia C.; Gray, Nancy M.; et al.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3100-10</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    </div><div class="casAbstract">N-Substituted cis-2-(1-pyrrolidinyl)-N-methylcyclohexylamines, were synthesized and their structure-activity requirements detd.  The compds. were synthesized by starting with the previously reported (±)-, 1S,2R-(+), and 1R,2S-(-)-cis-2-(1-pyrrolidinyl)-N-methylcyclohexylamines.  Anal. of σ ([3H](+)-PPP), κ ([3H]bremazocine and [3H]U69,593), dopamine-d2 ([3H]sulpiride), and phencyclidine (PCP) ([3H]TCP) receptor binding in guinea pig brain revealed a no. of highly potent and selective σ receptor ligands.  Notably, 1S,2R-cis-(-)-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]-2-naphthaleneacetamide (I), (±)-cis-2-amino-4,5-dichloro-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]benzeneacetamide, 1S,2R-(-)-cis-N-methyl-N-[2-(3,4-dichlorophenyl)ethyl]-N-[2-(1-pyrrolidinyl)cyclohexyl]amine, and 1R,2S-(+)-cis-N-methyl-N-[2-(3,4-dichlorophenyl)ethyl]-N-[2-(1-pyrrolidinyl)cyclohexyl]amine exhibited very high affinity at σ receptors, by displacement of [3H]-(+)-3-(3-hydroxyphenyl)-N-(1-propyl)piperidine ([3H](+)-3-PPP).  These compds. showed insignificant affinity for κ, dopamine, or PCP receptors, making them valuable tools for the study of σ receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo38ckLuefHc7Vg90H21EOLACvtfcHk0lgwsuiAeeIcRw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXitlOgtg%253D%253D&md5=3b87eb15b278f3eaaf769d0620b58b6d</span></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.1021%2Fjm00173a030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00173a030%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BCosta%26aufirst%3DB.%2BR.%26aulast%3DRice%26aufirst%3DK.%2BC.%26aulast%3DBowen%26aufirst%3DW.%2BD.%26aulast%3DThurkauf%26aufirst%3DA.%26aulast%3DRothman%26aufirst%3DR.%2BB.%26aulast%3DBand%26aufirst%3DL.%26aulast%3DJacobson%26aufirst%3DA.%2BE.%26aulast%3DRadesca%26aufirst%3DL.%26aulast%3DContreras%26aufirst%3DP.%2BC.%26aulast%3DGray%26aufirst%3DN.%2BM.%26aulast%3DDaly%26aufirst%3DI.%26aulast%3DIyengar%26aufirst%3DS.%26aulast%3DFinn%26aufirst%3DD.%2BT.%26aulast%3DVazirani%26aufirst%3DS.%26aulast%3DWalker%26aufirst%3DJ.%2BM.%26atitle%3DSynthesis%2520and%2520evaluation%2520of%2520N-substituted%2520cis-N-methyl-2-%25281-pyrrolidinyl%2529cyclohexylamines%2520as%2520high%2520affinity%2520sigma%2520receptor%2520ligands.%2520Identification%2520of%2520a%2520new%2520class%2520of%2520highly%2520potent%2520and%2520selective%2520sigma%2520receptor%2520probes%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1990%26volume%3D33%26spage%3D3100%26epage%3D3110%26doi%3D10.1021%2Fjm00173a030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref117"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref117'); return false;" data-citation="" class="refNumLink">117</a></strong><div class="NLM_citation" id="cit117"><span><span class="NLM_contrib-group"><span class="NLM_string-name">de Costa, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Radesca, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Paolo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowen, W. D.</span></span> <span> </span><span class="NLM_article-title">Synthesis, characterization, and biological evaluation of a novel class of N-(arylethyl)-N-alkyl-2-(1-pyrrolidinyl)ethylamines: structural requirements and binding affinity at the sigma receptor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1992</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">38</span>– <span class="NLM_lpage">47</span>, <span class="refDoi"> DOI: 10.1021/jm00079a004</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00079a004" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADyaK38Xkt1KhsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=1992&pages=38-47&author=B.+R.+de+Costaauthor=L.+Radescaauthor=L.+Di+Paoloauthor=W.+D.+Bowen&title=Synthesis%2C+characterization%2C+and+biological+evaluation+of+a+novel+class+of+N-%28arylethyl%29-N-alkyl-2-%281-pyrrolidinyl%29ethylamines%3A+structural+requirements+and+binding+affinity+at+the+sigma+receptor&doi=10.1021%2Fjm00079a004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit117R"><div class="casContent"><span class="casTitleNuber">117</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis, characterization, and biological evaluation of a novel class of N-(arylethyl)-N-alkyl-2-(1-pyrrolidinyl)ethylamines:  structural requirements and binding affinity at the σ receptor</span></div><div class="casAuthors">De Costa, Brian R.; Radesca, Lilian; Di Paolo, Lisa; Bowen, Wayne D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">38-47</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    </div><div class="casAbstract">Title compds., e.g. I (R = H, Me, Et, Pr, allyl, Bu, R1 = R2 = Cl; R = Me, R1, R2 = H, Cl; R1R2 = benzo), were prepd. and their binding affinity for σ-, phencyclidine, kappa opiate, and dopamine D2 receptors was measured.  Thus, pyrrolidine II (R3 = Cl) was aminated with H2NR to give II (R3 = NHR) which reacted with 3,4-dichlorophenylacetic acid and was reduced with AlH3/THF to give I (R = H, Me, Et, Pr, allyl, Bu, R1 = R2 = Cl).  When I (R = Me, R1 = R2 = Cl) was tested for its capacity to displace [3H]-(+)-3-PPP (PPP = 1-n-propyl-3-(3-hydroxyphenyl)piperidine) from guinea pig brain membranes, it exhibited a Ki of 0.34 nM.  Structure activity relationships were also examd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMksg4R4UY9LVg90H21EOLACvtfcHk0ljflf58GjaCyg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK38Xkt1KhsLo%253D&md5=47f25860bff66bed7175f73cc44012a9</span></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.1021%2Fjm00079a004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00079a004%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BCosta%26aufirst%3DB.%2BR.%26aulast%3DRadesca%26aufirst%3DL.%26aulast%3DDi%2BPaolo%26aufirst%3DL.%26aulast%3DBowen%26aufirst%3DW.%2BD.%26atitle%3DSynthesis%252C%2520characterization%252C%2520and%2520biological%2520evaluation%2520of%2520a%2520novel%2520class%2520of%2520N-%2528arylethyl%2529-N-alkyl-2-%25281-pyrrolidinyl%2529ethylamines%253A%2520structural%2520requirements%2520and%2520binding%2520affinity%2520at%2520the%2520sigma%2520receptor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1992%26volume%3D35%26spage%3D38%26epage%3D47%26doi%3D10.1021%2Fjm00079a004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref118"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref118'); return false;" data-citation="" class="refNumLink">118</a></strong><div class="NLM_citation" id="cit118"><span><span class="NLM_contrib-group"><span class="NLM_string-name">de Costa, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dominguez, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, X. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Radesca, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowen, W.</span></span> <span> </span><span class="NLM_article-title">Synthesis and biological evaluation of conformationally restricted 2-(1-pyrrolidinyl)-N-[2-(3,4-dichlorophenyl)ethyl]-N-methylethylenediam ines as sigma receptor ligands. 1. Pyrrolidine, piperidine, homopiperidine, and tetrahydroisoquinoline classes</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1992</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">4334</span>– <span class="NLM_lpage">4343</span>, <span class="refDoi"> DOI: 10.1021/jm00101a011</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00101a011" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADyaK38Xmtlekt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=1992&pages=4334-4343&author=B.+R.+de+Costaauthor=C.+Dominguezauthor=X.+S.+Heauthor=W.+Williamsauthor=L.+Radescaauthor=W.+Bowen&title=Synthesis+and+biological+evaluation+of+conformationally+restricted+2-%281-pyrrolidinyl%29-N-%5B2-%283%2C4-dichlorophenyl%29ethyl%5D-N-methylethylenediam+ines+as+sigma+receptor+ligands.+1.+Pyrrolidine%2C+piperidine%2C+homopiperidine%2C+and+tetrahydroisoquinoline+classes&doi=10.1021%2Fjm00101a011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit118R"><div class="casContent"><span class="casTitleNuber">118</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and biological evaluation of conformationally restricted 2-(1-pyrrolidinyl)-N-[2-(3,4-dichlorophenyl)ethyl]-N-methylethylenediamines as σ receptor ligands.  1.  Pyrrolidine, piperidine, homopiperidine, and tetrahydroisoquinoline classes</span></div><div class="casAuthors">De Costa, Brian R.; Dominguez, Celia; He, Xiao Shu; Williams, Wanda; Radesca, Lilian; Bowen, Wayne</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">4334-43</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    </div><div class="casAbstract">The synthesis and σ receptor affinity of a series of conformationally restricted derivs. of 2-(1-pyrrolidinyl)-N-[2-(3,4-dichlorophenyl)ethyl]-N-methylethylenediamine (1) are described.  The pyrrolidinyl (or N,N-dialkyl), ethylenediamine, N-alkyl, and phenylethyl portions of this σ receptor pharmacophore were restricted by its incorporation into 1,2-cyclohexanediamine-, pyrrolidine-, piperidine-, homopiperidine-, and tetrahydroisoquinoline-contg. ligands.  The σ receptor binding affinities of these compds. were detd. using [3H](+)-pentazocine in guinea pig brain homogenates.  The synthesis of all but one class was achieved by acylation and alane redn. of the appropriate diamine precursors whose synthesis is also reported.  The σ receptor affinities ranged from 1.34 nM for 6,7-dichloro-2-[2-(1-pyrrolidinyl)ethyl]tetrahydroisoquinoline to 455 nM for (1R,2R)-trans-N-[2-(3,4-dichlorophenyl)ethyl]-N-methyl-2-(1-pyrrolidinyl) cyclohexylamine.  In this displacement assay, (+)-pentazocine exhibited a Ki of 3.1 nM while DTG and haloperidol showed Ki values of 27.7 and 3.7 nM, resp.  The conformationally free parent compd. 1 exhibited a Ki value of 2.1 nM.  Comparison of both the σ receptor affinities and nitrogen atom geometry of the compds. revealed that a gauche relation of the N atoms of cis-1,2-cyclohexanediamines is not imperative for high affinity as previously thought.  It is highly likely that nitrogen lone pair orientations and steric factors on the aliph. portions of these ligands play a major role in the σ receptor binding of this pharmacophore.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHFiRFsAl737Vg90H21EOLACvtfcHk0ljflf58GjaCyg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK38Xmtlekt7c%253D&md5=3a971359707bd29bdecd4ea1e8de23b7</span></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.1021%2Fjm00101a011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00101a011%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BCosta%26aufirst%3DB.%2BR.%26aulast%3DDominguez%26aufirst%3DC.%26aulast%3DHe%26aufirst%3DX.%2BS.%26aulast%3DWilliams%26aufirst%3DW.%26aulast%3DRadesca%26aufirst%3DL.%26aulast%3DBowen%26aufirst%3DW.%26atitle%3DSynthesis%2520and%2520biological%2520evaluation%2520of%2520conformationally%2520restricted%25202-%25281-pyrrolidinyl%2529-N-%255B2-%25283%252C4-dichlorophenyl%2529ethyl%255D-N-methylethylenediam%2520ines%2520as%2520sigma%2520receptor%2520ligands.%25201.%2520Pyrrolidine%252C%2520piperidine%252C%2520homopiperidine%252C%2520and%2520tetrahydroisoquinoline%2520classes%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1992%26volume%3D35%26spage%3D4334%26epage%3D4343%26doi%3D10.1021%2Fjm00101a011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref119"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref119'); return false;" data-citation="" class="refNumLink">119</a></strong><div class="NLM_citation" id="cit119"><span><span class="NLM_contrib-group"><span class="NLM_string-name">de Costa, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, X. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Linders, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dominguez, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, Z. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowen, W. D.</span></span> <span> </span><span class="NLM_article-title">Synthesis and evaluation of conformationally restricted N-[2-(3,4-dichlorophenyl)ethyl]-N-methyl-2-(1-pyrrolidinyl)ethylamines at sigma receptors. 2. Piperazines, bicyclic amines, bridged bicyclic amines, and miscellaneous compounds</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">2311</span>– <span class="NLM_lpage">2320</span>, <span class="refDoi"> DOI: 10.1021/jm00068a007</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00068a007" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADyaK2cXhtVKqsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=1993&pages=2311-2320&author=B.+R.+de+Costaauthor=X.+S.+Heauthor=J.+T.+Lindersauthor=C.+Dominguezauthor=Z.+Q.+Guauthor=W.+Williamsauthor=W.+D.+Bowen&title=Synthesis+and+evaluation+of+conformationally+restricted+N-%5B2-%283%2C4-dichlorophenyl%29ethyl%5D-N-methyl-2-%281-pyrrolidinyl%29ethylamines+at+sigma+receptors.+2.+Piperazines%2C+bicyclic+amines%2C+bridged+bicyclic+amines%2C+and+miscellaneous+compounds&doi=10.1021%2Fjm00068a007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit119R"><div class="casContent"><span class="casTitleNuber">119</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and evaluation of conformationally restricted N-[2-(3,4-dichlorophenyl)ethyl]-N-methyl-2-(1-pyrrolidinyl)ethylamines at σ receptors. 2. Piperazines, bicyclic amines, bridged bicyclic amines, and miscellaneous compounds</span></div><div class="casAuthors">de Costa, Brian R.; He, Xiaoshu; Linders, Joannes T. M.; Dominguez, Celia; Gu, Zi Qiang; Williams, Wanda; Bowen, Wayne</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">2311-20</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    </div><div class="casAbstract">As a continuation of an earlier study (J. Med. Chem. 1992, 35, 4334-4343) the σ-receptor ligand was conformationally restricted in 2-(1-pyrrolidinyl)-N-[2-(3,4-dichlorophenyl)ethyl]-N-methylethylamine (I) by incorporating it into homologous piperazines and homopiperazines, diazabicyclononanes and decanes, bridgehead bicyclooctanes and nonanes as well as other misc. compds.  σ-Receptor binding affinities were obtained using [3H](+)-pentazocine in guinea pig brain membranes.  Probably the N lone pair orientation found in the piperazines affords the strongest binding interaction.  Other N lone pair orientations or compds. representing unlikely staggered conformations of I [as in 4-[2-(3,4-dichlorophenyl)ethyl]-1,4-diazabicyclo[3.2.2]nonane] show very weak σ interaction.  Comparison of the binding data of different N-substituted homologs of I with those of the 1-[2-(3,4-dichlorophenyl)ethyl]-4-alkylpiperazines suggests that the 2 N atoms of I are working in opposition to one another in terms of their sensitivity to steric bulk.  The high binding affinity of 1,4-diazabicyclo[4.3.0]nonanes suggests that these may approx. the Me and pyrrolidine ring conformations found in I when it is bound to the σ receptor.  Binding data suggest that the conformation of I favors strong binding interaction at σ-receptors.  σ-Receptor Ki's was 0.55 nM for 1-[2-(3,4-dichlorophenyl)ethyl]-4-n-butylpiperazine.  Overall comparison of the results indicate that I is subject to considerable conformational freedom and suggests that the σ receptor is not subject to rigid stereochem. restraints with I.  These results corroborate an earlier study where I was restrained using simple monocyclic heterocycles.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqyOzXD549F2bVg90H21EOLACvtfcHk0lin1gpfi47opw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXhtVKqsro%253D&md5=f09774edf56b0d4fe631332167d67480</span></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.1021%2Fjm00068a007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00068a007%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BCosta%26aufirst%3DB.%2BR.%26aulast%3DHe%26aufirst%3DX.%2BS.%26aulast%3DLinders%26aufirst%3DJ.%2BT.%26aulast%3DDominguez%26aufirst%3DC.%26aulast%3DGu%26aufirst%3DZ.%2BQ.%26aulast%3DWilliams%26aufirst%3DW.%26aulast%3DBowen%26aufirst%3DW.%2BD.%26atitle%3DSynthesis%2520and%2520evaluation%2520of%2520conformationally%2520restricted%2520N-%255B2-%25283%252C4-dichlorophenyl%2529ethyl%255D-N-methyl-2-%25281-pyrrolidinyl%2529ethylamines%2520at%2520sigma%2520receptors.%25202.%2520Piperazines%252C%2520bicyclic%2520amines%252C%2520bridged%2520bicyclic%2520amines%252C%2520and%2520miscellaneous%2520compounds%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1993%26volume%3D36%26spage%3D2311%26epage%3D2320%26doi%3D10.1021%2Fjm00068a007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref120"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref120'); return false;" data-citation="" class="refNumLink">120</a></strong><div class="NLM_citation" id="cit120"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torrence-Campbell, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowen, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rice, K. C.</span></span> <span> </span><span class="NLM_article-title">Characterization of novel N,N’-disubstituted piperazines as sigma receptor ligands</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">4950</span>– <span class="NLM_lpage">4957</span>, <span class="refDoi"> DOI: 10.1021/jm980143k</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm980143k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADyaK1cXnt1Cltb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=1998&pages=4950-4957&author=Y.+Zhangauthor=W.+Williamsauthor=C.+Torrence-Campbellauthor=W.+D.+Bowenauthor=K.+C.+Rice&title=Characterization+of+novel+N%2CN%E2%80%99-disubstituted+piperazines+as+sigma+receptor+ligands&doi=10.1021%2Fjm980143k"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit120R"><div class="casContent"><span class="casTitleNuber">120</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of Novel N,N'-Disubstituted Piperazines as σ Receptor Ligands</span></div><div class="casAuthors">Zhang, Ying; Williams, Wanda; Torrence-Campbell, Cheryl; Bowen, Wayne D.; Rice, Kenner C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">4950-4957</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">σ Receptors have been the focus of extensive studies because of their potential functional role in several important physiol. and biochem. processes.  To further evaluate the properties of σ receptors, esp. σ-1 and σ-2 subtypes, we have synthesized a series of 32 N,N'-disubstituted piperazine compds.  The design of these compds. was based upon the early structure-activity relationship (SAR) studies of the min. structural requirements of a mol. necessary to elicit σ receptor binding activity.  In the N-(3-phenylpropyl)piperazine series, compds. with the ethylenediamine moiety showed 6-20-fold higher affinity for σ-1 and 2-40-fold higher affinity for σ-2 relative to their corresponding amides.  The (m-nitrophenethyl)piperazine exhibits a subnanomolar affinity for the σ-1 site, whereas the corresponding o-nitro compd. shows the highest affinity for the σ-2 site (Ki = 4.9 nM).  Compds. with a free amino terminus were designed as precursors for use as bioconjugated affinity compds.  Some of these compds. displayed high affinity for σ-1 and moderate affinity for σ-2 sites and are currently used for the purifn. and characterization of the receptor subtypes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGra76qaE-298bVg90H21EOLACvtfcHk0lin1gpfi47opw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXnt1Cltb4%253D&md5=ef77cf7c7f695dbfe771f3acb90d62e1</span></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.1021%2Fjm980143k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm980143k%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DWilliams%26aufirst%3DW.%26aulast%3DTorrence-Campbell%26aufirst%3DC.%26aulast%3DBowen%26aufirst%3DW.%2BD.%26aulast%3DRice%26aufirst%3DK.%2BC.%26atitle%3DCharacterization%2520of%2520novel%2520N%252CN%25E2%2580%2599-disubstituted%2520piperazines%2520as%2520sigma%2520receptor%2520ligands%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1998%26volume%3D41%26spage%3D4950%26epage%3D4957%26doi%3D10.1021%2Fjm980143k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref121"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref121'); return false;" data-citation="" class="refNumLink">121</a></strong><div class="NLM_citation" id="cit121"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Foster, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowen, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsumoto, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coop, A.</span></span> <span> </span><span class="NLM_article-title">1,4-dibenzylpiperazines possess anticocaine activity</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">749</span>– <span class="NLM_lpage">751</span>, <span class="refDoi"> DOI: 10.1016/S0960-894X(02)01034-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1016%2FS0960-894X%2802%2901034-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=12639573" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BD3sXhvV2gt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2003&pages=749-751&author=A.+Fosterauthor=H.+Wuauthor=W.+Chenauthor=W.+Williamsauthor=W.+D.+Bowenauthor=R.+R.+Matsumotoauthor=A.+Coop&title=1%2C4-dibenzylpiperazines+possess+anticocaine+activity&doi=10.1016%2FS0960-894X%2802%2901034-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit121R"><div class="casContent"><span class="casTitleNuber">121</span><div class="casTitle"><span class="NLM_cas:atitle">1,4-Dibenzylpiperazines possess anticocaine activity</span></div><div class="casAuthors">Foster, Abby; Wu, Huifang; Chen, Weibin; Williams, Wanda; Bowen, Wayne D.; Matsumoto, Rae R.; Coop, Andrew</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">749-751</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">N,N-Dibenzylpiperazines have high affinity for sigma receptors, and we aimed to increase their anticocaine activity by introducing substituents known to enhance such activity in other sigma ligands.  Ligands with high affinity for sigma-1 receptors resulted, but their activity in attenuating cocaine-induced convulsions did not correlate with sigma-1 binding affinity, and may be more closely related to their sigma-2 binding affinities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrsKsFVsWiEebVg90H21EOLACvtfcHk0lin1gpfi47opw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXhvV2gt7o%253D&md5=3ed59384169b385501f8c6761e8bb476</span></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2802%2901034-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252802%252901034-X%26sid%3Dliteratum%253Aachs%26aulast%3DFoster%26aufirst%3DA.%26aulast%3DWu%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DW.%26aulast%3DWilliams%26aufirst%3DW.%26aulast%3DBowen%26aufirst%3DW.%2BD.%26aulast%3DMatsumoto%26aufirst%3DR.%2BR.%26aulast%3DCoop%26aufirst%3DA.%26atitle%3D1%252C4-dibenzylpiperazines%2520possess%2520anticocaine%2520activity%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2003%26volume%3D13%26spage%3D749%26epage%3D751%26doi%3D10.1016%2FS0960-894X%2802%2901034-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref122"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref122'); return false;" data-citation="" class="refNumLink">122</a></strong><div class="NLM_citation" id="cit122"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bedürftig, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wünsch, B.</span></span> <span> </span><span class="NLM_article-title">Chiral, nonracemic (piperazin-2-yl)methanol derivatives with sigma-receptor affinity</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">3299</span>– <span class="NLM_lpage">3311</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2004.03.059</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1016%2Fj.bmc.2004.03.059" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=15158798" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2004&pages=3299-3311&author=S.+Bed%C3%BCrftigauthor=B.+W%C3%BCnsch&title=Chiral%2C+nonracemic+%28piperazin-2-yl%29methanol+derivatives+with+sigma-receptor+affinity&doi=10.1016%2Fj.bmc.2004.03.059"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2004.03.059&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2004.03.059%26sid%3Dliteratum%253Aachs%26aulast%3DBed%25C3%25BCrftig%26aufirst%3DS.%26aulast%3DW%25C3%25BCnsch%26aufirst%3DB.%26atitle%3DChiral%252C%2520nonracemic%2520%2528piperazin-2-yl%2529methanol%2520derivatives%2520with%2520sigma-receptor%2520affinity%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2004%26volume%3D12%26spage%3D3299%26epage%3D3311%26doi%3D10.1016%2Fj.bmc.2004.03.059" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref123"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref123'); return false;" data-citation="" class="refNumLink">123</a></strong><div class="NLM_citation" id="cit123"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Holl, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schepmann, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wunsch, B.</span></span> <span> </span><span class="NLM_article-title">Homologous piperazine-alcanols: chiral pool synthesis and pharmacological evaluation</span>. <i>MedChemComm</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">673</span>, <span class="refDoi"> DOI: 10.1039/c2md20070h</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1039%2Fc2md20070h" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BC38XnvVyhsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=673&author=R.+Hollauthor=D.+Schepmannauthor=B.+Wunsch&title=Homologous+piperazine-alcanols%3A+chiral+pool+synthesis+and+pharmacological+evaluation&doi=10.1039%2Fc2md20070h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit123R"><div class="casContent"><span class="casTitleNuber">123</span><div class="casTitle"><span class="NLM_cas:atitle">Homologous piperazine-alkanols: chiral pool synthesis and pharmacological evaluation</span></div><div class="casAuthors">Holl, Ralph; Schepmann, Dirk; Wuensch, Bernhard</div><div class="citationInfo"><span class="NLM_cas:title">MedChemComm</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">673-679</span>CODEN:
                <span class="NLM_cas:coden">MCCEAY</span>;
        ISSN:<span class="NLM_cas:issn">2040-2503</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Starting with proteinogenic amino acids (S)-aspartate and (S)-glutamate, homologous piperazine-2-alkanol derivs. were prepd. by a five step synthesis.  Diversity was introduced by N-1 alkylation of the piperazinedione derivs. with various alkyl halides and subsequent LiAlH4 redn. of dioxopiperazine esters provided alc. derivs.  These ethanol derivs. show similar σ1-receptor affinity [σ-non-opioid intracellular receptor, σ-receptor 1] as other methanol derivs., but increased selectivity over the σ2 subtype [σ-non-opioid intracellular receptor, σ-receptor 2].  Corresponding propanol derivs. are considerably less potent.  A benzyl or dimethylallyl residue at N-1 appears to be optimal for high σ1 affinity (structure-activity relationship).  The synthesis of the target compds. was achieved using L-aspartic acid-derived piperazine ketone and L-glutamic acid derived piperazine ketone derivs. and amines as starting materials.  The title compds. thus formed included a piperazine-2-ethanol deriv. (I) and a piperazine-2-propanol deriv. (II) and related substances.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGosjCHrjfOiRrVg90H21EOLACvtfcHk0li3MmZs04KpVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XnvVyhsb8%253D&md5=68fa5af26634a8b1958be8bc8eab8b3f</span></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1039%2Fc2md20070h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc2md20070h%26sid%3Dliteratum%253Aachs%26aulast%3DHoll%26aufirst%3DR.%26aulast%3DSchepmann%26aufirst%3DD.%26aulast%3DWunsch%26aufirst%3DB.%26atitle%3DHomologous%2520piperazine-alcanols%253A%2520chiral%2520pool%2520synthesis%2520and%2520pharmacological%2520evaluation%26jtitle%3DMedChemComm%26date%3D2012%26volume%3D3%26spage%3D673%26doi%3D10.1039%2Fc2md20070h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref124"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref124'); return false;" data-citation="" class="refNumLink">124</a></strong><div class="NLM_citation" id="cit124"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Weigl, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bedürftig, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maier, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wünsch, B.</span></span> <span> </span><span class="NLM_article-title">Conformationally constrained ethylenediamines: synthesis and receptor binding of 6,8-diazabicyclo[3.2.2]nonanes</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">2245</span>– <span class="NLM_lpage">2257</span>, <span class="refDoi"> DOI: 10.1016/S0968-0896(02)00043-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1016%2FS0968-0896%2802%2900043-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=11983522" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BD38Xjt1Cqsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2002&pages=2245-2257&author=M.+Weiglauthor=S.+Bed%C3%BCrftigauthor=C.+A.+Maierauthor=B.+W%C3%BCnsch&title=Conformationally+constrained+ethylenediamines%3A+synthesis+and+receptor+binding+of+6%2C8-diazabicyclo%5B3.2.2%5Dnonanes&doi=10.1016%2FS0968-0896%2802%2900043-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit124R"><div class="casContent"><span class="casTitleNuber">124</span><div class="casTitle"><span class="NLM_cas:atitle">Conformationally constrained ethylenediamines: synthesis and receptor binding of 6,8-Diazabicyclo[3.2.2]nonanes</span></div><div class="casAuthors">Weigl, Manuela; Bedurftig, Stephan; Maier, Christoph A.; Wunsch, Bernhard</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2245-2257</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">Both (R)- and (S)-enantiomers of 6,8-diazabicyclo[3.2.2]nonanes I (R1 = R2 = Me; R1 = H, R2 = 3,4-Cl2C6H3CH2CO) representing conformationally constrained ethylenediamines were synthesized, and their receptor affinity was studied.  The Dieckmann-type cyclization of the (piperazinyl)propionate II followed by trapping of the product with Me3SiCl provided the bicyclononane III.  III was further stereoselectively transformed into I, which were investigated in competition expts. with radioligands for their σ1-, σ2-, κ-, and μ-receptor affinities.  The (2R)-I (R1 = R2 = Me) showed promising σ1-receptor affinity (Ki=23.8 nM) and selectivity, whereas the (2S)-I (R1 = H, R2 = 3,4-Cl2C6H3CH2CO) displayed a σ-receptor binding profile (σ1: Ki=184 nM; σ2: Ki=263 nM) very similar to the binding profile of the atypical antipsychotic BMY-14802.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEq7HgmkI3g7Vg90H21EOLACvtfcHk0li3MmZs04KpVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xjt1Cqsbc%253D&md5=240dccb500c528c6018cda8ed02be479</span></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=10.1016%2FS0968-0896%2802%2900043-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0968-0896%252802%252900043-3%26sid%3Dliteratum%253Aachs%26aulast%3DWeigl%26aufirst%3DM.%26aulast%3DBed%25C3%25BCrftig%26aufirst%3DS.%26aulast%3DMaier%26aufirst%3DC.%2BA.%26aulast%3DW%25C3%25BCnsch%26aufirst%3DB.%26atitle%3DConformationally%2520constrained%2520ethylenediamines%253A%2520synthesis%2520and%2520receptor%2520binding%2520of%25206%252C8-diazabicyclo%255B3.2.2%255Dnonanes%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2002%26volume%3D10%26spage%3D2245%26epage%3D2257%26doi%3D10.1016%2FS0968-0896%2802%2900043-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref125"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref125'); return false;" data-citation="" class="refNumLink">125</a></strong><div class="NLM_citation" id="cit125"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Weigl, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wünsch, B.</span></span> <span> </span><span class="NLM_article-title">Synthesis of bridged piperazines with sigma receptor affinity</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">1247</span>– <span class="NLM_lpage">1262</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2007.02.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1016%2Fj.ejmech.2007.02.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=17420073" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtFOjtrjM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2007&pages=1247-1262&author=M.+Weiglauthor=B.+W%C3%BCnsch&title=Synthesis+of+bridged+piperazines+with+sigma+receptor+affinity&doi=10.1016%2Fj.ejmech.2007.02.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit125R"><div class="casContent"><span class="casTitleNuber">125</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of bridged piperazines with σ receptor affinity</span></div><div class="casAuthors">Weigl, Manuela; Wuensch, Bernhard</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1247-1262</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Bridged piperazines I (R1 = Me, n-Bu, PhCH2CH2; R2 = H, R3 = HO, MeO, PhCH2O; R2 = R3 = MeO) were designed as conformationally restricted piperazine σ receptor ligands.  The chiral pool synthesis started from (S)-glutamate, which was transformed in five reaction steps into the piperazinediones bearing a propionic acid ester side chain.  Subsequent two-step Dieckmann cyclization provided the bicyclic ketones II as key intermediates.  The redn. of II with LiAlH4 followed by NaBH4 redn., Williamson ether synthesis and LiAlH4 redn. led to the Me and benzyl ethers I (R2 = H; R3 = MeO, PhCH2O).  High σ1 affinity is attained when one large substituent is introduced either at N-8 or O-2.  The most potent σ1 ligand in this series of compds. is I (R1 = n-Bu; R2 = H; R3 = MeO) (Ki = 13.2 nM, selectivity σ2:σ1 = 16).  Moreover, the N-Me derivs. I (R1 = Me; R2 = H; R3 = PhCH2O) (σ2: Ki = 30.4 nM) and I (R1 = Me; R2 = H; R3 = MeO) (σ2 preference) represent promising starting points for the development of potent and selective σ2 ligands.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqEahVlnmz8r7Vg90H21EOLACvtfcHk0li3MmZs04KpVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtFOjtrjM&md5=297e903f5741aae37fa81f16df51a6e2</span></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2007.02.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2007.02.005%26sid%3Dliteratum%253Aachs%26aulast%3DWeigl%26aufirst%3DM.%26aulast%3DW%25C3%25BCnsch%26aufirst%3DB.%26atitle%3DSynthesis%2520of%2520bridged%2520piperazines%2520with%2520sigma%2520receptor%2520affinity%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2007%26volume%3D42%26spage%3D1247%26epage%3D1262%26doi%3D10.1016%2Fj.ejmech.2007.02.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref126"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref126'); return false;" data-citation="" class="refNumLink">126</a></strong><div class="NLM_citation" id="cit126"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Holl, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schepmann, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fröhlich, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grünert, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bednarski, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wünsch, B.</span></span> <span> </span><span class="NLM_article-title">Dancing of the second aromatic residue around the 6,8-diazabicyclo[3.2.2]nonane framework: influence on sigma receptor affinity and cytotoxicity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">2126</span>– <span class="NLM_lpage">2137</span>, <span class="refDoi"> DOI: 10.1021/jm801522j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm801522j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BD1MXisVCjtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=2126-2137&author=R.+Hollauthor=D.+Schepmannauthor=R.+Fr%C3%B6hlichauthor=R.+Gr%C3%BCnertauthor=P.+J.+Bednarskiauthor=B.+W%C3%BCnsch&title=Dancing+of+the+second+aromatic+residue+around+the+6%2C8-diazabicyclo%5B3.2.2%5Dnonane+framework%3A+influence+on+sigma+receptor+affinity+and+cytotoxicity&doi=10.1021%2Fjm801522j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit126R"><div class="casContent"><span class="casTitleNuber">126</span><div class="casTitle"><span class="NLM_cas:atitle">Dancing of the Second Aromatic Residue around the 6,8-Diazabicyclo[3.2.2]nonane Framework: Influence on σ Receptor Affinity and Cytotoxicity</span></div><div class="casAuthors">Holl, Ralph; Schepmann, Dirk; Froehlich, Roland; Grunert, Renate; Bednarski, Patrick J.; Wunsch, Bernhard</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2126-2137</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of 6,8-diazabicyclo[3.2.2]nonane derivs. bearing two arom. moieties was prepd., the affinity toward σ1 and σ2 receptors was investigated, and the growth inhibition of six human tumor cell lines was detd.  The enantiopure bicyclic ketones 5a ((+)-(1S,5S)-6-allyl-8-(4-methoxybenzyl)-6,8-diazabicyclo[3.2.2]nonane-2,7,9-trione) and 5b ((+)-(1S,5S)-6-allyl-8-(2,4-dimethoxybenzyl)-6,8-diazabicyclo[3.2.2]nonane-2,7,9-trione) as well as their enantiomers ent-5a and ent-5b served as chiral building blocks, which were derived from (S)- and (R)-glutamate, resp.  Structure-affinity relationships revealed that 11a (Ki = 154 nM), ent-11a (Ki = 91 nM), and ent-17a (Ki = 104 nM) are the most potent σ1 ligands.  High σ2 affinity was achieved with 17b (Ki = 159 nM) and 8b (Ki = 400 nM).  The bicyclic σ ligands showed a selective growth inhibition of the small cell lung cancer cell line A-427 with the benzyl ethers 11 and the benzylidene derivs. 17 being the most potent compds.  11A has a cytotoxic potency (IC50 = 0.92 μM), which exceeds the activity of cisplatin and interacts considerably with both σ1 and σ2 receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMiz2RmGxA4bVg90H21EOLACvtfcHk0li3MmZs04KpVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXisVCjtL8%253D&md5=e7ba5fd031757e3ed8dcf0fd86bb0721</span></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=10.1021%2Fjm801522j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm801522j%26sid%3Dliteratum%253Aachs%26aulast%3DHoll%26aufirst%3DR.%26aulast%3DSchepmann%26aufirst%3DD.%26aulast%3DFr%25C3%25B6hlich%26aufirst%3DR.%26aulast%3DGr%25C3%25BCnert%26aufirst%3DR.%26aulast%3DBednarski%26aufirst%3DP.%2BJ.%26aulast%3DW%25C3%25BCnsch%26aufirst%3DB.%26atitle%3DDancing%2520of%2520the%2520second%2520aromatic%2520residue%2520around%2520the%25206%252C8-diazabicyclo%255B3.2.2%255Dnonane%2520framework%253A%2520influence%2520on%2520sigma%2520receptor%2520affinity%2520and%2520cytotoxicity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D2126%26epage%3D2137%26doi%3D10.1021%2Fjm801522j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref127"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref127'); return false;" data-citation="" class="refNumLink">127</a></strong><div class="NLM_citation" id="cit127"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Holl, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schepmann, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grünert, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bednarski, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wünsch, B.</span></span> <span> </span><span class="NLM_article-title">Relationships between the structure of 6-allyl-6,8-diazabicyclo[3.2.2]nonane derivatives and their sigma receptor affinity and cytotoxic activity</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">777</span>– <span class="NLM_lpage">793</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2008.11.043</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1016%2Fj.bmc.2008.11.043" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=19081725" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtFeqsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2009&pages=777-793&author=R.+Hollauthor=D.+Schepmannauthor=R.+Gr%C3%BCnertauthor=P.+J.+Bednarskiauthor=B.+W%C3%BCnsch&title=Relationships+between+the+structure+of+6-allyl-6%2C8-diazabicyclo%5B3.2.2%5Dnonane+derivatives+and+their+sigma+receptor+affinity+and+cytotoxic+activity&doi=10.1016%2Fj.bmc.2008.11.043"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit127R"><div class="casContent"><span class="casTitleNuber">127</span><div class="casTitle"><span class="NLM_cas:atitle">Relationships between the structure of 6-allyl-6,8-diazabicyclo[3.2.2]nonane derivatives and their σ receptor affinity and cytotoxic activity</span></div><div class="casAuthors">Holl, Ralph; Schepmann, Dirk; Gruenert, Renate; Bednarski, Patrick J.; Wuensch, Bernhard</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">777-793</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A series of bridged piperazine derivs. was prepd. and the affinity toward σ1 and σ2 receptors by means of radioligand binding assays as well as the inhibition of the growth of six human tumor cell lines was investigated.  All possible stereoisomers of the 2-hydroxy, 2-methoxy, 2,2-dimethoxy, 2-oxo, and 2-unsubstituted 6,8-diazabicyclo[3.2.2]nonanes were prepd. in a chiral pool synthesis starting with (S)- and (R)-glutamate.  A Dieckmann analogous cyclization was the key step in the synthesis of the bicyclic framework.  The configuration in position 2 was established by a diastereoselective LiBH4 redn. and subsequent Mitsunobu inversion.  Structure-affinity relationships demonstrate that substituents in position 2 decrease σ1 receptor affinity which might be due to unfavorable interactions with the σ1 receptor protein.  Without a substituent in position 2 high σ1 affinity was obtained (23a ((+)-(1S,5S)-6-allyl-8-(4-methoxybenzyl)-6,8-diazabicyclo[3.2.2]nonane): K i = 11 nM).  Expts. with six human tumor cell lines showed a weak but selective growth inhibition of the human small cell lung cancer cell line A-427 by the Me ethers ent-16b (IC50 = 18.9 μM), 21a (IC50 = 16.4 μM), ent-21a (IC50 = 20.4 μM), and 21b (IC50 = 27.1 μM) and the unsubstituted compds. 23a and 23b (42% inhibition at 20 μM).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEBsQOc45My7Vg90H21EOLACvtfcHk0lg1i40PIlt0Cw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtFeqsrY%253D&md5=e69818a3ef5def6300dc8ce5bc959797</span></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2008.11.043&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2008.11.043%26sid%3Dliteratum%253Aachs%26aulast%3DHoll%26aufirst%3DR.%26aulast%3DSchepmann%26aufirst%3DD.%26aulast%3DGr%25C3%25BCnert%26aufirst%3DR.%26aulast%3DBednarski%26aufirst%3DP.%2BJ.%26aulast%3DW%25C3%25BCnsch%26aufirst%3DB.%26atitle%3DRelationships%2520between%2520the%2520structure%2520of%25206-allyl-6%252C8-diazabicyclo%255B3.2.2%255Dnonane%2520derivatives%2520and%2520their%2520sigma%2520receptor%2520affinity%2520and%2520cytotoxic%2520activity%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2009%26volume%3D17%26spage%3D777%26epage%3D793%26doi%3D10.1016%2Fj.bmc.2008.11.043" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref128"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref128'); return false;" data-citation="" class="refNumLink">128</a></strong><div class="NLM_citation" id="cit128"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Holl, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schepmann, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bednarski, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grünert, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wünsch, B.</span></span> <span> </span><span class="NLM_article-title">Relationships between the structure of 6-substituted 6,8-diazabicyclo[3.2.2]nonan-2-ones and their sigma receptor affinity and cytotoxic activity</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">1445</span>– <span class="NLM_lpage">1455</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2009.01.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1016%2Fj.bmc.2009.01.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=19196515" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BD1MXitVyisL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2009&pages=1445-1455&author=R.+Hollauthor=D.+Schepmannauthor=P.+J.+Bednarskiauthor=R.+Gr%C3%BCnertauthor=B.+W%C3%BCnsch&title=Relationships+between+the+structure+of+6-substituted+6%2C8-diazabicyclo%5B3.2.2%5Dnonan-2-ones+and+their+sigma+receptor+affinity+and+cytotoxic+activity&doi=10.1016%2Fj.bmc.2009.01.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit128R"><div class="casContent"><span class="casTitleNuber">128</span><div class="casTitle"><span class="NLM_cas:atitle">Relationships between the structure of 6-substituted 6,8-diazabicyclo[3.2.2]nonan-2-ones and their σ receptor affinity and cytotoxic activity</span></div><div class="casAuthors">Holl, Ralph; Schepmann, Dirk; Bednarski, Patrick J.; Gruenert, Renate; Wuensch, Bernhard</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1445-1455</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A series of 2-oxo-6,8-diazabicyclo[3.2.2]nonane derivs. was prepd. and the affinity towards σ1 and σ2 receptors was investigated by means of radioligand binding assays as well as their inhibition of the growth of six human tumor cell lines was studied.  Starting from the enantiopure bicyclic ketones 3 and ent-3 bridged piperazines with different residues in position 6 were synthesized.  The N-6 allyl protective group was removed by a RhCl3 catalyzed double bond isomerization and subsequent hydrolysis of the resulting enamide 8.  After acetalization the secondary amide 10 was alkylated and arylated.  Structure affinity relationships show that a relatively large substituent, which has not necessarily to be an arom. one, is required in position 6 for high σ1 receptor affinity (e.g., 12 and ent-12 with a dimethylallyl residue: K i = 20 nM and 17 nM).  Furthermore, it was shown that substituents that reduce the basicity of N-6 led to a severe decrease in σ1 affinity.  Growth inhibition expts. with six human tumor cell lines revealed that the allyl and benzyl substituted 6,8-diazabicyclo[3.2.2]nonan-2-one derivs. 5, ent-5 and ent-14 are able to selectively inhibit the growth of the bladder cancer cell line 5637.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFTT1u_7JzY7Vg90H21EOLACvtfcHk0lg1i40PIlt0Cw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXitVyisL8%253D&md5=daf4343250a2cd50481485a248b73d8b</span></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2009.01.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2009.01.012%26sid%3Dliteratum%253Aachs%26aulast%3DHoll%26aufirst%3DR.%26aulast%3DSchepmann%26aufirst%3DD.%26aulast%3DBednarski%26aufirst%3DP.%2BJ.%26aulast%3DGr%25C3%25BCnert%26aufirst%3DR.%26aulast%3DW%25C3%25BCnsch%26aufirst%3DB.%26atitle%3DRelationships%2520between%2520the%2520structure%2520of%25206-substituted%25206%252C8-diazabicyclo%255B3.2.2%255Dnonan-2-ones%2520and%2520their%2520sigma%2520receptor%2520affinity%2520and%2520cytotoxic%2520activity%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2009%26volume%3D17%26spage%3D1445%26epage%3D1455%26doi%3D10.1016%2Fj.bmc.2009.01.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref129"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref129'); return false;" data-citation="" class="refNumLink">129</a></strong><div class="NLM_citation" id="cit129"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sunnam, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schepmann, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wibbeling, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wünsch, B.</span></span> <span> </span><span class="NLM_article-title">Bicyclic sigma receptor ligands by stereoselective Dieckmann analogous cyclization of piperazinebutyrate</span>. <i>Org. Biomol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">3715</span>– <span class="NLM_lpage">3722</span>, <span class="refDoi"> DOI: 10.1039/c003878d</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1039%2Fc003878d" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=20556273" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpsFeqsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2010&pages=3715-3722&author=S.+K.+Sunnamauthor=D.+Schepmannauthor=B.+Wibbelingauthor=B.+W%C3%BCnsch&title=Bicyclic+sigma+receptor+ligands+by+stereoselective+Dieckmann+analogous+cyclization+of+piperazinebutyrate&doi=10.1039%2Fc003878d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit129R"><div class="casContent"><span class="casTitleNuber">129</span><div class="casTitle"><span class="NLM_cas:atitle">Bicyclic σ receptor ligands by stereoselective Dieckmann analogous cyclization of piperazinebutyrate</span></div><div class="casAuthors">Sunnam, Sunil Kumar; Schepmann, Dirk; Wibbeling, Birgit; Wuensch, Bernhard</div><div class="citationInfo"><span class="NLM_cas:title">Organic & Biomolecular Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">3715-3722</span>CODEN:
                <span class="NLM_cas:coden">OBCRAK</span>;
        ISSN:<span class="NLM_cas:issn">1477-0520</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Starting from racemic 2-aminoadipic acid the piperazinedione I with a butyrate side chain was synthesized in four reaction steps.  The four-carbon bridge was established upon deprotonation of I with LHMDS and subsequent trapping of the lithium alcoholate with Me3SiCl to give diastereoselectively the mixed Me silyl ketal II in 94% yield.  The relative configuration of the new center of chirality was detd. by X-ray crystal structure anal. of II.  The high diastereoselectivity during the conversion of the butyrate I into the mixed Me silyl ketal II supports the formation of the lithium alcoholate as central intermediate.  Stereoselective redn. of the ketone with LiBH4 led to the alc., which was benzylated and reduced to provide the final bicyclic products III (R = H, Bn).  Whereas the alc. III (R = H) shows only moderate affinity to both σ receptor subtypes, the benzyl ether III (R = Bn) represents a potent and selective σ1 receptor ligand (Ki = 47 nM).  Comparison of the σ receptor affinities of III (R = H, Bn) with the smaller homologues IV (R = H, Me) clearly indicates that the size of the bridge and the O-substituent dets. subtype selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8zdqYzoKvQLVg90H21EOLACvtfcHk0lg1i40PIlt0Cw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpsFeqsL8%253D&md5=598c2048ff25585ff4ce098b43c117fd</span></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=10.1039%2Fc003878d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc003878d%26sid%3Dliteratum%253Aachs%26aulast%3DSunnam%26aufirst%3DS.%2BK.%26aulast%3DSchepmann%26aufirst%3DD.%26aulast%3DWibbeling%26aufirst%3DB.%26aulast%3DW%25C3%25BCnsch%26aufirst%3DB.%26atitle%3DBicyclic%2520sigma%2520receptor%2520ligands%2520by%2520stereoselective%2520Dieckmann%2520analogous%2520cyclization%2520of%2520piperazinebutyrate%26jtitle%3DOrg.%2520Biomol.%2520Chem.%26date%3D2010%26volume%3D8%26spage%3D3715%26epage%3D3722%26doi%3D10.1039%2Fc003878d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref130"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref130'); return false;" data-citation="" class="refNumLink">130</a></strong><div class="NLM_citation" id="cit130"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Geiger, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zelenka, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weigl, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fröhlich, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wibbeling, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehmkuhl, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schepmann, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grünert, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bednarski, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wünsch, B.</span></span> <span> </span><span class="NLM_article-title">Synthesis of bicyclic sigma receptor ligands with cytotoxic activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">6144</span>– <span class="NLM_lpage">6153</span>, <span class="refDoi"> DOI: 10.1021/jm070620b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm070620b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BD2sXht1CrurnM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=6144-6153&author=C.+Geigerauthor=C.+Zelenkaauthor=M.+Weiglauthor=R.+Fr%C3%B6hlichauthor=B.+Wibbelingauthor=K.+Lehmkuhlauthor=D.+Schepmannauthor=R.+Gr%C3%BCnertauthor=P.+J.+Bednarskiauthor=B.+W%C3%BCnsch&title=Synthesis+of+bicyclic+sigma+receptor+ligands+with+cytotoxic+activity&doi=10.1021%2Fjm070620b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit130R"><div class="casContent"><span class="casTitleNuber">130</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of Bicyclic σ Receptor Ligands with Cytotoxic Activity</span></div><div class="casAuthors">Geiger, Christian; Zelenka, Christel; Weigl, Manuela; Froehlich, Roland; Wibbeling, Birgit; Lehmkuhl, Kirstin; Schepmann, Dirk; Gruenert, Renate; Bednarski, Patrick J.; Wuensch, Bernhard</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">6144-6153</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">All possible stereoisomeric alcs. (6-benzyl-8-(4-methoxybenzyl)-6,8-diazabicyclo[3.2.2]nonan-2-ol) and Me ethers (6-benzyl-2-methoxy-8-(4-methoxybenzyl)-6,8-diazabicyclo[3.2.2]nonane) are prepd. from (R)- and (S)-glutamate.  A Dieckmann analogous cyclization, which makes use of trapping the primary cyclization product with Me3SiCl, generates the bicyclic framework.  Stereoselective LiBH4 redn. and Mitsunobu inversion establish the configuration in position 2.  Enantiomeric alcs. I (1S,2S,5R) and ent-I (1R,2R,5S) as well as diastereomeric Me ethers II (1R,2R,5S) and III (1R,2S,5S) display high σ1 receptor affinity.  Cell growth inhibition of the stereoisomeric alcs. and Me ethers against five human tumor cell lines is investigated.  In particular, at a concn. of 20 μM the four Me ethers stop completely the cell growth of the small cell lung cancer cell line A-427, indicating a specific target in this cell line.  The IC50-values of Me ethers II and III are in the range of the antitumor drugs cisplatin and oxaliplatin.  Binding assays show that the investigated tumor cell lines express considerable amts. of σ1 and σ2 receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpu13hI5qstBrVg90H21EOLACvtfcHk0ljL2XxYCH03eg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXht1CrurnM&md5=4b4723f550d614d2b1c26cfc4266aa3e</span></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=10.1021%2Fjm070620b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm070620b%26sid%3Dliteratum%253Aachs%26aulast%3DGeiger%26aufirst%3DC.%26aulast%3DZelenka%26aufirst%3DC.%26aulast%3DWeigl%26aufirst%3DM.%26aulast%3DFr%25C3%25B6hlich%26aufirst%3DR.%26aulast%3DWibbeling%26aufirst%3DB.%26aulast%3DLehmkuhl%26aufirst%3DK.%26aulast%3DSchepmann%26aufirst%3DD.%26aulast%3DGr%25C3%25BCnert%26aufirst%3DR.%26aulast%3DBednarski%26aufirst%3DP.%2BJ.%26aulast%3DW%25C3%25BCnsch%26aufirst%3DB.%26atitle%3DSynthesis%2520of%2520bicyclic%2520sigma%2520receptor%2520ligands%2520with%2520cytotoxic%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26spage%3D6144%26epage%3D6153%26doi%3D10.1021%2Fjm070620b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref131"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref131'); return false;" data-citation="" class="refNumLink">131</a></strong><div class="NLM_citation" id="cit131"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sunnam, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schepmann, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rack, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fröhlich, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korpis, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bednarski, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wünsch, B.</span></span> <span> </span><span class="NLM_article-title">Synthesis and biological evaluation of conformationally restricted σ(1) receptor ligands with 7,9-diazabicyclo[4.2.2]decane scaffold</span>. <i>Org. Biomol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">5525</span>– <span class="NLM_lpage">5540</span>, <span class="refDoi"> DOI: 10.1039/c0ob00402b</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1039%2Fc0ob00402b" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=20953473" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVOrs73O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2010&pages=5525-5540&author=S.+K.+Sunnamauthor=D.+Schepmannauthor=E.+Rackauthor=R.+Fr%C3%B6hlichauthor=K.+Korpisauthor=P.+J.+Bednarskiauthor=B.+W%C3%BCnsch&title=Synthesis+and+biological+evaluation+of+conformationally+restricted+%CF%83%281%29+receptor+ligands+with+7%2C9-diazabicyclo%5B4.2.2%5Ddecane+scaffold&doi=10.1039%2Fc0ob00402b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit131R"><div class="casContent"><span class="casTitleNuber">131</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and biological evaluation of conformationally restricted σ1 receptor ligands with 7,9-diazabicyclo[4.2.2]decane scaffold</span></div><div class="casAuthors">Sunnam, Sunil K.; Schepmann, Dirk; Rack, Elisabeth; Froehlich, Roland; Korpis, Katharina; Bednarski, Patrick J.; Wuensch, Bernhard</div><div class="citationInfo"><span class="NLM_cas:title">Organic & Biomolecular Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">5525-5540</span>CODEN:
                <span class="NLM_cas:coden">OBCRAK</span>;
        ISSN:<span class="NLM_cas:issn">1477-0520</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">The key step in the synthesis of the 7,9-diazabicyclo[4.2.2]decane system was a modified Dieckmann condensation of piperazinebutyrate I, which made use of trapping the first cyclized intermediate with TMS-Cl to provide bicyclic ketone II.  Compd. II was then used to prep. various derivs.  The σ1 and σ2 receptor affinities of these derivs. were investigated in receptor binding studies with radioligands.  All test compds. showed a lower σ1 affinity than the corresponding bicyclic derivs. with a three-membered bridge.  The reduced σ1 receptor affinity was attributed to the larger four-membered bridge.  This hypothesis was supported by alkene III, which represented the most potent σ1 ligand of this series (Ki = 7.5 nM).  In alkene III the size and flexibility of the bridge is considerably reduced by the double bond.  Compd. III and two other analogs revealed moderate inhibition of the growth of the human tumor cell lines A-427, 5637 and MCF-7.  Again, these compds. were less potent than the analogs with a three-membered bridge.  The IC50-value of III against the small cell lung cancer cell line A-427 (IC50 = 10 μM) should be emphasized, since this cell line is particularly sensitive to homologs with a three-carbon bridge.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJ-d3GvdXU4rVg90H21EOLACvtfcHk0ljL2XxYCH03eg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVOrs73O&md5=2e53b17fa9ab6ccae159aa987d718859</span></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=10.1039%2Fc0ob00402b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc0ob00402b%26sid%3Dliteratum%253Aachs%26aulast%3DSunnam%26aufirst%3DS.%2BK.%26aulast%3DSchepmann%26aufirst%3DD.%26aulast%3DRack%26aufirst%3DE.%26aulast%3DFr%25C3%25B6hlich%26aufirst%3DR.%26aulast%3DKorpis%26aufirst%3DK.%26aulast%3DBednarski%26aufirst%3DP.%2BJ.%26aulast%3DW%25C3%25BCnsch%26aufirst%3DB.%26atitle%3DSynthesis%2520and%2520biological%2520evaluation%2520of%2520conformationally%2520restricted%2520%25CF%2583%25281%2529%2520receptor%2520ligands%2520with%25207%252C9-diazabicyclo%255B4.2.2%255Ddecane%2520scaffold%26jtitle%3DOrg.%2520Biomol.%2520Chem.%26date%3D2010%26volume%3D8%26spage%3D5525%26epage%3D5540%26doi%3D10.1039%2Fc0ob00402b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref132"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref132'); return false;" data-citation="" class="refNumLink">132</a></strong><div class="NLM_citation" id="cit132"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Weber, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brune, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Börgel, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lange, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korpis, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bednarski, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laurini, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fermeglia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pricl, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schepmann, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wünsch, B.</span></span> <span> </span><span class="NLM_article-title">Rigidity versus Flexibility: Is This an Issue in σ1 Receptor Ligand Affinity and Activity?</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">5505</span>– <span class="NLM_lpage">5519</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00585</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00585" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BC28XnsVyitr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=5505-5519&author=F.+Weberauthor=S.+Bruneauthor=F.+B%C3%B6rgelauthor=C.+Langeauthor=K.+Korpisauthor=P.+J.+Bednarskiauthor=E.+Lauriniauthor=M.+Fermegliaauthor=S.+Priclauthor=D.+Schepmannauthor=B.+W%C3%BCnsch&title=Rigidity+versus+Flexibility%3A+Is+This+an+Issue+in+%CF%831+Receptor+Ligand+Affinity+and+Activity%3F&doi=10.1021%2Facs.jmedchem.6b00585"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit132R"><div class="casContent"><span class="casTitleNuber">132</span><div class="casTitle"><span class="NLM_cas:atitle">Rigidity versus Flexibility: Is This an Issue in σ1 Receptor Ligand Affinity and Activity?</span></div><div class="casAuthors">Weber, Frauke; Brune, Stefanie; Boergel, Frederik; Lange, Carsten; Korpis, Katharina; Bednarski, Patrick J.; Laurini, Erik; Fermeglia, Maurizio; Pricl, Sabrina; Schepmann, Dirk; Wuensch, Bernhard</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">5505-5519</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Stereoisomeric 2,5-diazabicyclo[2.2.2]octanes 14 and 15 were prepd. in a chiral-pool synthesis starting from (S)- or (R)-aspartate.  The key step in the synthesis was a Dieckmann-analogous cyclization of (dioxopiperazinyl)acetates 8, which involved trapping of the intermediate hemiketal anion with Me3SiCl.  The σ1 affinity was tested using membrane prepns. from animal (guinea pig) and human origin.  The binding of bicyclic compds. was analyzed by mol. dynamics simulations based on a 3D homol. model of the σ1 receptor.  The good correlation between Ki values obsd. in the σ1 assays and calcd. free binding energy, coupled with the identification of four crucial ligand/receptor interactions, allowed the formulation of structure-affinity relationships.  In an in vitro antitumor assay with seven human tumor cell lines, the bicyclic compds. inhibited selectively the growth of the cell line A427, which is due to induction of apoptosis.  In this assay, the compds. behave like the known σ1 receptor antagonist haloperidol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMpZXtybW1V7Vg90H21EOLACvtfcHk0ljL2XxYCH03eg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XnsVyitr0%253D&md5=d5fc4600fcd605c8b191a921bddf5e56</span></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00585&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00585%26sid%3Dliteratum%253Aachs%26aulast%3DWeber%26aufirst%3DF.%26aulast%3DBrune%26aufirst%3DS.%26aulast%3DB%25C3%25B6rgel%26aufirst%3DF.%26aulast%3DLange%26aufirst%3DC.%26aulast%3DKorpis%26aufirst%3DK.%26aulast%3DBednarski%26aufirst%3DP.%2BJ.%26aulast%3DLaurini%26aufirst%3DE.%26aulast%3DFermeglia%26aufirst%3DM.%26aulast%3DPricl%26aufirst%3DS.%26aulast%3DSchepmann%26aufirst%3DD.%26aulast%3DW%25C3%25BCnsch%26aufirst%3DB.%26atitle%3DRigidity%2520versus%2520Flexibility%253A%2520Is%2520This%2520an%2520Issue%2520in%2520%25CF%25831%2520Receptor%2520Ligand%2520Affinity%2520and%2520Activity%253F%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D5505%26epage%3D5519%26doi%3D10.1021%2Facs.jmedchem.6b00585" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref133"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref133'); return false;" data-citation="" class="refNumLink">133</a></strong><div class="NLM_citation" id="cit133"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Perregaard, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moltzen, E. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meier, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sánchez, C.</span></span> <span> </span><span class="NLM_article-title">Sigma ligands with subnanomolar affinity and preference for the sigma 2 binding site. 1. 3-(omega-aminoalkyl)-1H-indoles</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">1998</span>– <span class="NLM_lpage">2008</span>, <span class="refDoi"> DOI: 10.1021/jm00011a019</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00011a019" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADyaK2MXls1yqt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=1995&pages=1998-2008&author=J.+Perregaardauthor=E.+K.+Moltzenauthor=E.+Meierauthor=C.+S%C3%A1nchez&title=Sigma+ligands+with+subnanomolar+affinity+and+preference+for+the+sigma+2+binding+site.+1.+3-%28omega-aminoalkyl%29-1H-indoles&doi=10.1021%2Fjm00011a019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit133R"><div class="casContent"><span class="casTitleNuber">133</span><div class="casTitle"><span class="NLM_cas:atitle">σ Ligands with Subnanomolar Affinity and Preference for the σ2 Binding Site. 1. 3-(ω-Aminoalkyl)-1H-indoles</span></div><div class="casAuthors">Perregaard, Jens; Moltzen, Ejner K.; Meier, Eddi; Sanchez, Connie</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1998-2008</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of 4-(1H-indol-3-yl)-1-butyl-substituted 4-phenylpiperidines, 4-phenyl-1,2,3,6-tetrahydropyridines, and 4-phenylpiperazines was synthesized.  The Ph group was optionally substituted with 4-fluoro or 2-methoxy substituents.  High affinity for both σ1 and σ2 binding sites was achieved with these compds.  Addnl., these compds. had relatively high affinity for serotonin 5-HT1A and 5-HT2A, dopamine D2, and adrenergic α1 receptors.  Introduction of a 4-fluorophenyl substituent at the indole nitrogen atom rendered very selective σ2 ligands with subnanomolar affinity for the σ2 binding site.  The prototype of such a compd. was I.  This compd. had the following binding affinities: IC50 (σ1) = 16 nM, IC50 (σ2) = 0.27 nM, IC50 (5-HT1A) = 22 000 nM, IC50 (5-HT2A) = 270 nM, IC50 (D2) = 4200 nM, IC50 (α1) = 220 nM.  Spiro-joining of the Ph and the piperidine rings into a spiro[isobenzofuran-1(3H),4'-piperidine] ring system resulted in even more selective compds.  Variations of the 1-substituent at the indole and of the chain length of the alkylene spacer group were studied.  The optimal compd. was the spiro analog of I.  This compd. (II) had the binding affinities: IC50 (σ1) = 17 nM, IC50 (σ2) = 0.12 nM, IC50 (5-HT1A) = 21 000 nM, IC50 (5-HT2A) = 2000 nM, IC50 (D2) = 800 nM, IC50 (α1) = 330 nM.  However, the most selective σ2 vs. σ1 ligand was the tropane deriv. (III).  This compd. had the following binding affinities: IC50 (σ1) = 1200 nM, IC50 (σ2) = 2.5 nM.  Potent anxiolytic activity in the black/white box exploration test in rats was found with the two most prominent σ2 ligands Lu 29-253 and Lu 28-179.  Good penetration into the CNS was documented both after s.c. and peroral administration of Lu 28-179 by ex vivo binding studies.  Long duration of action was demonstrated both in ex vivo binding (T1/2 ∼ 20 h) and in the black/white box exploration test.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGraJL4h7Q5nXbVg90H21EOLACvtfcHk0ljXqy_RU_-mzA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXls1yqt7w%253D&md5=c7856739a0cfdd0615e1a6428d759445</span></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=10.1021%2Fjm00011a019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00011a019%26sid%3Dliteratum%253Aachs%26aulast%3DPerregaard%26aufirst%3DJ.%26aulast%3DMoltzen%26aufirst%3DE.%2BK.%26aulast%3DMeier%26aufirst%3DE.%26aulast%3DS%25C3%25A1nchez%26aufirst%3DC.%26atitle%3DSigma%2520ligands%2520with%2520subnanomolar%2520affinity%2520and%2520preference%2520for%2520the%2520sigma%25202%2520binding%2520site.%25201.%25203-%2528omega-aminoalkyl%2529-1H-indoles%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1995%26volume%3D38%26spage%3D1998%26epage%3D2008%26doi%3D10.1021%2Fjm00011a019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref134"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref134'); return false;" data-citation="" class="refNumLink">134</a></strong><div class="NLM_citation" id="cit134"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Berardi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferorelli, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abate, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colabufo, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Contino, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perrone, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tortorella, V.</span></span> <span> </span><span class="NLM_article-title">4-(tetralin-1-yl)- and 4-(naphthalen-1-yl)alkyl derivatives of 1-cyclohexylpiperazine as sigma receptor ligands with agonist sigma2 activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">2308</span>– <span class="NLM_lpage">2317</span>, <span class="refDoi"> DOI: 10.1021/jm031026e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm031026e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BD2cXis1Whs7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=2308-2317&author=F.+Berardiauthor=S.+Ferorelliauthor=C.+Abateauthor=N.+A.+Colabufoauthor=M.+Continoauthor=R.+Perroneauthor=V.+Tortorella&title=4-%28tetralin-1-yl%29-+and+4-%28naphthalen-1-yl%29alkyl+derivatives+of+1-cyclohexylpiperazine+as+sigma+receptor+ligands+with+agonist+sigma2+activity&doi=10.1021%2Fjm031026e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit134R"><div class="casContent"><span class="casTitleNuber">134</span><div class="casTitle"><span class="NLM_cas:atitle">4-(Tetralin-1-yl)- and 4-(Naphthalen-1-yl)alkyl Derivatives of 1-Cyclohexylpiperazine as σ Receptor Ligands with Agonist σ2 Activity</span></div><div class="casAuthors">Berardi, Francesco; Ferorelli, Savina; Abate, Carmen; Colabufo, Nicola Antonio; Contino, Marialessandra; Perrone, Roberto; Tortorella, Vincenzo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2308-2317</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Several 1-cyclohexylpiperazine derivs. related to σ2 receptor ligand 1-cyclohexyl-4-[3-(5-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)propyl]piperazine (I, Ki = 0.34 nM) were synthesized and tested in radioligand binding assays, to attempt a structure-affinity relationship study.  Intermediate alkyl chain length and methoxyl group position on the tetralin nucleus were varied.  A few naphthalene analogs were also prepd.  High affinities were found in σ2 receptor binding for almost all compds., some of which displayed Ki values in subnanomolar range, but low σ2/σ1 selectivities were found.  The highest σ2 affinities were displayed by compds. with an intermediate alkyl chain of three or five methylenes.  Quite high σ1 receptor affinity was found for compds. with a four-methylene chain.  Moreover, homologs of compd. I displayed also satisfactory selectivities over dopamine D2-like, serotonin 5-HT3, and adrenergic α1 receptors.  These compds. and a few others were tested in the inhibition of the elec. evoked contractions in guinea pig bladder and were demonstrated to be full σ2 agonists.  The activity values correlated well to the affinity scale (EC50 in μM range).  I and related compds. are proposed as a class of potential antineoplastic and PET diagnosis agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFYmaM73BtBLVg90H21EOLACvtfcHk0ljXqy_RU_-mzA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXis1Whs7k%253D&md5=d49b636ae09bd42fdfbc65404737767e</span></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=10.1021%2Fjm031026e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm031026e%26sid%3Dliteratum%253Aachs%26aulast%3DBerardi%26aufirst%3DF.%26aulast%3DFerorelli%26aufirst%3DS.%26aulast%3DAbate%26aufirst%3DC.%26aulast%3DColabufo%26aufirst%3DN.%2BA.%26aulast%3DContino%26aufirst%3DM.%26aulast%3DPerrone%26aufirst%3DR.%26aulast%3DTortorella%26aufirst%3DV.%26atitle%3D4-%2528tetralin-1-yl%2529-%2520and%25204-%2528naphthalen-1-yl%2529alkyl%2520derivatives%2520of%25201-cyclohexylpiperazine%2520as%2520sigma%2520receptor%2520ligands%2520with%2520agonist%2520sigma2%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26spage%3D2308%26epage%3D2317%26doi%3D10.1021%2Fjm031026e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref135"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref135'); return false;" data-citation="" class="refNumLink">135</a></strong><div class="NLM_citation" id="cit135"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Intagliata, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alsharif, W. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mesangeau, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fazio, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seminerio, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsumoto, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCurdy, C. R.</span></span> <span> </span><span class="NLM_article-title">Benzimidazolone-based selective σ(2) receptor ligands: Synthesis and pharmacological evaluation</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>165</i></span>,  <span class="NLM_fpage">250</span>– <span class="NLM_lpage">257</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2019.01.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1016%2Fj.ejmech.2019.01.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=30685525" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvFKks7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=165&publication_year=2019&pages=250-257&author=S.+Intagliataauthor=W.+F.+Alsharifauthor=C.+Mesangeauauthor=N.+Fazioauthor=M.+Seminerioauthor=Y.+T.+Xuauthor=R.+R.+Matsumotoauthor=C.+R.+McCurdy&title=Benzimidazolone-based+selective+%CF%83%282%29+receptor+ligands%3A+Synthesis+and+pharmacological+evaluation&doi=10.1016%2Fj.ejmech.2019.01.019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit135R"><div class="casContent"><span class="casTitleNuber">135</span><div class="casTitle"><span class="NLM_cas:atitle">Benzimidazolone-based selective σ2 receptor ligands: Synthesis and pharmacological evaluation</span></div><div class="casAuthors">Intagliata, Sebastiano; Alsharif, Walid F.; Mesangeau, Christophe; Fazio, Nicola; Seminerio, Michael; Xu, Yan-Tong; Matsumoto, Rae R.; McCurdy, Christopher R.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">165</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">250-257</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Sigma receptors (σRs) are considered to be a significant and valid target for developing new medications to address several diseases.  Their potential involvement in numerous central nervous system disorders, neuropathic pain, addiction, and cancer has been extensively reported.  In particular, the σ2R has been identified as potential target for the development of pharmaceutical agents intended to treat the neg. effects assocd. with drugs of abuse.  As a continuation of our previous efforts to develop new selective σ2R ligands, a series of benzimidazolone derivs. I (R1 = H, COCH3; R2 = H, CH3, C3H7, C5H11, C10H21; R3 = cyclohexyl, 4-FC6H4) was designed, synthesized, and characterized.  The newly synthesized ligands were evaluated through in vitro radioligand binding assays to det. their affinity and selectivity towards both σ1 and σ2 receptors.  Several derivs. displayed high affinity for the σ2R (Ki = 0.66-68.5 nM) and varied from preferring to selective values, compared to σ1R (σ1/σ2 = 5.8-1139).  Among them, compd. I (R1 = H; R2 = C3H7; R3 = 4-FC6H4) displayed the ability to produce a dose-dependent redn. in the convulsive effects of cocaine in a rodent model after injecting 10 mg/kg (i.p.).  These preliminary results support the use of selective σ2R ligands in the development of useful pharmacol. tools or potential pharmacotherapies for cocaine toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_xm6l0yxuALVg90H21EOLACvtfcHk0ljXqy_RU_-mzA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvFKks7o%253D&md5=38af6fa85bd035ad2dc497d21de12357</span></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2019.01.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2019.01.019%26sid%3Dliteratum%253Aachs%26aulast%3DIntagliata%26aufirst%3DS.%26aulast%3DAlsharif%26aufirst%3DW.%2BF.%26aulast%3DMesangeau%26aufirst%3DC.%26aulast%3DFazio%26aufirst%3DN.%26aulast%3DSeminerio%26aufirst%3DM.%26aulast%3DXu%26aufirst%3DY.%2BT.%26aulast%3DMatsumoto%26aufirst%3DR.%2BR.%26aulast%3DMcCurdy%26aufirst%3DC.%2BR.%26atitle%3DBenzimidazolone-based%2520selective%2520%25CF%2583%25282%2529%2520receptor%2520ligands%253A%2520Synthesis%2520and%2520pharmacological%2520evaluation%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2019%26volume%3D165%26spage%3D250%26epage%3D257%26doi%3D10.1016%2Fj.ejmech.2019.01.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref136"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref136'); return false;" data-citation="" class="refNumLink">136</a></strong><div class="NLM_citation" id="cit136"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lever, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lever, S. Z.</span></span> <span> </span><span class="NLM_article-title">Synthesis and in vitro evaluation of tetrahydroisoquinolinyl benzamides as ligands for sigma receptors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">2594</span>– <span class="NLM_lpage">2597</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2007.02.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1016%2Fj.bmcl.2007.02.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=17317173" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BD2sXktVentbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2007&pages=2594-2597&author=R.+Xuauthor=J.+R.+Leverauthor=S.+Z.+Lever&title=Synthesis+and+in+vitro+evaluation+of+tetrahydroisoquinolinyl+benzamides+as+ligands+for+sigma+receptors&doi=10.1016%2Fj.bmcl.2007.02.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit136R"><div class="casContent"><span class="casTitleNuber">136</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and in vitro evaluation of tetrahydroisoquinolinyl benzamides as ligands for σ receptors</span></div><div class="casAuthors">Xu, Rong; Lever, John R.; Lever, Susan Z.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2594-2597</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">5-Bromo-N-[4-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-2,3-dimethoxy-benzamide (I) is one of the most potent and selective σ 2 receptor ligands reported to date.  Previous structure-activity relationship studies of such tetrahydroisoquinolinyl benzamides have focused on the linker that connects the ring systems and the effects of benzamide ring substituents.  The present study explores the effects of fusing methylene-, ethylene-, and propylenedioxy rings onto the tetrahydroisoquinoline in place of the two methoxy groups.  These modifications decreased σ2 affinity by 8- to 12-fold, with no major differences noted with ring size.  By contrast, the methylenedioxy analog showed a 10-fold greater σ1 affinity than I, and progressively lower σ1 affinities were then noted with increasing ring size.  The tetrahydroisoquinoline ring of I was opened to study the effects of greater conformational fluidity on σ receptor binding.  The σ2 affinity of the open-ring compd. decreased by 1700-fold, while σ1 affinity was not changed.  Thus, a constrained tetrahydroisoquinoline ring system is key to the exceptional σ2 receptor binding affinity and selectivity of this active series.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqakEVagD56yrVg90H21EOLACvtfcHk0lg2hbOv2F1uZg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXktVentbY%253D&md5=31e997afa809148182c5701dd201fadd</span></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2007.02.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2007.02.005%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DR.%26aulast%3DLever%26aufirst%3DJ.%2BR.%26aulast%3DLever%26aufirst%3DS.%2BZ.%26atitle%3DSynthesis%2520and%2520in%2520vitro%2520evaluation%2520of%2520tetrahydroisoquinolinyl%2520benzamides%2520as%2520ligands%2520for%2520sigma%2520receptors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2007%26volume%3D17%26spage%3D2594%26epage%3D2597%26doi%3D10.1016%2Fj.bmcl.2007.02.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref137"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref137'); return false;" data-citation="" class="refNumLink">137</a></strong><div class="NLM_citation" id="cit137"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rothfuss, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vangveravong, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hotchkiss, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mach, R. H.</span></span> <span> </span><span class="NLM_article-title">Sigma-2 ligands induce tumour cell death by multiple signalling pathways</span>. <i>Br. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>106</i></span>,  <span class="NLM_fpage">693</span>– <span class="NLM_lpage">701</span>, <span class="refDoi"> DOI: 10.1038/bjc.2011.602</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1038%2Fbjc.2011.602" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=22251921" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BC38XisVGqtLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2012&pages=693-701&author=C.+Zengauthor=J.+Rothfussauthor=J.+Zhangauthor=W.+Chuauthor=S.+Vangveravongauthor=Z.+Tuauthor=F.+Panauthor=K.+C.+Changauthor=R.+Hotchkissauthor=R.+H.+Mach&title=Sigma-2+ligands+induce+tumour+cell+death+by+multiple+signalling+pathways&doi=10.1038%2Fbjc.2011.602"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit137R"><div class="casContent"><span class="casTitleNuber">137</span><div class="casTitle"><span class="NLM_cas:atitle">Sigma-2 ligands induce tumour cell death by multiple signalling pathways</span></div><div class="casAuthors">Zeng, C.; Rothfuss, J.; Zhang, J.; Chu, W.; Vangveravong, S.; Tu, Z.; Pan, F.; Chang, K. C.; Hotchkiss, R.; Mach, R. H.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">693-701</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The sigma-2 receptor has been identified as a biomarker of proliferating cells in solid tumors.  In the present study, we studied the mechanisms of sigma-2 ligand-induced cell death in the mouse breast cancer cell line EMT-6 and the human melanoma cell line MDA-MB-435.  EMT-6 and MDA-MB-435 cells were treated with sigma-2 ligands.  The modulation of multiple signaling pathways of cell death was evaluated.  Three sigma-2 ligands (WC-26, SV119 and RHM-138) induced DNA fragmentation, caspase-3 activation and PARP-1 cleavage.  The caspase inhibitor Z-VAD-FMK partially blocked DNA fragmentation and cytotoxicity caused by these compds.  These data suggest that sigma-2 ligand-induced apoptosis and caspase activation are partially responsible for the cell death.  WC-26 and siramesine induced formation of vacuoles in the cells.  WC-26, SV119, RHM-138 and siramesine increased the synthesis and processing of microtubule-assocd. protein light chain 3, an autophagosome marker, and decreased the expression levels of the downstream effectors of mammalian target of rapamycin (mTOR), p70S6K and 4EBP1, suggesting that sigma-2 ligands induce autophagy, probably by inhibition of the mTOR pathway.  All four sigma-2 ligands decreased the expression of cyclin D1 in a time-dependent manner.  In addn., WC-26 and SV119 mainly decreased cyclin B1, E2 and phosphorylation of retinoblastoma protein (pRb); RHM-138 mainly decreased cyclin E2; and 10 μ siramesine mainly decreased cyclin B1 and pRb.  These data suggest that sigma-2 ligands also impair cell-cycle progression in multiple phases of the cell cycle.  Sigma-2 ligands induce cell death by multiple signalling pathways.  British Journal of Cancer (2012) 106, 693-701; doi:10.1038/bjc.2011.602 www.bjcancer.com Published online 17 Jan. 2012.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrD3JJVld4hWbVg90H21EOLACvtfcHk0lg2hbOv2F1uZg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XisVGqtLc%253D&md5=2869df85c11d9213eafe6d7082bde86e</span></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=10.1038%2Fbjc.2011.602&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbjc.2011.602%26sid%3Dliteratum%253Aachs%26aulast%3DZeng%26aufirst%3DC.%26aulast%3DRothfuss%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DChu%26aufirst%3DW.%26aulast%3DVangveravong%26aufirst%3DS.%26aulast%3DTu%26aufirst%3DZ.%26aulast%3DPan%26aufirst%3DF.%26aulast%3DChang%26aufirst%3DK.%2BC.%26aulast%3DHotchkiss%26aufirst%3DR.%26aulast%3DMach%26aufirst%3DR.%2BH.%26atitle%3DSigma-2%2520ligands%2520induce%2520tumour%2520cell%2520death%2520by%2520multiple%2520signalling%2520pathways%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2012%26volume%3D106%26spage%3D693%26epage%3D701%26doi%3D10.1038%2Fbjc.2011.602" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref138"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref138'); return false;" data-citation="" class="refNumLink">138</a></strong><div class="NLM_citation" id="cit138"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wheeler, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mach, R. H.</span></span> <span> </span><span class="NLM_article-title">New N-substituted 9-azabicyclo[3.3.1]nonan-3alpha-yl phenylcarbamate analogs as sigma2 receptor ligands: synthesis, in vitro characterization, and evaluation as PET imaging and chemosensitization agents</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">1222</span>– <span class="NLM_lpage">1231</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2008.12.025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1016%2Fj.bmc.2008.12.025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=19119012" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtlOht7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2009&pages=1222-1231&author=W.+Chuauthor=J.+Xuauthor=D.+Zhouauthor=F.+Zhangauthor=L.+A.+Jonesauthor=K.+T.+Wheelerauthor=R.+H.+Mach&title=New+N-substituted+9-azabicyclo%5B3.3.1%5Dnonan-3alpha-yl+phenylcarbamate+analogs+as+sigma2+receptor+ligands%3A+synthesis%2C+in+vitro+characterization%2C+and+evaluation+as+PET+imaging+and+chemosensitization+agents&doi=10.1016%2Fj.bmc.2008.12.025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit138R"><div class="casContent"><span class="casTitleNuber">138</span><div class="casTitle"><span class="NLM_cas:atitle">New N-substituted 9-azabicyclo[3.3.1]nonan-3α-yl phenylcarbamate analogs as σ2 receptor ligands: Synthesis, in vitro characterization, and evaluation as PET imaging and chemosensitization agents</span></div><div class="casAuthors">Chu, Wenhua; Xu, Jinbin; Zhou, Dong; Zhang, Fanjie; Jones, Lynne A.; Wheeler, Kenneth T.; Mach, Robert H.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1222-1231</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A series of N-substituted 9-azabicyclo[3.3.1]nonan-3α-yl phenylcarbamate analogs were synthesized.  Among them, WC-26 and WC-59 were identified as the most potent σ2 receptor ligands (Ki = 2.58 and 0.82 nM, resp.) with high selectivity against σ1 (Ki of σ1/σ2 ratio = 557 and 2087, resp.). [18F]WC-59 was radiolabeled via a nucleophilic substitution of a mesylate precursor by [18F]fluoride, and in vitro direct binding studies of [18F]WC-59 were conducted using membrane prepns. from murine EMT-6 solid breast tumors.  The results indicate that [18F]WC-59 binds specifically to σ2 receptors in vitro (Kd = ∼2 nM).  Biodistribution studies of [18F]WC-59 in EMT-6 tumor-bearing mice indicated that the tracer was a less suitable candidate for clin. imaging studies than existing F-18 labeled σ2 receptor ligands.  The ability of WC-26 to enhance the cytotoxic effects of the chemotherapy drug, doxorubicin, was evaluated in cell culture using the mouse breast tumor EMT-6 and the human tumor MDA-MB435.  WC-26 greatly increased the ability of doxorubicin to kill these two tumor cell lines in vitro.  These results indicate that WC-26 is potentially a useful chemosensitizer for the treatment of cancer when combined with conventional chemotherapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqcNkdxZdeDmbVg90H21EOLACvtfcHk0lg2hbOv2F1uZg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtlOht7o%253D&md5=164a5c8a7e81d14338e3981d317d417b</span></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2008.12.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2008.12.025%26sid%3Dliteratum%253Aachs%26aulast%3DChu%26aufirst%3DW.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DZhou%26aufirst%3DD.%26aulast%3DZhang%26aufirst%3DF.%26aulast%3DJones%26aufirst%3DL.%2BA.%26aulast%3DWheeler%26aufirst%3DK.%2BT.%26aulast%3DMach%26aufirst%3DR.%2BH.%26atitle%3DNew%2520N-substituted%25209-azabicyclo%255B3.3.1%255Dnonan-3alpha-yl%2520phenylcarbamate%2520analogs%2520as%2520sigma2%2520receptor%2520ligands%253A%2520synthesis%252C%2520in%2520vitro%2520characterization%252C%2520and%2520evaluation%2520as%2520PET%2520imaging%2520and%2520chemosensitization%2520agents%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2009%26volume%3D17%26spage%3D1222%26epage%3D1231%26doi%3D10.1016%2Fj.bmc.2008.12.025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref139"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref139'); return false;" data-citation="" class="refNumLink">139</a></strong><div class="NLM_citation" id="cit139"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Azzariti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colabufo, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berardi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porcelli, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niso, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simone, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perrone, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paradiso, A.</span></span> <span> </span><span class="NLM_article-title">Cyclohexylpiperazine derivative PB28, a sigma2 agonist and sigma1 antagonist receptor, inhibits cell growth, modulates P-glycoprotein, and synergizes with anthracyclines in breast cancer</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">1807</span>– <span class="NLM_lpage">1816</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-05-0402</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1158%2F1535-7163.MCT-05-0402" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=16891467" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BD28XnslWksbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2006&pages=1807-1816&author=A.+Azzaritiauthor=N.+A.+Colabufoauthor=F.+Berardiauthor=L.+Porcelliauthor=M.+Nisoauthor=G.+M.+Simoneauthor=R.+Perroneauthor=A.+Paradiso&title=Cyclohexylpiperazine+derivative+PB28%2C+a+sigma2+agonist+and+sigma1+antagonist+receptor%2C+inhibits+cell+growth%2C+modulates+P-glycoprotein%2C+and+synergizes+with+anthracyclines+in+breast+cancer&doi=10.1158%2F1535-7163.MCT-05-0402"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit139R"><div class="casContent"><span class="casTitleNuber">139</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclohexylpiperazine derivative PB28, a σ2 agonist and σ1 antagonist receptor, inhibits cell growth, modulates P-glycoprotein, and synergizes with anthracyclines in breast cancer</span></div><div class="casAuthors">Azzariti, Amalia; Colabufo, Nicola A.; Berardi, Francesco; Porcelli, Letizia; Niso, Mauro; Simone, Grazia M.; Perrone, Roberto; Paradiso, Angelo</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1807-1816</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">σ Ligands have recently been shown to have cytotoxic activity, to induce ceramide-dependent/caspase-independent apoptosis, and to down-regulate P-glycoprotein (P-gp) mRNA levels in some mouse and human models.  In this study, we verified whether a mixed σ2 agonist/σ1 antagonist, PB28, was able to have antitumor activity and to enhance anthracycline efficacy in two human breast cancer cell lines, MCF7 and MCF7 ADR, both characterized by significant σ2 receptor expression, by high and low σ1 receptor expression, and low and high P-gp expression, resp.  In both cell lines, PB28 showed high σ2 receptor affinity and low σ1 receptor affinity; furthermore, it inhibited cell growth with a clear effect at 48 h (IC50 in nanomolar range), a consistent time exposure-independent increase of G0-G1-phase fraction (of ∼20% of both cell lines) and caspase-independent apoptosis (15% increased after 1-day drug exposure).  PB28 also reduced P-gp expression in a concn.- and time-dependent manner (∼60% in MCF7 and 90% in MCF7 ADR).  We showed also a strong synergism between PB28 and doxorubicin by adopting either simultaneous or sequential schedules of the two drugs.  We suggest that this synergism could depend on PB28-induced increase of intracellular accumulation of doxorubicin (∼50% in MCF7 and 75% in MCF7 ADR by flow cytometry anal.).  In conclusion, we suggest that the σ2 agonist PB28 could be an interesting antitumor agent either in monotherapy or in combination with conventional drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPbEQT82-rDrVg90H21EOLACvtfcHk0lhFMzjq6bTP2A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XnslWksbo%253D&md5=a0581c8aec111a6474b1b041d916bcf5</span></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-05-0402&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-05-0402%26sid%3Dliteratum%253Aachs%26aulast%3DAzzariti%26aufirst%3DA.%26aulast%3DColabufo%26aufirst%3DN.%2BA.%26aulast%3DBerardi%26aufirst%3DF.%26aulast%3DPorcelli%26aufirst%3DL.%26aulast%3DNiso%26aufirst%3DM.%26aulast%3DSimone%26aufirst%3DG.%2BM.%26aulast%3DPerrone%26aufirst%3DR.%26aulast%3DParadiso%26aufirst%3DA.%26atitle%3DCyclohexylpiperazine%2520derivative%2520PB28%252C%2520a%2520sigma2%2520agonist%2520and%2520sigma1%2520antagonist%2520receptor%252C%2520inhibits%2520cell%2520growth%252C%2520modulates%2520P-glycoprotein%252C%2520and%2520synergizes%2520with%2520anthracyclines%2520in%2520breast%2520cancer%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2006%26volume%3D5%26spage%3D1807%26epage%3D1816%26doi%3D10.1158%2F1535-7163.MCT-05-0402" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref140"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref140'); return false;" data-citation="" class="refNumLink">140</a></strong><div class="NLM_citation" id="cit140"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dence, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ponde, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wheeler, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Welch, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mach, R. H.</span></span> <span> </span><span class="NLM_article-title">Carbon-11 labeled sigma2 receptor ligands for imaging breast cancer</span>. <i>Nucl. Med. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">423</span>– <span class="NLM_lpage">430</span>, <span class="refDoi"> DOI: 10.1016/j.nucmedbio.2005.03.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1016%2Fj.nucmedbio.2005.03.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=15982571" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BD2MXlvVWmtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2005&pages=423-430&author=Z.+Tuauthor=C.+S.+Denceauthor=D.+E.+Pondeauthor=L.+Jonesauthor=K.+T.+Wheelerauthor=M.+J.+Welchauthor=R.+H.+Mach&title=Carbon-11+labeled+sigma2+receptor+ligands+for+imaging+breast+cancer&doi=10.1016%2Fj.nucmedbio.2005.03.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit140R"><div class="casContent"><span class="casTitleNuber">140</span><div class="casTitle"><span class="NLM_cas:atitle">Carbon-11 labeled σ2 receptor ligands for imaging breast cancer</span></div><div class="casAuthors">Tu, Zhude; Dence, Carmen S.; Ponde, Datta E.; Jones, Lynne; Wheeler, Kenneth T.; Welch, Michael J.; Mach, Robert H.</div><div class="citationInfo"><span class="NLM_cas:title">Nuclear Medicine and Biology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">423-430</span>CODEN:
                <span class="NLM_cas:coden">NMBIEO</span>;
        ISSN:<span class="NLM_cas:issn">0969-8051</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Four conformationally flexible benzamide analogs having a high affinity and outstanding selectivity for σ 2 vs. σ 1 receptors were synthesized and radiolabeled with carbon-11 by reaction with [11C]methyl iodide.  The four 11C-labeled radiotracers were evaluated for their potential to image the proliferative status of breast tumors with positron emission tomog. (PET).  In vivo studies in female BALB/C mice bearing EMT-6 breast tumors showed that one radiotracer, (2-methoxy-11C)-N-(4-(3,4-dihydro-6,7-dimethoxy-isoquinolin-2(1H)-yl)butyl)-5-methylbenzamide ([11C]2), had a high tumor uptake and suitable tumor/background ratio for imaging purposes.  Blocking studies were consistent with the labeling of σ 2 receptors in vivo.  A study comparing the in vivo properties of [11C]2 and 18F-3'-fluoro-3'-deoxy-L-thymidine ([18F]FLT) indicated that [11C]2 had either similar (lung, fat) or better (blood, muscle) tumor/organ ratios than [18F]FLT in the tissues that are important for breast tumor imaging.  Consequently, [11C]2 is a potential radiotracer for imaging the proliferative status of breast tumors in vivo with PET.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkQua1-WPjULVg90H21EOLACvtfcHk0lhFMzjq6bTP2A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXlvVWmtbw%253D&md5=2dc5b04da294d92bef1f5511d6e5054c</span></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=10.1016%2Fj.nucmedbio.2005.03.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.nucmedbio.2005.03.008%26sid%3Dliteratum%253Aachs%26aulast%3DTu%26aufirst%3DZ.%26aulast%3DDence%26aufirst%3DC.%2BS.%26aulast%3DPonde%26aufirst%3DD.%2BE.%26aulast%3DJones%26aufirst%3DL.%26aulast%3DWheeler%26aufirst%3DK.%2BT.%26aulast%3DWelch%26aufirst%3DM.%2BJ.%26aulast%3DMach%26aufirst%3DR.%2BH.%26atitle%3DCarbon-11%2520labeled%2520sigma2%2520receptor%2520ligands%2520for%2520imaging%2520breast%2520cancer%26jtitle%3DNucl.%2520Med.%2520Biol.%26date%3D2005%26volume%3D32%26spage%3D423%26epage%3D430%26doi%3D10.1016%2Fj.nucmedbio.2005.03.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref141"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref141'); return false;" data-citation="" class="refNumLink">141</a></strong><div class="NLM_citation" id="cit141"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Matsumoto, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lerner, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howard, E. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brackett, D. J.</span></span> <span> </span><span class="NLM_article-title">Sigma receptors: potential medications development target for anti-cocaine agents</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>469</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">12</span>, <span class="refDoi"> DOI: 10.1016/S0014-2999(03)01723-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1016%2FS0014-2999%2803%2901723-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=12782179" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BD3sXktFGltLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=469&publication_year=2003&pages=1-12&author=R.+R.+Matsumotoauthor=Y.+Liuauthor=M.+Lernerauthor=E.+W.+Howardauthor=D.+J.+Brackett&title=Sigma+receptors%3A+potential+medications+development+target+for+anti-cocaine+agents&doi=10.1016%2FS0014-2999%2803%2901723-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit141R"><div class="casContent"><span class="casTitleNuber">141</span><div class="casTitle"><span class="NLM_cas:atitle">σ Receptors: potential medications development target for anti-cocaine agents</span></div><div class="casAuthors">Matsumoto, Rae R.; Liu, Yun; Lerner, Megan; Howard, Eric W.; Brackett, Daniel J.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">469</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">1-12</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">A review.  The ability of cocaine to interact with σ receptors suggests a viable target for medications development.  Recently, numerous novel compds. and antisense oligodeoxynucleotides targeting σ receptors have been synthesized and shown to prevent the behavioral toxicity and psychomotor stimulant effects of cocaine in animals.  Protective doses of σ receptor antagonists have also been shown to prevent changes in gene expression that are induced by cocaine.  Together, the studies provide insight and promising future directions for the development of potential medications for the treatment of cocaine addiction and overdose.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoyVIAeqL1jAbVg90H21EOLACvtfcHk0lhFMzjq6bTP2A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXktFGltLk%253D&md5=cda4068319c69e00726295a4b19f00fa</span></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=10.1016%2FS0014-2999%2803%2901723-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0014-2999%252803%252901723-0%26sid%3Dliteratum%253Aachs%26aulast%3DMatsumoto%26aufirst%3DR.%2BR.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DLerner%26aufirst%3DM.%26aulast%3DHoward%26aufirst%3DE.%2BW.%26aulast%3DBrackett%26aufirst%3DD.%2BJ.%26atitle%3DSigma%2520receptors%253A%2520potential%2520medications%2520development%2520target%2520for%2520anti-cocaine%2520agents%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2003%26volume%3D469%26spage%3D1%26epage%3D12%26doi%3D10.1016%2FS0014-2999%2803%2901723-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref142"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref142'); return false;" data-citation="" class="refNumLink">142</a></strong><div class="NLM_citation" id="cit142"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mach, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">West, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whirrett, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Childers, S. R.</span></span> <span> </span><span class="NLM_article-title">The analgesic tropane analogue (±)-SM 21 has a high affinity for sigma2 receptors</span>. <i>Life Sci.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">PL131</span>– <span class="NLM_lpage">7</span>, <span class="refDoi"> DOI: 10.1016/S0024-3205(99)00014-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1016%2FS0024-3205%2899%2900014-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10096443" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=1999&pages=PL131-7&author=R.+H.+Machauthor=L.+Wuauthor=T.+Westauthor=B.+R.+Whirrettauthor=S.+R.+Childers&title=The+analgesic+tropane+analogue+%28%C2%B1%29-SM+21+has+a+high+affinity+for+sigma2+receptors&doi=10.1016%2FS0024-3205%2899%2900014-4"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=10.1016%2FS0024-3205%2899%2900014-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0024-3205%252899%252900014-4%26sid%3Dliteratum%253Aachs%26aulast%3DMach%26aufirst%3DR.%2BH.%26aulast%3DWu%26aufirst%3DL.%26aulast%3DWest%26aufirst%3DT.%26aulast%3DWhirrett%26aufirst%3DB.%2BR.%26aulast%3DChilders%26aufirst%3DS.%2BR.%26atitle%3DThe%2520analgesic%2520tropane%2520analogue%2520%2528%25C2%25B1%2529-SM%252021%2520has%2520a%2520high%2520affinity%2520for%2520sigma2%2520receptors%26jtitle%3DLife%2520Sci.%26date%3D1999%26volume%3D64%26spage%3DPL131%26epage%3D7%26doi%3D10.1016%2FS0024-3205%2899%2900014-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref143"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref143'); return false;" data-citation="" class="refNumLink">143</a></strong><div class="NLM_citation" id="cit143"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vangveravong, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mach, R. H.</span></span> <span> </span><span class="NLM_article-title">Synthesis of N-substituted 9-azabicyclo[3.3.1]nonan-3alpha-yl carbamate analogs as sigma2 receptor ligands</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">6988</span>– <span class="NLM_lpage">6997</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2006.06.028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1016%2Fj.bmc.2006.06.028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=16837201" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BD28XptFSksb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2006&pages=6988-6997&author=S.+Vangveravongauthor=J.+Xuauthor=C.+Zengauthor=R.+H.+Mach&title=Synthesis+of+N-substituted+9-azabicyclo%5B3.3.1%5Dnonan-3alpha-yl+carbamate+analogs+as+sigma2+receptor+ligands&doi=10.1016%2Fj.bmc.2006.06.028"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit143R"><div class="casContent"><span class="casTitleNuber">143</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of N-substituted 9-azabicyclo[3.3.1]nonan-3α-yl carbamate analogs as σ2 receptor ligands</span></div><div class="casAuthors">Vangveravong, Suwanna; Xu, Jinbin; Zeng, Chenbo; Mach, Robert H.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">6988-6997</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A series of N-substituted 9-azabicyclo[3.3.1]nonan-3α-yl phenylcarbamates was prepd. and their affinities for sigma (σ1 and σ2) receptors were measured in vitro.  The results of their structure-activity relationship study identified two new compds., N-(9-(4-aminobutyl)-9-azabicyclo[3.3.1]nonan-3α-yl)-N'-(2-methoxy-5-methylphenyl)carbamate and N-(9-(6-aminohexyl)-9-azabicyclo[3.3.1]nonan-3α-yl)-N'-(2-methoxy-5-methylphenyl)carbamate, having a high affinity and selectivity for σ2 vs. σ1 receptors.  These compds. were also used in the prepn. of biotinylated and fluorescent probes of the σ2 receptor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXF8zYVhnm77Vg90H21EOLACvtfcHk0limNklhlqPrew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XptFSksb4%253D&md5=47e29a60b0fcac2e986cec05be628ef8</span></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2006.06.028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2006.06.028%26sid%3Dliteratum%253Aachs%26aulast%3DVangveravong%26aufirst%3DS.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DZeng%26aufirst%3DC.%26aulast%3DMach%26aufirst%3DR.%2BH.%26atitle%3DSynthesis%2520of%2520N-substituted%25209-azabicyclo%255B3.3.1%255Dnonan-3alpha-yl%2520carbamate%2520analogs%2520as%2520sigma2%2520receptor%2520ligands%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2006%26volume%3D14%26spage%3D6988%26epage%3D6997%26doi%3D10.1016%2Fj.bmc.2006.06.028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref144"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref144'); return false;" data-citation="" class="refNumLink">144</a></strong><div class="NLM_citation" id="cit144"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hornick, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vangveravong, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitchem, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spitzer, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goedegebuure, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mach, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hawkins, W. G.</span></span> <span> </span><span class="NLM_article-title">The novel sigma-2 receptor ligand SW43 stabilizes pancreas cancer progression in combination with gemcitabine</span>. <i>Mol. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">298</span>, <span class="refDoi"> DOI: 10.1186/1476-4598-9-298</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1186%2F1476-4598-9-298" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=21092190" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsF2hs7vL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=298&author=J.+R.+Hornickauthor=J.+Xuauthor=S.+Vangveravongauthor=Z.+Tuauthor=J.+B.+Mitchemauthor=D.+Spitzerauthor=P.+Goedegebuureauthor=R.+H.+Machauthor=W.+G.+Hawkins&title=The+novel+sigma-2+receptor+ligand+SW43+stabilizes+pancreas+cancer+progression+in+combination+with+gemcitabine&doi=10.1186%2F1476-4598-9-298"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit144R"><div class="casContent"><span class="casTitleNuber">144</span><div class="casTitle"><span class="NLM_cas:atitle">The novel sigma-2 receptor ligand SW43 stabilizes pancreas cancer progression in combination with gemcitabine</span></div><div class="casAuthors">Hornick, John R.; Xu, Jinbin; Vangveravong, Suwanna; Tu, Zhude; Mitchem, Jonathan B.; Spitzer, Dirk; Goedegebuure, Peter; Mach, Robert H.; Hawkins, William G.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">298</span>CODEN:
                <span class="NLM_cas:coden">MCOACG</span>;
        ISSN:<span class="NLM_cas:issn">1476-4598</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Sigma-2 receptors are over-expressed in proliferating cancer cells, making an attractive target for the targeted treatment of pancreatic cancer.  In this study, we investigated the role of the novel sigma-2 receptor ligand SW43 to induce apoptosis and augment std. chemotherapy.  Results: The binding affinity for sigma-2 ligands is high in pancreas cancer, and they induce apoptosis with a rank order of SV119 < SW43 < SRM in vitro.  Combining these compds. with gemcitabine further increased apoptosis and decreased viability.  Our in vivo model showed that sigma-2 ligand treatment decreased tumor vol. to the same extent as gemcitabine.  However, SW43 combination treatment with gemcitabine was superior to the other compds. and resulted in stabilization of tumor vol. during treatment, with minimal toxicities.  Conclusions: This study shows that the sigma-2 ligand SW43 has the greatest capacity to augment gemcitabine in a pre-clin. model of pancreas cancer and has provided us with the rationale to move this compd. forward with clin. investigations for patients with pancreatic cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7apBSRKE1DrVg90H21EOLACvtfcHk0limNklhlqPrew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsF2hs7vL&md5=ff30e331ee6e3d4890f5b1fa01f86251</span></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=10.1186%2F1476-4598-9-298&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1476-4598-9-298%26sid%3Dliteratum%253Aachs%26aulast%3DHornick%26aufirst%3DJ.%2BR.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DVangveravong%26aufirst%3DS.%26aulast%3DTu%26aufirst%3DZ.%26aulast%3DMitchem%26aufirst%3DJ.%2BB.%26aulast%3DSpitzer%26aufirst%3DD.%26aulast%3DGoedegebuure%26aufirst%3DP.%26aulast%3DMach%26aufirst%3DR.%2BH.%26aulast%3DHawkins%26aufirst%3DW.%2BG.%26atitle%3DThe%2520novel%2520sigma-2%2520receptor%2520ligand%2520SW43%2520stabilizes%2520pancreas%2520cancer%2520progression%2520in%2520combination%2520with%2520gemcitabine%26jtitle%3DMol.%2520Cancer%26date%3D2010%26volume%3D9%26spage%3D298%26doi%3D10.1186%2F1476-4598-9-298" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref145"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref145'); return false;" data-citation="" class="refNumLink">145</a></strong><div class="NLM_citation" id="cit145"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vangveravong, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hyrc, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rothfuss, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldberg, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hotchkiss, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mach, R. H.</span></span> <span> </span><span class="NLM_article-title">Characterization and evaluation of two novel fluorescent sigma-2 receptor ligands as proliferation probes</span>. <i>Mol. Imaging</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">420</span>– <span class="NLM_lpage">433</span>, <span class="refDoi"> DOI: 10.2310/7290.2011.00009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.2310%2F7290.2011.00009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=22201533" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BC38XitlGnsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=420-433&author=C.+Zengauthor=S.+Vangveravongauthor=L.+A.+Jonesauthor=K.+Hyrcauthor=K.+C.+Changauthor=J.+Xuauthor=J.+M.+Rothfussauthor=M.+P.+Goldbergauthor=R.+S.+Hotchkissauthor=R.+H.+Mach&title=Characterization+and+evaluation+of+two+novel+fluorescent+sigma-2+receptor+ligands+as+proliferation+probes&doi=10.2310%2F7290.2011.00009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit145R"><div class="casContent"><span class="casTitleNuber">145</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization and evaluation of two novel fluorescent sigma-2 receptor ligands as proliferation probes</span></div><div class="casAuthors">Zeng, Chenbo; Vangveravong, Suwanna; Jones, Lynne A.; Hyrc, Krzystof; Chang, Katherine C.; Xu, Jinbin; Rothfuss, Justin M.; Goldberg, Mark P.; Hotchkiss, Richard S.; Mach, Robert H.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Imaging</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">420-433</span>CODEN:
                <span class="NLM_cas:coden">MIOMBP</span>;
        ISSN:<span class="NLM_cas:issn">1535-3508</span>.
    
            (<span class="NLM_cas:orgname">Decker Publishing</span>)
        </div><div class="casAbstract">We synthesized and characterized two novel fluorescent sigma-2 receptor selective ligands, SW120 and SW116, and evaluated these ligands as potential probes for imaging cell proliferation.  Both ligands are highly selective for sigma-2 receptors vs. sigma-1 receptors.  SW120 and SW116 were internalized into MDA-MB-435 cells, and 50% of the max. fluorescent intensity was reached in 11 and 24 min, resp.  In vitro studies showed that 50% of SW120 or SW116 washed out of cells in 1 h.  The internalization of SW120 was reduced ≈30% by phenylarsine oxide, an inhibitor of endocytosis, suggesting that sigma-2 ligands are internalized, in part, by an endocytotic pathway.  Subcellular localization studies using confocal and two-photon microscopy showed that SW120 and SW116 partially colocalized with fluorescent markers of mitochondria, endoplasmic reticulum, lysosomes, and the plasma membrane, suggesting that sigma-2 receptors localized to the cytoplasmic organelles and plasma membrane.  SW120 did not colocalize with the nuclear dye 4',6-diamidino-2-phenylindole.  In vivo studies showed that the uptake of SW120 in solid tumors and peripheral blood mononuclear cells of mice pos. correlated with the expression level of the cell proliferation marker Ki-67, suggesting that sigma-2 fluorescent probes may be used to image cell proliferation in mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpP5AnDOdYA4rVg90H21EOLACvtfcHk0lgs208SewH8uA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XitlGnsr8%253D&md5=4887fd2cbf00e42c7c4fb719ca4f4192</span></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=10.2310%2F7290.2011.00009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2310%252F7290.2011.00009%26sid%3Dliteratum%253Aachs%26aulast%3DZeng%26aufirst%3DC.%26aulast%3DVangveravong%26aufirst%3DS.%26aulast%3DJones%26aufirst%3DL.%2BA.%26aulast%3DHyrc%26aufirst%3DK.%26aulast%3DChang%26aufirst%3DK.%2BC.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DRothfuss%26aufirst%3DJ.%2BM.%26aulast%3DGoldberg%26aufirst%3DM.%2BP.%26aulast%3DHotchkiss%26aufirst%3DR.%2BS.%26aulast%3DMach%26aufirst%3DR.%2BH.%26atitle%3DCharacterization%2520and%2520evaluation%2520of%2520two%2520novel%2520fluorescent%2520sigma-2%2520receptor%2520ligands%2520as%2520proliferation%2520probes%26jtitle%3DMol.%2520Imaging%26date%3D2011%26volume%3D10%26spage%3D420%26epage%3D433%26doi%3D10.2310%2F7290.2011.00009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref146"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref146'); return false;" data-citation="" class="refNumLink">146</a></strong><div class="NLM_citation" id="cit146"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vangveravong, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDunn, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hawkins, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mach, R. H.</span></span> <span> </span><span class="NLM_article-title">Sigma-2 receptor ligand as a novel method for delivering a SMAC mimetic drug for treating ovarian cancer</span>. <i>Br. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>109</i></span>,  <span class="NLM_fpage">2368</span>– <span class="NLM_lpage">2377</span>, <span class="refDoi"> DOI: 10.1038/bjc.2013.593</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1038%2Fbjc.2013.593" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=24104966" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsFyntbfK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2013&pages=2368-2377&author=C.+Zengauthor=S.+Vangveravongauthor=J.+E.+McDunnauthor=W.+G.+Hawkinsauthor=R.+H.+Mach&title=Sigma-2+receptor+ligand+as+a+novel+method+for+delivering+a+SMAC+mimetic+drug+for+treating+ovarian+cancer&doi=10.1038%2Fbjc.2013.593"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit146R"><div class="casContent"><span class="casTitleNuber">146</span><div class="casTitle"><span class="NLM_cas:atitle">Sigma-2 receptor ligand as a novel method for delivering a SMAC mimetic drug for treating ovarian cancer</span></div><div class="casAuthors">Zeng, C.; Vangveravong, S.; McDunn, J. E.; Hawkins, W. G.; Mach, R. H.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2368-2377</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Background: The sigma-2 receptor has been validated as a biomarker for proliferating tumors.  Second mitochondria-derived activator of caspase (Smac) is a protein released from mitochondria into the cytosol, leading to apoptosis.  In this study, we investigated a sigma-2 ligand as a tumor-targeting drug delivery agent for treating ovarian cancer.  Methods: A sigma-2 ligand, SW 43, was conjugated with a Smac mimetic compd. (SMC), SW IV-52s, to form SW III-123.  The delivery function of the sigma-2 moiety and cell killing mechanisms of SW III-123 were examd. in human ovarian cancer cell lines.  Results: SW III-123 internalization into ovarian cancer cells was mediated by sigma-2 receptors.  SW III-123, but not SW IV-52s or SW 43, exhibited potent cytotoxicity in human ovarian cancer cell lines SKOV-3, CaOV-3 and BG-1 after 24-h treatment, suggesting that the sigma-2 ligand successfully delivered SMC into ovarian cancer cells.  SW III-123 induced rapid degrdn. of inhibitor of apoptosis proteins (cIAP1 and cIAP2), accumulation of NF-κB-inducing kinase (NIK) and phosphorylation of NF-κB p65, suggesting that SW III-123 activated both canonical and noncanonical NF-κB pathways in SKOV-3 cells.  SW III-123 cleaved caspase-8, -9 and -3.  Tumor necrosis factor alpha (TNFα) antibody markedly blocked SW III-123-induced cell death and caspase-3 activity in SKOV-3 cells, indicating that SW III-123 activated both intrinsic and extrinsic apoptotic pathways and induced TNFα-dependent cell death in SKOV-3 cells.  Conclusion: Sigma-2 ligands are a promising tumor-targeting drug delivery agent.  Sigma-2-conjugated SMC exemplifies a novel class of therapeutic drugs for treating ovarian cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrvRumJqiAfb7Vg90H21EOLACvtfcHk0ljO-47vP0n2MA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsFyntbfK&md5=d2f329d307adab71704872279f034320</span></div><a href="/servlet/linkout?suffix=cit146&amp;dbid=16384&amp;doi=10.1038%2Fbjc.2013.593&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbjc.2013.593%26sid%3Dliteratum%253Aachs%26aulast%3DZeng%26aufirst%3DC.%26aulast%3DVangveravong%26aufirst%3DS.%26aulast%3DMcDunn%26aufirst%3DJ.%2BE.%26aulast%3DHawkins%26aufirst%3DW.%2BG.%26aulast%3DMach%26aufirst%3DR.%2BH.%26atitle%3DSigma-2%2520receptor%2520ligand%2520as%2520a%2520novel%2520method%2520for%2520delivering%2520a%2520SMAC%2520mimetic%2520drug%2520for%2520treating%2520ovarian%2520cancer%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2013%26volume%3D109%26spage%3D2368%26epage%3D2377%26doi%3D10.1038%2Fbjc.2013.593" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref147"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref147'); return false;" data-citation="" class="refNumLink">147</a></strong><div class="NLM_citation" id="cit147"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Banister, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoo, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chua, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mach, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kassiou, M.</span></span> <span> </span><span class="NLM_article-title">N-Arylalkyl-2-azaadamantanes as cage-expanded polycarbocyclic sigma (σ) receptor ligands</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">5289</span>– <span class="NLM_lpage">5292</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2011.07.028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1016%2Fj.bmcl.2011.07.028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=21788137" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtVKisrfK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=5289-5292&author=S.+D.+Banisterauthor=D.+T.+Yooauthor=S.+W.+Chuaauthor=J.+Cuiauthor=R.+H.+Machauthor=M.+Kassiou&title=N-Arylalkyl-2-azaadamantanes+as+cage-expanded+polycarbocyclic+sigma+%28%CF%83%29+receptor+ligands&doi=10.1016%2Fj.bmcl.2011.07.028"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit147R"><div class="casContent"><span class="casTitleNuber">147</span><div class="casTitle"><span class="NLM_cas:atitle">N-Arylalkyl-2-azaadamantanes as cage-expanded polycarbocyclic sigma (σ) receptor ligands</span></div><div class="casAuthors">Banister, Samuel D.; Yoo, David T.; Chua, Sook Wern; Cui, Jinquan; Mach, Robert H.; Kassiou, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">5289-5292</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A series of racemic N-arylalkyl-2-azaadamantan-1-ols and the corresponding deoxygenated, achiral N-arylalkyl-2-azaadamantanes were synthesized and screened in competition binding assays against a panel of CNS targets.  Adamantyl hemiaminals (i.e., N-arylalkyl-2-azaadamantan-1-ols) displayed generally low affinity for both σ1 (Ki values = 294-1950 nM) and σ2 receptors (Ki values = 201-1020 nM), and negligible affinity for 42 other CNS proteins.  Deoxygenation of N-arylalkyl-2-azaadamantan-1-ols to give the corresponding achiral azaadamantanes N-arylalkyl-2-azaadamantanes greatly improved affinity for σ1 (Ki values = 8.3-239 nM) and σ2 receptors (Ki values = 34-312 nM).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTyzjKlJvqgLVg90H21EOLACvtfcHk0ljO-47vP0n2MA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtVKisrfK&md5=74c53cfd1870fbcc72d6345367ad26de</span></div><a href="/servlet/linkout?suffix=cit147&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2011.07.028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2011.07.028%26sid%3Dliteratum%253Aachs%26aulast%3DBanister%26aufirst%3DS.%2BD.%26aulast%3DYoo%26aufirst%3DD.%2BT.%26aulast%3DChua%26aufirst%3DS.%2BW.%26aulast%3DCui%26aufirst%3DJ.%26aulast%3DMach%26aufirst%3DR.%2BH.%26aulast%3DKassiou%26aufirst%3DM.%26atitle%3DN-Arylalkyl-2-azaadamantanes%2520as%2520cage-expanded%2520polycarbocyclic%2520sigma%2520%2528%25CF%2583%2529%2520receptor%2520ligands%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D21%26spage%3D5289%26epage%3D5292%26doi%3D10.1016%2Fj.bmcl.2011.07.028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref148"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref148'); return false;" data-citation="" class="refNumLink">148</a></strong><div class="NLM_citation" id="cit148"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Peeters, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romieu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maurice, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maloteaux, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hermans, E.</span></span> <span> </span><span class="NLM_article-title">Involvement of the sigma 1 receptor in the modulation of dopaminergic transmission by amantadine</span>. <i>Eur. J. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">2212</span>– <span class="NLM_lpage">2220</span>, <span class="refDoi"> DOI: 10.1111/j.0953-816X.2004.03297.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1111%2Fj.0953-816X.2004.03297.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=15090047" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A280%3ADC%252BD2c7ps1Crsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2004&pages=2212-2220&author=M.+Peetersauthor=P.+Romieuauthor=T.+Mauriceauthor=T.+P.+Suauthor=J.+M.+Maloteauxauthor=E.+Hermans&title=Involvement+of+the+sigma+1+receptor+in+the+modulation+of+dopaminergic+transmission+by+amantadine&doi=10.1111%2Fj.0953-816X.2004.03297.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit148R"><div class="casContent"><span class="casTitleNuber">148</span><div class="casTitle"><span class="NLM_cas:atitle">Involvement of the sigma 1 receptor in the modulation of dopaminergic transmission by amantadine</span></div><div class="casAuthors">Peeters Magali; Romieu Pascal; Maurice Tangui; Su Tsung-Ping; Maloteaux Jean-Marie; Hermans Emmanuel</div><div class="citationInfo"><span class="NLM_cas:title">The European journal of neuroscience</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2212-20</span>
        ISSN:<span class="NLM_cas:issn">0953-816X</span>.
    </div><div class="casAbstract">Pharmacological effects of amantadine on dopaminergic transmission are proposed to result from an uncompetitive antagonism at glutamate N-methyl-D-aspartate (NMDA) receptors.  However, our previous studies examining amantadine-mediated dopamine receptor regulation in the rat striatum revealed a discrepancy from a direct interference with glutamate transmission.  Preliminary in vitro binding data from the literature suggested the interaction of amantadine with the sigma1 receptor.  Therefore, we have now further characterized the pharmacological properties of amantadine and memantine at this receptor and investigated its involvement in the modulation of striatal dopaminergic transmission.  Our binding studies using [3H]-(+)SKF-10,047 indicated that amantadine and memantine behave as ligands of the sigma(1) receptor in rat forebrain homogenates (Ki values of 7.44 +/- 0.82 and 2.60 +/- 0.62 microm, respectively).  In NG108-15 neuroblastoma cells, both drugs (amantadine (100 microm) and memantine (10 microm)) potentiated the bradykinin-induced mobilization of intracellular Ca2+, mimicking the effect of the sigma1 receptor agonist PRE-084 (1 microm).  Finally, we previously showed that in striatal membranes from amantadine-treated rats, the functional coupling of dopamine receptors with G-proteins was enhanced.  Similarly, PRE-084 dose-dependently increased the [35S]GTPgammaS binding induced by dopamine (Emax 28 and 26% of basal, 0.3 and 1 mg/kg PRE-084, respectively).  By contrast, BD1047, which is without effect on its own, antagonized the effects of amantadine and PRE-084.  Together, these data demonstrate that aminoadamantanes behave as sigma1 receptor agonists, and confirm an involvement of this receptor in modulating dopamine receptors exerted by therapeutically relevant concentrations of amantadine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR6D1GR30Lj8xpyrDyM_m9cfW6udTcc2ebsfqQ19SG3mLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2c7ps1Crsg%253D%253D&md5=d616f11a3001addf47ace0c12fa9884a</span></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=10.1111%2Fj.0953-816X.2004.03297.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.0953-816X.2004.03297.x%26sid%3Dliteratum%253Aachs%26aulast%3DPeeters%26aufirst%3DM.%26aulast%3DRomieu%26aufirst%3DP.%26aulast%3DMaurice%26aufirst%3DT.%26aulast%3DSu%26aufirst%3DT.%2BP.%26aulast%3DMaloteaux%26aufirst%3DJ.%2BM.%26aulast%3DHermans%26aufirst%3DE.%26atitle%3DInvolvement%2520of%2520the%2520sigma%25201%2520receptor%2520in%2520the%2520modulation%2520of%2520dopaminergic%2520transmission%2520by%2520amantadine%26jtitle%3DEur.%2520J.%2520Neurosci.%26date%3D2004%26volume%3D19%26spage%3D2212%26epage%3D2220%26doi%3D10.1111%2Fj.0953-816X.2004.03297.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref149"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref149'); return false;" data-citation="" class="refNumLink">149</a></strong><div class="NLM_citation" id="cit149"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marrazzo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prezzavento, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pappalardo, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bousquet, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iadanza, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pike, V. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ronsisvalle, G.</span></span> <span> </span><span class="NLM_article-title">Synthesis of (+)- and (−)-cis-2-[(1-adamantylamino)-methyl]-1-phenylcyclopropane derivatives as high affinity probes for sigma1 and sigma2 binding sites</span>. <i>Farmaco</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">45</span>– <span class="NLM_lpage">53</span>, <span class="refDoi"> DOI: 10.1016/S0014-827X(01)01170-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1016%2FS0014-827X%2801%2901170-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=11902645" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BD38XhtF2isrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2002&pages=45-53&author=A.+Marrazzoauthor=O.+Prezzaventoauthor=M.+S.+Pappalardoauthor=E.+Bousquetauthor=M.+Iadanzaauthor=V.+W.+Pikeauthor=G.+Ronsisvalle&title=Synthesis+of+%28%2B%29-+and+%28%E2%88%92%29-cis-2-%5B%281-adamantylamino%29-methyl%5D-1-phenylcyclopropane+derivatives+as+high+affinity+probes+for+sigma1+and+sigma2+binding+sites&doi=10.1016%2FS0014-827X%2801%2901170-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit149R"><div class="casContent"><span class="casTitleNuber">149</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of (+)- and (-)-cis-2-[(1-adamantylamino)-methyl]-1-phenylcyclopropane derivatives as high affinity probes for σ1 and σ2 binding sites</span></div><div class="casAuthors">Marrazzo, Agostino; Prezzavento, Orazio; Pappalardo, Maria S.; Bousquet, Ennio; Iadanza, Manuela; Pike, Victor W.; Ronsisvalle, Giuseppe</div><div class="citationInfo"><span class="NLM_cas:title">Farmaco</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">45-53</span>CODEN:
                <span class="NLM_cas:coden">FRMCE8</span>;
        ISSN:<span class="NLM_cas:issn">0014-827X</span>.
    
            (<span class="NLM_cas:orgname">Editions Scientifiques et Medicales Elsevier</span>)
        </div><div class="casAbstract">Selective ligands for either sigma1 (σ1) or σ2 binding sites are potentially useful for gaining a better understanding of the physiol. functions of these proteins.  Moreover, potent and selective homochiral σ1 and σ2 binding site ligands represent leads to potential radioligands for tumor imaging with positron emission tomog. (PET).  On the basis of their structural similarity to previous leads, new (+)- and (-)-cis-2-[(1-adamantylamino)-methyl]-1-phenylcyclopropane derivs. were synthesized and their binding affinities for σ1 and σ2 binding sites were detd.  Each enantiomer showed high affinity for both σ1 and σ2 binding sites, but only (-)-cis-methyl-2-{[1-adamantyl(methyl)amino]methyl}-1-phenylcyclopropane-carboxylate, (-)-4, showed appreciable selectivity for binding to σ1 vs. σ2 sites.  The enantiomers of cis-(2-{[1-adamantyl(methyl)amino]methyl}-1-phenylcyclopropyl)methanol, 6, expressed the highest affinity for σ1 and σ2 binding sites.  Ligands (-)-4, (+)-6 and (-)-6 might be rapidly labeled in their N-Me groups by methylation of the N-desmethyl analogs with [11C]iodomethane to provide prospective radioligands for PET.  The N-desmethyl analogs, which are also high affinity ligands, were prepd. and shown to undergo satisfactory methylation with iodomethane.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpT3_FB3c2S_rVg90H21EOLACvtfcHk0lif91h7_rkKVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XhtF2isrg%253D&md5=0f3a1115c3c8f7bd0a305d26cb234d35</span></div><a href="/servlet/linkout?suffix=cit149&amp;dbid=16384&amp;doi=10.1016%2FS0014-827X%2801%2901170-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0014-827X%252801%252901170-3%26sid%3Dliteratum%253Aachs%26aulast%3DMarrazzo%26aufirst%3DA.%26aulast%3DPrezzavento%26aufirst%3DO.%26aulast%3DPappalardo%26aufirst%3DM.%2BS.%26aulast%3DBousquet%26aufirst%3DE.%26aulast%3DIadanza%26aufirst%3DM.%26aulast%3DPike%26aufirst%3DV.%2BW.%26aulast%3DRonsisvalle%26aufirst%3DG.%26atitle%3DSynthesis%2520of%2520%2528%252B%2529-%2520and%2520%2528%25E2%2588%2592%2529-cis-2-%255B%25281-adamantylamino%2529-methyl%255D-1-phenylcyclopropane%2520derivatives%2520as%2520high%2520affinity%2520probes%2520for%2520sigma1%2520and%2520sigma2%2520binding%2520sites%26jtitle%3DFarmaco%26date%3D2002%26volume%3D57%26spage%3D45%26epage%3D53%26doi%3D10.1016%2FS0014-827X%2801%2901170-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref150"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref150'); return false;" data-citation="" class="refNumLink">150</a></strong><div class="NLM_citation" id="cit150"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Intagliata, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agha, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kopajtic, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katz, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamble, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avery, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCurdy, C. R.</span></span> <span> </span><span class="NLM_article-title">Exploring 1-adamantanamine as an alternative amine moiety for metabolically labile azepane ring in newly synthesized benzo[d]thiazol-2(3H)one σ receptor ligands</span>. <i>Med. Chem. Res.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">1697</span>– <span class="NLM_lpage">1706</span>, <span class="refDoi"> DOI: 10.1007/s00044-020-02597-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1007%2Fs00044-020-02597-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=33584084" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtlCqtb%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2020&pages=1697-1706&author=S.+Intagliataauthor=H.+Aghaauthor=T.+A.+Kopajticauthor=J.+L.+Katzauthor=S.+H.+Kambleauthor=A.+Sharmaauthor=B.+A.+Averyauthor=C.+R.+McCurdy&title=Exploring+1-adamantanamine+as+an+alternative+amine+moiety+for+metabolically+labile+azepane+ring+in+newly+synthesized+benzo%5Bd%5Dthiazol-2%283H%29one+%CF%83+receptor+ligands&doi=10.1007%2Fs00044-020-02597-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit150R"><div class="casContent"><span class="casTitleNuber">150</span><div class="casTitle"><span class="NLM_cas:atitle">Exploring 1-adamantanamine as an alternative amine moiety for metabolically labile azepane ring in newly synthesized benzo[d]thiazol-2(3H)one σ receptor ligands</span></div><div class="casAuthors">Intagliata, Sebastiano; Agha, Hebaalla; Kopajtic, Theresa A.; Katz, Jonathan L.; Kamble, Shyam H.; Sharma, Abhisheak; Avery, Bonnie A.; McCurdy, Christopher R.</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Chemistry Research</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1697-1706</span>CODEN:
                <span class="NLM_cas:coden">MCREEB</span>;
        ISSN:<span class="NLM_cas:issn">1054-2523</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Abstr.: In this work we report the structure-affinity relationships, binding properties, and metabolic stability studies of a series of benzo[d]thiazol-2(3H)one as sigma receptor (σR) ligands.  Specifically, to improve the metabolic stability of the cyclic amine fragment of our lead compd. (SN56), the metabolically unstable azepane ring was replaced with a 1-adatamantamine moiety.  Within the synthesized analogs, compd. 12(I) had low nanomolar affinity for the σ1R (Ki = 7.2 nM) and moderate preference (61-fold) over the σ2R.  In vitro metabolic stability studies showed a slight improvement of the metabolic stability for 7-12, even though an extensive metab. in rat liver microsomes is being obsd.  Furthermore, metabolic soft spot identification of 12 suggested that the N-Me group of the adamantyl moiety is a major site of metab.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgLzdtkl59-bVg90H21EOLACvtfcHk0lif91h7_rkKVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtlCqtb%252FJ&md5=fa088b90e24345ad3b559684f8e94d8e</span></div><a href="/servlet/linkout?suffix=cit150&amp;dbid=16384&amp;doi=10.1007%2Fs00044-020-02597-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00044-020-02597-2%26sid%3Dliteratum%253Aachs%26aulast%3DIntagliata%26aufirst%3DS.%26aulast%3DAgha%26aufirst%3DH.%26aulast%3DKopajtic%26aufirst%3DT.%2BA.%26aulast%3DKatz%26aufirst%3DJ.%2BL.%26aulast%3DKamble%26aufirst%3DS.%2BH.%26aulast%3DSharma%26aufirst%3DA.%26aulast%3DAvery%26aufirst%3DB.%2BA.%26aulast%3DMcCurdy%26aufirst%3DC.%2BR.%26atitle%3DExploring%25201-adamantanamine%2520as%2520an%2520alternative%2520amine%2520moiety%2520for%2520metabolically%2520labile%2520azepane%2520ring%2520in%2520newly%2520synthesized%2520benzo%255Bd%255Dthiazol-2%25283H%2529one%2520%25CF%2583%2520receptor%2520ligands%26jtitle%3DMed.%2520Chem.%2520Res.%26date%3D2020%26volume%3D29%26spage%3D1697%26epage%3D1706%26doi%3D10.1007%2Fs00044-020-02597-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref151"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref151'); return false;" data-citation="" class="refNumLink">151</a></strong><div class="NLM_citation" id="cit151"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Groth-Pedersen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ostenfeld, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Høyer-Hansen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nylandsted, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jäättelä, M.</span></span> <span> </span><span class="NLM_article-title">Vincristine induces dramatic lysosomal changes and sensitizes cancer cells to lysosome-destabilizing siramesine</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>67</i></span>,  <span class="NLM_fpage">2217</span>– <span class="NLM_lpage">2225</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-06-3520</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1158%2F0008-5472.CAN-06-3520" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=17332352" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BD2sXitlSjs7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2007&pages=2217-2225&author=L.+Groth-Pedersenauthor=M.+S.+Ostenfeldauthor=M.+H%C3%B8yer-Hansenauthor=J.+Nylandstedauthor=M.+J%C3%A4%C3%A4ttel%C3%A4&title=Vincristine+induces+dramatic+lysosomal+changes+and+sensitizes+cancer+cells+to+lysosome-destabilizing+siramesine&doi=10.1158%2F0008-5472.CAN-06-3520"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit151R"><div class="casContent"><span class="casTitleNuber">151</span><div class="casTitle"><span class="NLM_cas:atitle">Vincristine Induces Dramatic Lysosomal Changes and Sensitizes Cancer Cells to Lysosome-Destabilizing Siramesine</span></div><div class="casAuthors">Groth-Pedersen, Line; Ostenfeld, Marie Stampe; Hoyer-Hansen, Maria; Nylandsted, Jesper; Jaeaettelae, Marja</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2217-2225</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Vincristine is a microtubule-destabilizing antimitotic drug that has been used in cancer therapy for over 40 years.  However, the knowledge on vincristine-induced cell death pathways is still sparse.  Here, we show that vincristine induces dramatic changes in the lysosomal compartment and sensitizes cells to lysosomal membrane permeabilization.  In HeLa cervix carcinoma cells, vincristine induced mitotic arrest and massive cell death assocd. with an early increase in the lysosomal vol. and lysosomal leakage followed by the activation of the intrinsic apoptosis program.  In contrast, the majority of vincristine-treated MCF-7 breast carcinoma cells resisted apoptosis.  Instead, they adapted to the spindle assembly checkpoint and escaped the mitotic arrest as micronucleated and senescent cells with an increase in the vol. and the activity of their lysosomal compartment.  Consistent with its substantial effects on the lysosomes, vincristine greatly sensitized cultured cancer cells as well as orthotopic breast cancer xenografts in mice to the cytotoxicity induced by siramesine, a sigma-2 receptor ligand that kills cancer cells by destabilizing their lysosomes.  Importantly, the combination of nontoxic concns. of vincristine and siramesine resulted in massive cell death even in MCF-7 cells that were capable of escaping vincristine-induced spindle assembly checkpoint and cell death.  Similar synergism was obsd. when siramesine was combined with a semisynthetic vincristine analog, vinorelbine, or with microtubule-stabilizing paclitaxel.  These data strongly suggest that combination therapies consisting of microtubule-disturbing and lysosome-destabilizing drugs may prove useful in the treatment of otherwise therapy-resistant human cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrvI_uHH5FhrLVg90H21EOLACvtfcHk0lif91h7_rkKVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXitlSjs7s%253D&md5=f5de3130e9fe376a8079ded0a3df9411</span></div><a href="/servlet/linkout?suffix=cit151&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-06-3520&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-06-3520%26sid%3Dliteratum%253Aachs%26aulast%3DGroth-Pedersen%26aufirst%3DL.%26aulast%3DOstenfeld%26aufirst%3DM.%2BS.%26aulast%3DH%25C3%25B8yer-Hansen%26aufirst%3DM.%26aulast%3DNylandsted%26aufirst%3DJ.%26aulast%3DJ%25C3%25A4%25C3%25A4ttel%25C3%25A4%26aufirst%3DM.%26atitle%3DVincristine%2520induces%2520dramatic%2520lysosomal%2520changes%2520and%2520sensitizes%2520cancer%2520cells%2520to%2520lysosome-destabilizing%2520siramesine%26jtitle%3DCancer%2520Res.%26date%3D2007%26volume%3D67%26spage%3D2217%26epage%3D2225%26doi%3D10.1158%2F0008-5472.CAN-06-3520" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref152"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref152'); return false;" data-citation="" class="refNumLink">152</a></strong><div class="NLM_citation" id="cit152"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ostenfeld, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Høyer-Hansen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bastholm, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fehrenbacher, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olsen, O. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groth-Pedersen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puustinen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirkegaard-Sørensen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nylandsted, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farkas, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jäättelä, M.</span></span> <span> </span><span class="NLM_article-title">Anti-cancer agent siramesine is a lysosomotropic detergent that induces cytoprotective autophagosome accumulation</span>. <i>Autophagy</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">487</span>– <span class="NLM_lpage">499</span>, <span class="refDoi"> DOI: 10.4161/auto.5774</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.4161%2Fauto.5774" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=18305408" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BD1cXntFynurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2008&pages=487-499&author=M.+S.+Ostenfeldauthor=M.+H%C3%B8yer-Hansenauthor=L.+Bastholmauthor=N.+Fehrenbacherauthor=O.+D.+Olsenauthor=L.+Groth-Pedersenauthor=P.+Puustinenauthor=T.+Kirkegaard-S%C3%B8rensenauthor=J.+Nylandstedauthor=T.+Farkasauthor=M.+J%C3%A4%C3%A4ttel%C3%A4&title=Anti-cancer+agent+siramesine+is+a+lysosomotropic+detergent+that+induces+cytoprotective+autophagosome+accumulation&doi=10.4161%2Fauto.5774"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit152R"><div class="casContent"><span class="casTitleNuber">152</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-cancer agent siramesine is a lysosomotropic detergent that induces cytoprotective autophagosome accumulation</span></div><div class="casAuthors">Ostenfeld, Marie Stampe; Hoeyer-Hansen, Maria; Bastholm, Lone; Fehrenbacher, Nicole; Olsen, Ole Dines; Groth-Pedersen, Line; Puustinen, Pietri; Kirkegaard-Soerensen, Thomas; Nylandsted, Jesper; Farkas, Thomas; Jaattela, Marja</div><div class="citationInfo"><span class="NLM_cas:title">Autophagy</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">487-499</span>CODEN:
                <span class="NLM_cas:coden">AUTOC9</span>;
        ISSN:<span class="NLM_cas:issn">1554-8627</span>.
    
            (<span class="NLM_cas:orgname">Landes Bioscience</span>)
        </div><div class="casAbstract">A σ-2 receptor ligand siramesine induces lysosomal leakage and cathepsin-dependent death of cancer cells in vitro and displays potent anti-cancer activity in vivo.  The mechanism by which siramesine destabilizes lysosomes is, however, unknown.  Here, we show that siramesine induces a rapid rise in the lysosomal pH that is followed by lysosomal leakage and dysfunction.  The rapid accumulation of siramesine into cancer cell lysosomes, its ability to destabilize isolated lysosomes, and its chem. structure as an amphiphilic amine indicate that it is a lysosomotropic detergent.  Notably, siramesine triggers also a substantial Atg6- and Atg7-dependent accumulation of autophagosomes that is assocd. with a rapid and sustained inhibition of mammalian target of rapamycin complex 1 (mTORC1; an inhibitor of autophagy).  Siramesine fails, however, to increase the degrdn. rate of long-lived proteins.  Thus, the massive accumulation of autophagosomes is likely to be due to a combined effect of activation of autophagy signaling and decreased autophagosome turnover.  Importantly, pharmacol. and RNA interference-based inhibition of autophagosome formation further sensitizes cancer cells to siramesine-induced cytotoxicity.  These data identify siramesine as a lysosomotropic detergent that triggers cell death via a direct destabilization of lysosomes and cytoprotection by inducing the accumulation of autophagosomes.  Therefore, the combination of siramesine with inhibitors of autophagosome formation appears as a promising approach for future cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJb0mggS39urVg90H21EOLACvtfcHk0liqYQOKbov4Ww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXntFynurk%253D&md5=9b3d02ef1cf41e1b3b433ca637e38cc2</span></div><a href="/servlet/linkout?suffix=cit152&amp;dbid=16384&amp;doi=10.4161%2Fauto.5774&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fauto.5774%26sid%3Dliteratum%253Aachs%26aulast%3DOstenfeld%26aufirst%3DM.%2BS.%26aulast%3DH%25C3%25B8yer-Hansen%26aufirst%3DM.%26aulast%3DBastholm%26aufirst%3DL.%26aulast%3DFehrenbacher%26aufirst%3DN.%26aulast%3DOlsen%26aufirst%3DO.%2BD.%26aulast%3DGroth-Pedersen%26aufirst%3DL.%26aulast%3DPuustinen%26aufirst%3DP.%26aulast%3DKirkegaard-S%25C3%25B8rensen%26aufirst%3DT.%26aulast%3DNylandsted%26aufirst%3DJ.%26aulast%3DFarkas%26aufirst%3DT.%26aulast%3DJ%25C3%25A4%25C3%25A4ttel%25C3%25A4%26aufirst%3DM.%26atitle%3DAnti-cancer%2520agent%2520siramesine%2520is%2520a%2520lysosomotropic%2520detergent%2520that%2520induces%2520cytoprotective%2520autophagosome%2520accumulation%26jtitle%3DAutophagy%26date%3D2008%26volume%3D4%26spage%3D487%26epage%3D499%26doi%3D10.4161%2Fauto.5774" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref153"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref153'); return false;" data-citation="" class="refNumLink">153</a></strong><div class="NLM_citation" id="cit153"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Parry, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alakoskela, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khandelia, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jäättelä, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahalka, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinnunen, P. K.</span></span> <span> </span><span class="NLM_article-title">High-affinity small molecule-phospholipid complex formation: binding of siramesine to phosphatidic acid</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>130</i></span>,  <span class="NLM_fpage">12953</span>– <span class="NLM_lpage">12960</span>, <span class="refDoi"> DOI: 10.1021/ja800516w</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja800516w" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVymtLjN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=130&publication_year=2008&pages=12953-12960&author=M.+J.+Parryauthor=J.+M.+Alakoskelaauthor=H.+Khandeliaauthor=S.+A.+Kumarauthor=M.+J%C3%A4%C3%A4ttel%C3%A4author=A.+K.+Mahalkaauthor=P.+K.+Kinnunen&title=High-affinity+small+molecule-phospholipid+complex+formation%3A+binding+of+siramesine+to+phosphatidic+acid&doi=10.1021%2Fja800516w"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit153R"><div class="casContent"><span class="casTitleNuber">153</span><div class="casTitle"><span class="NLM_cas:atitle">High-Affinity Small Molecule-Phospholipid Complex Formation: Binding of Siramesine to Phosphatidic Acid</span></div><div class="casAuthors">Parry, Mikko J.; Alakoskela, Juha-Matti I.; Khandelia, Himanshu; Kumar, Subramanian Arun; Jaattela, Marja; Mahalka, Ajay K.; Kinnunen, Paavo K. J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">130</span>
        (<span class="NLM_cas:issue">39</span>),
    <span class="NLM_cas:pages">12953-12960</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Siramesine (SRM) is a σ-2 receptor agonist which has been recently shown to inhibit growth of cancer cells.  Fluorescence spectroscopy expts. revealed two distinct binding sites for this drug in phospholipid membranes.  More specifically, acidic phospholipids retain siramesine on the bilayer surface due to a high-affinity interaction, reaching satn. at an apparent 1:1 drug-acidic phospholipid stoichiometry, where after the drug penetrates into the hydrocarbon core of the membrane.  This behavior was confirmed using Langmuir films.  Of the anionic phospholipids, the highest affinity, comparable to the affinities for the binding of small mol. ligands to proteins, was measured for phosphatidic acid (PA, mole fraction of XPA = 0.2 in phosphatidylcholine vesicles), yielding a mol. partition coeff. of 240 ± 80 × 106.  An MD simulation on the siramesine:PA interaction was in agreement with the above data.  Taking into account the key role of PA as a signaling mol. promoting cell growth our results suggest a new paradigm for the development of anticancer drugs, viz.  Design of small mols. specifically scavenging phospholipids involved in the signaling cascades controlling cell behavior.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohibvMcWOby7Vg90H21EOLACvtfcHk0liqYQOKbov4Ww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVymtLjN&md5=d45a6fd73bc046be4774db13fa8ee3e5</span></div><a href="/servlet/linkout?suffix=cit153&amp;dbid=16384&amp;doi=10.1021%2Fja800516w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja800516w%26sid%3Dliteratum%253Aachs%26aulast%3DParry%26aufirst%3DM.%2BJ.%26aulast%3DAlakoskela%26aufirst%3DJ.%2BM.%26aulast%3DKhandelia%26aufirst%3DH.%26aulast%3DKumar%26aufirst%3DS.%2BA.%26aulast%3DJ%25C3%25A4%25C3%25A4ttel%25C3%25A4%26aufirst%3DM.%26aulast%3DMahalka%26aufirst%3DA.%2BK.%26aulast%3DKinnunen%26aufirst%3DP.%2BK.%26atitle%3DHigh-affinity%2520small%2520molecule-phospholipid%2520complex%2520formation%253A%2520binding%2520of%2520siramesine%2520to%2520phosphatidic%2520acid%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2008%26volume%3D130%26spage%3D12953%26epage%3D12960%26doi%3D10.1021%2Fja800516w" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref154"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref154'); return false;" data-citation="" class="refNumLink">154</a></strong><div class="NLM_citation" id="cit154"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jonhede, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petersen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zetterberg, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karlsson, J. O.</span></span> <span> </span><span class="NLM_article-title">Acute effects of the sigma-2 receptor agonist siramesine on lysosomal and extra-lysosomal proteolytic systems in lens epithelial cells</span>. <i>Mol. Vision</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">819</span>– <span class="NLM_lpage">827</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=20461150" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BC3cXmtl2gsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2010&pages=819-827&author=S.+Jonhedeauthor=A.+Petersenauthor=M.+Zetterbergauthor=J.+O.+Karlsson&title=Acute+effects+of+the+sigma-2+receptor+agonist+siramesine+on+lysosomal+and+extra-lysosomal+proteolytic+systems+in+lens+epithelial+cells"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit154R"><div class="casContent"><span class="casTitleNuber">154</span><div class="casTitle"><span class="NLM_cas:atitle">Acute effects of the sigma-2 receptor agonist siramesine on lysosomal and extra-lysosomal proteolytic systems in lens epithelial cells</span></div><div class="casAuthors">Jonhede, S.; Petersen, A.; Zetterberg, M.; Karlsson, J.-O.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Vision</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">819-827</span>CODEN:
                <span class="NLM_cas:coden">MVEPFB</span>;
        ISSN:<span class="NLM_cas:issn">1090-0535</span>.
    
            (<span class="NLM_cas:orgname">Molecular Vision</span>)
        </div><div class="casAbstract">Purpose: The aim of the present study was to examine the effects of the sigma-2 receptor agonist, siramesine, on morphol., growth, cell death, lysosomal function, and effects on extra-lysosomal proteolytic systems in human lens epithelial cells.  Methods: Human lens epithelial cells in culture were exposed to siramesine and examd. for morphol. changes using Nomarski optics or calcein.  Lysosomes were evaluated using acridine orange and Magic Red (RR-cresyl violet).  Nuclear morphol. was studied using Hoechst 33342 and propidium iodide.  Enzymic activities in living cells or cell lysates were studied using fluorogenic substrates.  Results: Siramesine at low concns. increased the cytoplasmic proteolytic activity of the proteasome and the calpain system.  Effects were also obsd. with respect to lysosomal morphol., acidity and function.  In addn., activation of caspase-3 and the appearance of nuclei with an apoptotic morphol. was found.  Conclusions: Siramesine at low concns. affects lens epithelial cells with perturbations of the major proteolytic systems and lysosomal morphol., resulting in caspase activation and cell death.  Siramesine may be a possible substance for the treatment or prevention of posterior capsular opacification (PCO).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8GZEyfaEcYLVg90H21EOLACvtfcHk0liqYQOKbov4Ww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXmtl2gsLo%253D&md5=6cfdd2882ba59fb5c39c268ad876233e</span></div><a href="/servlet/linkout?suffix=cit154&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJonhede%26aufirst%3DS.%26aulast%3DPetersen%26aufirst%3DA.%26aulast%3DZetterberg%26aufirst%3DM.%26aulast%3DKarlsson%26aufirst%3DJ.%2BO.%26atitle%3DAcute%2520effects%2520of%2520the%2520sigma-2%2520receptor%2520agonist%2520siramesine%2520on%2520lysosomal%2520and%2520extra-lysosomal%2520proteolytic%2520systems%2520in%2520lens%2520epithelial%2520cells%26jtitle%3DMol.%2520Vision%26date%3D2010%26volume%3D16%26spage%3D819%26epage%3D827" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref155"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref155'); return false;" data-citation="" class="refNumLink">155</a></strong><div class="NLM_citation" id="cit155"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rothfuss, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vangveravong, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mach, R. H.</span></span> <span> </span><span class="NLM_article-title">Functional assays to define agonists and antagonists of the sigma-2 receptor</span>. <i>Anal. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>448</i></span>,  <span class="NLM_fpage">68</span>– <span class="NLM_lpage">74</span>, <span class="refDoi"> DOI: 10.1016/j.ab.2013.12.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1016%2Fj.ab.2013.12.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=24333652" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitleltbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=448&publication_year=2014&pages=68-74&author=C.+Zengauthor=J.+M.+Rothfussauthor=J.+Zhangauthor=S.+Vangveravongauthor=W.+Chuauthor=S.+Liauthor=Z.+Tuauthor=J.+Xuauthor=R.+H.+Mach&title=Functional+assays+to+define+agonists+and+antagonists+of+the+sigma-2+receptor&doi=10.1016%2Fj.ab.2013.12.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit155R"><div class="casContent"><span class="casTitleNuber">155</span><div class="casTitle"><span class="NLM_cas:atitle">Functional assays to define agonists and antagonists of the sigma-2 receptor</span></div><div class="casAuthors">Zeng, Chenbo; Rothfuss, Justin M.; Zhang, Jun; Vangveravong, Suwanna; Chu, Wenhua; Li, Shihong; Tu, Zhude; Xu, Jinbin; Mach, Robert H.</div><div class="citationInfo"><span class="NLM_cas:title">Analytical Biochemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">448</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">68-74</span>CODEN:
                <span class="NLM_cas:coden">ANBCA2</span>;
        ISSN:<span class="NLM_cas:issn">0003-2697</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The sigma-2 receptor has been identified as a biomarker in proliferating tumors.  To date there is no well-established functional assay for defining sigma-2 agonists and antagonists.  Many sigma-2 ligands with diverse structures have been shown to induce cell death in a variety of cancer cells by triggering caspase-dependent and independent apoptosis.  Therefore, in the current study, we used the cell viability assay and the caspase-3 activity assay to det. sigma-2 agonists and antagonists.  Three classes of sigma-2 ligands developed in our lab. were evaluated for their potency to induce cell death in two tumor cell lines, mouse breast cancer cell line EMT-6 and human melanoma cell line MDA-MB-435.  The data showed that the EC50 values of the sigma-2 ligands using the cell viability assay ranged from 11.4 μM to >200 μM, which were comparable with the EC50 values obtained using the caspase-3 assay.  Based on the cytotoxicity of a sigma-2 ligand relative to that of siramesine, a commonly accepted sigma-2 agonist, we have categorized our sigma-2 ligands into agonists, partial agonists, and antagonists.  The establishment of functional assays for defining sigma-2 agonists and antagonists will facilitate functional characterization of sigma-2 receptor ligands and sigma-2 receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFM0mxQ6ge67Vg90H21EOLACvtfcHk0liqYQOKbov4Ww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitleltbw%253D&md5=4f50b1c949dfd9ffaf07b539e109d741</span></div><a href="/servlet/linkout?suffix=cit155&amp;dbid=16384&amp;doi=10.1016%2Fj.ab.2013.12.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ab.2013.12.008%26sid%3Dliteratum%253Aachs%26aulast%3DZeng%26aufirst%3DC.%26aulast%3DRothfuss%26aufirst%3DJ.%2BM.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DVangveravong%26aufirst%3DS.%26aulast%3DChu%26aufirst%3DW.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DTu%26aufirst%3DZ.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DMach%26aufirst%3DR.%2BH.%26atitle%3DFunctional%2520assays%2520to%2520define%2520agonists%2520and%2520antagonists%2520of%2520the%2520sigma-2%2520receptor%26jtitle%3DAnal.%2520Biochem.%26date%3D2014%26volume%3D448%26spage%3D68%26epage%3D74%26doi%3D10.1016%2Fj.ab.2013.12.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref156"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref156'); return false;" data-citation="" class="refNumLink">156</a></strong><div class="NLM_citation" id="cit156"><span><span class="NLM_contrib-group"><span class="NLM_string-name">C̆esen, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Repnik, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turk, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turk, B.</span></span> <span> </span><span class="NLM_article-title">Siramesine triggers cell death through destabilisation of mitochondria, but not lysosomes</span>. <i>Cell Death Dis.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>4</i></span>, <span class="NLM_elocation-id">e818</span> <span class="refDoi"> DOI: 10.1038/cddis.2013.361</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1038%2Fcddis.2013.361" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=24091661" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&author=M.+H.+C%CC%86esenauthor=U.+Repnikauthor=V.+Turkauthor=B.+Turk&title=Siramesine+triggers+cell+death+through+destabilisation+of+mitochondria%2C+but+not+lysosomes&doi=10.1038%2Fcddis.2013.361"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit156&amp;dbid=16384&amp;doi=10.1038%2Fcddis.2013.361&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fcddis.2013.361%26sid%3Dliteratum%253Aachs%26aulast%3DC%25CC%2586esen%26aufirst%3DM.%2BH.%26aulast%3DRepnik%26aufirst%3DU.%26aulast%3DTurk%26aufirst%3DV.%26aulast%3DTurk%26aufirst%3DB.%26atitle%3DSiramesine%2520triggers%2520cell%2520death%2520through%2520destabilisation%2520of%2520mitochondria%252C%2520but%2520not%2520lysosomes%26jtitle%3DCell%2520Death%2520Dis.%26date%3D2013%26volume%3D4%26doi%3D10.1038%2Fcddis.2013.361" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref157"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref157'); return false;" data-citation="" class="refNumLink">157</a></strong><div class="NLM_citation" id="cit157"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ma, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dielschneider, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henson, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choquette, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blankstein, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibson, S. B.</span></span> <span> </span><span class="NLM_article-title">Ferroptosis and autophagy induced cell death occur independently after siramesine and lapatinib treatment in breast cancer cells</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>12</i></span>, <span class="NLM_elocation-id">e0182921</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0182921</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1371%2Fjournal.pone.0182921" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=28827805" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BC1cXps1Gltw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2017&author=S.+Maauthor=R.+F.+Dielschneiderauthor=E.+S.+Hensonauthor=W.+Xiaoauthor=T.+R.+Choquetteauthor=A.+R.+Blanksteinauthor=Y.+Chenauthor=S.+B.+Gibson&title=Ferroptosis+and+autophagy+induced+cell+death+occur+independently+after+siramesine+and+lapatinib+treatment+in+breast+cancer+cells&doi=10.1371%2Fjournal.pone.0182921"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit157R"><div class="casContent"><span class="casTitleNuber">157</span><div class="casTitle"><span class="NLM_cas:atitle">Ferroptosis and autophagy induced cell death occur independently after siramesine and lapatinib treatment in breast cancer cells</span></div><div class="casAuthors">Ma, Shumei; Dielschneider, Rebecca F.; Henson, Elizabeth S.; Xiao, Wenyan; Choquette, Tricia R.; Blankstein, Anna R.; Chen, Yongqiang; Gibson, Spencer B.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">e0182921/1-e0182921/14</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Ferroptosis is a cell death pathway characterized by iron-dependent accumulation of reactive oxygen species (ROS) within the cell.  The combination of siramesine, a lysosome disruptor, and lapatinib, a dual tyrosine kinase inhibitor, has been shown to synergistically induce cell death in breast cancer cells mediated by ferroptosis.  These treatments also induce autophagy but its role in this synergistic cell death is unclear.  In this study, we detd. that siramesine and lapatinib initially induced ferroptosis but changes to an autophagy induced cell death after 24 h.  Furthermore, we found that intracellular iron level increased in a time dependent manner following treatment accompanied by an increase in ROS.  Using the iron chelator deferoxamine (DFO) or the ROS scavenger alpha-tocopherol decreased both autophagy flux and cell death.  We further discovered that decreased expression of the iron storage protein, ferritin was partially dependent upon autophagy degrdn.  In contrast, the expression of transferrin, which is responsible for the transport of iron into cells, is increased following treatment with lapatinib alone or in combination with siramesine.  This indicates that ferroptosis and autophagy induced cell death occur independently but both are mediated by iron dependent ROS generation in breast cancer cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXjALGki64VbVg90H21EOLACvtfcHk0liJ_OLAMq9MvA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXps1Gltw%253D%253D&md5=a8da6a20f81c76164abdf2a9dd55337b</span></div><a href="/servlet/linkout?suffix=cit157&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0182921&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0182921%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DS.%26aulast%3DDielschneider%26aufirst%3DR.%2BF.%26aulast%3DHenson%26aufirst%3DE.%2BS.%26aulast%3DXiao%26aufirst%3DW.%26aulast%3DChoquette%26aufirst%3DT.%2BR.%26aulast%3DBlankstein%26aufirst%3DA.%2BR.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DGibson%26aufirst%3DS.%2BB.%26atitle%3DFerroptosis%2520and%2520autophagy%2520induced%2520cell%2520death%2520occur%2520independently%2520after%2520siramesine%2520and%2520lapatinib%2520treatment%2520in%2520breast%2520cancer%2520cells%26jtitle%3DPLoS%2520One%26date%3D2017%26volume%3D12%26doi%3D10.1371%2Fjournal.pone.0182921" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref158"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref158'); return false;" data-citation="" class="refNumLink">158</a></strong><div class="NLM_citation" id="cit158"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Niso, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abate, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Contino, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferorelli, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Azzariti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perrone, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colabufo, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berardi, F.</span></span> <span> </span><span class="NLM_article-title">Sigma-2 receptor agonists as possible antitumor agents in resistant tumors: hints for collateral sensitivity</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">2026</span>– <span class="NLM_lpage">2035</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201300291</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1002%2Fcmdc.201300291" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=24106081" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsFOlt7vE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=2026-2035&author=M.+Nisoauthor=C.+Abateauthor=M.+Continoauthor=S.+Ferorelliauthor=A.+Azzaritiauthor=R.+Perroneauthor=N.+A.+Colabufoauthor=F.+Berardi&title=Sigma-2+receptor+agonists+as+possible+antitumor+agents+in+resistant+tumors%3A+hints+for+collateral+sensitivity&doi=10.1002%2Fcmdc.201300291"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit158R"><div class="casContent"><span class="casTitleNuber">158</span><div class="casTitle"><span class="NLM_cas:atitle">Sigma-2 Receptor Agonists as Possible Antitumor Agents in Resistant Tumors: Hints for Collateral Sensitivity</span></div><div class="casAuthors">Niso, Mauro; Abate, Carmen; Contino, Marialessandra; Ferorelli, Savina; Azzariti, Amalia; Perrone, Roberto; Colabufo, Nicola Antonio; Berardi, Francesco</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2026-2035</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">With the aim of contributing to the development of novel antitumor agents, high-affinity σ2 receptor agonists were developed, with 6,7-dimethoxy-2-[4-[1-(4-fluorophenyl)-1H-indol-3-yl]butyl]-1,2,3,4-tetrahydroisoquinoline (15) and 9-[4-(6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolin-2-yl)butyl]-9H-carbazole (25) showing exceptional selectivity for the σ2 subtype.  Most of the compds. displayed notable antiproliferative activity in human MCF7 breast adenocarcinoma cells, with similar activity in the corresponding doxorubicin-resistant MCF7adr cell line.  Surprisingly, a few compds., including 25, displayed enhanced activity in MCF7adr cells over parent cells, recalling the phenomenon of collateral sensitivity, which is under study for the treatment of drug-resistant tumors.  All of the compds. showed interaction with P-glycoprotein (P-gp), and 15 and 25, with the greatest activity, were able to revert P-gp-mediated resistance and reestablish the antitumor effect of doxorubicin in MCF7adr cells.  The authors therefore identified a series of σ2 receptor agonists endowed with intriguing antitumor properties; these compds. deserve further investigation for the development of alternate strategies against multidrug-resistant cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGrW9r580YjbVg90H21EOLACvtfcHk0liJ_OLAMq9MvA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsFOlt7vE&md5=cd4926ffa90d3fd1c2761bfe2cbe777c</span></div><a href="/servlet/linkout?suffix=cit158&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201300291&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201300291%26sid%3Dliteratum%253Aachs%26aulast%3DNiso%26aufirst%3DM.%26aulast%3DAbate%26aufirst%3DC.%26aulast%3DContino%26aufirst%3DM.%26aulast%3DFerorelli%26aufirst%3DS.%26aulast%3DAzzariti%26aufirst%3DA.%26aulast%3DPerrone%26aufirst%3DR.%26aulast%3DColabufo%26aufirst%3DN.%2BA.%26aulast%3DBerardi%26aufirst%3DF.%26atitle%3DSigma-2%2520receptor%2520agonists%2520as%2520possible%2520antitumor%2520agents%2520in%2520resistant%2520tumors%253A%2520hints%2520for%2520collateral%2520sensitivity%26jtitle%3DChemMedChem%26date%3D2013%26volume%3D8%26spage%3D2026%26epage%3D2035%26doi%3D10.1002%2Fcmdc.201300291" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref159"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref159'); return false;" data-citation="" class="refNumLink">159</a></strong><div class="NLM_citation" id="cit159"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xie, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kniess, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neuber, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deuther-Conrad, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mamat, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lieberman, B. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mach, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brust, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinbach, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pietzsch, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, H.</span></span> <span> </span><span class="NLM_article-title">Novel indole-based sigma-2 receptor ligands: synthesis, structure-affinity relationship and antiproliferative activity</span>. <i>MedChemComm</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">1093</span>– <span class="NLM_lpage">1103</span>, <span class="refDoi"> DOI: 10.1039/C5MD00079C</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1039%2FC5MD00079C" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BC2MXmslGgtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=1093-1103&author=F.+Xieauthor=T.+Kniessauthor=C.+Neuberauthor=W.+Deuther-Conradauthor=C.+Mamatauthor=B.+P.+Liebermanauthor=B.+Liuauthor=R.+H.+Machauthor=P.+Brustauthor=J.+Steinbachauthor=J.+Pietzschauthor=H.+Jia&title=Novel+indole-based+sigma-2+receptor+ligands%3A+synthesis%2C+structure-affinity+relationship+and+antiproliferative+activity&doi=10.1039%2FC5MD00079C"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit159R"><div class="casContent"><span class="casTitleNuber">159</span><div class="casTitle"><span class="NLM_cas:atitle">Novel indole-based sigma-2 receptor ligands: synthesis, structure-affinity relationship and antiproliferative activity</span></div><div class="casAuthors">Xie, Fang; Kniess, Torsten; Neuber, Christin; Deuther-Conrad, Winnie; Mamat, Constantin; Lieberman, Brian P.; Liu, Boli; Mach, Robert H.; Brust, Peter; Steinbach, Jorg; Pietzsch, Jens; Jia, Hongmei</div><div class="citationInfo"><span class="NLM_cas:title">MedChemComm</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1093-1103</span>CODEN:
                <span class="NLM_cas:coden">MCCEAY</span>;
        ISSN:<span class="NLM_cas:issn">2040-2503</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">The synthesis and biol. evaluation of a series of indole-based σ2 receptor ligands I [R = 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolinyl, 5,6-dimethoxyisoindolinyl, 4-phenylpiperidinyl-4-carbonitrile, etc.] derived from siramesine was reported.  In vitro competition binding assays showed that these analogs possessed high to moderate affinity and selectivity for σ2 receptors.  Structure-affinity relationship analyses of these indole-based σ2 receptor ligands were performed.  In the 3-(4,5-dimethythiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, I [R = 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolinyl, 5,6-dimethoxyisoindolinyl] displayed significant and comparable antiproliferative activity in DU145, MCF7 and C6 cells to siramesine.  In cell cycle analyses, compds. I [R = 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolinyl, 5,6-dimethoxyisoindolinyl] and siramesine were found to induce a G1 phase cell cycle arrest in DU145 cells using flow cytometry.  The combination of 5,6-dimethoxyisoindoline scaffold and N-(4-fluorophenyl)indole moiety was identified as a new σ2 receptor ligand deserving further investigation as an antitumor agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqtDXWI6Q_fILVg90H21EOLACvtfcHk0liazUJLiQ181Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXmslGgtbk%253D&md5=766f04340f2e6ec6f64c7dcd3790334b</span></div><a href="/servlet/linkout?suffix=cit159&amp;dbid=16384&amp;doi=10.1039%2FC5MD00079C&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC5MD00079C%26sid%3Dliteratum%253Aachs%26aulast%3DXie%26aufirst%3DF.%26aulast%3DKniess%26aufirst%3DT.%26aulast%3DNeuber%26aufirst%3DC.%26aulast%3DDeuther-Conrad%26aufirst%3DW.%26aulast%3DMamat%26aufirst%3DC.%26aulast%3DLieberman%26aufirst%3DB.%2BP.%26aulast%3DLiu%26aufirst%3DB.%26aulast%3DMach%26aufirst%3DR.%2BH.%26aulast%3DBrust%26aufirst%3DP.%26aulast%3DSteinbach%26aufirst%3DJ.%26aulast%3DPietzsch%26aufirst%3DJ.%26aulast%3DJia%26aufirst%3DH.%26atitle%3DNovel%2520indole-based%2520sigma-2%2520receptor%2520ligands%253A%2520synthesis%252C%2520structure-affinity%2520relationship%2520and%2520antiproliferative%2520activity%26jtitle%3DMedChemComm%26date%3D2015%26volume%3D6%26spage%3D1093%26epage%3D1103%26doi%3D10.1039%2FC5MD00079C" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref160"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref160'); return false;" data-citation="" class="refNumLink">160</a></strong><div class="NLM_citation" id="cit160"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Abate, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niso, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abatematteo, F. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Contino, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colabufo, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berardi, F.</span></span> <span> </span><span class="NLM_article-title">PB28, the Sigma-1 and Sigma-2 Receptors Modulator With Potent Anti-SARS-CoV-2 Activity: A Review About Its Pharmacological Properties and Structure Affinity Relationships</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">589810</span>, <span class="refDoi"> DOI: 10.3389/fphar.2020.589810</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.3389%2Ffphar.2020.589810" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=33364961" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BB3MXjs1Squ7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2020&pages=589810&author=C.+Abateauthor=M.+Nisoauthor=F.+S.+Abatematteoauthor=M.+Continoauthor=N.+A.+Colabufoauthor=F.+Berardi&title=PB28%2C+the+Sigma-1+and+Sigma-2+Receptors+Modulator+With+Potent+Anti-SARS-CoV-2+Activity%3A+A+Review+About+Its+Pharmacological+Properties+and+Structure+Affinity+Relationships&doi=10.3389%2Ffphar.2020.589810"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit160R"><div class="casContent"><span class="casTitleNuber">160</span><div class="casTitle"><span class="NLM_cas:atitle">PB28, the Sigma-1 and Sigma-2 receptors modulator with potent anti-SARS-CoV-2 activity: a review about its pharmacological properties and structure affinity relationships</span></div><div class="casAuthors">Abate, Carmen; Niso, Mauro; Abatematteo, Francesca Serena; Contino, Marialessandra; Colabufo, Nicola Antonio; Berardi, Francesco</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Pharmacology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">589810</span>CODEN:
                <span class="NLM_cas:coden">FPRHAU</span>;
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">A review.  These un precedented times have forced the scientific community to gather to face the COVID -19 pandemic.  Efforts in diverse direction s have been made.  A multi-university team has focused on the identification of the host (human) proteins interacting with SAR S-CoV-2 viral proteins, with the aim of hampering these interactions that may cause severe COVI D- 19 symptoms.  Sigma-1 and sigma-2 receptors surprisingly belong to the ''druggable'' host proteins found, with the pan-sigma receptor modulator PB28 displaying the most potent anti- SARS- CoV-2 activity in in vitro assays.  Being 20-fold more active than hydroxychloroquine, without cardiac side effects, PB 28 is a promising antiviral candidate worthy of further investigation .  Our research group developed PB28 in 1996 and have thoroughly characterized its biol. properties since then.  Structure-affinity relationship (SAfiR) studies at the sigma receptor subtypes were also undertaken with PB28 as the lead compd.  We herein report our knowledge of PB 28 to share information that may help to gain insight into the antiviral action of this compd. and sigma receptors, while providing structural hints that may speed up the translation into therapeutics of this class of ligands.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqk1RpLTKAzz7Vg90H21EOLACvtfcHk0liazUJLiQ181Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3MXjs1Squ7s%253D&md5=e2462870af8b9f38306c795248658775</span></div><a href="/servlet/linkout?suffix=cit160&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2020.589810&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2020.589810%26sid%3Dliteratum%253Aachs%26aulast%3DAbate%26aufirst%3DC.%26aulast%3DNiso%26aufirst%3DM.%26aulast%3DAbatematteo%26aufirst%3DF.%2BS.%26aulast%3DContino%26aufirst%3DM.%26aulast%3DColabufo%26aufirst%3DN.%2BA.%26aulast%3DBerardi%26aufirst%3DF.%26atitle%3DPB28%252C%2520the%2520Sigma-1%2520and%2520Sigma-2%2520Receptors%2520Modulator%2520With%2520Potent%2520Anti-SARS-CoV-2%2520Activity%253A%2520A%2520Review%2520About%2520Its%2520Pharmacological%2520Properties%2520and%2520Structure%2520Affinity%2520Relationships%26jtitle%3DFront.%2520Pharmacol.%26date%3D2020%26volume%3D11%26spage%3D589810%26doi%3D10.3389%2Ffphar.2020.589810" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref161"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref161'); return false;" data-citation="" class="refNumLink">161</a></strong><div class="NLM_citation" id="cit161"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Colabufo, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leopoldo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferorelli, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abate, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Contino, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perrone, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niso, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perrone, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berardi, F.</span></span> <span> </span><span class="NLM_article-title">Why PB28 Could Be a Covid 2019 Game Changer?</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">2048</span>– <span class="NLM_lpage">2050</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.0c00271</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.0c00271" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhs1Sku7zK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2020&pages=2048-2050&author=N.+A.+Colabufoauthor=M.+Leopoldoauthor=S.+Ferorelliauthor=C.+Abateauthor=M.+Continoauthor=M.+G.+Perroneauthor=M.+Nisoauthor=R.+Perroneauthor=F.+Berardi&title=Why+PB28+Could+Be+a+Covid+2019+Game+Changer%3F&doi=10.1021%2Facsmedchemlett.0c00271"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit161R"><div class="casContent"><span class="casTitleNuber">161</span><div class="casTitle"><span class="NLM_cas:atitle">Why PB28 Could Be a Covid 2019 Game Changer?</span></div><div class="casAuthors">Colabufo, Nicola Antonio; Leopoldo, Marcello; Ferorelli, Savina; Abate, Carmen; Contino, Marialessandra; Perrone, Maria Grazia; Niso, Mauro; Perrone, Roberto; Berardi, Francesco</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2048-2050</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">PB28, a cyclohexylpiperazine deriv., could be a potential strategy for Covid 19 because in a recent study it has been found more active than hydroxychloroquine without interaction with cardiac proteins.  PB28 has been designed, developed, and biol. evaluated in the past decade in our research group.  A possible mechanism to explain its surprising anti-COVID-19 activity is suggested..</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbkFHE-HKT8LVg90H21EOLACvtfcHk0liazUJLiQ181Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhs1Sku7zK&md5=fb909aba5c7e289f25ef382edc290db2</span></div><a href="/servlet/linkout?suffix=cit161&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.0c00271&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.0c00271%26sid%3Dliteratum%253Aachs%26aulast%3DColabufo%26aufirst%3DN.%2BA.%26aulast%3DLeopoldo%26aufirst%3DM.%26aulast%3DFerorelli%26aufirst%3DS.%26aulast%3DAbate%26aufirst%3DC.%26aulast%3DContino%26aufirst%3DM.%26aulast%3DPerrone%26aufirst%3DM.%2BG.%26aulast%3DNiso%26aufirst%3DM.%26aulast%3DPerrone%26aufirst%3DR.%26aulast%3DBerardi%26aufirst%3DF.%26atitle%3DWhy%2520PB28%2520Could%2520Be%2520a%2520Covid%25202019%2520Game%2520Changer%253F%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2020%26volume%3D11%26spage%3D2048%26epage%3D2050%26doi%3D10.1021%2Facsmedchemlett.0c00271" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref162"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref162'); return false;" data-citation="" class="refNumLink">162</a></strong><div class="NLM_citation" id="cit162"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Riganti, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giampietro, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kopecka, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costamagna, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abatematteo, F. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Contino, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abate, C.</span></span> <span> </span><span class="NLM_article-title">MRP1-Collateral Sensitizers as a Novel Therapeutic Approach in Resistant Cancer Therapy: An In Vitro and In Vivo Study in Lung Resistant Tumor</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">3333</span>, <span class="refDoi"> DOI: 10.3390/ijms21093333</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.3390%2Fijms21093333" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhvVOjtr7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2020&pages=3333&author=C.+Rigantiauthor=R.+Giampietroauthor=J.+Kopeckaauthor=C.+Costamagnaauthor=F.+S.+Abatematteoauthor=M.+Continoauthor=C.+Abate&title=MRP1-Collateral+Sensitizers+as+a+Novel+Therapeutic+Approach+in+Resistant+Cancer+Therapy%3A+An+In+Vitro+and+In+Vivo+Study+in+Lung+Resistant+Tumor&doi=10.3390%2Fijms21093333"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit162R"><div class="casContent"><span class="casTitleNuber">162</span><div class="casTitle"><span class="NLM_cas:atitle">MRP1-collateral sensitizers as a novel therapeutic approach in resistant cancer therapy: an in vitro and in vivo study in lung resistant tumor</span></div><div class="casAuthors">Riganti, Chiara; Giampietro, Roberta; Kopecka, Joanna; Costamagna, Costanzo; Abatematteo, Francesca Serena; Contino, Marialessandra; Abate, Carmen</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3333</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Multidrug resistance (MDR) is the main obstacle to current chemotherapy and it is mainly due to the overexpression of some efflux transporters such as MRP1.  One of the most studied strategies to overcome MDR has been the inhibition of MDR pumps through small mols., but its translation into the clinic unfortunately failed.  Recently, a phenomenon called collateral sensitivity (CS) emerged as a new strategy to hamper MDR acting as a synthetic lethality, where the genetic changes developed upon the acquisition of resistance towards a specific agent are followed by the development of hypersensitivity towards a second agent.  Among our library of sigma ligands acting as MDR modulators, we identified three compds., F397, F400, and F421, acting as CS-promoting agents.  We deepened their CS mechanisms in the "pure" model of MRP1-expressing cells (MDCK-MRP1) and in MRP1-expressing/drug resistant non-small cell lung cancer cells (A549/DX).  The in vitro results demonstrated that (i) the three ligands are highly cytotoxic for MRP1-expressing cells; (ii) their effect is MRP1-mediated; (iii) they increase the cytotoxicity induced by cis-Pt, the therapeutic agent commonly used in the treatment of lung tumors; and (iv) their effect is ROS-mediated.  Moreover, a preclin. in vivo study performed in lung tumor xenografts confirms the in vitro findings, making the three CS-promoting agents candidates for a novel therapeutic approach in lung resistant tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2NdF_JUOCXbVg90H21EOLACvtfcHk0liazUJLiQ181Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhvVOjtr7E&md5=cb2dfd75f3f115dcd7bc0c92c65b5c8e</span></div><a href="/servlet/linkout?suffix=cit162&amp;dbid=16384&amp;doi=10.3390%2Fijms21093333&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms21093333%26sid%3Dliteratum%253Aachs%26aulast%3DRiganti%26aufirst%3DC.%26aulast%3DGiampietro%26aufirst%3DR.%26aulast%3DKopecka%26aufirst%3DJ.%26aulast%3DCostamagna%26aufirst%3DC.%26aulast%3DAbatematteo%26aufirst%3DF.%2BS.%26aulast%3DContino%26aufirst%3DM.%26aulast%3DAbate%26aufirst%3DC.%26atitle%3DMRP1-Collateral%2520Sensitizers%2520as%2520a%2520Novel%2520Therapeutic%2520Approach%2520in%2520Resistant%2520Cancer%2520Therapy%253A%2520An%2520In%2520Vitro%2520and%2520In%2520Vivo%2520Study%2520in%2520Lung%2520Resistant%2520Tumor%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2020%26volume%3D21%26spage%3D3333%26doi%3D10.3390%2Fijms21093333" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref163"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref163'); return false;" data-citation="" class="refNumLink">163</a></strong><div class="NLM_citation" id="cit163"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Abate, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elenewski, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niso, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berardi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colabufo, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Azzariti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perrone, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glennon, R. A.</span></span> <span> </span><span class="NLM_article-title">Interaction of the sigma(2) receptor ligand PB28 with the human nucleosome: computational and experimental probes of interaction with the H2A/H2B dimer</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">268</span>– <span class="NLM_lpage">273</span>, <span class="refDoi"> DOI: 10.1002/cmdc.200900402</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1002%2Fcmdc.200900402" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=20077462" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtl2ntr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2010&pages=268-273&author=C.+Abateauthor=J.+Elenewskiauthor=M.+Nisoauthor=F.+Berardiauthor=N.+A.+Colabufoauthor=A.+Azzaritiauthor=R.+Perroneauthor=R.+A.+Glennon&title=Interaction+of+the+sigma%282%29+receptor+ligand+PB28+with+the+human+nucleosome%3A+computational+and+experimental+probes+of+interaction+with+the+H2A%2FH2B+dimer&doi=10.1002%2Fcmdc.200900402"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit163R"><div class="casContent"><span class="casTitleNuber">163</span><div class="casTitle"><span class="NLM_cas:atitle">Interaction of the σ2 Receptor Ligand PB28 with the Human Nucleosome: Computational and Experimental Probes of Interaction with the H2A/H2B Dimer</span></div><div class="casAuthors">Abate, Carmen; Elenewski, Justin; Niso, Mauro; Berardi, Francesco; Colabufo, Nicola Antonio; Azzariti, Amalia; Perrone, Roberto; Glennon, Richard A.</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">268-273</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Sigma-2 (σ2) binding sites are an emerging target for anti-neoplastic agents due to the strong apoptotic effect exhibited by σ2 agonists in vitro and the overexpression of these sites in tumor cells.  Nonetheless, no σ2 receptor protein has been identified.  Affinity chromatog. using the high-affinity σ2 ligand PB28 and human SK-N-SH neuroblastoma cells was previously utilized to identify σ2 ligand binding proteins, specifically histones H1, H2A, H2B, and H3.3a.  To rationalize this finding, homol. modeling and automated docking studies were employed to probe intermol. interactions between PB28 and human nucleosomal proteins.  These studies predicted interaction of PB28 with the H2A/H2B dimer at a series of sites previously implicated in chromatin compaction and nucleosomal assembly.  To exptl. verify this prediction, a competitive binding assay was performed on the reconstituted H2A/H2B dimer using [3H]PB28 as radioligand, and an IC50 value of 0.50 nM was detd. for PB28 binding.  In addn., [3H]PB28 was found to accumulate with up to a fivefold excess in nuclear fractions over cytosolic fractions of SK-N-SH and MCF7 cells, indicating that PB28 is capable of entering the nucleus to interact with histone proteins.  In conjunction with computational results, these data suggest that PB28 may exert its cytotoxic effect through direct interaction with nuclear material.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkk6FOeqP6z7Vg90H21EOLACvtfcHk0ljSUA4FFCY1YQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtl2ntr4%253D&md5=34320626eb0e20f03b814697c5ee59b0</span></div><a href="/servlet/linkout?suffix=cit163&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.200900402&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.200900402%26sid%3Dliteratum%253Aachs%26aulast%3DAbate%26aufirst%3DC.%26aulast%3DElenewski%26aufirst%3DJ.%26aulast%3DNiso%26aufirst%3DM.%26aulast%3DBerardi%26aufirst%3DF.%26aulast%3DColabufo%26aufirst%3DN.%2BA.%26aulast%3DAzzariti%26aufirst%3DA.%26aulast%3DPerrone%26aufirst%3DR.%26aulast%3DGlennon%26aufirst%3DR.%2BA.%26atitle%3DInteraction%2520of%2520the%2520sigma%25282%2529%2520receptor%2520ligand%2520PB28%2520with%2520the%2520human%2520nucleosome%253A%2520computational%2520and%2520experimental%2520probes%2520of%2520interaction%2520with%2520the%2520H2A%252FH2B%2520dimer%26jtitle%3DChemMedChem%26date%3D2010%26volume%3D5%26spage%3D268%26epage%3D273%26doi%3D10.1002%2Fcmdc.200900402" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref164"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref164'); return false;" data-citation="" class="refNumLink">164</a></strong><div class="NLM_citation" id="cit164"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Abate, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niso, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berardi, F.</span></span> <span> </span><span class="NLM_article-title">Sigma-2 receptor: past, present and perspectives on multiple therapeutic exploitations</span>. <i>Future Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1997</span>– <span class="NLM_lpage">2018</span>, <span class="refDoi"> DOI: 10.4155/fmc-2018-0072</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.4155%2Ffmc-2018-0072" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=29966437" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsFagtr%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2018&pages=1997-2018&author=C.+Abateauthor=M.+Nisoauthor=F.+Berardi&title=Sigma-2+receptor%3A+past%2C+present+and+perspectives+on+multiple+therapeutic+exploitations&doi=10.4155%2Ffmc-2018-0072"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit164R"><div class="casContent"><span class="casTitleNuber">164</span><div class="casTitle"><span class="NLM_cas:atitle">Sigma-2 receptor: past, present and perspectives on multiple therapeutic exploitations</span></div><div class="casAuthors">Abate, Carmen; Niso, Mauro; Berardi, Francesco</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">1997-2018</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">Identification of sigma-2 receptor (sig-2R) has been controversial.  Nevertheless, interest in sig-2R is high for its overexpression in tumors and potentials in oncol.  Addnl., sig-2R antagonists inhibit Aβ binding at neurons, blocking the cognitive impairments of Alzheimer's disease.  The most representative classes of sig-2R ligands are herein treated with focus on compds. that served to study sig-2R biol. and to produce sig-2R: fluorescent ligands; multifunctional anticancer agents; and targeting nanoparticles.  Although fluorescent ligands serve as 'green' pharmacol. tools, sig-2R-multifunctional conjugates and sig-2R-targeted nanoparticles show how sig-2R targeting increases the activity of anticancer drugs in tumors with reduced toxicity.  Altogether, this review draws a picture of the multiple approaches of sig-2R ligands in cancer therapy and as Alzheimer's disease modifying disease agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpld3SYZuyx8bVg90H21EOLACvtfcHk0ljSUA4FFCY1YQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsFagtr%252FP&md5=f0024b9581e1a7804165f215f99c15ac</span></div><a href="/servlet/linkout?suffix=cit164&amp;dbid=16384&amp;doi=10.4155%2Ffmc-2018-0072&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc-2018-0072%26sid%3Dliteratum%253Aachs%26aulast%3DAbate%26aufirst%3DC.%26aulast%3DNiso%26aufirst%3DM.%26aulast%3DBerardi%26aufirst%3DF.%26atitle%3DSigma-2%2520receptor%253A%2520past%252C%2520present%2520and%2520perspectives%2520on%2520multiple%2520therapeutic%2520exploitations%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2018%26volume%3D10%26spage%3D1997%26epage%3D2018%26doi%3D10.4155%2Ffmc-2018-0072" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref165"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref165'); return false;" data-citation="" class="refNumLink">165</a></strong><div class="NLM_citation" id="cit165"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Berardi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abate, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferorelli, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uricchio, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colabufo, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niso, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perrone, R.</span></span> <span> </span><span class="NLM_article-title">Exploring the importance of piperazine N-atoms for sigma(2) receptor affinity and activity in a series of analogs of 1-cyclohexyl-4-[3-(5-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)propyl]piperazine (PB28)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">7817</span>– <span class="NLM_lpage">7828</span>, <span class="refDoi"> DOI: 10.1021/jm9007505</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm9007505" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht12iu7bP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=7817-7828&author=F.+Berardiauthor=C.+Abateauthor=S.+Ferorelliauthor=V.+Uricchioauthor=N.+A.+Colabufoauthor=M.+Nisoauthor=R.+Perrone&title=Exploring+the+importance+of+piperazine+N-atoms+for+sigma%282%29+receptor+affinity+and+activity+in+a+series+of+analogs+of+1-cyclohexyl-4-%5B3-%285-methoxy-1%2C2%2C3%2C4-tetrahydronaphthalen-1-yl%29propyl%5Dpiperazine+%28PB28%29&doi=10.1021%2Fjm9007505"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit165R"><div class="casContent"><span class="casTitleNuber">165</span><div class="casTitle"><span class="NLM_cas:atitle">Exploring the Importance of Piperazine N-Atoms for σ2 Receptor Affinity and Activity in a Series of Analogs of 1-Cyclohexyl-4-[3-(5-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)propyl]piperazine (PB28)</span></div><div class="casAuthors">Berardi, Francesco; Abate, Carmen; Ferorelli, Savina; Uricchio, Vincenzo; Colabufo, Nicola A.; Niso, Mauro; Perrone, Roberto</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">7817-7828</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">σ2-Agonist 1-cyclohexyl-4-[3-(5-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)propyl]piperazine (7, PB 28), which proved to revert doxorubicin resistance in breast cancer cells, was taken as a template to prep. new analogs.  One of the two basic N-atoms was alternatively replaced by a methine or converted into an amide or ammonium function, with the aim of finding out which of them was essential for σ2 receptor affinity and activity.  Some simply 4-substituted 1-cyclohexylpiperazines were also investigated.  None of the compds. was as high-affinity as 7 (σ2Ki = 0.68, σ1Ki = 0.38 nM), proving that both basic N-atoms ensure better σ2 receptor binding.  Amide 36 emerged as high-affinity (Ki = 0.11 nM) and noteworthy selective (1627-fold) σ1 ligand.  Small N-cyclohexylpiperazine 59 displayed the highest σ2 affinity (Ki = 4.70 nM).  The σ2/σ1 selectivities were generally low.  Antiproliferative assay in SK-N-SH cells revealed piperidines 24 and 15 as putative σ2 agonists (EC50s 1.40 and 3.64 μM resp.) more potent than 7.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5IKlpVJCy1LVg90H21EOLACvtfcHk0ljSUA4FFCY1YQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht12iu7bP&md5=5f58080ebd8d153b325e005024babd88</span></div><a href="/servlet/linkout?suffix=cit165&amp;dbid=16384&amp;doi=10.1021%2Fjm9007505&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm9007505%26sid%3Dliteratum%253Aachs%26aulast%3DBerardi%26aufirst%3DF.%26aulast%3DAbate%26aufirst%3DC.%26aulast%3DFerorelli%26aufirst%3DS.%26aulast%3DUricchio%26aufirst%3DV.%26aulast%3DColabufo%26aufirst%3DN.%2BA.%26aulast%3DNiso%26aufirst%3DM.%26aulast%3DPerrone%26aufirst%3DR.%26atitle%3DExploring%2520the%2520importance%2520of%2520piperazine%2520N-atoms%2520for%2520sigma%25282%2529%2520receptor%2520affinity%2520and%2520activity%2520in%2520a%2520series%2520of%2520analogs%2520of%25201-cyclohexyl-4-%255B3-%25285-methoxy-1%252C2%252C3%252C4-tetrahydronaphthalen-1-yl%2529propyl%255Dpiperazine%2520%2528PB28%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D7817%26epage%3D7828%26doi%3D10.1021%2Fjm9007505" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref166"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref166'); return false;" data-citation="" class="refNumLink">166</a></strong><div class="NLM_citation" id="cit166"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nicholson, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Comeau, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mesangeau, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCurdy, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowen, W. D.</span></span> <span> </span><span class="NLM_article-title">Characterization of CM572, a Selective Irreversible Partial Agonist of the Sigma-2 Receptor with Antitumor Activity</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>354</i></span>,  <span class="NLM_fpage">203</span>– <span class="NLM_lpage">212</span>, <span class="refDoi"> DOI: 10.1124/jpet.115.224105</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1124%2Fjpet.115.224105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=26034081" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFyltL%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=354&publication_year=2015&pages=203-212&author=H.+Nicholsonauthor=A.+Comeauauthor=C.+Mesangeauauthor=C.+R.+McCurdyauthor=W.+D.+Bowen&title=Characterization+of+CM572%2C+a+Selective+Irreversible+Partial+Agonist+of+the+Sigma-2+Receptor+with+Antitumor+Activity&doi=10.1124%2Fjpet.115.224105"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit166R"><div class="casContent"><span class="casTitleNuber">166</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of CM572, a selective irreversible partial agonist of the sigma-2 receptor with antitumor activity</span></div><div class="casAuthors">Nicholson, Hilary; Comeau, Anthony; Mesangeau, Christophe; McCurdy, Christopher R.; Bowen, Wayne D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">354</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">203-212</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The sigma-2 receptors are promising therapeutic targets due to significant upregulation in tumor cells compared to normal tissue.  Here we characterize CM572 (3-(4-(4-(4-fluorophenyl)piperazin-1-yl)butyl)-6-isothiocyanatobenzo[d]oxazol-2(3H)-one) (sigma-1 Ki ≥ 10 μM, sigma-2 Ki = 14.6±6.9 nM), a novel isothiocyanate deriv. of the putative sigma-2 antagonist, SN79 (6-acetyl-3-(4-(4-(4-fluorophenyl)piperazin-1-yl)butyl)benzo[d]oxazol-2(3H)-one).  CM572 binds irreversibly to sigma-2 receptors by virtue of the isothiocyanate moiety, but not to sigma-1.  Studies in human SK-N-SH neuroblastoma cells revealed that CM572 induced an immediate, dose-dependent rise in cytosolic calcium concn.  A 24 h treatment of SK-N-SH cells with CM572 induced dose-dependent cell death, with an EC50 =7.6±1.7 μM.  This effect was sustained over 24 h even after a 60 min pretreatment with CM572, followed by extensive washing to remove ligand, indicating an irreversible effect consistent with the irreversible binding data.  Western blot anal. revealed that CM572 also induced cleavage activation of pro-apoptotic Bid.  These data suggest irreversible agonist-like activity.  Low concns. of CM572 that were minimally effective were able to significantly attenuate the calcium signal and cell death induced by the sigma-2 agonist CB-64D ((+)-1R,5R-(E)-8-benzylidene-5-(3-hydroxyphenyl)-2-methylmorphan-7-one).  CM572 was also cytotoxic against PANC-1 pancreatic and MCF-7 breast cancer cell lines.  The cytotoxic activity of CM572 was selective for cancer cells over normal cells, being much less potent against primary human melanocytes and human mammary epithelial cells.  Taken together, these data show that CM572 is a selective, irreversible sigma-2 receptor partial agonist.  This novel irreversible ligand may further our understanding of the endogenous role of this receptor, in addn. to having potential use in targeted cancer diagnosis and therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrP_-A6OU9fyrVg90H21EOLACvtfcHk0ljwPrRCHNrNEw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFyltL%252FO&md5=35573ea29dcf6dbc6544f4c20c4f69d6</span></div><a href="/servlet/linkout?suffix=cit166&amp;dbid=16384&amp;doi=10.1124%2Fjpet.115.224105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.115.224105%26sid%3Dliteratum%253Aachs%26aulast%3DNicholson%26aufirst%3DH.%26aulast%3DComeau%26aufirst%3DA.%26aulast%3DMesangeau%26aufirst%3DC.%26aulast%3DMcCurdy%26aufirst%3DC.%2BR.%26aulast%3DBowen%26aufirst%3DW.%2BD.%26atitle%3DCharacterization%2520of%2520CM572%252C%2520a%2520Selective%2520Irreversible%2520Partial%2520Agonist%2520of%2520the%2520Sigma-2%2520Receptor%2520with%2520Antitumor%2520Activity%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2015%26volume%3D354%26spage%3D203%26epage%3D212%26doi%3D10.1124%2Fjpet.115.224105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref167"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref167'); return false;" data-citation="" class="refNumLink">167</a></strong><div class="NLM_citation" id="cit167"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nicholson, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alsharif, W. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Comeau, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mesangeau, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Intagliata, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mottinelli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCurdy, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowen, W. D.</span></span> <span> </span><span class="NLM_article-title">Divergent Cytotoxic and Metabolically Stimulative Functions of Sigma-2 Receptors: Structure-Activity Relationships of 6-Acetyl-3-(4-(4-(4-fluorophenyl)piperazin-1-yl)butyl)benzo[d]oxazol-2(3H)-one (SN79) Derivatives</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>368</i></span>,  <span class="NLM_fpage">272</span>– <span class="NLM_lpage">281</span>, <span class="refDoi"> DOI: 10.1124/jpet.118.253484</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1124%2Fjpet.118.253484" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=30530624" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BC1MXns1Wjs78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=368&publication_year=2019&pages=272-281&author=H.+E.+Nicholsonauthor=W.+F.+Alsharifauthor=A.+B.+Comeauauthor=C.+Mesangeauauthor=S.+Intagliataauthor=M.+Mottinelliauthor=C.+R.+McCurdyauthor=W.+D.+Bowen&title=Divergent+Cytotoxic+and+Metabolically+Stimulative+Functions+of+Sigma-2+Receptors%3A+Structure-Activity+Relationships+of+6-Acetyl-3-%284-%284-%284-fluorophenyl%29piperazin-1-yl%29butyl%29benzo%5Bd%5Doxazol-2%283H%29-one+%28SN79%29+Derivatives&doi=10.1124%2Fjpet.118.253484"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit167R"><div class="casContent"><span class="casTitleNuber">167</span><div class="casTitle"><span class="NLM_cas:atitle">Divergent cytotoxic and metabolically stimulative functions of sigma-2 receptors: structure-activity relationships of 6-Acetyl-3- (4-(4-(4-fluorophenyl)piperazin-1-yl)butyl)benzo[d]oxazol-2(3H)-one (SN79) derivativess</span></div><div class="casAuthors">Nicholson, Hilary E.; Alsharif, Walid F.; Comeau, Anthony B.; Mesangeau, Christophe; Intagliata, Sebastiano; Mottinelli, Marco; McCurdy, Christopher R.; Bowen, Wayne D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">368</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">272-281, 1-9</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Here we investigate a series of 6-substituted SN79 analogs to assess the structural determinants governing these divergent effects.  Substitutions on the benzoxazolone ring of the core SN79 structure resulted in high-affinity sigma-2 receptor ligands (Ki = 0.56-17.9 nM), with replacement of the heterocyclic oxygen by N-Me (producing N-methylbenzimidazolones) generally decreasing sigma-1 affinity and a sulfur substitution (producing benzothiazolones) imparting high affinity at both subtypes, lowering subtype selectivity.  Substitution at the 6-position with COCH3, NO2, NH2, or F resulted in ligands that were not cytotoxic.  Five of these ligands induced an increase in metabolic activity, as measured by increased redn. of MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) in human SK-N-SH neuroblastoma cells, further supporting a role for sigma-2 receptors in metab.  Substitutionwith 6-isothiocyanate resulted in ligands that were sigma-2 selective and that irreversibly bound to the sigma-2 receptor, but not to the sigma-1 receptor.  These ligands induced cell death upon both acute and continuous treatment (EC50 = 7.6-32.8 muM), suggesting that irreversible receptor binding plays a role in cytotoxicity.  These ligands will be useful for further study of these divergent roles of sigma-2 receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCm9hpQzXLhLVg90H21EOLACvtfcHk0ljwPrRCHNrNEw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXns1Wjs78%253D&md5=daa90a75b164799d819e46fa246d3370</span></div><a href="/servlet/linkout?suffix=cit167&amp;dbid=16384&amp;doi=10.1124%2Fjpet.118.253484&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.118.253484%26sid%3Dliteratum%253Aachs%26aulast%3DNicholson%26aufirst%3DH.%2BE.%26aulast%3DAlsharif%26aufirst%3DW.%2BF.%26aulast%3DComeau%26aufirst%3DA.%2BB.%26aulast%3DMesangeau%26aufirst%3DC.%26aulast%3DIntagliata%26aufirst%3DS.%26aulast%3DMottinelli%26aufirst%3DM.%26aulast%3DMcCurdy%26aufirst%3DC.%2BR.%26aulast%3DBowen%26aufirst%3DW.%2BD.%26atitle%3DDivergent%2520Cytotoxic%2520and%2520Metabolically%2520Stimulative%2520Functions%2520of%2520Sigma-2%2520Receptors%253A%2520Structure-Activity%2520Relationships%2520of%25206-Acetyl-3-%25284-%25284-%25284-fluorophenyl%2529piperazin-1-yl%2529butyl%2529benzo%255Bd%255Doxazol-2%25283H%2529-one%2520%2528SN79%2529%2520Derivatives%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2019%26volume%3D368%26spage%3D272%26epage%3D281%26doi%3D10.1124%2Fjpet.118.253484" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref168"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref168'); return false;" data-citation="" class="refNumLink">168</a></strong><div class="NLM_citation" id="cit168"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mach, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freeman, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vangveravong, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luedtke, R. R.</span></span> <span> </span><span class="NLM_article-title">Conformationally-flexible benzamide analogues as dopamine D3 and sigma 2 receptor ligands</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">195</span>– <span class="NLM_lpage">202</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2003.09.083</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1016%2Fj.bmcl.2003.09.083" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=14684327" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BD3sXpvVWntbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2004&pages=195-202&author=R.+H.+Machauthor=Y.+Huangauthor=R.+A.+Freemanauthor=L.+Wuauthor=S.+Vangveravongauthor=R.+R.+Luedtke&title=Conformationally-flexible+benzamide+analogues+as+dopamine+D3+and+sigma+2+receptor+ligands&doi=10.1016%2Fj.bmcl.2003.09.083"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit168R"><div class="casContent"><span class="casTitleNuber">168</span><div class="casTitle"><span class="NLM_cas:atitle">Conformationally-flexible benzamide analogues as dopamine D3 and σ2 receptor ligands</span></div><div class="casAuthors">Mach, Robert H.; Huang, Yunsheng; Freeman, Rebekah A.; Wu, Li; Vangveravong, Suwanna; Luedtke, Robert R.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">195-202</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">A series of conformationally-flexible analogs was prepd. and their affinities for D2-like dopamine (D2, D3 and D4) were detd. using in vitro radioligand binding assays.  The results of this structure-activity relationship study identified one compd. that bound with high affinity (Ki value=2 nM) and moderate selectivity (30-fold) for D3 compared to D2 receptors.  In addn., this series of compds. were also tested for affinity at σ1 and σ2 receptors.  We evaluated the affinity of these dopaminergic compds. at sigma receptors because (a) several antipsychotic drugs, which are high affinity antagonists at dopamine D2-like receptors, also bind to sigma receptors and (b) sigma receptors are expressed ubiquitously and at high levels (picomoles per mg proteins).  It was obsd. that a no. of analogs displayed high affinity and excellent selectivity for σ2 vs. σ1 receptors.  Consequently, these novel compds. may be useful for characterizing the functional role of σ2 receptors and for imaging the σ2 receptor status of tumors in vivo with PET.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTCz3LVM_ZorVg90H21EOLACvtfcHk0ljwPrRCHNrNEw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXpvVWntbk%253D&md5=2fae22514cbeaa1ff88eecec09de31ec</span></div><a href="/servlet/linkout?suffix=cit168&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2003.09.083&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2003.09.083%26sid%3Dliteratum%253Aachs%26aulast%3DMach%26aufirst%3DR.%2BH.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DFreeman%26aufirst%3DR.%2BA.%26aulast%3DWu%26aufirst%3DL.%26aulast%3DVangveravong%26aufirst%3DS.%26aulast%3DLuedtke%26aufirst%3DR.%2BR.%26atitle%3DConformationally-flexible%2520benzamide%2520analogues%2520as%2520dopamine%2520D3%2520and%2520sigma%25202%2520receptor%2520ligands%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2004%26volume%3D14%26spage%3D195%26epage%3D202%26doi%3D10.1016%2Fj.bmcl.2003.09.083" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref169"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref169'); return false;" data-citation="" class="refNumLink">169</a></strong><div class="NLM_citation" id="cit169"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mach, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wheeler, K. T.</span></span> <span> </span><span class="NLM_article-title">Development of molecular probes for imaging sigma-2 receptors in vitro and in vivo</span>. <i>Cent. Nerv. Syst. Agents Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">230</span>– <span class="NLM_lpage">245</span>, <span class="refDoi"> DOI: 10.2174/1871524910909030230</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.2174%2F1871524910909030230" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=20021357" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtVWnt7rJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2009&pages=230-245&author=R.+H.+Machauthor=K.+T.+Wheeler&title=Development+of+molecular+probes+for+imaging+sigma-2+receptors+in+vitro+and+in+vivo&doi=10.2174%2F1871524910909030230"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit169R"><div class="casContent"><span class="casTitleNuber">169</span><div class="casTitle"><span class="NLM_cas:atitle">Development of molecular probes for imaging sigma-2 receptors in vitro and in vivo</span></div><div class="casAuthors">Mach, Robert Henry; Wheeler, Kenneth Theodore</div><div class="citationInfo"><span class="NLM_cas:title">Central Nervous System Agents in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">230-245</span>CODEN:
                <span class="NLM_cas:coden">CNSAC3</span>;
        ISSN:<span class="NLM_cas:issn">1871-5249</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The sigma-2 (σ2) receptor is proving to be an important protein in the field of cancer biol.  The observations that σ2 receptors have a 10-fold higher d. in proliferating tumor cells than in quiescent tumor cells, and that σ2 receptor agonists are capable of killing tumor cells via apoptotic and non-apoptotic mechanisms, indicate that this receptor is an important mol. target for the development of radiotracers for imaging tumors using techniques such as Positron Emission Tomog. (PET) and Single Photon Emission Computed Tomog. (SPECT) and for the development of cancer chemotherapeutic agents.  In spite of recent promising results towards achieving these goals, research in this field has been hampered by the fact that the mol. identity of the protein sequence of the σ2 receptor is currently not known.  Consequently, most of what is known about this protein has been obtained using either radiolabeled or fluorescent probes for this receptor, or biochem. anal. of the effect of σ2 selective ligands on cells growing under tissue culture conditions.  This article provides a review of the development and use of σ2 receptor ligands, and how these ligands have been used with a variety of in vitro and in vivo models to gain a greater understanding of the role this receptor plays in cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpC9Mm5Pn8dtbVg90H21EOLACvtfcHk0ljz6xWMLai11g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtVWnt7rJ&md5=1babf73dd3a6dcf8eb3eb8b29702360e</span></div><a href="/servlet/linkout?suffix=cit169&amp;dbid=16384&amp;doi=10.2174%2F1871524910909030230&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1871524910909030230%26sid%3Dliteratum%253Aachs%26aulast%3DMach%26aufirst%3DR.%2BH.%26aulast%3DWheeler%26aufirst%3DK.%2BT.%26atitle%3DDevelopment%2520of%2520molecular%2520probes%2520for%2520imaging%2520sigma-2%2520receptors%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DCent.%2520Nerv.%2520Syst.%2520Agents%2520Med.%2520Chem.%26date%3D2009%26volume%3D9%26spage%3D230%26epage%3D245%26doi%3D10.2174%2F1871524910909030230" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref170"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref170'); return false;" data-citation="" class="refNumLink">170</a></strong><div class="NLM_citation" id="cit170"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, G. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, X. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mach, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y. S.</span></span> <span> </span><span class="NLM_article-title">Synthesis and pharmacological evaluation of 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline derivatives as sigma-2 receptor ligands</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>147</i></span>,  <span class="NLM_fpage">227</span>– <span class="NLM_lpage">237</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2017.11.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1016%2Fj.ejmech.2017.11.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=29438891" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BC1cXis1SmtLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=147&publication_year=2018&pages=227-237&author=Y.+T.+Sunauthor=G.+F.+Wangauthor=Y.+Q.+Yangauthor=F.+Jinauthor=Y.+Wangauthor=X.+Y.+Xieauthor=R.+H.+Machauthor=Y.+S.+Huang&title=Synthesis+and+pharmacological+evaluation+of+6%2C7-dimethoxy-1%2C2%2C3%2C4-tetrahydroisoquinoline+derivatives+as+sigma-2+receptor+ligands&doi=10.1016%2Fj.ejmech.2017.11.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit170R"><div class="casContent"><span class="casTitleNuber">170</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and pharmacological evaluation of 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline derivatives as sigma-2 receptor ligands</span></div><div class="casAuthors">Sun, Yu-Tong; Wang, Gui-Fei; Yang, Yi-Qiu; Jin, Fujun; Wang, Yifei; Xie, Xiao-Yang; Mach, Robert H.; Huang, Yun-Sheng</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">147</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">227-237</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">The compds. 6,7-Dimethoxy-1,2,3,4-tetrahydroisoquinolinylalkyl benzamides I (R = 4-methoxy-2-methylphenyl, 2,4-dimethoxyphenyl, 2-hydroxy-3,4,5-trimethoxy-6-methylphenyl; n = 1, 2, 4), II (R1 = 4-methoxy-2-methylphenyl, 2,4-dimethoxyphenyl; n = 1, 2, 4) and III [R2 = 6,7-(MeO2), 6-NO2-7-Cl; X = CH2, (CH2)2, (CH2)3] are among a few categories of structures that have demonstrated high affinities and selectivities for sigma-2 receptor and been used extensively as study tools in various tumor imaging and therapy.  As a continuous effort, a new series of 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline derivs. I, II and III was synthesized and evaluated for their affinities for both sigma-1 and sigma-2 receptors.  Most of these newly developed analogs showed good to excellent binding affinities for sigma-2 receptor with no or low affinities for sigma-1 receptor.  In particular, compds. I (R = 4-methoxy-2-methylphenyl, 2,4-dimethoxyphenyl; n = 4) and II (R1 = 4-methoxy-2-methylphenyl, 2,4-dimethoxyphenyl; x = 4) demonstrated Ki values of 5-6 nM affinities and excellent selectivities for sigma-2 receptor.  In addn., these analogs also demonstrated moderate anticancer activities against human liver Huh-7 tumor cells and human esophagus KYSE-140 cancer cells.  But their cytotoxicities seem not to be correlated with their sigma-2 receptor affinities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGplR07xXaNwMrVg90H21EOLACvtfcHk0ljz6xWMLai11g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXis1SmtLw%253D&md5=c55a4c98ed32db97e8aeb14bf2bcf782</span></div><a href="/servlet/linkout?suffix=cit170&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2017.11.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2017.11.016%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DY.%2BT.%26aulast%3DWang%26aufirst%3DG.%2BF.%26aulast%3DYang%26aufirst%3DY.%2BQ.%26aulast%3DJin%26aufirst%3DF.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DXie%26aufirst%3DX.%2BY.%26aulast%3DMach%26aufirst%3DR.%2BH.%26aulast%3DHuang%26aufirst%3DY.%2BS.%26atitle%3DSynthesis%2520and%2520pharmacological%2520evaluation%2520of%25206%252C7-dimethoxy-1%252C2%252C3%252C4-tetrahydroisoquinoline%2520derivatives%2520as%2520sigma-2%2520receptor%2520ligands%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D147%26spage%3D227%26epage%3D237%26doi%3D10.1016%2Fj.ejmech.2017.11.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref171"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref171'); return false;" data-citation="" class="refNumLink">171</a></strong><div class="NLM_citation" id="cit171"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xie, X. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riad, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mach, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y. S.</span></span> <span> </span><span class="NLM_article-title">Synthesis, binding, and functional properties of tetrahydroisoquinolino-2-alkyl phenones as selective σ(2)R/TMEM97 ligands</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2021</span>,  <span class="NLM_volume"><i>209</i></span>,  <span class="NLM_fpage">112906</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2020.112906</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1016%2Fj.ejmech.2020.112906" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=33049607" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BB3cXitVOrtb7N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=209&publication_year=2021&pages=112906&author=X.+Y.+Xieauthor=Y.+Y.+Liauthor=W.+H.+Maauthor=A.+F.+Chenauthor=Y.+T.+Sunauthor=J.+Y.+Leeauthor=A.+Riadauthor=D.+H.+Xuauthor=R.+H.+Machauthor=Y.+S.+Huang&title=Synthesis%2C+binding%2C+and+functional+properties+of+tetrahydroisoquinolino-2-alkyl+phenones+as+selective+%CF%83%282%29R%2FTMEM97+ligands&doi=10.1016%2Fj.ejmech.2020.112906"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit171R"><div class="casContent"><span class="casTitleNuber">171</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis, binding and functional properties of tetrahydroisoquinolino-2-alkyl phenones as selective σ2R/TMEM97 ligands</span></div><div class="casAuthors">Xie, Xiao-Yang; Li, Yu-Yun; Ma, Wen-Hui; Chen, Ai-Fang; Sun, Yu-Tong; Lee, Ji Youn; Riad, Aladdin; Xu, Dao-Hua; Mach, Robert H.; Huang, Yun-Sheng</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2021</span>),
    <span class="NLM_cas:volume">209</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">112906</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A series of tetrahydroisoquinolino-2-alkyl phenones I [R1 = H, OMe; R2 = H, OMe; n = 2, 3, 4, 5, 6] was synthesized and identified as selective σ2R/TMEM97 ligands.  Among the synthesized compds., four analogs I [R1 = R2 = H, n = 3, 4, 5, 6] demonstrated the best affinity with Ki values of 5.1, 3.0, 0.38 and 1.33 nM, resp., for σ2R/TMEM97 and selectivity ratios of >196, 53, >2631 and > 751, resp., for σ2R/TMEM97 over σ1R.  Functional assays indicated that these four most potent analogs I [R1 = R2 = H, n = 3, 4, 5, 6] had no effects on intracellular calcium concn. and were classified as putative σ2R/TMEM97 antagonists according to current understanding.  The σ2R/TMEM97 was suggested to play important roles in the central nervous system.  Based on published pharmacol. and clin. results from several regarded σ2R/TMEM97 antagonists, these analogs I may potentially be useful for the treatment of various neurodegenerative diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpN7ViTUty9tbVg90H21EOLACvtfcHk0ljz6xWMLai11g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXitVOrtb7N&md5=b3f0363b6da78d49b62f8ca635d0171f</span></div><a href="/servlet/linkout?suffix=cit171&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2020.112906&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2020.112906%26sid%3Dliteratum%253Aachs%26aulast%3DXie%26aufirst%3DX.%2BY.%26aulast%3DLi%26aufirst%3DY.%2BY.%26aulast%3DMa%26aufirst%3DW.%2BH.%26aulast%3DChen%26aufirst%3DA.%2BF.%26aulast%3DSun%26aufirst%3DY.%2BT.%26aulast%3DLee%26aufirst%3DJ.%2BY.%26aulast%3DRiad%26aufirst%3DA.%26aulast%3DXu%26aufirst%3DD.%2BH.%26aulast%3DMach%26aufirst%3DR.%2BH.%26aulast%3DHuang%26aufirst%3DY.%2BS.%26atitle%3DSynthesis%252C%2520binding%252C%2520and%2520functional%2520properties%2520of%2520tetrahydroisoquinolino-2-alkyl%2520phenones%2520as%2520selective%2520%25CF%2583%25282%2529R%252FTMEM97%2520ligands%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2021%26volume%3D209%26spage%3D112906%26doi%3D10.1016%2Fj.ejmech.2020.112906" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref172"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref172'); return false;" data-citation="" class="refNumLink">172</a></strong><div class="NLM_citation" id="cit172"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Abate, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferorelli, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Contino, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marottoli, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colabufo, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perrone, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berardi, F.</span></span> <span> </span><span class="NLM_article-title">Arylamides hybrids of two high-affinity σ2 receptor ligands as tools for the development of PET radiotracers</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">4733</span>– <span class="NLM_lpage">4741</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2011.05.057</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1016%2Fj.ejmech.2011.05.057" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=21684636" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtV2rtbnN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2011&pages=4733-4741&author=C.+Abateauthor=S.+Ferorelliauthor=M.+Continoauthor=R.+Marottoliauthor=N.+A.+Colabufoauthor=R.+Perroneauthor=F.+Berardi&title=Arylamides+hybrids+of+two+high-affinity+%CF%832+receptor+ligands+as+tools+for+the+development+of+PET+radiotracers&doi=10.1016%2Fj.ejmech.2011.05.057"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit172R"><div class="casContent"><span class="casTitleNuber">172</span><div class="casTitle"><span class="NLM_cas:atitle">Arylamides hybrids of two high-affinity σ2 receptor ligands as tools for the development of PET radiotracers</span></div><div class="casAuthors">Abate, Carmen; Ferorelli, Savina; Contino, Marialessandra; Marottoli, Roberta; Colabufo, Nicola Antonio; Perrone, Roberto; Berardi, Francesco</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4733-4741</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">1-Cyclohexyl-4-[3-(5-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)propyl]piperazine 1 (PB28) and 2-Methoxy-5-methyl-N-[4-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)butyl]benzamide 2 (RHM-1) represent leads for tumor diagnosis, given their high affinity at σ2 receptors.  With the purpose of obtaining good candidates for σ2 PET tracers development, hybrid structures between 1 and 2 were designed.  Excellent σ1/σ2 selectivities were reached when 6,7-dimethoxytetrahydroisoquinoline was linked to an o-methoxy substituted arylamide (11a, 12a, 15a), and for these benzamides an intramol. H-bond in the active conformation at the σ sites, was hypothesized.  However these excellent σ2 ligands were accompanied by interaction with P-gp, which may limit their use as σ2 receptor PET agents when tumors overexpress P-gp.  Compd. 15a whose P-gp interaction was just moderate represents an interesting tool for the development of σ2 PET tracers useful in tumors overexpressing P-gp.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrlYNVyEcnCB7Vg90H21EOLACvtfcHk0ljCcC2sVc7EAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtV2rtbnN&md5=a01159535eddfd4206a80b173da9e51e</span></div><a href="/servlet/linkout?suffix=cit172&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2011.05.057&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2011.05.057%26sid%3Dliteratum%253Aachs%26aulast%3DAbate%26aufirst%3DC.%26aulast%3DFerorelli%26aufirst%3DS.%26aulast%3DContino%26aufirst%3DM.%26aulast%3DMarottoli%26aufirst%3DR.%26aulast%3DColabufo%26aufirst%3DN.%2BA.%26aulast%3DPerrone%26aufirst%3DR.%26aulast%3DBerardi%26aufirst%3DF.%26atitle%3DArylamides%2520hybrids%2520of%2520two%2520high-affinity%2520%25CF%25832%2520receptor%2520ligands%2520as%2520tools%2520for%2520the%2520development%2520of%2520PET%2520radiotracers%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2011%26volume%3D46%26spage%3D4733%26epage%3D4741%26doi%3D10.1016%2Fj.ejmech.2011.05.057" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref173"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref173'); return false;" data-citation="" class="refNumLink">173</a></strong><div class="NLM_citation" id="cit173"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Niso, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mosier, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marottoli, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferorelli, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cassano, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gasparre, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leopoldo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berardi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abate, C.</span></span> <span> </span><span class="NLM_article-title">High-affinity sigma-1 (σ(1)) receptor ligands based on the σ(1) antagonist PB212</span>. <i>Future Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">2547</span>– <span class="NLM_lpage">2562</span>, <span class="refDoi"> DOI: 10.4155/fmc-2019-0042</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.4155%2Ffmc-2019-0042" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=31633399" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvF2hu77F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2019&pages=2547-2562&author=M.+Nisoauthor=P.+D.+Mosierauthor=R.+Marottoliauthor=S.+Ferorelliauthor=G.+Cassanoauthor=G.+Gasparreauthor=M.+Leopoldoauthor=F.+Berardiauthor=C.+Abate&title=High-affinity+sigma-1+%28%CF%83%281%29%29+receptor+ligands+based+on+the+%CF%83%281%29+antagonist+PB212&doi=10.4155%2Ffmc-2019-0042"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit173R"><div class="casContent"><span class="casTitleNuber">173</span><div class="casTitle"><span class="NLM_cas:atitle">High-affinity sigma-1 (σ1) receptor ligands based on the σ1 antagonist PB212</span></div><div class="casAuthors">Niso, Mauro; Mosier, Philip D.; Marottoli, Roberta; Ferorelli, Savina; Cassano, Giuseppe; Gasparre, Giuseppe; Leopoldo, Marcello; Berardi, Francesco; Abate, Carmen</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">2547-2562</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">The σ1 receptor is a druggable target involved in many physiol. processes and diseases.  To clarify its physiol. and derive therapeutic benefit, nine analogs based on the σ1 antagonist PB212 were synthesized replacing the 4-methylpiperidine with basic moieties of varying size and degree of conformational freedom.  A 3-Phenylpyrrolidine, 4-phenylpiperidine or granatane derivs. displayed the highest affinity (Ki.#x00A0; = 0.12, 0.31 or 1.03 nM).  Calcium flux assays in MCF7s1 cells indicated that the highest σ1 receptor affinity are σ1 antagonists.  Mol. models provided a structural basis for understanding the σ1 affinity and functional activity of the analogs and incorporated Glennon's σ1 pharmacophore model.  Herein, we identify new compds. exploitable as therapeutic drug leads or as tools to study σ1 receptor physiol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNdKWlbfMVGbVg90H21EOLACvtfcHk0ljCcC2sVc7EAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvF2hu77F&md5=7aeacec7b3775acb3dffc268b4cd81be</span></div><a href="/servlet/linkout?suffix=cit173&amp;dbid=16384&amp;doi=10.4155%2Ffmc-2019-0042&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc-2019-0042%26sid%3Dliteratum%253Aachs%26aulast%3DNiso%26aufirst%3DM.%26aulast%3DMosier%26aufirst%3DP.%2BD.%26aulast%3DMarottoli%26aufirst%3DR.%26aulast%3DFerorelli%26aufirst%3DS.%26aulast%3DCassano%26aufirst%3DG.%26aulast%3DGasparre%26aufirst%3DG.%26aulast%3DLeopoldo%26aufirst%3DM.%26aulast%3DBerardi%26aufirst%3DF.%26aulast%3DAbate%26aufirst%3DC.%26atitle%3DHigh-affinity%2520sigma-1%2520%2528%25CF%2583%25281%2529%2529%2520receptor%2520ligands%2520based%2520on%2520the%2520%25CF%2583%25281%2529%2520antagonist%2520PB212%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2019%26volume%3D11%26spage%3D2547%26epage%3D2562%26doi%3D10.4155%2Ffmc-2019-0042" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref174"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref174'); return false;" data-citation="" class="refNumLink">174</a></strong><div class="NLM_citation" id="cit174"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Niso, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pati, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berardi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abate, C.</span></span> <span> </span><span class="NLM_article-title">Rigid versus flexible anilines or anilides confirm the bicyclic ring as the hydrophobic portion for optimal σ2 receptor binding and provide novel tools for the development of future σ2 receptor PET radiotracers</span>. <i>RSC Adv.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">88508</span>– <span class="NLM_lpage">88518</span>, <span class="refDoi"> DOI: 10.1039/C6RA15783A</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1039%2FC6RA15783A" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsV2hurvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2016&pages=88508-88518&author=M.+Nisoauthor=M.+L.+Patiauthor=F.+Berardiauthor=C.+Abate&title=Rigid+versus+flexible+anilines+or+anilides+confirm+the+bicyclic+ring+as+the+hydrophobic+portion+for+optimal+%CF%832+receptor+binding+and+provide+novel+tools+for+the+development+of+future+%CF%832+receptor+PET+radiotracers&doi=10.1039%2FC6RA15783A"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit174R"><div class="casContent"><span class="casTitleNuber">174</span><div class="casTitle"><span class="NLM_cas:atitle">Rigid versus flexible anilines or anilides confirm the bicyclic ring as the hydrophobic portion for optimal σ2 receptor binding and provide novel tools for the development of future σ2 receptor PET radiotracers</span></div><div class="casAuthors">Niso, Mauro; Pati, Maria Laura; Berardi, Francesco; Abate, Carmen</div><div class="citationInfo"><span class="NLM_cas:title">RSC Advances</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">91</span>),
    <span class="NLM_cas:pages">88508-88518</span>CODEN:
                <span class="NLM_cas:coden">RSCACL</span>;
        ISSN:<span class="NLM_cas:issn">2046-2069</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Despite their uncertain identification, σ2 receptors are promising targets for the development of diagnostics and therapeutics for tumor diseases.  Among the σ2 ligands developed, the class of the flexible benzamides furnished an optimal pharmacophore for σ2 receptor high affinity ligands.  Herein, the bicyclic-preferred conformation for σ2 binding was confirmed through the development of 3,4-dihydroquinolin-(1H)2-one isomeric derivs., 1,2,3,4-tetrahydroquinolines and the corresponding flexible anilides and anilines, all linked to the 6,7-dimethoxytetrahydroisoquinoline as a basic moiety. 3,4-Dihydroisoquinolin-(1H)2-one (10a) and 1,2,3,4-tetrahydroisoquinoline (11b) emerged for high σ2 affinity combined to an excellent σ2vs. σ1 selectivity.  In particular, compd. 11b with its low nanomolar σ2 affinity and impressive 2807-fold σ2vs. σ1 selectivity largely exceeded the biol. profile of the best 3,4-dihydroisoquinolin-(2H)1-one ref. compds. (1).  Because of the absence of a cytotoxic effect, the modest interaction with the P-gp, an appropriate lipophilicity and the presence of easily radiolabeling functions, 11b deserves further investigation for the imaging of σ2 receptors via PET in tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpS9WsRZfp-sLVg90H21EOLACvtfcHk0ljCcC2sVc7EAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsV2hurvI&md5=81a4e20ee40dd8b3dbf753caa0f0c528</span></div><a href="/servlet/linkout?suffix=cit174&amp;dbid=16384&amp;doi=10.1039%2FC6RA15783A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC6RA15783A%26sid%3Dliteratum%253Aachs%26aulast%3DNiso%26aufirst%3DM.%26aulast%3DPati%26aufirst%3DM.%2BL.%26aulast%3DBerardi%26aufirst%3DF.%26aulast%3DAbate%26aufirst%3DC.%26atitle%3DRigid%2520versus%2520flexible%2520anilines%2520or%2520anilides%2520confirm%2520the%2520bicyclic%2520ring%2520as%2520the%2520hydrophobic%2520portion%2520for%2520optimal%2520%25CF%25832%2520receptor%2520binding%2520and%2520provide%2520novel%2520tools%2520for%2520the%2520development%2520of%2520future%2520%25CF%25832%2520receptor%2520PET%2520radiotracers%26jtitle%3DRSC%2520Adv.%26date%3D2016%26volume%3D6%26spage%3D88508%26epage%3D88518%26doi%3D10.1039%2FC6RA15783A" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref175"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref175'); return false;" data-citation="" class="refNumLink">175</a></strong><div class="NLM_citation" id="cit175"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Abate, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Selivanova, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krämer, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schibli, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marottoli, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perrone, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berardi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niso, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ametamey, S. M.</span></span> <span> </span><span class="NLM_article-title">Development of 3,4-dihydroisoquinolin-1(2H)-one derivatives for the Positron Emission Tomography (PET) imaging of σ<sub>2</sub> receptors</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>69</i></span>,  <span class="NLM_fpage">920</span>– <span class="NLM_lpage">930</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2013.09.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1016%2Fj.ejmech.2013.09.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=24161678" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhslarur%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2013&pages=920-930&author=C.+Abateauthor=S.+V.+Selivanovaauthor=A.+M%C3%BCllerauthor=S.+D.+Kr%C3%A4merauthor=R.+Schibliauthor=R.+Marottoliauthor=R.+Perroneauthor=F.+Berardiauthor=M.+Nisoauthor=S.+M.+Ametamey&title=Development+of+3%2C4-dihydroisoquinolin-1%282H%29-one+derivatives+for+the+Positron+Emission+Tomography+%28PET%29+imaging+of+%CF%832+receptors&doi=10.1016%2Fj.ejmech.2013.09.018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit175R"><div class="casContent"><span class="casTitleNuber">175</span><div class="casTitle"><span class="NLM_cas:atitle">Development of 3,4-dihydroisoquinolin-1(2H)-one derivatives for the Positron Emission Tomography (PET) imaging of σ2 receptors</span></div><div class="casAuthors">Abate, Carmen; Selivanova, Svetlana V.; Muller, Adrienne; Kramer, Stefanie D.; Schibli, Roger; Marottoli, Roberta; Perrone, Roberto; Berardi, Francesco; Niso, Mauro; Ametamey, Simon M.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">920-930</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">σ2 Receptors are promising biomarkers for cancer diagnosis given the relationship between the proliferative status of tumors and their d.  With the aim of contributing to the research of σ2 receptor Positron Emission Tomog. (PET) probes, we developed 2-[3-[6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl]propyl]-3,4-dihydroisoquinolin-1(2H)-one (3), with optimal σ2 pharmacol. properties and appropriate lipophilicity.  Hence, 3 served as the lead compd. for the development of a series of dihydroisoquinolinones amenable to radiolabeling.  Radiosynthesis for compd. 26, which displayed the most appropriate σ2 profile, was developed and σ2 specific binding for the corresponding [18F]-26 was confirmed by in vitro autoradiog. on rat brain slices.  Despite the excellent in vitro properties, [18F]-26 could not successfully image σ2 receptors in the rat brain in vivo, maybe because of its interaction with P-gp.  Nevertheless, [18F]-26 may still be worthy of further investigation for the imaging of σ2 receptors in peripheral tumors devoid of P-gp overexpression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrW5YBLkmnQ9rVg90H21EOLACvtfcHk0lj2vwlvmzDFiQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhslarur%252FE&md5=ffff00424b23e5a01c49ce26fa9c9736</span></div><a href="/servlet/linkout?suffix=cit175&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2013.09.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2013.09.018%26sid%3Dliteratum%253Aachs%26aulast%3DAbate%26aufirst%3DC.%26aulast%3DSelivanova%26aufirst%3DS.%2BV.%26aulast%3DM%25C3%25BCller%26aufirst%3DA.%26aulast%3DKr%25C3%25A4mer%26aufirst%3DS.%2BD.%26aulast%3DSchibli%26aufirst%3DR.%26aulast%3DMarottoli%26aufirst%3DR.%26aulast%3DPerrone%26aufirst%3DR.%26aulast%3DBerardi%26aufirst%3DF.%26aulast%3DNiso%26aufirst%3DM.%26aulast%3DAmetamey%26aufirst%3DS.%2BM.%26atitle%3DDevelopment%2520of%25203%252C4-dihydroisoquinolin-1%25282H%2529-one%2520derivatives%2520for%2520the%2520Positron%2520Emission%2520Tomography%2520%2528PET%2529%2520imaging%2520of%2520%25CF%25832%2520receptors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2013%26volume%3D69%26spage%3D920%26epage%3D930%26doi%3D10.1016%2Fj.ejmech.2013.09.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref176"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref176'); return false;" data-citation="" class="refNumLink">176</a></strong><div class="NLM_citation" id="cit176"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shi, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunosewoyo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, L.</span></span> <span> </span><span class="NLM_article-title">Synthesis and pharmacological evaluation of σ2 receptor ligands based on a 3-alkoxyisoxazole scaffold: potential antitumor effects against osteosarcoma</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2021</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">524</span>– <span class="NLM_lpage">536</span>, <span class="refDoi"> DOI: 10.1002/cmdc.202000461</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1002%2Fcmdc.202000461" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=32964625" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BB3cXitFynu73M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2021&pages=524-536&author=J.+J.+Shiauthor=K.+H.+Jiaauthor=H.+Sunauthor=H.+Gunosewoyoauthor=F.+Yangauthor=J.+Tangauthor=J.+Luoauthor=L.+Yu&title=Synthesis+and+pharmacological+evaluation+of+%CF%832+receptor+ligands+based+on+a+3-alkoxyisoxazole+scaffold%3A+potential+antitumor+effects+against+osteosarcoma&doi=10.1002%2Fcmdc.202000461"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit176R"><div class="casContent"><span class="casTitleNuber">176</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Pharmacological Evaluation of σ2 Receptor Ligands Based on a 3-Alkoxyisoxazole Scaffold: Potential Antitumor Effects against Osteosarcoma</span></div><div class="casAuthors">Shi, Jun-Jie; Jia, Kun-Hang; Sun, Hao; Gunosewoyo, Hendra; Yang, Fan; Tang, Jie; Luo, Jian; Yu, Li-Fang</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2021</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">524-536</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Since its initial discovery as the basis for nicotinic acetylcholine receptor ligands, the 3-alkoxyisoxazole scaffold has been shown to be a versatile platform for the development of potent σ1 and σ2 receptor ligands.  Herein we report a further SAR exploration of the 3-alkoxyisoxazole scaffold with the aim of obtaining potent σ2 receptor ligands.  Various substitutions on the benzene ring and at the basic amino regions resulted in a total of 21 compds. that were tested for their binding affinities for the σ2 receptor.  In particular, compd. 51 [(2S)-1-(4-ammoniobutyl)-2-(((5-((3,4-dichlorophenoxy)methyl)isoxazol-3-yl)oxy)methyl)pyrrolidin-1-ium chloride] was identified as one of the most potent σ2 ligands within the series, with a Ki value of 7.9 nM.  It demonstrated potent antiproliferative effects on both osteosarcoma cell lines 143B and MOS-J (IC50 values of 0.89 and 0.71 μM, resp.), relative to siramesine (IC50 values of 1.81 and 2.01 μM).  Moreover, compd. 51 inhibited clonal formation of osteosarcoma 143B cells at 1 μM, corresponding to half the dose required of siramesine for similar effects.  The general cytotoxicity profile of compd. 51 was assessed in a no. of normal cell lines, including HaCaT, HAF, and LO2 cells.  Furthermore, FACS anal. showed that compd. 51 likely inhibits osteosarcoma cell growth by disruption of the cell cycle and promotion of apoptosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVKnzjY_scVLVg90H21EOLACvtfcHk0lj2vwlvmzDFiQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXitFynu73M&md5=290203492ee0e5d70c002b6a595737e8</span></div><a href="/servlet/linkout?suffix=cit176&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.202000461&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.202000461%26sid%3Dliteratum%253Aachs%26aulast%3DShi%26aufirst%3DJ.%2BJ.%26aulast%3DJia%26aufirst%3DK.%2BH.%26aulast%3DSun%26aufirst%3DH.%26aulast%3DGunosewoyo%26aufirst%3DH.%26aulast%3DYang%26aufirst%3DF.%26aulast%3DTang%26aufirst%3DJ.%26aulast%3DLuo%26aufirst%3DJ.%26aulast%3DYu%26aufirst%3DL.%26atitle%3DSynthesis%2520and%2520pharmacological%2520evaluation%2520of%2520%25CF%25832%2520receptor%2520ligands%2520based%2520on%2520a%25203-alkoxyisoxazole%2520scaffold%253A%2520potential%2520antitumor%2520effects%2520against%2520osteosarcoma%26jtitle%3DChemMedChem%26date%3D2021%26volume%3D16%26spage%3D524%26epage%3D536%26doi%3D10.1002%2Fcmdc.202000461" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref177"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref177'); return false;" data-citation="" class="refNumLink">177</a></strong><div class="NLM_citation" id="cit177"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yu, L. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunosewoyo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozikowski, A. P.</span></span> <span> </span><span class="NLM_article-title">From α4β2 Nicotinic Ligands to the Discovery of σ1 Receptor Ligands: Pharmacophore Analysis and Rational Design</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">1054</span>– <span class="NLM_lpage">1058</span>, <span class="refDoi"> DOI: 10.1021/ml3002715</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml3002715" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFamtr3K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=1054-1058&author=L.+F.+Yuauthor=H.+K.+Zhangauthor=H.+Gunosewoyoauthor=A.+P.+Kozikowski&title=From+%CE%B14%CE%B22+Nicotinic+Ligands+to+the+Discovery+of+%CF%831+Receptor+Ligands%3A+Pharmacophore+Analysis+and+Rational+Design&doi=10.1021%2Fml3002715"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit177R"><div class="casContent"><span class="casTitleNuber">177</span><div class="casTitle"><span class="NLM_cas:atitle">From α4β2 Nicotinic Ligands to the Discovery of σ1 Receptor Ligands: Pharmacophore Analysis and Rational Design</span></div><div class="casAuthors">Yu, Li-Fang; Zhang, Han-Kun; Gunosewoyo, Hendra; Kozikowski, Alan P.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1054-1058</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Comparative analyses of the pharmacophoric elements required for σ1 and nicotinic ligands led to the identification of a potent and selective σ1 ligand (15, I).  Compd. 15 displayed high selectivity for the σ1 receptor (Ki, σ1 = 4.1 nM; Ki, σ2 = 1312 nM) with moderate binding affinity for the DAT (Ki = 373 nM) and NET (Ki = 203 nM) in the PDSP broad screening panel of common CNS neurotransmitter transporters and receptors.  The key finding in this present work is that a subtle structural modification could be used as a tool to switch a ligand's selectivity between nAChRs and sigma receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp00SphSwYKLrVg90H21EOLACvtfcHk0lhpU5w6iIemZg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFamtr3K&md5=908dc6a13498beb6e751249b33d35e71</span></div><a href="/servlet/linkout?suffix=cit177&amp;dbid=16384&amp;doi=10.1021%2Fml3002715&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml3002715%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DL.%2BF.%26aulast%3DZhang%26aufirst%3DH.%2BK.%26aulast%3DGunosewoyo%26aufirst%3DH.%26aulast%3DKozikowski%26aufirst%3DA.%2BP.%26atitle%3DFrom%2520%25CE%25B14%25CE%25B22%2520Nicotinic%2520Ligands%2520to%2520the%2520Discovery%2520of%2520%25CF%25831%2520Receptor%2520Ligands%253A%2520Pharmacophore%2520Analysis%2520and%2520Rational%2520Design%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D3%26spage%3D1054%26epage%3D1058%26doi%3D10.1021%2Fml3002715" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref178"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref178'); return false;" data-citation="" class="refNumLink">178</a></strong><div class="NLM_citation" id="cit178"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neue, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schepmann, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yanagisawa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamaguchi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Würthwein, E. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Itami, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wünsch, B.</span></span> <span> </span><span class="NLM_article-title">Improvement of σ1 receptor affinity by late-stage C-H-bond arylation of spirocyclic lactones</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">1844</span>– <span class="NLM_lpage">1856</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2013.01.038</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1016%2Fj.bmc.2013.01.038" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=23462714" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BC3sXivF2rur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2013&pages=1844-1856&author=C.+Meyerauthor=B.+Neueauthor=D.+Schepmannauthor=S.+Yanagisawaauthor=J.+Yamaguchiauthor=E.+U.+W%C3%BCrthweinauthor=K.+Itamiauthor=B.+W%C3%BCnsch&title=Improvement+of+%CF%831+receptor+affinity+by+late-stage+C-H-bond+arylation+of+spirocyclic+lactones&doi=10.1016%2Fj.bmc.2013.01.038"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit178R"><div class="casContent"><span class="casTitleNuber">178</span><div class="casTitle"><span class="NLM_cas:atitle">Improvement of σ1 receptor affinity by late-stage C-H-bond arylation of spirocyclic lactones</span></div><div class="casAuthors">Meyer, Christina; Neue, Benedikt; Schepmann, Dirk; Yanagisawa, Shuichi; Yamaguchi, Junichiro; Wuerthwein, Ernst-Ulrich; Itami, Kenichiro; Wuensch, Bernhard</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1844-1856</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The direct C-H-bond arylation of the complex spirocyclic lactones 13 (I), 14 (II), and 18 (III) allows the introduction of diverse aryl moieties in the last step of the synthesis.  A selective α-arylation of the thiophene moiety was performed with the catalytic system PdCl2/2,2'-bipyridyl/Ag2CO3, whereas the β-position of the thiophene ring was addressed by using the alternative catalytic system PdCl2/P[OCH(CF3)2]3/Ag2CO3.  Due to electronic and steric reasons the arylation of the five-membered lactone 18 occurred in both α-positions providing 4'-mono-, 6'-mono- and 4',6'-diarylated thiophenes 22-26a-c.  Compds. with an addnl. aryl moiety at the 'upper left (top)' position (1'-position of 13, 3'-position of 14, 4'-position of 18) showed increased σ1 affinity compared to the non-arylated parent compds.  A Ph moiety at the 'left' position (2'-position in 20a) also increased the σ1 affinity but to a lower extent.  A considerable redn. of σ1 affinity was obsd. after introducing an aryl moiety in 6'-position of 18, which might result from shielding the tertiary amine, which is crucial for interaction with the σ1 receptor.  The discussion of the exptl. results is supported by high-level quantum chem. DFT-calcns. of the NBO-charges of 13 and 18 and the relative energies of the related arylated products.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpyzGVeovUWVbVg90H21EOLACvtfcHk0lhpU5w6iIemZg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXivF2rur4%253D&md5=80f77a4c4e526bf9b34d4def3ed81b92</span></div><a href="/servlet/linkout?suffix=cit178&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2013.01.038&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2013.01.038%26sid%3Dliteratum%253Aachs%26aulast%3DMeyer%26aufirst%3DC.%26aulast%3DNeue%26aufirst%3DB.%26aulast%3DSchepmann%26aufirst%3DD.%26aulast%3DYanagisawa%26aufirst%3DS.%26aulast%3DYamaguchi%26aufirst%3DJ.%26aulast%3DW%25C3%25BCrthwein%26aufirst%3DE.%2BU.%26aulast%3DItami%26aufirst%3DK.%26aulast%3DW%25C3%25BCnsch%26aufirst%3DB.%26atitle%3DImprovement%2520of%2520%25CF%25831%2520receptor%2520affinity%2520by%2520late-stage%2520C-H-bond%2520arylation%2520of%2520spirocyclic%2520lactones%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2013%26volume%3D21%26spage%3D1844%26epage%3D1856%26doi%3D10.1016%2Fj.bmc.2013.01.038" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref179"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref179'); return false;" data-citation="" class="refNumLink">179</a></strong><div class="NLM_citation" id="cit179"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pluchino, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldsborough, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Callaghan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gottesman, M. M.</span></span> <span> </span><span class="NLM_article-title">Collateral sensitivity as a strategy against cancer multidrug resistance</span>. <i>Drug Resist. Updates</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">98</span>– <span class="NLM_lpage">105</span>, <span class="refDoi"> DOI: 10.1016/j.drup.2012.03.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1016%2Fj.drup.2012.03.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=22483810" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BC38XmslynsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2012&pages=98-105&author=K.+M.+Pluchinoauthor=M.+D.+Hallauthor=A.+S.+Goldsboroughauthor=R.+Callaghanauthor=M.+M.+Gottesman&title=Collateral+sensitivity+as+a+strategy+against+cancer+multidrug+resistance&doi=10.1016%2Fj.drup.2012.03.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit179R"><div class="casContent"><span class="casTitleNuber">179</span><div class="casTitle"><span class="NLM_cas:atitle">Collateral sensitivity as a strategy against cancer multidrug resistance</span></div><div class="casAuthors">Pluchino, Kristen M.; Hall, Matthew D.; Goldsborough, Andrew S.; Callaghan, Richard; Gottesman, Michael M.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Resistance Updates</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">98-105</span>CODEN:
                <span class="NLM_cas:coden">DRUPFW</span>;
        ISSN:<span class="NLM_cas:issn">1368-7646</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  While chemotherapy remains the most effective treatment for disseminated tumors, acquired or intrinsic drug resistance accounts for approx. 90% of treatment failure.  Multidrug resistance (MDR), the simultaneous resistance to drugs that differ both structurally and mechanistically, often results from drug efflux pumps in the cell membrane that reduce intracellular drug levels to less than therapeutic concns.  Expression of the MDR transporter P-glycoprotein (P-gp, MDR1, ABCB1) has been shown to correlate with overall poor chemotherapy response and prognosis.  This review will focus on collateral sensitivity (CS), the ability of compds. to kill MDR cells selectively over the parental cells from which they were derived.  Insights into CS may offer an alternative strategy for the clin. resoln. of MDR, as highly selective and potent CS agents may lead to drugs that are effective at MDR cell killing and tumor resensitization.  Four main mechanistic hypotheses for CS will be reviewed, followed by a discussion on quant. and exptl. evaluation of CS.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGox5FqYWa-hS7Vg90H21EOLACvtfcHk0lhpU5w6iIemZg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmslynsLg%253D&md5=237f7f798703a7f9c45e75796e0b5d2d</span></div><a href="/servlet/linkout?suffix=cit179&amp;dbid=16384&amp;doi=10.1016%2Fj.drup.2012.03.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drup.2012.03.002%26sid%3Dliteratum%253Aachs%26aulast%3DPluchino%26aufirst%3DK.%2BM.%26aulast%3DHall%26aufirst%3DM.%2BD.%26aulast%3DGoldsborough%26aufirst%3DA.%2BS.%26aulast%3DCallaghan%26aufirst%3DR.%26aulast%3DGottesman%26aufirst%3DM.%2BM.%26atitle%3DCollateral%2520sensitivity%2520as%2520a%2520strategy%2520against%2520cancer%2520multidrug%2520resistance%26jtitle%3DDrug%2520Resist.%2520Updates%26date%3D2012%26volume%3D15%26spage%3D98%26epage%3D105%26doi%3D10.1016%2Fj.drup.2012.03.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref180"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref180'); return false;" data-citation="" class="refNumLink">180</a></strong><div class="NLM_citation" id="cit180"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maher, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haas, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Longen, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oyer, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, F. J.</span></span> <span> </span><span class="NLM_article-title">Small-Molecule Sigma1Modulator Induces Autophagic Degradation of PD-L1</span>. <i>Mol. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">243</span>– <span class="NLM_lpage">255</span>, <span class="refDoi"> DOI: 10.1158/1541-7786.MCR-17-0166</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1158%2F1541-7786.MCR-17-0166" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=29117944" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitVeiurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2018&pages=243-255&author=C.+M.+Maherauthor=J.+D.+Thomasauthor=D.+A.+Haasauthor=C.+G.+Longenauthor=H.+M.+Oyerauthor=J.+Y.+Tongauthor=F.+J.+Kim&title=Small-Molecule+Sigma1Modulator+Induces+Autophagic+Degradation+of+PD-L1&doi=10.1158%2F1541-7786.MCR-17-0166"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit180R"><div class="casContent"><span class="casTitleNuber">180</span><div class="casTitle"><span class="NLM_cas:atitle">Small-Molecule Sigma1 Modulator Induces Autophagic Degradation of PD-L1</span></div><div class="casAuthors">Maher, Christina M.; Thomas, Jeffrey D.; Haas, Derick A.; Longen, Charles G.; Oyer, Halley M.; Tong, Jane Y.; Kim, Felix J.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">243-255</span>CODEN:
                <span class="NLM_cas:coden">MCROC5</span>;
        ISSN:<span class="NLM_cas:issn">1541-7786</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Emerging evidence suggests that Sigma1 (SIGMAR1, also known as sigma-1 receptor) is a unique ligand-regulated integral membrane scaffolding protein that contributes to cellular protein and lipid homeostasis.  Previously, we demonstrated that some small-mol. modulators of Sigma1 alter endoplasmic reticulum (ER)-assocd. protein homeostasis pathways in cancer cells, including the unfolded protein response and autophagy.  Programmed death-ligand 1 (PD-L1) is a type I integral membrane glycoprotein that is cotranslationally inserted into the ER and is processed and transported through the secretory pathway.  Once at the surface of cancer cells, PD-L1 acts as a T-cell inhibitory checkpoint mol. and suppresses antitumor immunity.  Here, we demonstrate that in Sigma1-expressing triple-neg. breast and androgen-independent prostate cancer cells, PD-L1 protein levels were suppressed by RNAi knockdown of Sigma1 and by small-mol. inhibition of Sigma1.  Sigma1-mediated action was confirmed by pharmacol. competition between Sigma1-selective inhibitor and activator ligands.  When administered alone, the Sigma1 inhibitor decreased cell surface PD-L1 expression and suppressed functional interaction of PD-1 and PD-L1 in a coculture of T cells and cancer cells.  Conversely, the Sigma1 activator increased PD-L1 cell surface expression, demonstrating the ability to pos. and neg. modulate Sigma1 assocd. PD-L1 processing.  We discovered that the Sigma1 inhibitor induced degrdn. of PD-L1 via autophagy, by a mechanism distinct from bulk macroautophagy or general ER stress-assocd. autophagy.  Finally, the Sigma1 inhibitor suppressed IFNγ-induced PD-L1.  Our data demonstrate that small-mol. Sigma1 modulators can be used to regulate PD-L1 in cancer cells and trigger its degrdn. by selective autophagy.  Implications: Sigma1 modulators sequester and eliminate PD-L1 by autophagy, thus preventing functional PD-L1 expression at the cell surface.  This posits Sigma1 modulators as novel therapeutic agents in PD-L1/PD-1 blockade strategies that regulate the tumor immune microenvironment.  Visual Overview: http//mcr.accrjournals.org/content/molcanres/16/02/243/F1.large.jpg.  Mol Cancer Res; 16(2); 243-55. ©2017 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPoBdyWoswA7Vg90H21EOLACvtfcHk0lhHEHsGjIgnCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitVeiurc%253D&md5=84f9aee84ada0bb2b7ce13f2d210b52b</span></div><a href="/servlet/linkout?suffix=cit180&amp;dbid=16384&amp;doi=10.1158%2F1541-7786.MCR-17-0166&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1541-7786.MCR-17-0166%26sid%3Dliteratum%253Aachs%26aulast%3DMaher%26aufirst%3DC.%2BM.%26aulast%3DThomas%26aufirst%3DJ.%2BD.%26aulast%3DHaas%26aufirst%3DD.%2BA.%26aulast%3DLongen%26aufirst%3DC.%2BG.%26aulast%3DOyer%26aufirst%3DH.%2BM.%26aulast%3DTong%26aufirst%3DJ.%2BY.%26aulast%3DKim%26aufirst%3DF.%2BJ.%26atitle%3DSmall-Molecule%2520Sigma1Modulator%2520Induces%2520Autophagic%2520Degradation%2520of%2520PD-L1%26jtitle%3DMol.%2520Cancer%2520Res.%26date%3D2018%26volume%3D16%26spage%3D243%26epage%3D255%26doi%3D10.1158%2F1541-7786.MCR-17-0166" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref181"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref181'); return false;" data-citation="" class="refNumLink">181</a></strong><div class="NLM_citation" id="cit181"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, S. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xia, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuo, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khoo, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cha, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsu, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsu, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamaguchi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sahin, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allison, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hortobagyi, G. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hung, M. C.</span></span> <span> </span><span class="NLM_article-title">Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">12632</span>, <span class="refDoi"> DOI: 10.1038/ncomms12632</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1038%2Fncomms12632" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=27572267" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVKjsbnJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=12632&author=C.+W.+Liauthor=S.+O.+Limauthor=W.+Xiaauthor=H.+H.+Leeauthor=L.+C.+Chanauthor=C.+W.+Kuoauthor=K.+H.+Khooauthor=S.+S.+Changauthor=J.+H.+Chaauthor=T.+Kimauthor=J.+L.+Hsuauthor=Y.+Wuauthor=J.+M.+Hsuauthor=H.+Yamaguchiauthor=Q.+Dingauthor=Y.+Wangauthor=J.+Yaoauthor=C.+C.+Leeauthor=H.+J.+Wuauthor=A.+A.+Sahinauthor=J.+P.+Allisonauthor=D.+Yuauthor=G.+N.+Hortobagyiauthor=M.+C.+Hung&title=Glycosylation+and+stabilization+of+programmed+death+ligand-1+suppresses+T-cell+activity&doi=10.1038%2Fncomms12632"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit181R"><div class="casContent"><span class="casTitleNuber">181</span><div class="casTitle"><span class="NLM_cas:atitle">Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity</span></div><div class="casAuthors">Li, Chia-Wei; Lim, Seung-Oe; Xia, Weiya; Lee, Heng-Huan; Chan, Li-Chuan; Kuo, Chu-Wei; Khoo, Kay-Hooi; Chang, Shih-Shin; Cha, Jong-Ho; Kim, Taewan; Hsu, Jennifer L.; Wu, Yun; Hsu, Jung-Mao; Yamaguchi, Hirohito; Ding, Qingqing; Wang, Yan; Yao, Jun; Lee, Cheng-Chung; Wu, Hsing-Ju; Sahin, Aysegul A.; Allison, James P.; Yu, Dihua; Hortobagyi, Gabriel N.; Hung, Mien-Chie</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">12632</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Extracellular interaction between programmed death ligand-1 (PD-L1) and programmed cell death protein-1 (PD-1) leads to tumor-assocd. immune escape.  Here we show that the immunosuppression activity of PD-L1 is stringently modulated by ubiquitination and N-glycosylation.  We show that glycogen synthase kinase 3β (GSK3β) interacts with PD-L1 and induces phosphorylation-dependent proteasome degrdn. of PD-L1 by β-TrCP.  In-depth anal. of PD-L1 N192, N200 and N219 glycosylation suggests that glycosylation antagonizes GSK3β binding.  In this regard, only non-glycosylated PD-L1 forms a complex with GSK3β and β-TrCP.  We also demonstrate that epidermal growth factor (EGF) stabilizes PD-L1 via GSK3β inactivation in basal-like breast cancer.  Inhibition of EGF signalling by gefitinib destabilizes PD-L1, enhances antitumor T-cell immunity and therapeutic efficacy of PD-1 blockade in syngeneic mouse models.  Together, our results link ubiquitination and glycosylation pathways to the stringent regulation of PD-L1, which could lead to potential therapeutic strategies to enhance cancer immune therapy efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQnyTgbFXcD7Vg90H21EOLACvtfcHk0lhHEHsGjIgnCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVKjsbnJ&md5=35cab8a1af28193769fe685c0e1f37b7</span></div><a href="/servlet/linkout?suffix=cit181&amp;dbid=16384&amp;doi=10.1038%2Fncomms12632&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms12632%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DC.%2BW.%26aulast%3DLim%26aufirst%3DS.%2BO.%26aulast%3DXia%26aufirst%3DW.%26aulast%3DLee%26aufirst%3DH.%2BH.%26aulast%3DChan%26aufirst%3DL.%2BC.%26aulast%3DKuo%26aufirst%3DC.%2BW.%26aulast%3DKhoo%26aufirst%3DK.%2BH.%26aulast%3DChang%26aufirst%3DS.%2BS.%26aulast%3DCha%26aufirst%3DJ.%2BH.%26aulast%3DKim%26aufirst%3DT.%26aulast%3DHsu%26aufirst%3DJ.%2BL.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DHsu%26aufirst%3DJ.%2BM.%26aulast%3DYamaguchi%26aufirst%3DH.%26aulast%3DDing%26aufirst%3DQ.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DYao%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DC.%2BC.%26aulast%3DWu%26aufirst%3DH.%2BJ.%26aulast%3DSahin%26aufirst%3DA.%2BA.%26aulast%3DAllison%26aufirst%3DJ.%2BP.%26aulast%3DYu%26aufirst%3DD.%26aulast%3DHortobagyi%26aufirst%3DG.%2BN.%26aulast%3DHung%26aufirst%3DM.%2BC.%26atitle%3DGlycosylation%2520and%2520stabilization%2520of%2520programmed%2520death%2520ligand-1%2520suppresses%2520T-cell%2520activity%26jtitle%3DNat.%2520Commun.%26date%3D2016%26volume%3D7%26spage%3D12632%26doi%3D10.1038%2Fncomms12632" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref182"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref182'); return false;" data-citation="" class="refNumLink">182</a></strong><div class="NLM_citation" id="cit182"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Proschak, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stark, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merk, D.</span></span> <span> </span><span class="NLM_article-title">Polypharmacology by Design: A Medicinal Chemist’s Perspective on Multitargeting Compounds</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">420</span>– <span class="NLM_lpage">444</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00760</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00760" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlKms7fE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=420-444&author=E.+Proschakauthor=H.+Starkauthor=D.+Merk&title=Polypharmacology+by+Design%3A+A+Medicinal+Chemist%E2%80%99s+Perspective+on+Multitargeting+Compounds&doi=10.1021%2Facs.jmedchem.8b00760"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit182R"><div class="casContent"><span class="casTitleNuber">182</span><div class="casTitle"><span class="NLM_cas:atitle">Polypharmacology by Design: A Medicinal Chemist's Perspective on Multitargeting Compounds</span></div><div class="casAuthors">Proschak, Ewgenij; Stark, Holger; Merk, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">420-444</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Multitargeting compds. comprising activity on more than a single biol. target have gained remarkable relevance in drug discovery owing to the complexity of multifactorial diseases such as cancer, inflammation, or the metabolic syndrome.  Polypharmacol. drug profiles can produce additive or synergistic effects while reducing side effects and significantly contribute to the high therapeutic success of indispensable drugs such as aspirin.  While their identification has long been the result of serendipity, medicinal chem. now tends to design polypharmacol.  Modern in vitro pharmacol. methods and chem. probes allow a systematic search for rational target combinations and recent innovations in computational technologies, crystallog., or fragment-based design equip multitarget compd. development with valuable tools.  In this Perspective, we analyze the relevance of multiple ligands in drug discovery and the versatile toolbox to design polypharmacol.  We conclude that despite some characteristic challenges remaining unresolved, designed polypharmacol. holds enormous potential to secure future therapeutic innovation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOEwJSxWw3vbVg90H21EOLACvtfcHk0lhHEHsGjIgnCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlKms7fE&md5=6dc4b8e1c4777372396626140a302663</span></div><a href="/servlet/linkout?suffix=cit182&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00760%26sid%3Dliteratum%253Aachs%26aulast%3DProschak%26aufirst%3DE.%26aulast%3DStark%26aufirst%3DH.%26aulast%3DMerk%26aufirst%3DD.%26atitle%3DPolypharmacology%2520by%2520Design%253A%2520A%2520Medicinal%2520Chemist%25E2%2580%2599s%2520Perspective%2520on%2520Multitargeting%2520Compounds%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D420%26epage%3D444%26doi%3D10.1021%2Facs.jmedchem.8b00760" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref183"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref183'); return false;" data-citation="" class="refNumLink">183</a></strong><div class="NLM_citation" id="cit183"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H.</span></span> <span> </span><span class="NLM_article-title">Rational Design of Multitarget-Directed Ligands: Strategies and Emerging Paradigms</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">8881</span>– <span class="NLM_lpage">8914</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00017</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00017" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BC1MXptlKrt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=8881-8914&author=J.+Zhouauthor=X.+Jiangauthor=S.+Heauthor=H.+Jiangauthor=F.+Fengauthor=W.+Liuauthor=W.+Quauthor=H.+Sun&title=Rational+Design+of+Multitarget-Directed+Ligands%3A+Strategies+and+Emerging+Paradigms&doi=10.1021%2Facs.jmedchem.9b00017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit183R"><div class="casContent"><span class="casTitleNuber">183</span><div class="casTitle"><span class="NLM_cas:atitle">Rational Design of Multitarget-Directed Ligands: Strategies and Emerging Paradigms</span></div><div class="casAuthors">Zhou, Junting; Jiang, Xueyang; He, Siyu; Jiang, Hongli; Feng, Feng; Liu, Wenyuan; Qu, Wei; Sun, Haopeng</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">8881-8914</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Due to the complexity of multifactorial diseases, single-target drugs do not always exhibit satisfactory efficacy.  Recently, increasing evidence indicates that simultaneous modulation of multiple targets may improve both therapeutic safety and efficacy, compared with single-target drugs.  However, few multitarget drugs are on market or in clin. trials, despite the best efforts of medicinal chemists.  This article discusses the systematic establishment of target combination, lead generation, and optimization of multitarget-directed ligands (MTDLs).  Moreover, we analyze some MTDLs research cases for several complex diseases in recent years and the physicochem. properties of 117 clin. multitarget drugs, with the aim to reveal the trends and insights of the potential use of MTDLs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGraLqk7hMZnoLVg90H21EOLACvtfcHk0lgxtWzVVCPMMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXptlKrt7k%253D&md5=37adb9bc31802e62fd7f8d0d6e7697e3</span></div><a href="/servlet/linkout?suffix=cit183&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00017%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DJ.%26aulast%3DJiang%26aufirst%3DX.%26aulast%3DHe%26aufirst%3DS.%26aulast%3DJiang%26aufirst%3DH.%26aulast%3DFeng%26aufirst%3DF.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DQu%26aufirst%3DW.%26aulast%3DSun%26aufirst%3DH.%26atitle%3DRational%2520Design%2520of%2520Multitarget-Directed%2520Ligands%253A%2520Strategies%2520and%2520Emerging%2520Paradigms%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D8881%26epage%3D8914%26doi%3D10.1021%2Facs.jmedchem.9b00017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref184"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref184'); return false;" data-citation="" class="refNumLink">184</a></strong><div class="NLM_citation" id="cit184"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mangiatordi, G. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Intranuovo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delre, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abatematteo, F. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abate, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niso, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Creanza, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ancona, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stefanachi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Contino, M.</span></span> <span> </span><span class="NLM_article-title">Cannabinoid Receptor Subtype 2 (CB2R) in a Multitarget Approach: Perspective of an Innovative Strategy in Cancer and Neurodegeneration</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">14448</span>– <span class="NLM_lpage">14469</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.0c01357</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.0c01357" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BB3cXitFagtLbI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=14448-14469&author=G.+F.+Mangiatordiauthor=F.+Intranuovoauthor=P.+Delreauthor=F.+S.+Abatematteoauthor=C.+Abateauthor=M.+Nisoauthor=T.+M.+Creanzaauthor=N.+Anconaauthor=A.+Stefanachiauthor=M.+Contino&title=Cannabinoid+Receptor+Subtype+2+%28CB2R%29+in+a+Multitarget+Approach%3A+Perspective+of+an+Innovative+Strategy+in+Cancer+and+Neurodegeneration&doi=10.1021%2Facs.jmedchem.0c01357"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit184R"><div class="casContent"><span class="casTitleNuber">184</span><div class="casTitle"><span class="NLM_cas:atitle">Cannabinoid Receptor Subtype 2 (CB2R) in a Multitarget Approach: Perspective of an Innovative Strategy in Cancer and Neurodegeneration</span></div><div class="casAuthors">Mangiatordi, Giuseppe Felice; Intranuovo, Francesca; Delre, Pietro; Abatematteo, Francesca Serena; Abate, Carmen; Niso, Mauro; Creanza, Teresa Maria; Ancona, Nicola; Stefanachi, Angela; Contino, Marialessandra</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">14448-14469</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The cannabinoid receptor subtype 2 (CB2R) represents an interesting and new therapeutic target for its involvement in the first steps of neurodegeneration as well as in cancer onset and progression.  Several studies, focused on different types of tumors, report a promising anticancer activity induced by CB2R agonists due to their ability to reduce inflammation and cell proliferation.  Moreover, in neuroinflammation, the stimulation of CB2R, overexpressed in microglial cells, exerts beneficial effects in neurodegenerative disorders.  With the aim to overcome current treatment limitations, new drugs can be developed by specifically modulating, together with CB2R, other targets involved in such multifactorial disorders.  Building on successful case studies of already developed multitarget strategies involving CB2R, in this Perspective we aim at prompting the scientific community to consider new promising target assocns. involving HDACs (histone deacetylases) and σ receptors by employing modern approaches based on mol. hybridization, computational polypharmacol., and machine learning algorithms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTiSamPzU_wLVg90H21EOLACvtfcHk0lgxtWzVVCPMMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXitFagtLbI&md5=bd76a9dd2196d6362df55b79f25ecdc2</span></div><a href="/servlet/linkout?suffix=cit184&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.0c01357%26sid%3Dliteratum%253Aachs%26aulast%3DMangiatordi%26aufirst%3DG.%2BF.%26aulast%3DIntranuovo%26aufirst%3DF.%26aulast%3DDelre%26aufirst%3DP.%26aulast%3DAbatematteo%26aufirst%3DF.%2BS.%26aulast%3DAbate%26aufirst%3DC.%26aulast%3DNiso%26aufirst%3DM.%26aulast%3DCreanza%26aufirst%3DT.%2BM.%26aulast%3DAncona%26aufirst%3DN.%26aulast%3DStefanachi%26aufirst%3DA.%26aulast%3DContino%26aufirst%3DM.%26atitle%3DCannabinoid%2520Receptor%2520Subtype%25202%2520%2528CB2R%2529%2520in%2520a%2520Multitarget%2520Approach%253A%2520Perspective%2520of%2520an%2520Innovative%2520Strategy%2520in%2520Cancer%2520and%2520Neurodegeneration%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D14448%26epage%3D14469%26doi%3D10.1021%2Facs.jmedchem.0c01357" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67'],'ref68':['cit68'],'ref69':['cit69'],'ref70':['cit70'],'ref71':['cit71'],'ref72':['cit72'],'ref73':['cit73'],'ref74':['cit74'],'ref75':['cit75'],'ref76':['cit76'],'ref77':['cit77'],'ref78':['cit78'],'ref79':['cit79'],'ref80':['cit80'],'ref81':['cit81'],'ref82':['cit82'],'ref83':['cit83'],'ref84':['cit84'],'ref85':['cit85'],'ref86':['cit86'],'ref87':['cit87'],'ref88':['cit88'],'ref89':['cit89'],'ref90':['cit90'],'ref91':['cit91'],'ref92':['cit92'],'ref93':['cit93'],'ref94':['cit94'],'ref95':['cit95'],'ref96':['cit96'],'ref97':['cit97'],'ref98':['cit98'],'ref99':['cit99'],'ref100':['cit100'],'ref101':['cit101'],'ref102':['cit102'],'ref103':['cit103'],'ref104':['cit104'],'ref105':['cit105'],'ref106':['cit106'],'ref107':['cit107'],'ref108':['cit108'],'ref109':['cit109'],'ref110':['cit110'],'ref111':['cit111'],'ref112':['cit112'],'ref113':['cit113'],'ref114':['cit114'],'ref115':['cit115'],'ref116':['cit116'],'ref117':['cit117'],'ref118':['cit118'],'ref119':['cit119'],'ref120':['cit120'],'ref121':['cit121'],'ref122':['cit122'],'ref123':['cit123'],'ref124':['cit124'],'ref125':['cit125'],'ref126':['cit126'],'ref127':['cit127'],'ref128':['cit128'],'ref129':['cit129'],'ref130':['cit130'],'ref131':['cit131'],'ref132':['cit132'],'ref133':['cit133'],'ref134':['cit134'],'ref135':['cit135'],'ref136':['cit136'],'ref137':['cit137'],'ref138':['cit138'],'ref139':['cit139'],'ref140':['cit140'],'ref141':['cit141'],'ref142':['cit142'],'ref143':['cit143'],'ref144':['cit144'],'ref145':['cit145'],'ref146':['cit146'],'ref147':['cit147'],'ref148':['cit148'],'ref149':['cit149'],'ref150':['cit150'],'ref151':['cit151'],'ref152':['cit152'],'ref153':['cit153'],'ref154':['cit154'],'ref155':['cit155'],'ref156':['cit156'],'ref157':['cit157'],'ref158':['cit158'],'ref159':['cit159'],'ref160':['cit160'],'ref161':['cit161'],'ref162':['cit162'],'ref163':['cit163'],'ref164':['cit164'],'ref165':['cit165'],'ref166':['cit166'],'ref167':['cit167'],'ref168':['cit168'],'ref169':['cit169'],'ref170':['cit170'],'ref171':['cit171'],'ref172':['cit172'],'ref173':['cit173'],'ref174':['cit174'],'ref175':['cit175'],'ref176':['cit176'],'ref177':['cit177'],'ref178':['cit178'],'ref179':['cit179'],'ref180':['cit180'],'ref181':['cit181'],'ref182':['cit182'],'ref183':['cit183'],'ref184':['cit184']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article has not yet been cited by other publications.</p></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/medium/jm0c02265_0031.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/large/jm0c02265_0031.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02265&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/medium/jm0c02265_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/large/jm0c02265_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. (A) Cartoon representation of the σ<sub>1</sub>R crystal structure (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5HK1">5HK1</a>); each color outlines a distinguished σ<sub>1</sub>R protomer which forms the σ<sub>1</sub>R trimer. (B) 2D and 3D representation of protein–ligand interactions of the σ<sub>1</sub>R with PD144418 (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5HK1">5HK1</a>). The ionic bond between the basic nitrogen of PD144418 and the Glu172 amino acid residue is shown as a dashed yellow line.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/large/jm0c02265_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02265&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/medium/jm0c02265_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/large/jm0c02265_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Selected historic and representative σR ligands.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/large/jm0c02265_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02265&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/medium/jm0c02265_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/large/jm0c02265_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. σRs ligands in clinical trials.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/large/jm0c02265_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02265&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/medium/jm0c02265_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/large/jm0c02265_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. (A) The proposed pharmacophore model by Gilligan et al. (B) Glennon’s pharmacophore model.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/large/jm0c02265_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02265&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/medium/jm0c02265_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/large/jm0c02265_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. 3D pharmacophore models for σ<sub>1</sub>R: (A) Pharmacophore mapping of compound <b>A</b> in 3D models derived by Vio et al. (B) Pharmacophore mapping of compound <b>B</b> in 3D models derived by Meyer et al. (C) Pharmacophore mapping of PD144418 in 3D models derived by ESTEVE. Color coded as follows: PI (red), HYAr or HYD (light blue), HY (pink), HBA (light green), excluded volumes (gray). Adapted with permission from refs <a onclick="showRef(event, 'ref82 ref83'); return false;" href="javascript:void(0);" class="ref ref82 ref83">(82and83)</a>. Copyright 2009 and 2012 American Chemical Society.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/large/jm0c02265_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02265&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/medium/jm0c02265_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/large/jm0c02265_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. 3D pharmacophore models for σ<sub>2</sub>R: (A) Pharmacophore mapping of compound <b>C</b> in 3D models derived by Vio et al. (B) Pharmacophore mapping of compound <b>D</b> in 3D models derived by Iyamu et al. Color coded as follows: PI (red), HYAr or HYD (light blue), HY (pink), HBA (light green), excluded volumes (gray).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/large/jm0c02265_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02265&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/medium/jm0c02265_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/large/jm0c02265_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Schematized representation of the high-throughput structure-based computational docking approach for the discovery of new σ<sub>1</sub>R ligands proposed by Greenfield et al. Adapted with permission from ref <a onclick="showRef(event, 'ref90'); return false;" href="javascript:void(0);" class="ref ref90">(90)</a>. Copyright 2020 American Chemical Society.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/large/jm0c02265_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02265&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/medium/jm0c02265_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/large/jm0c02265_0008.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Representative structures of antiproliferative σ<sub>1</sub>R ligands with their σRs binding profile.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/large/jm0c02265_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02265&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/medium/jm0c02265_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/large/jm0c02265_0009.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. <i>N</i>,<i>N</i>-Dialkyl and <i>N</i>-alkyl-<i>N</i>-aralkyl fenpropimorph-derived compounds <b>1</b>–<b>6</b> and their σRs binding profile.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/large/jm0c02265_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02265&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/medium/jm0c02265_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/large/jm0c02265_0010.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Spipethiane and general structure of spipethiane derivatives <b>7</b>–<b>11</b> and <b>12</b>–<b>15</b> with their σRs binding profile.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/large/jm0c02265_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02265&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/medium/jm0c02265_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/large/jm0c02265_0011.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Structures of selected spiropiperidines with a thienofuran and thienopyran scaffold (<b>16</b>–<b>21</b>) and their σRs binding profile.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/large/jm0c02265_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02265&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig12" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/medium/jm0c02265_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/large/jm0c02265_0012.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Historically relevant ethylenediamine <b>22</b>–<b>24</b> with their σRs binding profile. The ethylenediamine structure is highlighted in light blue.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/large/jm0c02265_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02265&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig13" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/medium/jm0c02265_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/large/jm0c02265_0013.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. General structures of piperazine derivatives and structures of compounds <b>25</b>–<b>28</b> with σRs binding profile.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/large/jm0c02265_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02265&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig14" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/medium/jm0c02265_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/large/jm0c02265_0014.jpeg" id="rightTab-gr14" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. General structure of bicyclic piperazines, chemical structures of 6,8-diazabicyclo[3.2.2]nonanes <b>29</b> and <b>30</b>, and 7,9-diazabicyclo[4.2.2]decane derivatives <b>31</b>–<b>37</b> with their σRs binding profile.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/large/jm0c02265_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02265&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig15" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/medium/jm0c02265_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/large/jm0c02265_0015.jpeg" id="rightTab-gr15" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 15. General structure of 2,5-diazabicyclo[2.2.2]octane derivatives <b>38</b>–<b>43</b> and <b>ent-38</b>–<b>43</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/large/jm0c02265_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02265&amp;id=fig15"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig16" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 16</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/medium/jm0c02265_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/large/jm0c02265_0016.jpeg" id="rightTab-gr16" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 16. (A) 2D schematic representation of the identified interactions between compound <b>42</b> and the main amino acid residues. (B) 3D protein–ligand binding interactions of compound <b>42</b> with the σ<sub>1</sub>R homology model. Color-coded as follows: PI (red), HYAr or HYD (light blue), HY (pink), HBA (light green), π-interactions (Arg119 and Tyr120, cyan), salt bridge (Asp126, red), hydrophobic interactions (Ile128, Phe133, Tyr173, and Leu186, purple), and hydrogen bond (Thr181, green). Adapted with permission from ref <a onclick="showRef(event, 'ref132'); return false;" href="javascript:void(0);" class="ref ref132">(132)</a>. Copyright 2016 American Chemical Society.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/large/jm0c02265_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02265&amp;id=fig16"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig17" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Figure 17</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/medium/jm0c02265_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/large/jm0c02265_0017.jpeg" id="rightTab-gr17" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 17. Representative structures for different chemical classes of σ<sub>2</sub>R ligands.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/large/jm0c02265_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02265&amp;id=fig17"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig18" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Figure 18</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/medium/jm0c02265_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/large/jm0c02265_0018.jpeg" id="rightTab-gr18" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 18. Chemical structure and σRs binding profile of selective <i>N</i>-substituted 9-azabicyclo[3.3.1]nonan-3α-yl phenylcarbamate derivatives and conjugated derivative SW III-123.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/large/jm0c02265_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02265&amp;id=fig18"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig19" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Figure 19</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/medium/jm0c02265_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/large/jm0c02265_0019.jpeg" id="rightTab-gr19" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 19. Early structural modification of siramesine and its analogs <b>44</b>–<b>48</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/large/jm0c02265_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02265&amp;id=fig19"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig20" data-index="20" class="article__inlineFigure"><h2 class="fig-label">Figure 20</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/medium/jm0c02265_0020.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/large/jm0c02265_0020.jpeg" id="rightTab-gr20" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 20. General structure and σRs binding profile of siramesine-related derivatives.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/large/jm0c02265_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02265&amp;id=fig20"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig21" data-index="21" class="article__inlineFigure"><h2 class="fig-label">Figure 21</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/medium/jm0c02265_0021.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/large/jm0c02265_0021.jpeg" id="rightTab-gr21" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 21. General structure and σRs binding profile of siramesine-related derivatives <b>51</b>, <b>52</b>, and <b>53</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/large/jm0c02265_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02265&amp;id=fig21"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig22" data-index="22" class="article__inlineFigure"><h2 class="fig-label">Figure 22</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/medium/jm0c02265_0022.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/large/jm0c02265_0022.jpeg" id="rightTab-gr22" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 22. General structure of PB28 analogs with reduced lipophilicity and σRs binding profile of compound <b>54</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/large/jm0c02265_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02265&amp;id=fig22"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig23" data-index="23" class="article__inlineFigure"><h2 class="fig-label">Figure 23</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/medium/jm0c02265_0023.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/large/jm0c02265_0023.jpeg" id="rightTab-gr23" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 23. Representative structural modification for PB28 analogs on propylene linker and tetralin scaffold (<b>55</b> and <b>56</b>), piperazine ring (PB221), basic <i>N</i>-atom (<b>57</b>), piperazine substitution (<b>58</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/large/jm0c02265_0023.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02265&amp;id=fig23"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig24" data-index="24" class="article__inlineFigure"><h2 class="fig-label">Figure 24</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/medium/jm0c02265_0024.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/large/jm0c02265_0024.jpeg" id="rightTab-gr24" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 24. Chemical structure and σRs binding profile of <i>N</i>-(4-fluorophenyl)piperazine derivatives.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/large/jm0c02265_0024.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02265&amp;id=fig24"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig25" data-index="25" class="article__inlineFigure"><h2 class="fig-label">Figure 25</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/medium/jm0c02265_0025.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/large/jm0c02265_0025.jpeg" id="rightTab-gr25" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 25. Chemical structure and σRs binding profile of early 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline analogs <b>59</b>–<b>64</b>, reported by Mach and co-workers.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/large/jm0c02265_0025.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02265&amp;id=fig25"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig26" data-index="26" class="article__inlineFigure"><h2 class="fig-label">Figure 26</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/medium/jm0c02265_0026.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/large/jm0c02265_0026.jpeg" id="rightTab-gr26" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 26. Chemical structure and σRs binding profile of 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline analogs <b>65</b>–<b>67</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/large/jm0c02265_0026.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02265&amp;id=fig26"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig27" data-index="27" class="article__inlineFigure"><h2 class="fig-label">Figure 27</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/medium/jm0c02265_0027.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/large/jm0c02265_0027.jpeg" id="rightTab-gr27" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 27. Chemical structure and σRs binding profile of 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline analogs <b>68</b>–<b>70</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/large/jm0c02265_0027.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02265&amp;id=fig27"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig28" data-index="28" class="article__inlineFigure"><h2 class="fig-label">Figure 28</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/medium/jm0c02265_0028.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/large/jm0c02265_0028.jpeg" id="rightTab-gr28" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 28. Chemical structure and σRs binding profile of compounds <b>71</b>–<b>75</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/large/jm0c02265_0028.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02265&amp;id=fig28"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig29" data-index="29" class="article__inlineFigure"><h2 class="fig-label">Figure 29</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/medium/jm0c02265_0029.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/large/jm0c02265_0029.jpeg" id="rightTab-gr29" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 29. Chemical structure and σRs binding profile of compounds <b>76</b>–<b>81</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/large/jm0c02265_0029.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02265&amp;id=fig29"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig30" data-index="30" class="article__inlineFigure"><h2 class="fig-label">Figure 30</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/medium/jm0c02265_0030.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/large/jm0c02265_0030.jpeg" id="rightTab-gr30" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 30. Chemical structures of 3-alkoxyisoxazoles <b>82</b>–<b>90</b> and their σRs binding profile.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/acs.jmedchem.0c02265/20210616/images/large/jm0c02265_0030.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c02265&amp;id=fig30"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i35">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_64352" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_64352" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 184 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Heron, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, R. N.</span></span> <span> </span><span class="NLM_article-title">Changes in the Leading Cause of Death: Recent Patterns in Heart Disease and Cancer Mortality</span>. <i>NCHS data Brief.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">8</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=27598767" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A280%3ADC%252BC2szot1ektg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&pages=1-8&author=M.+Heronauthor=R.+N.+Anderson&title=Changes+in+the+Leading+Cause+of+Death%3A+Recent+Patterns+in+Heart+Disease+and+Cancer+Mortality"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Changes in the Leading Cause of Death: Recent Patterns in Heart Disease and Cancer Mortality</span></div><div class="casAuthors">Heron Melonie; Anderson Robert N</div><div class="citationInfo"><span class="NLM_cas:title">NCHS data brief</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume"></span>
        (<span class="NLM_cas:issue">254</span>),
    <span class="NLM_cas:pages">1-8</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">KEY FINDINGS:  Data from the National Vital Statistics System •Heart disease has consistently been the leading cause of death in the United States and remained so in 2014. •The gap between the number of heart disease and cancer deaths generally widened from 1950 through 1968, narrowed from 1968 through 2012, and then slightly widened again from 2012 through 2014. •The mortality burden of cancer has surpassed that of heart disease in several states.  In 2000, there were only 2 states where cancer was the leading cause of death; in 2014, there were 22. •Heart disease remained the leading cause of death for the non-Hispanic white and non-Hispanic black populations in 2014. •Cancer is now the leading cause of death for the non-Hispanic Asian or Pacific Islander and Hispanic populations.  The timing of the leading-cause crossover varied by group.  For the total U.S. population, heart disease has been the leading cause of death for decades, with cancer the second leading cause (1).  However, the ranking of these causes has varied across demographic group and geographic unit over time.  Rankings are based on the number of deaths and reflect mortality burden rather than risk of death (2).  This report highlights changes in the mortality burden of heart disease and cancer and presents findings by state, race, and Hispanic origin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTseAgqV32DDFMGsG_HTXYFfW6udTcc2eboeNVIIZg2JLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2szot1ektg%253D%253D&md5=830dd4c4fcf1f34497f4dc9c8ec34d10</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHeron%26aufirst%3DM.%26aulast%3DAnderson%26aufirst%3DR.%2BN.%26atitle%3DChanges%2520in%2520the%2520Leading%2520Cause%2520of%2520Death%253A%2520Recent%2520Patterns%2520in%2520Heart%2520Disease%2520and%2520Cancer%2520Mortality%26jtitle%3DNCHS%2520data%2520Brief.%26date%3D2016%26spage%3D1%26epage%3D8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chidambaram, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manavalan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kathiresan, K.</span></span> <span> </span><span class="NLM_article-title">Nanotherapeutics to overcome conventional cancer chemotherapy limitations</span>. <i>J. Pharm. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">67</span>– <span class="NLM_lpage">77</span>, <span class="refDoi"> DOI: 10.18433/J30C7D</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.18433%2FJ30C7D" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=21501554" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A280%3ADC%252BC3MvksF2juw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2011&pages=67-77&author=M.+Chidambaramauthor=R.+Manavalanauthor=K.+Kathiresan&title=Nanotherapeutics+to+overcome+conventional+cancer+chemotherapy+limitations&doi=10.18433%2FJ30C7D"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Nanotherapeutics to overcome conventional cancer chemotherapy limitations</span></div><div class="casAuthors">Chidambaram Moorthi; Manavalan R; Kathiresan K</div><div class="citationInfo"><span class="NLM_cas:title">Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">67-77</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Cancer is one of the major causes of death worldwide and chemotherapy is a major therapeutic approach for the treatment which may be used alone or combined with other forms of therapy.  However, conventional chemotherapy suffers lack of aqueous solubility, lack of selectivity and multidrug resistance.  Nanotherapeutics is rapidly progressing aimed to solve several limitations of conventional drug delivery systems.  Nonspecific target of cancer chemotherapy leads to damage rapidly proliferating normal cells and can be significantly reduced through folate and transferrin mediated nanotherapeutics which are aimed to target cancerous cells.  Multidrug resistance is challenge in cancer chemotherapy which can be significantly reversed by solid lipid nanoparticles, polymeric nanoparticles, mesoporous silica nanoparticles, nanoparticulated chemosensitizer, nanoparticluated poloxamer and magnetic nanoparticles.  Hydrophobic nature of chemotherapeutics leads to poor aqueous solubility and low bioavailability which can be overcome by nanocrystals, albumin based nanoparticles, liposomal formulation, polymeric micelles, cyclodextrin and chitosan based nanoparticles.  This review focuses the role of nanotherapeutics to overcome lack of selectivity, multidrug resistance and lack of aqueous solubility of conventional cancer chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQb9xNNgG2B7xFwe7cAcrfPfW6udTcc2eboeNVIIZg2JLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3MvksF2juw%253D%253D&md5=afab976d9f9335614563ad4883cd7d13</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.18433%2FJ30C7D&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18433%252FJ30C7D%26sid%3Dliteratum%253Aachs%26aulast%3DChidambaram%26aufirst%3DM.%26aulast%3DManavalan%26aufirst%3DR.%26aulast%3DKathiresan%26aufirst%3DK.%26atitle%3DNanotherapeutics%2520to%2520overcome%2520conventional%2520cancer%2520chemotherapy%2520limitations%26jtitle%3DJ.%2520Pharm.%2520Pharm.%2520Sci.%26date%3D2011%26volume%3D14%26spage%3D67%26epage%3D77%26doi%3D10.18433%2FJ30C7D" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vanneman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dranoff, G.</span></span> <span> </span><span class="NLM_article-title">Combining immunotherapy and targeted therapies in cancer treatment</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">237</span>– <span class="NLM_lpage">251</span>, <span class="refDoi"> DOI: 10.1038/nrc3237</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1038%2Fnrc3237" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=22437869" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BC38XksVehtrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2012&pages=237-251&author=M.+Vannemanauthor=G.+Dranoff&title=Combining+immunotherapy+and+targeted+therapies+in+cancer+treatment&doi=10.1038%2Fnrc3237"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Combining immunotherapy and targeted therapies in cancer treatment</span></div><div class="casAuthors">Vanneman, Matthew; Dranoff, Glenn</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">237-251</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  During the past two decades, the paradigm for cancer treatment has evolved from relatively nonspecific cytotoxic agents to selective, mechanism-based therapeutics.  Cancer chemotherapies were initially identified through screens for compds. that killed rapidly dividing cells.  These drugs remain the backbone of current treatment, but they are limited by a narrow therapeutic index, significant toxicities and frequently acquired resistance.  More recently, an improved understanding of cancer pathogenesis has given rise to new treatment options, including targeted agents and cancer immunotherapy.  Targeted approaches aim to inhibit mol. pathways that are crucial for tumor growth and maintenance; whereas, immunotherapy endeavors to stimulate a host immune response that effectuates long-lived tumor destruction.  Targeted therapies and cytotoxic agents also modulate immune responses, which raises the possibility that these treatment strategies might be effectively combined with immunotherapy to improve clin. outcomes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXt9BTvySH7rVg90H21EOLACvtfcHk0liVhtTGN2VR0w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XksVehtrg%253D&md5=e1ed968896a11cea34456010a72fca57</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fnrc3237&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc3237%26sid%3Dliteratum%253Aachs%26aulast%3DVanneman%26aufirst%3DM.%26aulast%3DDranoff%26aufirst%3DG.%26atitle%3DCombining%2520immunotherapy%2520and%2520targeted%2520therapies%2520in%2520cancer%2520treatment%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2012%26volume%3D12%26spage%3D237%26epage%3D251%26doi%3D10.1038%2Fnrc3237" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kunick, C.</span></span> <span> </span><span class="NLM_article-title">Novel molecular targets in cancer chemotherapy waiting for discovery</span>. <i>Curr. Med. Chem.: Anti-Cancer Agents</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">421</span>– <span class="NLM_lpage">423</span>, <span class="refDoi"> DOI: 10.2174/1568011043352858</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.2174%2F1568011043352858" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=15379696" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BD2cXntVertbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2004&pages=421-423&author=C.+Kunick&title=Novel+molecular+targets+in+cancer+chemotherapy+waiting+for+discovery&doi=10.2174%2F1568011043352858"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Novel molecular targets in cancer chemotherapy waiting for discovery</span></div><div class="casAuthors">Kunick, Conrad</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry: Anti-Cancer Agents</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">421-423</span>CODEN:
                <span class="NLM_cas:coden">CMCACI</span>;
        ISSN:<span class="NLM_cas:issn">1568-0118</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Despite a no. of advances in the past decades the medicinal cancer therapy is hampered by problems of severe unwanted side effects and the development of resistances.  Many established anti-cancer drugs are directed toward targets that are not specific for cancer but are essential biochem. mols. in living cells.  Because cancer cells do not only carry one but multiple genetic alterations which are more characteristic for the individual patient than for the tumor entity, an individualized medicinal approach could improve the success of a tumor therapy.  A prerequisite for personalized tumor therapies is an upgrade of the array of anticancer drugs directed to different mol. targets.  Therefore, a systematic search for anticancer drug targets should constitute a research priority.  The database of fingerprints of new chem. entities generated in the National Cancer Institute's Anticancer Drug Screening is a rich source of novel targets which might be uncovered by the interdisciplinary application of methods from bioinformatics, biochem., chem., tumor biol., and related sciences.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq0V-ryJFjEG7Vg90H21EOLACvtfcHk0liMLsq3a0I-wA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXntVertbw%253D&md5=5b11e88a896c1126944fd5e15853d08e</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.2174%2F1568011043352858&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568011043352858%26sid%3Dliteratum%253Aachs%26aulast%3DKunick%26aufirst%3DC.%26atitle%3DNovel%2520molecular%2520targets%2520in%2520cancer%2520chemotherapy%2520waiting%2520for%2520discovery%26jtitle%3DCurr.%2520Med.%2520Chem.%253A%2520Anti-Cancer%2520Agents%26date%3D2004%26volume%3D4%26spage%3D421%26epage%3D423%26doi%3D10.2174%2F1568011043352858" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, H.-Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, D.-H.</span></span> <span> </span><span class="NLM_article-title">Editorial: Novel Targets and Biomarkers in Solid Tumors</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">828</span>, <span class="refDoi"> DOI: 10.3389/fphar.2019.00828</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.3389%2Ffphar.2019.00828" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=31417402" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BB3cXksFSiur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=828&author=Z.+Shiauthor=H.-Q.+Guoauthor=P.+A.+Cohenauthor=D.-H.+Yang&title=Editorial%3A+Novel+Targets+and+Biomarkers+in+Solid+Tumors&doi=10.3389%2Ffphar.2019.00828"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Editorial: novel targets and biomarkers in solid tumors</span></div><div class="casAuthors">Shi, Zhi; Guo, Hui-Qin; Cohen, Pascale A.; Yang, Dong-Hua</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Pharmacology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">828</span>CODEN:
                <span class="NLM_cas:coden">FPRHAU</span>;
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">Our aim was to generate a collaborative discussion contributing to the future direction of pharmaceutical drug development and therapeutic options.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKHN6FNcSRfrVg90H21EOLACvtfcHk0liMLsq3a0I-wA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXksFSiur4%253D&md5=34686f468132f386e48bc2d6266ce755</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2019.00828&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2019.00828%26sid%3Dliteratum%253Aachs%26aulast%3DShi%26aufirst%3DZ.%26aulast%3DGuo%26aufirst%3DH.-Q.%26aulast%3DCohen%26aufirst%3DP.%2BA.%26aulast%3DYang%26aufirst%3DD.-H.%26atitle%3DEditorial%253A%2520Novel%2520Targets%2520and%2520Biomarkers%2520in%2520Solid%2520Tumors%26jtitle%3DFront.%2520Pharmacol.%26date%3D2019%26volume%3D10%26spage%3D828%26doi%3D10.3389%2Ffphar.2019.00828" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Oyer, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanders, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, F. J.</span></span> <span> </span><span class="NLM_article-title">Small-Molecule Modulators of Sigma1 and Sigma2/TMEM97 in the Context of Cancer: Foundational Concepts and Emerging Themes</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1141</span>, <span class="refDoi"> DOI: 10.3389/fphar.2019.01141</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.3389%2Ffphar.2019.01141" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=31695608" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BB3cXpvVeqsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=1141&author=H.+M.+Oyerauthor=C.+M.+Sandersauthor=F.+J.+Kim&title=Small-Molecule+Modulators+of+Sigma1+and+Sigma2%2FTMEM97+in+the+Context+of+Cancer%3A+Foundational+Concepts+and+Emerging+Themes&doi=10.3389%2Ffphar.2019.01141"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Small-molecule modulators of Sigma1 and Sigma2/TMEM97 in the context of cancer: foundational concepts and emerging themes</span></div><div class="casAuthors">Oyer, Halley M.; Sanders, Christina M.; Kim, Felix J.</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Pharmacology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1141</span>CODEN:
                <span class="NLM_cas:coden">FPRHAU</span>;
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">A review.  There are two known subtypes of the so-called sigma receptors, Sigma1 and Sigma2.  Sigma1 (encoded by the SIGMAR1 gene and also known as Sigma-1 receptor, S1R) is a unique pharmacol. regulated integral membrane chaperone or scaffolding protein that allosterically modulates the activity of its assocd. proteins.  Sigma2, recently identified as transmembrane protein 97 (TMEM97), is an integral membrane protein implicated in cellular cholesterol homeostasis.  A no. of publications over the past two decades have suggested a role for both sigma proteins in tumor biol.  Although there is currently no clin. used anti-cancer drug that targets Sigma1 or Sigma2/TMEM97, a growing body of evidence supports the potential of small-mol. compds. with affinity for these proteins, putative sigma ligands, as therapeutic agents to treat cancer.  In preclin. models, these compds. have been reported to inhibit cancer cell proliferation, survival, adhesion, and migration; furthermore, they have been demonstrated to suppress tumor growth, to alleviate cancer-assocd. pain, and to exert immunomodulatory properties.  Here, we will address the known knowns and the known unknowns of Sigma1 and Sigma2/TMEM97 ligand actions in the context of cancer.  This review will highlight key discoveries and published evidence in support of a role for sigma proteins in cancer and will discuss several fundamental questions regarding the physiol. roles of sigma proteins in cancer and sigma ligand mechanism of action.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSrAyrTeGahrVg90H21EOLACvtfcHk0liMLsq3a0I-wA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXpvVeqsbY%253D&md5=af4db128dd079492a68d665068414c93</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2019.01141&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2019.01141%26sid%3Dliteratum%253Aachs%26aulast%3DOyer%26aufirst%3DH.%2BM.%26aulast%3DSanders%26aufirst%3DC.%2BM.%26aulast%3DKim%26aufirst%3DF.%2BJ.%26atitle%3DSmall-Molecule%2520Modulators%2520of%2520Sigma1%2520and%2520Sigma2%252FTMEM97%2520in%2520the%2520Context%2520of%2520Cancer%253A%2520Foundational%2520Concepts%2520and%2520Emerging%2520Themes%26jtitle%3DFront.%2520Pharmacol.%26date%3D2019%26volume%3D10%26spage%3D1141%26doi%3D10.3389%2Ffphar.2019.01141" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Izzo, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colom-Cadena, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riad, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abate, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cahill, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spires-Jones, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowen, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mach, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Catalano, S. M.</span></span> <span> </span><span class="NLM_article-title">Proceedings from the Fourth International Symposium on σ-2 Receptors: Role in Health and Disease</span>. <i>eNeuro</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">ENEURO.0317-20.2020</span>, <span class="refDoi"> DOI: 10.1523/ENEURO.0317-20.2020</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1523%2FENEURO.0317-20.2020" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2020&pages=ENEURO.0317-20.2020&author=N.+J.+Izzoauthor=M.+Colom-Cadenaauthor=A.+A.+Riadauthor=J.+Xuauthor=M.+Singhauthor=C.+Abateauthor=M.+A.+Cahillauthor=T.+L.+Spires-Jonesauthor=W.+D.+Bowenauthor=R.+H.+Machauthor=S.+M.+Catalano&title=Proceedings+from+the+Fourth+International+Symposium+on+%CF%83-2+Receptors%3A+Role+in+Health+and+Disease&doi=10.1523%2FENEURO.0317-20.2020"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1523%2FENEURO.0317-20.2020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1523%252FENEURO.0317-20.2020%26sid%3Dliteratum%253Aachs%26aulast%3DIzzo%26aufirst%3DN.%2BJ.%26aulast%3DColom-Cadena%26aufirst%3DM.%26aulast%3DRiad%26aufirst%3DA.%2BA.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DSingh%26aufirst%3DM.%26aulast%3DAbate%26aufirst%3DC.%26aulast%3DCahill%26aufirst%3DM.%2BA.%26aulast%3DSpires-Jones%26aufirst%3DT.%2BL.%26aulast%3DBowen%26aufirst%3DW.%2BD.%26aulast%3DMach%26aufirst%3DR.%2BH.%26aulast%3DCatalano%26aufirst%3DS.%2BM.%26atitle%3DProceedings%2520from%2520the%2520Fourth%2520International%2520Symposium%2520on%2520%25CF%2583-2%2520Receptors%253A%2520Role%2520in%2520Health%2520and%2520Disease%26jtitle%3DeNeuro%26date%3D2020%26volume%3D7%26spage%3DENEURO.0317-20.2020%26doi%3D10.1523%2FENEURO.0317-20.2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kruse, A. C.</span></span> <span> </span><span class="NLM_article-title">The Molecular Function of σ Receptors: Past, Present, and Future</span>. <i>Trends Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">636</span>– <span class="NLM_lpage">654</span>, <span class="refDoi"> DOI: 10.1016/j.tips.2019.07.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1016%2Fj.tips.2019.07.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=31387763" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsVeqs7bJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2019&pages=636-654&author=H.+R.+Schmidtauthor=A.+C.+Kruse&title=The+Molecular+Function+of+%CF%83+Receptors%3A+Past%2C+Present%2C+and+Future&doi=10.1016%2Fj.tips.2019.07.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">The Molecular Function of σ Receptors: Past, Present, and Future</span></div><div class="casAuthors">Schmidt, Hayden R.; Kruse, Andrew C.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Pharmacological Sciences</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">636-654</span>CODEN:
                <span class="NLM_cas:coden">TPHSDY</span>;
        ISSN:<span class="NLM_cas:issn">0165-6147</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The σ1 and σ2 receptors are enigmatic proteins that have attracted attention for decades due to the chem. diversity and therapeutic potential of their ligands.  However, despite ongoing clin. trials with σ receptor ligands for multiple conditions, relatively little is known regarding the mol. function of these receptors.  In this review, we revisit past research on σ receptors and discuss the interpretation of these data in light of recent developments.  We provide a synthesis of emerging structural and genetic data on the σ1 receptor and discuss the recent cloning of the σ2 receptor.  Finally, we discuss the major questions that remain in the study of σ receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonQzGSQdFecbVg90H21EOLACvtfcHk0liKaY_NM3Y4ig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsVeqs7bJ&md5=03896ad7b332beb873ad3fbc32c96423</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2019.07.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2019.07.006%26sid%3Dliteratum%253Aachs%26aulast%3DSchmidt%26aufirst%3DH.%2BR.%26aulast%3DKruse%26aufirst%3DA.%2BC.%26atitle%3DThe%2520Molecular%2520Function%2520of%2520%25CF%2583%2520Receptors%253A%2520Past%252C%2520Present%252C%2520and%2520Future%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2019%26volume%3D40%26spage%3D636%26epage%3D654%26doi%3D10.1016%2Fj.tips.2019.07.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Su, T. P.</span></span> <span> </span><span class="NLM_article-title">Psychotomimetic opioid binding: specific binding of [3H]SKF-10047 to etorphine-inaccessible sites in guinea-pig brain</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1981</span>,  <span class="NLM_volume"><i>75</i></span>,  <span class="NLM_fpage">81</span>– <span class="NLM_lpage">82</span>, <span class="refDoi"> DOI: 10.1016/0014-2999(81)90352-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1016%2F0014-2999%2881%2990352-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=6274661" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADyaL38XksFyisQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=1981&pages=81-82&author=T.+P.+Su&title=Psychotomimetic+opioid+binding%3A+specific+binding+of+%5B3H%5DSKF-10047+to+etorphine-inaccessible+sites+in+guinea-pig+brain&doi=10.1016%2F0014-2999%2881%2990352-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Psychotomimetic opioid binding:  specific binding of [3H]SKF-10047 to etorphine-inaccessible sites in guinea pig brain</span></div><div class="casAuthors">Su, Tsung Ping</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">1981</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">81-2</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    </div><div class="casAbstract">At 0.1-250 μM, etorphine (I)  [14521-96-1] consistently exhibited a max. (∼82%) inhibition of specific SKF 10047 (II)  [14198-28-8] binding in guinea pig brain homogenates indicating that I binding also occurs at sites which are inaccessible to I.  The binding of II to I-inaccessible sites was saturable and heat-sensitive, and represented ∼70% of total binding.  Opioids which are not traditional morphine-like drugs and several non-opioid drugs were potent inhibitors of the binding.  The binding exhibited stereospecificity, which is the reverse of that for a μ-receptor.  Thus, II binds to a class of I-inaccessible sites which are not μ-receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_2Ld2NXzbq7Vg90H21EOLACvtfcHk0liKaY_NM3Y4ig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL38XksFyisQ%253D%253D&md5=e098b702f8a81c78a592c80b8702d880</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2F0014-2999%2881%2990352-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0014-2999%252881%252990352-6%26sid%3Dliteratum%253Aachs%26aulast%3DSu%26aufirst%3DT.%2BP.%26atitle%3DPsychotomimetic%2520opioid%2520binding%253A%2520specific%2520binding%2520of%2520%255B3H%255DSKF-10047%2520to%2520etorphine-inaccessible%2520sites%2520in%2520guinea-pig%2520brain%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D1981%26volume%3D75%26spage%3D81%26epage%3D82%26doi%3D10.1016%2F0014-2999%2881%2990352-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Martin, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eades, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huppler, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilbert, P. E.</span></span> <span> </span><span class="NLM_article-title">The effects of morphine- and nalorphine- like drugs in the nondependent and morphine-dependent chronic spinal dog</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">1976</span>,  <span class="NLM_volume"><i>197</i></span>,  <span class="NLM_fpage">517</span>– <span class="NLM_lpage">532</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=945347" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADyaE28XltlOhurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=197&publication_year=1976&pages=517-532&author=W.+R.+Martinauthor=C.+G.+Eadesauthor=J.+A.+Thompsonauthor=R.+E.+Hupplerauthor=P.+E.+Gilbert&title=The+effects+of+morphine-+and+nalorphine-+like+drugs+in+the+nondependent+and+morphine-dependent+chronic+spinal+dog"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">The effects of morphine- and nalorphine-like drugs in the nondependent and morphine-dependent chronic spinal dog</span></div><div class="casAuthors">Martin, W. R.; Eades, C. G.; Thompson, J. A.; Huppler, R. E.; Gilbert, P. E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">1976</span>),
    <span class="NLM_cas:volume">197</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">517-32</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    </div><div class="casAbstract">Three different syndromes produced by congeners of morphine sulfate (I sulfate) [64-31-3] were identified in the nondependent chronic spinal dog.  These syndromes were attributed to interaction of agonists with three distinguishable receptors (μ, κ and σ).  I was the prototype agonist for the μ receptor, ketocyclazocine lactate [59985-33-0] for the κ receptor and SKF-10,047 lactate [59985-34-1] for the σ receptor.  The I syndrome (μ) in the dog was characterized by miosis, bradycardia, hypothermia, a general depression of the nociceptive responses and indifferences to environmental stimuli.  Ketocyclazocine (κ) constricted pupils, depressed the flexor reflex and produced sedation but did not markedly alter pulse rate or the skin twitch reflex.  SKF-10,047 (σ) caused mydriasis, tachypnea, tachycardia and mania.  The effects of these three drugs was antagonized by the pure antagonist naltrexone-HCl, indicating that they are agonists.  Further, chronic administration of I, ketocyclazocine and SKF-10,047 induced tolerance to their agonistic effects.  I suppressed abstinence in I-dependent dogs while ketocyclazocine did not.  Ketocyclazocine at best pptd. only a liminal abstinence syndrome in the I-dependent dog, indicating that it had little affinity for the I receptor.  Ketocyclazocine thus appears to be a selective agonist at the κ receptor.  Buprenorphine-HCl [53152-21-9] was a partial agonist of the μ type which both suppressed and pptd. abstinence in the I-dependent dog while I and d-propoxyphene-HCl [1639-60-7] were stronger agonists.  Apomorphine-HCl [314-19-2] and SKF-10,047 produced similar pharmacol. effects suggesting that σ activity may involve a dopaminergic mechanism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr6rgyf41iRTbVg90H21EOLACvtfcHk0liKaY_NM3Y4ig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE28XltlOhurw%253D&md5=ca7c637f336ac9ecc2c3bb040dbcdbee</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMartin%26aufirst%3DW.%2BR.%26aulast%3DEades%26aufirst%3DC.%2BG.%26aulast%3DThompson%26aufirst%3DJ.%2BA.%26aulast%3DHuppler%26aufirst%3DR.%2BE.%26aulast%3DGilbert%26aufirst%3DP.%2BE.%26atitle%3DThe%2520effects%2520of%2520morphine-%2520and%2520nalorphine-%2520like%2520drugs%2520in%2520the%2520nondependent%2520and%2520morphine-dependent%2520chronic%2520spinal%2520dog%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D1976%26volume%3D197%26spage%3D517%26epage%3D532" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hayashi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, T. P.</span></span> <span> </span><span class="NLM_article-title">Sigma-1 receptors (sigma(1) binding sites) form raft-like microdomains and target lipid droplets on the endoplasmic reticulum: roles in endoplasmic reticulum lipid compartmentalization and export</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>306</i></span>,  <span class="NLM_fpage">718</span>– <span class="NLM_lpage">725</span>, <span class="refDoi"> DOI: 10.1124/jpet.103.051284</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1124%2Fjpet.103.051284" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=12730355" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BD3sXlslGlu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=306&publication_year=2003&pages=718-725&author=T.+Hayashiauthor=T.+P.+Su&title=Sigma-1+receptors+%28sigma%281%29+binding+sites%29+form+raft-like+microdomains+and+target+lipid+droplets+on+the+endoplasmic+reticulum%3A+roles+in+endoplasmic+reticulum+lipid+compartmentalization+and+export&doi=10.1124%2Fjpet.103.051284"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">σ-1 Receptors (σ1 binding sites) form raft-like microdomains and target lipid droplets on the endoplasmic reticulum: Roles in endoplasmic reticulum lipid compartmentalization and export</span></div><div class="casAuthors">Hayashi, Teruo; Su, Tsung-Ping</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">306</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">718-725</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The brain σ-1 receptors can bind neurosteroids and psychotropic drugs, including neuroleptics and cocaine and are implicated in schizophrenia, depression, and drug dependence.  In this study, we found that σ-1 receptors specifically target lipid storage sites (lipid droplets) on the endoplasmic reticulum by forming a distinct class of lipid microdomains.  Both endogenously expressing σ-1 receptors and transfected C-terminally enhanced yellow fluorescent protein (EYFP)-tagged σ-1 receptors (Sig-1R-EYFP) target unique "ring-like" structures assocd. with endoplasmic reticulum reticular networks in NG108-15 cells.  The ring-like structures contain neutral lipids and are enlarged by the oleate treatment, indicating that they are endoplasmic reticulum-assocd. lipid droplets (ER-LDs).  σ-1 Receptors colocalize with caveolin-2, a cholesterol-binding protein in lipid rafts on the ER-LDs, but not with adipocyte differentiation-related protein (ADRP), a cytosolic lipid droplet (c-LD)-specific protein.  When the double-arginine ER retention signal on the N terminus of σ-1 receptors is truncated, σ-1 receptors no longer exist on ER-LDs, but predominantly target c-LDs, which contain ADRP.  σ-1 Receptors on ER-LDs form detergent-resistant raft-like lipid microdomains, the buoyancy of which is different from that of plasma membrane lipid rafts.  (+)-Pentazocine causes σ-1 receptors to disappear from the microdomains.  N-Terminally EYFP-tagged σ-1 receptors (EYFP-Sig-1R) failed to target ER-LDs.  EYFP-Sig-1R-transfected cells showed an unrestricted distribution of neutral lipids all over the endoplasmic reticulum network, decreases in c-LDs and cholesterol in plasma membranes, and the bulbous aggregation of endoplasmic reticulum.  Thus, σ-1 receptors are unique endoplasmic reticulum proteins that regulate the compartmentalization of lipids on the endoplasmic reticulum and their export from the endoplasmic reticulum to plasma membrane and c-LDs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqucsqmLw2q4rVg90H21EOLACvtfcHk0lipWL4oU5jamQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXlslGlu7s%253D&md5=d2ae26871c09e84930a0643ddfa0d768</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1124%2Fjpet.103.051284&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.103.051284%26sid%3Dliteratum%253Aachs%26aulast%3DHayashi%26aufirst%3DT.%26aulast%3DSu%26aufirst%3DT.%2BP.%26atitle%3DSigma-1%2520receptors%2520%2528sigma%25281%2529%2520binding%2520sites%2529%2520form%2520raft-like%2520microdomains%2520and%2520target%2520lipid%2520droplets%2520on%2520the%2520endoplasmic%2520reticulum%253A%2520roles%2520in%2520endoplasmic%2520reticulum%2520lipid%2520compartmentalization%2520and%2520export%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2003%26volume%3D306%26spage%3D718%26epage%3D725%26doi%3D10.1124%2Fjpet.103.051284" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Itzhak, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stein, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kassim, C. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cristante, D.</span></span> <span> </span><span class="NLM_article-title">Binding of sigma-ligands to C57BL/6 mouse brain membranes: effects of monoamine oxidase inhibitors and subcellular distribution studies suggest the existence of sigma-receptor subtypes</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">1991</span>,  <span class="NLM_volume"><i>257</i></span>,  <span class="NLM_fpage">141</span>– <span class="NLM_lpage">148</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1850463" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADyaK3MXksVWkuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=257&publication_year=1991&pages=141-148&author=Y.+Itzhakauthor=I.+Steinauthor=S.+H.+Zhangauthor=C.+O.+Kassimauthor=D.+Cristante&title=Binding+of+sigma-ligands+to+C57BL%2F6+mouse+brain+membranes%3A+effects+of+monoamine+oxidase+inhibitors+and+subcellular+distribution+studies+suggest+the+existence+of+sigma-receptor+subtypes"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Binding of σ-ligands to C57BL/6 mouse brain membranes:  effects of monoamine oxidase inhibitors and subcellular distribution studies suggest the existence of σ-receptor subtypes</span></div><div class="casAuthors">Itzhak, Yossef; Stein, Ira; Zhang, She Hui; Kassim, Claude O.; Cristante, Daniela</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">257</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">141-8</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    </div><div class="casAbstract">Preliminary studies indicated that certain monoamine oxidase (MAO) inhibitors display high affinity for the σ-binding sites labeled with (+)[3H]-3-(3-hydroxyphenyl)-N-1-(propyl)piperidine [(+)[3H]-3-PPP] in C57BL/6 mouse brain (Itzhak, Y., and Kassim, 1990).  In the present study, the drug specificity and the subcellular distribution of (+)[3H]-3-PPP, (+)[3H]-N-allylnormetazocine [(+)[3H]SKF 10047] and [3H]1,3-di-O-tolyl-guanidine ([3H]DTG) binding sites in C57BL/6 mouse brain were investigated, and the properties of clorgyline interaction with the (+)-3-PPP/σ-binding site(s) were examd.  (+)[3H]-3-PPP binding, but not [3H]DTG binding, is inhibited by low concns. (nM) of the dextrorotatory (+)-isomers of SKF 10047, 3-PPP and deprenyl and the type A MAO inhibitor, clorgyline.  The haloperidol-sensitive/(+)[3H]SKF 10047 binding sites display virtually identical sensitivity towards the MAO inhibitors as (+)-3-PPP binding sites.  These observations suggest a distinction between [3H]DTG and (+)[3H]-3-PPP/(+)[3H]SKF 10047 binding sites in the mouse brain.  Clorgyline interaction with (+)-3-PPP/δ-sites is competitive and reversible unlike the interaction of clorgyline with MAO-A.  The σ-ligands tested do not inhibit MAO activity and bind to sites that are apparently distinct from the MAO binding sites labeled with [3H]-N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.  However, the mitochondrial fraction of the mouse brain that expresses MAO activity and high d. of [3H]-N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine binding sites also comprises high d. of (+)-3-PPP/(+)SKF 10047 binding sites.  These findings suggest that clorgyline-sensitive/σ-binding sites may coexist with MAO in the mitochondrial fraction of mouse brain.  High d. of DTG binding sites is present in the microsomal fraction of the mouse brain, which also constitutes high d. of (+)-3-PPP/(+)SKF 10047 binding sites.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-Wd-Eay8LY7Vg90H21EOLACvtfcHk0lipWL4oU5jamQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXksVWkuro%253D&md5=729e135b8075cb9bfc08b7700a1f79a3</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DItzhak%26aufirst%3DY.%26aulast%3DStein%26aufirst%3DI.%26aulast%3DZhang%26aufirst%3DS.%2BH.%26aulast%3DKassim%26aufirst%3DC.%2BO.%26aulast%3DCristante%26aufirst%3DD.%26atitle%3DBinding%2520of%2520sigma-ligands%2520to%2520C57BL%252F6%2520mouse%2520brain%2520membranes%253A%2520effects%2520of%2520monoamine%2520oxidase%2520inhibitors%2520and%2520subcellular%2520distribution%2520studies%2520suggest%2520the%2520existence%2520of%2520sigma-receptor%2520subtypes%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D1991%26volume%3D257%26spage%3D141%26epage%3D148" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Iwamoto, E. T.</span></span> <span> </span><span class="NLM_article-title">Pharmacologic effects of N-allylnormetazocine (SKF-10047)</span>. <i>NIDA Res. Monogr.</i> <span class="NLM_year" style="font-weight: bold;">1981</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">82</span>– <span class="NLM_lpage">88</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=6783955" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A280%3ADyaL3M7ntlShtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=1981&pages=82-88&author=E.+T.+Iwamoto&title=Pharmacologic+effects+of+N-allylnormetazocine+%28SKF-10047%29"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacologic effects of N-allylnormetazocine (SKF-10047)</span></div><div class="casAuthors">Iwamoto E T</div><div class="citationInfo"><span class="NLM_cas:title">NIDA research monograph</span>
        (<span class="NLM_cas:date">1981</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">82-8</span>
        ISSN:<span class="NLM_cas:issn">1046-9516</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSvDQTl2-0_KFm8bhe6roZYfW6udTcc2eYiNfTOAkMOB7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaL3M7ntlShtg%253D%253D&md5=c5bad204462d5ce6c9a4220721678145</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DIwamoto%26aufirst%3DE.%2BT.%26atitle%3DPharmacologic%2520effects%2520of%2520N-allylnormetazocine%2520%2528SKF-10047%2529%26jtitle%3DNIDA%2520Res.%2520Monogr.%26date%3D1981%26volume%3D34%26spage%3D82%26epage%3D88" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tam, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cook, L.</span></span> <span> </span><span class="NLM_article-title">Sigma opiates and certain antipsychotic drugs mutually inhibit (+)-[3H] SKF 10,047 and [3H]haloperidol binding in guinea pig brain membranes</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">1984</span>,  <span class="NLM_volume"><i>81</i></span>,  <span class="NLM_fpage">5618</span>– <span class="NLM_lpage">5621</span>, <span class="refDoi"> DOI: 10.1073/pnas.81.17.5618</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1073%2Fpnas.81.17.5618" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=6147851" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADyaL2cXmtVCiu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=81&publication_year=1984&pages=5618-5621&author=S.+W.+Tamauthor=L.+Cook&title=Sigma+opiates+and+certain+antipsychotic+drugs+mutually+inhibit+%28%2B%29-%5B3H%5D+SKF+10%2C047+and+%5B3H%5Dhaloperidol+binding+in+guinea+pig+brain+membranes&doi=10.1073%2Fpnas.81.17.5618"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">σ Opiates and certain antipsychotic drugs mutually inhibit (+)-[3H]SKF 10,047 and [3H]haloperidol binding in guinea pig brain membranes</span></div><div class="casAuthors">Tam, S. William; Cook, Leonard</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1984</span>),
    <span class="NLM_cas:volume">81</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">5618-21</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    </div><div class="casAbstract">The relationship between binding of antipsychotic drugs and σ psychotomimetic opiates to binding sites for the σ agonist 3H-labeled (+)-SKF 10,047  [58640-82-7] and to dopamine D2 sites was investigated.  In guinea pig brain membranes, (+)-[3H]SKF 10,047 bound to a single class of sites with a Kd of 4 × 10-8M and a Bmax of 333 fmol/mg of protein.  This binding was different from μ, κ, or δ opiate receptor binding.  It was inhibited by opiates that produce psychotomimetic activities but not by opiates that lack such activities.  Some antipsychotic drugs inhibited (+)-[3H]SKF 10,047 binding with high to moderate affinities in the following order of potency: haloperidol  [52-86-8] > perphenazine  [58-39-9] > fluphenazine  [69-23-8] > acetophenazine  [2751-68-0] > trifluoperazine  [117-89-5] > molindone  [7416-34-4] ≥ pimozide  [2062-78-4] ≥ thioridazine  [50-52-2] ≥ chlorpromazine  [50-53-3] ≥ triflupromazine  [146-54-3].  However, there were other antipsychotic drugs such as spiperone  [749-02-0] and clozapine  [5786-21-0] that showed low affinity for the (+)-[3H]SKF 10,047 binding sites.  Affinities of antipsychotic drugs for (+)-[3H]SKF 10,047 binding sites did not correlate with those for [3H]spiperone (dopamine D2) sites.  [3H]-Haloperidol binding in whole brain membranes was also inhibited by the σ opiates pentazocine  [359-83-1], cyclazocine  [3572-80-3], and (+)-SKF 10,047.  In the striatum, about half of the saturable [3H]haloperidol binding was to [3H]spiperone (D2) sites and the other half was to sites similar to (+)-[3H]SKF 10,047 binding sites.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3J2yT0mD-vLVg90H21EOLACvtfcHk0lipWL4oU5jamQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2cXmtVCiu7w%253D&md5=bdb8459ffe1755e96b9cba9d63186817</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1073%2Fpnas.81.17.5618&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.81.17.5618%26sid%3Dliteratum%253Aachs%26aulast%3DTam%26aufirst%3DS.%2BW.%26aulast%3DCook%26aufirst%3DL.%26atitle%3DSigma%2520opiates%2520and%2520certain%2520antipsychotic%2520drugs%2520mutually%2520inhibit%2520%2528%252B%2529-%255B3H%255D%2520SKF%252010%252C047%2520and%2520%255B3H%255Dhaloperidol%2520binding%2520in%2520guinea%2520pig%2520brain%2520membranes%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1984%26volume%3D81%26spage%3D5618%26epage%3D5621%26doi%3D10.1073%2Fpnas.81.17.5618" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Navarro, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beltrán, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavas, M.</span></span> <span> </span><span class="NLM_article-title">Effects of (+) SKF 10,047, a sigma-1 receptor agonist, on anxiety, tested in two laboratory models in mice</span>. <i>Psicothema</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">427</span>– <span class="NLM_lpage">430</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=22748735" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A280%3ADC%252BC38jmt1entw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2012&pages=427-430&author=J.+F.+Navarroauthor=D.+Beltr%C3%A1nauthor=M.+Cavas&title=Effects+of+%28%2B%29+SKF+10%2C047%2C+a+sigma-1+receptor+agonist%2C+on+anxiety%2C+tested+in+two+laboratory+models+in+mice"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of (+) SKF 10,047, a sigma-1 receptor agonist, on anxiety,tested in two laboratory models in mice</span></div><div class="casAuthors">Navarro Jose Francisco; Beltran David; Cavas Maria</div><div class="citationInfo"><span class="NLM_cas:title">Psicothema</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">427-30</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Recently, sigma-1 receptor modulators have been considered drugs with an interesting therapeutic potential for the treatment of anxiety.  However, there is no clear information in preclinical studies about the possible effects of sigma-1 ligands on anxiety in experimental animal models.  Therefore, the present study examined the effects of (+)SKF 10,047 (2-8 mg/kg, ip), a sigma-1 agonist, on anxiety, tested in two classical laboratory models (social interaction test and elevated plus maze). (+)SKF 10,047 (8 mg/kg) produced a significant decrease of social investigation in the "social interaction test", whereas in the "elevated plus maze", the drug (4 and 8 mg/kg) provoked a significant reduction in the number of entries into open arms, as well as in the time spent in this area, as compared with the control group, without affecting motor activity.  Overall, these findings indicate that (+)SKF 10,047 exhibits an anxiogenic-like profile in mice.  It is suggested that anxiogenic effects of this sigma-1 ligand could be related to its potent ability to modulate diverse neurotransmitter systems involved in anxiety regulation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ-5aBXYB9pjhgd2Wuil24tfW6udTcc2eYBbaJLodew-Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38jmt1entw%253D%253D&md5=5b0d245b7f4afce7c6fdd1d612a5439d</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNavarro%26aufirst%3DJ.%2BF.%26aulast%3DBeltr%25C3%25A1n%26aufirst%3DD.%26aulast%3DCavas%26aufirst%3DM.%26atitle%3DEffects%2520of%2520%2528%252B%2529%2520SKF%252010%252C047%252C%2520a%2520sigma-1%2520receptor%2520agonist%252C%2520on%2520anxiety%252C%2520tested%2520in%2520two%2520laboratory%2520models%2520in%2520mice%26jtitle%3DPsicothema%26date%3D2012%26volume%3D24%26spage%3D427%26epage%3D430" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hayashi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujimoto, M.</span></span> <span> </span><span class="NLM_article-title">Detergent-resistant microdomains determine the localization of sigma-1 receptors to the endoplasmic reticulum-mitochondria junction</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>77</i></span>,  <span class="NLM_fpage">517</span>– <span class="NLM_lpage">528</span>, <span class="refDoi"> DOI: 10.1124/mol.109.062539</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1124%2Fmol.109.062539" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=20053954" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BC3cXkvVyktbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2010&pages=517-528&author=T.+Hayashiauthor=M.+Fujimoto&title=Detergent-resistant+microdomains+determine+the+localization+of+sigma-1+receptors+to+the+endoplasmic+reticulum-mitochondria+junction&doi=10.1124%2Fmol.109.062539"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Detergent-resistant microdomains determine the localization of σ-1 receptors to the endoplasmic reticulum-mitochondria junction</span></div><div class="casAuthors">Hayashi, Teruo; Fujimoto, Michiko</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">517-528</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">σ-1 Receptors (Sig-1Rs) that bind diverse synthetic and endogenous compds. have been implicated in the pathophysiol. of several human diseases such as drug addiction, depression, neurodegenerative disorders, pain-related disorders, and cancer.  Sig-1Rs were identified recently as novel ligand-operated mol. chaperones.  Although Sig-1Rs are predominantly expressed at endoplasmic reticulum (ER) subdomains apposing mitochondria [i.e., the mitochondria-assocd. ER membrane (MAM)], they dynamically change the cellular distribution, thus regulating both MAM-specific and plasma membrane proteins.  However, what dets. the location of Sig-1R at the MAM and how the receptor translocation is initiated is unknown.  Here we report that the detergent-resistant membranes (DRMs) play an important role in anchoring Sig-1Rs to the MAM.  The MAM, which is highly capable of accumulating ceramides, is enriched with both cholesterol and simple sphingolipids, thus forming Triton X-114-resistant DRMs.  Sig-1Rs assoc. with MAM-derived DRMs but not with those from microsomes.  A lipid overlay assay found that solubilized Sig-1Rs preferentially assoc. with simple sphingolipids such as ceramides.  Disrupting DRMs by lowering cholesterol or inhibiting de novo synthesis of ceramides at the ER largely decreases Sig-1R at DRMs and causes translocation of Sig-1R from the MAM to ER cisternae.  These findings suggest that the MAM, bearing cholesterol and ceramide-enriched microdomains at the ER, may use the microdomains to anchor Sig-1Rs to the location; thus, it serves to stage Sig-1R at ER-mitochondria junctions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZYY_eReHQzbVg90H21EOLACvtfcHk0lijILP6zRo33g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXkvVyktbY%253D&md5=f36cef4c5a43f799cf7fbdef27bb968f</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1124%2Fmol.109.062539&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.109.062539%26sid%3Dliteratum%253Aachs%26aulast%3DHayashi%26aufirst%3DT.%26aulast%3DFujimoto%26aufirst%3DM.%26atitle%3DDetergent-resistant%2520microdomains%2520determine%2520the%2520localization%2520of%2520sigma-1%2520receptors%2520to%2520the%2520endoplasmic%2520reticulum-mitochondria%2520junction%26jtitle%3DMol.%2520Pharmacol.%26date%3D2010%26volume%3D77%26spage%3D517%26epage%3D528%26doi%3D10.1124%2Fmol.109.062539" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, T.</span></span> <span> </span><span class="NLM_article-title">The Roles of Intracellular Chaperone Proteins, Sigma Receptors, in Parkinson’s Disease (PD) and Major Depressive Disorder (MDD)</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">528</span>, <span class="refDoi"> DOI: 10.3389/fphar.2019.00528</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.3389%2Ffphar.2019.00528" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=31178723" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A280%3ADC%252BB3M3kslaqtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=528&author=K.+Yangauthor=C.+Wangauthor=T.+Sun&title=The+Roles+of+Intracellular+Chaperone+Proteins%2C+Sigma+Receptors%2C+in+Parkinson%E2%80%99s+Disease+%28PD%29+and+Major+Depressive+Disorder+%28MDD%29&doi=10.3389%2Ffphar.2019.00528"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">The Roles of Intracellular Chaperone Proteins, Sigma Receptors, in Parkinson's Disease (PD) and Major Depressive Disorder (MDD)</span></div><div class="casAuthors">Yang Kai; Wang Changcai; Sun Taolei; Sun Taolei</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in pharmacology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">528</span>
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    </div><div class="casAbstract">Sigma receptors, including Sigma-1 receptors and Sigma-2 receptors, are highly expressed in the CNS.  They are intracellular chaperone proteins.  Sigma-1 receptors localize mainly at the mitochondria-associated endoplasmic reticulum (ER) membrane (MAM).  Upon stimulation, they translocate from MAM to plasma membrane (PM) and nucleus, where they interact with many proteins and ion channels.  Sigma-1 receptor could interact with itself to form oligomers, its oligomerization states affect its ability to interact with client proteins including ion channels and BiP.  Sigma-1 receptor shows high affinity for many unrelated and structurally diverse ligands, but the mechanism for this diverse drug receptor interaction remains unknown.  Sigma-1 receptors also directly bind many proteins including G protein-coupled receptors (GPCRs) and ion channels.  In recent years, significant progress has been made in our understanding of roles of the Sigma-1 receptors in normal and pathological conditions, but more studies are still required for the Sigma-2 receptors.  The physiological roles of Sigma-1 receptors in the CNS are discussed.  They can modulate the activity of many ion channels including voltage-dependent ion channels including Ca(2+), Na(+), K(+) channels and NMDAR, thus affecting neuronal excitability and synaptic activity.  They are also involved in synaptic plasticity and learning and memory.  Moreover, the activation of Sigma receptors protects neurons from death via the modulation of ER stress, neuroinflammation, and Ca(2+) homeostasis.  Evidences about the involvement of Sigma-1 receptors in Parkinson's disease (PD) and Major Depressive Disorder (MDD) are also presented, indicating Sigma-1 receptors might be promising targets for pharmacologically treating PD and MDD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTX1yhwJRUF1HT4ugvCDgnZfW6udTcc2eYBbaJLodew-Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3M3kslaqtw%253D%253D&md5=fdec2ea27cf307a82d5a574da02b4f37</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2019.00528&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2019.00528%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DK.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DSun%26aufirst%3DT.%26atitle%3DThe%2520Roles%2520of%2520Intracellular%2520Chaperone%2520Proteins%252C%2520Sigma%2520Receptors%252C%2520in%2520Parkinson%25E2%2580%2599s%2520Disease%2520%2528PD%2529%2520and%2520Major%2520Depressive%2520Disorder%2520%2528MDD%2529%26jtitle%3DFront.%2520Pharmacol.%26date%3D2019%26volume%3D10%26spage%3D528%26doi%3D10.3389%2Ffphar.2019.00528" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hanner, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moebius, F. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flandorfer, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knaus, H. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Striessnig, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kempner, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glossmann, H.</span></span> <span> </span><span class="NLM_article-title">Purification, molecular cloning, and expression of the mammalian sigma1-binding site</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>93</i></span>,  <span class="NLM_fpage">8072</span>– <span class="NLM_lpage">8077</span>, <span class="refDoi"> DOI: 10.1073/pnas.93.15.8072</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1073%2Fpnas.93.15.8072" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=8755605" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADyaK28XksFSqsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=1996&pages=8072-8077&author=M.+Hannerauthor=F.+F.+Moebiusauthor=A.+Flandorferauthor=H.+G.+Knausauthor=J.+Striessnigauthor=E.+Kempnerauthor=H.+Glossmann&title=Purification%2C+molecular+cloning%2C+and+expression+of+the+mammalian+sigma1-binding+site&doi=10.1073%2Fpnas.93.15.8072"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Purification, molecular cloning, and expression of the mammalian sigma1-binding site</span></div><div class="casAuthors">Hanner, Markus; Moebius, Fabian F.; Flandorfer, Astrid; Knaus, Hans-Guenther; Striessnig, Joerg; Kempner, Ellis; Glossman, Hartmut</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">93</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">8072-8077</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Sigma-ligands comprise several chem. unrelated drugs such as haloperidol, pentazocine, and ditolylguanidine, which bind to a family of low mol. mass proteins in the endoplasmic reticulum.  These so-called sigma-receptors are believed to mediate various pharmacol. effects of sigma-ligands by as yet unknown mechanisms.  Based on their opposite enantioselectivity for benzomorphans and different mol. masses, two subtypes are differentiated.  We purified the sigma1-binding site as a single 30-kDa protein from guinea pig liver employing the benzomorphan (+)[3H]pentazocine and the aryladize (-)[3H]azidopamil as specific probes.  The purified (+)[3H]pentazocine-binding protein retained its high affinity for haloperidol, pentazocine, and ditolylguanidine.  Partial amino acid sequence obtained after trypsinolysis revealed no homol. to known proteins.  Radiation inactivation of the pentazocine-labeled sigma1-binding site yielded a mol. mass of 24 kDa.  The corresponding cDNA was cloned using degenerate oligonucleotides and cDNA library screening.  Its open reading frame encoded a 25.3-kDa protein with at least one putative transmembrane segment.  The protein expressed in yeast cells transformed with the cDNA showed the pharmacol. characteristics of the brain and liver sigma1-binding site.  The deduced amino acid sequence was structurally unrelated to known mammalian proteins but it shared homol. with fungal proteins involved in sterol synthesis.  Northern blots showed high densities of the sigma1-binding site mRNA in sterol-producing tissues.  This is also in agreement with the known ability of sigma1-binding sites to interact with steroids, such as progesterone.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3kp2l6ZPKdrVg90H21EOLACvtfcHk0lhfSbh0axkNgA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XksFSqsr8%253D&md5=01c7d3bbab83dd5d18531845213bf267</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1073%2Fpnas.93.15.8072&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.93.15.8072%26sid%3Dliteratum%253Aachs%26aulast%3DHanner%26aufirst%3DM.%26aulast%3DMoebius%26aufirst%3DF.%2BF.%26aulast%3DFlandorfer%26aufirst%3DA.%26aulast%3DKnaus%26aufirst%3DH.%2BG.%26aulast%3DStriessnig%26aufirst%3DJ.%26aulast%3DKempner%26aufirst%3DE.%26aulast%3DGlossmann%26aufirst%3DH.%26atitle%3DPurification%252C%2520molecular%2520cloning%252C%2520and%2520expression%2520of%2520the%2520mammalian%2520sigma1-binding%2520site%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1996%26volume%3D93%26spage%3D8072%26epage%3D8077%26doi%3D10.1073%2Fpnas.93.15.8072" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Quirion, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowen, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Itzhak, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Junien, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Musacchio, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rothman, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tam, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, D. P.</span></span> <span> </span><span class="NLM_article-title">A proposal for the classification of sigma binding sites</span>. <i>Trends Pharmacol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">1992</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">85</span>– <span class="NLM_lpage">86</span>, <span class="refDoi"> DOI: 10.1016/0165-6147(92)90030-A</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1016%2F0165-6147%2892%2990030-A" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1315463" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A280%3ADyaK383ksFGrsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=1992&pages=85-86&author=R.+Quirionauthor=W.+D.+Bowenauthor=Y.+Itzhakauthor=J.+L.+Junienauthor=J.+M.+Musacchioauthor=R.+B.+Rothmanauthor=T.+P.+Suauthor=S.+W.+Tamauthor=D.+P.+Taylor&title=A+proposal+for+the+classification+of+sigma+binding+sites&doi=10.1016%2F0165-6147%2892%2990030-A"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">A proposal for the classification of sigma binding sites</span></div><div class="casAuthors">Quirion R; Bowen W D; Itzhak Y; Junien J L; Musacchio J M; Rothman R B; Su T P; Tam S W; Taylor D P</div><div class="citationInfo"><span class="NLM_cas:title">Trends in pharmacological sciences</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">85-6</span>
        ISSN:<span class="NLM_cas:issn">0165-6147</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR9QiJWG_oOy3p3bfzSLaX5fW6udTcc2eaDcbqMoFgcqrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK383ksFGrsQ%253D%253D&md5=bdbde1d04c3c3e627e4ff512102ddf5d</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2F0165-6147%2892%2990030-A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0165-6147%252892%252990030-A%26sid%3Dliteratum%253Aachs%26aulast%3DQuirion%26aufirst%3DR.%26aulast%3DBowen%26aufirst%3DW.%2BD.%26aulast%3DItzhak%26aufirst%3DY.%26aulast%3DJunien%26aufirst%3DJ.%2BL.%26aulast%3DMusacchio%26aufirst%3DJ.%2BM.%26aulast%3DRothman%26aufirst%3DR.%2BB.%26aulast%3DSu%26aufirst%3DT.%2BP.%26aulast%3DTam%26aufirst%3DS.%2BW.%26aulast%3DTaylor%26aufirst%3DD.%2BP.%26atitle%3DA%2520proposal%2520for%2520the%2520classification%2520of%2520sigma%2520binding%2520sites%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D1992%26volume%3D13%26spage%3D85%26epage%3D86%26doi%3D10.1016%2F0165-6147%2892%2990030-A" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gurpinar, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koehl, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manglik, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kruse, A. C.</span></span> <span> </span><span class="NLM_article-title">Crystal structure of the human σ1 receptor</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>532</i></span>,  <span class="NLM_fpage">527</span>– <span class="NLM_lpage">530</span>, <span class="refDoi"> DOI: 10.1038/nature17391</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1038%2Fnature17391" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=27042935" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BC28Xlsl2gt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=532&publication_year=2016&pages=527-530&author=H.+R.+Schmidtauthor=S.+Zhengauthor=E.+Gurpinarauthor=A.+Koehlauthor=A.+Manglikauthor=A.+C.+Kruse&title=Crystal+structure+of+the+human+%CF%831+receptor&doi=10.1038%2Fnature17391"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Crystal structure of the human σ1 receptor</span></div><div class="casAuthors">Schmidt, Hayden R.; Zheng, Sanduo; Gurpinar, Esin; Koehl, Antoine; Manglik, Aashish; Kruse, Andrew C.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">532</span>
        (<span class="NLM_cas:issue">7600</span>),
    <span class="NLM_cas:pages">527-530</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The human σ1 receptor is an enigmatic endoplasmic reticulum (ER)-resident transmembrane protein implicated in a variety of disorders including depression, drug addiction, and neuropathic pain.  Recently, an addnl. connection to amyotrophic lateral sclerosis has emerged from studies of human genetics and mouse models.  Unlike many transmembrane receptors that belong to large, extensively studied families such as G-protein-coupled receptors or ligand-gated ion channels, the σ1 receptor is an evolutionary isolate with no discernible similarity to any other human protein.  Despite its increasingly clear importance in human physiol. and disease, the mol. architecture of the σ1 receptor and its regulation by drug-like compds. remain poorly defined.  Here, the authors report crystal structures of the human σ1 receptor in complex with 2 chem. divergent ligands, PD 144418 and 4-(N-benzylpiperidin-4-yl)-4-iodobenzamide (4-IBP).  The structures revealed a trimeric architecture with a single transmembrane domain in each protomer.  The C-terminal domain of the receptor showed an extensive flat, hydrophobic membrane-proximal surface, suggesting an intimate assocn. with the cytosolic surface of the ER membrane in cells.  This domain included a cupin-like β-barrel with the ligand-binding site buried at its center.  This large, hydrophobic ligand-binding cavity showed remarkable plasticity in ligand recognition, binding the 2 ligands in similar positions despite dissimilar chem. structures.  Taken together, these results revealed the overall architecture, oligomerization state, and mol. basis for ligand recognition by this important but poorly understood protein.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokQBAf03Pml7Vg90H21EOLACvtfcHk0lhfSbh0axkNgA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xlsl2gt7o%253D&md5=fb6df7814060fbd05ba41261ad1061f5</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1038%2Fnature17391&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature17391%26sid%3Dliteratum%253Aachs%26aulast%3DSchmidt%26aufirst%3DH.%2BR.%26aulast%3DZheng%26aufirst%3DS.%26aulast%3DGurpinar%26aufirst%3DE.%26aulast%3DKoehl%26aufirst%3DA.%26aulast%3DManglik%26aufirst%3DA.%26aulast%3DKruse%26aufirst%3DA.%2BC.%26atitle%3DCrystal%2520structure%2520of%2520the%2520human%2520%25CF%25831%2520receptor%26jtitle%3DNature%26date%3D2016%26volume%3D532%26spage%3D527%26epage%3D530%26doi%3D10.1038%2Fnature17391" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Betz, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dror, R. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kruse, A. C.</span></span> <span> </span><span class="NLM_article-title">Structural basis for σ(1) receptor ligand recognition</span>. <i>Nat. Struct. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">981</span>– <span class="NLM_lpage">987</span>, <span class="refDoi"> DOI: 10.1038/s41594-018-0137-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1038%2Fs41594-018-0137-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=30291362" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvVOjsbvM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2018&pages=981-987&author=H.+R.+Schmidtauthor=R.+M.+Betzauthor=R.+O.+Drorauthor=A.+C.+Kruse&title=Structural+basis+for+%CF%83%281%29+receptor+ligand+recognition&doi=10.1038%2Fs41594-018-0137-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Structural basis for σ1 receptor ligand recognition</span></div><div class="casAuthors">Schmidt, Hayden R.; Betz, Robin M.; Dror, Ron O.; Kruse, Andrew C.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Structural & Molecular Biology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">981-987</span>CODEN:
                <span class="NLM_cas:coden">NSMBCU</span>;
        ISSN:<span class="NLM_cas:issn">1545-9993</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">The s1 receptor is a poorly understood membrane protein expressed throughout the human body.  Ligands targeting the s1 receptor are in clin. trials for treatment of Alzheimer's disease, ischemic stroke, and neuropathic pain.  However, relatively little is known regarding the s1 receptor's mol. function.  Here, we present crystal structures of human s1 receptor bound to the antagonists haloperidol and NE-100, and the agonist (+)-pentazocine, at crystallog. resolns. of 3.1 Å, 2.9 Å, and 3.1 Å, resp.  These structures reveal a unique binding pose for the agonist.  The structures and accompanying mol. dynamics (MD) simulations identify agonist-induced structural rearrangements in the receptor.  Addnl., we show that ligand binding to s1 is a multistep process that is rate limited by receptor conformational change.  We used MD simulations to reconstruct a ligand binding pathway involving two major conformational changes.  These data provide a framework for understanding the mol. basis for s1 agonism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQ2dgVTV70vbVg90H21EOLACvtfcHk0lhfSbh0axkNgA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvVOjsbvM&md5=d12d12aecbd89684824975977ec03e4b</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1038%2Fs41594-018-0137-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41594-018-0137-2%26sid%3Dliteratum%253Aachs%26aulast%3DSchmidt%26aufirst%3DH.%2BR.%26aulast%3DBetz%26aufirst%3DR.%2BM.%26aulast%3DDror%26aufirst%3DR.%2BO.%26aulast%3DKruse%26aufirst%3DA.%2BC.%26atitle%3DStructural%2520basis%2520for%2520%25CF%2583%25281%2529%2520receptor%2520ligand%2520recognition%26jtitle%3DNat.%2520Struct.%2520Mol.%2520Biol.%26date%3D2018%26volume%3D25%26spage%3D981%26epage%3D987%26doi%3D10.1038%2Fs41594-018-0137-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ryskamp, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korban, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhemkov, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kraskovskaya, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bezprozvanny, I.</span></span> <span> </span><span class="NLM_article-title">Neuronal Sigma-1 Receptors: Signaling Functions and Protective Roles in Neurodegenerative Diseases</span>. <i>Front. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">862</span>, <span class="refDoi"> DOI: 10.3389/fnins.2019.00862</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.3389%2Ffnins.2019.00862" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=31551669" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A280%3ADC%252BB3MnhvVWjsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2019&pages=862&author=D.+A.+Ryskampauthor=S.+Korbanauthor=V.+Zhemkovauthor=N.+Kraskovskayaauthor=I.+Bezprozvanny&title=Neuronal+Sigma-1+Receptors%3A+Signaling+Functions+and+Protective+Roles+in+Neurodegenerative+Diseases&doi=10.3389%2Ffnins.2019.00862"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Neuronal Sigma-1 Receptors: Signaling Functions and Protective Roles in Neurodegenerative Diseases</span></div><div class="casAuthors">Ryskamp Daniel A; Zhemkov Vladimir; Bezprozvanny Ilya; Korban Svetlana; Kraskovskaya Nina; Bezprozvanny Ilya</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in neuroscience</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">862</span>
        ISSN:<span class="NLM_cas:issn">1662-4548</span>.
    </div><div class="casAbstract">Sigma-1 receptor (S1R) is a multi-functional, ligand-operated protein situated in endoplasmic reticulum (ER) membranes and changes in its function and/or expression have been associated with various neurological disorders including amyotrophic lateral sclerosis/frontotemporal dementia, Alzheimer's (AD) and Huntington's diseases (HD).  S1R agonists are broadly neuroprotective and this is achieved through a diversity of S1R-mediated signaling functions that are generally pro-survival and anti-apoptotic; yet, relatively little is known regarding the exact mechanisms of receptor functioning at the molecular level.  This review summarizes therapeutically relevant mechanisms by which S1R modulates neurophysiology and implements neuroprotective functions in neurodegenerative diseases.  These mechanisms are diverse due to the fact that S1R can bind to and modulate a large range of client proteins, including many ion channels in both ER and plasma membranes.  We summarize the effect of S1R on its interaction partners and consider some of the cell type- and disease-specific aspects of these actions.  Besides direct protein interactions in the endoplasmic reticulum, S1R is likely to function at the cellular/interorganellar level by altering the activity of several plasmalemmal ion channels through control of trafficking, which may help to reduce excitotoxicity.  Moreover, S1R is situated in lipid rafts where it binds cholesterol and regulates lipid and protein trafficking and calcium flux at the mitochondrial-associated membrane (MAM) domain.  This may have important implications for MAM stability and function in neurodegenerative diseases as well as cellular bioenergetics.  We also summarize the structural and biochemical features of S1R proposed to underlie its activity.  In conclusion, S1R is incredibly versatile in its ability to foster neuronal homeostasis in the context of several neurodegenerative disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTnXmondofHvmyYR5VtavbzfW6udTcc2eZUwYHB32TsKrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MnhvVWjsA%253D%253D&md5=b8a65774a44e82a94e5049247c993883</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.3389%2Ffnins.2019.00862&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffnins.2019.00862%26sid%3Dliteratum%253Aachs%26aulast%3DRyskamp%26aufirst%3DD.%2BA.%26aulast%3DKorban%26aufirst%3DS.%26aulast%3DZhemkov%26aufirst%3DV.%26aulast%3DKraskovskaya%26aufirst%3DN.%26aulast%3DBezprozvanny%26aufirst%3DI.%26atitle%3DNeuronal%2520Sigma-1%2520Receptors%253A%2520Signaling%2520Functions%2520and%2520Protective%2520Roles%2520in%2520Neurodegenerative%2520Diseases%26jtitle%3DFront.%2520Neurosci.%26date%3D2019%26volume%3D13%26spage%3D862%26doi%3D10.3389%2Ffnins.2019.00862" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Katz, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hiranita, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kopajtic, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rice, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mesangeau, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narayanan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abdelazeem, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCurdy, C. R.</span></span> <span> </span><span class="NLM_article-title">Blockade of Cocaine or σ Receptor Agonist Self Administration by Subtype-Selective σ Receptor Antagonists</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>358</i></span>,  <span class="NLM_fpage">109</span>– <span class="NLM_lpage">124</span>, <span class="refDoi"> DOI: 10.1124/jpet.116.232728</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1124%2Fjpet.116.232728" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=27189970" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsFOhsLnK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=358&publication_year=2016&pages=109-124&author=J.+L.+Katzauthor=T.+Hiranitaauthor=T.+A.+Kopajticauthor=K.+C.+Riceauthor=C.+Mesangeauauthor=S.+Narayananauthor=A.+H.+Abdelazeemauthor=C.+R.+McCurdy&title=Blockade+of+Cocaine+or+%CF%83+Receptor+Agonist+Self+Administration+by+Subtype-Selective+%CF%83+Receptor+Antagonists&doi=10.1124%2Fjpet.116.232728"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Blockade of cocaine or σ receptor agonist self administration by subtype-selective σ receptor antagonists</span></div><div class="casAuthors">Katz, Jonathan L.; Hiranita, Takato; Kopajtic, Theresa A.; Rice, Kenner C.; Mesangeau, Christophe; Narayanan, Sanju; Abdelazeem, Ahmed H.; McCurdy, Christopher R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">358</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">109-124</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The identification of sigma receptor (σR) subtypes has been based on radioligand binding and, despite progress with σ1R cellular function, less is known about σR subtype functions in vivo.  Recent findings that cocaine self administration experience will trigger σR agonist self administration was used in this study to assess the in vivo receptor subtype specificity of the agonists (1)-pentazocine, PRE-084 [2-(4-morpholinethyl) 1-phenylcyclohexanecarboxylate hydrochloride], and 1,3-di-o-tolylguanidine (DTG) and several novel putative σR antagonists.  Radioligand binding studies detd. in vitro σR selectivity of the novel compds., which were subsequently studied for self administration and antagonism of cocaine, (1)-pentazocine, PRE-084, or DTG self administration.  Across the dose ranges studied, none of the novel compds. were self administered, nor did they alter cocaine self administration.  All compds. blocked DTG self administration, with a subset also blocking (1)-pentazocine and PRE-084 self administration.  The most selective of the compds. in binding σ1Rs blocked cocaine self administration when combined with a dopamine transport inhibitor, either methylphenidate or nomifensine.  These drug combinations did not decrease rates of responding maintained by food reinforcement.  In contrast, the most selective of the compds. in binding σ2Rs had no effect on cocaine self administration in combination with either dopamine transport inhibitor.  Thus, these results identify subtype-specific in vivo antagonists, and the utility of σR agonist substitution for cocaine self administration as an assay capable of distinguishing σR subtype selectivity in vivo.  These results further suggest that effectiveness of dual σR antagonism and dopamine transport inhibition in blocking cocaine self administration is specific for σ1Rs and further support this dual targeting approach to development of cocaine antagonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqz4jCUfp7CsLVg90H21EOLACvtfcHk0lhNqyUrmgEFXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsFOhsLnK&md5=721dfe4db5a272382b8c6a50b1dda748</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1124%2Fjpet.116.232728&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.116.232728%26sid%3Dliteratum%253Aachs%26aulast%3DKatz%26aufirst%3DJ.%2BL.%26aulast%3DHiranita%26aufirst%3DT.%26aulast%3DKopajtic%26aufirst%3DT.%2BA.%26aulast%3DRice%26aufirst%3DK.%2BC.%26aulast%3DMesangeau%26aufirst%3DC.%26aulast%3DNarayanan%26aufirst%3DS.%26aulast%3DAbdelazeem%26aufirst%3DA.%2BH.%26aulast%3DMcCurdy%26aufirst%3DC.%2BR.%26atitle%3DBlockade%2520of%2520Cocaine%2520or%2520%25CF%2583%2520Receptor%2520Agonist%2520Self%2520Administration%2520by%2520Subtype-Selective%2520%25CF%2583%2520Receptor%2520Antagonists%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2016%26volume%3D358%26spage%3D109%26epage%3D124%26doi%3D10.1124%2Fjpet.116.232728" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gordon, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jang, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bouhaddou, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obernier, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Meara, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rezelj, V. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, J. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swaney, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tummino, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hüttenhain, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaake, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richards, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tutuncuoglu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foussard, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Batra, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haas, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Modak, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haas, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polacco, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Braberg, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fabius, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eckhardt, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soucheray, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bennett, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cakir, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGregor, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roesch, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vallet, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mac Kain, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miorin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreno, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naing, Z. Z. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirby, I. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melnyk, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chorba, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lou, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrio-Hernandez, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Memon, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hernandez-Armenta, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathy, C. J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perica, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pilla, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganesan, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saltzberg, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rakesh, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenthal, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calviello, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venkataramanan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liboy-Lugo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wankowicz, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bohn, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Safari, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ugur, F. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koh, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savar, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tran, Q. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shengjuler, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fletcher, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Neal, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, J. C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Broadhurst, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klippsten, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharp, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wenzell, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuzuoglu-Ozturk, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trenker, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavero, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hiatt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rathore, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Subramanian, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noack, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hubert, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stroud, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frankel, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosenberg, O. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verba, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agard, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ott, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emerman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jura, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Zastrow, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verdin, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashworth, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">d’Enfert, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mukherjee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malik, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujimori, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ideker, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Craik, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Floor, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fraser, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gross, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sali, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruggero, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taunton, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kortemme, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beltrao, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vignuzzi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">García-Sastre, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shokat, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shoichet, B. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krogan, N. J.</span></span> <span> </span><span class="NLM_article-title">A SARS-CoV-2 protein interaction map reveals targets for drug repurposing</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>583</i></span>,  <span class="NLM_fpage">459</span>– <span class="NLM_lpage">468</span>, <span class="refDoi"> DOI: 10.1038/s41586-020-2286-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1038%2Fs41586-020-2286-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=32353859" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtlCqtbrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=583&publication_year=2020&pages=459-468&author=D.+E.+Gordonauthor=G.+M.+Jangauthor=M.+Bouhaddouauthor=J.+Xuauthor=K.+Obernierauthor=K.+M.+Whiteauthor=M.+J.+O%E2%80%99Mearaauthor=V.+V.+Rezeljauthor=J.+Z.+Guoauthor=D.+L.+Swaneyauthor=T.+A.+Tumminoauthor=R.+H%C3%BCttenhainauthor=R.+M.+Kaakeauthor=A.+L.+Richardsauthor=B.+Tutuncuogluauthor=H.+Foussardauthor=J.+Batraauthor=K.+Haasauthor=M.+Modakauthor=M.+Kimauthor=P.+Haasauthor=B.+J.+Polaccoauthor=H.+Brabergauthor=J.+M.+Fabiusauthor=M.+Eckhardtauthor=M.+Soucherayauthor=M.+J.+Bennettauthor=M.+Cakirauthor=M.+J.+McGregorauthor=Q.+Liauthor=B.+Meyerauthor=F.+Roeschauthor=T.+Valletauthor=A.+Mac+Kainauthor=L.+Miorinauthor=E.+Morenoauthor=Z.+Z.+C.+Naingauthor=Y.+Zhouauthor=S.+Pengauthor=Y.+Shiauthor=Z.+Zhangauthor=W.+Shenauthor=I.+T.+Kirbyauthor=J.+E.+Melnykauthor=J.+S.+Chorbaauthor=K.+Louauthor=S.+A.+Daiauthor=I.+Barrio-Hernandezauthor=D.+Memonauthor=C.+Hernandez-Armentaauthor=J.+Lyuauthor=C.+J.+P.+Mathyauthor=T.+Pericaauthor=K.+B.+Pillaauthor=S.+J.+Ganesanauthor=D.+J.+Saltzbergauthor=R.+Rakeshauthor=X.+Liuauthor=S.+B.+Rosenthalauthor=L.+Calvielloauthor=S.+Venkataramananauthor=J.+Liboy-Lugoauthor=Y.+Linauthor=X.+P.+Huangauthor=Y.+Liuauthor=S.+A.+Wankowiczauthor=M.+Bohnauthor=M.+Safariauthor=F.+S.+Ugurauthor=C.+Kohauthor=N.+S.+Savarauthor=Q.+D.+Tranauthor=D.+Shengjulerauthor=S.+J.+Fletcherauthor=M.+C.+O%E2%80%99Nealauthor=Y.+Caiauthor=J.+C.+J.+Changauthor=D.+J.+Broadhurstauthor=S.+Klippstenauthor=P.+P.+Sharpauthor=N.+A.+Wenzellauthor=D.+Kuzuoglu-Ozturkauthor=H.+Y.+Wangauthor=R.+Trenkerauthor=J.+M.+Youngauthor=D.+A.+Caveroauthor=J.+Hiattauthor=T.+L.+Rothauthor=U.+Rathoreauthor=A.+Subramanianauthor=J.+Noackauthor=M.+Hubertauthor=R.+M.+Stroudauthor=A.+D.+Frankelauthor=O.+S.+Rosenbergauthor=K.+A.+Verbaauthor=D.+A.+Agardauthor=M.+Ottauthor=M.+Emermanauthor=N.+Juraauthor=M.+von+Zastrowauthor=E.+Verdinauthor=A.+Ashworthauthor=O.+Schwartzauthor=C.+d%E2%80%99Enfertauthor=S.+Mukherjeeauthor=M.+Jacobsonauthor=H.+S.+Malikauthor=D.+G.+Fujimoriauthor=T.+Idekerauthor=C.+S.+Craikauthor=S.+N.+Floorauthor=J.+S.+Fraserauthor=J.+D.+Grossauthor=A.+Saliauthor=B.+L.+Rothauthor=D.+Ruggeroauthor=J.+Tauntonauthor=T.+Kortemmeauthor=P.+Beltraoauthor=M.+Vignuzziauthor=A.+Garc%C3%ADa-Sastreauthor=K.+M.+Shokatauthor=B.+K.+Shoichetauthor=N.+J.+Krogan&title=A+SARS-CoV-2+protein+interaction+map+reveals+targets+for+drug+repurposing&doi=10.1038%2Fs41586-020-2286-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">A SARS-CoV-2 protein interaction map reveals targets for drug repurposing</span></div><div class="casAuthors">Gordon, David E.; Jang, Gwendolyn M.; Bouhaddou, Mehdi; Xu, Jiewei; Obernier, Kirsten; White, Kris M.; O'Meara, Matthew J.; Rezelj, Veronica V.; Guo, Jeffrey Z.; Swaney, Danielle L.; Tummino, Tia A.; Huttenhain, Ruth; Kaake, Robyn M.; Richards, Alicia L.; Tutuncuoglu, Beril; Foussard, Helene; Batra, Jyoti; Haas, Kelsey; Modak, Maya; Kim, Minkyu; Haas, Paige; Polacco, Benjamin J.; Braberg, Hannes; Fabius, Jacqueline M.; Eckhardt, Manon; Soucheray, Margaret; Bennett, Melanie J.; Cakir, Merve; McGregor, Michael J.; Li, Qiongyu; Meyer, Bjoern; Roesch, Ferdinand; Vallet, Thomas; Mac Kain, Alice; Miorin, Lisa; Moreno, Elena; Naing, Zun Zar Chi; Zhou, Yuan; Peng, Shiming; Shi, Ying; Zhang, Ziyang; Shen, Wenqi; Kirby, Ilsa T.; Melnyk, James E.; Chorba, John S.; Lou, Kevin; Dai, Shizhong A.; Barrio-Hernandez, Inigo; Memon, Danish; Hernandez-Armenta, Claudia; Lyu, Jiankun; Mathy, Christopher J. P.; Perica, Tina; Pilla, Kala Bharath; Ganesan, Sai J.; Saltzberg, Daniel J.; Rakesh, Ramachandran; Liu, Xi; Rosenthal, Sara B.; Calviello, Lorenzo; Venkataramanan, Srivats; Liboy-Lugo, Jose; Lin, Yizhu; Huang, Xi-Ping; Liu, YongFeng; Wankowicz, Stephanie A.; Bohn, Markus; Safari, Maliheh; Ugur, Fatima S.; Koh, Cassandra; Savar, Nastaran Sadat; Tran, Quang Dinh; Shengjuler, Djoshkun; Fletcher, Sabrina J.; O'Neal, Michael C.; Cai, Yiming; Chang, Jason C. J.; Broadhurst, David J.; Klippsten, Saker; Sharp, Phillip P.; Wenzell, Nicole A.; Kuzuoglu-Ozturk, Duygu; Wang, Hao-Yuan; Trenker, Raphael; Young, Janet M.; Cavero, Devin A.; Hiatt, Joseph; Roth, Theodore L.; Rathore, Ujjwal; Subramanian, Advait; Noack, Julia; Hubert, Mathieu; Stroud, Robert M.; Frankel, Alan D.; Rosenberg, Oren S.; Verba, Kliment A.; Agard, David A.; Ott, Melanie; Emerman, Michael; Jura, Natalia; von Zastrow, Mark; Verdin, Eric; Ashworth, Alan; Schwartz, Olivier; d'Enfert, Christophe; Mukherjee, Shaeri; Jacobson, Matt; Malik, Harmit S.; Fujimori, Danica G.; Ideker, Trey; Craik, Charles S.; Floor, Stephen N.; Fraser, James S.; Gross, John D.; Sali, Andrej; Roth, Bryan L.; Ruggero, Davide; Taunton, Jack; Kortemme, Tanja; Beltrao, Pedro; Vignuzzi, Marco; Garcia-Sastre, Adolfo; Shokat, Kevan M.; Shoichet, Brian K.; Krogan, Nevan J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">583</span>
        (<span class="NLM_cas:issue">7816</span>),
    <span class="NLM_cas:pages">459-468</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Abstr.: A newly described coronavirus named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is the causative agent of coronavirus disease 2019 (COVID-19), has infected over 2.3 million people, led to the death of more than 160,000 individuals and caused worldwide social and economic disruption1,2.  There are no antiviral drugs with proven clin. efficacy for the treatment of COVID-19, nor are there any vaccines that prevent infection with SARS-CoV-2, and efforts to develop drugs and vaccines are hampered by the limited knowledge of the mol. details of how SARS-CoV-2 infects cells.  Here we cloned, tagged and expressed 26 of the 29 SARS-CoV-2 proteins in human cells and identified the human proteins that phys. assocd. with each of the SARS-CoV-2 proteins using affinity-purifn. mass spectrometry, identifying 332 high-confidence protein-protein interactions between SARS-CoV-2 and human proteins.  Among these, we identify 66 druggable human proteins or host factors targeted by 69 compds. (of which, 29 drugs are approved by the US Food and Drug Administration, 12 are in clin. trials and 28 are preclin. compds.).  We screened a subset of these in multiple viral assays and found two sets of pharmacol. agents that displayed antiviral activity: inhibitors of mRNA translation and predicted regulators of the sigma-1 and sigma-2 receptors.  Further studies of these host-factor-targeting agents, including their combination with drugs that directly target viral enzymes, could lead to a therapeutic regimen to treat COVID-19.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDvJUIvi-Ws7Vg90H21EOLACvtfcHk0lhWZzMa-N05Mg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtlCqtbrI&md5=ce8b172ae73aacd3b3d8bb64877f4435</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1038%2Fs41586-020-2286-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41586-020-2286-9%26sid%3Dliteratum%253Aachs%26aulast%3DGordon%26aufirst%3DD.%2BE.%26aulast%3DJang%26aufirst%3DG.%2BM.%26aulast%3DBouhaddou%26aufirst%3DM.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DObernier%26aufirst%3DK.%26aulast%3DWhite%26aufirst%3DK.%2BM.%26aulast%3DO%25E2%2580%2599Meara%26aufirst%3DM.%2BJ.%26aulast%3DRezelj%26aufirst%3DV.%2BV.%26aulast%3DGuo%26aufirst%3DJ.%2BZ.%26aulast%3DSwaney%26aufirst%3DD.%2BL.%26aulast%3DTummino%26aufirst%3DT.%2BA.%26aulast%3DH%25C3%25BCttenhain%26aufirst%3DR.%26aulast%3DKaake%26aufirst%3DR.%2BM.%26aulast%3DRichards%26aufirst%3DA.%2BL.%26aulast%3DTutuncuoglu%26aufirst%3DB.%26aulast%3DFoussard%26aufirst%3DH.%26aulast%3DBatra%26aufirst%3DJ.%26aulast%3DHaas%26aufirst%3DK.%26aulast%3DModak%26aufirst%3DM.%26aulast%3DKim%26aufirst%3DM.%26aulast%3DHaas%26aufirst%3DP.%26aulast%3DPolacco%26aufirst%3DB.%2BJ.%26aulast%3DBraberg%26aufirst%3DH.%26aulast%3DFabius%26aufirst%3DJ.%2BM.%26aulast%3DEckhardt%26aufirst%3DM.%26aulast%3DSoucheray%26aufirst%3DM.%26aulast%3DBennett%26aufirst%3DM.%2BJ.%26aulast%3DCakir%26aufirst%3DM.%26aulast%3DMcGregor%26aufirst%3DM.%2BJ.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DMeyer%26aufirst%3DB.%26aulast%3DRoesch%26aufirst%3DF.%26aulast%3DVallet%26aufirst%3DT.%26aulast%3DMac%2BKain%26aufirst%3DA.%26aulast%3DMiorin%26aufirst%3DL.%26aulast%3DMoreno%26aufirst%3DE.%26aulast%3DNaing%26aufirst%3DZ.%2BZ.%2BC.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DPeng%26aufirst%3DS.%26aulast%3DShi%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DShen%26aufirst%3DW.%26aulast%3DKirby%26aufirst%3DI.%2BT.%26aulast%3DMelnyk%26aufirst%3DJ.%2BE.%26aulast%3DChorba%26aufirst%3DJ.%2BS.%26aulast%3DLou%26aufirst%3DK.%26aulast%3DDai%26aufirst%3DS.%2BA.%26aulast%3DBarrio-Hernandez%26aufirst%3DI.%26aulast%3DMemon%26aufirst%3DD.%26aulast%3DHernandez-Armenta%26aufirst%3DC.%26aulast%3DLyu%26aufirst%3DJ.%26aulast%3DMathy%26aufirst%3DC.%2BJ.%2BP.%26aulast%3DPerica%26aufirst%3DT.%26aulast%3DPilla%26aufirst%3DK.%2BB.%26aulast%3DGanesan%26aufirst%3DS.%2BJ.%26aulast%3DSaltzberg%26aufirst%3DD.%2BJ.%26aulast%3DRakesh%26aufirst%3DR.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DRosenthal%26aufirst%3DS.%2BB.%26aulast%3DCalviello%26aufirst%3DL.%26aulast%3DVenkataramanan%26aufirst%3DS.%26aulast%3DLiboy-Lugo%26aufirst%3DJ.%26aulast%3DLin%26aufirst%3DY.%26aulast%3DHuang%26aufirst%3DX.%2BP.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DWankowicz%26aufirst%3DS.%2BA.%26aulast%3DBohn%26aufirst%3DM.%26aulast%3DSafari%26aufirst%3DM.%26aulast%3DUgur%26aufirst%3DF.%2BS.%26aulast%3DKoh%26aufirst%3DC.%26aulast%3DSavar%26aufirst%3DN.%2BS.%26aulast%3DTran%26aufirst%3DQ.%2BD.%26aulast%3DShengjuler%26aufirst%3DD.%26aulast%3DFletcher%26aufirst%3DS.%2BJ.%26aulast%3DO%25E2%2580%2599Neal%26aufirst%3DM.%2BC.%26aulast%3DCai%26aufirst%3DY.%26aulast%3DChang%26aufirst%3DJ.%2BC.%2BJ.%26aulast%3DBroadhurst%26aufirst%3DD.%2BJ.%26aulast%3DKlippsten%26aufirst%3DS.%26aulast%3DSharp%26aufirst%3DP.%2BP.%26aulast%3DWenzell%26aufirst%3DN.%2BA.%26aulast%3DKuzuoglu-Ozturk%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DH.%2BY.%26aulast%3DTrenker%26aufirst%3DR.%26aulast%3DYoung%26aufirst%3DJ.%2BM.%26aulast%3DCavero%26aufirst%3DD.%2BA.%26aulast%3DHiatt%26aufirst%3DJ.%26aulast%3DRoth%26aufirst%3DT.%2BL.%26aulast%3DRathore%26aufirst%3DU.%26aulast%3DSubramanian%26aufirst%3DA.%26aulast%3DNoack%26aufirst%3DJ.%26aulast%3DHubert%26aufirst%3DM.%26aulast%3DStroud%26aufirst%3DR.%2BM.%26aulast%3DFrankel%26aufirst%3DA.%2BD.%26aulast%3DRosenberg%26aufirst%3DO.%2BS.%26aulast%3DVerba%26aufirst%3DK.%2BA.%26aulast%3DAgard%26aufirst%3DD.%2BA.%26aulast%3DOtt%26aufirst%3DM.%26aulast%3DEmerman%26aufirst%3DM.%26aulast%3DJura%26aufirst%3DN.%26aulast%3Dvon%2BZastrow%26aufirst%3DM.%26aulast%3DVerdin%26aufirst%3DE.%26aulast%3DAshworth%26aufirst%3DA.%26aulast%3DSchwartz%26aufirst%3DO.%26aulast%3Dd%25E2%2580%2599Enfert%26aufirst%3DC.%26aulast%3DMukherjee%26aufirst%3DS.%26aulast%3DJacobson%26aufirst%3DM.%26aulast%3DMalik%26aufirst%3DH.%2BS.%26aulast%3DFujimori%26aufirst%3DD.%2BG.%26aulast%3DIdeker%26aufirst%3DT.%26aulast%3DCraik%26aufirst%3DC.%2BS.%26aulast%3DFloor%26aufirst%3DS.%2BN.%26aulast%3DFraser%26aufirst%3DJ.%2BS.%26aulast%3DGross%26aufirst%3DJ.%2BD.%26aulast%3DSali%26aufirst%3DA.%26aulast%3DRoth%26aufirst%3DB.%2BL.%26aulast%3DRuggero%26aufirst%3DD.%26aulast%3DTaunton%26aufirst%3DJ.%26aulast%3DKortemme%26aufirst%3DT.%26aulast%3DBeltrao%26aufirst%3DP.%26aulast%3DVignuzzi%26aufirst%3DM.%26aulast%3DGarc%25C3%25ADa-Sastre%26aufirst%3DA.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26aulast%3DShoichet%26aufirst%3DB.%2BK.%26aulast%3DKrogan%26aufirst%3DN.%2BJ.%26atitle%3DA%2520SARS-CoV-2%2520protein%2520interaction%2520map%2520reveals%2520targets%2520for%2520drug%2520repurposing%26jtitle%3DNature%26date%3D2020%26volume%3D583%26spage%3D459%26epage%3D468%26doi%3D10.1038%2Fs41586-020-2286-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vela, J. M.</span></span> <span> </span><span class="NLM_article-title">Repurposing Sigma-1 Receptor Ligands for COVID-19 Therapy?</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">582310</span>, <span class="refDoi"> DOI: 10.3389/fphar.2020.582310</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.3389%2Ffphar.2020.582310" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=33364957" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BB3MXjsl2isb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2020&pages=582310&author=J.+M.+Vela&title=Repurposing+Sigma-1+Receptor+Ligands+for+COVID-19+Therapy%3F&doi=10.3389%2Ffphar.2020.582310"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Repurposing sigma-1 receptor ligands for COVID-19 therapy?</span></div><div class="casAuthors">Vela, Jose Miguel</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Pharmacology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">582310</span>CODEN:
                <span class="NLM_cas:coden">FPRHAU</span>;
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">Outbreaks of emerging infections, such as COVID-19 pandemic esp., confront health professionals with the unique challenge of treating patients.  With no time to discover new drugs, repurposing of approved drugs or in clin. development is likely the only soln.  Replication of coronaviruses (CoVs) occurs in a modified membranous compartment derived from the endoplasmic reticulum (ER), causes host cell ER stress and activates pathways to facilitate adaptation of the host cell machinery to viral needs.  Accordingly, modulation of ER remodeling and ER stress response might be pivotal in elucidating CoVhost interactions and provide a rationale for new therapeutic, host-based antiviral approaches.  The sigma-1 receptor (Sig-1R) is a ligand-operated, ER membranebound chaperone that acts as an upstream modulator of ER stress and thus a candidate host protein for host-based repurposing approaches to treat COVID-19 patients.  Sig-1R ligands are frequently identified in in vitro drug repurposing screens aiming to identify antiviral compds. against CoVs, including severe acute respiratory syndrome CoV-2 (SARS-CoV-2).  Sig-1R regulates key mechanisms of the adaptive host cell stress response and takes part in early steps of viral replication.  It is enriched in lipid rafts and detergent-resistant ER membranes, where it colocalizes with viral replicase proteins.  Indeed, the non-structural SARS-CoV-2 protein Nsp6 interacts with Sig-1R.  The activity of Sig-1R ligands against COVID-19 remains to be specifically assessed in clin. trials.  This review provides a rationale for targeting Sig-1R as a host-based drug repurposing approach to treat COVID-19 patients.  Evidence gained using Sig-1R ligands in unbiased in vitro antiviral drug screens and the potential mechanisms underlying the modulatory effect of Sig-1R on the host cell response are discussed.  Targeting Sig-1R is not expected to reduce dramatically established viral replication, but it might interfere with early steps of virus-induced host cell reprogramming, aid to slow down the course of infection, prevent the aggravation of the disease and/or allow a time window to mature a protective immune response.  Sig-1R-based medicines could provide benefit not only as early intervention, preventive but also as adjuvant therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpah9yXKMk0xLVg90H21EOLACvtfcHk0lhWZzMa-N05Mg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3MXjsl2isb4%253D&md5=d1cd496f4e4deb2da04626d7de035c04</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2020.582310&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2020.582310%26sid%3Dliteratum%253Aachs%26aulast%3DVela%26aufirst%3DJ.%2BM.%26atitle%3DRepurposing%2520Sigma-1%2520Receptor%2520Ligands%2520for%2520COVID-19%2520Therapy%253F%26jtitle%3DFront.%2520Pharmacol.%26date%3D2020%26volume%3D11%26spage%3D582310%26doi%3D10.3389%2Ffphar.2020.582310" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alon, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sahn, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kruse, A. C.</span></span> <span> </span><span class="NLM_article-title">Identification of the gene that codes for the σ</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>114</i></span>,  <span class="NLM_fpage">7160</span>– <span class="NLM_lpage">7165</span>, <span class="refDoi"> DOI: 10.1073/pnas.1705154114</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1073%2Fpnas.1705154114" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=28559337" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BC2sXovVSisrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2017&pages=7160-7165&author=A.+Alonauthor=H.+R.+Schmidtauthor=M.+D.+Woodauthor=J.+J.+Sahnauthor=S.+F.+Martinauthor=A.+C.+Kruse&title=Identification+of+the+gene+that+codes+for+the+%CF%83&doi=10.1073%2Fpnas.1705154114"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of the gene that codes for the σ2 receptor</span></div><div class="casAuthors">Alon, Assaf; Schmidt, Hayden R.; Wood, Michael D.; Sahn, James J.; Martin, Stephen F.; Kruse, Andrew C.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">114</span>
        (<span class="NLM_cas:issue">27</span>),
    <span class="NLM_cas:pages">7160-7165</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The σ2 receptor is an enigmatic protein that has attracted significant attention because of its involvement in diseases as diverse as cancer and neurol. disorders.  Unlike virtually all other receptors of medical interest, it has eluded mol. cloning since its discovery, and the gene that codes for the receptor remains unknown, precluding the use of modern biol. methods to study its function.  Using a chem. biol. approach, we purified the σ2 receptor from tissue, revealing its identity as TMEM97, an endoplasmic reticulum-resident transmembrane protein that regulates the sterol transporter NPC1.  We show that TMEM97 possesses the full suite of mol. properties that define the σ2 receptor, and we identify Asp29 and Asp56 as essential for ligand recognition.  Cloning the σ2 receptor resolves a longstanding mystery and will enable therapeutic targeting of this potential drug target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqsoAS9Q6KtY7Vg90H21EOLACvtfcHk0liXCoNYzLQQdQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXovVSisrw%253D&md5=71d3c246ebe6ac84c33980b97cb9889c</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1705154114&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1705154114%26sid%3Dliteratum%253Aachs%26aulast%3DAlon%26aufirst%3DA.%26aulast%3DSchmidt%26aufirst%3DH.%2BR.%26aulast%3DWood%26aufirst%3DM.%2BD.%26aulast%3DSahn%26aufirst%3DJ.%2BJ.%26aulast%3DMartin%26aufirst%3DS.%2BF.%26aulast%3DKruse%26aufirst%3DA.%2BC.%26atitle%3DIdentification%2520of%2520the%2520gene%2520that%2520codes%2520for%2520the%2520%25CF%2583%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2017%26volume%3D114%26spage%3D7160%26epage%3D7165%26doi%3D10.1073%2Fpnas.1705154114" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rothfuss, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vangveravong, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnston, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spitzer, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hotchkiss, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hawkins, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wheeler, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mach, R. H.</span></span> <span> </span><span class="NLM_article-title">Identification of the PGRMC1 protein complex as the putative sigma-2 receptor binding site</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">380</span>, <span class="refDoi"> DOI: 10.1038/ncomms1386</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1038%2Fncomms1386" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=21730960" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A280%3ADC%252BC3MnlvVKgtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2011&pages=380&author=J.+Xuauthor=C.+Zengauthor=W.+Chuauthor=F.+Panauthor=J.+M.+Rothfussauthor=F.+Zhangauthor=Z.+Tuauthor=D.+Zhouauthor=D.+Zengauthor=S.+Vangveravongauthor=F.+Johnstonauthor=D.+Spitzerauthor=K.+C.+Changauthor=R.+S.+Hotchkissauthor=W.+G.+Hawkinsauthor=K.+T.+Wheelerauthor=R.+H.+Mach&title=Identification+of+the+PGRMC1+protein+complex+as+the+putative+sigma-2+receptor+binding+site&doi=10.1038%2Fncomms1386"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of the PGRMC1 protein complex as the putative sigma-2 receptor binding site</span></div><div class="casAuthors">Xu Jinbin; Zeng Chenbo; Chu Wenhua; Pan Fenghui; Rothfuss Justin M; Zhang Fanjie; Tu Zhude; Zhou Dong; Zeng Dexing; Vangveravong Suwanna; Johnston Fabian; Spitzer Dirk; Chang Katherine C; Hotchkiss Richard S; Hawkins William G; Wheeler Kenneth T; Mach Robert H</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">380</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The sigma-2 receptor, whose gene remains to be cloned, has been validated as a biomarker for tumour cell proliferation.  Here we report the use of a novel photoaffinity probe, WC-21, to identify the sigma-2 receptor-binding site.  WC-21, a sigma-2 ligand containing both a photoactive azide moiety and a fluorescein isothiocyanate group, irreversibly labels sigma-2 receptors in rat liver; the membrane-bound protein was identified as PGRMC1 (progesterone receptor membrane component 1).  Immunocytochemistry reveals that both PGRMC1 and SW120, a fluorescent sigma-2 receptor ligand, colocalize with molecular markers of the endoplasmic reticulum and mitochondria in HeLa cells.  Overexpression and knockdown of the PGRMC1 protein results in an increase and a decrease in binding of a sigma-2 selective radioligand, respectively.  The identification of the putative sigma-2 receptor-binding site as PGRMC1 should stimulate the development of unique imaging agents and cancer therapeutics that target the sigma-2 receptor/PGRMC1 complex.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRKpNfsa0DIvIJKJbLTgsvCfW6udTcc2eYZHXQKgNLhErntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3MnlvVKgtQ%253D%253D&md5=46675c07c87eccab091f8a8ec0f12db6</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1038%2Fncomms1386&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms1386%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DZeng%26aufirst%3DC.%26aulast%3DChu%26aufirst%3DW.%26aulast%3DPan%26aufirst%3DF.%26aulast%3DRothfuss%26aufirst%3DJ.%2BM.%26aulast%3DZhang%26aufirst%3DF.%26aulast%3DTu%26aufirst%3DZ.%26aulast%3DZhou%26aufirst%3DD.%26aulast%3DZeng%26aufirst%3DD.%26aulast%3DVangveravong%26aufirst%3DS.%26aulast%3DJohnston%26aufirst%3DF.%26aulast%3DSpitzer%26aufirst%3DD.%26aulast%3DChang%26aufirst%3DK.%2BC.%26aulast%3DHotchkiss%26aufirst%3DR.%2BS.%26aulast%3DHawkins%26aufirst%3DW.%2BG.%26aulast%3DWheeler%26aufirst%3DK.%2BT.%26aulast%3DMach%26aufirst%3DR.%2BH.%26atitle%3DIdentification%2520of%2520the%2520PGRMC1%2520protein%2520complex%2520as%2520the%2520putative%2520sigma-2%2520receptor%2520binding%2520site%26jtitle%3DNat.%2520Commun.%26date%3D2011%26volume%3D2%26spage%3D380%26doi%3D10.1038%2Fncomms1386" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Riad, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weng, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winters, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Makvandi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metz, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mach, R. H.</span></span> <span> </span><span class="NLM_article-title">Sigma-2 Receptor/TMEM97 and PGRMC-1 Increase the Rate of Internalization of LDL by LDL Receptor through the Formation of a Ternary Complex</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">16845</span>, <span class="refDoi"> DOI: 10.1038/s41598-018-35430-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1038%2Fs41598-018-35430-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=30443021" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A280%3ADC%252BB3crhsVKktg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2018&pages=16845&author=A.+Riadauthor=C.+Zengauthor=C.+C.+Wengauthor=H.+Wintersauthor=K.+Xuauthor=M.+Makvandiauthor=T.+Metzauthor=S.+Carlinauthor=R.+H.+Mach&title=Sigma-2+Receptor%2FTMEM97+and+PGRMC-1+Increase+the+Rate+of+Internalization+of+LDL+by+LDL+Receptor+through+the+Formation+of+a+Ternary+Complex&doi=10.1038%2Fs41598-018-35430-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Sigma-2 Receptor/TMEM97 and PGRMC-1 Increase the Rate of Internalization of LDL by LDL Receptor through the Formation of a Ternary Complex</span></div><div class="casAuthors">Riad Aladdin; Zeng Chenbo; Weng Chi-Chang; Winters Harrison; Xu Kuiying; Makvandi Mehran; Metz Tyler; Carlin Sean; Mach Robert H</div><div class="citationInfo"><span class="NLM_cas:title">Scientific reports</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">16845</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">CRISPR/Cas gene studies were conducted in HeLa cells where either PGRMC1, TMEM97 or both proteins were removed via gene editing.  A series of radioligand binding studies, confocal microscopy studies, and internalization of radiolabeled or fluorescently tagged LDL particles were then conducted in these cells.  The results indicate that PGRMC1 knockout (KO) did not reduce the density of binding sites for the sigma-2 receptor (σ2R) radioligands, [(125)I]RHM-4 or [(3)H]DTG, but a reduction in the receptor affinity of both radioligands was observed.  TMEM97 KO resulted in a complete loss of binding of [(125)I]RHM-4 and a significant reduction in binding of [(3)H]DTG.  TMEM97 KO and PGRMC1 KO resulted in an equal reduction in the rate of uptake of fluorescently-tagged or (3)H-labeled LDL, and knocking out both proteins did not result in a further rate of reduction of LDL uptake.  Confocal microscopy and Proximity Ligation Assay studies indicated a clear co-localization of LDLR, PGRMC1 and TMEM97.  These data indicate that the formation of a ternary complex of LDLR-PGRMC1-TMEM97 is necessary for the rapid internalization of LDL by LDLR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTJbdh-iRrqnedfST00W0BcfW6udTcc2eYZHXQKgNLhErntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3crhsVKktg%253D%253D&md5=b042e5184b567292abe352343f434486</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1038%2Fs41598-018-35430-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41598-018-35430-3%26sid%3Dliteratum%253Aachs%26aulast%3DRiad%26aufirst%3DA.%26aulast%3DZeng%26aufirst%3DC.%26aulast%3DWeng%26aufirst%3DC.%2BC.%26aulast%3DWinters%26aufirst%3DH.%26aulast%3DXu%26aufirst%3DK.%26aulast%3DMakvandi%26aufirst%3DM.%26aulast%3DMetz%26aufirst%3DT.%26aulast%3DCarlin%26aufirst%3DS.%26aulast%3DMach%26aufirst%3DR.%2BH.%26atitle%3DSigma-2%2520Receptor%252FTMEM97%2520and%2520PGRMC-1%2520Increase%2520the%2520Rate%2520of%2520Internalization%2520of%2520LDL%2520by%2520LDL%2520Receptor%2520through%2520the%2520Formation%2520of%2520a%2520Ternary%2520Complex%26jtitle%3DSci.%2520Rep.%26date%3D2018%26volume%3D8%26spage%3D16845%26doi%3D10.1038%2Fs41598-018-35430-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kargbo, R. B.</span></span> <span> </span><span class="NLM_article-title">Sigma-1 and Sigma-2 Receptor Modulators as Potential Therapeutics for Alzheimer’s Disease</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2021</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">178</span>– <span class="NLM_lpage">179</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.1c00002</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.1c00002" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BB3MXhvVWrs7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2021&pages=178-179&author=R.+B.+Kargbo&title=Sigma-1+and+Sigma-2+Receptor+Modulators+as+Potential+Therapeutics+for+Alzheimer%E2%80%99s+Disease&doi=10.1021%2Facsmedchemlett.1c00002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Sigma-1 and Sigma-2 Receptor Modulators as Potential Therapeutics for Alzheimer's Disease</span></div><div class="casAuthors">Kargbo, Robert B.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2021</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">178-179</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKheuSFPPDoLVg90H21EOLACvtfcHk0ljXj54D_wlciw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3MXhvVWrs7o%253D&md5=6c751a49db3193a37628ffa4acc81726</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.1c00002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.1c00002%26sid%3Dliteratum%253Aachs%26aulast%3DKargbo%26aufirst%3DR.%2BB.%26atitle%3DSigma-1%2520and%2520Sigma-2%2520Receptor%2520Modulators%2520as%2520Potential%2520Therapeutics%2520for%2520Alzheimer%25E2%2580%2599s%2520Disease%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2021%26volume%3D12%26spage%3D178%26epage%3D179%26doi%3D10.1021%2Facsmedchemlett.1c00002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sánchez-Blázquez, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortés-Montero, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodríguez-Muñoz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merlos, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garzón-Niño, J.</span></span> <span> </span><span class="NLM_article-title">The Sigma 2 receptor promotes and the Sigma 1 receptor inhibits mu-opioid receptor-mediated antinociception</span>. <i>Mol. Brain</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">150</span>, <span class="refDoi"> DOI: 10.1186/s13041-020-00676-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1186%2Fs13041-020-00676-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=33176836" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BB3cXitlygtL3K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2020&pages=150&author=P.+S%C3%A1nchez-Bl%C3%A1zquezauthor=E.+Cort%C3%A9s-Monteroauthor=M.+Rodr%C3%ADguez-Mu%C3%B1ozauthor=M.+Merlosauthor=J.+Garz%C3%B3n-Ni%C3%B1o&title=The+Sigma+2+receptor+promotes+and+the+Sigma+1+receptor+inhibits+mu-opioid+receptor-mediated+antinociception&doi=10.1186%2Fs13041-020-00676-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">The Sigma 2 receptor promotes and the Sigma 1 receptor inhibits mu-opioid receptor-mediated antinociception</span></div><div class="casAuthors">Sanchez-Blazquez, Pilar; Cortes-Montero, Elsa; Rodriguez-Munoz, Maria; Merlos, Manuel; Garzon-Nino, Javier</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Brain</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">150</span>CODEN:
                <span class="NLM_cas:coden">MBORAO</span>;
        ISSN:<span class="NLM_cas:issn">1756-6606</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">The Sigma-1 receptor (σ1R) has emerged as an interesting pharmacol. target because it inhibits analgesia mediated by mu-opioid receptors (MOR), and also facilitates the development of neuropathic pain.  Based on these findings, the recent cloning of the Sigma-2 receptor (σ2R) led us to investigate its potential role as a regulator of opioid analgesia and of pain hypersensitivity in σ2R knockout mice.  In contrast to σ1R deficient mice, σ2R knockout mice developed mech. allodynia following establishment of chronic constriction injury-induced neuropathic pain, which was alleviated by the σ1R antagonist S1RA.  The analgesic effects of morphine, [D-Ala, N-MePhe, Gly-ol]-encephalin (DAMGO) and β-endorphin increased in σ1R-/- mice and diminished in σ2R-/- mice.  The analgesic effect of morphine was increased in σ2R-/- mice by treatment with S1RA.  However, σ2R-/- mice and wild-type mice exhibited comparable antinociceptive responses to the delta receptor agonist [D-Pen2,5]-encephalin (DPDPE), the cannabinoid type 1 receptor agonist WIN55,212-2 and the α2-adrenergic receptor agonist clonidine.  Therefore, while σR1 inhibits and σ2R facilitates MOR-mediated analgesia these receptors exchange their roles when regulating neuropathic pain perception.  Our study may help identify new pharmacol. targets for diminishing pain perception and improving opioid detoxification therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2GokgU9eshrVg90H21EOLACvtfcHk0ljXj54D_wlciw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXitlygtL3K&md5=bcbcb76385f92a3b398a005bc12600d4</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1186%2Fs13041-020-00676-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13041-020-00676-4%26sid%3Dliteratum%253Aachs%26aulast%3DS%25C3%25A1nchez-Bl%25C3%25A1zquez%26aufirst%3DP.%26aulast%3DCort%25C3%25A9s-Montero%26aufirst%3DE.%26aulast%3DRodr%25C3%25ADguez-Mu%25C3%25B1oz%26aufirst%3DM.%26aulast%3DMerlos%26aufirst%3DM.%26aulast%3DGarz%25C3%25B3n-Ni%25C3%25B1o%26aufirst%3DJ.%26atitle%3DThe%2520Sigma%25202%2520receptor%2520promotes%2520and%2520the%2520Sigma%25201%2520receptor%2520inhibits%2520mu-opioid%2520receptor-mediated%2520antinociception%26jtitle%3DMol.%2520Brain%26date%3D2020%26volume%3D13%26spage%3D150%26doi%3D10.1186%2Fs13041-020-00676-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schmit, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michiels, C.</span></span> <span> </span><span class="NLM_article-title">TMEM Proteins in Cancer: A Review</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1345</span>, <span class="refDoi"> DOI: 10.3389/fphar.2018.01345</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.3389%2Ffphar.2018.01345" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=30574087" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BC1MXht1OlurvF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=1345&author=K.+Schmitauthor=C.+Michiels&title=TMEM+Proteins+in+Cancer%3A+A+Review&doi=10.3389%2Ffphar.2018.01345"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">TMEM proteins in cancer: a review</span></div><div class="casAuthors">Schmit, Kathleen; Michiels, Carine</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Pharmacology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1345</span>CODEN:
                <span class="NLM_cas:coden">FPRHAU</span>;
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">A review.  A transmembrane protein (TMEM) is a type of protein that spans biol. membranes.  Many of them extend through the lipid bilayer of the plasma membrane but others are located to the membrane of organelles.  The TMEM family gathers proteins of mostly unknown functions.  Many studies showed that TMEM expression can be down- or up-regulated in tumor tissues compared to adjacent healthy tissues.  Indeed, some TMEMs such as TMEM48 or TMEM97 are defined as potential prognostic biomarkers for lung cancer.  Furthermore, exptl. evidence suggests that TMEM proteins can be described as tumor suppressors or oncogenes.  TMEMs, such as TMEM45A and TMEM205, have also been implicated in tumor progression and invasion but also in chemoresistance.  Thus, a better characterization of these proteins could help to better understand their implication in cancer and to allow the development of improved therapy strategies in the future.  This review gives an overview of the implication of TMEM proteins in cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQ4DXcuh3IG7Vg90H21EOLACvtfcHk0ljXj54D_wlciw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXht1OlurvF&md5=a7b274b43919962695b219cba0ef6ea9</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2018.01345&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2018.01345%26sid%3Dliteratum%253Aachs%26aulast%3DSchmit%26aufirst%3DK.%26aulast%3DMichiels%26aufirst%3DC.%26atitle%3DTMEM%2520Proteins%2520in%2520Cancer%253A%2520A%2520Review%26jtitle%3DFront.%2520Pharmacol.%26date%3D2018%26volume%3D9%26spage%3D1345%26doi%3D10.3389%2Ffphar.2018.01345" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vilner, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">John, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowen, W. D.</span></span> <span> </span><span class="NLM_article-title">Sigma-1 and sigma-2 receptors are expressed in a wide variety of human and rodent tumor cell lines</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">408</span>– <span class="NLM_lpage">413</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=7812973" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADyaK2MXjtFyjtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=1995&pages=408-413&author=B.+J.+Vilnerauthor=C.+S.+Johnauthor=W.+D.+Bowen&title=Sigma-1+and+sigma-2+receptors+are+expressed+in+a+wide+variety+of+human+and+rodent+tumor+cell+lines"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Sigma-1 and sigma-2 receptors are expressed in a wide variety of human and rodent tumor cell lines</span></div><div class="casAuthors">Vilner, Bertold J.; John, Christy S.; Bowen, Wayne D.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">408-13</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Thirteen tumor-derived cell lines of human and nonhuman origin and from various tissues were examd. for the presence and d. of sigma-1 and sigma-2 receptors.  Sigma-1 receptors of a crude membrane fraction were labeled using [3H](+)-pentazocine, and sigma-2 receptors were labeled with [3H]1,3-di-o-tolylguanidine ([3H]DTG); in the presence or absence of dextrallorphan.  [3H](+)-Pentazocine-binding sites were heterogeneous.  In rodent cell lines (e.g., C6 glioma, NIE-115 neuroblastoma, and NG108-15 neuroblastoma × glioma hybrid), human T47D breast ductal carcinoma, human NCI-H727 lung carcinoid, and human A375 melanoma, [3H](+)-pentazocine bound to high- and low-affinity sites with Kd1 = 0.67-7.0 nM, Bmax 1 = 25.5-108 fmol/mg protein, Kd2 = 127-600 nM, and Bmax2 = 942-5431 fmol/mg protein.  However, [3H](+)-pentazocine bound to a single site in other cell lines.  In human U-138MG glioblastoma, SK-N-sh neuroblastoma, and LNCaP.FGC prostate, Kd=28-61nM and Bmax-1411 fmol/mg protein.  The sigma-1-like nature of [3H](+)-pentazocine-binding sites was confirmed by competition studies which revealed high affinity for haloperidol and enantioselectivity for (+)-pentazocine over (-)-pentazocine.  Interestingly, human MCF-7 breast adenocarcinoma showed little or no specific binding of [3H](+)-pentazocine, suggesting the absence of sigma-1 receptors in this cell line.  All cell lines examd. expressed a high d. of sigma-2 receptors with Kd values for [3H]DTG ranging from 20 to 101 nM and Bmax values of 491 to 7324 fmol/mg protein.  Competition studies indicated possible heterogeneity of sigma-2 receptors.  While sites labeled by [3H]DTG in all cell lines tested exhibited affinity for haloperidol and approx. 10-fold lower affinity for (-)-pentazocine compared with the rodent cell lines.  The high d. of sigma-1 and sigma-2 binding sites in these cell lines suggests important cellular functions in cancer, as well as potential diagnostic utility for tumor-imaging agents which target sigma sites.  These cell lines may be useful as model systems in which to study the functions of sigma sites in normal tissues, as well as their possible role in tumor biol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomx5dT2-5Hz7Vg90H21EOLACvtfcHk0lh4sgfnhr26sA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXjtFyjtr8%253D&md5=80276a71555fdb08d76ae39b73d1cbe1</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DVilner%26aufirst%3DB.%2BJ.%26aulast%3DJohn%26aufirst%3DC.%2BS.%26aulast%3DBowen%26aufirst%3DW.%2BD.%26atitle%3DSigma-1%2520and%2520sigma-2%2520receptors%2520are%2520expressed%2520in%2520a%2520wide%2520variety%2520of%2520human%2520and%2520rodent%2520tumor%2520cell%2520lines%26jtitle%3DCancer%2520Res.%26date%3D1995%26volume%3D55%26spage%3D408%26epage%3D413" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Collina, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bignardi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rui, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rossi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaggeri, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zamagni, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortesi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tesei, A.</span></span> <span> </span><span class="NLM_article-title">Are sigma modulators an effective opportunity for cancer treatment? A patent overview (1996–2016)</span>. <i>Expert Opin. Ther. Pat.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">565</span>– <span class="NLM_lpage">578</span>, <span class="refDoi"> DOI: 10.1080/13543776.2017.1276569</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1080%2F13543776.2017.1276569" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=28051882" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BC2sXpsFOjtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2017&pages=565-578&author=S.+Collinaauthor=E.+Bignardiauthor=M.+Ruiauthor=D.+Rossiauthor=R.+Gaggeriauthor=A.+Zamagniauthor=M.+Cortesiauthor=A.+Tesei&title=Are+sigma+modulators+an+effective+opportunity+for+cancer+treatment%3F+A+patent+overview+%281996%E2%80%932016%29&doi=10.1080%2F13543776.2017.1276569"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Are sigma modulators an effective opportunity for cancer treatment? A patent overview (1996-2016)</span></div><div class="casAuthors">Collina, Simona; Bignardi, Emanuele; Rui, Marta; Rossi, Daniela; Gaggeri, Raffaella; Zamagni, Alice; Cortesi, Michela; Tesei, Anna</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">565-578</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Although several mol. targets against cancer have been identified, there is a continuous need for new therapeutic strategies.  Sigma Receptors (SRs) overexpression has been recently assocd. with different cancer conditions.  Therefore, novel anticancer agents targeting SRs may increase the specificity of therapies, overcoming some of the common drawbacks of conventional chemotherapy.  The present review focuses on patent documents disclosing SR modulators with possible application in cancer therapy and diagnosis.  The anal. reviews patents of the last two decades (1996-2016); patents were grouped according to target subtypes (S1R, S2R, pan-SRs) and relevant Applicants.  The literature was searched through Espacenet, ISI Web, PatentScope and PubMed databases.  The no. of patents related to SRs and cancer has increased in the last twenty years, confirming the importance of this receptor family as valuable target against neoplasias.  Despite their short history in the cancer scenario, many SR modulators are at pre-clin. stage and one is undergoing a phase II clin. trial.  SRs ligands may represent a powerful source of innovative antitumor therapeutics.  Further investigation is needed for validating SR modulators as anti-cancer drugs.  We strongly hope that this review could stimulate the interest of both Academia and pharmaceutical companies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqcMac8vpx9c7Vg90H21EOLACvtfcHk0lh4sgfnhr26sA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXpsFOjtg%253D%253D&md5=081e1a949ad2185865e73ff32955ce29</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1080%2F13543776.2017.1276569&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F13543776.2017.1276569%26sid%3Dliteratum%253Aachs%26aulast%3DCollina%26aufirst%3DS.%26aulast%3DBignardi%26aufirst%3DE.%26aulast%3DRui%26aufirst%3DM.%26aulast%3DRossi%26aufirst%3DD.%26aulast%3DGaggeri%26aufirst%3DR.%26aulast%3DZamagni%26aufirst%3DA.%26aulast%3DCortesi%26aufirst%3DM.%26aulast%3DTesei%26aufirst%3DA.%26atitle%3DAre%2520sigma%2520modulators%2520an%2520effective%2520opportunity%2520for%2520cancer%2520treatment%253F%2520A%2520patent%2520overview%2520%25281996%25E2%2580%25932016%2529%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2017%26volume%3D27%26spage%3D565%26epage%3D578%26doi%3D10.1080%2F13543776.2017.1276569" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Georgiadis, M. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karoutzou, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foscolos, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papanastasiou, I.</span></span> <span> </span><span class="NLM_article-title">Sigma Receptor (σR) Ligands with Antiproliferative and Anticancer Activity</span>. <i>Molecules</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">1408</span>, <span class="refDoi"> DOI: 10.3390/molecules22091408</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.3390%2Fmolecules22091408" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhslWgt73J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2017&pages=1408&author=M.+O.+Georgiadisauthor=O.+Karoutzouauthor=A.+S.+Foscolosauthor=I.+Papanastasiou&title=Sigma+Receptor+%28%CF%83R%29+Ligands+with+Antiproliferative+and+Anticancer+Activity&doi=10.3390%2Fmolecules22091408"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Sigma receptor (σR) ligands with antiproliferative and anticancer activity</span></div><div class="casAuthors">Georgiadis, Markos-Orestis; Karoutzou, Olga; Foscolos, Angeliki-Sofia; Papanastasiou, Ioannis</div><div class="citationInfo"><span class="NLM_cas:title">Molecules</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1408/1-1408/18</span>CODEN:
                <span class="NLM_cas:coden">MOLEFW</span>;
        ISSN:<span class="NLM_cas:issn">1420-3049</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Sigma receptor (σR) ligands have proven to be useful as cancer diagnostics and anticancer therapeutics and their ligands have been developed as mol. probes in oncol.  Moreover, various σR ligands generate cancer cell death in vitro and in vivo.  These σR ligands have exhibited promising results against numerous human and rodent cancers and are investigated under preclin. and clin. study trials, indicating a new category of drugs in cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomgqdswubm2LVg90H21EOLACvtfcHk0lh4sgfnhr26sA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhslWgt73J&md5=9a651a3d8f09047f6685eea198b3a9fe</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.3390%2Fmolecules22091408&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmolecules22091408%26sid%3Dliteratum%253Aachs%26aulast%3DGeorgiadis%26aufirst%3DM.%2BO.%26aulast%3DKaroutzou%26aufirst%3DO.%26aulast%3DFoscolos%26aufirst%3DA.%2BS.%26aulast%3DPapanastasiou%26aufirst%3DI.%26atitle%3DSigma%2520Receptor%2520%2528%25CF%2583R%2529%2520Ligands%2520with%2520Antiproliferative%2520and%2520Anticancer%2520Activity%26jtitle%3DMolecules%26date%3D2017%26volume%3D22%26spage%3D1408%26doi%3D10.3390%2Fmolecules22091408" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Berardi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abate, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferorelli, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Robertis, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leopoldo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colabufo, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niso, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perrone, R.</span></span> <span> </span><span class="NLM_article-title">Novel 4-(4-aryl)cyclohexyl-1-(2-pyridyl)piperazines as Delta(8)-Delta(7) sterol isomerase (emopamil binding protein) selective ligands with antiproliferative activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">7523</span>– <span class="NLM_lpage">7531</span>, <span class="refDoi"> DOI: 10.1021/jm800965b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm800965b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVWks77N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=7523-7531&author=F.+Berardiauthor=C.+Abateauthor=S.+Ferorelliauthor=A.+F.+de+Robertisauthor=M.+Leopoldoauthor=N.+A.+Colabufoauthor=M.+Nisoauthor=R.+Perrone&title=Novel+4-%284-aryl%29cyclohexyl-1-%282-pyridyl%29piperazines+as+Delta%288%29-Delta%287%29+sterol+isomerase+%28emopamil+binding+protein%29+selective+ligands+with+antiproliferative+activity&doi=10.1021%2Fjm800965b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Novel 4-(4-Aryl)cyclohexyl-1-(2-pyridyl)piperazines as Δ8-Δ7 Sterol Isomerase (Emopamil Binding Protein) Selective Ligands with Antiproliferative Activity</span></div><div class="casAuthors">Berardi, Francesco; Abate, Carmen; Ferorelli, Savina; de Robertis, Anna F.; Leopoldo, Marcello; Colabufo, Nicola A.; Niso, Mauro; Perrone, Roberto</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">7523-7531</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">To find Δ8-Δ7 sterol isomerase (EBP) selective ligands, various arylpiperazines previously studied and structurally related to some σ receptors ligands were preliminarily screened.  Consequently, a novel series of 2- or 2,6-disubstituted (CH3, CH3O, Cl, F) cis- and trans-4-(4-aryl)cyclohexyl-1-(2-pyridyl)piperazines was developed.  Radioreceptor binding assays evidenced cis-19, cis-30 and cis-33 as new ligands with nanomolar affinity toward EBP site and a good selectivity relative to EBP-related σ receptors.  The most selective 2,6-dimethoxy deriv. (cis-33) demonstrated the highest potency (EC50 = 12.9 μM) and efficacy (70%) in inhibiting proliferation of human prostate cancer PC-3 cell line.  Among the ref. compds., σ2 agonist 36 (PB28) reached the max. efficacy (100%), suggesting the contribution of the σ2 receptor to the antiproliferative activity.  This novel class of EBP inhibitors represents a valuable tool for investigating the last steps of cholesterol biosynthesis and related pathologies, as well as a starting point for developing new anticancer drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqM-0fpVS1nMLVg90H21EOLACvtfcHk0lh4sgfnhr26sA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVWks77N&md5=4f65b6b9418fa3a6dff7d9400017d7a1</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1021%2Fjm800965b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm800965b%26sid%3Dliteratum%253Aachs%26aulast%3DBerardi%26aufirst%3DF.%26aulast%3DAbate%26aufirst%3DC.%26aulast%3DFerorelli%26aufirst%3DS.%26aulast%3Dde%2BRobertis%26aufirst%3DA.%2BF.%26aulast%3DLeopoldo%26aufirst%3DM.%26aulast%3DColabufo%26aufirst%3DN.%2BA.%26aulast%3DNiso%26aufirst%3DM.%26aulast%3DPerrone%26aufirst%3DR.%26atitle%3DNovel%25204-%25284-aryl%2529cyclohexyl-1-%25282-pyridyl%2529piperazines%2520as%2520Delta%25288%2529-Delta%25287%2529%2520sterol%2520isomerase%2520%2528emopamil%2520binding%2520protein%2529%2520selective%2520ligands%2520with%2520antiproliferative%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D7523%26epage%3D7531%26doi%3D10.1021%2Fjm800965b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pati, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hornick, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niso, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berardi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spitzer, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abate, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hawkins, W.</span></span> <span> </span><span class="NLM_article-title">Sigma-2 receptor agonist derivatives of 1-Cyclohexyl-4-[3-(5-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)propyl]piperazine (PB28) induce cell death via mitochondrial superoxide production and caspase activation in pancreatic cancer</span>. <i>BMC Cancer</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">51</span>, <span class="refDoi"> DOI: 10.1186/s12885-016-3040-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1186%2Fs12885-016-3040-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=28086830" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BC1cXjs12mtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2017&pages=51&author=M.+L.+Patiauthor=J.+R.+Hornickauthor=M.+Nisoauthor=F.+Berardiauthor=D.+Spitzerauthor=C.+Abateauthor=W.+Hawkins&title=Sigma-2+receptor+agonist+derivatives+of+1-Cyclohexyl-4-%5B3-%285-methoxy-1%2C2%2C3%2C4-tetrahydronaphthalen-1-yl%29propyl%5Dpiperazine+%28PB28%29+induce+cell+death+via+mitochondrial+superoxide+production+and+caspase+activation+in+pancreatic+cancer&doi=10.1186%2Fs12885-016-3040-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Sigma-2 receptor agonist derivatives of 1-Cyclohexyl-4-[3-(5-methoxy-1,2,3,4- tetrahydronaphthalen-1-yl)propyl]piperazine (PB28) induce cell death via mitochondrial superoxide production and caspase activation in pancreatic cancer</span></div><div class="casAuthors">Pati, Maria Laura; Hornick, John R.; Niso, Mauro; Berardi, Francesco; Spitzer, Dirk; Abate, Carmen; Hawkins, William</div><div class="citationInfo"><span class="NLM_cas:title">BMC Cancer</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">51/1-51/12</span>CODEN:
                <span class="NLM_cas:coden">BCMACL</span>;
        ISSN:<span class="NLM_cas:issn">1471-2407</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Despite considerable efforts by scientific research, pancreatic cancer is the fourth leading cause of cancer related mortalities.  Sigma-2 receptors, which are overexpressed in several tumors, represent promising targets for triggering selective pancreatic cancer cells death.  We selected five differently structured high-affinity sigma-2 ligands (PB28, PB183, PB221, F281 and PB282) to study how they affect the viability of diverse pancreatic cancer cells (human cell lines BxPC3, AsPC1, Mia PaCa-2, and Panc1 and mouse Panc-02, KCKO and KP-02) and how this is reflected in vivo in a tumor model.  Important cytotoxicity was shown by the compds. in the aggressive Panc02 cells, where cytotoxic activity was caspase-3 independent for four of the five compds.  However, both cytotoxicity and caspase-3 activation involved generation of Reactive Oxygen Species (ROS), which could be partially reverted by the lipid antioxidant a-tocopherol, but not by the hydrophilic N-acetylcysteine (NAC) indicating crucial differences in the intracellular sites exposed to oxidative stress induced by sigma-2 receptor ligands.  Importantly, all the compds. strongly increased the prodn. of mitochondrial superoxide radicals except for PB282.  Despite a poor match between in vitro and the in vivo efficacy, daily treatment of C57BL/6 mice bearing Panc02 tumors resulted in promising effects with PB28 and PB282 which were similar compared to the current std.-of-care chemotherapeutic gemcitabine without showing signs of systemic toxicities.  Overall, this study identified differential sensitivities of pancreatic cancer cells to structurally diverse sigma-2 receptor ligands.  Of note, we identified the mitochondrial superoxide pathway as a previously unrecognized sigma-2 receptor-activated process, which encourages further studies on sigma-2 ligand-mediated cancer cell death for the targeted treatment of pancreatic tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokTrvVNhfXn7Vg90H21EOLACvtfcHk0lg15QRvM52zvA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXjs12mtbo%253D&md5=f8dce42ee93876e672a4d0705d8dc890</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1186%2Fs12885-016-3040-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12885-016-3040-4%26sid%3Dliteratum%253Aachs%26aulast%3DPati%26aufirst%3DM.%2BL.%26aulast%3DHornick%26aufirst%3DJ.%2BR.%26aulast%3DNiso%26aufirst%3DM.%26aulast%3DBerardi%26aufirst%3DF.%26aulast%3DSpitzer%26aufirst%3DD.%26aulast%3DAbate%26aufirst%3DC.%26aulast%3DHawkins%26aufirst%3DW.%26atitle%3DSigma-2%2520receptor%2520agonist%2520derivatives%2520of%25201-Cyclohexyl-4-%255B3-%25285-methoxy-1%252C2%252C3%252C4-tetrahydronaphthalen-1-yl%2529propyl%255Dpiperazine%2520%2528PB28%2529%2520induce%2520cell%2520death%2520via%2520mitochondrial%2520superoxide%2520production%2520and%2520caspase%2520activation%2520in%2520pancreatic%2520cancer%26jtitle%3DBMC%2520Cancer%26date%3D2017%26volume%3D17%26spage%3D51%26doi%3D10.1186%2Fs12885-016-3040-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weng, C.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puentes, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riad, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Makvandi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hawkins, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mach, R. H.</span></span> <span> </span><span class="NLM_article-title">TMEM97 and PGRMC1 do not mediate sigma-2 ligand-induced cell death</span>. <i>Cell Death Discovery</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">58</span>, <span class="refDoi"> DOI: 10.1038/s41420-019-0141-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1038%2Fs41420-019-0141-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=30701090" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A280%3ADC%252BB3cjntF2jtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2019&pages=58&author=C.+Zengauthor=C.-C.+Wengauthor=M.+E.+Schneiderauthor=L.+Puentesauthor=A.+Riadauthor=K.+Xuauthor=M.+Makvandiauthor=L.+Jinauthor=W.+G.+Hawkinsauthor=R.+H.+Mach&title=TMEM97+and+PGRMC1+do+not+mediate+sigma-2+ligand-induced+cell+death&doi=10.1038%2Fs41420-019-0141-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">TMEM97 and PGRMC1 do not mediate sigma-2 ligand-induced cell death</span></div><div class="casAuthors">Zeng Chenbo; Weng Chi-Chang; Schneider Mark E Jr; Puentes Laura; Riad Aladdin; Xu Kuiying; Makvandi Mehran; Mach Robert H; Jin Linda; Hawkins William G</div><div class="citationInfo"><span class="NLM_cas:title">Cell death discovery</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">58</span>
        ISSN:<span class="NLM_cas:issn">2058-7716</span>.
    </div><div class="casAbstract">Sigma-2 receptors have been implicated in both tumor proliferation and neurodegenerative diseases.  Recently the sigma-2 receptor was identified as transmembrane protein 97 (TMEM97).  Progesterone receptor membrane component 1 (PGRMC1) was also recently reported to form a complex with TMEM97 and the low density lipoprotein (LDL) receptor, and this trimeric complex is responsible for the rapid internalization of LDL.  Sigma-2 receptor ligands with various structures have been shown to induce cell death in cancer cells.  In the current study, we examined the role of TMEM97 and PGRMC1 in mediating sigma-2 ligand-induced cell death.  Cell viability and caspase-3 assays were performed in control, TMEM97 knockout (KO), PGRMC1 KO, and TMEM97/PGRMC1 double KO cell lines treated with several sigma-2 ligands.  The data showed that knockout of TMEM97, PGRMC1, or both did not affect the concentrations of sigma-2 ligands that induced 50% of cell death (EC50), suggesting that cytotoxic effects of these compounds are not mediated by TMEM97 or PGRMC1.  Sigma-1 receptor ligands, (+)-pentazocine and NE-100, did not block sigma-2 ligand cytotoxicity, suggesting that sigma-1 receptor was not responsible for sigma-2 ligand cytotoxicity.  We also examined whether the alternative, residual binding site (RBS) of 1,3-Di-o-tolylguanidine (DTG) could be responsible for sigma-2 ligand cytotoxicity.  Our data showed that the binding affinities (Ki) of sigma-2 ligands on the DTG RBS did not correlate with the cytotoxicity potency (EC50) of these ligands, suggesting that the DTG RBS was not fully responsible for sigma-2 ligand cytotoxicity.  In addition, we showed that knocking out TMEM97, PGRMC1, or both reduced the initial internalization rate of a sigma-2 fluorescent ligand, SW120.  However, concentrations of internalized SW120 became identical later in the control and knockout cells.  These data suggest that the initial internalization process of sigma-2 ligands does not appear to mediate the cell-killing effect of sigma-2 ligands.  In summary, we have provided evidence that sigma-2 receptor/TMEM97 and PGRMC1 do not mediate sigma-2 ligand cytotoxicity.  Our work will facilitate elucidating mechanisms of sigma-2 ligand cytotoxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRfU8tat7Clh0EksK8CslK8fW6udTcc2ebfcrsN-mlrtrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cjntF2jtA%253D%253D&md5=72af79dc6b0bc2995f8be565d15e1a7f</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1038%2Fs41420-019-0141-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41420-019-0141-2%26sid%3Dliteratum%253Aachs%26aulast%3DZeng%26aufirst%3DC.%26aulast%3DWeng%26aufirst%3DC.-C.%26aulast%3DSchneider%26aufirst%3DM.%2BE.%26aulast%3DPuentes%26aufirst%3DL.%26aulast%3DRiad%26aufirst%3DA.%26aulast%3DXu%26aufirst%3DK.%26aulast%3DMakvandi%26aufirst%3DM.%26aulast%3DJin%26aufirst%3DL.%26aulast%3DHawkins%26aufirst%3DW.%2BG.%26aulast%3DMach%26aufirst%3DR.%2BH.%26atitle%3DTMEM97%2520and%2520PGRMC1%2520do%2520not%2520mediate%2520sigma-2%2520ligand-induced%2520cell%2520death%26jtitle%3DCell%2520Death%2520Discovery%26date%3D2019%26volume%3D5%26spage%3D58%26doi%3D10.1038%2Fs41420-019-0141-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ha, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liou, G. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonsalvez, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bollinger, K. E.</span></span> <span> </span><span class="NLM_article-title">Sigma receptor ligand, (+)-pentazocine, suppresses inflammatory responses of retinal microglia</span>. <i>Invest. Ophthalmol. Visual Sci.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">3375</span>– <span class="NLM_lpage">3384</span>, <span class="refDoi"> DOI: 10.1167/iovs.13-12823</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1167%2Fiovs.13-12823" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=24812552" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVSqur7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2014&pages=3375-3384&author=J.+Zhaoauthor=Y.+Haauthor=G.+I.+Liouauthor=G.+B.+Gonsalvezauthor=S.+B.+Smithauthor=K.+E.+Bollinger&title=Sigma+receptor+ligand%2C+%28%2B%29-pentazocine%2C+suppresses+inflammatory+responses+of+retinal+microglia&doi=10.1167%2Fiovs.13-12823"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Sigma receptor ligand, (+)-pentazocine, suppresses inflammatory responses of retinal microglia</span></div><div class="casAuthors">Zhao, Jing; Ha, Yonju; Liou, Gregory I.; Gonsalvez, Graydon B.; Smith, Sylvia B.; Bollinger, Kathryn E.</div><div class="citationInfo"><span class="NLM_cas:title">Investigative Ophthalmology & Visual Science</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">3375-3384</span>CODEN:
                <span class="NLM_cas:coden">IOVSDA</span>;
        ISSN:<span class="NLM_cas:issn">1552-5783</span>.
    
            (<span class="NLM_cas:orgname">Association for Research in Vision and Ophthalmology</span>)
        </div><div class="casAbstract">PURPOSE. To evaluate the effects of the σ 1 receptor (σR1) agonist, (+)-pentazocine, on lipopolysaccharide (LPS)-induced inflammatory changes in retinal microglia cells.  METHODS. Retinal microglia cells were isolated from Sprague-Dawley rat pups.  Cells were treated with LPS with or without (+)-pentazocine and with or without the σR1 antagonist BD1063.  Morphol. changes were assayed.  Cell viability was assessed by using MTT assay.  Supernatant levels of tumor necrosis factor α (TNF-α), interleukin 10, (IL-10), monocyte chemoattractant protein-1 (MCP-1), and nitric oxide (NO) were detd.  Reactive oxygen species (ROS) formation was assayed, and levels of mitogen-activated protein kinases (MAPKs) were analyzed by using Western blot.  RESULTS. The σR1 protein was expressed in retinal microglia.  Incubation with LPS and/or (+)- pentazocine did not alter cell viability or σR1 protein levels.  Incubation with LPS for 24 h induced a marked change in microglial morphol. and a significant increase in secreted levels of TNF-α, IL-10, MCP-1, and NO.  Pretreatment with (+)-pentazocine inhibited the LPS-induced morphol. changes.  Release of TNF-α, IL-10, MCP-1, and NO was reduced with (+)- pentazocine.  Intracellular ROS formation was suppressed with (+)-pentazocine.  Phosphorylation of extracellular signal-regulated kinase (ERK) and c-Jun N-terminal kinase (JNK) was reduced in the presence of (+)-pentazocine.  The σR1 antagonist BD1063 blocked the (+)-pentazocine-mediated inhibition of LPS-induced morphol. changes.  In addn., BD1063 treatment blocked (+)-pentazocine-mediated suppression of LPS-induced TNF-α, IL-10, MCP-1, NO, and intracellular ROS release.  CONCLUSIONS. Treatment with (+)-pentazocine suppressed inflammatory responses of retinal microglia and inhibited LPS-induced activation of ERK/JNK MAPK.  In neurodegenerative disease, (+)-pentazocine may exert neuroprotective effects through manipulation of microglia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqkRG40_9ttkrVg90H21EOLACvtfcHk0ljQczzxAhnKfA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVSqur7E&md5=5921c39790ee8b4a8beead13ea3d3ee3</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1167%2Fiovs.13-12823&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1167%252Fiovs.13-12823%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DJ.%26aulast%3DHa%26aufirst%3DY.%26aulast%3DLiou%26aufirst%3DG.%2BI.%26aulast%3DGonsalvez%26aufirst%3DG.%2BB.%26aulast%3DSmith%26aufirst%3DS.%2BB.%26aulast%3DBollinger%26aufirst%3DK.%2BE.%26atitle%3DSigma%2520receptor%2520ligand%252C%2520%2528%252B%2529-pentazocine%252C%2520suppresses%2520inflammatory%2520responses%2520of%2520retinal%2520microglia%26jtitle%3DInvest.%2520Ophthalmol.%2520Visual%2520Sci.%26date%3D2014%26volume%3D55%26spage%3D3375%26epage%3D3384%26doi%3D10.1167%2Fiovs.13-12823" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bai, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.</span></span> <span> </span><span class="NLM_article-title">Haloperidol, a sigma receptor 1 antagonist, promotes ferroptosis in hepatocellular carcinoma cells</span>. <i>Biochem. Biophys. Res. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>491</i></span>,  <span class="NLM_fpage">919</span>– <span class="NLM_lpage">925</span>, <span class="refDoi"> DOI: 10.1016/j.bbrc.2017.07.136</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1016%2Fj.bbrc.2017.07.136" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=28756230" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht1GisbrK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=491&publication_year=2017&pages=919-925&author=T.+Baiauthor=S.+Wangauthor=Y.+Zhaoauthor=R.+Zhuauthor=W.+Wangauthor=Y.+Sun&title=Haloperidol%2C+a+sigma+receptor+1+antagonist%2C+promotes+ferroptosis+in+hepatocellular+carcinoma+cells&doi=10.1016%2Fj.bbrc.2017.07.136"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Haloperidol, a sigma receptor 1 antagonist, promotes ferroptosis in hepatocellular carcinoma cells</span></div><div class="casAuthors">Bai, Tao; Wang, Shuai; Zhao, Yipu; Zhu, Rongtao; Wang, Weijie; Sun, Yuling</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical and Biophysical Research Communications</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">491</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">919-925</span>CODEN:
                <span class="NLM_cas:coden">BBRCA9</span>;
        ISSN:<span class="NLM_cas:issn">0006-291X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Ferroptosis is a novel form of cell death, which is characterized by accumulation of reactive oxygen species (ROS).  Sigma 1 receptor (S1R) has been suggested to function in oxidative stress metab.  Both erastin and sorafenib significantly induced S1R protein expression.  Haloperidol strongly promoted erastin- and sorafenib-induced cell death, which was blocked by ferrostatin-1 but not ZVAD-FMK or necrosulfonamide.  During ferroptosis, haloperidol substantially increased the cellular levels of Fe2+, GSH and lipid peroxidn.  Furthermore, several ferroptosis-related protein targets were up-regulated in the absence of haloperidol.  Thus, Our study identified an assocn. between haloperidol and ferroptosis for the first time.  Our analyses of a combination of drugs may provide a novel strategy of hepatocellular carcinoma (HCC) therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbCPPfWoO81rVg90H21EOLACvtfcHk0ljQczzxAhnKfA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht1GisbrK&md5=29e2b7138c4e91f542b771ba8bc3244c</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1016%2Fj.bbrc.2017.07.136&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbrc.2017.07.136%26sid%3Dliteratum%253Aachs%26aulast%3DBai%26aufirst%3DT.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DZhu%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DSun%26aufirst%3DY.%26atitle%3DHaloperidol%252C%2520a%2520sigma%2520receptor%25201%2520antagonist%252C%2520promotes%2520ferroptosis%2520in%2520hepatocellular%2520carcinoma%2520cells%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D2017%26volume%3D491%26spage%3D919%26epage%3D925%26doi%3D10.1016%2Fj.bbrc.2017.07.136" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, Y. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, X. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, X. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, H. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X. Y.</span></span> <span> </span><span class="NLM_article-title">Sigma-1 receptor agonist increases axon outgrowth of hippocampal neurons via voltage-gated calcium ions channels</span>. <i>CNS Neurosci. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">930</span>– <span class="NLM_lpage">939</span>, <span class="refDoi"> DOI: 10.1111/cns.12768</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1111%2Fcns.12768" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=28990373" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhslyhsr7O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2017&pages=930-939&author=D.+Liauthor=S.+Z.+Zhangauthor=Y.+H.+Yaoauthor=Y.+Xiangauthor=X.+Y.+Maauthor=X.+L.+Weiauthor=H.+T.+Yanauthor=X.+Y.+Liu&title=Sigma-1+receptor+agonist+increases+axon+outgrowth+of+hippocampal+neurons+via+voltage-gated+calcium+ions+channels&doi=10.1111%2Fcns.12768"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Sigma-1 receptor agonist increases axon outgrowth of hippocampal neurons via voltage-gated calcium ions channels</span></div><div class="casAuthors">Li, Dong; Zhang, Shu-Zhuo; Yao, Yu-Hong; Xiang, Yun; Ma, Xiao-Yun; Wei, Xiao-Li; Yan, Hai-Tao; Liu, Xiao-Yan</div><div class="citationInfo"><span class="NLM_cas:title">CNS Neuroscience & Therapeutics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">930-939</span>CODEN:
                <span class="NLM_cas:coden">CNTNAB</span>;
        ISSN:<span class="NLM_cas:issn">1755-5930</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Summary : Introduction : Sigma-1 receptors (Sig-1Rs) are unique endoplasmic reticulum proteins that have been implicated in both neurodegenerative and ischemic diseases, such as Alzheimer's disease and stroke.  Accumulating evidence has suggested that Sig-1R plays a role in neuroprotection and axon outgrowth.  The underlying mechanisms of Sig-1R-mediated neuroprotection have been well elucidated.  However, the mechanisms underlying the effects of Sig-1R on axon outgrowth are not fully understood.  Methods : To clarify this issue, we utilized immunofluorescence to compare the axon lengths of cultured naive hippocampal neurons before and after the application of the Sig-1R agonist, SA4503.  Then, electrophysiol. and immunofluorescence were used to examine voltage-gated calcium ion channel (VGCCs) currents in the cell membranes and growth cones.  Results : We found that Sig-1R activation dramatically enhanced the axonal length of the naive hippocampal neurons.  Application of the Sig-1R antagonist NE100 and gene knockdown techniques both demonstrated the effects of Sig-1R.  The growth-promoting effect of SA4503 was accompanied by the inhibition of voltage-gated Ca2+ influx and was recapitulated by incubating the neurons with the L-type, N-type, and P/Q-type VGCC blockers, nimodipine, MVIIA and ω-agatoxin IVA, resp.  This effect was unrelated to glial cells.  The application of SA4503 transformed the growth cone morphologies from complicated to simple, which favored axon outgrowth.  Conclusion : Sig-1R activation can enhance axon outgrowth and may have a substantial influence on neurogenesis and neurodegenerative diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqmWsTwTP6fLVg90H21EOLACvtfcHk0ljQczzxAhnKfA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhslyhsr7O&md5=2adffff3d75ec0ae3325b47b275caa25</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1111%2Fcns.12768&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fcns.12768%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DD.%26aulast%3DZhang%26aufirst%3DS.%2BZ.%26aulast%3DYao%26aufirst%3DY.%2BH.%26aulast%3DXiang%26aufirst%3DY.%26aulast%3DMa%26aufirst%3DX.%2BY.%26aulast%3DWei%26aufirst%3DX.%2BL.%26aulast%3DYan%26aufirst%3DH.%2BT.%26aulast%3DLiu%26aufirst%3DX.%2BY.%26atitle%3DSigma-1%2520receptor%2520agonist%2520increases%2520axon%2520outgrowth%2520of%2520hippocampal%2520neurons%2520via%2520voltage-gated%2520calcium%2520ions%2520channels%26jtitle%3DCNS%2520Neurosci.%2520Ther.%26date%3D2017%26volume%3D23%26spage%3D930%26epage%3D939%26doi%3D10.1111%2Fcns.12768" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Colabufo, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berardi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Contino, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niso, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abate, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perrone, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tortorella, V.</span></span> <span> </span><span class="NLM_article-title">Antiproliferative and cytotoxic effects of some sigma2 agonists and sigma1 antagonists in tumour cell lines</span>. <i>Naunyn-Schmiedeberg's Arch. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>370</i></span>,  <span class="NLM_fpage">106</span>– <span class="NLM_lpage">113</span>, <span class="refDoi"> DOI: 10.1007/s00210-004-0961-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1007%2Fs00210-004-0961-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=15322732" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BD2cXoslyrtrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=370&publication_year=2004&pages=106-113&author=N.+A.+Colabufoauthor=F.+Berardiauthor=M.+Continoauthor=M.+Nisoauthor=C.+Abateauthor=R.+Perroneauthor=V.+Tortorella&title=Antiproliferative+and+cytotoxic+effects+of+some+sigma2+agonists+and+sigma1+antagonists+in+tumour+cell+lines&doi=10.1007%2Fs00210-004-0961-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Antiproliferative and cytotoxic effects of some σ2 agonists and σ1 antagonists in tumour cell lines</span></div><div class="casAuthors">Colabufo, Nicola Antonio; Berardi, Francesco; Contino, Marialessandra; Niso, Mauro; Abate, Carmen; Perrone, Roberto; Tortorella, Vincenzo</div><div class="citationInfo"><span class="NLM_cas:title">Naunyn-Schmiedeberg's Archives of Pharmacology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">370</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">106-113</span>CODEN:
                <span class="NLM_cas:coden">NSAPCC</span>;
        ISSN:<span class="NLM_cas:issn">0028-1298</span>.
    
            (<span class="NLM_cas:orgname">Springer GmbH</span>)
        </div><div class="casAbstract">To establish the activity of σ ligands at σ1 and σ2 receptor, we chose two tumor cell lines, the human SK-N-SH neuroblastoma and the rat C6 glioma lines, which express σ2 receptors at a high d. and σ1 receptors in their high-affinity or low-affinity state.  We tested the σ2 receptor agonist PB28 and the σ2 antagonist AC927, and (+)-pentazocine and NE100 as agonist and antagonist, resp., at σ1 receptors, with regard to antiproliferative and cytotoxic effects.  In addn., 1,3-di (2-tolyl)guanidine (DTG) and haloperidol were tested as ref. compds. displaying nearly equipotent σ affinity (σ2>σ1 and σ1>σ2, resp.).  In both SK-N-SH and C6 cells, PB28 and NE100 displayed the most potent results both in antiproliferative and cytotoxic assay while AC927 and (+)-pentazocine were inactive in both assays.  The cytotoxic and antiproliferative effects of DTG and haloperidol reflected their σ1 antagonist activity and σ2 agonist activity.  Moreover, our results in the tumor cell lines correlated well with those for σ2 activity found previously in a functional assay in the guinea-pig bladder.  These findings establish a new model for evaluating both σ2 and σ1 receptor activity of σ ligands, which could be useful for developing new ligands having mixed σ2 agonist/σ1 antagonist activity as potential antineoplastic agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrs66SL4M6j97Vg90H21EOLACvtfcHk0ljQczzxAhnKfA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXoslyrtrg%253D&md5=3adb421f453f96086fd45096dc49366c</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1007%2Fs00210-004-0961-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00210-004-0961-2%26sid%3Dliteratum%253Aachs%26aulast%3DColabufo%26aufirst%3DN.%2BA.%26aulast%3DBerardi%26aufirst%3DF.%26aulast%3DContino%26aufirst%3DM.%26aulast%3DNiso%26aufirst%3DM.%26aulast%3DAbate%26aufirst%3DC.%26aulast%3DPerrone%26aufirst%3DR.%26aulast%3DTortorella%26aufirst%3DV.%26atitle%3DAntiproliferative%2520and%2520cytotoxic%2520effects%2520of%2520some%2520sigma2%2520agonists%2520and%2520sigma1%2520antagonists%2520in%2520tumour%2520cell%2520lines%26jtitle%3DNaunyn-Schmiedeberg%2527s%2520Arch.%2520Pharmacol.%26date%3D2004%26volume%3D370%26spage%3D106%26epage%3D113%26doi%3D10.1007%2Fs00210-004-0961-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vilner, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowen, W. D.</span></span> <span> </span><span class="NLM_article-title">Sigma receptor-active neuroleptics are cytotoxic to C6 glioma cells in culture</span>. <i>Eur. J. Pharmacol., Mol. Pharmacol. Sect.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>244</i></span>,  <span class="NLM_fpage">199</span>– <span class="NLM_lpage">201</span>, <span class="refDoi"> DOI: 10.1016/0922-4106(93)90029-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1016%2F0922-4106%2893%2990029-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=8094338" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADyaK3sXhtl2ksLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=244&publication_year=1993&pages=199-201&author=B.+J.+Vilnerauthor=W.+D.+Bowen&title=Sigma+receptor-active+neuroleptics+are+cytotoxic+to+C6+glioma+cells+in+culture&doi=10.1016%2F0922-4106%2893%2990029-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">σ Receptor-active neuroleptics are cytotoxic to C6 glioma cells in culture</span></div><div class="casAuthors">Vilner, Bertold J.; Bowen, Wayne D.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology, Molecular Pharmacology Section</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">244</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">199-201</span>CODEN:
                <span class="NLM_cas:coden">EJPPET</span>;
        ISSN:<span class="NLM_cas:issn">0922-4106</span>.
    </div><div class="casAbstract">When exposed to neuroleptics (100 μM), C6 glioma cells exhibited marked changes in cell morphol., accompanied by cessation of cell division and ultimately cell death.  The degree of activity generally correlated with binding affinity at σ sites: fluphenazine = perphenazine = haloperidol = reduced haloperidol > pimozide = spiperone » (-)-sulpiride.  σ-Inactive compds. (100 μM) which block dopamine, serotonin, phencyclidine, muscarinic receptor and adrenoceptors showed no effect.  These results may suggest a role of σ binding sites in maintenance of cell viability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2v7cjcUdcf7Vg90H21EOLACvtfcHk0lhwPZVJirYt4w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXhtl2ksLw%253D&md5=bcb055ae2d3807d99d74d07443cda16e</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1016%2F0922-4106%2893%2990029-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0922-4106%252893%252990029-9%26sid%3Dliteratum%253Aachs%26aulast%3DVilner%26aufirst%3DB.%2BJ.%26aulast%3DBowen%26aufirst%3DW.%2BD.%26atitle%3DSigma%2520receptor-active%2520neuroleptics%2520are%2520cytotoxic%2520to%2520C6%2520glioma%2520cells%2520in%2520culture%26jtitle%3DEur.%2520J.%2520Pharmacol.%252C%2520Mol.%2520Pharmacol.%2520Sect.%26date%3D1993%26volume%3D244%26spage%3D199%26epage%3D201%26doi%3D10.1016%2F0922-4106%2893%2990029-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vilner, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Costa, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowen, W. D.</span></span> <span> </span><span class="NLM_article-title">Cytotoxic effects of sigma ligands: sigma receptor-mediated alterations in cellular morphology and viability</span>. <i>J. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">117</span>– <span class="NLM_lpage">134</span>, <span class="refDoi"> DOI: 10.1523/JNEUROSCI.15-01-00117.1995</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1523%2FJNEUROSCI.15-01-00117.1995" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=7823122" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADyaK2MXjtFejtLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=1995&pages=117-134&author=B.+J.+Vilnerauthor=B.+R.+de+Costaauthor=W.+D.+Bowen&title=Cytotoxic+effects+of+sigma+ligands%3A+sigma+receptor-mediated+alterations+in+cellular+morphology+and+viability&doi=10.1523%2FJNEUROSCI.15-01-00117.1995"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Cytotoxic effects of sigma ligands: sigma receptor-mediated alterations in cellular morphology and viability</span></div><div class="casAuthors">Vilner, Bertold J.; de Costa, Brian R.; Bowen, Wayne D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">1, Pt. 1</span>),
    <span class="NLM_cas:pages">117-34</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-6474</span>.
    
            (<span class="NLM_cas:orgname">Society for Neuroscience</span>)
        </div><div class="casAbstract">The morphol. effects of several neuroleptics as well as other novel and prototypic sigma ligands were examd. by addn. to cultures of C6 glioma cells.  Sigma ligands caused loss of processes, assumption of spherical shape, and cessation of cell division.  The time course and magnitude of this effect were dependent on the concn. of sigma ligand.  Continued exposure to sigma compds. ultimately resulted in cell death.  However, the morphol. effect was reversible when sigma ligand was removed shortly after rounding.  The potency of compds. to produce these effects generally correlated with binding affinity at sigma receptors of C6 glioma cells membranes labeled with [3H](+)-pentazocine.  At a concn. of 100 μM, haloperidol, reduced haloperidol, fluphenazine, perphenazine, trifluoperazine, BD737, LR172, BE1008, and SH344 produced significant effects in 3-6 h of exposure.  Other compds., such as trifluoperidol, thioridazine, and (-)-butaclamol, produced significant effects by 24 h of exposure.  Despite the requirement of micromolar concns. of ligand (some compds. were effective at 30 μm), the effect showed a remarkable specificity for compds. exhibiting sigma receptor binding affinity.  Neuroleptics lacking potent sigma affinity [e.g., (-)-sulpiride, (+)-butaclamol, and clozapine] and other compds. that lack significant sigma affinity but that are agonists or antagonists at dopamine, serotonin, adrenergic, glutamate, phencyclidine, GABA, opiate, or muscarinic cholinergic receptors were without effect on cellular morphol. at concns. up to 300 μM over a period of 72 h.  Likewise, blockers and activators of Na+, K+, and Ca2+ channels and a monoamine oxidase inhibitor devoid of sigma affinity were without effect.  Interestingly, 1,3-di-o-tolylguanidine (DTG), (+)-3-(3-hydroxyphenyl)-N-(1-propyl)piperidine [(+)-3-PPP], (+)-pentazocine, (+)-cyclazocine, and other sigma-active benzomorphans and morphinans appeared inactive in up to 72 h of culture.  However, these compds. interacted synergistically with a subeffective dose of BD737 (30 μM) to produce effects usually in 6 h or less.  Also, the pH of the culture medium had a profound effect on the activity of sigma compds.  Increasing the pH from the normal range of 7.2-7.4 to pH 8.3-8.5 shifted the dose curves (30, 100, 300 μM) for all sigma compds. to the left.  Under these conditions, DTG,(+)-3-PPP, and benzomorphans produced effects in 24 h or less.  Decreasing the medium pH to 6.5-6.7 markedly reduced the activity of all sigma ligands, producing significant protection from cytotoxic effects.  Importantly, compds. that lacked sigma binding affinity showed neither synergism with 30 μM MD737 nor an increase in activity at higher pH.  These results confirm the sigma receptor specificity of this effect.  Sigma ligands had similar effects on other cells of neuronal and non-neuronal origin, including SK-N-SH and SH-SY5Y neuroblastomas, NCB-20 hybridoma, NG 108-15 neuroblastoma-glioma hybrid, COS-7 (kidney), MRS-5 (lung), and PC12 pheochromosome vital role in cell function and may have important implications for neurodegenerative disorders and neuroleptic treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWmjOwA6xlzLVg90H21EOLACvtfcHk0lhwPZVJirYt4w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXjtFejtLc%253D&md5=ec404f0a920da3fb64fb5fbc75c311e4</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1523%2FJNEUROSCI.15-01-00117.1995&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1523%252FJNEUROSCI.15-01-00117.1995%26sid%3Dliteratum%253Aachs%26aulast%3DVilner%26aufirst%3DB.%2BJ.%26aulast%3Dde%2BCosta%26aufirst%3DB.%2BR.%26aulast%3DBowen%26aufirst%3DW.%2BD.%26atitle%3DCytotoxic%2520effects%2520of%2520sigma%2520ligands%253A%2520sigma%2520receptor-mediated%2520alterations%2520in%2520cellular%2520morphology%2520and%2520viability%26jtitle%3DJ.%2520Neurosci.%26date%3D1995%26volume%3D15%26spage%3D117%26epage%3D134%26doi%3D10.1523%2FJNEUROSCI.15-01-00117.1995" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Romeo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prezzavento, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Intagliata, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pittalà, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Modica, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marrazzo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turnaturi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parenti, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiechio, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arena, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campisi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sposito, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salerno, L.</span></span> <span> </span><span class="NLM_article-title">Synthesis, in vitro and in vivo characterization of new benzoxazole and benzothiazole-based sigma receptor ligands</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>174</i></span>,  <span class="NLM_fpage">226</span>– <span class="NLM_lpage">235</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2019.04.056</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1016%2Fj.ejmech.2019.04.056" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=31042618" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BC1MXos12isLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=174&publication_year=2019&pages=226-235&author=G.+Romeoauthor=O.+Prezzaventoauthor=S.+Intagliataauthor=V.+Pittal%C3%A0author=M.+N.+Modicaauthor=A.+Marrazzoauthor=R.+Turnaturiauthor=C.+Parentiauthor=S.+Chiechioauthor=E.+Arenaauthor=A.+Campisiauthor=G.+Spositoauthor=L.+Salerno&title=Synthesis%2C+in+vitro+and+in+vivo+characterization+of+new+benzoxazole+and+benzothiazole-based+sigma+receptor+ligands&doi=10.1016%2Fj.ejmech.2019.04.056"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis, in vitro and in vivo characterization of new benzoxazole and benzothiazole-based sigma receptor ligands</span></div><div class="casAuthors">Romeo, Giuseppe; Prezzavento, Orazio; Intagliata, Sebastiano; Pittala, Valeria; Modica, Maria N.; Marrazzo, Agostino; Turnaturi, Rita; Parenti, Carmela; Chiechio, Santina; Arena, Emanuela; Campisi, Agata; Sposito, Giovanni; Salerno, Loredana</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">174</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">226-235</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A new set of 5-chlorobenzoxazole- and 5-chlorobenzothiazole-based derivs. I and II [X = O, S; n = 2, 3, 4] contg. the azepane ring as a basic moiety was designed, synthesized and evaluated through binding assays to measure their affinity and selectivity towards σ1 and σ2 receptors.  Compds. I [X = S; n = 3] and II [X = O; n = 4; X = S, n = 4], with a four units spacer between the bicyclic scaffold and the azepane ring, showed nanomolar affinity towards both receptor subtype and the best Ki values (Ki σ1 = 1.27, 2.30 and 0.78 and Ki σ2 = 7.9, 3.8 and 7.61 nM, resp.).  Evaluation of cytotoxic and apoptotic effects in MCF-7 human cancer cells was useful to assess σ2 receptor activity, while an in-vivo mice model of inflammatory pain allowed to analyze σ1 receptor pharmacol. properties.  In-vitro and in-vivo results suggested that compd. I [X = S, n = 3] was a σ1/σ2 agonist, compd. II [X = S, n = 4] a σ1 antagonist/σ2 agonist, whereas compd. II [X = O, n = 4] might act as σ1 antagonist/σ2 partial agonist.  Due to their pharmacol. profile, a potential therapeutic application in cancer of aforesaid novel σ1/σ2 receptor ligands, esp. compds. II [X = O; n = 4; X = S; n = 4], was proposed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2eACohvx7VLVg90H21EOLACvtfcHk0lhwPZVJirYt4w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXos12isLY%253D&md5=6a2ff604f935292ea9d5a0218baefa52</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2019.04.056&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2019.04.056%26sid%3Dliteratum%253Aachs%26aulast%3DRomeo%26aufirst%3DG.%26aulast%3DPrezzavento%26aufirst%3DO.%26aulast%3DIntagliata%26aufirst%3DS.%26aulast%3DPittal%25C3%25A0%26aufirst%3DV.%26aulast%3DModica%26aufirst%3DM.%2BN.%26aulast%3DMarrazzo%26aufirst%3DA.%26aulast%3DTurnaturi%26aufirst%3DR.%26aulast%3DParenti%26aufirst%3DC.%26aulast%3DChiechio%26aufirst%3DS.%26aulast%3DArena%26aufirst%3DE.%26aulast%3DCampisi%26aufirst%3DA.%26aulast%3DSposito%26aufirst%3DG.%26aulast%3DSalerno%26aufirst%3DL.%26atitle%3DSynthesis%252C%2520in%2520vitro%2520and%2520in%2520vivo%2520characterization%2520of%2520new%2520benzoxazole%2520and%2520benzothiazole-based%2520sigma%2520receptor%2520ligands%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2019%26volume%3D174%26spage%3D226%26epage%3D235%26doi%3D10.1016%2Fj.ejmech.2019.04.056" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mégalizzi, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Decaestecker, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Debeir, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spiegl-Kreinecker, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berger, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lefranc, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kast, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiss, R.</span></span> <span> </span><span class="NLM_article-title">Screening of anti-glioma effects induced by sigma-1 receptor ligands: potential new use for old anti-psychiatric medicines</span>. <i>Eur. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">2893</span>– <span class="NLM_lpage">2905</span>, <span class="refDoi"> DOI: 10.1016/j.ejca.2009.07.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1016%2Fj.ejca.2009.07.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=19679463" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtlSqsL3K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2009&pages=2893-2905&author=V.+M%C3%A9galizziauthor=C.+Decaesteckerauthor=O.+Debeirauthor=S.+Spiegl-Kreineckerauthor=W.+Bergerauthor=F.+Lefrancauthor=R.+E.+Kastauthor=R.+Kiss&title=Screening+of+anti-glioma+effects+induced+by+sigma-1+receptor+ligands%3A+potential+new+use+for+old+anti-psychiatric+medicines&doi=10.1016%2Fj.ejca.2009.07.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Screening of anti-glioma effects induced by sigma-1 receptor ligands: Potential new use for old anti-psychiatric medicines</span></div><div class="casAuthors">Megalizzi, Veronique; Decaestecker, Christine; Debeir, Olivier; Spiegl-Kreinecker, Sabine; Berger, Walter; Lefranc, Florence; Kast, Richard E.; Kiss, Robert</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Cancer</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">2893-2905</span>CODEN:
                <span class="NLM_cas:coden">EJCAEL</span>;
        ISSN:<span class="NLM_cas:issn">0959-8049</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The prognosis of glioblastoma (GBM) remains poor.  Diffuse invasion of distant brain tissue by migrating cells from the primary tumor mass has already occurred at time of diagnosis.  Anti-cancer effects of a selective sigma-1 agonist, 4-(N-benzylpiperidin-4-yl)-4-iodobenzamide (4-IBP), in glioblastoma were shown previously, leading to the present work where the effects on glioblastoma cells of 17 agonists or antagonists of sigma-1 receptors were studied, including currently marketed drugs fluvoxamine, dextromethorphan, donepezil, memantine and haloperidol.  We first showed that established GBM cell lines, primary cultures and surgical specimens express sigma-1 receptors.  In vitro analyses then focused on anti-proliferation and anti-migratory effects on human glioblastoma cell lines using quant. videomicroscopy analyses.  These cell monitoring assays revealed specific impacts on the mitotic cell process.  Using an aggressive glioma model orthotopically grafted into the brains of immunocompromised mice, we showed that combining donepezil and temozolomide gave additive benefit in terms of long survivors as compared to temozolomide or donepezil alone.  Clin. study is planned if further rodent dose-ranging studies of donepezil with temozolomide continue to show evidence of benefit in this model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoOqvYlLDZFJrVg90H21EOLACvtfcHk0lj4RdXrpCcY7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtlSqsL3K&md5=a8809714c0c9930dd8a0556061568666</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1016%2Fj.ejca.2009.07.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejca.2009.07.011%26sid%3Dliteratum%253Aachs%26aulast%3DM%25C3%25A9galizzi%26aufirst%3DV.%26aulast%3DDecaestecker%26aufirst%3DC.%26aulast%3DDebeir%26aufirst%3DO.%26aulast%3DSpiegl-Kreinecker%26aufirst%3DS.%26aulast%3DBerger%26aufirst%3DW.%26aulast%3DLefranc%26aufirst%3DF.%26aulast%3DKast%26aufirst%3DR.%2BE.%26aulast%3DKiss%26aufirst%3DR.%26atitle%3DScreening%2520of%2520anti-glioma%2520effects%2520induced%2520by%2520sigma-1%2520receptor%2520ligands%253A%2520potential%2520new%2520use%2520for%2520old%2520anti-psychiatric%2520medicines%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D2009%26volume%3D45%26spage%3D2893%26epage%3D2905%26doi%3D10.1016%2Fj.ejca.2009.07.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nordenberg, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perlmutter, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lavie, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beery, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uziel, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgenstern, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fenig, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weizman, A.</span></span> <span> </span><span class="NLM_article-title">Anti-proliferative activity of haloperidol in B16 mouse and human SK-MEL-28 melanoma cell lines</span>. <i>Int. J. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">1097</span>– <span class="NLM_lpage">1103</span>, <span class="refDoi"> DOI: 10.3892/ijo.27.4.1097</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.3892%2Fijo.27.4.1097" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=16142328" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtFeisrrE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2005&pages=1097-1103&author=J.+Nordenbergauthor=I.+Perlmutterauthor=G.+Lavieauthor=E.+Beeryauthor=O.+Uzielauthor=C.+Morgensternauthor=E.+Fenigauthor=A.+Weizman&title=Anti-proliferative+activity+of+haloperidol+in+B16+mouse+and+human+SK-MEL-28+melanoma+cell+lines&doi=10.3892%2Fijo.27.4.1097"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-proliferative activity of haloperidol in B16 mouse and human SK-MEL-28 melanoma cell lines</span></div><div class="casAuthors">Nordenberg, Jardena; Perlmutter, Israela; Lavie, Gad; Beery, Einat; Uziel, Orit; Morgenstern, Chaya; Fenig, Eyal; Weizman, Abraham</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Oncology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1097-1103</span>CODEN:
                <span class="NLM_cas:coden">IJONES</span>;
        ISSN:<span class="NLM_cas:issn">1019-6439</span>.
    
            (<span class="NLM_cas:orgname">International Journal of Oncology</span>)
        </div><div class="casAbstract">Sigma receptors are present in cancer cell lines.  The aim of the present study is to evaluate the anti-tumor activity of a series of sigma 1, sigma 2 and sigma 1/2 ligands in B16 melanoma cell lines.  Proliferation, apoptosis, intracellular ATP content, cell cycle and mol. regulators were analyzed.  Cell growth was detd. using the sulforhodamine B (SRB) colorimetric cytotoxicity assay.  Apoptosis was assessed by flow cytometry and DNA fragmentation, using ELISA Cell Death assay.  ATP content was measured spectrofluorometrically and cell cycle anal. was performed by flow cytometry.  The cytoplasmic and nuclear expression of cell cycle regulatory mols., cyclin D and CDK2 (cyclin dependent kinase 2) were detd. by Western blot anal. and quantified by densitometry.  The sigma ligands in single digit micromolar concns. inhibited B16 and multidrug-resistant B16 COL/R cell growth, leading to cell death at higher concns.  The potency order was: haloperidol, reduced-haloperidol, ifenprodil tartrate, opipramol and carbetapentane citrate.  B16 COL/R cells were to some extent, less sensitive to sigma ligands.  Further studies have shown that the growth inhibitory effect of sigma ligands could be attributed to G1 arrest of the cell cycle, mediated by a marked decrease in cytoplasmic and nuclear cyclin D and CDK2 protein expression, though haloperidol induced loss of cell viability due to apoptosis.  Sigma ligands induced an early decrease in ATP content.  These data stimulated us to examine the combined anti-proliferative activity of haloperidol and the tyrosine kinase inhibitor imatinib mesylate (STI 571), on SK-MEL-28 human melanoma cells.  Preliminary expts. demonstrated a marked synergistic interaction between the two agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrfMlHU_Jhtj7Vg90H21EOLACvtfcHk0lj4RdXrpCcY7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtFeisrrE&md5=33cf7006f587d4e8bfbb538b2af1c179</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.3892%2Fijo.27.4.1097&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3892%252Fijo.27.4.1097%26sid%3Dliteratum%253Aachs%26aulast%3DNordenberg%26aufirst%3DJ.%26aulast%3DPerlmutter%26aufirst%3DI.%26aulast%3DLavie%26aufirst%3DG.%26aulast%3DBeery%26aufirst%3DE.%26aulast%3DUziel%26aufirst%3DO.%26aulast%3DMorgenstern%26aufirst%3DC.%26aulast%3DFenig%26aufirst%3DE.%26aulast%3DWeizman%26aufirst%3DA.%26atitle%3DAnti-proliferative%2520activity%2520of%2520haloperidol%2520in%2520B16%2520mouse%2520and%2520human%2520SK-MEL-28%2520melanoma%2520cell%2520lines%26jtitle%3DInt.%2520J.%2520Oncol.%26date%3D2005%26volume%3D27%26spage%3D1097%26epage%3D1103%26doi%3D10.3892%2Fijo.27.4.1097" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moody, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leyton, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">John, C.</span></span> <span> </span><span class="NLM_article-title">Sigma ligands inhibit the growth of small cell lung cancer cells</span>. <i>Life Sci.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">1979</span>– <span class="NLM_lpage">1986</span>, <span class="refDoi"> DOI: 10.1016/S0024-3205(00)00523-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1016%2FS0024-3205%2800%2900523-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10821122" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BD3cXisFKksbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2000&pages=1979-1986&author=T.+W.+Moodyauthor=J.+Leytonauthor=C.+John&title=Sigma+ligands+inhibit+the+growth+of+small+cell+lung+cancer+cells&doi=10.1016%2FS0024-3205%2800%2900523-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Sigma ligands inhibit the growth of small cell lung cancer cells</span></div><div class="casAuthors">Moody, T. W.; Leyton, J.; John, C.</div><div class="citationInfo"><span class="NLM_cas:title">Life Sciences</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">1979-1986</span>CODEN:
                <span class="NLM_cas:coden">LIFSAK</span>;
        ISSN:<span class="NLM_cas:issn">0024-3205</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Inc.</span>)
        </div><div class="casAbstract">The effects of sigma ligands on small cell lung cancer (SCLC) cells were investigated.  125I-N-(2-(piperidino)ethyl)-2-iodobenzamide (2-IBP) bound with high affinity to SCLC cell line NCl-H209 and NCl-N417.  Specific 125I-2-IBP binding was inhibited with high affinity by infedipin, haloperidol, (2-piperidinyl-aminoethyl)-4-iodobenzamide (IPAB) and 1,3-ditolylguanidine (DTG) with IC50 values of 3, 10, 15 and 90 nM resp.  In vitro, 10μM 2-IBP, haloperidol or IPAB inhibited NCl-N417 proliferation using a MTT or clonogenic assay.  In vivo, 4 mg/kg IPAB or 2-IBP inhibited NCl-N417 xenograft proliferation.  125I-2-IBP localized to the SCLC tumors after s.c. injection.  These results suggest that sigma ligands may be utilized to localize and inhibit the proliferation of SCLC tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq_KpqFXYchU7Vg90H21EOLACvtfcHk0lj4RdXrpCcY7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXisFKksbk%253D&md5=0f72e887b15a400ac0ef105efc1bced2</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1016%2FS0024-3205%2800%2900523-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0024-3205%252800%252900523-3%26sid%3Dliteratum%253Aachs%26aulast%3DMoody%26aufirst%3DT.%2BW.%26aulast%3DLeyton%26aufirst%3DJ.%26aulast%3DJohn%26aufirst%3DC.%26atitle%3DSigma%2520ligands%2520inhibit%2520the%2520growth%2520of%2520small%2520cell%2520lung%2520cancer%2520cells%26jtitle%3DLife%2520Sci.%26date%3D2000%26volume%3D66%26spage%3D1979%26epage%3D1986%26doi%3D10.1016%2FS0024-3205%2800%2900523-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schläger, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schepmann, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehmkuhl, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holenz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vela, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buschmann, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wünsch, B.</span></span> <span> </span><span class="NLM_article-title">Combination of two pharmacophoric systems: synthesis and pharmacological evaluation of spirocyclic pyranopyrazoles with high σ<sub>1</sub> receptor affinity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">6704</span>– <span class="NLM_lpage">6713</span>, <span class="refDoi"> DOI: 10.1021/jm200585k</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm200585k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtFygurfF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=6704-6713&author=T.+Schl%C3%A4gerauthor=D.+Schepmannauthor=K.+Lehmkuhlauthor=J.+Holenzauthor=J.+M.+Velaauthor=H.+Buschmannauthor=B.+W%C3%BCnsch&title=Combination+of+two+pharmacophoric+systems%3A+synthesis+and+pharmacological+evaluation+of+spirocyclic+pyranopyrazoles+with+high+%CF%831+receptor+affinity&doi=10.1021%2Fjm200585k"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Combination of two pharmacophoric systems: Synthesis and pharmacological evaluation of spirocyclic pyranopyrazoles with high σ1 receptor affinity</span></div><div class="casAuthors">Schlager, Torsten; Schepmann, Dirk; Lehmkuhl, Kirstin; Holenz, Jorg; Vela, Jose Miguel; Buschmann, Helmut; Wunsch, Bernhard</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">6704-6713</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The novel class of spirocyclic σ1 ligands (6',7'-dihydro-1'H-spiro[piperidine-4,4'-pyrano[4,3-c]pyrazoles]) I was designed by the combination of the potent σ1 ligands II and III(n = 0, 1) in one mol.  Thorough structure affinity relationships were derived by the variation of the substituents in position 1', 1, and 6'.  Whereas the small electron rich methylpyrazole heterocycle was less tolerated by the σ1 receptor protein, the introduction of a Ph substituent instead of the Me group led to ligands with a high σ1 affinity.  It is postulated that the addnl. Ph substituent occupies a previously unrecognized hydrophobic region of the σ1 receptor resulting in addnl. lipophilic interactions.  The spirocyclic pyranopyrazoles are very selective against the σ2 subtype, the PCP binding site of the NMDA receptor, and further targets.  Despite high σ1 affinity, the cyclohexylmethyl deriv. I(R1 = Ph, R2 = C6H11CH2, R3 = MeO) (Ki (σ1) = 0.55 nM) and the isopentenyl deriv. I(R1 = Ph, R2 = isopentenyl, R3 = MeO) (Ki (σ1) = 1.6 nM) showed only low antiallodynic activity in the capsaicin assay.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWuyeWYkUMbLVg90H21EOLACvtfcHk0lixVnFDImm5wg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtFygurfF&md5=af670e6a4bc3cc2eed6ac3407dbce682</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1021%2Fjm200585k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200585k%26sid%3Dliteratum%253Aachs%26aulast%3DSchl%25C3%25A4ger%26aufirst%3DT.%26aulast%3DSchepmann%26aufirst%3DD.%26aulast%3DLehmkuhl%26aufirst%3DK.%26aulast%3DHolenz%26aufirst%3DJ.%26aulast%3DVela%26aufirst%3DJ.%2BM.%26aulast%3DBuschmann%26aufirst%3DH.%26aulast%3DW%25C3%25BCnsch%26aufirst%3DB.%26atitle%3DCombination%2520of%2520two%2520pharmacophoric%2520systems%253A%2520synthesis%2520and%2520pharmacological%2520evaluation%2520of%2520spirocyclic%2520pyranopyrazoles%2520with%2520high%2520%25CF%25831%2520receptor%2520affinity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D6704%26epage%3D6713%26doi%3D10.1021%2Fjm200585k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Akunne, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whetzel, S. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiley, J. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corbin, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ninteman, F. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tecle, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pei, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pugsley, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heffner, T. G.</span></span> <span> </span><span class="NLM_article-title">The pharmacology of the novel and selective sigma ligand, PD 144418</span>. <i>Neuropharmacology</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">51</span>– <span class="NLM_lpage">62</span>, <span class="refDoi"> DOI: 10.1016/S0028-3908(96)00161-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1016%2FS0028-3908%2896%2900161-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=9144641" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADyaK2sXhvF2ms7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=1997&pages=51-62&author=H.+C.+Akunneauthor=S.+Z.+Whetzelauthor=J.+N.+Wileyauthor=A.+E.+Corbinauthor=F.+W.+Nintemanauthor=H.+Tecleauthor=Y.+Peiauthor=T.+A.+Pugsleyauthor=T.+G.+Heffner&title=The+pharmacology+of+the+novel+and+selective+sigma+ligand%2C+PD+144418&doi=10.1016%2FS0028-3908%2896%2900161-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">The pharmacology of the novel and selective sigma ligand, PD 144418</span></div><div class="casAuthors">Akunne, H. C.; Whetzel, S. Z.; Wiley, J. N.; Corbin, A. E.; Ninteman, F. W.; Tecle, H.; Pei, Y.; Pugsley, T. A.; Heffner, T. G.</div><div class="citationInfo"><span class="NLM_cas:title">Neuropharmacology</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">51-62</span>CODEN:
                <span class="NLM_cas:coden">NEPHBW</span>;
        ISSN:<span class="NLM_cas:issn">0028-3908</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">The pharmacol. of PD 144418 (1-propyl-5-(3-p-tolyl-isoxazol -5-yl)-1,2,3,6-tetrahydropyridine) was characterized using neurochem., biochem. and behavioral techniques.  For sigma (σ1 and σ2, resp.) sites, PD 144418 affinities were detd. using whole guinea pig brain membranes with [3H](+)-pentazocine and neuroblastoma × glioma cell membranes using [3H]1,3-di-o-tolylguanidine (DTG) in the presence of 200 nM (+)-pentazocine.  PD 144418 exhibited an affinity for σ1 of 0.08 nM (Ki) vs. a Ki of 1377 nM for σ2 site.  Addnl. receptor binding studies indicated that PD 144418 lacked affinity for dopaminergic, adrenergic, muscarinic and a variety of other receptors.  In vitro studies indicated that PD 144418 reversed the N-methyl-D-aspartate (NMDA)-induced increase in cyclic GMP (cGMP) in rat cerebellar slices without affecting the basal levels, suggesting that σ1 sites may be important in the regulation of glutamine-induced actions.  PD 144418 potentiated the decrease in 5-hydroxytryptophan caused by haloperidol in the mesolimbic region, but by itself had no effect in 5-hydroxytrypamine (5-HT) and dopamine (DA) synthesis.  Behaviorally, similar to other σ ligands, PD 144418 antagonized mescaline-induced scratching at doses that did not alter spontaneous motor activity.  This action is suggestive of potential antipsychotic property.  It exhibited no anxiolytic and antidepressant properties in the models used.  These results show that PD 144418 is a very selective σ1 agent, devoid of any significant affinity for other receptors and that σ1 site may modulate actions in the CNS.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq8tFKmm7SP57Vg90H21EOLACvtfcHk0lixVnFDImm5wg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXhvF2ms7s%253D&md5=cd99a62e955ddfdd9e05b883bc0d7cfb</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1016%2FS0028-3908%2896%2900161-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0028-3908%252896%252900161-X%26sid%3Dliteratum%253Aachs%26aulast%3DAkunne%26aufirst%3DH.%2BC.%26aulast%3DWhetzel%26aufirst%3DS.%2BZ.%26aulast%3DWiley%26aufirst%3DJ.%2BN.%26aulast%3DCorbin%26aufirst%3DA.%2BE.%26aulast%3DNinteman%26aufirst%3DF.%2BW.%26aulast%3DTecle%26aufirst%3DH.%26aulast%3DPei%26aufirst%3DY.%26aulast%3DPugsley%26aufirst%3DT.%2BA.%26aulast%3DHeffner%26aufirst%3DT.%2BG.%26atitle%3DThe%2520pharmacology%2520of%2520the%2520novel%2520and%2520selective%2520sigma%2520ligand%252C%2520PD%2520144418%26jtitle%3DNeuropharmacology%26date%3D1997%26volume%3D36%26spage%3D51%26epage%3D62%26doi%3D10.1016%2FS0028-3908%2896%2900161-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">John, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vilner, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowen, W. D.</span></span> <span> </span><span class="NLM_article-title">Synthesis and characterization of [125I]-N-(N-benzylpiperidin-4-yl)-4- iodobenzamide, a new sigma receptor radiopharmaceutical: high-affinity binding to MCF-7 breast tumor cells</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">1737</span>– <span class="NLM_lpage">1739</span>, <span class="refDoi"> DOI: 10.1021/jm00038a002</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00038a002" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADyaK2cXktlGhuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=1994&pages=1737-1739&author=C.+S.+Johnauthor=B.+J.+Vilnerauthor=W.+D.+Bowen&title=Synthesis+and+characterization+of+%5B125I%5D-N-%28N-benzylpiperidin-4-yl%29-4-+iodobenzamide%2C+a+new+sigma+receptor+radiopharmaceutical%3A+high-affinity+binding+to+MCF-7+breast+tumor+cells&doi=10.1021%2Fjm00038a002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Characterization of [125I]-N-(N-Benzylpiperidin-4-yl)-4-iodobenzamide, a New σ Receptor Radiopharmaceutical: High-Affinity Binding to MCF-7 Breast Tumor Cells</span></div><div class="casAuthors">John, Christy S.; Vilner, Bertold J.; Bowen, Wayne D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1737-9</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    </div><div class="casAbstract">(N-benzylpiperidin-4-yl)-iodobenzamides I (R = 2-I, 3-I, 4-I) were prepd. and evaluated for their affinities for sigma receptors.  All three I showed high affinities for sigma-1 receptors in guinea pig brain membranes (Ki = 1.64 ± 0.15 nM, 3.02 ± 1.06 nM, 1.70 ± 0.15 nM resp.) against [3H](+)-pentazocine, a sigma-1 selective ligand.  I (R = 2-I, 4-I) showed modest affinity for sigma-2 sites (Ki = 29.6 ± 0.49 nM, 25.2 ± 1.28 nM resp.) against [3H]DTG in the presence of dextrallorphan to mask sigma-1 sites.  I (R = 4-I) had a weak affinity for D-2 dopamine receptors as found by competition with [3H](-)-sulpiride in rat brain membranes.  In order to obtain high yields (with high specific activity) of radioiodinated ligand, I (R = 4-SnBu3) was synthesized from I (R = 4-I) by a palladium catalyzed reaction with Bu3SnSnBu3.  I (R = 4-125I) was prepd. in high yields from I (R = SnBu3) using chloramine-T or hydrogen peroxide as an oxidizing agent.  The competition binding studies of I (R = 4-125I) in MCF-7 breast tumor cells with haloperidol and DTG (known sigma ligands) showed complete displacement and high affinity binding (Ki = 4.6 and 60 nM resp.) demonstrating that sigma receptors are expressed in MCF-7 breast tumor cells.  Furthermore, the Scatchard anal. of [3H]DTG binding in MCF-7 cells gave Kd of 38.2 nM and a Bmax of 3867 fmol/mg of protein.  These results demonstrate that high d. of sigma receptors are expressed in MCF-7 cells and that I (R = 4-125I) has potential for imaging breast cancer by targeting sigma sites.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqf5CdIQQi59rVg90H21EOLACvtfcHk0lixVnFDImm5wg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXktlGhuro%253D&md5=86fd60c122b8ff0d82b92c1fde361969</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1021%2Fjm00038a002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00038a002%26sid%3Dliteratum%253Aachs%26aulast%3DJohn%26aufirst%3DC.%2BS.%26aulast%3DVilner%26aufirst%3DB.%2BJ.%26aulast%3DBowen%26aufirst%3DW.%2BD.%26atitle%3DSynthesis%2520and%2520characterization%2520of%2520%255B125I%255D-N-%2528N-benzylpiperidin-4-yl%2529-4-%2520iodobenzamide%252C%2520a%2520new%2520sigma%2520receptor%2520radiopharmaceutical%253A%2520high-affinity%2520binding%2520to%2520MCF-7%2520breast%2520tumor%2520cells%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1994%26volume%3D37%26spage%3D1737%26epage%3D1739%26doi%3D10.1021%2Fjm00038a002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bowen, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertha, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vilner, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rice, K. C.</span></span> <span> </span><span class="NLM_article-title">CB-64D and CB-184: ligands with high sigma 2 receptor affinity and subtype selectivity</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>278</i></span>,  <span class="NLM_fpage">257</span>– <span class="NLM_lpage">260</span>, <span class="refDoi"> DOI: 10.1016/0014-2999(95)00176-L</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1016%2F0014-2999%2895%2900176-L" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=7589164" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADyaK2MXlvFKns70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=278&publication_year=1995&pages=257-260&author=W.+D.+Bowenauthor=C.+M.+Berthaauthor=B.+J.+Vilnerauthor=K.+C.+Rice&title=CB-64D+and+CB-184%3A+ligands+with+high+sigma+2+receptor+affinity+and+subtype+selectivity&doi=10.1016%2F0014-2999%2895%2900176-L"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">CB-64D and CB-184: ligands with high σ2 receptor affinity and subtype selectivity</span></div><div class="casAuthors">Bowen, Wayne D.; Bertha, Craig M.; Vilner, Bertold J.; Rice, Kenner C.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">278</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">257-60</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Four members of a novel class of sigma (σ) ligands were investigated for σ subtype selectivity. (-)-1S,5S- and (+)-1R,5R-(E)-8-Benzylidene-5-(3-hydroxyphenyl)-2-methylmorphan-7-one (CB-64L and CB-64D, resp.) exhibited σ1 Ki = 10.5 nM and 3063 nM; σ2 Ki = 154 nM and 16.5 nM, resp.  The corresponding 3,4-dichloro derivs., (-)-1S,5S- and (+)-1R,5R-(E)-8-(3,4-dichlorobenzylidene)-5-(3-hydroxyphenyl)-2-Me morphan-7-one (CB-182 and CB-184, resp.) were also examd.  CB-182 ((-)-isomer) showed σ1 and σ2 Ki = 27.3 nM and 35.5 nM, resp., whereas CB-184 ((+)-isomer) exhibited σ1 and σ2 Ki = 7436 nM and 13.4 nM, resp.  Thus, the two σ subtypes showed opposite enantioselectivity for these compds., with (-)>(+) at σ1 and (+)>(-) at σ2.  Importantly, CB-64D and CB-184 showed high σ2 affinity and, resp., 185-fold and 554-fold selectivity for σ2 receptors over σ1.  While high σ2 selectivity relative to σ1 was achieved with these compds., they both exhibited high affinity at mu (μ) opioid receptors (Ki = 37.6 nM and 4.5 nM, resp.).  Despite this, CB-64D and CB-184 will be useful tools for further characterization of σ2 receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpx0pBVs3KXDrVg90H21EOLACvtfcHk0lhsbU6a0GA_oA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXlvFKns70%253D&md5=b5497d6699586de5508e8239ad433268</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1016%2F0014-2999%2895%2900176-L&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0014-2999%252895%252900176-L%26sid%3Dliteratum%253Aachs%26aulast%3DBowen%26aufirst%3DW.%2BD.%26aulast%3DBertha%26aufirst%3DC.%2BM.%26aulast%3DVilner%26aufirst%3DB.%2BJ.%26aulast%3DRice%26aufirst%3DK.%2BC.%26atitle%3DCB-64D%2520and%2520CB-184%253A%2520ligands%2520with%2520high%2520sigma%25202%2520receptor%2520affinity%2520and%2520subtype%2520selectivity%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D1995%26volume%3D278%26spage%3D257%26epage%3D260%26doi%3D10.1016%2F0014-2999%2895%2900176-L" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mach, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Childers, S. R.</span></span> <span> </span><span class="NLM_article-title">Ibogaine possesses a selective affinity for σ2 receptors</span>. <i>Life Sci.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">PL57</span>– <span class="NLM_lpage">PL62</span>, <span class="refDoi"> DOI: 10.1016/0024-3205(95)00301-L</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1016%2F0024-3205%2895%2900301-L" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=7603301" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=1995&pages=PL57-PL62&author=R.+H.+Machauthor=C.+R.+Smithauthor=S.+R.+Childers&title=Ibogaine+possesses+a+selective+affinity+for+%CF%832+receptors&doi=10.1016%2F0024-3205%2895%2900301-L"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1016%2F0024-3205%2895%2900301-L&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0024-3205%252895%252900301-L%26sid%3Dliteratum%253Aachs%26aulast%3DMach%26aufirst%3DR.%2BH.%26aulast%3DSmith%26aufirst%3DC.%2BR.%26aulast%3DChilders%26aufirst%3DS.%2BR.%26atitle%3DIbogaine%2520possesses%2520a%2520selective%2520affinity%2520for%2520%25CF%25832%2520receptors%26jtitle%3DLife%2520Sci.%26date%3D1995%26volume%3D57%26spage%3DPL57%26epage%3DPL62%26doi%3D10.1016%2F0024-3205%2895%2900301-L" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bowen, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vilner, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertha, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuehne, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobson, A. E.</span></span> <span> </span><span class="NLM_article-title">Ibogaine and its congeners are sigma 2 receptor-selective ligands with moderate affinity</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>279</i></span>,  <span class="NLM_fpage">R1</span>– <span class="NLM_lpage">3</span>, <span class="refDoi"> DOI: 10.1016/0014-2999(95)00247-I</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1016%2F0014-2999%2895%2900247-I" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=7556375" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADyaK2MXmtVymtro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=279&publication_year=1995&pages=R1-3&author=W.+D.+Bowenauthor=B.+J.+Vilnerauthor=W.+Williamsauthor=C.+M.+Berthaauthor=M.+E.+Kuehneauthor=A.+E.+Jacobson&title=Ibogaine+and+its+congeners+are+sigma+2+receptor-selective+ligands+with+moderate+affinity&doi=10.1016%2F0014-2999%2895%2900247-I"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Ibogaine and its congeners are σ2 receptor-selective ligands with moderate affinity</span></div><div class="casAuthors">Bowen, Wayne D.; Vilner, Bertold J.; Williams, Wanda; Bertha, Craig M.; Kuehne, Martin E.; Jacobson, Arthur E.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">279</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">R1-R3</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Ibogaine (12-methoxyibogamine) exhibited moderate affinity for σ2 sites (Ki = 201 nM) and low affinity for σ1 sites (Ki = 8554 nM), thus showing 43-fold selectivity for σ2 receptors.  Tabernanthine (13-methoxyibogamine) and (±)-ibogamine had σ2 Ki = 194 nM and 137 nM, resp.  However, they showed 3- to 5-fold higher σ1 affinity compared to ibogaine, resulting in about 14-fold selectivity for σ2 sites over σ1.  A potential ibogaine metabolite, O-des-methyl-ibogaine, had markedly reduced σ2 affinity relative to ibogaine (Ki = 5,226 nM) and also lacked significant affinity for σ1 sites. (±)-Coronaridine ((±)-18-carbomethoxyibogamine) and harmaline (1-methyl-7-methoxy-3,4-dihydro-β-carboline) lacked significant affinity for either σ subtype.  Thus, σ2 receptors could play a role in the actions of ibogaine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqycw-jz291ZbVg90H21EOLACvtfcHk0lhsbU6a0GA_oA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXmtVymtro%253D&md5=94dd768cd7cb3b523d8031353ecadff1</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1016%2F0014-2999%2895%2900247-I&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0014-2999%252895%252900247-I%26sid%3Dliteratum%253Aachs%26aulast%3DBowen%26aufirst%3DW.%2BD.%26aulast%3DVilner%26aufirst%3DB.%2BJ.%26aulast%3DWilliams%26aufirst%3DW.%26aulast%3DBertha%26aufirst%3DC.%2BM.%26aulast%3DKuehne%26aufirst%3DM.%2BE.%26aulast%3DJacobson%26aufirst%3DA.%2BE.%26atitle%3DIbogaine%2520and%2520its%2520congeners%2520are%2520sigma%25202%2520receptor-selective%2520ligands%2520with%2520moderate%2520affinity%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D1995%26volume%3D279%26spage%3DR1%26epage%3D3%26doi%3D10.1016%2F0014-2999%2895%2900247-I" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wheeler, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mach, R. H.</span></span> <span> </span><span class="NLM_article-title">New N-substituted 9-azabicyclo[3.3.1]nonan-3alpha-yl phenylcarbamate analogs as sigma2 receptor ligands: synthesis, in vitro characterization, and evaluation as PET imaging and chemosensitization agents</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">1222</span>– <span class="NLM_lpage">1231</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2008.12.025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1016%2Fj.bmc.2008.12.025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=19119012" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtlOht7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2009&pages=1222-1231&author=W.+Chuauthor=J.+Xuauthor=D.+Zhouauthor=F.+Zhangauthor=L.+A.+Jonesauthor=K.+T.+Wheelerauthor=R.+H.+Mach&title=New+N-substituted+9-azabicyclo%5B3.3.1%5Dnonan-3alpha-yl+phenylcarbamate+analogs+as+sigma2+receptor+ligands%3A+synthesis%2C+in+vitro+characterization%2C+and+evaluation+as+PET+imaging+and+chemosensitization+agents&doi=10.1016%2Fj.bmc.2008.12.025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">New N-substituted 9-azabicyclo[3.3.1]nonan-3α-yl phenylcarbamate analogs as σ2 receptor ligands: Synthesis, in vitro characterization, and evaluation as PET imaging and chemosensitization agents</span></div><div class="casAuthors">Chu, Wenhua; Xu, Jinbin; Zhou, Dong; Zhang, Fanjie; Jones, Lynne A.; Wheeler, Kenneth T.; Mach, Robert H.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1222-1231</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A series of N-substituted 9-azabicyclo[3.3.1]nonan-3α-yl phenylcarbamate analogs were synthesized.  Among them, WC-26 and WC-59 were identified as the most potent σ2 receptor ligands (Ki = 2.58 and 0.82 nM, resp.) with high selectivity against σ1 (Ki of σ1/σ2 ratio = 557 and 2087, resp.). [18F]WC-59 was radiolabeled via a nucleophilic substitution of a mesylate precursor by [18F]fluoride, and in vitro direct binding studies of [18F]WC-59 were conducted using membrane prepns. from murine EMT-6 solid breast tumors.  The results indicate that [18F]WC-59 binds specifically to σ2 receptors in vitro (Kd = ∼2 nM).  Biodistribution studies of [18F]WC-59 in EMT-6 tumor-bearing mice indicated that the tracer was a less suitable candidate for clin. imaging studies than existing F-18 labeled σ2 receptor ligands.  The ability of WC-26 to enhance the cytotoxic effects of the chemotherapy drug, doxorubicin, was evaluated in cell culture using the mouse breast tumor EMT-6 and the human tumor MDA-MB435.  WC-26 greatly increased the ability of doxorubicin to kill these two tumor cell lines in vitro.  These results indicate that WC-26 is potentially a useful chemosensitizer for the treatment of cancer when combined with conventional chemotherapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqcNkdxZdeDmbVg90H21EOLACvtfcHk0lj9hbFGXZr5yw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtlOht7o%253D&md5=164a5c8a7e81d14338e3981d317d417b</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2008.12.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2008.12.025%26sid%3Dliteratum%253Aachs%26aulast%3DChu%26aufirst%3DW.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DZhou%26aufirst%3DD.%26aulast%3DZhang%26aufirst%3DF.%26aulast%3DJones%26aufirst%3DL.%2BA.%26aulast%3DWheeler%26aufirst%3DK.%2BT.%26aulast%3DMach%26aufirst%3DR.%2BH.%26atitle%3DNew%2520N-substituted%25209-azabicyclo%255B3.3.1%255Dnonan-3alpha-yl%2520phenylcarbamate%2520analogs%2520as%2520sigma2%2520receptor%2520ligands%253A%2520synthesis%252C%2520in%2520vitro%2520characterization%252C%2520and%2520evaluation%2520as%2520PET%2520imaging%2520and%2520chemosensitization%2520agents%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2009%26volume%3D17%26spage%3D1222%26epage%3D1231%26doi%3D10.1016%2Fj.bmc.2008.12.025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sahn, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mejia, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ray, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Price, T. J.</span></span> <span> </span><span class="NLM_article-title">Sigma 2 Receptor/Tmem97 Agonists Produce Long Lasting Antineuropathic Pain Effects in Mice</span>. <i>ACS Chem. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1801</span>– <span class="NLM_lpage">1811</span>, <span class="refDoi"> DOI: 10.1021/acschemneuro.7b00200</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschemneuro.7b00200" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtVCkt73I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=1801-1811&author=J.+J.+Sahnauthor=G.+L.+Mejiaauthor=P.+R.+Rayauthor=S.+F.+Martinauthor=T.+J.+Price&title=Sigma+2+Receptor%2FTmem97+Agonists+Produce+Long+Lasting+Antineuropathic+Pain+Effects+in+Mice&doi=10.1021%2Facschemneuro.7b00200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Sigma 2 Receptor/Tmem97 Agonists Produce Long Lasting Antineuropathic Pain Effects in Mice</span></div><div class="casAuthors">Sahn, James J.; Mejia, Galo L.; Ray, Pradipta R.; Martin, Stephen F.; Price, Theodore J.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Neuroscience</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1801-1811</span>CODEN:
                <span class="NLM_cas:coden">ACNCDM</span>;
        ISSN:<span class="NLM_cas:issn">1948-7193</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Neuropathic pain is an important medical problem with few effective treatments.  The sigma 1 receptor (σ1R) is a potential target for neuropathic pain therapeutics, and antagonists for this receptor are effective in preclin. models and are currently in phase II clin. trials.  Relatively little is known about the σ2R, which has recently been identified as transmembrane protein 97 (Tmem97).  The authors generated a series of σ1R and σ2R/Tmem97 agonists and antagonists and tested them for efficacy in the mouse spared nerve injury (SNI) model.  In agreement with previous reports, the authors find that σ1R ligands given intrathecally (IT) produce relief of SNI-induced mech. hypersensitivity.  The authors also find that the putative σ2R/Tmem97 agonists, DKR-1005, DKR-1051 and UKH-1114 (Ki ∼ 46 nM) lead to relief of SNI-induced mech. hypersensitivity, peaking at 48 h after dosing when given IT.  This effect is blocked by the putative σ2R/Tmem97 antagonist SAS-0132.  Systemic administration of UKH-1114 (10 mg/kg) relieves SNI-induced mech. hypersensitivity for 48 h with a peak magnitude of effect equiv. to 100 mg/kg gabapentin and without producing any motor impairment.  Finally, the authors find that the Tmem97 gene is expressed in mouse and human dorsal root ganglion (DRG) including populations of neurons that are involved in pain; however, the gene is also likely expressed in non-neuronal cells that may contribute to the obsd. behavioral effects.  The authors' results show robust anti-neuropathic pain effects of σ1R and σ2R/Tmem97 ligands, demonstrate that σ2R/Tmem97 is a novel neuropathic pain target, and identify UKH-1114 as a lead mol. for further development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrz2DAhBH9TXLVg90H21EOLACvtfcHk0lj9hbFGXZr5yw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtVCkt73I&md5=27d14b5ef6645a02332f051fab254f51</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1021%2Facschemneuro.7b00200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschemneuro.7b00200%26sid%3Dliteratum%253Aachs%26aulast%3DSahn%26aufirst%3DJ.%2BJ.%26aulast%3DMejia%26aufirst%3DG.%2BL.%26aulast%3DRay%26aufirst%3DP.%2BR.%26aulast%3DMartin%26aufirst%3DS.%2BF.%26aulast%3DPrice%26aufirst%3DT.%2BJ.%26atitle%3DSigma%25202%2520Receptor%252FTmem97%2520Agonists%2520Produce%2520Long%2520Lasting%2520Antineuropathic%2520Pain%2520Effects%2520in%2520Mice%26jtitle%3DACS%2520Chem.%2520Neurosci.%26date%3D2017%26volume%3D8%26spage%3D1801%26epage%3D1811%26doi%3D10.1021%2Facschemneuro.7b00200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Intagliata, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">King, T. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mesangeau, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seminerio, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chin, F. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsumoto, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLaughlin, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avery, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCurdy, C. R.</span></span> <span> </span><span class="NLM_article-title">Discovery of a Highly Selective Sigma-2 Receptor Ligand, 1-(4-(6,7-Dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)butyl)-3-methyl-1H-benzo[d]imidazol-2(3H)-one (CM398), with Drug-Like Properties and Antinociceptive Effects In Vivo</span>. <i>AAPS J.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">94</span>, <span class="refDoi"> DOI: 10.1208/s12248-020-00472-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1208%2Fs12248-020-00472-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=32691179" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhsVaqtb3J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2020&pages=94&author=S.+Intagliataauthor=A.+Sharmaauthor=T.+I.+Kingauthor=C.+Mesangeauauthor=M.+Seminerioauthor=F.+T.+Chinauthor=L.+L.+Wilsonauthor=R.+R.+Matsumotoauthor=J.+P.+McLaughlinauthor=B.+A.+Averyauthor=C.+R.+McCurdy&title=Discovery+of+a+Highly+Selective+Sigma-2+Receptor+Ligand%2C+1-%284-%286%2C7-Dimethoxy-3%2C4-dihydroisoquinolin-2%281H%29-yl%29butyl%29-3-methyl-1H-benzo%5Bd%5Dimidazol-2%283H%29-one+%28CM398%29%2C+with+Drug-Like+Properties+and+Antinociceptive+Effects+In+Vivo&doi=10.1208%2Fs12248-020-00472-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Highly Selective Sigma-2 Receptor Ligand, 1-(4-(6,7-Dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)butyl)-3-methyl-1H-benzo[d]imidazol-2(3H)-one (CM398), with Drug-Like Properties and Antinociceptive Effects In Vivo</span></div><div class="casAuthors">Intagliata, Sebastiano; Sharma, Abhisheak; King, Tamara I.; Mesangeau, Christophe; Seminerio, Michael; Chin, Frederick T.; Wilson, Lisa L.; Matsumoto, Rae R.; McLaughlin, Jay P.; Avery, Bonnie A.; McCurdy, Christopher R.</div><div class="citationInfo"><span class="NLM_cas:title">AAPS Journal</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">94</span>CODEN:
                <span class="NLM_cas:coden">AJAOB6</span>;
        ISSN:<span class="NLM_cas:issn">1550-7416</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">The sigma-2 receptor has been cloned and identified as Tmem97, which is a transmembrane protein involved in intracellular Ca2+ regulation and cholesterol homeostasis.  Since its discovery, the sigma-2 receptor has been an extremely controversial target, and many efforts have been made to elucidate the functional role of this receptor during physiol. and pathol. conditions.  Recently, this receptor has been proposed as a potential target to treat neuropathic pain due to the ability of sigma-2 receptor agonists to relieve mech. hyperalgesia in mice model of chronic pain.  In the present work, we developed a highly selective sigma-2 receptor ligand (sigma-1/sigma-2 selectivity ratio > 1000), 1-(4-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)butyl)-3-methyl-1H- benzo[d]imidazol-2(3H)-one (CM398), with an encouraging in vitro and in vivo pharmacol. profile in rodents.  In particular, radioligand binding studies demonstrated that CM398 had preferential affinity for sigma-2 receptor compared with sigma-1 receptor and at least four other neurotransmitter receptors sites, including the norepinephrine transporter.  Following oral administration, CM398 showed rapid absorption and peak plasma concn. (Cmax) occurred within 10 min of dosing.  Moreover, the compd. showed adequate, abs. oral bioavailability of 29.0%.  Finally, CM398 showed promising anti-inflammatory analgesic effects in the formalin model of inflammatory pain in mice.  The results collected in this study provide more evidence that selective sigma-2 receptor ligands can be useful tools in the development of novel pain therapeutics and altogether, these data suggest that CM398 is a suitable lead candidate for further evaluation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopUUccVNqFTLVg90H21EOLACvtfcHk0lj9hbFGXZr5yw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhsVaqtb3J&md5=91e614b3d520e9d8cc6ac195fe490220</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1208%2Fs12248-020-00472-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1208%252Fs12248-020-00472-x%26sid%3Dliteratum%253Aachs%26aulast%3DIntagliata%26aufirst%3DS.%26aulast%3DSharma%26aufirst%3DA.%26aulast%3DKing%26aufirst%3DT.%2BI.%26aulast%3DMesangeau%26aufirst%3DC.%26aulast%3DSeminerio%26aufirst%3DM.%26aulast%3DChin%26aufirst%3DF.%2BT.%26aulast%3DWilson%26aufirst%3DL.%2BL.%26aulast%3DMatsumoto%26aufirst%3DR.%2BR.%26aulast%3DMcLaughlin%26aufirst%3DJ.%2BP.%26aulast%3DAvery%26aufirst%3DB.%2BA.%26aulast%3DMcCurdy%26aufirst%3DC.%2BR.%26atitle%3DDiscovery%2520of%2520a%2520Highly%2520Selective%2520Sigma-2%2520Receptor%2520Ligand%252C%25201-%25284-%25286%252C7-Dimethoxy-3%252C4-dihydroisoquinolin-2%25281H%2529-yl%2529butyl%2529-3-methyl-1H-benzo%255Bd%255Dimidazol-2%25283H%2529-one%2520%2528CM398%2529%252C%2520with%2520Drug-Like%2520Properties%2520and%2520Antinociceptive%2520Effects%2520In%2520Vivo%26jtitle%3DAAPS%2520J.%26date%3D2020%26volume%3D22%26spage%3D94%26doi%3D10.1208%2Fs12248-020-00472-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bruna, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Videla, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Argyriou, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Velasco, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villoria, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santos, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nadal, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavaletti, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alberti, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Briani, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalofonos, H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortinovis, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sust, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaqué, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klein, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plata-Salamán, C.</span></span> <span> </span><span class="NLM_article-title">Efficacy of a Novel Sigma-1 Receptor Antagonist for Oxaliplatin-Induced Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase IIa Clinical Trial</span>. <i>Neurotherapeutics</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">178</span>– <span class="NLM_lpage">189</span>, <span class="refDoi"> DOI: 10.1007/s13311-017-0572-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1007%2Fs13311-017-0572-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=28924870" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhsFantb3E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2018&pages=178-189&author=J.+Brunaauthor=S.+Videlaauthor=A.+A.+Argyriouauthor=R.+Velascoauthor=J.+Villoriaauthor=C.+Santosauthor=C.+Nadalauthor=G.+Cavalettiauthor=P.+Albertiauthor=C.+Brianiauthor=H.+P.+Kalofonosauthor=D.+Cortinovisauthor=M.+Sustauthor=A.+Vaqu%C3%A9author=T.+Kleinauthor=C.+Plata-Salam%C3%A1n&title=Efficacy+of+a+Novel+Sigma-1+Receptor+Antagonist+for+Oxaliplatin-Induced+Neuropathy%3A+A+Randomized%2C+Double-Blind%2C+Placebo-Controlled+Phase+IIa+Clinical+Trial&doi=10.1007%2Fs13311-017-0572-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy of a Novel Sigma-1 Receptor Antagonist for Oxaliplatin-Induced Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase IIa Clinical Trial</span></div><div class="casAuthors">Bruna, Jordi; Videla, Sebastian; Argyriou, Andreas A.; Velasco, Roser; Villoria, Jesus; Santos, Cristina; Nadal, Cristina; Cavaletti, Guido; Alberti, Paola; Briani, Chiara; Kalofonos, Haralabos P.; Cortinovis, Diego; Sust, Mariano; Vaque, Anna; Klein, Thomas; Plata-Salaman, Carlos</div><div class="citationInfo"><span class="NLM_cas:title">Neurotherapeutics</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">178-189</span>CODEN:
                <span class="NLM_cas:coden">NEURNV</span>;
        ISSN:<span class="NLM_cas:issn">1878-7479</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">This trial assessed the efficacy of MR309 (a novel selective sigma-1 receptor ligand previously developed as E-52862) in ameliorating oxaliplatin-induced peripheral neuropathy (oxaipn).  A discontinuous regimen of MR309 (400 mg/day, 5 days per cycle) was tested in patients with colorectal cancer receiving FOLFOX in a phase II, randomized, double-blind, placebo-controlled, multicenter clin. trial.  Outcome measures included changes in 24-wk quant. measures of thermal sensitivity and total neuropathy score.  In total, 124 patients were randomized (1:1) to MR309 or placebo.  Sixty-three (50.8%) patients withdrew prematurely before completing 12 planned oxaliplatin cycles.  Premature withdrawal because of cancer progression was less frequent in the MR309 group (7.4% vs 25.0% with placebo; p = 0.054).  MR309 significantly reduced cold pain threshold temp. [mean treatment effect difference (SE) vs placebo: 5.29 (1.60)°C; p = 0.001] and suprathreshold cold stimulus-evoked pain intensity [mean treatment effect difference: 1.24 (0.57) points; p = 0.032].  Total neuropathy score, health-related quality-of-life measures, and nerve-conduction parameters changed similarly in both arms, whereas the proportion of patients with severe chronic neuropathy (National Cancer Institute Common Terminol. Criteria for Adverse Events ≥ 3) was significantly lower in the MR309 group (3.0% vs 18.2% with placebo; p = 0.046).  The total amt. of oxaliplatin delivered was greater in the active arm (1618.9 mg vs 1453.8 mg with placebo; p = 0.049).  Overall, 19.0% of patients experienced at least 1 treatment-related adverse event (25.8% and 11.9% with MR309 and placebo, resp.).  Intermittent treatment with MR309 was assocd. with reduced acute oxaipn and higher oxaliplatin exposure, and showed a potential neuroprotective role for chronic cumulative oxaipn.  Furthermore, MR309 showed an acceptable safety profile.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTkVyo1fPRe7Vg90H21EOLACvtfcHk0liUkv4d6r2fUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhsFantb3E&md5=78eac14b1175a004af19c4c9a53af1be</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1007%2Fs13311-017-0572-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs13311-017-0572-5%26sid%3Dliteratum%253Aachs%26aulast%3DBruna%26aufirst%3DJ.%26aulast%3DVidela%26aufirst%3DS.%26aulast%3DArgyriou%26aufirst%3DA.%2BA.%26aulast%3DVelasco%26aufirst%3DR.%26aulast%3DVilloria%26aufirst%3DJ.%26aulast%3DSantos%26aufirst%3DC.%26aulast%3DNadal%26aufirst%3DC.%26aulast%3DCavaletti%26aufirst%3DG.%26aulast%3DAlberti%26aufirst%3DP.%26aulast%3DBriani%26aufirst%3DC.%26aulast%3DKalofonos%26aufirst%3DH.%2BP.%26aulast%3DCortinovis%26aufirst%3DD.%26aulast%3DSust%26aufirst%3DM.%26aulast%3DVaqu%25C3%25A9%26aufirst%3DA.%26aulast%3DKlein%26aufirst%3DT.%26aulast%3DPlata-Salam%25C3%25A1n%26aufirst%3DC.%26atitle%3DEfficacy%2520of%2520a%2520Novel%2520Sigma-1%2520Receptor%2520Antagonist%2520for%2520Oxaliplatin-Induced%2520Neuropathy%253A%2520A%2520Randomized%252C%2520Double-Blind%252C%2520Placebo-Controlled%2520Phase%2520IIa%2520Clinical%2520Trial%26jtitle%3DNeurotherapeutics%26date%3D2018%26volume%3D15%26spage%3D178%26epage%3D189%26doi%3D10.1007%2Fs13311-017-0572-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hjørnevik, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cipriano, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gulaka, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holley, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gandhi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoon, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mittra, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaharchuk, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gambhir, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCurdy, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chin, F. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biswal, S.</span></span> <span> </span><span class="NLM_article-title">Biodistribution and Radiation Dosimetry of (18)F-FTC-146 in Humans</span>. <i>J. Nucl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">2004</span>– <span class="NLM_lpage">2009</span>, <span class="refDoi"> DOI: 10.2967/jnumed.117.192641</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.2967%2Fjnumed.117.192641" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=28572487" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A280%3ADC%252BC1cnktVOguw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2017&pages=2004-2009&author=T.+Hj%C3%B8rnevikauthor=P.+W.+Ciprianoauthor=B.+Shenauthor=J.+H.+Parkauthor=P.+Gulakaauthor=D.+Holleyauthor=H.+Gandhiauthor=D.+Yoonauthor=E.+S.+Mittraauthor=G.+Zaharchukauthor=S.+S.+Gambhirauthor=C.+R.+McCurdyauthor=F.+T.+Chinauthor=S.+Biswal&title=Biodistribution+and+Radiation+Dosimetry+of+%2818%29F-FTC-146+in+Humans&doi=10.2967%2Fjnumed.117.192641"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Biodistribution and Radiation Dosimetry of (18)F-FTC-146 in Humans</span></div><div class="casAuthors">Hjornevik Trine; Cipriano Peter W; Shen Bin; Park Jun Hyung; Gulaka Praveen; Holley Dawn; Gandhi Harsh; Yoon Daehyun; Mittra Erik S; Zaharchuk Greg; Gambhir Sanjiv S; Chin Frederick T; Biswal Sandip; Hjornevik Trine; Hjornevik Trine; McCurdy Christopher R; McCurdy Christopher R</div><div class="citationInfo"><span class="NLM_cas:title">Journal of nuclear medicine : official publication, Society of Nuclear Medicine</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2004-2009</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The purpose of this study was to assess safety, biodistribution, and radiation dosimetry in humans for the highly selective σ-1 receptor PET agent (18)F-6-(3-fluoropropyl)-3-(2-(azepan-1-yl)ethyl)benzo[d]thiazol-2(3H)-one ((18)F-FTC-146).  Methods: Ten healthy volunteers (5 women, 5 men; age ± SD, 34.3 ± 6.5 y) were recruited, and written informed consent was obtained from all participants.  Series of whole-body PET/MRI examinations were acquired for up to 3 h after injection (357.2 ± 48.8 MBq).  Blood samples were collected, and standard vital signs (heart rate, pulse oximetry, and body temperature) were monitored at regular intervals.  Regions of interest were delineated, time-activity curves were calculated, and organ uptake and dosimetry were estimated.  Results: All subjects tolerated the PET/MRI examination well, and no adverse reactions to (18)F-FTC-146 were reported.  High accumulation of (18)F-FTC-146 was observed in σ-1 receptor-dense organs such as the pancreas and spleen, moderate uptake in the brain and myocardium, and low uptake in bone and muscle.  High uptake was also observed in the kidneys and bladder, indicating renal tracer clearance.  The effective dose of (18)F-FTC-146 was 0.0259 ± 0.0034 mSv/MBq (range, 0.0215-0.0301 mSv/MBq).  Conclusion: First-in-human studies with clinical-grade (18)F-FTC-146 were successful.  Injection of (18)F-FTC-146 is safe, and absorbed doses are acceptable.  The potential of (18)F-FTC-146 as an imaging agent for a variety of neuroinflammatory diseases is currently under investigation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRJ_SCYdyBBVOIHSmpohpd0fW6udTcc2eZhzI0Ud2kshrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cnktVOguw%253D%253D&md5=00a57b42e5557e5ad6655d45188a21d1</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.2967%2Fjnumed.117.192641&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2967%252Fjnumed.117.192641%26sid%3Dliteratum%253Aachs%26aulast%3DHj%25C3%25B8rnevik%26aufirst%3DT.%26aulast%3DCipriano%26aufirst%3DP.%2BW.%26aulast%3DShen%26aufirst%3DB.%26aulast%3DPark%26aufirst%3DJ.%2BH.%26aulast%3DGulaka%26aufirst%3DP.%26aulast%3DHolley%26aufirst%3DD.%26aulast%3DGandhi%26aufirst%3DH.%26aulast%3DYoon%26aufirst%3DD.%26aulast%3DMittra%26aufirst%3DE.%2BS.%26aulast%3DZaharchuk%26aufirst%3DG.%26aulast%3DGambhir%26aufirst%3DS.%2BS.%26aulast%3DMcCurdy%26aufirst%3DC.%2BR.%26aulast%3DChin%26aufirst%3DF.%2BT.%26aulast%3DBiswal%26aufirst%3DS.%26atitle%3DBiodistribution%2520and%2520Radiation%2520Dosimetry%2520of%2520%252818%2529F-FTC-146%2520in%2520Humans%26jtitle%3DJ.%2520Nucl.%2520Med.%26date%3D2017%26volume%3D58%26spage%3D2004%26epage%3D2009%26doi%3D10.2967%2Fjnumed.117.192641" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Avery, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vuppala, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jamalapuram, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mesangeau, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chin, F. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCurdy, C. R.</span></span> <span> </span><span class="NLM_article-title">Quantification of highly selective sigma-1 receptor antagonist CM304 using liquid chromatography tandem mass spectrometry and its application to a pre-clinical pharmacokinetic study</span>. <i>Drug Test. Anal.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1236</span>– <span class="NLM_lpage">1242</span>, <span class="refDoi"> DOI: 10.1002/dta.2156</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1002%2Fdta.2156" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=28039926" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BC2sXlvVClsrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2017&pages=1236-1242&author=B.+A.+Averyauthor=P.+K.+Vuppalaauthor=S.+Jamalapuramauthor=A.+Sharmaauthor=C.+Mesangeauauthor=F.+T.+Chinauthor=C.+R.+McCurdy&title=Quantification+of+highly+selective+sigma-1+receptor+antagonist+CM304+using+liquid+chromatography+tandem+mass+spectrometry+and+its+application+to+a+pre-clinical+pharmacokinetic+study&doi=10.1002%2Fdta.2156"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Quantification of highly selective sigma-1 receptor antagonist CM304 using liquid chromatography tandem mass spectrometry and its application to a pre-clinical pharmacokinetic study</span></div><div class="casAuthors">Avery, Bonnie A.; Vuppala, Pradeep K.; Jamalapuram, Seshulatha; Sharma, Abhisheak; Mesangeau, Christophe; Chin, Frederick T.; McCurdy, Christopher R.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Testing and Analysis</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1236-1242</span>CODEN:
                <span class="NLM_cas:coden">DTARBG</span>;
        ISSN:<span class="NLM_cas:issn">1942-7603</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">An ultra-performance liq. chromatog.-tandem mass spectrometry (UPLC-MS/MS) method was developed and validated for quantification of CM304, a novel and highly selective sigma-1 receptor antagonist that has recently entered into human clin. trials.  A structural analog of CM304, SN56, was used as the internal std. (IS).  Chromatog. sepn. was achieved on an Acquity UPLC® BEH C18 (1.7 μm, 2.1 mm × 50 mm) column using a mobile phase [water:methanol (0.1%vol./vol. formic acid; 50:50, %vol./vol.)] at a flow rate of 0.2 mL/min.  Mass spectrometric detection was performed in the pos. ionization mode with multiple reaction monitoring (MRM) using m/z transitions of 337 > 238 for CM304 and 319 > 220 for the IS.  The method was found to be linear and reproducible with a regression coeff. consistently >0.99 for the calibration range of 3 to 3000 ng/mL.  The extn. recovery ranged from 91.5 to 98.4% from spiked (7.5, 300 and 2526 ng/mL) plasma quality control samples.  The precision (%RSD; 1.1 to 2.9%) and accuracy (%RE; -1.9 to 1.8%) were within acceptable limit.  The validated method was successfully applied to a single dose oral and i.v. (I.V.) pharmacokinetic study of CM304 in rats.  Following I. V. administration, the compd. exhibited adequate exposure along with high extravascular distribution and insignificant amt. of extra hepatic metab.  Copyright © 2016 John Wiley & Sons, Ltd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpxx25OJ92NuLVg90H21EOLACvtfcHk0ljMU_eue40tLw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXlvVClsrc%253D&md5=7b647717f8384c5222631a6926fa5e5d</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1002%2Fdta.2156&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fdta.2156%26sid%3Dliteratum%253Aachs%26aulast%3DAvery%26aufirst%3DB.%2BA.%26aulast%3DVuppala%26aufirst%3DP.%2BK.%26aulast%3DJamalapuram%26aufirst%3DS.%26aulast%3DSharma%26aufirst%3DA.%26aulast%3DMesangeau%26aufirst%3DC.%26aulast%3DChin%26aufirst%3DF.%2BT.%26aulast%3DMcCurdy%26aufirst%3DC.%2BR.%26atitle%3DQuantification%2520of%2520highly%2520selective%2520sigma-1%2520receptor%2520antagonist%2520CM304%2520using%2520liquid%2520chromatography%2520tandem%2520mass%2520spectrometry%2520and%2520its%2520application%2520to%2520a%2520pre-clinical%2520pharmacokinetic%2520study%26jtitle%3DDrug%2520Test.%2520Anal.%26date%3D2017%26volume%3D9%26spage%3D1236%26epage%3D1242%26doi%3D10.1002%2Fdta.2156" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span> <i>ClinicalTrails.gov</i>, <span class="NLM_publisher-name">NIH</span>, <span class="NLM_publisher-loc">Bethesda, MD</span>. Identifier: NCT02753101,
[18F]FTC-146 PET/MRI in Healthy Volunteers and in CRPS and Sciatica.
Available from: <a href="https://clinicaltrials.gov/ct2/show/NCT02753101?term=FTC146&amp;draw=2&amp;rank=1" class="extLink">https://clinicaltrials.gov/ct2/show/NCT02753101?term=FTC146&draw=2&rank=1</a> (accessed Feb 16, 2017).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+ClinicalTrails.gov%2C+NIH%2C+Bethesda%2C+MD.+Identifier%3A+NCT02753101%2C%0A%5B18F%5DFTC-146+PET%2FMRI+in+Healthy+Volunteers+and+in+CRPS+and+Sciatica.%0AAvailable+from%3A+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT02753101%3Fterm%3DFTC146%26draw%3D2%26rank%3D1+%28accessed+Feb+16%2C+2017%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DClinicalTrails.gov%26pub%3DNIH" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cirino, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eans, S. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medina, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mottinelli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Intagliata, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCurdy, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLaughlin, J. P.</span></span> <span> </span><span class="NLM_article-title">Characterization of Sigma 1 Receptor Antagonist CM-304 and Its Analog, AZ-66: Novel Therapeutics Against Allodynia and Induced Pain</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">678</span>, <span class="refDoi"> DOI: 10.3389/fphar.2019.00678</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.3389%2Ffphar.2019.00678" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=31258480" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BB3cXktlGqsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=678&author=T.+J.+Cirinoauthor=S.+O.+Eansauthor=J.+M.+Medinaauthor=L.+L.+Wilsonauthor=M.+Mottinelliauthor=S.+Intagliataauthor=C.+R.+McCurdyauthor=J.+P.+McLaughlin&title=Characterization+of+Sigma+1+Receptor+Antagonist+CM-304+and+Its+Analog%2C+AZ-66%3A+Novel+Therapeutics+Against+Allodynia+and+Induced+Pain&doi=10.3389%2Ffphar.2019.00678"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of sigma 1 receptor antagonist CM-304 and its analog, AZ-66: novel therapeutics against allodynia and induced pain</span></div><div class="casAuthors">Cirino, Thomas J.; Eans, Shainnel O.; Medina, Jessica M.; Wilson, Lisa L.; Mottinelli, Marco; Intagliata, Sebastiano; McCurdy, Christopher R.; McLaughlin, Jay P.</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Pharmacology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">678</span>CODEN:
                <span class="NLM_cas:coden">FPRHAU</span>;
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">Sigma-1 receptors (S1R) and sigma-2 receptors (S2R) may modulate nociception without the liabilities of opioids, offering a promising therapeutic target to treat pain.  The purpose of this study was to investigate the in vivo analgesic and anti-allodynic activity of two novel sigma receptor antagonists, the S1R-selective CM-304 and its analog the non-selective S1R/S2R antagonist AZ-66.  Inhibition of thermal, induced chem. or inflammatory pain, as well as the allodynia resulting from chronic nerve constriction injury (CCI) and cisplatin exposure as models of neuropathic pain were assessed in male mice.  Both sigma receptor antagonists dose-dependently (10-45 mg/kg, i.p.) reduced allodynia in the CCI and cisplatin neuropathic pain models, equiv. at the higher dose to the effect of the control analgesic gabapentin (50 mg/kg, i.p.), although AZ-66 demonstrated a much longer duration of action.  Both CM-304 and AZ-66 produced antinociception in the writhing test [0.48 (0.09-1.82) and 2.31 (1.02-4.81) mg/kg, i.p., resp.] equiv. to morphine [1.75 (0.31-7.55) mg/kg, i.p.].  Likewise, pretreatment (i.p.) with either sigma-receptor antagonist dose-dependently produced antinociception in the formalin paw assay of inflammatory pain.  However, CM-304 [17.5 (12.7-25.2) mg/kg, i.p.) and AZ-66 [11.6 (8.29-15.6) mg/kg, i.p.) were less efficacious than morphine [3.87 (2.85-5.18) mg/kg, i.p.] in the 55°C warm-water tail-withdrawal assay.  While AZ-66 exhibited modest sedative effects in a rotarod assay and conditioned place aversion, CM-304 did not produce significant effects in the place conditioning assay.  Overall, these results demonstrate the S1R selective antagonist CM-304 produces antinociception and anti-allodynia with fewer liabilities than established therapeutics, supporting the use of S1R antagonists as potential treatments for chronic pain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSXYurn5Us5bVg90H21EOLACvtfcHk0liMi3q-U6z1Ow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXktlGqsbY%253D&md5=f271c2c690934da285e86b94d0d86920</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2019.00678&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2019.00678%26sid%3Dliteratum%253Aachs%26aulast%3DCirino%26aufirst%3DT.%2BJ.%26aulast%3DEans%26aufirst%3DS.%2BO.%26aulast%3DMedina%26aufirst%3DJ.%2BM.%26aulast%3DWilson%26aufirst%3DL.%2BL.%26aulast%3DMottinelli%26aufirst%3DM.%26aulast%3DIntagliata%26aufirst%3DS.%26aulast%3DMcCurdy%26aufirst%3DC.%2BR.%26aulast%3DMcLaughlin%26aufirst%3DJ.%2BP.%26atitle%3DCharacterization%2520of%2520Sigma%25201%2520Receptor%2520Antagonist%2520CM-304%2520and%2520Its%2520Analog%252C%2520AZ-66%253A%2520Novel%2520Therapeutics%2520Against%2520Allodynia%2520and%2520Induced%2520Pain%26jtitle%3DFront.%2520Pharmacol.%26date%3D2019%26volume%3D10%26spage%3D678%26doi%3D10.3389%2Ffphar.2019.00678" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Popa, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamble, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanumuri, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">King, T. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berthold, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Intagliata, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCurdy, C. R.</span></span> <span> </span><span class="NLM_article-title">Bioanalytical method development and pharmacokinetics of MCI-92, a sigma-1 receptor ligand</span>. <i>J. Pharm. Biomed. Anal.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>191</i></span>,  <span class="NLM_fpage">113610</span>, <span class="refDoi"> DOI: 10.1016/j.jpba.2020.113610</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1016%2Fj.jpba.2020.113610" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=32971495" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhvV2ms7rE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=191&publication_year=2020&pages=113610&author=R.+Popaauthor=S.+H.+Kambleauthor=R.+S.+Kanumuriauthor=T.+I.+Kingauthor=E.+C.+Bertholdauthor=S.+Intagliataauthor=A.+Sharmaauthor=C.+R.+McCurdy&title=Bioanalytical+method+development+and+pharmacokinetics+of+MCI-92%2C+a+sigma-1+receptor+ligand&doi=10.1016%2Fj.jpba.2020.113610"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Bioanalytical method development and pharmacokinetics of MCI-92, a sigma-1 receptor ligand</span></div><div class="casAuthors">Popa, Raluca; Kamble, Shyam H.; Kanumuri, Raju S.; King, Tamara I.; Berthold, Erin C.; Intagliata, Sebastiano; Sharma, Abhisheak; McCurdy, Christopher R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmaceutical and Biomedical Analysis</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">191</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">113610</span>CODEN:
                <span class="NLM_cas:coden">JPBADA</span>;
        ISSN:<span class="NLM_cas:issn">0731-7085</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Sigma-1 receptors are found throughout the nervous system and play a role in regulating nociception.  They are highly expressed in nerve injury, making them a potential target for the treatment of neuropathic pain.  Although sigma-1 receptor antagonists have been shown to have anti-nociceptive and anti-allodynic effects, improved selectivity of these ligands is needed to further investigate their potential to treat neuropathic pain.  MCI-92 is a novel, selective sigma-1 receptor ligand developed to address this need.  A sensitive and rapid ultra-performance liq. chromatog. tandem mass spectrometry (UPLC-MS/MS) method was developed and validated for the quantification of MCI-92 in mouse plasma and brain homogenate.  A structural analog of the analyte, MCI-147, was used as the internal std. (IS).  The chromatog. sepn. was achieved on an Acquity UPLC BEH C18 column using a mobile phase consisting of water acidified with 0.1% vol./vol. formic acid and acetonitrile with gradient elution over 3.2 min.  The method was linear over a concn. range of 1-200 ng/mL.  Multiple reaction monitoring in the pos. ionization mode was used for the mass spectrometric quantitation using m/z transitions 369.2 > 126.0 for MCI-92 and 448.9 > 350.1 for the IS.  The method was successfully applied to the anal. of plasma and brain samples obtained in the course of oral and i.v. pharmacokinetic studies in CD-1 mice.  MCI-92 showed a high vol. of distribution (11.3 ± 0.6 L/kg) and rapid clearance (6.1 ± 0.8 L/h/kg) from systemic circulation.  The concn. of the MCI-92 was higher in the brain than in plasma throughout all terminal time points, indicating high blood-to-brain partitioning and slow brain clearance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQD73nMkm8QrVg90H21EOLACvtfcHk0lhuUMM6WCNIWQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhvV2ms7rE&md5=5492bcf0f2472efc9d9ef4eb90ced605</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1016%2Fj.jpba.2020.113610&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jpba.2020.113610%26sid%3Dliteratum%253Aachs%26aulast%3DPopa%26aufirst%3DR.%26aulast%3DKamble%26aufirst%3DS.%2BH.%26aulast%3DKanumuri%26aufirst%3DR.%2BS.%26aulast%3DKing%26aufirst%3DT.%2BI.%26aulast%3DBerthold%26aufirst%3DE.%2BC.%26aulast%3DIntagliata%26aufirst%3DS.%26aulast%3DSharma%26aufirst%3DA.%26aulast%3DMcCurdy%26aufirst%3DC.%2BR.%26atitle%3DBioanalytical%2520method%2520development%2520and%2520pharmacokinetics%2520of%2520MCI-92%252C%2520a%2520sigma-1%2520receptor%2520ligand%26jtitle%3DJ.%2520Pharm.%2520Biomed.%2520Anal.%26date%3D2020%26volume%3D191%26spage%3D113610%26doi%3D10.1016%2Fj.jpba.2020.113610" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Villard, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Espallergues, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keller, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vamvakides, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maurice, T.</span></span> <span> </span><span class="NLM_article-title">Anti-amnesic and neuroprotective potentials of the mixed muscarinic receptor/sigma 1 (σ1) ligand ANAVEX2–73, a novel aminotetrahydrofuran derivative</span>. <i>J. Psychopharmacol. (London, U. K.)</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">1101</span>– <span class="NLM_lpage">1117</span>, <span class="refDoi"> DOI: 10.1177/0269881110379286</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1177%2F0269881110379286" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=20829307" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1Gkur%252FF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2011&pages=1101-1117&author=V.+Villardauthor=J.+Espallerguesauthor=E.+Kellerauthor=A.+Vamvakidesauthor=T.+Maurice&title=Anti-amnesic+and+neuroprotective+potentials+of+the+mixed+muscarinic+receptor%2Fsigma+1+%28%CF%831%29+ligand+ANAVEX2%E2%80%9373%2C+a+novel+aminotetrahydrofuran+derivative&doi=10.1177%2F0269881110379286"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-amnesic and neuroprotective potentials of the mixed muscarinic receptor/sigma1 (σ1) ligand ANAVEX2-73, a novel aminotetrahydrofuran derivative</span></div><div class="casAuthors">Villard, Vanessa; Espallergues, Julie; Keller, Emeline; Vamvakides, Alexandre; Maurice, Tangui</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Psychopharmacology (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1101-1117</span>CODEN:
                <span class="NLM_cas:coden">JOPSEQ</span>;
        ISSN:<span class="NLM_cas:issn">0269-8811</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications Ltd.</span>)
        </div><div class="casAbstract">Tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride (ANAVEX2-73) binds to muscarinic acetylcholine and sigma1 (σ1) receptors with affinities in the low micromolar range.  We characterized its anti-amnesic and neuroprotective potentials in pharmacol. and pathol. amnesia models.  Spatial working memory was evaluated using spontaneous alternation in the Y-maze and non-spatial memory using passive avoidance procedures.  ANAVEX2-73 (0.01-3.0 mg/kg i.p.) alleviated the scopolamine- and dizocilpine-induced learning impairments.  ANAVEX2-73 (300 μg/kg) also reversed the learning deficits in mice injected with Aβ25-35 peptide, a non-transgenic Alzheimer's disease model.  When the drug was injected simultaneously with Aβ25-35, 7 days before the tests, it blocked the appearance of learning impairments.  This protective activity was confirmed since ANAVEX2-73 blocked the Aβ25-35-induced oxidative stress in the hippocampus.  This effect was differentially sensitive to the muscarinic receptor antagonist scopolamine or the σ1 protein antagonist BD1047, confirming the mixed muscarinic/σ1 pharmacol. action.  Finally, its unique demethyl metabolite, ANAVEX19-144, was also effective and ANAVEX2-73 presented a longer duration of action, effective 12 h before Aβ25-35, than its related compd. ANAVEX1-41.  The neuroprotective activity of ANAVEX2-73, its mixed cholinergic/σ1 activity, its low active dose range and its long duration of action together reinforce its therapeutic potential in Alzheimer's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWVEQ6V9EfObVg90H21EOLACvtfcHk0lhuUMM6WCNIWQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1Gkur%252FF&md5=4a9ed81d07ba7a7e11b72385f60d941f</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1177%2F0269881110379286&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F0269881110379286%26sid%3Dliteratum%253Aachs%26aulast%3DVillard%26aufirst%3DV.%26aulast%3DEspallergues%26aufirst%3DJ.%26aulast%3DKeller%26aufirst%3DE.%26aulast%3DVamvakides%26aufirst%3DA.%26aulast%3DMaurice%26aufirst%3DT.%26atitle%3DAnti-amnesic%2520and%2520neuroprotective%2520potentials%2520of%2520the%2520mixed%2520muscarinic%2520receptor%252Fsigma%25201%2520%2528%25CF%25831%2529%2520ligand%2520ANAVEX2%25E2%2580%259373%252C%2520a%2520novel%2520aminotetrahydrofuran%2520derivative%26jtitle%3DJ.%2520Psychopharmacol.%2520%2528London%252C%2520U.%2520K.%2529%26date%3D2011%26volume%3D25%26spage%3D1101%26epage%3D1117%26doi%3D10.1177%2F0269881110379286" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hirata, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamaguchi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takamura, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takagi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukushima, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwakami, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saitoh, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakagawa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamada, T.</span></span> <span> </span><span class="NLM_article-title">A novel neurotrophic agent, T-817MA [1-{3-[2-(1-benzothiophen-5-yl) ethoxy] propyl}-3-azetidinol maleate], attenuates amyloid-beta-induced neurotoxicity and promotes neurite outgrowth in rat cultured central nervous system neurons</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>314</i></span>,  <span class="NLM_fpage">252</span>– <span class="NLM_lpage">259</span>, <span class="refDoi"> DOI: 10.1124/jpet.105.083543</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1124%2Fjpet.105.083543" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=15798005" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BD2MXmtVeju7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=314&publication_year=2005&pages=252-259&author=K.+Hirataauthor=H.+Yamaguchiauthor=Y.+Takamuraauthor=A.+Takagiauthor=T.+Fukushimaauthor=N.+Iwakamiauthor=A.+Saitohauthor=M.+Nakagawaauthor=T.+Yamada&title=A+novel+neurotrophic+agent%2C+T-817MA+%5B1-%7B3-%5B2-%281-benzothiophen-5-yl%29+ethoxy%5D+propyl%7D-3-azetidinol+maleate%5D%2C+attenuates+amyloid-beta-induced+neurotoxicity+and+promotes+neurite+outgrowth+in+rat+cultured+central+nervous+system+neurons&doi=10.1124%2Fjpet.105.083543"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">A novel neurotrophic agent, T-817MA [1-{3-[2-(1-benzothiophen-5-yl)ethoxy]propyl}-3-azetidinol maleate], attenuates amyloid-β-induced neurotoxicity and promotes neurite outgrowth in rat cultured central nervous system neurons</span></div><div class="casAuthors">Hirata, Kazunari; Yamaguchi, Hidetoshi; Takamura, Yusaku; Takagi, Akiko; Fukushima, Tetsuo; Iwakami, Noboru; Saitoh, Akihito; Nakagawa, Masaya; Yamada, Tatsuo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">314</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">252-259</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Progressive neuronal loss in Alzheimer's disease (AD) is considered to be a consequence of the neurotoxic properties of amyloid-β peptides (Aβ).  T-817MA was screened as a candidate therapeutic agent for the treatment of AD based on its neuroprotective potency against Aβ-induced neurotoxicity and its effect of enhancing axonal regeneration in the sciatic nerve axotomy model.  The neuroprotective effect of T-817MA against Aβ(1-42) or oxidative stress-induced neurotoxicity was assessed using a coculture of rat cortical neurons with glia.  T-817MA (0.1 and 1 μM) was strongly protective against Aβ(1-42)-induced (10 μM for 48 h) or H2O2-induced (100 μM for 24 h) neuronal death.  T-817MA suppressed the decrease of GSH levels induced by H2O2 exposure (30 μM for 4 h) in cortical neuron culture; therefore, T-817MA was likely to alleviate oxidative stress.  Besides the neuroprotective effect, T-817MA (0.1 and 1 μM) promoted neurite outgrowth in hippocampal slice cultures and reaggregation culture of rat cortical neurons.  T-817MA also increased the growth-assocd. protein 43 content in the reaggregation culture of cortical neurons.  These findings suggest that T-817MA exerts neuroprotective effect and promotes neurite outgrowth in rat primary cultured neurons.  Based on these neurotrophic features, T-817MA may have a potential for disease modification and be useful for patients with neurodegenerative diseases, such as AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpYEzJ50bSUcbVg90H21EOLACvtfcHk0lgckF9g-zlZmA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXmtVeju7w%253D&md5=bab946365eb087fe5302b3aa91e376d3</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1124%2Fjpet.105.083543&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.105.083543%26sid%3Dliteratum%253Aachs%26aulast%3DHirata%26aufirst%3DK.%26aulast%3DYamaguchi%26aufirst%3DH.%26aulast%3DTakamura%26aufirst%3DY.%26aulast%3DTakagi%26aufirst%3DA.%26aulast%3DFukushima%26aufirst%3DT.%26aulast%3DIwakami%26aufirst%3DN.%26aulast%3DSaitoh%26aufirst%3DA.%26aulast%3DNakagawa%26aufirst%3DM.%26aulast%3DYamada%26aufirst%3DT.%26atitle%3DA%2520novel%2520neurotrophic%2520agent%252C%2520T-817MA%2520%255B1-%257B3-%255B2-%25281-benzothiophen-5-yl%2529%2520ethoxy%255D%2520propyl%257D-3-azetidinol%2520maleate%255D%252C%2520attenuates%2520amyloid-beta-induced%2520neurotoxicity%2520and%2520promotes%2520neurite%2520outgrowth%2520in%2520rat%2520cultured%2520central%2520nervous%2520system%2520neurons%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2005%26volume%3D314%26spage%3D252%26epage%3D259%26doi%3D10.1124%2Fjpet.105.083543" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Matsuno, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakazawa, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okamoto, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawashima, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mita, S.</span></span> <span> </span><span class="NLM_article-title">Binding properties of SA4503, a novel and selective sigma 1 receptor agonist</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>306</i></span>,  <span class="NLM_fpage">271</span>– <span class="NLM_lpage">279</span>, <span class="refDoi"> DOI: 10.1016/0014-2999(96)00201-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1016%2F0014-2999%2896%2900201-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=8813641" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADyaK28Xktl2ntbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=306&publication_year=1996&pages=271-279&author=K.+Matsunoauthor=M.+Nakazawaauthor=K.+Okamotoauthor=Y.+Kawashimaauthor=S.+Mita&title=Binding+properties+of+SA4503%2C+a+novel+and+selective+sigma+1+receptor+agonist&doi=10.1016%2F0014-2999%2896%2900201-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Binding properties of SA4503, a novel and selective σ1 receptor agonist</span></div><div class="casAuthors">Matsuno, Kiyoshi; Nakazawa, Minako; Okamoto, Kazuyoshi; Kawashima, Yoichi; Mita, Shiro</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">306</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">271-279</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">The binding profiles of SA4503 (1-(3,4-dimethoxyphenethyl)-4-(3-phenylpropyl)piperazine dihydrochloride), a novel σ receptor ligand, to σ1 and σ2 receptor subtypes in guinea pig and rat brain membranes were evaluated.  SA4503 showed a high affinity for the σ1 receptor subtype labeled by (+)-[3H]pentazocine (IC50 = 17.4±1.9 nM), while it had about 100-fold less affinity for the σ2 receptor subtype labeled by [3H]1,3-di(2-tolyl)guanidine ([3H]DTG) in the presence of 200 nM (+)-pentazocine.  SA4503 showed little affinity for 36 other receptors, ion channels and second messenger systems.  The inhibition curves of SA4503 for (+)-[3H]pentazocine binding were shifted to the right in the presence of guanosine 5'-o-(3-thiotriphosphate)(GTPγS), as similar to those of (+)-3-(3-hydroxyphenyl)-N-(1-propyl)piperidine ((+)-3-PPP) and (+)-pentazocine, σ1 receptor agonists.  SA4503 significantly increased the KD value, but did not affect the Bmax value for specific (+)-[3H]pentazocine binding.  These results indicated that SA4503 is a potent and selective agonist for the σ1 receptor subtype in the brain.  In addn., SA4503 inhibited specific (+)-[3H]pentazocine binding in a competitive manner.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2Wso8XHzUE7Vg90H21EOLACvtfcHk0lgckF9g-zlZmA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28Xktl2ntbs%253D&md5=587287bfffd018c8b316255cbf14a026</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1016%2F0014-2999%2896%2900201-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0014-2999%252896%252900201-4%26sid%3Dliteratum%253Aachs%26aulast%3DMatsuno%26aufirst%3DK.%26aulast%3DNakazawa%26aufirst%3DM.%26aulast%3DOkamoto%26aufirst%3DK.%26aulast%3DKawashima%26aufirst%3DY.%26aulast%3DMita%26aufirst%3DS.%26atitle%3DBinding%2520properties%2520of%2520SA4503%252C%2520a%2520novel%2520and%2520selective%2520sigma%25201%2520receptor%2520agonist%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D1996%26volume%3D306%26spage%3D271%26epage%3D279%26doi%3D10.1016%2F0014-2999%2896%2900201-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Urfer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moebius, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skoloudik, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santamarina, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sato, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mita, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muir, K. W.</span></span> <span> </span><span class="NLM_article-title">Phase II trial of the Sigma-1 receptor agonist cutamesine (SA4503) for recovery enhancement after acute ischemic stroke</span>. <i>Stroke</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">3304</span>– <span class="NLM_lpage">3310</span>, <span class="refDoi"> DOI: 10.1161/STROKEAHA.114.005835</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1161%2FSTROKEAHA.114.005835" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=25270629" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitVKrtrbP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2014&pages=3304-3310&author=R.+Urferauthor=H.+J.+Moebiusauthor=D.+Skoloudikauthor=E.+Santamarinaauthor=W.+Satoauthor=S.+Mitaauthor=K.+W.+Muir&title=Phase+II+trial+of+the+Sigma-1+receptor+agonist+cutamesine+%28SA4503%29+for+recovery+enhancement+after+acute+ischemic+stroke&doi=10.1161%2FSTROKEAHA.114.005835"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Phase II Trial of the Sigma-1 Receptor Agonist Cutamesine (SA4503) for Recovery Enhancement After Acute Ischemic Stroke</span></div><div class="casAuthors">Urfer, Roman; Moebius, Hans J.; Skoloudik, David; Santamarina, Estevo; Sato, Wakao; Mita, Shiro; Muir, Keith W.</div><div class="citationInfo"><span class="NLM_cas:title">Stroke</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3304-3310</span>CODEN:
                <span class="NLM_cas:coden">SJCCA7</span>;
        ISSN:<span class="NLM_cas:issn">0039-2499</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">BACKGROUND AND PURPOSE-: The σ-1 receptor (Sig-1R) agonist cutamesine (SA4503) enhanced functional recovery after exptl. stroke with a treatment initiation window of 48 h and chronic treatment for 28 days.  We conducted a phase 2 clin. trial exploring the safety, tolerability, dose range, and functional effects of cutamesine in patients with ischemic stroke.  METHODS-: Subjects were randomized between 48 and 72 h after stroke to receive cutamesine 1 mg/d, 3 mg/d, or placebo for 28 days.  Effects on safety and function were assessed at baseline, at end of treatment (day 28), and at end of follow-up (day 56).  RESULTS-: In 60 patients, treatment with both cutamesine dosages was safe and well tolerated without significant differences in nos. of treatment emergent or serious adverse events.  No significant effect was obsd. on the primary efficacy measure (change in National Institutes of Health Stroke Scale from baseline to day 56) or modified Rankin Scale and Barthel Index scores.  Post hoc anal. of moderately and severely affected patients (baseline National Institutes of Health Stroke Scale, ≥7 and ≥10) showed greater National Institutes of Health Stroke Scale improvements in the 3 mg/d cutamesine group when compared with placebo (P=0.034 and P=0.038, resp.).  A trend toward a higher proportion being able to complete a 10m timed walk was obsd. for cutamesine-treated subjects.  CONCLUSIONS-: Cutamesine was safe and well tolerated at both dosage levels.  Although no significant effects on functional end points were seen in the population as a whole, greater improvement in National Institutes of Health Stroke Scale scores among patients with greater pretreatment deficits seen in post hoc anal. warrants further investigation.  Addnl. studies should focus on the patient population with moderate-to-severe stroke.  Clin. TRIAL REGISTRATION-: URL: http://www.clinicaltrials.gov/show/NCT00639249.  Unique identifier: NCT00639249.  The EudraCT no. is 2007-004840-60 (https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-004840-60/GB).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDEGW1pd0NnLVg90H21EOLACvtfcHk0liMCr66LsElTQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitVKrtrbP&md5=cdf635de1aff93573aab643921d25acf</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1161%2FSTROKEAHA.114.005835&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1161%252FSTROKEAHA.114.005835%26sid%3Dliteratum%253Aachs%26aulast%3DUrfer%26aufirst%3DR.%26aulast%3DMoebius%26aufirst%3DH.%2BJ.%26aulast%3DSkoloudik%26aufirst%3DD.%26aulast%3DSantamarina%26aufirst%3DE.%26aulast%3DSato%26aufirst%3DW.%26aulast%3DMita%26aufirst%3DS.%26aulast%3DMuir%26aufirst%3DK.%2BW.%26atitle%3DPhase%2520II%2520trial%2520of%2520the%2520Sigma-1%2520receptor%2520agonist%2520cutamesine%2520%2528SA4503%2529%2520for%2520recovery%2520enhancement%2520after%2520acute%2520ischemic%2520stroke%26jtitle%3DStroke%26date%3D2014%26volume%3D45%26spage%3D3304%26epage%3D3310%26doi%3D10.1161%2FSTROKEAHA.114.005835" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Davidson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saoud, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staner, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noel, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luthringer, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Werner, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reilly, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaffhauser, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rabinowitz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiser, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luthringer, R.</span></span> <span> </span><span class="NLM_article-title">Efficacy and Safety of MIN-101: A 12-Week Randomized, Double-Blind, Placebo-Controlled Trial of a New Drug in Development for the Treatment of Negative Symptoms in Schizophrenia</span>. <i>Am. J. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>174</i></span>,  <span class="NLM_fpage">1195</span>– <span class="NLM_lpage">1202</span>, <span class="refDoi"> DOI: 10.1176/appi.ajp.2017.17010122</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1176%2Fappi.ajp.2017.17010122" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=28750582" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A280%3ADC%252BC1cfhvVartg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=174&publication_year=2017&pages=1195-1202&author=M.+Davidsonauthor=J.+Saoudauthor=C.+Stanerauthor=N.+Noelauthor=E.+Luthringerauthor=S.+Wernerauthor=J.+Reillyauthor=J.+Y.+Schaffhauserauthor=J.+Rabinowitzauthor=M.+Weiserauthor=R.+Luthringer&title=Efficacy+and+Safety+of+MIN-101%3A+A+12-Week+Randomized%2C+Double-Blind%2C+Placebo-Controlled+Trial+of+a+New+Drug+in+Development+for+the+Treatment+of+Negative+Symptoms+in+Schizophrenia&doi=10.1176%2Fappi.ajp.2017.17010122"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and Safety of MIN-101: A 12-Week Randomized, Double-Blind, Placebo-Controlled Trial of a New Drug in Development for the Treatment of Negative Symptoms in Schizophrenia</span></div><div class="casAuthors">Davidson Michael; Saoud Jay; Staner Corinne; Noel Nadine; Luthringer Elisabeth; Werner Sandra; Reilly Joseph; Schaffhauser Jean-Yves; Rabinowitz Jonathan; Weiser Mark; Luthringer Remy</div><div class="citationInfo"><span class="NLM_cas:title">The American journal of psychiatry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">174</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1195-1202</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">OBJECTIVE:  The authors assessed the efficacy, safety, and tolerability of MIN-101, a compound with affinities for sigma-2 and 5-HT2A receptors and no direct dopamine affinities, in comparison with placebo in treating negative symptoms in stabilized patients with schizophrenia.  METHOD:  The trial enrolled 244 patients who had been symptomatically stable for at least 3 months and had scores of at least 20 on the negative subscale of the Positive and Negative Syndrome Scale (PANSS).  After at least 5 days' withdrawal from all antipsychotic medication, patients were randomly assigned to receive placebo or 32 mg/day or 64 mg/day of MIN-101 for 12 weeks.  The primary outcome measure was the PANSS negative factor score (pentagonal structure model).  Secondary outcome measures were PANSS total score and scores on the Clinical Global Impressions Scale (CGI), the Brief Negative Symptom Scale, the Brief Assessment of Cognition in Schizophrenia, and the Calgary Depression Scale for Schizophrenia.  RESULTS:  A statistically significant difference in PANSS negative factor score was observed, with lower scores for the MIN-101 32 mg/day and 64 mg/day groups compared with the placebo group (effect sizes, d=0.45 and d=0.57, respectively).  Supporting these findings were similar effects on several of the secondary outcome measures, such as the PANSS negative symptom, total, and activation factor scores, the CGI severity item, and the Brief Negative Symptom Scale.  There were no statistically significant differences in PANSS positive scale score between the MIN-101 and placebo groups.  No clinically significant changes were observed in vital signs, routine laboratory values, weight, metabolic indices, and Abnormal Involuntary Movement Scale score.  CONCLUSIONS:  MIN-101 demonstrated statistically significant efficacy in reducing negative symptoms and good tolerability in stable schizophrenia patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQJp7PYq61mjVHFYivNCdPRfW6udTcc2eZqnE3NACawGrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cfhvVartg%253D%253D&md5=cbc089cc56f69145a1974424b68d84f3</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1176%2Fappi.ajp.2017.17010122&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1176%252Fappi.ajp.2017.17010122%26sid%3Dliteratum%253Aachs%26aulast%3DDavidson%26aufirst%3DM.%26aulast%3DSaoud%26aufirst%3DJ.%26aulast%3DStaner%26aufirst%3DC.%26aulast%3DNoel%26aufirst%3DN.%26aulast%3DLuthringer%26aufirst%3DE.%26aulast%3DWerner%26aufirst%3DS.%26aulast%3DReilly%26aufirst%3DJ.%26aulast%3DSchaffhauser%26aufirst%3DJ.%2BY.%26aulast%3DRabinowitz%26aufirst%3DJ.%26aulast%3DWeiser%26aufirst%3DM.%26aulast%3DLuthringer%26aufirst%3DR.%26atitle%3DEfficacy%2520and%2520Safety%2520of%2520MIN-101%253A%2520A%252012-Week%2520Randomized%252C%2520Double-Blind%252C%2520Placebo-Controlled%2520Trial%2520of%2520a%2520New%2520Drug%2520in%2520Development%2520for%2520the%2520Treatment%2520of%2520Negative%2520Symptoms%2520in%2520Schizophrenia%26jtitle%3DAm.%2520J.%2520Psychiatry%26date%3D2017%26volume%3D174%26spage%3D1195%26epage%3D1202%26doi%3D10.1176%2Fappi.ajp.2017.17010122" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grundman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lickliter, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeKosky, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Izzo, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guttendorf, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Higgin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pribyl, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mozzoni, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Safferstein, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Catalano, S. M.</span></span> <span> </span><span class="NLM_article-title">A phase 1 clinical trial of the sigma-2 receptor complex allosteric antagonist CT1812, a novel therapeutic candidate for Alzheimer’s disease</span>. <i>Alzheimer’s Dementia</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">20</span>– <span class="NLM_lpage">26</span>, <span class="refDoi"> DOI: 10.1016/j.trci.2018.11.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1016%2Fj.trci.2018.11.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A280%3ADC%252BB3cjpsVyhtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2019&pages=20-26&author=M.+Grundmanauthor=R.+Morganauthor=J.+D.+Lickliterauthor=L.+S.+Schneiderauthor=S.+DeKoskyauthor=N.+J.+Izzoauthor=R.+Guttendorfauthor=M.+Higginauthor=J.+Pribylauthor=K.+Mozzoniauthor=H.+Saffersteinauthor=S.+M.+Catalano&title=A+phase+1+clinical+trial+of+the+sigma-2+receptor+complex+allosteric+antagonist+CT1812%2C+a+novel+therapeutic+candidate+for+Alzheimer%E2%80%99s+disease&doi=10.1016%2Fj.trci.2018.11.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">A phase 1 clinical trial of the sigma-2 receptor complex allosteric antagonist CT1812, a novel therapeutic candidate for Alzheimer's disease</span></div><div class="casAuthors">Grundman Michael; Grundman Michael; Morgan Roger; Lickliter Jason D; Schneider Lon S; DeKosky Steven; Izzo Nicholas J; Mozzoni Kelsie; Safferstein Hank; Catalano Susan M; Guttendorf Robert; Higgin Michelle; Pribyl Julie</div><div class="citationInfo"><span class="NLM_cas:title">Alzheimer's & dementia (New York, N. Y.)</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">20-26</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Background:  Elayta (CT1812) is a novel allosteric antagonist of the sigma-2 receptor complex that prevents and displaces binding of Aβ oligomers to neurons.  By stopping a key initiating event in Alzheimer's disease, this first-in-class drug candidate mitigates downstream synaptotoxicity and restores cognitive function in aged transgenic mouse models of Alzheimer's disease.  Methods:  A phase 1, two-part single and multiple ascending dose study was conducted in 7 and 4 cohorts of healthy human subjects, respectively.  In part A, healthy, young subjects (<65 years old) received CT1812 doses ranging from 10 to 1120 mg (6:2 active to placebo [A:P] per cohort).  In part B, subjects were administered 280, 560, and 840 mg once daily for 14 days (8:2 A:P per cohort).  An elderly cohort, aged 65-75 years, was dosed at 560 mg once daily for 14 days (7:2 A:P).  Serum concentrations of CT1812 in part B were measured on day 3 and 14 and cerebrospinal fluid concentrations on day 7 or 9.  Cognitive testing was performed in the healthy elderly cohort at baseline and at day 14 of treatment.  Results:  Treatment with CT1812 was well tolerated in all cohorts.  Adverse events were mild to moderate in severity and included headache and GI tract symptoms.  Plasma concentrations of drug were dose proportional across two orders of magnitude with minimal accumulation over 14 days.  Cognitive scores in the healthy elderly cohort were similar before and after treatment.  Conclusions:  CT1812 was well tolerated with single dose administration up to 1120 mg and with multiple dose administration up to 840 mg and 560 mg in healthy young and healthy elderly subjects, respectively.  CT1812 is currently being studied in early phase 2 trials in patients with Alzheimer's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTgFoKQ-yRX76Nc3HjJRoFAfW6udTcc2eb2jA5UXr1Xsrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cjpsVyhtg%253D%253D&md5=58b0f34902f93608fac1f2dcd6b1573e</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1016%2Fj.trci.2018.11.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.trci.2018.11.001%26sid%3Dliteratum%253Aachs%26aulast%3DGrundman%26aufirst%3DM.%26aulast%3DMorgan%26aufirst%3DR.%26aulast%3DLickliter%26aufirst%3DJ.%2BD.%26aulast%3DSchneider%26aufirst%3DL.%2BS.%26aulast%3DDeKosky%26aufirst%3DS.%26aulast%3DIzzo%26aufirst%3DN.%2BJ.%26aulast%3DGuttendorf%26aufirst%3DR.%26aulast%3DHiggin%26aufirst%3DM.%26aulast%3DPribyl%26aufirst%3DJ.%26aulast%3DMozzoni%26aufirst%3DK.%26aulast%3DSafferstein%26aufirst%3DH.%26aulast%3DCatalano%26aufirst%3DS.%2BM.%26atitle%3DA%2520phase%25201%2520clinical%2520trial%2520of%2520the%2520sigma-2%2520receptor%2520complex%2520allosteric%2520antagonist%2520CT1812%252C%2520a%2520novel%2520therapeutic%2520candidate%2520for%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DAlzheimer%25E2%2580%2599s%2520Dementia%26date%3D2019%26volume%3D5%26spage%3D20%26epage%3D26%26doi%3D10.1016%2Fj.trci.2018.11.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref69"><div class="reference"><strong class="refLabel"><a href="#ref69" class="rightTabRefNumLink">69</a></strong><div class="NLM_citation" id="rightTab-cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maher, C. M.</span></span> <span> </span><span class="NLM_article-title">Sigma1 Pharmacology in the Context of Cancer</span>. <i>Handb. Exp. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>244</i></span>,  <span class="NLM_fpage">237</span>– <span class="NLM_lpage">308</span>, <span class="refDoi"> DOI: 10.1007/164_2017_38</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1007%2F164_2017_38" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=28744586" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvFeitbvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=244&publication_year=2017&pages=237-308&author=F.+J.+Kimauthor=C.+M.+Maher&title=Sigma1+Pharmacology+in+the+Context+of+Cancer&doi=10.1007%2F164_2017_38"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Sigma1 pharmacology in the context of cancer</span></div><div class="casAuthors">Kim, Felix J.; Maher, Christina M.</div><div class="citationInfo"><span class="NLM_cas:title">Handbook of Experimental Pharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">244</span>
        (<span class="NLM_cas:issue">Sigma Proteins: Evolution of the Concept of Sigma Receptors</span>),
    <span class="NLM_cas:pages">237-308</span>CODEN:
                <span class="NLM_cas:coden">HEPHD2</span>;
        ISSN:<span class="NLM_cas:issn">1865-0325</span>.
    
            (<span class="NLM_cas:orgname">Springer GmbH</span>)
        </div><div class="casAbstract">A review.  Sigma1 (also known as sigma-1 receptor, Sig1R, s1 receptor) is a unique pharmacol. regulated integral membrane chaperone or scaffolding protein.  The majority of publications on the subject have focused on the neuropharmacol. of Sigma1.  However, a no. of publications have also suggested a role for Sigma1 in cancer.  Although there is currently no clin. used anti-cancer drug that targets Sigma1, a growing body of evidence supports the potential of Sigma1 ligands as therapeutic agents to treat cancer.  In preclin. models, compds. with affinity for Sigma1 have been reported to inhibit cancer cell proliferation and survival, cell adhesion and migration, tumor growth, to alleviate cancer-assocd. pain, and to have immunomodulatory properties.  This review will highlight that although the literature supports a role for Sigma1 in cancer, several fundamental questions regarding drug mechanism of action and the physiol. relevance of aberrant SIGMAR1 transcript and Sigma1 protein expression in certain cancers remain unanswered or only partially answered.  However, emerging lines of evidence suggest that Sigma1 is a component of the cancer cell support machinery, that it facilitates protein interaction networks, that it allosterically modulates the activity of its assocd. proteins, and that Sigma1 is a selectively multifunctional drug target.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGolV7ANX6gwGLVg90H21EOLACvtfcHk0ljsKruytbPG0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvFeitbvI&md5=6c5d82c84dce7107d0d471a678bd6cd7</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1007%2F164_2017_38&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F164_2017_38%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DF.%2BJ.%26aulast%3DMaher%26aufirst%3DC.%2BM.%26atitle%3DSigma1%2520Pharmacology%2520in%2520the%2520Context%2520of%2520Cancer%26jtitle%3DHandb.%2520Exp.%2520Pharmacol.%26date%3D2017%26volume%3D244%26spage%3D237%26epage%3D308%26doi%3D10.1007%2F164_2017_38" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref70"><div class="reference"><strong class="refLabel"><a href="#ref70" class="rightTabRefNumLink">70</a></strong><div class="NLM_citation" id="rightTab-cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Spruce, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McTavish, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Appleyard, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Neill, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howie, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watt, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murray, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLean, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leslie, N. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Safrany, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferguson, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peters, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prescott, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Box, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayes, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nutley, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raynaud, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Downes, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lambert, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eccles, S.</span></span> <span> </span><span class="NLM_article-title">Small molecule antagonists of the sigma-1 receptor cause selective release of the death program in tumor and self-reliant cells and inhibit tumor growth in vitro and in vivo</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">4875</span>– <span class="NLM_lpage">4886</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-03-3180</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1158%2F0008-5472.CAN-03-3180" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=15256458" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BD2cXls1Omtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2004&pages=4875-4886&author=B.+A.+Spruceauthor=L.+A.+Campbellauthor=N.+McTavishauthor=M.+A.+Cooperauthor=M.+V.+Appleyardauthor=M.+O%E2%80%99Neillauthor=J.+Howieauthor=J.+Samsonauthor=S.+Wattauthor=K.+Murrayauthor=D.+McLeanauthor=N.+R.+Leslieauthor=S.+T.+Safranyauthor=M.+J.+Fergusonauthor=J.+A.+Petersauthor=A.+R.+Prescottauthor=G.+Boxauthor=A.+Hayesauthor=B.+Nutleyauthor=F.+Raynaudauthor=C.+P.+Downesauthor=J.+J.+Lambertauthor=A.+M.+Thompsonauthor=S.+Eccles&title=Small+molecule+antagonists+of+the+sigma-1+receptor+cause+selective+release+of+the+death+program+in+tumor+and+self-reliant+cells+and+inhibit+tumor+growth+in+vitro+and+in+vivo&doi=10.1158%2F0008-5472.CAN-03-3180"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Small Molecule Antagonists of the σ-1 Receptor Cause Selective Release of the Death Program in Tumor and Self-Reliant Cells and Inhibit Tumor Growth in Vitro and in Vivo</span></div><div class="casAuthors">Spruce, Barbara A.; Campbell, Lorna A.; McTavish, Niall; Cooper, Michelle A.; Appleyard, M. Virginia L.; O'Neill, Mary; Howie, Jacqueline; Samson, Jayne; Watt, Stephen; Murray, Karen; McLean, Doris; Leslie, Nick R.; Safrany, Stephen T.; Ferguson, Michelle J.; Peters, John A.; Prescott, Alan R.; Box, Gary; Hayes, Angela; Nutley, Bernard; Raynaud, Florence; Downes, C. Peter; Lambert, Jeremy J.; Thompson, Alastair M.; Eccles, Suzanne</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">4875-4886</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The acquisition of resistance to apoptosis, the cell's intrinsic suicide program, is essential for cancers to arise and progress and is a major reason behind treatment failures.  We show in this article that small mol. antagonists of the σ-1 receptor inhibit tumor cell survival to reveal caspase-dependent apoptosis.  σ-Antagonist-mediated caspase activation and cell death are substantially attenuated by the prototypic -1 agonists (+)-SKF10,047 and (+)-pentazocine.  Although several normal cell types such as fibroblasts, epithelial cells, and even σ receptor-rich neurons are resistant to the apoptotic effects of σ antagonists, cells that can promote autocrine survival such as lens epithelial and microvascular endothelial cells are as susceptible as tumor cells.  Cellular susceptibility appears to correlate with differences in σ receptor coupling rather than levels of expression.  In susceptible cells only, σ antagonists evoke a rapid rise in cytosolic calcium that is inhibited by σ-1 agonists.  In at least some tumor cells, σ antagonists cause calcium-dependent activation of phospholipase C and concomitant calcium-independent inhibition of phosphatidylinositol 3'-kinase pathway signaling.  BSystemic administration of σ antagonists significantly inhibits the growth of evolving and established hormone-sensitive and hormone-insensitive mammary carcinoma xenografts, orthotopic prostate tumors, and p53-null lung carcinoma xenografts in immunocompromised mice in the absence of side effects.  Release of a σ receptor-mediated brake on apoptosis may offer a new approach to cancer treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpSCoAyVi6oLVg90H21EOLACvtfcHk0ljsKruytbPG0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXls1Omtr8%253D&md5=a91eaaa7754714c7113c8107ffedc965</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-03-3180&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-03-3180%26sid%3Dliteratum%253Aachs%26aulast%3DSpruce%26aufirst%3DB.%2BA.%26aulast%3DCampbell%26aufirst%3DL.%2BA.%26aulast%3DMcTavish%26aufirst%3DN.%26aulast%3DCooper%26aufirst%3DM.%2BA.%26aulast%3DAppleyard%26aufirst%3DM.%2BV.%26aulast%3DO%25E2%2580%2599Neill%26aufirst%3DM.%26aulast%3DHowie%26aufirst%3DJ.%26aulast%3DSamson%26aufirst%3DJ.%26aulast%3DWatt%26aufirst%3DS.%26aulast%3DMurray%26aufirst%3DK.%26aulast%3DMcLean%26aufirst%3DD.%26aulast%3DLeslie%26aufirst%3DN.%2BR.%26aulast%3DSafrany%26aufirst%3DS.%2BT.%26aulast%3DFerguson%26aufirst%3DM.%2BJ.%26aulast%3DPeters%26aufirst%3DJ.%2BA.%26aulast%3DPrescott%26aufirst%3DA.%2BR.%26aulast%3DBox%26aufirst%3DG.%26aulast%3DHayes%26aufirst%3DA.%26aulast%3DNutley%26aufirst%3DB.%26aulast%3DRaynaud%26aufirst%3DF.%26aulast%3DDownes%26aufirst%3DC.%2BP.%26aulast%3DLambert%26aufirst%3DJ.%2BJ.%26aulast%3DThompson%26aufirst%3DA.%2BM.%26aulast%3DEccles%26aufirst%3DS.%26atitle%3DSmall%2520molecule%2520antagonists%2520of%2520the%2520sigma-1%2520receptor%2520cause%2520selective%2520release%2520of%2520the%2520death%2520program%2520in%2520tumor%2520and%2520self-reliant%2520cells%2520and%2520inhibit%2520tumor%2520growth%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DCancer%2520Res.%26date%3D2004%26volume%3D64%26spage%3D4875%26epage%3D4886%26doi%3D10.1158%2F0008-5472.CAN-03-3180" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref71"><div class="reference"><strong class="refLabel"><a href="#ref71" class="rightTabRefNumLink">71</a></strong><div class="NLM_citation" id="rightTab-cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Crawford, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowen, W. D.</span></span> <span> </span><span class="NLM_article-title">Sigma-2 receptor agonists activate a novel apoptotic pathway and potentiate antineoplastic drugs in breast tumor cell lines</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">313</span>– <span class="NLM_lpage">322</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=11782394" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BD38XntV2gug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2002&pages=313-322&author=K.+W.+Crawfordauthor=W.+D.+Bowen&title=Sigma-2+receptor+agonists+activate+a+novel+apoptotic+pathway+and+potentiate+antineoplastic+drugs+in+breast+tumor+cell+lines"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Sigma-2 receptor agonists activate a novel apoptotic pathway and potentiate antineoplastic drugs in breast tumor cell lines</span></div><div class="casAuthors">Crawford, Keith W.; Bowen, Wayne D.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">313-322</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">We have reported previously that sigma-2 receptors are expressed in high densities in a variety of tumor cell types and that various sigma ligands have cytotoxic effects.  Other investigators have demonstrated increased expression of sigma-2 receptors in rapidly proliferating tumors and the ability of some sigma ligands to inhibit proliferation.  We demonstrate here the ability of sigma-2 receptor agonists to induce cell death by a mechanism consistent with apoptosis.  In breast tumor cell lines that are sensitive (MCF-7) and resistant (MCF-7/Adr-, T47D, and SKBr3) to antineoplastic agents, incubation with the sigma-2 subtype-selective agonists CB-64D and CB-184 produced dose-dependent cytotoxicity (measured by lactate dehydrogenase release into medium).  The EC50 for this response was similar across cell lines, irresp. of p53 genotype and drug-resistance phenotype.  CB-64D and the subtype nonselective sigma-2 agonists haloperidol and reduced haloperidol induced terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling staining in MCF-7 and T47D cells, indicating that cell death occurs via apoptosis.  Apoptosis was also indicated by increases in Annexin V binding caused by CB-64D.  In MCF-7 cells, cytotoxicity and Annexin V binding induced by the antineoplastics doxorubicin and actinomycin D was partially or completely abrogated by certain specific and general inhibitors of caspases.  In contrast, caspase inhibitors had no effect on sigma-2 receptor-mediated (CB-64D and CB-184) cytotoxicity or Annexin V binding.  Marked potentiation of cytotoxicity was obsd. when a subtoxic dose of CB-184 was combined with doxorubicin or actinomycin D, both in drug-sensitive (MCF-7) and drug-resistant (MCF-7/Adr-) cell lines.  Haloperidol potentiated doxorubicin only in drug-resistant cells.  These findings suggest the involvement of a novel p53- and caspase-independent apoptotic pathway used by sigma-2 receptors, which is distinct from mechanisms used by some DNA-damaging, antineoplastic agents and other apoptotic stimuli.  These observations further suggest that sigma-2 receptors may be targets that can be therapeutically exploited in the treatment of both drug-sensitive and drug-resistant metastatic tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpEJugG63Xfy7Vg90H21EOLACvtfcHk0lihwmVLY3ONqA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XntV2gug%253D%253D&md5=89feb1caf2fa574ba2f49aff8be7d920</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCrawford%26aufirst%3DK.%2BW.%26aulast%3DBowen%26aufirst%3DW.%2BD.%26atitle%3DSigma-2%2520receptor%2520agonists%2520activate%2520a%2520novel%2520apoptotic%2520pathway%2520and%2520potentiate%2520antineoplastic%2520drugs%2520in%2520breast%2520tumor%2520cell%2520lines%26jtitle%3DCancer%2520Res.%26date%3D2002%26volume%3D62%26spage%3D313%26epage%3D322" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref72"><div class="reference"><strong class="refLabel"><a href="#ref72" class="rightTabRefNumLink">72</a></strong><div class="NLM_citation" id="rightTab-cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ostenfeld, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fehrenbacher, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Høyer-Hansen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomsen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farkas, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jäättelä, M.</span></span> <span> </span><span class="NLM_article-title">Effective tumor cell death by sigma-2 receptor ligand siramesine involves lysosomal leakage and oxidative stress</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>65</i></span>,  <span class="NLM_fpage">8975</span>– <span class="NLM_lpage">8983</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-05-0269</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1158%2F0008-5472.CAN-05-0269" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=16204071" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVKiu7rP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2005&pages=8975-8983&author=M.+S.+Ostenfeldauthor=N.+Fehrenbacherauthor=M.+H%C3%B8yer-Hansenauthor=C.+Thomsenauthor=T.+Farkasauthor=M.+J%C3%A4%C3%A4ttel%C3%A4&title=Effective+tumor+cell+death+by+sigma-2+receptor+ligand+siramesine+involves+lysosomal+leakage+and+oxidative+stress&doi=10.1158%2F0008-5472.CAN-05-0269"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Effective Tumor Cell Death by σ-2 Receptor Ligand Siramesine Involves Lysosomal Leakage and Oxidative Stress</span></div><div class="casAuthors">Ostenfeld, Marie Stampe; Fehrenbacher, Nicole; Hoyer-Hansen, Maria; Thomsen, Christian; Farkas, Thomas; Jaeaettelae, Marja</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">8975-8983</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Acquired resistance to classic caspase-mediated apoptosis is a common problem for the treatment of human cancer.  Here, we show that siramesine, a novel σ-2 receptor ligand, effectively induces caspase-independent programmed cell death in immortalized and transformed cells of various origins.  Siramesine-treated tumor cells displayed increased levels of reactive oxygen species, lysosomal membrane permeabilization, chromatin condensation, and shrinkage and detachment of cells.  Lipid antioxidants (α-tocopherol and γ-tocopherol), but not other tested antioxidants (butylated hydroxyanisol or N-acetyl cysteine), effectively inhibited siramesine-induced morphol. changes and cell death.  Cathepsin B inhibitors (CA-074-Me and R-2525) conferred similar, but less pronounced protection, whereas ectopic expression of antiapoptotic protein Bcl-2, lack of wild-type p53 as well as pharmacol. inhibitors of caspases (zVAD-fmk, DEVD-CHO, and LEHD-CHO), calpains (PD150606), and serine proteases (N-tosyl-L-phenylalanine chloromethyl ketone and pefabloc) failed to protect cells against siramesine-induced death.  Importantly, transformation of murine embryonic fibroblasts with activated c-src or v-Ha-ras oncogenes greatly sensitized them to siramesine-induced cytotoxicity.  Furthermore, p.o. administration of well-tolerated doses of siramesine had a significant antitumorigenic effect in orthotopic breast cancer and s.c. fibrosarcoma models in mice.  These results present siramesine as a promising new drug for the treatment of tumors resistant to traditional therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRyz3SkulSoLVg90H21EOLACvtfcHk0lihwmVLY3ONqA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVKiu7rP&md5=8f3f4852a795c78230545c5bad292d8e</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-05-0269&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-05-0269%26sid%3Dliteratum%253Aachs%26aulast%3DOstenfeld%26aufirst%3DM.%2BS.%26aulast%3DFehrenbacher%26aufirst%3DN.%26aulast%3DH%25C3%25B8yer-Hansen%26aufirst%3DM.%26aulast%3DThomsen%26aufirst%3DC.%26aulast%3DFarkas%26aufirst%3DT.%26aulast%3DJ%25C3%25A4%25C3%25A4ttel%25C3%25A4%26aufirst%3DM.%26atitle%3DEffective%2520tumor%2520cell%2520death%2520by%2520sigma-2%2520receptor%2520ligand%2520siramesine%2520involves%2520lysosomal%2520leakage%2520and%2520oxidative%2520stress%26jtitle%3DCancer%2520Res.%26date%3D2005%26volume%3D65%26spage%3D8975%26epage%3D8983%26doi%3D10.1158%2F0008-5472.CAN-05-0269" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref73"><div class="reference"><strong class="refLabel"><a href="#ref73" class="rightTabRefNumLink">73</a></strong><div class="NLM_citation" id="rightTab-cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rothfuss, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vangveravong, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mach, R. H.</span></span> <span> </span><span class="NLM_article-title">Functional assays to define agonists and antagonists of the sigma-2 receptor</span>. <i>Anal. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>448</i></span>,  <span class="NLM_fpage">68</span>– <span class="NLM_lpage">74</span>, <span class="refDoi"> DOI: 10.1016/j.ab.2013.12.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1016%2Fj.ab.2013.12.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=24333652" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitleltbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=448&publication_year=2014&pages=68-74&author=C.+Zengauthor=J.+M.+Rothfussauthor=J.+Zhangauthor=S.+Vangveravongauthor=W.+Chuauthor=S.+Liauthor=Z.+Tuauthor=J.+Xuauthor=R.+H.+Mach&title=Functional+assays+to+define+agonists+and+antagonists+of+the+sigma-2+receptor&doi=10.1016%2Fj.ab.2013.12.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Functional assays to define agonists and antagonists of the sigma-2 receptor</span></div><div class="casAuthors">Zeng, Chenbo; Rothfuss, Justin M.; Zhang, Jun; Vangveravong, Suwanna; Chu, Wenhua; Li, Shihong; Tu, Zhude; Xu, Jinbin; Mach, Robert H.</div><div class="citationInfo"><span class="NLM_cas:title">Analytical Biochemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">448</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">68-74</span>CODEN:
                <span class="NLM_cas:coden">ANBCA2</span>;
        ISSN:<span class="NLM_cas:issn">0003-2697</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The sigma-2 receptor has been identified as a biomarker in proliferating tumors.  To date there is no well-established functional assay for defining sigma-2 agonists and antagonists.  Many sigma-2 ligands with diverse structures have been shown to induce cell death in a variety of cancer cells by triggering caspase-dependent and independent apoptosis.  Therefore, in the current study, we used the cell viability assay and the caspase-3 activity assay to det. sigma-2 agonists and antagonists.  Three classes of sigma-2 ligands developed in our lab. were evaluated for their potency to induce cell death in two tumor cell lines, mouse breast cancer cell line EMT-6 and human melanoma cell line MDA-MB-435.  The data showed that the EC50 values of the sigma-2 ligands using the cell viability assay ranged from 11.4 μM to >200 μM, which were comparable with the EC50 values obtained using the caspase-3 assay.  Based on the cytotoxicity of a sigma-2 ligand relative to that of siramesine, a commonly accepted sigma-2 agonist, we have categorized our sigma-2 ligands into agonists, partial agonists, and antagonists.  The establishment of functional assays for defining sigma-2 agonists and antagonists will facilitate functional characterization of sigma-2 receptor ligands and sigma-2 receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFM0mxQ6ge67Vg90H21EOLACvtfcHk0lgq5GNCGDGHuQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitleltbw%253D&md5=4f50b1c949dfd9ffaf07b539e109d741</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1016%2Fj.ab.2013.12.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ab.2013.12.008%26sid%3Dliteratum%253Aachs%26aulast%3DZeng%26aufirst%3DC.%26aulast%3DRothfuss%26aufirst%3DJ.%2BM.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DVangveravong%26aufirst%3DS.%26aulast%3DChu%26aufirst%3DW.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DTu%26aufirst%3DZ.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DMach%26aufirst%3DR.%2BH.%26atitle%3DFunctional%2520assays%2520to%2520define%2520agonists%2520and%2520antagonists%2520of%2520the%2520sigma-2%2520receptor%26jtitle%3DAnal.%2520Biochem.%26date%3D2014%26volume%3D448%26spage%3D68%26epage%3D74%26doi%3D10.1016%2Fj.ab.2013.12.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref74"><div class="reference"><strong class="refLabel"><a href="#ref74" class="rightTabRefNumLink">74</a></strong><div class="NLM_citation" id="rightTab-cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dehdashti, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laforest, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shoghi, K. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aft, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nussenbaum, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kreisel, F. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartlett, N. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cashen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner-Johnston, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mach, R. H.</span></span> <span> </span><span class="NLM_article-title">Assessment of cellular proliferation in tumors by PET using 18F-ISO-1</span>. <i>J. Nucl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">350</span>– <span class="NLM_lpage">357</span>, <span class="refDoi"> DOI: 10.2967/jnumed.112.111948</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.2967%2Fjnumed.112.111948" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=23359657" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BC3sXltV2ksr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2013&pages=350-357&author=F.+Dehdashtiauthor=R.+Laforestauthor=F.+Gaoauthor=K.+I.+Shoghiauthor=R.+L.+Aftauthor=B.+Nussenbaumauthor=F.+H.+Kreiselauthor=N.+L.+Bartlettauthor=A.+Cashenauthor=N.+Wagner-Johnstonauthor=R.+H.+Mach&title=Assessment+of+cellular+proliferation+in+tumors+by+PET+using+18F-ISO-1&doi=10.2967%2Fjnumed.112.111948"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Assessment of cellular proliferation in tumors by PET using 18F-ISO-1</span></div><div class="casAuthors">Dehdashti, Farrokh; Laforest, Richard; Gao, Feng; Shoghi, Kooresh I.; Aft, Rebecca L.; Nussenbaum, Brian; Kreisel, Friederike H.; Bartlett, Nancy L.; Cashen, Amanda; Wagner-Johnston, Nina; Mach, Robert H.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Nuclear Medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">350-357</span>CODEN:
                <span class="NLM_cas:coden">JNMEAQ</span>;
        ISSN:<span class="NLM_cas:issn">0161-5505</span>.
    
            (<span class="NLM_cas:orgname">Society of Nuclear Medicine and Molecular Imaging</span>)
        </div><div class="casAbstract">This first study in humans was designed to evaluate the safety and dosimetry of a cellular proliferative marker, N-(4-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)butyl)-2-(2-18F-fluoro-ethoxy)-5-methylbenzamide (18F-ISO-1), and evaluate the feasibility of imaging tumor proliferation by PET in patients with newly diagnosed malignant neoplasms.  Methods: Patients with biopsy-proven lymphoma, breast cancer, or head and neck cancer underwent 18F-ISO-1 PET.  Tumor 18F-ISO-1 uptake was assessed semiquant. by max. standardized uptake value, ratios of tumor to normal tissue and tumor to muscle, and relative distribution vol. ratio.  The PET results were correlated with tumor Ki-67 and mitotic index, from in vitro assays of the tumor tissue.  The biodistribution of 18F-ISO-1 and human dosimetry were evaluated.  Results: Thirty patients with primary breast cancer (n = 13), head and neck cancer (n = 10), and lymphoma (n = 7) were evaluated.  In the entire group, tumor max. standardized uptake value and tumor-to-muscle ratio correlated significantly with Ki-67 (*au = 0.27, P = 0.04, and *au = 0.38, P = 0.003, resp.), but no significant correlation was obsd. between Ki-67 and tumor-to-normal-tissue ratio (*au = 0.07, P = 0.56) or distribution vol. ratio (*au = 0.26, P = 0.14).  On the basis of whole-body PET data, the gallbladder is the dose-limiting organ, with an av. radiation dose of 0.091 mGy/MBq.  The whole-body and EDs were 0.012 mGy/MBq and 0.016 mSv/MBq, resp.  No adverse effects of 18F-ISO-1 were encountered.  Conclusion: The presence of a significant correlation between 18F-ISO-1 and Ki-67 makes this agent promising for evaluation of the proliferative status of solid tumors.  The relatively small absorbed doses to normal organs allow for the safe administration of up to 550 MBq, which is sufficient for PET imaging in clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEJzNLBiXZh7Vg90H21EOLACvtfcHk0lgq5GNCGDGHuQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXltV2ksr4%253D&md5=c746f6bb256184c9e2e2dfa164be875f</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.2967%2Fjnumed.112.111948&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2967%252Fjnumed.112.111948%26sid%3Dliteratum%253Aachs%26aulast%3DDehdashti%26aufirst%3DF.%26aulast%3DLaforest%26aufirst%3DR.%26aulast%3DGao%26aufirst%3DF.%26aulast%3DShoghi%26aufirst%3DK.%2BI.%26aulast%3DAft%26aufirst%3DR.%2BL.%26aulast%3DNussenbaum%26aufirst%3DB.%26aulast%3DKreisel%26aufirst%3DF.%2BH.%26aulast%3DBartlett%26aufirst%3DN.%2BL.%26aulast%3DCashen%26aufirst%3DA.%26aulast%3DWagner-Johnston%26aufirst%3DN.%26aulast%3DMach%26aufirst%3DR.%2BH.%26atitle%3DAssessment%2520of%2520cellular%2520proliferation%2520in%2520tumors%2520by%2520PET%2520using%252018F-ISO-1%26jtitle%3DJ.%2520Nucl.%2520Med.%26date%3D2013%26volume%3D54%26spage%3D350%26epage%3D357%26doi%3D10.2967%2Fjnumed.112.111948" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref75"><div class="reference"><strong class="refLabel"><a href="#ref75" class="rightTabRefNumLink">75</a></strong><div class="NLM_citation" id="rightTab-cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McDonald, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doot, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schubert, E. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tchou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pryma, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farwell, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nayak, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ziober, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feldman, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeMichele, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clark, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shah, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carlin, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mach, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mankoff, D. A.</span></span> <span> </span><span class="NLM_article-title">Breast Cancer (18)F-ISO-1 Uptake as a Marker of Proliferation Status</span>. <i>J. Nucl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">665</span>– <span class="NLM_lpage">670</span>, <span class="refDoi"> DOI: 10.2967/jnumed.119.232363</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.2967%2Fjnumed.119.232363" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=31836680" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhvVOis77L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2020&pages=665-670&author=E.+S.+McDonaldauthor=R.+K.+Dootauthor=A.+J.+Youngauthor=E.+K.+Schubertauthor=J.+Tchouauthor=D.+A.+Prymaauthor=M.+D.+Farwellauthor=A.+Nayakauthor=A.+Zioberauthor=M.+D.+Feldmanauthor=A.+DeMicheleauthor=A.+S.+Clarkauthor=P.+D.+Shahauthor=H.+Leeauthor=S.+D.+Carlinauthor=R.+H.+Machauthor=D.+A.+Mankoff&title=Breast+Cancer+%2818%29F-ISO-1+Uptake+as+a+Marker+of+Proliferation+Status&doi=10.2967%2Fjnumed.119.232363"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">Breast cancer 18F-ISO-1 uptake as a marker of proliferation status</span></div><div class="casAuthors">Mcdonald, Elizabeth S.; Doot, Robert K.; Young, Anthony J.; Schubert, Erin K.; Tchou, Julia; Pryma, Daniel A.; Farwell, Michael D.; Nayak, Anupma; Ziober, Amy; Feldman, Michael D.; Demichele, Angela; Clark, Amy S.; Shah, Payal D.; Lee, Hsiaoju; Carlin, Sean D.; MacH, Robert H.; Mankoff, David A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Nuclear Medicine</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">665-671</span>CODEN:
                <span class="NLM_cas:coden">JNMEAQ</span>;
        ISSN:<span class="NLM_cas:issn">1535-5667</span>.
    
            (<span class="NLM_cas:orgname">Society of Nuclear Medicine and Molecular Imaging</span>)
        </div><div class="casAbstract">The σ 2 receptor is a potential in vivo target for measuring proliferative status in cancer.  The feasibility of using N-(4-(6,7-dimethoxy-3,4- dihydroisoquinolin-2(1 H)-yl)butyl)-2-(2-18F-fluoroethoxy)-5-methylbenzamide (18F-ISO-1) to image solid tumors in lymphoma, breast cancer, and head and neck cancer has been previously established.  Here, we report the results of the first dedicated clin. trial of 18FISO-1 in women with primary breast cancer.  Our study objective was to det. whether 18F-ISO-1 PET could provide an in vivo measure of tumor proliferative status, and we hypothesized that uptake would correlate with a tissue-based assay of proliferation, namely Ki-67 expression.  Twenty-eight women with 29 primary invasive breast cancers were prospectively enrolled in a clin. trial (NCT 02284919) between March 2015 and Jan. 2017.  Each received an injection of 278-527 MBq of 18F-ISO-1 and then underwent PET/CT imaging of the breasts 50-55 min later.  In vivo uptake of 18F-ISO-1 was quantitated by SUVmax and distribution vol. ratios and was compared with ex vivo immunohistochem. for Ki-67.  Wilcoxon rank-sum tests assessed uptake differences across Ki-67 thresholds, and Spearman correlation tested assocns. between uptake and Ki-67.  Tumor SUVmax (median, 2.0 g/mL; range, 1.3-3.3 g/mL), partial-vol.-cor. SUV max, and SUV ratios were tested against Ki-67.  Tumors stratified into the high-Ki-67 ($20%) group had SUVmax greater than the low-Ki-67 (,20%) group (P 5 0.02).  SUVmax exhibited a pos. correlation with Ki-67 across all breast cancer subtypes (ρ 5 0.46, P 5 0.01, n 5 29).  Partial-vol.-cor. SUVmax was pos. correlated with Ki-67 for invasive ductal carcinoma (ρ 5 0.51, P 5 0.02, n 5 21).  Tumor-to-normal-tissue ratios and tumor distribution vol. ratio did not correlate with Ki-67 (P . 0.05).  18F-ISO-1 uptake in breast cancer modestly correlates with an in vitro assay of proliferation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpAknHL7ikKYrVg90H21EOLACvtfcHk0lgq5GNCGDGHuQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhvVOis77L&md5=b78d0f4ece45a307e173b3d56dcd60e6</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.2967%2Fjnumed.119.232363&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2967%252Fjnumed.119.232363%26sid%3Dliteratum%253Aachs%26aulast%3DMcDonald%26aufirst%3DE.%2BS.%26aulast%3DDoot%26aufirst%3DR.%2BK.%26aulast%3DYoung%26aufirst%3DA.%2BJ.%26aulast%3DSchubert%26aufirst%3DE.%2BK.%26aulast%3DTchou%26aufirst%3DJ.%26aulast%3DPryma%26aufirst%3DD.%2BA.%26aulast%3DFarwell%26aufirst%3DM.%2BD.%26aulast%3DNayak%26aufirst%3DA.%26aulast%3DZiober%26aufirst%3DA.%26aulast%3DFeldman%26aufirst%3DM.%2BD.%26aulast%3DDeMichele%26aufirst%3DA.%26aulast%3DClark%26aufirst%3DA.%2BS.%26aulast%3DShah%26aufirst%3DP.%2BD.%26aulast%3DLee%26aufirst%3DH.%26aulast%3DCarlin%26aufirst%3DS.%2BD.%26aulast%3DMach%26aufirst%3DR.%2BH.%26aulast%3DMankoff%26aufirst%3DD.%2BA.%26atitle%3DBreast%2520Cancer%2520%252818%2529F-ISO-1%2520Uptake%2520as%2520a%2520Marker%2520of%2520Proliferation%2520Status%26jtitle%3DJ.%2520Nucl.%2520Med.%26date%3D2020%26volume%3D61%26spage%3D665%26epage%3D670%26doi%3D10.2967%2Fjnumed.119.232363" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref76"><div class="reference"><strong class="refLabel"><a href="#ref76" class="rightTabRefNumLink">76</a></strong><div class="NLM_citation" id="rightTab-cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riad, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mach, R. H.</span></span> <span> </span><span class="NLM_article-title">The Biological Function of Sigma-2 Receptor/TMEM97 and Its Utility in PET Imaging Studies in Cancer</span>. <i>Cancers</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">1877</span>, <span class="refDoi"> DOI: 10.3390/cancers12071877</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.3390%2Fcancers12071877" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BB3cXisFKntLfP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2020&pages=1877&author=C.+Zengauthor=A.+Riadauthor=R.+H.+Mach&title=The+Biological+Function+of+Sigma-2+Receptor%2FTMEM97+and+Its+Utility+in+PET+Imaging+Studies+in+Cancer&doi=10.3390%2Fcancers12071877"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">The biological function of sigma-2receptor/TMEM97 and its utility inPET imaging studies in cancer</span></div><div class="casAuthors">Zeng, Chenbo; Riad, Aladdin; Mach, Robert H.</div><div class="citationInfo"><span class="NLM_cas:title">Cancers</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1877</span>CODEN:
                <span class="NLM_cas:coden">CANCCT</span>;
        ISSN:<span class="NLM_cas:issn">2072-6694</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">The sigma-2 receptor was originally defined pharmacol. and recently identified as TMEM97.  TMEM97 has been validated as a biomarker of proliferative status and the radioligand of TMEM97, [18F]ISO-1, has been developed and validated as a PET imaging biomarker of proliferative status of tumors and as a predictor of the cancer therapy response. [18F]ISO-1 PET imaging should be useful to guide treatment for cancer patients.  TMEM97 is a membrane-bound protein and localizes in multiple subcellular organelles including endoplasmic reticulum and lysosomes.  TMEM97 plays distinct roles in cancer.  It is reported that TMEM97 is upregulated in some tumors but downregulated in other tumors and it is required for cell proliferation in certain tumor cells.  TMEM97 plays important roles in cholesterol homeostasis.  TMEM97 expression is regulated by cholesterol-regulating signals such as sterol depletion and SREBP expression levels.  TMEM97 regulates cholesterol trafficking processes such as low d. lipoprotein (LDL) uptake by forming complexes with PGRMC1 and low d. lipoprotein receptor (LDLR), as well as cholesterol transport out of lysosome by interacting with and regulating NPC1 protein.  Understanding mol. functions of TMEM97 in proliferation and cholesterol metab. will be important to develop strategies to diagnose and treat cancer and cholesterol disorders using a rich collection of TMEM97 radiotracers and ligands.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUb0WUMHzwTLVg90H21EOLACvtfcHk0lgqzZX8S9zoqQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXisFKntLfP&md5=87dd4415becc2f44bb03ac1238044095</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.3390%2Fcancers12071877&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fcancers12071877%26sid%3Dliteratum%253Aachs%26aulast%3DZeng%26aufirst%3DC.%26aulast%3DRiad%26aufirst%3DA.%26aulast%3DMach%26aufirst%3DR.%2BH.%26atitle%3DThe%2520Biological%2520Function%2520of%2520Sigma-2%2520Receptor%252FTMEM97%2520and%2520Its%2520Utility%2520in%2520PET%2520Imaging%2520Studies%2520in%2520Cancer%26jtitle%3DCancers%26date%3D2020%26volume%3D12%26spage%3D1877%26doi%3D10.3390%2Fcancers12071877" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref77"><div class="reference"><strong class="refLabel"><a href="#ref77" class="rightTabRefNumLink">77</a></strong><div class="NLM_citation" id="rightTab-cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Agha, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCurdy, C. R.</span></span> <span> </span><span class="NLM_article-title">In vitro and in vivo sigma 1 receptor imaging studies in different disease states</span>. <i>RSC Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2021</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">154</span>– <span class="NLM_lpage">177</span>, <span class="refDoi"> DOI: 10.1039/D0MD00186D</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1039%2FD0MD00186D" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=34046607" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BB3cXitVSrtb3O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2021&pages=154-177&author=H.+Aghaauthor=C.+R.+McCurdy&title=In+vitro+and+in+vivo+sigma+1+receptor+imaging+studies+in+different+disease+states&doi=10.1039%2FD0MD00186D"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro and in vivo sigma 1 receptor imaging studies in different disease states</span></div><div class="casAuthors">Agha, Hebaalla; McCurdy, Christopher R.</div><div class="citationInfo"><span class="NLM_cas:title">RSC Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2021</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">154-177</span>CODEN:
                <span class="NLM_cas:coden">RMCSEZ</span>;
        ISSN:<span class="NLM_cas:issn">2632-8682</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A review.  The sigma receptor system has been classified into two distinct subtypes, sigma 1 (σ1R) and sigma 2 (σ2R).  Sigma 1 receptors (σ1Rs) are involved in many neurodegenerative diseases and different central nervous system disorders such as Alzheimer's disease, Parkinson's disease, schizophrenia, and drug addiction, and pain.  This makes them attractive targets for developing radioligands as tools to gain a better understanding of disease pathophysiol. and clin. diagnosis.  Over the years, several σ1R radioligands have been developed to image the changes in σ1R distribution and d. providing insights into their role in disease development.  Moreover, the involvement of both σ1Rs and σ2Rs with cancer make these ligands, esp. those that are σ2R selective, great tools for imaging different types of tumors.  This will discuss the principles of mol. imaging using PET and SPECT, known σ1R radioligands and their applications for labeling σ1Rs under different disease conditions.  Furthermore, this will highlight σ1R radioligands that have demonstrated considerable potential as biomarkers, and an opportunity to fulfill the ultimate goal of better healthcare outcomes and improving human health.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBJH6I2iaq9rVg90H21EOLACvtfcHk0lgqzZX8S9zoqQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXitVSrtb3O&md5=4b8d16ab6b72a8fef621a9b0bfc42927</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1039%2FD0MD00186D&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FD0MD00186D%26sid%3Dliteratum%253Aachs%26aulast%3DAgha%26aufirst%3DH.%26aulast%3DMcCurdy%26aufirst%3DC.%2BR.%26atitle%3DIn%2520vitro%2520and%2520in%2520vivo%2520sigma%25201%2520receptor%2520imaging%2520studies%2520in%2520different%2520disease%2520states%26jtitle%3DRSC%2520Med.%2520Chem.%26date%3D2021%26volume%3D12%26spage%3D154%26epage%3D177%26doi%3D10.1039%2FD0MD00186D" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref78"><div class="reference"><strong class="refLabel"><a href="#ref78" class="rightTabRefNumLink">78</a></strong><div class="NLM_citation" id="rightTab-cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Drake, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hillmer, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, Z.</span></span> <span> </span><span class="NLM_article-title">Approaches to PET Imaging of Glioblastoma</span>. <i>Molecules</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">568</span>, <span class="refDoi"> DOI: 10.3390/molecules25030568</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.3390%2Fmolecules25030568" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BB3cXksVamu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2020&pages=568&author=L.+R.+Drakeauthor=A.+T.+Hillmerauthor=Z.+Cai&title=Approaches+to+PET+Imaging+of+Glioblastoma&doi=10.3390%2Fmolecules25030568"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Approaches to PET Imaging of Glioblastoma</span></div><div class="casAuthors">Drake, Lindsey R.; Hillmer, Ansel T.; Cai, Zhengxin</div><div class="citationInfo"><span class="NLM_cas:title">Molecules</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">568</span>CODEN:
                <span class="NLM_cas:coden">MOLEFW</span>;
        ISSN:<span class="NLM_cas:issn">1420-3049</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Glioblastoma multiforme (GBM) is the deadliest type of brain tumor, affecting approx. three in 100,000 adults annually.  Positron emission tomog. (PET) imaging provides an important non-invasive method of measuring biochem. specific targets at GBM lesions.  These powerful data can characterize tumors, predict treatment effectiveness, and monitor treatment.  This review will discuss the PET imaging agents that have already been evaluated in GBM patients so far, and new imaging targets with promise for future use.  Previously used PET imaging agents include the tracers for markers of proliferation ([11C]methionine; [18F]fluoro-ethyl- L-tyrosine, [18F]Fluorodopa,[18F]fluoro-thymidine, and [18F]clofarabine), hypoxia sensing ([18F]FMISO, [18F]FET-NIM, [18F]EF5, [18F]HX4, and [64Cu]ATSM), and ligands for inflammation.  As cancer therapeutics evolve toward personalized medicine and therapies centered on tumor biomarkers, the development of complimentary selective PET agents can dramatically enhance these efforts.  Newer biomarkers for GBM PET imaging are discussed, with some already in use for PET imaging other cancers and neurol. disorders.  These targets include Sigma 1, Sigma 2, programmed death ligand 1, poly-ADP-ribose polymerase, and isocitrate dehydrogenase.  For GBM, these imaging agents come with addnl. considerations such as blood-brain barrier penetration, quant. modeling approaches, and nonspecific binding.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGol3qcmGFKhP7Vg90H21EOLACvtfcHk0lgqzZX8S9zoqQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXksVamu7Y%253D&md5=b0f8beeed3ed4b7efc695c3acc38467f</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.3390%2Fmolecules25030568&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmolecules25030568%26sid%3Dliteratum%253Aachs%26aulast%3DDrake%26aufirst%3DL.%2BR.%26aulast%3DHillmer%26aufirst%3DA.%2BT.%26aulast%3DCai%26aufirst%3DZ.%26atitle%3DApproaches%2520to%2520PET%2520Imaging%2520of%2520Glioblastoma%26jtitle%3DMolecules%26date%3D2020%26volume%3D25%26spage%3D568%26doi%3D10.3390%2Fmolecules25030568" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref79"><div class="reference"><strong class="refLabel"><a href="#ref79" class="rightTabRefNumLink">79</a></strong><div class="NLM_citation" id="rightTab-cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, C. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abate, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiang, C. S.</span></span> <span> </span><span class="NLM_article-title">Sigma-2 receptor/TMEM97 agonist PB221 as an alternative drug for brain tumor</span>. <i>BMC Cancer</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">473</span>, <span class="refDoi"> DOI: 10.1186/s12885-019-5700-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1186%2Fs12885-019-5700-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=31109310" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A280%3ADC%252BB3M7nvVWisw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2019&pages=473&author=C.+C.+Liuauthor=C.+F.+Yuauthor=S.+C.+Wangauthor=H.+Y.+Liauthor=C.+M.+Linauthor=H.+H.+Wangauthor=C.+Abateauthor=C.+S.+Chiang&title=Sigma-2+receptor%2FTMEM97+agonist+PB221+as+an+alternative+drug+for+brain+tumor&doi=10.1186%2Fs12885-019-5700-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">Sigma-2 receptor/TMEM97 agonist PB221 as an alternative drug for brain tumor</span></div><div class="casAuthors">Liu Chia-Chi; Li Hsueh-Yin; Lin Chiu-Min; Wang Hsia-Han; Chiang Chi-Shiun; Liu Chia-Chi; Yu Ching-Fang; Wang Shu-Chi; Abate Carmen; Chiang Chi-Shiun; Chiang Chi-Shiun</div><div class="citationInfo"><span class="NLM_cas:title">BMC cancer</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">473</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  There are limited effective drugs that can reach the brain to target brain tumors, in particular glioblastoma, which is one of the most difficult cancers to be cured from.  Because the overexpression of the sigma-2 receptor is frequently reported in glioma clinical samples and associated with poor prognosis and malignancy, we herein studied the anti-tumor effect of the sigma-2 receptor agonist PB221 (4-cyclohexyl-1-[3-(5-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)propyl]piperidine) on an anaplastic astrocytoma tumor model based on previous encouraging results in pancreatic cancer and neuroblastoma SK-N-SH cells.  METHODS:  The expression of the sigma-2 receptor, transmembrane protein 97 (TMEM97), in ALTS1C1 and UN-KC6141 cell lines was measured by RT-PCR and quantitative RT-PCR.  The binding of sigma-2 receptor fluorescent ligands PB385 (6-[5-[3-(4-cyclohexylpiperazin-1-yl)propyl]-5,6,7,8-tetrahydronaphthalen-5-yloxy]-N-(7-nitro-2,1,3-benzoxadiazol-4-yl)hexanamine) and NO1 (2-{6-[2-(3-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)propyl)-3,4-dihydroisoquinolin-1(2H)-one-5-yloxy]hexyl}-5-(dimethylamino)isoindoline-1,3-dione) was examined by flow cytometry and the fluorescent plate reader.  The antitumor activity of PB221 was initially examined in the murine brain tumor cell line ALTS1C1 and then in the murine pancreatic cell line UN-KC6141.  The potential therapeutic efficacy of PB221 for murine brain tumors was examined by in vitro migration and invasion assays and in vivo ectopic and orthotopic ALTS1C1 tumor models.  RESULTS:  The IC50 of PB221 for ALTS1C1 and UN-KC6141 cell lines was 10.61 ± 0.96 and 13.13 ± 1.15 μM, respectively.  A low dose of PB221 (1 μM) significantly repressed the migration and invasion of ALTS1C1 cells, and a high dose of PB221 (20 μM) resulted in the apoptotic cell death of ALTS1C1 cells.  These effects were reduced by the lipid antioxidant α-tocopherol, but not by the hydrophilic N-acetylcysteine, suggesting mitochondrial oxidative stress is involved.  The in vivo study revealed that PB221 effectively retarded tumor growth to 36% of the control tumor volume in the ectopic intramuscular tumor model and increased the overall survival time by 20% (from 26 to 31 days) in the orthotopic intracerebral tumor model.  CONCLUSIONS:  This study demonstrates that the sigma-2 receptor agonist PB221 has the potential to be an alternative chemotherapeutic drug for brain tumors with comparable side effects as the current standard-of-care drug, temozolomide.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRjG6m4HxP7vNbHMBt0mMIXfW6udTcc2ebdblPdLGQ0U7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3M7nvVWisw%253D%253D&md5=93bf8f0d4844d5d59039fe750b6ba33c</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1186%2Fs12885-019-5700-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12885-019-5700-7%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DC.%2BC.%26aulast%3DYu%26aufirst%3DC.%2BF.%26aulast%3DWang%26aufirst%3DS.%2BC.%26aulast%3DLi%26aufirst%3DH.%2BY.%26aulast%3DLin%26aufirst%3DC.%2BM.%26aulast%3DWang%26aufirst%3DH.%2BH.%26aulast%3DAbate%26aufirst%3DC.%26aulast%3DChiang%26aufirst%3DC.%2BS.%26atitle%3DSigma-2%2520receptor%252FTMEM97%2520agonist%2520PB221%2520as%2520an%2520alternative%2520drug%2520for%2520brain%2520tumor%26jtitle%3DBMC%2520Cancer%26date%3D2019%26volume%3D19%26spage%3D473%26doi%3D10.1186%2Fs12885-019-5700-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref80"><div class="reference"><strong class="refLabel"><a href="#ref80" class="rightTabRefNumLink">80</a></strong><div class="NLM_citation" id="rightTab-cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gilligan, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cain, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christos, T. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cook, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drummond, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kergaye, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McElroy, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rohrbach, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, W. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tam, S. W.</span></span> <span> </span><span class="NLM_article-title">Novel piperidine sigma receptor ligands as potential antipsychotic drugs</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1992</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">4344</span>– <span class="NLM_lpage">4361</span>, <span class="refDoi"> DOI: 10.1021/jm00101a012</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00101a012" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADyaK3sXlvFGnsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=1992&pages=4344-4361&author=P.+J.+Gilliganauthor=G.+A.+Cainauthor=T.+E.+Christosauthor=L.+Cookauthor=S.+Drummondauthor=A.+L.+Johnsonauthor=A.+A.+Kergayeauthor=J.+F.+McElroyauthor=K.+W.+Rohrbachauthor=W.+K.+Schmidtauthor=S.+W.+Tam&title=Novel+piperidine+sigma+receptor+ligands+as+potential+antipsychotic+drugs&doi=10.1021%2Fjm00101a012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">Novel piperidine σ receptor ligands as potential antipsychotic drugs</span></div><div class="casAuthors">Gilligan, Paul J.; Cain, Gary A.; Christos, Thomas E.; Cook, Leonard; Drummond, Spencer; Johnson, Alexander L.; Kergaye, Ahmed A.; McElroy, John F.; Rohrbach, Kenneth W.; et al.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">4344-61</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    </div><div class="casAbstract">σ Receptor ligands represent a new class of potential antipsychotic drugs.  This paper presents the structure-activity relationships leading to novel disubstituted piperidine σ ligands, which have little or no affinity for dopamine D2 receptors.  Selectivity for σ sites over dopamine D2 or serotonin 5-HT2 receptors appears to be governed by the chem. nature of the piperidine nitrogen substituent, its distance from the basic nitrogen, and its orientation relative to the other piperidine substituent.  Several of these compds. have good oral potency in some animal models used to evaluate potential antipsychotic drugs.  The N-cyclopropylmethyl ketones and ethers I (R = cyano, F; X = CO, O) have the best in vivo potency.  I (R = cyano, F; X = CO) did not cause catalepsy in the rat, even at very high doses.  Based on the pharmacol. profiles of these σ ligands, these compds. may be effective antipsychotic drugs, which do not induce extrapyramidal side effects or tardive dyskinesia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAaGTuY9sV5rVg90H21EOLACvtfcHk0lhIlDK4z_ftCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXlvFGnsg%253D%253D&md5=0d30d6e5f7874b7cb26237b6418d7202</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1021%2Fjm00101a012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00101a012%26sid%3Dliteratum%253Aachs%26aulast%3DGilligan%26aufirst%3DP.%2BJ.%26aulast%3DCain%26aufirst%3DG.%2BA.%26aulast%3DChristos%26aufirst%3DT.%2BE.%26aulast%3DCook%26aufirst%3DL.%26aulast%3DDrummond%26aufirst%3DS.%26aulast%3DJohnson%26aufirst%3DA.%2BL.%26aulast%3DKergaye%26aufirst%3DA.%2BA.%26aulast%3DMcElroy%26aufirst%3DJ.%2BF.%26aulast%3DRohrbach%26aufirst%3DK.%2BW.%26aulast%3DSchmidt%26aufirst%3DW.%2BK.%26aulast%3DTam%26aufirst%3DS.%2BW.%26atitle%3DNovel%2520piperidine%2520sigma%2520receptor%2520ligands%2520as%2520potential%2520antipsychotic%2520drugs%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1992%26volume%3D35%26spage%3D4344%26epage%3D4361%26doi%3D10.1021%2Fjm00101a012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref81"><div class="reference"><strong class="refLabel"><a href="#ref81" class="rightTabRefNumLink">81</a></strong><div class="NLM_citation" id="rightTab-cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Abate, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mosier, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berardi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glennon, R. A.</span></span> <span> </span><span class="NLM_article-title">A structure-affinity and comparative molecular field analysis of sigma-2 (sigma2) receptor ligands</span>. <i>Cent. Nerv. Syst. Agents Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">246</span>– <span class="NLM_lpage">257</span>, <span class="refDoi"> DOI: 10.2174/1871524910909030246</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.2174%2F1871524910909030246" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=20021358" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtVWnt7rK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2009&pages=246-257&author=C.+Abateauthor=P.+D.+Mosierauthor=F.+Berardiauthor=R.+A.+Glennon&title=A+structure-affinity+and+comparative+molecular+field+analysis+of+sigma-2+%28sigma2%29+receptor+ligands&doi=10.2174%2F1871524910909030246"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">A structure-affinity and comparative molecular field analysis of sigma-2 (σ2) receptor ligands</span></div><div class="casAuthors">Abate, Carmen; Mosier, Philip Daniel; Berardi, Francesco; Glennon, Richard A.</div><div class="citationInfo"><span class="NLM_cas:title">Central Nervous System Agents in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">246-257</span>CODEN:
                <span class="NLM_cas:coden">CNSAC3</span>;
        ISSN:<span class="NLM_cas:issn">1871-5249</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">Several σ1 receptor ligands with sub-nanomolar affinity and excellent selectivity have been reported, but relatively few σ2-selective ligands are known.  1-Cyclohexyl-4-[3-(5-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)propyl] piperazine (PB28; 1) has been reported by us as a high-affinity σ2 receptor ligand with significant σ2 selectivity, and several analogs of (1) now have been developed.  Among these are the class of cyclohexylpiperazines that display a good compromise between affinity/activity and selectivity for σ2 receptors.  Very little is currently known about the nature of σ2 receptors.  In the absence of structure-based receptor information, we applied a comparative mol. field anal. (CoMFA) - a three-dimensional structure-activity relationship (3D-QSAR) method - to a set of cyclohexylpiperazine σ2 ligands to develop a predictive model that might provide information about the stereoelectronic nature of the receptor binding site.  Two CoMFA models were generated from two different alignments: the first used an automated FlexS algorithm, and the second used a rationally-driven manual alignment.  Significantly better predictivity was obtained with the manual alignment (TSET: q2 = 0.73, r2 = 0.95; PSET: r2 = 0.55/0.73) than from the automated alignment (TSET: q2 = 0.69, r2 = 0.98; PSET: r2 = 0.13/0.16).  The resulting CoMFA maps account for obsd. structure-affinity relationships and suggest a possible anatomy for the σ2 receptor/cyclohexylpiperazine binding site.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNSRDXO2Ws7bVg90H21EOLACvtfcHk0lhJY1aCHD7q2Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtVWnt7rK&md5=b1203a3a8343205b4439481c0ece5a8e</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.2174%2F1871524910909030246&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1871524910909030246%26sid%3Dliteratum%253Aachs%26aulast%3DAbate%26aufirst%3DC.%26aulast%3DMosier%26aufirst%3DP.%2BD.%26aulast%3DBerardi%26aufirst%3DF.%26aulast%3DGlennon%26aufirst%3DR.%2BA.%26atitle%3DA%2520structure-affinity%2520and%2520comparative%2520molecular%2520field%2520analysis%2520of%2520sigma-2%2520%2528sigma2%2529%2520receptor%2520ligands%26jtitle%3DCent.%2520Nerv.%2520Syst.%2520Agents%2520Med.%2520Chem.%26date%3D2009%26volume%3D9%26spage%3D246%26epage%3D257%26doi%3D10.2174%2F1871524910909030246" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref82"><div class="reference"><strong class="refLabel"><a href="#ref82" class="rightTabRefNumLink">82</a></strong><div class="NLM_citation" id="rightTab-cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zampieri, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mamolo, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laurini, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Florio, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zanette, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fermeglia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Posocco, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paneni, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pricl, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vio, L.</span></span> <span> </span><span class="NLM_article-title">Synthesis, biological evaluation, and three-dimensional in silico pharmacophore model for sigma(1) receptor ligands based on a series of substituted benzo[d]oxazol-2(3H)-one derivatives</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">5380</span>– <span class="NLM_lpage">5393</span>, <span class="refDoi"> DOI: 10.1021/jm900366z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm900366z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BD1MXpslaht78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=5380-5393&author=D.+Zampieriauthor=M.+G.+Mamoloauthor=E.+Lauriniauthor=C.+Florioauthor=C.+Zanetteauthor=M.+Fermegliaauthor=P.+Posoccoauthor=M.+S.+Paneniauthor=S.+Priclauthor=L.+Vio&title=Synthesis%2C+biological+evaluation%2C+and+three-dimensional+in+silico+pharmacophore+model+for+sigma%281%29+receptor+ligands+based+on+a+series+of+substituted+benzo%5Bd%5Doxazol-2%283H%29-one+derivatives&doi=10.1021%2Fjm900366z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis, Biological Evaluation, and Three-Dimensional in Silico Pharmacophore Model for σ1 Receptor Ligands Based on a Series of Substituted Benzo[d]oxazol-2(3H)-one Derivatives</span></div><div class="casAuthors">Zampieri, Daniele; Mamolo, Maria Grazia; Laurini, Erik; Florio, Chiara; Zanette, Caterina; Fermeglia, Maurizio; Posocco, Paola; Paneni, Maria Silvia; Pricl, Sabrina; Vio, Luciano</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">5380-5393</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Novel benzo[d]oxazol-2(3H)-one derivs. were designed and synthesized, and their affinities against σ receptors were evaluated.  On the basis of 31 compds., a three-dimensional pharmacophore model for the σ1 receptor binding site was developed using the Catalyst 4.9 software package.  The best 3D pharmacophore hypothesis, consisting of one pos. ionizable, one hydrogen bond acceptor, two hydrophobic arom., and one hydrophobic features provided a 3D-QSAR model with a correlation coeff. of 0.89.  The best hypothesis was also validated by three independent methods, i.e., the Fisher randomization test included in the CatScramble functionality of Catalyst, the leave-one-out test, and activity prediction of an addnl. test set.  The achieved results will allow researchers to use this 3D pharmacophore model for the design and synthesis of a second generation of high affinity σ1 ligands, as well as to discover other lead compds. for this class of receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZ7dYDBRve47Vg90H21EOLACvtfcHk0lhJY1aCHD7q2Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXpslaht78%253D&md5=678e879dd9b79c55fc61bfec02d3b927</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1021%2Fjm900366z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm900366z%26sid%3Dliteratum%253Aachs%26aulast%3DZampieri%26aufirst%3DD.%26aulast%3DMamolo%26aufirst%3DM.%2BG.%26aulast%3DLaurini%26aufirst%3DE.%26aulast%3DFlorio%26aufirst%3DC.%26aulast%3DZanette%26aufirst%3DC.%26aulast%3DFermeglia%26aufirst%3DM.%26aulast%3DPosocco%26aufirst%3DP.%26aulast%3DPaneni%26aufirst%3DM.%2BS.%26aulast%3DPricl%26aufirst%3DS.%26aulast%3DVio%26aufirst%3DL.%26atitle%3DSynthesis%252C%2520biological%2520evaluation%252C%2520and%2520three-dimensional%2520in%2520silico%2520pharmacophore%2520model%2520for%2520sigma%25281%2529%2520receptor%2520ligands%2520based%2520on%2520a%2520series%2520of%2520substituted%2520benzo%255Bd%255Doxazol-2%25283H%2529-one%2520derivatives%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D5380%26epage%3D5393%26doi%3D10.1021%2Fjm900366z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref83"><div class="reference"><strong class="refLabel"><a href="#ref83" class="rightTabRefNumLink">83</a></strong><div class="NLM_citation" id="rightTab-cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schepmann, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yanagisawa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamaguchi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dal Col, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laurini, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Itami, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pricl, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wünsch, B.</span></span> <span> </span><span class="NLM_article-title">Pd-catalyzed direct C-H bond functionalization of spirocyclic σ1 ligands: generation of a pharmacophore model and analysis of the reverse binding mode by docking into a 3D homology model of the σ1 receptor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">8047</span>– <span class="NLM_lpage">8065</span>, <span class="refDoi"> DOI: 10.1021/jm300894h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300894h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1CisrjN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=8047-8065&author=C.+Meyerauthor=D.+Schepmannauthor=S.+Yanagisawaauthor=J.+Yamaguchiauthor=V.+Dal+Colauthor=E.+Lauriniauthor=K.+Itamiauthor=S.+Priclauthor=B.+W%C3%BCnsch&title=Pd-catalyzed+direct+C-H+bond+functionalization+of+spirocyclic+%CF%831+ligands%3A+generation+of+a+pharmacophore+model+and+analysis+of+the+reverse+binding+mode+by+docking+into+a+3D+homology+model+of+the+%CF%831+receptor&doi=10.1021%2Fjm300894h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">Pd-Catalyzed Direct C-H Bond Functionalization of Spirocyclic σ1 Ligands: Generation of a Pharmacophore Model and Analysis of the Reverse Binding Mode by Docking into a 3D Homology Model of the σ1 Receptor</span></div><div class="casAuthors">Meyer, Christina; Schepmann, Dirk; Yanagisawa, Shuichi; Yamaguchi, Junichiro; Dal Col, Valentina; Laurini, Erik; Itami, Kenichiro; Pricl, Sabrina; Wuensch, Bernhard</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">8047-8065</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">To explore the hydrophobic binding region of the σ1 receptor protein, regioisomeric spirocyclic thiophenes I (R = H) and II (R1 = R2 = H; R3 = H, MeO) were developed as versatile building blocks.  Regioselective α- and β-arylation using the catalyst systems PdCl2/bipy/Ag2CO3 and PdCl2/P[OCH(CF3)2]3/Ag2CO3 allowed the introduction of various aryl moieties at different positions in the last step of the synthesis.  The increasing σ1 affinity in the order I (R = Ph, 4-MeOC6H4, 4-NCC6H4, 4-PhC6H4) < II (R1 = Ph, 4-MeC6H4, 1-naphthyl, 3-pyridyl, etc.; R2 = H; R3 = H, MeO) < II (R1 = H; R2 = Ph, 4-MeOC6H4, 4-MeC6H4; R3 = H, MeO) indicated that the positions of the addnl. aryl moiety and the S atom in the spirocyclic thiophene systems control the σ1 affinity.  The main features of the pharmacophore model developed for this class of σ1 ligands are a pos. ionizable group, a H-bond acceptor group, two hydrophobic moieties, and one hydrophobic arom. group.  Docking of the ligands into a σ1 3D homol. model via mol. mechanics/Poisson-Boltzmann surface area calcns. led to a very good correlation between the exptl. detd. and estd. free energy of receptor binding.  These calcns. supported the hypothesis of a reverse binding mode of ligands bearing the aryl moiety at the "top" [e.g. compds. II (R1 = H; R2 = Ph, 4-MeC6H4, 4-MeOC6H4; R3 = H, MeO)] and "left" [e.g. compds. I (R = Ph, 4-MeOC6H4, etc.) and II (R1 = Ph, 4-MeC6H4, etc.; R2 = H; R3 = H, MeO)] positions, resp.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGof-c_9FzrfCbVg90H21EOLACvtfcHk0lhJY1aCHD7q2Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1CisrjN&md5=a7a89849dff3c9f177eac824df9d5f0f</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1021%2Fjm300894h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300894h%26sid%3Dliteratum%253Aachs%26aulast%3DMeyer%26aufirst%3DC.%26aulast%3DSchepmann%26aufirst%3DD.%26aulast%3DYanagisawa%26aufirst%3DS.%26aulast%3DYamaguchi%26aufirst%3DJ.%26aulast%3DDal%2BCol%26aufirst%3DV.%26aulast%3DLaurini%26aufirst%3DE.%26aulast%3DItami%26aufirst%3DK.%26aulast%3DPricl%26aufirst%3DS.%26aulast%3DW%25C3%25BCnsch%26aufirst%3DB.%26atitle%3DPd-catalyzed%2520direct%2520C-H%2520bond%2520functionalization%2520of%2520spirocyclic%2520%25CF%25831%2520ligands%253A%2520generation%2520of%2520a%2520pharmacophore%2520model%2520and%2520analysis%2520of%2520the%2520reverse%2520binding%2520mode%2520by%2520docking%2520into%2520a%25203D%2520homology%2520model%2520of%2520the%2520%25CF%25831%2520receptor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D8047%26epage%3D8065%26doi%3D10.1021%2Fjm300894h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref84"><div class="reference"><strong class="refLabel"><a href="#ref84" class="rightTabRefNumLink">84</a></strong><div class="NLM_citation" id="rightTab-cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Laurini, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zampieri, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mamolo, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vio, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zanette, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Florio, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Posocco, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fermeglia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pricl, S.</span></span> <span> </span><span class="NLM_article-title">A 3D-pharmacophore model for sigma2 receptors based on a series of substituted benzo[d]oxazol-2(3H)-one derivatives</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">2954</span>– <span class="NLM_lpage">2957</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2010.03.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1016%2Fj.bmcl.2010.03.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=20347592" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BC3cXkvFCjsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=2954-2957&author=E.+Lauriniauthor=D.+Zampieriauthor=M.+G.+Mamoloauthor=L.+Vioauthor=C.+Zanetteauthor=C.+Florioauthor=P.+Posoccoauthor=M.+Fermegliaauthor=S.+Pricl&title=A+3D-pharmacophore+model+for+sigma2+receptors+based+on+a+series+of+substituted+benzo%5Bd%5Doxazol-2%283H%29-one+derivatives&doi=10.1016%2Fj.bmcl.2010.03.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">A 3D-pharmacophore model for σ2 receptors based on a series of substituted benzo[d]oxazol-2(3H)-one derivatives</span></div><div class="casAuthors">Laurini, Erik; Zampieri, Daniele; Mamolo, Maria Grazia; Vio, Luciano; Zanette, Caterina; Florio, Chiara; Posocco, Paola; Fermeglia, Maurizio; Pricl, Sabrina</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2954-2957</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">In this work we developed a 3D-pharmacophore model for σ2 receptor based on 19 benzooxazolone derivs.  The best 3D-pharmacophore hypothesis, consisting of five features: a pos. ionizable, a hydrogen bond acceptor, a hydrophobic arom., a hydrophobic aliph., and a generic hydrophobic provided a 3D-QSAR model with a correlation coeff. of 0.97 and a RMSD of 0.48.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcKZ2Af8LJdLVg90H21EOLACvtfcHk0ljzvCNunGbXLQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXkvFCjsbw%253D&md5=c33600826462836d4d6301e85d387df0</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2010.03.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2010.03.009%26sid%3Dliteratum%253Aachs%26aulast%3DLaurini%26aufirst%3DE.%26aulast%3DZampieri%26aufirst%3DD.%26aulast%3DMamolo%26aufirst%3DM.%2BG.%26aulast%3DVio%26aufirst%3DL.%26aulast%3DZanette%26aufirst%3DC.%26aulast%3DFlorio%26aufirst%3DC.%26aulast%3DPosocco%26aufirst%3DP.%26aulast%3DFermeglia%26aufirst%3DM.%26aulast%3DPricl%26aufirst%3DS.%26atitle%3DA%25203D-pharmacophore%2520model%2520for%2520sigma2%2520receptors%2520based%2520on%2520a%2520series%2520of%2520substituted%2520benzo%255Bd%255Doxazol-2%25283H%2529-one%2520derivatives%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D2954%26epage%3D2957%26doi%3D10.1016%2Fj.bmcl.2010.03.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref85"><div class="reference"><strong class="refLabel"><a href="#ref85" class="rightTabRefNumLink">85</a></strong><div class="NLM_citation" id="rightTab-cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pascual, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Almansa, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plata-Salamán, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vela, J. M.</span></span> <span> </span><span class="NLM_article-title">A New Pharmacophore Model for the Design of Sigma-1 Ligands Validated on a Large Experimental Dataset</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">519</span>, <span class="refDoi"> DOI: 10.3389/fphar.2019.00519</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.3389%2Ffphar.2019.00519" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=31214020" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BB3cXktFOnsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=519&author=R.+Pascualauthor=C.+Almansaauthor=C.+Plata-Salam%C3%A1nauthor=J.+M.+Vela&title=A+New+Pharmacophore+Model+for+the+Design+of+Sigma-1+Ligands+Validated+on+a+Large+Experimental+Dataset&doi=10.3389%2Ffphar.2019.00519"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">A new pharmacophore model for the design of sigma-1 ligands validated on a large experimental dataset</span></div><div class="casAuthors">Pascual, Rosalia; Almansa, Carmen; Plata-Salaman, Carlos; Vela, Jose Miguel</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Pharmacology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">519</span>CODEN:
                <span class="NLM_cas:coden">FPRHAU</span>;
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">The recent publication of the σ1R crystal structure is an important cornerstone for the derivation of more accurate activity prediction models.  We report here a comparative study involving a set of more than 25,000 structures from our internal database that had been screened for σ1R affinity.  Using the recently published crystal structure, 5HK1, two new pharmacophore models were generated.  The first one, 5HK1-Ph.A, was obtained by an algorithm that identifies the most important receptor-ligand interactions including vol. restrictions enforced by the at. structure of the recognition site.  The second, 5HK1-Ph.B, resulted from a manual edition of the first one by the fusion of two hydrophobic (HYD) features.  Finally, we also docked the database using a high throughput docking technique and scored the resulting poses with seven different scoring functions.  Statistical performance measures were obtained for the two models, comparing them with previously published σ1R pharmacophores (Hit Rate, sensitivity, specificity, and Receiver Operator Characteristic) and 5HK1-Ph.B emerged as the best one in discriminating between active and inactive compds., with a ROC-AUC value above 0.8 and enrichment values above 3 at different fractions of screened samples. 5HK1-Ph.B also showed better results than the direct docking, which may be due to the rigidity of the crystal structure in the docking process (i.e., feature tolerances in the pharmacophore model).  Addnl., the impact of the HYD interactions and the penalty for desolvating ligands with polar atoms may be not adequately captured by scoring functions, whereas HYD groups filling up such regions of the binding site are entailed in the pharmacophore model.  Altogether, using annotated data from a large and diverse compd. collection together with crystal structure information provides a sound basis for the generation and validation of predictive models to design new mols.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGommlNCghqBXrVg90H21EOLACvtfcHk0ljzvCNunGbXLQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXktFOnsr0%253D&md5=156ec236d1cf03779cae199e0716b497</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2019.00519&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2019.00519%26sid%3Dliteratum%253Aachs%26aulast%3DPascual%26aufirst%3DR.%26aulast%3DAlmansa%26aufirst%3DC.%26aulast%3DPlata-Salam%25C3%25A1n%26aufirst%3DC.%26aulast%3DVela%26aufirst%3DJ.%2BM.%26atitle%3DA%2520New%2520Pharmacophore%2520Model%2520for%2520the%2520Design%2520of%2520Sigma-1%2520Ligands%2520Validated%2520on%2520a%2520Large%2520Experimental%2520Dataset%26jtitle%3DFront.%2520Pharmacol.%26date%3D2019%26volume%3D10%26spage%3D519%26doi%3D10.3389%2Ffphar.2019.00519" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref86"><div class="reference"><strong class="refLabel"><a href="#ref86" class="rightTabRefNumLink">86</a></strong><div class="NLM_citation" id="rightTab-cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Iyamu, I. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lv, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malik, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mishra, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schiltz, G. E.</span></span> <span> </span><span class="NLM_article-title">Development of Tetrahydroindazole-Based Potent and Selective Sigma-2 Receptor Ligands</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">1248</span>– <span class="NLM_lpage">1256</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201900203</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1002%2Fcmdc.201900203" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=31071238" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtVOns7%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2019&pages=1248-1256&author=I.+D.+Iyamuauthor=W.+Lvauthor=N.+Malikauthor=R.+K.+Mishraauthor=G.+E.+Schiltz&title=Development+of+Tetrahydroindazole-Based+Potent+and+Selective+Sigma-2+Receptor+Ligands&doi=10.1002%2Fcmdc.201900203"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">Development of Tetrahydroindazole-Based Potent and Selective Sigma-2 Receptor Ligands</span></div><div class="casAuthors">Iyamu, Iredia D.; Lv, Wei; Malik, Neha; Mishra, Rama K.; Schiltz, Gary E.</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1248-1256</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">The sigma-2 receptor has been shown to play important roles in a no. of important diseases, including central nervous system (CNS) disorders and cancer.  However, mechanisms by which sigma-2 contributes to these diseases remain unclear.  The development of new sigma-2 ligands that can be used to probe the function of this protein and potentially as drug discovery leads is therefore of great importance.  Herein we report the development of a series of tetrahydroindazole compds. that are highly potent and selective for sigma-2.  Structure-activity relationship data were used to generate a pharmacophore model that summarizes the common features present in the potent ligands.  Assays for soly. and microsomal stability showed that several members of this compd. series possess promising characteristics for further development of useful chem. probes or drug discovery leads.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrVYUrjkbc4rVg90H21EOLACvtfcHk0ljzvCNunGbXLQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtVOns7%252FI&md5=95f910086e2082c97b83a7526eb8223a</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201900203&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201900203%26sid%3Dliteratum%253Aachs%26aulast%3DIyamu%26aufirst%3DI.%2BD.%26aulast%3DLv%26aufirst%3DW.%26aulast%3DMalik%26aufirst%3DN.%26aulast%3DMishra%26aufirst%3DR.%2BK.%26aulast%3DSchiltz%26aufirst%3DG.%2BE.%26atitle%3DDevelopment%2520of%2520Tetrahydroindazole-Based%2520Potent%2520and%2520Selective%2520Sigma-2%2520Receptor%2520Ligands%26jtitle%3DChemMedChem%26date%3D2019%26volume%3D14%26spage%3D1248%26epage%3D1256%26doi%3D10.1002%2Fcmdc.201900203" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref87"><div class="reference"><strong class="refLabel"><a href="#ref87" class="rightTabRefNumLink">87</a></strong><div class="NLM_citation" id="rightTab-cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Glennon, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ismaiel, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">el-Ashmawy, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Battaglia, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, J. B.</span></span> <span> </span><span class="NLM_article-title">Identification and exploitation of the sigma-opiate pharmacophore</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1991</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">1094</span>– <span class="NLM_lpage">1098</span>, <span class="refDoi"> DOI: 10.1021/jm00107a033</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00107a033" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADyaK3MXit1ynsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=1991&pages=1094-1098&author=R.+A.+Glennonauthor=J.+D.+Smithauthor=A.+M.+Ismaielauthor=M.+el-Ashmawyauthor=G.+Battagliaauthor=J.+B.+Fischer&title=Identification+and+exploitation+of+the+sigma-opiate+pharmacophore&doi=10.1021%2Fjm00107a033"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">Identification and exploitation of the σ-opiate pharmacophore</span></div><div class="casAuthors">Glennon, Richard A.; Smith, J. Doyle; Ismaiel, Abd M.; El-Ashmawy, Mahmoud; Battaglia, George; Fischer, James B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1094-8</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    </div><div class="casAbstract">Reductive alkylation of PhCH2CH(NH2)Me gave (R)- and (S)-RR1NCHMeCH2Ph [I; R = Et, Pr, Bu, CH2Ph, CHMePh, CH2CH2Ph, (CH2)3Ph, (CH2)4Ph, (CH2)5Ph, C:CHPh, CH2OPh, etc.; R1 = H, Me].  E.g., alkylation of (R)-PhCH2CH(NH2)Me with PhCH2CH2CHO gave (R)-PhCH2CH2CH2NHCHMeCH2Ph.  I were tested for their affinity to σ-receptors and their psychotomimetic activity; the structure-activity relationship was discussed.  The role of I as a component of a benzomorphan structure was studied; the presence of a 1-phenyl-2-aminopropane nucleus was sufficient for binding at the σ-site, provided that the terminal amine is not a tertiary amine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp30jRVEOn-j7Vg90H21EOLACvtfcHk0lgHTP0WB9-7Og"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXit1ynsbc%253D&md5=202d16f2d33e4fff57f736617d3d1377</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1021%2Fjm00107a033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00107a033%26sid%3Dliteratum%253Aachs%26aulast%3DGlennon%26aufirst%3DR.%2BA.%26aulast%3DSmith%26aufirst%3DJ.%2BD.%26aulast%3DIsmaiel%26aufirst%3DA.%2BM.%26aulast%3Del-Ashmawy%26aufirst%3DM.%26aulast%3DBattaglia%26aufirst%3DG.%26aulast%3DFischer%26aufirst%3DJ.%2BB.%26atitle%3DIdentification%2520and%2520exploitation%2520of%2520the%2520sigma-opiate%2520pharmacophore%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1991%26volume%3D34%26spage%3D1094%26epage%3D1098%26doi%3D10.1021%2Fjm00107a033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref88"><div class="reference"><strong class="refLabel"><a href="#ref88" class="rightTabRefNumLink">88</a></strong><div class="NLM_citation" id="rightTab-cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Glennon, R. A.</span></span> <span> </span><span class="NLM_article-title">Pharmacophore identification for sigma-1 (sigma1) receptor binding: application of the “deconstruction-reconstruction-elaboration” approach</span>. <i>Mini-Rev. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">927</span>– <span class="NLM_lpage">940</span>, <span class="refDoi"> DOI: 10.2174/138955705774329519</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.2174%2F138955705774329519" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=16250835" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVWku7rM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2005&pages=927-940&author=R.+A.+Glennon&title=Pharmacophore+identification+for+sigma-1+%28sigma1%29+receptor+binding%3A+application+of+the+%E2%80%9Cdeconstruction-reconstruction-elaboration%E2%80%9D+approach&doi=10.2174%2F138955705774329519"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacophore identification for sigma-1 (σ1) receptor binding: Application of the deconstruction - reconstruction - elaboration approach</span></div><div class="casAuthors">Glennon, R. A.</div><div class="citationInfo"><span class="NLM_cas:title">Mini-Reviews in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">927-940</span>CODEN:
                <span class="NLM_cas:coden">MMCIAE</span>;
        ISSN:<span class="NLM_cas:issn">1389-5575</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  At least two different types of sigma σ (σ1 and σ2) receptors have been identified.  A structural feature common to high-affinity (Ki <10 nM) σ1 ligands is: C-N(R)-X-Ph; both C and Ph are assocd. with regions of bulk tolerance.  Numerous other ligands bind, but typically do so with lower affinity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGot_9JlDBLhrbVg90H21EOLACvtfcHk0lgHTP0WB9-7Og"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVWku7rM&md5=66ae2e51d57fa97cd3954ae90e7e3167</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.2174%2F138955705774329519&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138955705774329519%26sid%3Dliteratum%253Aachs%26aulast%3DGlennon%26aufirst%3DR.%2BA.%26atitle%3DPharmacophore%2520identification%2520for%2520sigma-1%2520%2528sigma1%2529%2520receptor%2520binding%253A%2520application%2520of%2520the%2520%25E2%2580%259Cdeconstruction-reconstruction-elaboration%25E2%2580%259D%2520approach%26jtitle%3DMini-Rev.%2520Med.%2520Chem.%26date%3D2005%26volume%3D5%26spage%3D927%26epage%3D940%26doi%3D10.2174%2F138955705774329519" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref89"><div class="reference"><strong class="refLabel"><a href="#ref89" class="rightTabRefNumLink">89</a></strong><div class="NLM_citation" id="rightTab-cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Conroy, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manohar, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilkinson, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webster, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lieberman, B. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banister, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reekie, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mach, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rendina, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kassiou, M.</span></span> <span> </span><span class="NLM_article-title">A systematic exploration of the effects of flexibility and basicity on sigma (σ) receptor binding in a series of substituted diamines</span>. <i>Org. Biomol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">9388</span>– <span class="NLM_lpage">9405</span>, <span class="refDoi"> DOI: 10.1039/C6OB00615A</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1039%2FC6OB00615A" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=27714195" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsFSgurfK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2016&pages=9388-9405&author=T.+Conroyauthor=M.+Manoharauthor=Y.+Gongauthor=S.+M.+Wilkinsonauthor=M.+Websterauthor=B.+P.+Liebermanauthor=S.+D.+Banisterauthor=T.+A.+Reekieauthor=R.+H.+Machauthor=L.+M.+Rendinaauthor=M.+Kassiou&title=A+systematic+exploration+of+the+effects+of+flexibility+and+basicity+on+sigma+%28%CF%83%29+receptor+binding+in+a+series+of+substituted+diamines&doi=10.1039%2FC6OB00615A"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">A systematic exploration of the effects of flexibility and basicity on sigma (σ) receptor binding in a series of substituted diamines</span></div><div class="casAuthors">Conroy, Trent; Manohar, Madhura; Gong, Yu; Wilkinson, Shane M.; Webster, Michael; Lieberman, Brian P.; Banister, Samuel D.; Reekie, Tristan A.; Mach, Robert H.; Rendina, Louis M.; Kassiou, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Organic & Biomolecular Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">39</span>),
    <span class="NLM_cas:pages">9388-9405</span>CODEN:
                <span class="NLM_cas:coden">OBCRAK</span>;
        ISSN:<span class="NLM_cas:issn">1477-0520</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">The sigma-1 receptor (S1R) has attracted a great deal of attention as a prospective drug target due to its involvement in numerous neurol. disorders and, more recently, for its therapeutic potential in neuropathic pain.  As there was no crystal structure of this membrane-bound protein reported until 2016, ligand generation was driven by pharmacophore refinements to the general model suggested by Glennon and coworkers.  The generalized S1R pharmacophore comprises a central region where a basic amino group is preferred, flanked by two hydrophobic groups.  Guided by this pharmacophore, S1R ligands contg. piperazines, piperazinones, and ethylenediamines have been developed.  In the current work, the authors systematically deconstructed the piperazine core of a prototypic piperazine S1R ligand (vide infra) developed in the labs.  Although the authors did not improve the affinity at the S1R compared to the lead, the authors identified several features important for affinity and selectivity.  These included at least one basic nitrogen atom, conformational flexibility and, for S1R, a secondary or tertiary amine group proximal to the anisole.  Furthermore, S2R selectivity can be tailored with functional group modifications of the N-atom proximal to the anisole.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrRblD6b2r0b7Vg90H21EOLACvtfcHk0lgHTP0WB9-7Og"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsFSgurfK&md5=77e2e441b882243c72ac119a24e8db3d</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1039%2FC6OB00615A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC6OB00615A%26sid%3Dliteratum%253Aachs%26aulast%3DConroy%26aufirst%3DT.%26aulast%3DManohar%26aufirst%3DM.%26aulast%3DGong%26aufirst%3DY.%26aulast%3DWilkinson%26aufirst%3DS.%2BM.%26aulast%3DWebster%26aufirst%3DM.%26aulast%3DLieberman%26aufirst%3DB.%2BP.%26aulast%3DBanister%26aufirst%3DS.%2BD.%26aulast%3DReekie%26aufirst%3DT.%2BA.%26aulast%3DMach%26aufirst%3DR.%2BH.%26aulast%3DRendina%26aufirst%3DL.%2BM.%26aulast%3DKassiou%26aufirst%3DM.%26atitle%3DA%2520systematic%2520exploration%2520of%2520the%2520effects%2520of%2520flexibility%2520and%2520basicity%2520on%2520sigma%2520%2528%25CF%2583%2529%2520receptor%2520binding%2520in%2520a%2520series%2520of%2520substituted%2520diamines%26jtitle%3DOrg.%2520Biomol.%2520Chem.%26date%3D2016%26volume%3D14%26spage%3D9388%26epage%3D9405%26doi%3D10.1039%2FC6OB00615A" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref90"><div class="reference"><strong class="refLabel"><a href="#ref90" class="rightTabRefNumLink">90</a></strong><div class="NLM_citation" id="rightTab-cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Greenfield, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skiba, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mandler, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sliz, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kruse, A. C.</span></span> <span> </span><span class="NLM_article-title">Virtual Screening for Ligand Discovery at the σ(1) Receptor</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">1555</span>– <span class="NLM_lpage">1561</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.9b00314</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.9b00314" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhsVGns7nF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2020&pages=1555-1561&author=D.+A.+Greenfieldauthor=H.+R.+Schmidtauthor=M.+A.+Skibaauthor=M.+D.+Mandlerauthor=J.+R.+Andersonauthor=P.+Slizauthor=A.+C.+Kruse&title=Virtual+Screening+for+Ligand+Discovery+at+the+%CF%83%281%29+Receptor&doi=10.1021%2Facsmedchemlett.9b00314"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">Virtual Screening for Ligand Discovery at the σ1 Receptor</span></div><div class="casAuthors">Greenfield, Daniel A.; Schmidt, Hayden R.; Skiba, Meredith A.; Mandler, Michael D.; Anderson, Jacob R.; Sliz, Piotr; Kruse, Andrew C.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1555-1561</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The σ1 receptor is a transmembrane protein implicated in several pathophysiol. conditions, including neurodegenerative disease, drug addiction, cancer, and pain.  However, there are no high-throughput functional assays for σ1 receptor drug discovery.  Here, we assessed high-throughput structure-based computational docking for discovery of novel ligands of the σ1 receptor.  We screened a library of over 6 million compds. using the Schr.ovrddot.odinger Glide package, followed by exptl. characterization of top-scoring candidates. 77% of tested candidates bound σ1 with high affinity (KD < 1 μM).  These include compds. with high selectivity for the σ1 receptor compared to the genetically unrelated but pharmacol. similar σ2 receptor, as well as compds. with substantial crossreactivity between the two receptors.  These results establish structure-based virtual screening as a highly effective platform for σ1 receptor ligand discovery and provide compds. to prioritize in studies of σ1 biol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqiDfUmoQaAcLVg90H21EOLACvtfcHk0ljEAbH7kCBOXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhsVGns7nF&md5=f9bb32db3e629e604044651de2147bb5</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.9b00314&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.9b00314%26sid%3Dliteratum%253Aachs%26aulast%3DGreenfield%26aufirst%3DD.%2BA.%26aulast%3DSchmidt%26aufirst%3DH.%2BR.%26aulast%3DSkiba%26aufirst%3DM.%2BA.%26aulast%3DMandler%26aufirst%3DM.%2BD.%26aulast%3DAnderson%26aufirst%3DJ.%2BR.%26aulast%3DSliz%26aufirst%3DP.%26aulast%3DKruse%26aufirst%3DA.%2BC.%26atitle%3DVirtual%2520Screening%2520for%2520Ligand%2520Discovery%2520at%2520the%2520%25CF%2583%25281%2529%2520Receptor%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2020%26volume%3D11%26spage%3D1555%26epage%3D1561%26doi%3D10.1021%2Facsmedchemlett.9b00314" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref91"><div class="reference"><strong class="refLabel"><a href="#ref91" class="rightTabRefNumLink">91</a></strong><div class="NLM_citation" id="rightTab-cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">March-Vila, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pinzi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sturm, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tinivella, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engkvist, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rastelli, G.</span></span> <span> </span><span class="NLM_article-title">On the Integration of In Silico Drug Design Methods for Drug Repurposing</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">298</span>, <span class="refDoi"> DOI: 10.3389/fphar.2017.00298</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.3389%2Ffphar.2017.00298" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=28588497" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvFentbbP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=298&author=E.+March-Vilaauthor=L.+Pinziauthor=N.+Sturmauthor=A.+Tinivellaauthor=O.+Engkvistauthor=H.+Chenauthor=G.+Rastelli&title=On+the+Integration+of+In+Silico+Drug+Design+Methods+for+Drug+Repurposing&doi=10.3389%2Ffphar.2017.00298"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">On the integration of in silico drug design methods for drug repurposing</span></div><div class="casAuthors">March-Vila, Eric; Pinzi, Luca; Sturm, Noe; Tinivella, Annachiara; Engkvist, Ola; Chen, Hongming; Rastelli, Giulio</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Pharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">298/1-298/7</span>CODEN:
                <span class="NLM_cas:coden">FPRHAU</span>;
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">Drug repurposing has become an important branch of drug discovery.  Several computational approaches that help to uncover new repurposing opportunities and aid the discovery process have been put forward, or adapted from previous applications.  A no. of successful examples are now available.  Overall, future developments will greatly benefit from integration of different methods, approaches and disciplines.  Steps forward in this direction are expected to help to clarify, and therefore to rationally predict, new drug-target, target-disease, and ultimately drug-disease assocns.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-SylGJO5wt7Vg90H21EOLACvtfcHk0ljEAbH7kCBOXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvFentbbP&md5=cf38db8a704a52cddbd6949caca49783</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2017.00298&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2017.00298%26sid%3Dliteratum%253Aachs%26aulast%3DMarch-Vila%26aufirst%3DE.%26aulast%3DPinzi%26aufirst%3DL.%26aulast%3DSturm%26aufirst%3DN.%26aulast%3DTinivella%26aufirst%3DA.%26aulast%3DEngkvist%26aufirst%3DO.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DRastelli%26aufirst%3DG.%26atitle%3DOn%2520the%2520Integration%2520of%2520In%2520Silico%2520Drug%2520Design%2520Methods%2520for%2520Drug%2520Repurposing%26jtitle%3DFront.%2520Pharmacol.%26date%3D2017%26volume%3D8%26spage%3D298%26doi%3D10.3389%2Ffphar.2017.00298" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref92"><div class="reference"><strong class="refLabel"><a href="#ref92" class="rightTabRefNumLink">92</a></strong><div class="NLM_citation" id="rightTab-cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gilmore, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsumoto, R. R.</span></span> <span> </span><span class="NLM_article-title">Review of the pharmacological and clinical profile of rimcazole</span>. <i>CNS Drug Rev.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">22</span>, <span class="refDoi"> DOI: 10.1111/j.1527-3458.2004.tb00001.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1111%2Fj.1527-3458.2004.tb00001.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=14978511" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BD2cXjtlClu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2004&pages=1-22&author=D.+L.+Gilmoreauthor=Y.+Liuauthor=R.+R.+Matsumoto&title=Review+of+the+pharmacological+and+clinical+profile+of+rimcazole&doi=10.1111%2Fj.1527-3458.2004.tb00001.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">Review of the pharmacological and clinical profile of rimcazole</span></div><div class="casAuthors">Gilmore, Deborah L.; Liu, Yun; Matsumoto, Rae R.</div><div class="citationInfo"><span class="NLM_cas:title">CNS Drug Reviews</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-22</span>CODEN:
                <span class="NLM_cas:coden">CDREFB</span>;
        ISSN:<span class="NLM_cas:issn">1080-563X</span>.
    
            (<span class="NLM_cas:orgname">Neva Press</span>)
        </div><div class="casAbstract">A review.  Rimcazole is a carbazole deriv. that acts in part as a σ receptor antagonist.  Wellcome Research Labs. introduced this compd. during the 1980s when it was hypothesized to be a novel antipsychotic with an improved side effect profile.  However, subsequent clin. trials demonstrated that rimcazole lacked efficacy in schizophrenic patients and it is now primarily used as an exptl. tool.  In addn. to its actions as a σ receptor antagonist, rimcazole also has high affinity for dopamine transporters, and in recent years it has served as a lead compd. for the development of novel dopamine transporter ligands.  Although rimcazole cannot be considered a selective ligand for σ receptors, the recent development of other selective agonists and antagonists for σ receptors have aided in clarifying the involvement of these receptors in the actions of rimcazole.  Many of the physiol. and behavioral effects of rimcazole can in fact be ascribed to its action as a σ receptor antagonist, although there are exceptions.  Rimcazole is likely to have a continued role in elucidating σ receptor function in either in vitro or in vivo systems where σ receptor-mediated effects can be studied independently of the influence of dopamine and serotonin transporters.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnDturAcy-MbVg90H21EOLACvtfcHk0ljEAbH7kCBOXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXjtlClu7k%253D&md5=4acf91e4e7b49d1d74372dc095b07594</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1111%2Fj.1527-3458.2004.tb00001.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1527-3458.2004.tb00001.x%26sid%3Dliteratum%253Aachs%26aulast%3DGilmore%26aufirst%3DD.%2BL.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DMatsumoto%26aufirst%3DR.%2BR.%26atitle%3DReview%2520of%2520the%2520pharmacological%2520and%2520clinical%2520profile%2520of%2520rimcazole%26jtitle%3DCNS%2520Drug%2520Rev.%26date%3D2004%26volume%3D10%26spage%3D1%26epage%3D22%26doi%3D10.1111%2Fj.1527-3458.2004.tb00001.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref93"><div class="reference"><strong class="refLabel"><a href="#ref93" class="rightTabRefNumLink">93</a></strong><div class="NLM_citation" id="rightTab-cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Happy, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dejoie, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zajac, C. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortez, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chakraborty, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aderemi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sauane, M.</span></span> <span> </span><span class="NLM_article-title">Sigma 1 Receptor antagonist potentiates the anti-cancer effect of p53 by regulating ER stress, ROS production, Bax levels, and caspase-3 activation</span>. <i>Biochem. Biophys. Res. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>456</i></span>,  <span class="NLM_fpage">683</span>– <span class="NLM_lpage">688</span>, <span class="refDoi"> DOI: 10.1016/j.bbrc.2014.12.029</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1016%2Fj.bbrc.2014.12.029" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=25511708" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BC2MXkslGrsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=456&publication_year=2015&pages=683-688&author=M.+Happyauthor=J.+Dejoieauthor=C.+K.+Zajacauthor=B.+Cortezauthor=K.+Chakrabortyauthor=J.+Aderemiauthor=M.+Sauane&title=Sigma+1+Receptor+antagonist+potentiates+the+anti-cancer+effect+of+p53+by+regulating+ER+stress%2C+ROS+production%2C+Bax+levels%2C+and+caspase-3+activation&doi=10.1016%2Fj.bbrc.2014.12.029"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">Sigma 1 Receptor antagonist potentiates the anti-cancer effect of p53 by regulating ER stress, ROS production, Bax levels, and caspase-3 activation</span></div><div class="casAuthors">Happy, Mireille; Dejoie, Jordan; Zajac, Cynthia K.; Cortez, Briseida; Chakraborty, Karabi; Aderemi, Joseph; Sauane, Moira</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical and Biophysical Research Communications</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">456</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">683-688</span>CODEN:
                <span class="NLM_cas:coden">BBRCA9</span>;
        ISSN:<span class="NLM_cas:issn">0006-291X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Over the last years, many improvements have been made in the treatment of breast cancer; however, novel and less toxic therapies are still needed, esp. for relapsing and chemo-resistant patients.  Here, we analyzed the therapeutic potential of p53 and Rimcazole, a Sigma 1 Receptor antagonist.  Rimcazole and p53 are being evaluated in preclin. and clin. trials, resp.  While p53 is a promising antitumor therapeutic agent, antagonists of Sigma 1 Receptor also inhibit tumor cell survival and induce apoptosis.  Our current study demonstrates for the first time the synergistic effect of p53 in combination with the Sigma 1 Receptor antagonist Rimcazole.  Furthermore, we show that shRNA knockdown of Sigma 1 Receptor in combination with p53, lead to a similar synergistic effect, and that this synergistic effect, in breast cancer growth suppression occurs independent of p53 status.  Furthermore, this combination treatment induced ER stress, p38 MAPK activation, ROS prodn., and proteins involved in apoptosis (caspases-3, Bax) in breast cancer cells.  Combining these therapeutic anti-cancer mols. provides an innovative approach for potentially treating human breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-olGz9KhR_7Vg90H21EOLACvtfcHk0licKlr-b8CCPg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXkslGrsw%253D%253D&md5=2ead9d26d94e08d8174230536ba4db63</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1016%2Fj.bbrc.2014.12.029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbrc.2014.12.029%26sid%3Dliteratum%253Aachs%26aulast%3DHappy%26aufirst%3DM.%26aulast%3DDejoie%26aufirst%3DJ.%26aulast%3DZajac%26aufirst%3DC.%2BK.%26aulast%3DCortez%26aufirst%3DB.%26aulast%3DChakraborty%26aufirst%3DK.%26aulast%3DAderemi%26aufirst%3DJ.%26aulast%3DSauane%26aufirst%3DM.%26atitle%3DSigma%25201%2520Receptor%2520antagonist%2520potentiates%2520the%2520anti-cancer%2520effect%2520of%2520p53%2520by%2520regulating%2520ER%2520stress%252C%2520ROS%2520production%252C%2520Bax%2520levels%252C%2520and%2520caspase-3%2520activation%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D2015%26volume%3D456%26spage%3D683%26epage%3D688%26doi%3D10.1016%2Fj.bbrc.2014.12.029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref94"><div class="reference"><strong class="refLabel"><a href="#ref94" class="rightTabRefNumLink">94</a></strong><div class="NLM_citation" id="rightTab-cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Achison, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boylan, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hupp, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spruce, B. A.</span></span> <span> </span><span class="NLM_article-title">HIF-1alpha contributes to tumour-selective killing by the sigma receptor antagonist rimcazole</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">1137</span>– <span class="NLM_lpage">1146</span>, <span class="refDoi"> DOI: 10.1038/sj.onc.1209890</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1038%2Fsj.onc.1209890" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=16924239" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhvF2jur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2007&pages=1137-1146&author=M.+Achisonauthor=M.+T.+Boylanauthor=T.+R.+Huppauthor=B.+A.+Spruce&title=HIF-1alpha+contributes+to+tumour-selective+killing+by+the+sigma+receptor+antagonist+rimcazole&doi=10.1038%2Fsj.onc.1209890"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">HIF-1α contributes to tumour-selective killing by the sigma receptor antagonist rimcazole</span></div><div class="casAuthors">Achison, M.; Boylan, M. T.; Hupp, T. R.; Spruce, B. A.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1137-1146</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">We have previously reported tumor-selective killing by the sigma (σ) receptor ligand rimcazole.  We now report that rimcazole elevates hypoxia inducible factor-1α (HIF-1α) protein levels under normoxic conditions in colorectal (HCT-116) and mammary carcinoma (MDA MB 231) cells but fails to induce HIF-1α in normal fibroblasts or mammary epithelial cells.  Combining the σ-1 agonist (+)-pentazocine with rimcazole substantially reduces the accumulation of HIF-1α, confirming that the effect is mediated at least partly by antagonism of σ-1 sites.  HIF-1α knockdown by RNA interference attenuates rimcazole-induced cell death in both cell types.  Thus, the induction of HIF-1α by rimcazole contributes to tumor cell killing.  In a comparison of HCT-116p53+/+ and HCT-116p53-/- cells, HIF-1α levels are consistently higher after rimcazole treatment in HCT-116p53+/+ cells.  Furthermore, although rimcazole kills HCT-116p53-/- cells, it has a more potent apoptosis-inducing effect in HCT-116p53+/+ cells.  This suggests that the presence of functional p53 protein may enhance death induction by rimcazole in part through greater induction of HIF-1α. p53 is not required, however, for the rimcazole-induced engagement of HIF-1α in proapoptotic mode as HIF-1α knockdown attenuates rimcazole-induced death to comparable extents in p53 mutant and wild-type cell systems.  Knowledge of HIF-1α involvement may assist the re-profiling of rimcazole and other σ ligands as cancer therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrD0Ge5Ue_R4LVg90H21EOLACvtfcHk0licKlr-b8CCPg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhvF2jur0%253D&md5=58fcdc8182174be1f97d2dd9ea78279b</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1209890&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1209890%26sid%3Dliteratum%253Aachs%26aulast%3DAchison%26aufirst%3DM.%26aulast%3DBoylan%26aufirst%3DM.%2BT.%26aulast%3DHupp%26aufirst%3DT.%2BR.%26aulast%3DSpruce%26aufirst%3DB.%2BA.%26atitle%3DHIF-1alpha%2520contributes%2520to%2520tumour-selective%2520killing%2520by%2520the%2520sigma%2520receptor%2520antagonist%2520rimcazole%26jtitle%3DOncogene%26date%3D2007%26volume%3D26%26spage%3D1137%26epage%3D1146%26doi%3D10.1038%2Fsj.onc.1209890" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref95"><div class="reference"><strong class="refLabel"><a href="#ref95" class="rightTabRefNumLink">95</a></strong><div class="NLM_citation" id="rightTab-cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schrock, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spino, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Longen, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stabler, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marino, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasternak, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, F. J.</span></span> <span> </span><span class="NLM_article-title">Sequential cytoprotective responses to Sigma1 ligand-induced endoplasmic reticulum stress</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>84</i></span>,  <span class="NLM_fpage">751</span>– <span class="NLM_lpage">762</span>, <span class="refDoi"> DOI: 10.1124/mol.113.087809</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1124%2Fmol.113.087809" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=24006496" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1KjtLbE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=84&publication_year=2013&pages=751-762&author=J.+M.+Schrockauthor=C.+M.+Spinoauthor=C.+G.+Longenauthor=S.+M.+Stablerauthor=J.+C.+Marinoauthor=G.+W.+Pasternakauthor=F.+J.+Kim&title=Sequential+cytoprotective+responses+to+Sigma1+ligand-induced+endoplasmic+reticulum+stress&doi=10.1124%2Fmol.113.087809"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">Sequential cytoprotective responses to Sigma1 ligand-induced endoplasmic reticulum stress</span></div><div class="casAuthors">Schrock, Joel M.; Spino, Christina M.; Longen, Charles G.; Stabler, Stacy M.; Marino, Jacqueline C.; Pasternak, Gavril W.; Kim, Felix J.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">84</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">751-762</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">1521-0111</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The Sigma1 receptor (Sigma1) is an endoplasmic reticulum (ER) integral membrane protein that is highly expressed in a no. of cancer cell lines.  Small mol. compds. targeting Sigma1 (Sigma1 ligands) inhibit cancer cell proliferation and induce apoptotic cell death in vitro and inhibit tumor growth in xenograft expts.  However, the cellular pathways activated by Sigma1 protein-ligand interaction are not well defined.  Here, we find that treatment with some Sigma1 ligands induces ER stress and activates the unfolded protein response (UPR) in a dose- and time-responsive manner in a range of adenocarcinoma cell lines.  Autophagy is engaged after extended treatment with Sigma1 ligands, which suggests that protracted UPR results in autophagy as a secondary response.  Inhibition of UPR by RNAi-mediated knockdown of inositol-requiring enzyme 1α and activating transcription factor 4 abrogates autophagosome formation, as does knockdown of essential autophagy gene products Beclin1 and autophagy protein 5.  Knockdown of Sigma1 also suppresses IPAG [1-(4-iodophenyl)-3-(2-adamantyl) guanidine] induced UPR marker and autophagosome levels, indicating that this response is indeed Sigma1-mediated.  We find that UPR activation precedes autophagosome formation and autophagy precedes apoptosis in Sigma1 ligand-treated cells.  These processes are reversible, and washout of IPAG before cell death results in a return of autophagosomes and UPR markers toward basal levels.  However, inhibition of Sigma1 ligand-induced UPR or autophagy accelerates apoptotic cell death.  Together, these data suggest that UPR and autophagy are engaged as primary and secondary cytoprotective responses, resp., to Sigma1 ligand-induced disruption of cancer cell protein homeostasis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXXCF4X7v7r7Vg90H21EOLACvtfcHk0lhWOndwKTkw4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1KjtLbE&md5=3f3f80e868c04d3358ceeb423beacd47</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1124%2Fmol.113.087809&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.113.087809%26sid%3Dliteratum%253Aachs%26aulast%3DSchrock%26aufirst%3DJ.%2BM.%26aulast%3DSpino%26aufirst%3DC.%2BM.%26aulast%3DLongen%26aufirst%3DC.%2BG.%26aulast%3DStabler%26aufirst%3DS.%2BM.%26aulast%3DMarino%26aufirst%3DJ.%2BC.%26aulast%3DPasternak%26aufirst%3DG.%2BW.%26aulast%3DKim%26aufirst%3DF.%2BJ.%26atitle%3DSequential%2520cytoprotective%2520responses%2520to%2520Sigma1%2520ligand-induced%2520endoplasmic%2520reticulum%2520stress%26jtitle%3DMol.%2520Pharmacol.%26date%3D2013%26volume%3D84%26spage%3D751%26epage%3D762%26doi%3D10.1124%2Fmol.113.087809" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref96"><div class="reference"><strong class="refLabel"><a href="#ref96" class="rightTabRefNumLink">96</a></strong><div class="NLM_citation" id="rightTab-cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Berthois, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bourrié, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galiègue, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vidal, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carayon, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casellas, P.</span></span> <span> </span><span class="NLM_article-title">SR31747A is a sigma receptor ligand exhibiting antitumoural activity both in vitro and in vivo</span>. <i>Br. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>88</i></span>,  <span class="NLM_fpage">438</span>– <span class="NLM_lpage">446</span>, <span class="refDoi"> DOI: 10.1038/sj.bjc.6600709</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1038%2Fsj.bjc.6600709" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=12569389" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BD3sXoslKmtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=88&publication_year=2003&pages=438-446&author=Y.+Berthoisauthor=B.+Bourri%C3%A9author=S.+Gali%C3%A8gueauthor=H.+Vidalauthor=P.+Carayonauthor=P.+M.+Martinauthor=P.+Casellas&title=SR31747A+is+a+sigma+receptor+ligand+exhibiting+antitumoural+activity+both+in+vitro+and+in+vivo&doi=10.1038%2Fsj.bjc.6600709"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">SR31747A is a sigma receptor ligand exhibiting antitumoural activity both in vitro and in vivo</span></div><div class="casAuthors">Berthois, Y.; Bourrie, B.; Galiegue, S.; Vidal, H.; Carayon, P.; Martin, P. M.; Casellas, P.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">88</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">438-446</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">SR31747A is a recently described sigma receptor ligand that binds SR31747A-binding protein 1 (SR-BP) and emopamil-binding protein (EBP) (also called the sigma 1 receptor and the human sterol isomerase (HSI), resp.), and has immunoregulatory and antiproliferative activities.  To further investigate its antitumor activity and focusing on cancers, which are sensitive to the mol., we measured the proliferation of different human epithelial breast or prostate cancer cell lines following in vitro and in vivo SR31747A treatment.  Firstly, in vitro, we found that nanomolar concns. of SR31747A dramatically inhibited cell proliferation in both hormono-responsive and -unresponsive cancer cell lines.  Secondly, tumor development was significantly decreased in mice treated with SR31747A.  In an attempt to decipher the SR31747A mode of action, we found that the two binding sites may not fully account for this activity.  Indeed, while competitive expts. indicated that EBP prevails in mediating SR31747A antiproliferative activity, an anal. of the expression of both receptors indicated that the cellular sensitivity to SR31747A is not correlated with either EBP or SR-BP expression.  These data suggest that addnl. binding sites may exist.  Preliminary binding studies demonstrated that SR31747A also binds to sigma2, a protein that has not yet been cloned, but which is considered as a potential marker of the proliferative status of tumor cells.  Altogether, our data demonstrate the antitumoral activity of SR31747A both in vitro and in vivo in two different cancer models, broaden the spectrum of its binding proteins and enhance the potential for further therapeutic development of the mol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpP61EjXFMPiLVg90H21EOLACvtfcHk0lhWOndwKTkw4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXoslKmtQ%253D%253D&md5=c03c521472c1ae7e1a8e387c1d201fc4</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjc.6600709&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjc.6600709%26sid%3Dliteratum%253Aachs%26aulast%3DBerthois%26aufirst%3DY.%26aulast%3DBourri%25C3%25A9%26aufirst%3DB.%26aulast%3DGali%25C3%25A8gue%26aufirst%3DS.%26aulast%3DVidal%26aufirst%3DH.%26aulast%3DCarayon%26aufirst%3DP.%26aulast%3DMartin%26aufirst%3DP.%2BM.%26aulast%3DCasellas%26aufirst%3DP.%26atitle%3DSR31747A%2520is%2520a%2520sigma%2520receptor%2520ligand%2520exhibiting%2520antitumoural%2520activity%2520both%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2003%26volume%3D88%26spage%3D438%26epage%3D446%26doi%3D10.1038%2Fsj.bjc.6600709" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref97"><div class="reference"><strong class="refLabel"><a href="#ref97" class="rightTabRefNumLink">97</a></strong><div class="NLM_citation" id="rightTab-cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Casellas, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galiegue, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bourrie, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrini, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jbilo, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vidal, H.</span></span> <span> </span><span class="NLM_article-title">SR31747A: a peripheral sigma ligand with potent antitumor activities</span>. <i>Anti-Cancer Drugs</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">113</span>– <span class="NLM_lpage">118</span>, <span class="refDoi"> DOI: 10.1097/00001813-200402000-00003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1097%2F00001813-200402000-00003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=15075666" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BD2cXivFaktrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2004&pages=113-118&author=P.+Casellasauthor=S.+Galiegueauthor=B.+Bourrieauthor=J.+B.+Ferriniauthor=O.+Jbiloauthor=H.+Vidal&title=SR31747A%3A+a+peripheral+sigma+ligand+with+potent+antitumor+activities&doi=10.1097%2F00001813-200402000-00003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">SR31747A: a peripheral σ ligand with potent antitumor activities</span></div><div class="casAuthors">Casellas, Pierre; Galiegue, Sylvaine; Bourrie, Bernard; Ferrini, Jean-Bernard; Jbilo, Omar; Vidal, Hubert</div><div class="citationInfo"><span class="NLM_cas:title">Anti-Cancer Drugs</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">113-118</span>CODEN:
                <span class="NLM_cas:coden">ANTDEV</span>;
        ISSN:<span class="NLM_cas:issn">0959-4973</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">A review.  SR31747A is currently being evaluated in phase IIb clin. trials for prostate cancer treatment.  The mol. is a peripheral σ ligand that binds four proteins in human cells, i.e. SRBP-1, σ-2, HSI and its relative SRBP-2.  SR31747A is a dual agent with both immunomodulatory and antiproliferative activities.  The mol. blocks proliferation of human and mouse lymphocytes, modulates the expression of pro- and anti-inflammatory cytokines, and was shown to protect animals in vivo against acute and chronic inflammatory conditions such as acute graft-vs.-host reaction, lethality induced by staphylococcal enterotoxin B and lipopolysaccharide or rheumatoid arthritis.  Besides these immunomodulatory activities, the mol. also inhibits the proliferation of various tumor cell lines in vitro in a time- and concn.-dependent manner.  In vivo, SR31747A has potent antitumoral activity as demonstrated against mammary and prostatic tumoral cell lines injected into nude mice, where both tumor incidence and growth were decreased by more than 40% following daily SR31747A treatment at 25 mg/kg i.p.  The recent literature on SR31747A in cancer is reviewed here.  We focus specifically on preclin. data obtained in vivo and on studies aimed at deciphering the mode of action of the mol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4Y06fjIaU8LVg90H21EOLACvtfcHk0lhWOndwKTkw4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXivFaktrg%253D&md5=3de4da66fa0c2c11575f5ed2a1181b3c</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1097%2F00001813-200402000-00003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F00001813-200402000-00003%26sid%3Dliteratum%253Aachs%26aulast%3DCasellas%26aufirst%3DP.%26aulast%3DGaliegue%26aufirst%3DS.%26aulast%3DBourrie%26aufirst%3DB.%26aulast%3DFerrini%26aufirst%3DJ.%2BB.%26aulast%3DJbilo%26aufirst%3DO.%26aulast%3DVidal%26aufirst%3DH.%26atitle%3DSR31747A%253A%2520a%2520peripheral%2520sigma%2520ligand%2520with%2520potent%2520antitumor%2520activities%26jtitle%3DAnti-Cancer%2520Drugs%26date%3D2004%26volume%3D15%26spage%3D113%26epage%3D118%26doi%3D10.1097%2F00001813-200402000-00003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref98"><div class="reference"><strong class="refLabel"><a href="#ref98" class="rightTabRefNumLink">98</a></strong><div class="NLM_citation" id="rightTab-cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hajipour, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sievert, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arbabian, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruoho, A. E.</span></span> <span> </span><span class="NLM_article-title">Characterization of the cocaine binding site on the sigma-1 receptor</span>. <i>Biochemistry</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">3532</span>– <span class="NLM_lpage">3542</span>, <span class="refDoi"> DOI: 10.1021/bi061727o</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi061727o" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhvF2rt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2007&pages=3532-3542&author=Y.+Chenauthor=A.+R.+Hajipourauthor=M.+K.+Sievertauthor=M.+Arbabianauthor=A.+E.+Ruoho&title=Characterization+of+the+cocaine+binding+site+on+the+sigma-1+receptor&doi=10.1021%2Fbi061727o"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of the Cocaine Binding Site on the Sigma-1 Receptor</span></div><div class="casAuthors">Chen, Yuenmu; Hajipour, Abdol R.; Sievert, Michael K.; Arbabian, Marty; Ruoho, Arnold E.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3532-3542</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The cocaine photoaffinity label 3-iodo-4-azido-cocaine ([125I]IACoc) binds to the sigma-1 receptor with an affinity that is 2-3 orders of magnitude higher than the parent compd. cocaine.  In the present study, the binding properties of several cocaine derivs. to the guinea pig liver sigma-1 receptor were detd.  The results from assessing the affinity of various derivs. of cocaine which were substituted on the Ph ring indicated that an important determinant of binding to the guinea pig sigma-1 receptor binding site may be the development of a dipole in the ring in which the π electron d. of the Ph ring is reduced.  This implies that an electron-rich source is present in the sigma-1 receptor binding site, such as the π system of an arom. ring or other electron-rich side chains, which interact with the Ph ring of cocaine.  The precise [125I]IACoc derivatization site in the guinea pig sigma-1 receptor was identified using chem. cleavage and purifn. of the resulting labeled peptides.  Cyanogen bromide cleavage of the [125I]IACoc photolabeled sigma-1 receptor followed by radio-sequencing identified Asp188, which is located in the putative steroid binding domain-like II (SBDL II) near the carboxyl terminus, as the site of [125I]IACoc insertion.  Systematic truncation of the C-terminus indicated the requirement for the last 15 amino acid residues of the receptor for [125I]IACoc photolabeling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGouSQz-3lvCbbVg90H21EOLACvtfcHk0lhgEC_S56qiyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhvF2rt7Y%253D&md5=64d49c672bcdb3da82000805d05aaeea</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1021%2Fbi061727o&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi061727o%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DY.%26aulast%3DHajipour%26aufirst%3DA.%2BR.%26aulast%3DSievert%26aufirst%3DM.%2BK.%26aulast%3DArbabian%26aufirst%3DM.%26aulast%3DRuoho%26aufirst%3DA.%2BE.%26atitle%3DCharacterization%2520of%2520the%2520cocaine%2520binding%2520site%2520on%2520the%2520sigma-1%2520receptor%26jtitle%3DBiochemistry%26date%3D2007%26volume%3D46%26spage%3D3532%26epage%3D3542%26doi%3D10.1021%2Fbi061727o" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref99"><div class="reference"><strong class="refLabel"><a href="#ref99" class="rightTabRefNumLink">99</a></strong><div class="NLM_citation" id="rightTab-cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pal, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hajipour, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fontanilla, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramachandran, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, U. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mavlyutov, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruoho, A. E.</span></span> <span> </span><span class="NLM_article-title">Identification of regions of the sigma-1 receptor ligand binding site using a novel photoprobe</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>72</i></span>,  <span class="NLM_fpage">921</span>– <span class="NLM_lpage">933</span>, <span class="refDoi"> DOI: 10.1124/mol.107.038307</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1124%2Fmol.107.038307" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=17622576" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtFaiu7%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2007&pages=921-933&author=A.+Palauthor=A.+R.+Hajipourauthor=D.+Fontanillaauthor=S.+Ramachandranauthor=U.+B.+Chuauthor=T.+Mavlyutovauthor=A.+E.+Ruoho&title=Identification+of+regions+of+the+sigma-1+receptor+ligand+binding+site+using+a+novel+photoprobe&doi=10.1124%2Fmol.107.038307"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of regions of the σ-1 receptor ligand binding site using a novel photoprobe</span></div><div class="casAuthors">Pal, Arindam; Hajipour, Abdol R.; Fontanilla, Dominique; Ramachandran, Subramaniam; Chu, Uyen B.; Mavlyutov, Timur; Ruoho, Arnold E.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">921-933</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">0026-895X</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">σ Receptors, once considered a class of opioid receptors, are now regarded as a unique class of receptors that contain binding sites for a wide range of ligands, including the drug 1-N(2',6'-dimethylmorpholino)3-(4-t-butylpropylamine) (fenpropimorph), a yeast sterol isomerase inhibitor.  Because fenpropimorph has high-binding affinity to the σ-1 receptor, the authors have synthesized a series of fenpropimorph-like derivs. with varying Ph ring substituents and have characterized their binding affinities to the σ-1 receptor.  In addn., the authors have synthesized a carrier-free, radioiodinated fenpropimorph-like photoaffinity label, 1-N-(2',6'-dimethyl-morpholino)-3-(4-azido-3-[125I]iodo- phenyl)propane ([125I]IAF), which covalently derivatized the σ-1 receptor (25.3 kDa) in both the rat liver and guinea pig liver membranes and the σ-2 receptor (18 kDa) in rat liver membranes with high specificity.  Furthermore, after cleaving the specific [125I]AF-photolabeled σ-1 receptor in guinea pig and rat liver membranes and the pure guinea pig σ-1 receptor with EndoLys-C and cyanogen bromide, the [125I]IAF label was identified both in a peptide contg. steroid binding domain-like I (SBDLI) (amino acids 91-109) and in a peptide contg. steroid binding domain-like II (SBDLII) (amino acids 176-194).  Because a single population of binding sites (R2 = 0.992) for [125I]IAF interaction with the σ-1 receptor was identified by (+)-[3H]pentazocine competitive binding with nonradioactive [127I]IAF, it was concluded that SBDLI (amino acids 91-109) and SBDLII (amino acids 176-194) comprises, at least in part, regions of the σ-1 receptor ligand binding site(s).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzaWBnxuOtA7Vg90H21EOLACvtfcHk0lhgEC_S56qiyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtFaiu7%252FJ&md5=a0496b04f5f98df95eaf2402e0790c2d</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1124%2Fmol.107.038307&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.107.038307%26sid%3Dliteratum%253Aachs%26aulast%3DPal%26aufirst%3DA.%26aulast%3DHajipour%26aufirst%3DA.%2BR.%26aulast%3DFontanilla%26aufirst%3DD.%26aulast%3DRamachandran%26aufirst%3DS.%26aulast%3DChu%26aufirst%3DU.%2BB.%26aulast%3DMavlyutov%26aufirst%3DT.%26aulast%3DRuoho%26aufirst%3DA.%2BE.%26atitle%3DIdentification%2520of%2520regions%2520of%2520the%2520sigma-1%2520receptor%2520ligand%2520binding%2520site%2520using%2520a%2520novel%2520photoprobe%26jtitle%3DMol.%2520Pharmacol.%26date%3D2007%26volume%3D72%26spage%3D921%26epage%3D933%26doi%3D10.1124%2Fmol.107.038307" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref100"><div class="reference"><strong class="refLabel"><a href="#ref100" class="rightTabRefNumLink">100</a></strong><div class="NLM_citation" id="rightTab-cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ramachandran, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prabhu, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruoho, A. E.</span></span> <span> </span><span class="NLM_article-title">Purification and characterization of the guinea pig sigma-1 receptor functionally expressed in Escherichia coli</span>. <i>Protein Expression Purif.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">283</span>– <span class="NLM_lpage">292</span>, <span class="refDoi"> DOI: 10.1016/j.pep.2006.07.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1016%2Fj.pep.2006.07.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=16962337" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BD28Xht1Klt7fK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2007&pages=283-292&author=S.+Ramachandranauthor=H.+Luauthor=U.+Prabhuauthor=A.+E.+Ruoho&title=Purification+and+characterization+of+the+guinea+pig+sigma-1+receptor+functionally+expressed+in+Escherichia+coli&doi=10.1016%2Fj.pep.2006.07.019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">Purification and characterization of the guinea pig sigma-1 receptor functionally expressed in Escherichia coli</span></div><div class="casAuthors">Ramachandran, Subramaniam; Lu, Hongliang; Prabhu, Usha; Ruoho, Arnold E.</div><div class="citationInfo"><span class="NLM_cas:title">Protein Expression and Purification</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">283-292</span>CODEN:
                <span class="NLM_cas:coden">PEXPEJ</span>;
        ISSN:<span class="NLM_cas:issn">1046-5928</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Sigma receptors once considered as a class of opioid receptors are now regarded as unique orphan receptors, distinguished by the ability to bind various pharmacol. agents such as the progesterone (steroid), haloperidol (anti-psychotic), and drugs of abuse such as cocaine and methamphetamine.  The sigma-1 receptor is a 223 amino acid protein, proposed to have two transmembrane segments.  The authors have developed a scheme for the purifn. of the guinea pig sigma-1 receptor following overexpression in Escherichia coli as a maltose binding protein (MBP) fusion and extn. with Triton X-100.  Affinity chromatog. using an amylose column and Ni2+ affinity column was used to purify the sigma-1 receptor.  The sigma-1 receptor purified by this method is a 26-kDa polypeptide as assessed by SDS-PAGE, binds sigma ligands with high affinity and can be specifically photoaffinity labeled with the sigma-1 receptor photoprobe, [125I]-iodoazidococaine.  Ligand binding using [3H]-(+)-pentazocine indicated that approx. half of the purified protein in Triton X-100 bound to radioligand.  The MBP-sigma-1 receptor and the sigma-1 receptor in 0.5% Triton were maximally stable for approx. two weeks at -20° in buffer contg. 30% glycerol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpodBNpteBB-rVg90H21EOLACvtfcHk0lhgEC_S56qiyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xht1Klt7fK&md5=f9204212cac015ca49604e6401700406</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1016%2Fj.pep.2006.07.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pep.2006.07.019%26sid%3Dliteratum%253Aachs%26aulast%3DRamachandran%26aufirst%3DS.%26aulast%3DLu%26aufirst%3DH.%26aulast%3DPrabhu%26aufirst%3DU.%26aulast%3DRuoho%26aufirst%3DA.%2BE.%26atitle%3DPurification%2520and%2520characterization%2520of%2520the%2520guinea%2520pig%2520sigma-1%2520receptor%2520functionally%2520expressed%2520in%2520Escherichia%2520coli%26jtitle%3DProtein%2520Expression%2520Purif.%26date%3D2007%26volume%3D51%26spage%3D283%26epage%3D292%26doi%3D10.1016%2Fj.pep.2006.07.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref101"><div class="reference"><strong class="refLabel"><a href="#ref101" class="rightTabRefNumLink">101</a></strong><div class="NLM_citation" id="rightTab-cit101"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hajipour, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fontanilla, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, U. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arbabian, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruoho, A. E.</span></span> <span> </span><span class="NLM_article-title">Synthesis and characterization of N,N-dialkyl and N-alkyl-N-aralkyl fenpropimorph-derived compounds as high affinity ligands for sigma receptors</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">4397</span>– <span class="NLM_lpage">4404</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2010.04.078</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1016%2Fj.bmc.2010.04.078" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=20493718" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BC3cXntV2rurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2010&pages=4397-4404&author=A.+R.+Hajipourauthor=D.+Fontanillaauthor=U.+B.+Chuauthor=M.+Arbabianauthor=A.+E.+Ruoho&title=Synthesis+and+characterization+of+N%2CN-dialkyl+and+N-alkyl-N-aralkyl+fenpropimorph-derived+compounds+as+high+affinity+ligands+for+sigma+receptors&doi=10.1016%2Fj.bmc.2010.04.078"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and characterization of N,N-dialkyl and N-alkyl-N-aralkyl fenpropimorph-derived compounds as high affinity ligands for sigma receptors</span></div><div class="casAuthors">Hajipour, Abdol R.; Fontanilla, Dominique; Chu, Uyen B.; Arbabian, Marty; Ruoho, Arnold E.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">4397-4404</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The sigma-1 receptor is a unique non-opioid, non-PCP binding site that has been implicated in many different pathophysiol. conditions including psychosis, drug addiction, retinal degeneration and cancer.  Based on the structure of fenpropimorph, a high affinity (K i = 0.005 nM) sigma-1 receptor ligand and strong inhibitor of the yeast sterol isomerase (ERG2), we previously deduced a basic sigma-1 receptor pharmacophore or chem. backbone composed of a Ph ring attached to a di-substituted nitrogen atom via an alkyl chain.  Here, we report the design and synthesis of various N,N-dialkyl or N-alkyl-N-aralkyl derivs. based on this pharmacophore as well as their binding affinities to the sigma-1 receptor.  We introduce three high affinity sigma-1 receptor compds., N,N-dibutyl-3-(4-fluorophenyl)propylamine (9)(I), N,N-dibutyl-3-(4-nitrophenyl)propylamine (3)(II), and N-propyl-N'-4-aminophenylethyl-3-(4-nitrophenyl)propylamine (20)(III) with K i values of 17.7 nM, 0.36 nM, and 6 nM, resp.  In addn. to sigma receptor affinity, we show through cytotoxicity assays that growth inhibition of various tumor cell lines occurs with our high affinity N,N-dialkyl or N-alkyl-N-aralkyl derivs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQLoE6p6LHRrVg90H21EOLACvtfcHk0ljvJKHyK6JO3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXntV2rurY%253D&md5=26b58c34a1ba0337bd0f7a4258f7df00</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2010.04.078&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2010.04.078%26sid%3Dliteratum%253Aachs%26aulast%3DHajipour%26aufirst%3DA.%2BR.%26aulast%3DFontanilla%26aufirst%3DD.%26aulast%3DChu%26aufirst%3DU.%2BB.%26aulast%3DArbabian%26aufirst%3DM.%26aulast%3DRuoho%26aufirst%3DA.%2BE.%26atitle%3DSynthesis%2520and%2520characterization%2520of%2520N%252CN-dialkyl%2520and%2520N-alkyl-N-aralkyl%2520fenpropimorph-derived%2520compounds%2520as%2520high%2520affinity%2520ligands%2520for%2520sigma%2520receptors%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2010%26volume%3D18%26spage%3D4397%26epage%3D4404%26doi%3D10.1016%2Fj.bmc.2010.04.078" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref102"><div class="reference"><strong class="refLabel"><a href="#ref102" class="rightTabRefNumLink">102</a></strong><div class="NLM_citation" id="rightTab-cit102"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ablordeppey, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glennon, R. A.</span></span> <span> </span><span class="NLM_article-title">Is a nitrogen atom an important pharmacophoric element in sigma ligand binding?</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">2105</span>– <span class="NLM_lpage">2111</span>, <span class="refDoi"> DOI: 10.1016/S0968-0896(00)00148-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1016%2FS0968-0896%2800%2900148-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=11003156" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BD3cXls1Cmsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2000&pages=2105-2111&author=S.+Y.+Ablordeppeyauthor=J.+B.+Fischerauthor=R.+A.+Glennon&title=Is+a+nitrogen+atom+an+important+pharmacophoric+element+in+sigma+ligand+binding%3F&doi=10.1016%2FS0968-0896%2800%2900148-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit102R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">Is a Nitrogen Atom an Important Pharmacophoric Element in Sigma Ligand Binding?</span></div><div class="casAuthors">Ablordeppey, S. Y.; Fischer, J. B.; Glennon, R. A.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2105-2111</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A lingering question in σ receptor ligand development is whether a nitrogen atom serves as an important pharmacophoric element in binding affinity.  To address this question, we have synthesized several phenylalkylpiperidines and phenylalkylpiperazines and demonstrated that removal of the N atom from a typical phenylalkylpiperidine led to little or no binding to σ receptors.  In addn., where two N atoms occur in a compd., such as with phenylalkylpiperazines, the N atom on the longer alkyl chain appears to be more important.  Thus, based on this study, the N atom is an important pharmacophoric element in the binding of phenylalkylpiperidines and phenylalkylpiperazines to σ receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqetIuRV7wqmrVg90H21EOLACvtfcHk0ljvJKHyK6JO3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXls1Cmsrs%253D&md5=b1d5bb18bb50fb4cacc63c1ad739a57b</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.1016%2FS0968-0896%2800%2900148-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0968-0896%252800%252900148-6%26sid%3Dliteratum%253Aachs%26aulast%3DAblordeppey%26aufirst%3DS.%2BY.%26aulast%3DFischer%26aufirst%3DJ.%2BB.%26aulast%3DGlennon%26aufirst%3DR.%2BA.%26atitle%3DIs%2520a%2520nitrogen%2520atom%2520an%2520important%2520pharmacophoric%2520element%2520in%2520sigma%2520ligand%2520binding%253F%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2000%26volume%3D8%26spage%3D2105%26epage%3D2111%26doi%3D10.1016%2FS0968-0896%2800%2900148-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref103"><div class="reference"><strong class="refLabel"><a href="#ref103" class="rightTabRefNumLink">103</a></strong><div class="NLM_citation" id="rightTab-cit103"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Piergentili, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amantini, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Del Bello, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giannella, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mattioli, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmery, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perfumi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pigini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santoni, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tucci, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zotti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quaglia, W.</span></span> <span> </span><span class="NLM_article-title">Novel highly potent and selective sigma 1 receptor antagonists related to spipethiane</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">1261</span>– <span class="NLM_lpage">1269</span>, <span class="refDoi"> DOI: 10.1021/jm901542q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901542q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BC3cXkt1Wktg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=1261-1269&author=A.+Piergentiliauthor=C.+Amantiniauthor=F.+Del+Belloauthor=M.+Giannellaauthor=L.+Mattioliauthor=M.+Palmeryauthor=M.+Perfumiauthor=M.+Piginiauthor=G.+Santoniauthor=P.+Tucciauthor=M.+Zottiauthor=W.+Quaglia&title=Novel+highly+potent+and+selective+sigma+1+receptor+antagonists+related+to+spipethiane&doi=10.1021%2Fjm901542q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Highly Potent and Selective σ1 Receptor Antagonists Related to Spipethiane</span></div><div class="casAuthors">Piergentili, Alessandro; Amantini, Consuelo; Del Bello, Fabio; Giannella, Mario; Mattioli, Laura; Palmery, Maura; Perfumi, Marina; Pigini, Maria; Santoni, Giorgio; Tucci, Paolo; Zotti, Margherita; Quaglia, Wilma</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1261-1269</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Conservative chem. modifications of the core structure of the lead spipethiane (1) afforded novel potent σ1 ligands. σ1 affinity and σ1/σ2 selectivity proved to be favored by the introduction of polar functions (oxygen atom or carbonyl group) in position 3 or 4 (4-6) or by the elongation of the distance between the two hydrophobic portions of the mol. with the simultaneous presence of a carbonyl group in position 4 (8 and 9).  The obsd. cytostatic effect against the human breast cancer cell line MCF-7/ADR, highly expressing σ1 receptors, and not against MCF-7, as well as the enhancement of morphine analgesia highlighted the σ1 antagonist profile of this series of compds.  In particular, due to its high σ1 affinity (pKi = 10.28) and σ1/σ2 selectivity ratio (29510), compd. 9 (I) might be a novel valuable tool for σ receptor characterization and a suitable template for the rational design of potential therapeutically useful σ1 antagonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7JWhD2T1LHrVg90H21EOLACvtfcHk0ljvJKHyK6JO3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXkt1Wktg%253D%253D&md5=ab40c7eaaf8f259f9796d38d48af96a8</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1021%2Fjm901542q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901542q%26sid%3Dliteratum%253Aachs%26aulast%3DPiergentili%26aufirst%3DA.%26aulast%3DAmantini%26aufirst%3DC.%26aulast%3DDel%2BBello%26aufirst%3DF.%26aulast%3DGiannella%26aufirst%3DM.%26aulast%3DMattioli%26aufirst%3DL.%26aulast%3DPalmery%26aufirst%3DM.%26aulast%3DPerfumi%26aufirst%3DM.%26aulast%3DPigini%26aufirst%3DM.%26aulast%3DSantoni%26aufirst%3DG.%26aulast%3DTucci%26aufirst%3DP.%26aulast%3DZotti%26aufirst%3DM.%26aulast%3DQuaglia%26aufirst%3DW.%26atitle%3DNovel%2520highly%2520potent%2520and%2520selective%2520sigma%25201%2520receptor%2520antagonists%2520related%2520to%2520spipethiane%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D1261%26epage%3D1269%26doi%3D10.1021%2Fjm901542q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref104"><div class="reference"><strong class="refLabel"><a href="#ref104" class="rightTabRefNumLink">104</a></strong><div class="NLM_citation" id="rightTab-cit104"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Azzariti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colabufo, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berardi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porcelli, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niso, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simone, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perrone, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paradiso, A.</span></span> <span> </span><span class="NLM_article-title">Cyclohexylpiperazine derivative PB28, a sigma2 agonist and sigma1 antagonist receptor, inhibits cell growth, modulates P-glycoprotein, and synergizes with anthracyclines in breast cancer</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">1807</span>– <span class="NLM_lpage">1816</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-05-0402</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1158%2F1535-7163.MCT-05-0402" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=16891467" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BD28XnslWksbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2006&pages=1807-1816&author=A.+Azzaritiauthor=N.+A.+Colabufoauthor=F.+Berardiauthor=L.+Porcelliauthor=M.+Nisoauthor=G.+M.+Simoneauthor=R.+Perroneauthor=A.+Paradiso&title=Cyclohexylpiperazine+derivative+PB28%2C+a+sigma2+agonist+and+sigma1+antagonist+receptor%2C+inhibits+cell+growth%2C+modulates+P-glycoprotein%2C+and+synergizes+with+anthracyclines+in+breast+cancer&doi=10.1158%2F1535-7163.MCT-05-0402"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit104R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclohexylpiperazine derivative PB28, a σ2 agonist and σ1 antagonist receptor, inhibits cell growth, modulates P-glycoprotein, and synergizes with anthracyclines in breast cancer</span></div><div class="casAuthors">Azzariti, Amalia; Colabufo, Nicola A.; Berardi, Francesco; Porcelli, Letizia; Niso, Mauro; Simone, Grazia M.; Perrone, Roberto; Paradiso, Angelo</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1807-1816</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">σ Ligands have recently been shown to have cytotoxic activity, to induce ceramide-dependent/caspase-independent apoptosis, and to down-regulate P-glycoprotein (P-gp) mRNA levels in some mouse and human models.  In this study, we verified whether a mixed σ2 agonist/σ1 antagonist, PB28, was able to have antitumor activity and to enhance anthracycline efficacy in two human breast cancer cell lines, MCF7 and MCF7 ADR, both characterized by significant σ2 receptor expression, by high and low σ1 receptor expression, and low and high P-gp expression, resp.  In both cell lines, PB28 showed high σ2 receptor affinity and low σ1 receptor affinity; furthermore, it inhibited cell growth with a clear effect at 48 h (IC50 in nanomolar range), a consistent time exposure-independent increase of G0-G1-phase fraction (of ∼20% of both cell lines) and caspase-independent apoptosis (15% increased after 1-day drug exposure).  PB28 also reduced P-gp expression in a concn.- and time-dependent manner (∼60% in MCF7 and 90% in MCF7 ADR).  We showed also a strong synergism between PB28 and doxorubicin by adopting either simultaneous or sequential schedules of the two drugs.  We suggest that this synergism could depend on PB28-induced increase of intracellular accumulation of doxorubicin (∼50% in MCF7 and 75% in MCF7 ADR by flow cytometry anal.).  In conclusion, we suggest that the σ2 agonist PB28 could be an interesting antitumor agent either in monotherapy or in combination with conventional drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPbEQT82-rDrVg90H21EOLACvtfcHk0lj2UQkX_b1WYQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XnslWksbo%253D&md5=a0581c8aec111a6474b1b041d916bcf5</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-05-0402&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-05-0402%26sid%3Dliteratum%253Aachs%26aulast%3DAzzariti%26aufirst%3DA.%26aulast%3DColabufo%26aufirst%3DN.%2BA.%26aulast%3DBerardi%26aufirst%3DF.%26aulast%3DPorcelli%26aufirst%3DL.%26aulast%3DNiso%26aufirst%3DM.%26aulast%3DSimone%26aufirst%3DG.%2BM.%26aulast%3DPerrone%26aufirst%3DR.%26aulast%3DParadiso%26aufirst%3DA.%26atitle%3DCyclohexylpiperazine%2520derivative%2520PB28%252C%2520a%2520sigma2%2520agonist%2520and%2520sigma1%2520antagonist%2520receptor%252C%2520inhibits%2520cell%2520growth%252C%2520modulates%2520P-glycoprotein%252C%2520and%2520synergizes%2520with%2520anthracyclines%2520in%2520breast%2520cancer%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2006%26volume%3D5%26spage%3D1807%26epage%3D1816%26doi%3D10.1158%2F1535-7163.MCT-05-0402" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref105"><div class="reference"><strong class="refLabel"><a href="#ref105" class="rightTabRefNumLink">105</a></strong><div class="NLM_citation" id="rightTab-cit105"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alonso, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phan, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guillemain, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saunier, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Legrand, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anoal, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maurice, T.</span></span> <span> </span><span class="NLM_article-title">Immunocytochemical localization of the sigma(1) receptor in the adult rat central nervous system</span>. <i>Neuroscience</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>97</i></span>,  <span class="NLM_fpage">155</span>– <span class="NLM_lpage">170</span>, <span class="refDoi"> DOI: 10.1016/S0306-4522(00)00014-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1016%2FS0306-4522%2800%2900014-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10771347" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BD3cXisFGhurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=97&publication_year=2000&pages=155-170&author=G.+Alonsoauthor=V.+Phanauthor=I.+Guillemainauthor=M.+Saunierauthor=A.+Legrandauthor=M.+Anoalauthor=T.+Maurice&title=Immunocytochemical+localization+of+the+sigma%281%29+receptor+in+the+adult+rat+central+nervous+system&doi=10.1016%2FS0306-4522%2800%2900014-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit105R"><div class="casContent"><span class="casTitleNuber">105</span><div class="casTitle"><span class="NLM_cas:atitle">Immunocytochemical localization of the sigma1 receptor in the adult rat central nervous system</span></div><div class="casAuthors">Alonso, G.; Phan, V.-L.; Guillemain, I.; Saunier, M.; Legrand, A.; Anoal, M.; Maurice, T.</div><div class="citationInfo"><span class="NLM_cas:title">Neuroscience (Oxford)</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">97</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">155-170</span>CODEN:
                <span class="NLM_cas:coden">NRSCDN</span>;
        ISSN:<span class="NLM_cas:issn">0306-4522</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">To characterize the localization of the sigma1 receptor in the adult rat central nervous system, a polyclonal antibody was raised against a 20 amino acid peptide, corresponding to the fragment 143-162 of the cloned sigma1 receptor protein.  Throughout the rostrocaudal regions of the central nervous system extending from the olfactory bulb to the spinal cord, intense to moderate immunostaining was found to be assocd. with: (i) ependymocytes bordering the entire ventricular system, and (ii) neuron-like structures located within the parenchyma.  Double fluorescence studies confirmed that, throughout the parenchyma, sigma1 receptor-immunostaining was essentially assocd. with neuronal structures immunostained for the neuronal marker βIII-tubulin.  In all rats examd., high levels of immunostaining were always assocd. with neurons located within specific regions including the granular layer of the olfactory bulb, various hypothalamic nuclei, the septum, the central gray, motor nuclei of the hindbrain and the dorsal horn of the spinal cord.  In contrast, only faint immunostaining was assocd. with neurons located in the caudate-putamen and the cerebellum.  Electron microscope studies indicated that sigma1 receptor immunostaining was mostly assocd. with neuronal perikarya and dendrites, where it was localized to the limiting plasma membrane, the membrane of mitochondria and of some cisternae of the endoplasmic reticulum.  At the level of synaptic contacts, intense immunostaining was assocd. with postsynaptic structures including the postsynaptic thickening and some polymorphous vesicles, whereas the presynaptic axons were devoid of immunostaining.  These data indicate that the sigma1 receptor antibody prepd. here, represents a promising tool for further investigating the role of σ1 receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqsAacDelSDfbVg90H21EOLACvtfcHk0lj2UQkX_b1WYQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXisFGhurg%253D&md5=2df1ba6a60488364ad458069e059354d</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.1016%2FS0306-4522%2800%2900014-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0306-4522%252800%252900014-2%26sid%3Dliteratum%253Aachs%26aulast%3DAlonso%26aufirst%3DG.%26aulast%3DPhan%26aufirst%3DV.%26aulast%3DGuillemain%26aufirst%3DI.%26aulast%3DSaunier%26aufirst%3DM.%26aulast%3DLegrand%26aufirst%3DA.%26aulast%3DAnoal%26aufirst%3DM.%26aulast%3DMaurice%26aufirst%3DT.%26atitle%3DImmunocytochemical%2520localization%2520of%2520the%2520sigma%25281%2529%2520receptor%2520in%2520the%2520adult%2520rat%2520central%2520nervous%2520system%26jtitle%3DNeuroscience%26date%3D2000%26volume%3D97%26spage%3D155%26epage%3D170%26doi%3D10.1016%2FS0306-4522%2800%2900014-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref106"><div class="reference"><strong class="refLabel"><a href="#ref106" class="rightTabRefNumLink">106</a></strong><div class="NLM_citation" id="rightTab-cit106"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tseng, L. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hogan, Q. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, H. E.</span></span> <span> </span><span class="NLM_article-title">(+)-Morphine attenuates the (−)-morphine-produced tail-flick inhibition via the sigma-1 receptor in the mouse spinal cord</span>. <i>Life Sci.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>89</i></span>,  <span class="NLM_fpage">875</span>– <span class="NLM_lpage">877</span>, <span class="refDoi"> DOI: 10.1016/j.lfs.2011.09.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1016%2Fj.lfs.2011.09.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=21989208" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsV2msr%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=89&publication_year=2011&pages=875-877&author=L.+F.+Tsengauthor=Q.+H.+Hoganauthor=H.+E.+Wu&title=%28%2B%29-Morphine+attenuates+the+%28%E2%88%92%29-morphine-produced+tail-flick+inhibition+via+the+sigma-1+receptor+in+the+mouse+spinal+cord&doi=10.1016%2Fj.lfs.2011.09.018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">(+)-Morphine attenuates the (-)-morphine-produced tail-flick inhibition via the sigma-1 receptor in the mouse spinal cord</span></div><div class="casAuthors">Tseng, Leon F.; Hogan, Quinn H.; Wu, Hsiang-En</div><div class="citationInfo"><span class="NLM_cas:title">Life Sciences</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">89</span>
        (<span class="NLM_cas:issue">23-24</span>),
    <span class="NLM_cas:pages">875-877</span>CODEN:
                <span class="NLM_cas:coden">LIFSAK</span>;
        ISSN:<span class="NLM_cas:issn">0024-3205</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Aims: We have previously demonstrated that pretreatment with (+)-morphine given intrathecally attenuates the intrathecal (-)-morphine-produced tail-flick inhibition.  The phenomenon has been defined as antianalgesia against (-)-morphine-produced analgesia.  Present expts. were then undertaken to det. if the antianalgesic effect induced by (+)-morphine given spinally is mediated by the stimulation of the sigma-1 receptor in the mouse spinal cord.  Main methods: Sigma-1 receptor ligands, N-[2-(3,4-Dichlorophenyl)ethyl]-N-methyl-2-(dimethylamino)ethylamine dihydrobromide (BD1047) and (+)-pentazocine were used to det. if (+)-morphine-induced antianalgesia is mediated by the stimulation of sigma-1 receptors in the mouse spinal cord.  Tail-flick test was employed to measure the nociceptive response.  All compds. were given intrathecally.  Key findings: Pretreatment with BD1047 (1-10 μg) or (+)-pentazocine (0.1-10 μg) dose-dependently reversed the attenuation of the (-)-morphine-produced tail-flick inhibition induced by (+)-morphine (10 pg).  BD1047 and (+)-pentazocine injected alone did not affect (-)-morphine-produced tail-flick inhibition.  Significance: The finding indicates that (+)-morphine attenuates the (-)-morphine-produced tail-flick inhibition via the activation of the sigma-1 receptors in the mouse spinal cord.  Sigma-1 receptors may play an important role in opioid analgesia in the mouse spinal cord.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYY2oyslQc3rVg90H21EOLACvtfcHk0ljrsMySjtnZKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsV2msr%252FO&md5=d86f7a9043beada5e17931f17e92a866</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1016%2Fj.lfs.2011.09.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.lfs.2011.09.018%26sid%3Dliteratum%253Aachs%26aulast%3DTseng%26aufirst%3DL.%2BF.%26aulast%3DHogan%26aufirst%3DQ.%2BH.%26aulast%3DWu%26aufirst%3DH.%2BE.%26atitle%3D%2528%252B%2529-Morphine%2520attenuates%2520the%2520%2528%25E2%2588%2592%2529-morphine-produced%2520tail-flick%2520inhibition%2520via%2520the%2520sigma-1%2520receptor%2520in%2520the%2520mouse%2520spinal%2520cord%26jtitle%3DLife%2520Sci.%26date%3D2011%26volume%3D89%26spage%3D875%26epage%3D877%26doi%3D10.1016%2Fj.lfs.2011.09.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref107"><div class="reference"><strong class="refLabel"><a href="#ref107" class="rightTabRefNumLink">107</a></strong><div class="NLM_citation" id="rightTab-cit107"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Merlos, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burgueño, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Portillo-Salido, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plata-Salamán, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vela, J. M.</span></span> <span> </span><span class="NLM_article-title">Pharmacological Modulation of the Sigma 1 Receptor and the Treatment of Pain</span>. <i>Adv. Exp. Med. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>964</i></span>,  <span class="NLM_fpage">85</span>– <span class="NLM_lpage">107</span>, <span class="refDoi"> DOI: 10.1007/978-3-319-50174-1_8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1007%2F978-3-319-50174-1_8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=28315267" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtFegtb7O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=964&publication_year=2017&pages=85-107&author=M.+Merlosauthor=J.+Burgue%C3%B1oauthor=E.+Portillo-Salidoauthor=C.+R.+Plata-Salam%C3%A1nauthor=J.+M.+Vela&title=Pharmacological+Modulation+of+the+Sigma+1+Receptor+and+the+Treatment+of+Pain&doi=10.1007%2F978-3-319-50174-1_8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit107R"><div class="casContent"><span class="casTitleNuber">107</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological modulation of the sigma 1 receptor and the treatment of pain</span></div><div class="casAuthors">Merlos, Manuel; Burgueno, Javier; Portillo-Salido, Enrique; Plata-Salaman, Carlos Ramon; Vela, Jose Miguel</div><div class="citationInfo"><span class="NLM_cas:title">Advances in Experimental Medicine and Biology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">964</span>
        (<span class="NLM_cas:issue">Sigma Receptors: Their Role in Disease and as Therapeutic Targets</span>),
    <span class="NLM_cas:pages">85-107</span>CODEN:
                <span class="NLM_cas:coden">AEMBAP</span>;
        ISSN:<span class="NLM_cas:issn">2214-8019</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">There is a crit. need for new analgesics acting through new mechanisms of action, which could increase the efficacy with respect to existing therapies and reduce their unwanted effects.  Current preclin. evidence supports the modulatory role of sigma-1 receptors (σ1R) in nociception, mainly based on the pain-attenuated phenotype of σ1R knockout mice and on the antinociceptive effect exerted by σ1R antagonists on pains of different etiologies. σ1R is highly expressed in different pain areas of the CNS and the periphery (particularly dorsal root ganglia), and interacts and modulates the functionality of different receptors and ion channels.  The antagonism of σ1R leads to decreased amplification of pain signaling within the spinal cord (central sensitization), but recent data also support a role at the periphery. σ1R antagonists have consistently demonstrated efficacy in neuropathic pain, but also in other types of pain including inflammatory, orofacial, visceral, and post-operative pain.  Apart from acting alone, when combined with opioids, σ1R antagonists enhance opioid analgesia but not opioid-induced unwanted effects.  Interestingly, unlike opioids, σ1R antagonists do not modify normal sensory mech. and thermal sensitivity thresholds but they exert antihypersensitive effects in sensitizing conditions, enabling the reversal of nociceptive thresholds back to normal values.  Accordingly, σ1R antagonists are not strictly analgesics; they are antiallodynic and antihyperalgesic drugs acting when the system is sensitized following prolonged noxious stimulation or persistent abnormal afferent input (e.g., secondary to nerve injury).  These are distinctive features allowing σ1R antagonists to exert a modulatory effect specifically in pathophysiol. conditions such as chronic pain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwcRJqz4BxF7Vg90H21EOLACvtfcHk0ljrsMySjtnZKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtFegtb7O&md5=212a8fac96a772a7888762da8e70fc0d</span></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1007%2F978-3-319-50174-1_8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-3-319-50174-1_8%26sid%3Dliteratum%253Aachs%26aulast%3DMerlos%26aufirst%3DM.%26aulast%3DBurgue%25C3%25B1o%26aufirst%3DJ.%26aulast%3DPortillo-Salido%26aufirst%3DE.%26aulast%3DPlata-Salam%25C3%25A1n%26aufirst%3DC.%2BR.%26aulast%3DVela%26aufirst%3DJ.%2BM.%26atitle%3DPharmacological%2520Modulation%2520of%2520the%2520Sigma%25201%2520Receptor%2520and%2520the%2520Treatment%2520of%2520Pain%26jtitle%3DAdv.%2520Exp.%2520Med.%2520Biol.%26date%3D2017%26volume%3D964%26spage%3D85%26epage%3D107%26doi%3D10.1007%2F978-3-319-50174-1_8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref108"><div class="reference"><strong class="refLabel"><a href="#ref108" class="rightTabRefNumLink">108</a></strong><div class="NLM_citation" id="rightTab-cit108"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chambers, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Billington, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knight, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Middlemiss, D. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, E. H.</span></span> <span> </span><span class="NLM_article-title">Spiropiperidines as high-affinity, selective sigma ligands</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1992</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">2033</span>– <span class="NLM_lpage">2039</span>, <span class="refDoi"> DOI: 10.1021/jm00089a013</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00089a013" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADyaK38XisFGntrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=1992&pages=2033-2039&author=M.+S.+Chambersauthor=R.+Bakerauthor=D.+C.+Billingtonauthor=A.+K.+Knightauthor=D.+N.+Middlemissauthor=E.+H.+Wong&title=Spiropiperidines+as+high-affinity%2C+selective+sigma+ligands&doi=10.1021%2Fjm00089a013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit108R"><div class="casContent"><span class="casTitleNuber">108</span><div class="casTitle"><span class="NLM_cas:atitle">Spiropiperidines as high-affinity, selective σ ligands.</span></div><div class="casAuthors">Chambers, Mark S.; Baker, Raymond; Billington, David C.; Knight, Anthony K.; Middlemiss, D. N.; Wong, Eric H. F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2033-9</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    </div><div class="casAbstract">A variety of achiral conformationally restricted spirocyclic piperidines were prepd. in an attempt to investigate the functional role of the central σ recognition site.  All compds. possessed a lipophilic N-substituent incorporating either a tetralin (I; n = 2, R = PhCH2, Bu, hexyl, 2-picolyl, cyclohexylmethyl, CH2CH:CH2, 2-furylmethyl, 2-thienylmethyl, CH2CH:CMe2, etc.), indan (I; n = 1, R = PhCH2, PhCH2CH2, CH2CH:CMe2, Bu, etc.), or benzocycloheptane skeleton (I; n = 3, R = PhCH2, Bu).  Their in vitro affinity at the σ site was assessed in radioligand displacement expts. with guinea pig cerebellum homogenates using the σ-specific radioligand N,N-di-o-[5-3H]-tolylguanidine (II).  A study of the structure-activity relationships identified the N-Bu and N-dimethylallyl substituents as the optimum groups for high affinity and selectivity at the σ site, e.g., I (n = 1, R = CH2CH:CMe2), pIC50 = 8.9 vs II and >10,000-fold selective over the dopamine D2 receptor.  Such compds. are amongst the highest affinity σ ligands reported to date, with excellent selectivity over the dopamine D2 receptor, and may serve as a useful tool for exploring the physiol. role of the σ site.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr90qP5qz7Mm7Vg90H21EOLACvtfcHk0ljrsMySjtnZKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK38XisFGntrg%253D&md5=1d61ff31c46c1c2febdfccd3673799da</span></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1021%2Fjm00089a013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00089a013%26sid%3Dliteratum%253Aachs%26aulast%3DChambers%26aufirst%3DM.%2BS.%26aulast%3DBaker%26aufirst%3DR.%26aulast%3DBillington%26aufirst%3DD.%2BC.%26aulast%3DKnight%26aufirst%3DA.%2BK.%26aulast%3DMiddlemiss%26aufirst%3DD.%2BN.%26aulast%3DWong%26aufirst%3DE.%2BH.%26atitle%3DSpiropiperidines%2520as%2520high-affinity%252C%2520selective%2520sigma%2520ligands%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1992%26volume%3D35%26spage%3D2033%26epage%3D2039%26doi%3D10.1021%2Fjm00089a013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref109"><div class="reference"><strong class="refLabel"><a href="#ref109" class="rightTabRefNumLink">109</a></strong><div class="NLM_citation" id="rightTab-cit109"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moltzen, E. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perregaard, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meier, E.</span></span> <span> </span><span class="NLM_article-title">Sigma ligands with subnanomolar affinity and preference for the sigma 2 binding site. 2. Spiro-joined benzofuran, isobenzofuran, and benzopyran piperidines</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">2009</span>– <span class="NLM_lpage">2017</span>, <span class="refDoi"> DOI: 10.1021/jm00011a020</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00011a020" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADyaK2MXls1yqt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=1995&pages=2009-2017&author=E.+K.+Moltzenauthor=J.+Perregaardauthor=E.+Meier&title=Sigma+ligands+with+subnanomolar+affinity+and+preference+for+the+sigma+2+binding+site.+2.+Spiro-joined+benzofuran%2C+isobenzofuran%2C+and+benzopyran+piperidines&doi=10.1021%2Fjm00011a020"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit109R"><div class="casContent"><span class="casTitleNuber">109</span><div class="casTitle"><span class="NLM_cas:atitle">σ Ligands with Subnanomolar Affinity and Preference for the σ2 Binding Site. 2. Spiro-Joined Benzofuran, Isobenzofuran, and Benzopyran Piperidines</span></div><div class="casAuthors">Moltzen, Ejner K.; Perregaard, Jens; Meier, Eddi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2009-17</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">MSpiro[isobenzofuran-1(3H),4'-piperidines] and the corresponding benzofuran and benzopyran derivs. were synthesized and evaluated as σ ligands.  The compds. are related to Lu 28-179 that has been demonstrated to be a selective σ2 ligand with affinity in the subnanomolar range.  The object of the study was to det. the structural factors governing σ1/σ2 affinity and selectivity within this class of compds.  The N-substituent in spiro[isobenzofuran-1(3H),4'-piperidines] is highly important, both for affinity and selectivity.  Spiropiperidines with no or small N-substituents (H, Me, Et) exert very low affinity for both σ1 and σ2 binding sites (IC50(σ1,σ2) > 100 nM), whereas medium-sized substituents (e.g., Pr, Bu, Ph(CH2)2) result in potent, but unselective compds. (IC50(σ1,σ2) = 2-5 nM).  Increasing the chain length and the lipophilicity of the N-substituent result in compds. in which high affinity for σ2 binding sites is retained and with selectivity for σ2 vs σ1 binding sites (e.g., 4-cyclohexyl-1-butyl: IC50(σ1) = 1.5 nM, IC50(σ2) = 0.07 nM).  Introduction of substituents in the benzene ring of the spiro[isobenzofuran-1(3H),4'-piperidine] ring system of Lu 28-179 mainly affects affinity for σ1 binding sites.  Compds. with substituents (F, CF3) in the 4- or 7-position of the isobenzofuran display high affinity for σ2 binding sites (IC50(σ2) = 0.5-2 nM) and very low affinity for σ1 binding sites (IC50(σ1) > 100 nM).  Compds. with substituents (F, CF3, Me) in the 5- or 6-position of the isobenzofuran exert increased affinity for σ1 binding sites (IC50(σ1) = 5-30 nM, IC50(σ2) = 0.3-7 nM), thus rendering unselective compds.  Exchanging the isobenzofuran moiety of Lu 28-179 with thioisobenzofuran, benzofuran, or benzopyran also has a pronounced effect on both affinity and selectivity for σ binding sites.  The position of the oxygen atom and the position of the spiroconnection with the 4-position of the piperidine ring were varied, and only compds. in which both the benzene ring and the heteroatom are attached directly to the piperidine ring retain high affinity and selectivity for σ2 binding sites (e.g., 3,4-dihydro-1'-[4-[1-(4-fluorophenyl)-1H-indol-3-yl]-1-butyl]spiro[1H-2-benzopyran-1,4'- piperidine]: IC50(σ1) = 53 nM, IC50(σ2) = 0.9 nM).  All other variations result either in unselective compds. or in compds. with low affinity for σ binding sites.  The data presented provide detailed information concerning structural requirements for binding to σ1 and σ2 binding sites, resp., and together with Lu 28-179, some of the compds. presented in this work belong to the most potent and selective σ2 ligands described so far.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovu0LdT7foS7Vg90H21EOLACvtfcHk0lgoTWuyU4rpug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXls1yqt70%253D&md5=4d3db3729dd2c7ab50529eac32ac7225</span></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1021%2Fjm00011a020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00011a020%26sid%3Dliteratum%253Aachs%26aulast%3DMoltzen%26aufirst%3DE.%2BK.%26aulast%3DPerregaard%26aufirst%3DJ.%26aulast%3DMeier%26aufirst%3DE.%26atitle%3DSigma%2520ligands%2520with%2520subnanomolar%2520affinity%2520and%2520preference%2520for%2520the%2520sigma%25202%2520binding%2520site.%25202.%2520Spiro-joined%2520benzofuran%252C%2520isobenzofuran%252C%2520and%2520benzopyran%2520piperidines%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1995%26volume%3D38%26spage%3D2009%26epage%3D2017%26doi%3D10.1021%2Fjm00011a020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref110"><div class="reference"><strong class="refLabel"><a href="#ref110" class="rightTabRefNumLink">110</a></strong><div class="NLM_citation" id="rightTab-cit110"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maier, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wünsch, B.</span></span> <span> </span><span class="NLM_article-title">Novel spiropiperidines as highly potent and subtype selective sigma-receptor ligands. Part 1</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">438</span>– <span class="NLM_lpage">448</span>, <span class="refDoi"> DOI: 10.1021/jm010992z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm010992z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BD3MXptFyjsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2002&pages=438-448&author=C.+A.+Maierauthor=B.+W%C3%BCnsch&title=Novel+spiropiperidines+as+highly+potent+and+subtype+selective+sigma-receptor+ligands.+Part+1&doi=10.1021%2Fjm010992z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit110R"><div class="casContent"><span class="casTitleNuber">110</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Spiropiperidines as Highly Potent and Subtype Selective σ-Receptor Ligands. Part 1</span></div><div class="casAuthors">Maier, Christoph A.; Wuensch, Bernhard</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">438-448</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of spiro[[2]benzopyran-1,4'-piperidines] and spiro[[2]benzofuran-1,4'-piperidines] of general structure I [X = (CH2)n] is prepd., and the affinity for σ1- and σ2-receptors is investigated by means of radioligand binding assays.  The synthesis of the spiropiperidines, 1'-benzyl-3-methoxy-3,4-dihydrospiro[[2]benzopyran-1,4'-piperidine] (II) and the 1'-benzyl-3-methoxy-3H-spiro[[2]benzofuran-1,4'-piperidine] (III), proceeds via bromine/lithium exchange of the bromoacetals, e.g., 2-(2-bromophenyl)acetaldehyde di-Me acetal in the case of II, addn. to N-benzylpiperidin-4-one, and subsequent cyclization.  Systematic variations of the substituent R at the nitrogen atom, the group Y in position 3, and the ring size of the oxygen heterocycle are performed.  The σ1- and σ2-receptor affinities are detd. with guinea pig brain and rat liver membrane prepns. using [3H]-labeled (+)-pentazocine and ditolylguanidine, resp.  Test results show that a benzyl residue at the piperidine nitrogen atom and a methoxy group in position 3 are advantageous for high σ1-receptor affinity.  In this series II and III are among the most potent σ1-ligands interacting in the low nanomolar range with σ1-receptors (14a, Ki = 1.29 nM; 23, Ki = 1.14 nM).  Variation of the nitrogen substituent R from benzyl to H, alkyl, Ph, or ω-phenylalkyl and the group Y from methoxy to hydroxy, carbonyl, or alkyloxy led to reduced σ1-receptor affinity.  In addn. to their high σ1-receptor affinity, the spiropiperidines II and III display excellent selectivity toward σ2-receptors (σ1/σ2 = 2708 and 1130) and several other receptor and reuptake systems.  Introduction of a polar hydroxy group in position 3 and elongation of the distance between the piperidine nitrogen atom and the Ph moiety result in ligands with considerable σ2-receptor affinity and therefore diminished σ1/σ2-receptor selectivity.  The hemiacetalic 1'-(3-phenylpropyl)-3,4-dihydrospiro[[2]benzopyran-1,4'-piperidin]-3-ol represents the most active σ2-receptor ligand in this series with a Ki value of 83.1 nM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfVYGDmsjdLLVg90H21EOLACvtfcHk0lgoTWuyU4rpug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXptFyjsLg%253D&md5=13fb1c59fd2f82c128a18d487a6ee8b8</span></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.1021%2Fjm010992z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm010992z%26sid%3Dliteratum%253Aachs%26aulast%3DMaier%26aufirst%3DC.%2BA.%26aulast%3DW%25C3%25BCnsch%26aufirst%3DB.%26atitle%3DNovel%2520spiropiperidines%2520as%2520highly%2520potent%2520and%2520subtype%2520selective%2520sigma-receptor%2520ligands.%2520Part%25201%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2002%26volume%3D45%26spage%3D438%26epage%3D448%26doi%3D10.1021%2Fjm010992z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref111"><div class="reference"><strong class="refLabel"><a href="#ref111" class="rightTabRefNumLink">111</a></strong><div class="NLM_citation" id="rightTab-cit111"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neue, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schepmann, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yanagisawa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamaguchi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Würthwein, E. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Itami, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wünsch, B.</span></span> <span> </span><span class="NLM_article-title">Exploitation of an additional hydrophobic pocket of σ1 receptors: late-stage diverse modifications of spirocyclic thiophenes by C-H bond functionalization</span>. <i>Org. Biomol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">8016</span>– <span class="NLM_lpage">8029</span>, <span class="refDoi"> DOI: 10.1039/c1ob06149f</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1039%2Fc1ob06149f" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=21986584" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVGmt7fP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2011&pages=8016-8029&author=C.+Meyerauthor=B.+Neueauthor=D.+Schepmannauthor=S.+Yanagisawaauthor=J.+Yamaguchiauthor=E.+U.+W%C3%BCrthweinauthor=K.+Itamiauthor=B.+W%C3%BCnsch&title=Exploitation+of+an+additional+hydrophobic+pocket+of+%CF%831+receptors%3A+late-stage+diverse+modifications+of+spirocyclic+thiophenes+by+C-H+bond+functionalization&doi=10.1039%2Fc1ob06149f"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit111R"><div class="casContent"><span class="casTitleNuber">111</span><div class="casTitle"><span class="NLM_cas:atitle">Exploitation of an additional hydrophobic pocket of σ1 receptors: Late-stage diverse modifications of spirocyclic thiophenes by C-H bond functionalization</span></div><div class="casAuthors">Meyer, Christina; Neue, Benedikt; Schepmann, Dirk; Yanagisawa, Shuichi; Yamaguchi, Junichiro; Wuerthwein, Ernst-Ulrich; Itami, Kenichiro; Wuensch, Bernhard</div><div class="citationInfo"><span class="NLM_cas:title">Organic & Biomolecular Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">8016-8029</span>CODEN:
                <span class="NLM_cas:coden">OBCRAK</span>;
        ISSN:<span class="NLM_cas:issn">1477-0520</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">The hypothesis that the σ1 receptor will tolerate an addnl. aryl moiety in position 1 of the spirocyclic system was based on spirocyclic pyrazole derivs., pharmacophore models of σ1 receptor ligands and DFT calcns.  The strategy of introducing the aryl residue at the final step of the synthesis allowed the prepn. of a large set of diverse ligands for the exploitation of the hydrophobic pocket of the σ1 receptor protein.  The catalyst system PdCl2/2,2'-bipyridyl/Ag2CO3 is able to introduce various aryl groups onto the α-positions of spirocyclic thiophene derivs. to afford the target aryl-appended spirocyclic thiophenes .  Although the σ1 affinity of the 1-Ph substituted spirocyclic thiophenes is slightly reduced compared with the σ1 affinity of the non-arylated compds. , both compds. represent very potent σ1 receptor ligands (3a: Ki = 4.5 nM; 4a: Ki = 1.0 nM).  This result indicates that an aryl moiety in position 1 is well tolerated by the σ1 receptor protein.  The substitution pattern of the addnl. Ph moiety has only weak effects on the σ1 affinity.  Decrease of σ1 affinity by extension of the π-system to a biphenylyl substituent (: Ki = 30 nM) indicates that the biphenylyl residue is too large for the primary hydrophobic binding pocket of the σ1 receptor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpaw7IyfcAY7Vg90H21EOLACvtfcHk0lgoTWuyU4rpug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVGmt7fP&md5=7390f878648e602f7339c987eb62fe8f</span></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1039%2Fc1ob06149f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc1ob06149f%26sid%3Dliteratum%253Aachs%26aulast%3DMeyer%26aufirst%3DC.%26aulast%3DNeue%26aufirst%3DB.%26aulast%3DSchepmann%26aufirst%3DD.%26aulast%3DYanagisawa%26aufirst%3DS.%26aulast%3DYamaguchi%26aufirst%3DJ.%26aulast%3DW%25C3%25BCrthwein%26aufirst%3DE.%2BU.%26aulast%3DItami%26aufirst%3DK.%26aulast%3DW%25C3%25BCnsch%26aufirst%3DB.%26atitle%3DExploitation%2520of%2520an%2520additional%2520hydrophobic%2520pocket%2520of%2520%25CF%25831%2520receptors%253A%2520late-stage%2520diverse%2520modifications%2520of%2520spirocyclic%2520thiophenes%2520by%2520C-H%2520bond%2520functionalization%26jtitle%3DOrg.%2520Biomol.%2520Chem.%26date%3D2011%26volume%3D9%26spage%3D8016%26epage%3D8029%26doi%3D10.1039%2Fc1ob06149f" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref112"><div class="reference"><strong class="refLabel"><a href="#ref112" class="rightTabRefNumLink">112</a></strong><div class="NLM_citation" id="rightTab-cit112"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nicholson, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mesangeau, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCurdy, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowen, W. D.</span></span> <span> </span><span class="NLM_article-title">Sigma-2 Receptors Play a Role in Cellular Metabolism: Stimulation of Glycolytic Hallmarks by CM764 in Human SK-N-SH Neuroblastoma</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>356</i></span>,  <span class="NLM_fpage">232</span>– <span class="NLM_lpage">243</span>, <span class="refDoi"> DOI: 10.1124/jpet.115.228387</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1124%2Fjpet.115.228387" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=26574517" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsFGjt7zF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=356&publication_year=2016&pages=232-243&author=H.+Nicholsonauthor=C.+Mesangeauauthor=C.+R.+McCurdyauthor=W.+D.+Bowen&title=Sigma-2+Receptors+Play+a+Role+in+Cellular+Metabolism%3A+Stimulation+of+Glycolytic+Hallmarks+by+CM764+in+Human+SK-N-SH+Neuroblastoma&doi=10.1124%2Fjpet.115.228387"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit112R"><div class="casContent"><span class="casTitleNuber">112</span><div class="casTitle"><span class="NLM_cas:atitle">Sigma-2 receptors play a role in cellular metabolism: stimulation of glycolytic hallmarks by CM764 in human SK-N-SH neuroblastoma</span></div><div class="casAuthors">Nicholson, Hilary; Mesangeau, Christophe; McCurdy, Christopher R.; Bowen, Wayne D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">356</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">232-243</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Sigma-2 receptors are attractive antineoplastic targets due to their ability to induce apoptosis and their upregulation in rapidly proliferating cancer cells compared with healthy tissue.  However, this role is inconsistent with overexpression in cancer, which is typically assocd. with upregulation of prosurvival factors.  Here, we report a novel metabolic regulatory function for sigma-2 receptors.  CM764 [6-acetyl-3-(4-(4-(2-amino-4-fluorophenyl)piperazin-1-yl)butyl)benzo[d]oxazol-2(3H)-one] binds with Ki values of 86.6 ± 2.8 and 3.5 ± 0.9 nM at the sigma-1 and sigma-2 receptors, resp.  CM764 increased redn. of MTT [3-[4,5 dimethylthiazol-2-yl]-2,5 diphenyltetrazolium bromide] in human SK-N-SH neuroblastoma compared with untreated cells, an effect not due to proliferation.  This effect was attenuated by five different sigma antagonists, including CM572 [3-(4-(4-(4-fluorophenyl)piperazin-1-yl)butyl)-6-isothiocyanatobenzo[d]oxazol-2(3H)-one], which has no significant affinity for sigma-1 receptors.  This effect was also obsd. in MG-63 osteosarcoma and HEK293T cells, indicating that this function is not exclusive to neuroblastoma or to cancer cells.  CM764 produced an immediate, robust, and transient increase in cytosolic calcium, consistent with sigma-2 receptor activation.  Addnl., we obsd. an increase in the total NAD+/NADH level and the ATP level in CM764-treated SK-N-SH cells compared with untreated cells.  After only 4 h of treatment, basal levels of reactive oxygen species were reduced by 90% in cells treated with CM764 over untreated cells, and HIF1α and VEGF levels were increased after 3-24 h of treatment.  These data indicate that sigma-2 receptors may play a role in induction of glycolysis, representing a possible prosurvival function for the sigma-2 receptor that is consistent with its upregulation in cancer cells compared with healthy tissue.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtpMnc20DMxbVg90H21EOLACvtfcHk0lgoTWuyU4rpug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsFGjt7zF&md5=91ec2b962d347ff47ebfa98342ca0dca</span></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.1124%2Fjpet.115.228387&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.115.228387%26sid%3Dliteratum%253Aachs%26aulast%3DNicholson%26aufirst%3DH.%26aulast%3DMesangeau%26aufirst%3DC.%26aulast%3DMcCurdy%26aufirst%3DC.%2BR.%26aulast%3DBowen%26aufirst%3DW.%2BD.%26atitle%3DSigma-2%2520Receptors%2520Play%2520a%2520Role%2520in%2520Cellular%2520Metabolism%253A%2520Stimulation%2520of%2520Glycolytic%2520Hallmarks%2520by%2520CM764%2520in%2520Human%2520SK-N-SH%2520Neuroblastoma%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2016%26volume%3D356%26spage%3D232%26epage%3D243%26doi%3D10.1124%2Fjpet.115.228387" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref113"><div class="reference"><strong class="refLabel"><a href="#ref113" class="rightTabRefNumLink">113</a></strong><div class="NLM_citation" id="rightTab-cit113"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schepmann, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neue, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westphälinger, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bracher, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lange, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bednarski, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Almansa, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedland, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Räbiger, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Düfer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wünsch, B.</span></span> <span> </span><span class="NLM_article-title">Pharmacological characterization of high-affinity σ(1) receptor ligands with spirocyclic thienopyran and thienofuran scaffold</span>. <i>J. Pharm. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>72</i></span>,  <span class="NLM_fpage">236</span>– <span class="NLM_lpage">248</span>, <span class="refDoi"> DOI: 10.1111/jphp.13196</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1111%2Fjphp.13196" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=31743446" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitFOru7vO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2020&pages=236-248&author=D.+Schepmannauthor=C.+Neueauthor=S.+Westph%C3%A4lingerauthor=C.+M%C3%BCllerauthor=F.+Bracherauthor=C.+Langeauthor=P.+Bednarskiauthor=C.+Almansaauthor=K.+Friedlandauthor=V.+R%C3%A4bigerauthor=M.+D%C3%BCferauthor=B.+W%C3%BCnsch&title=Pharmacological+characterization+of+high-affinity+%CF%83%281%29+receptor+ligands+with+spirocyclic+thienopyran+and+thienofuran+scaffold&doi=10.1111%2Fjphp.13196"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit113R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological characterization of high-affinity s1 receptor ligands with spirocyclic thienopyran and thienofuran scaffold</span></div><div class="casAuthors">Schepmann, Dirk; Neue, Christina; Westphaelinger, Stefanie; Mueller, Christoph; Bracher, Franz; Lange, Carsten; Bednarski, Patrick; Almansa, Carmen; Friedland, Kristina; Raebiger, Vivien; Duefer, Martina; Wuensch, Bernhard</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacy and Pharmacology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">236-248</span>CODEN:
                <span class="NLM_cas:coden">JPPMAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3573</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">In this study, the pharmacol. properties of six spirocyclic piperidines 1-6 showing very high s1 receptor affinity (Ki = 0.2-16 nM) were investigated.  In vitro receptor binding studies, retinal ganglion assay and in vivo capsaicin assay were used to det. the affinity, selectivity and activity.  Influence on human tumor cell growth (cell lines A427, LCLC-103H, 5637 and DAN-G) was detd. in different assays.  The effect on the ergosterol and cholesterol biosynthesis was detd. by GLC/MS anal.  Receptor binding studies demonstrated high selectivity for the s1 receptor.  The increased Ca2+ influx mediated by 2 and the analgesic activity of 1, 4, 5 and 6 confirm s1 receptor antagonistic activity.  Inhibition of human tumor cell growth further supports the s1 antagonistic effects.  Treatment of A427 tumor cells with 2 led to cell detachment and cell degrdn.  Whereas the ergosterol biosynthesis was not affected, the sterol C14-reductase, a key enzyme in the cholesterol biosynthesis, was weakly inhibited.  Due to the high selectivity, off-target effects are not expected.  The antiallodynic activity underlines the clin. potential of the spirocyclic piperidines for the treatment of neuropathic pain.  Due to the antiproliferative activity, the spirocyclic s1 antagonists represent promising antitumor agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxRwwNlSXePLVg90H21EOLACvtfcHk0lgvxWiavKQ2iw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitFOru7vO&md5=408d16fe23a338e8c25f374d918c6d60</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1111%2Fjphp.13196&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fjphp.13196%26sid%3Dliteratum%253Aachs%26aulast%3DSchepmann%26aufirst%3DD.%26aulast%3DNeue%26aufirst%3DC.%26aulast%3DWestph%25C3%25A4linger%26aufirst%3DS.%26aulast%3DM%25C3%25BCller%26aufirst%3DC.%26aulast%3DBracher%26aufirst%3DF.%26aulast%3DLange%26aufirst%3DC.%26aulast%3DBednarski%26aufirst%3DP.%26aulast%3DAlmansa%26aufirst%3DC.%26aulast%3DFriedland%26aufirst%3DK.%26aulast%3DR%25C3%25A4biger%26aufirst%3DV.%26aulast%3DD%25C3%25BCfer%26aufirst%3DM.%26aulast%3DW%25C3%25BCnsch%26aufirst%3DB.%26atitle%3DPharmacological%2520characterization%2520of%2520high-affinity%2520%25CF%2583%25281%2529%2520receptor%2520ligands%2520with%2520spirocyclic%2520thienopyran%2520and%2520thienofuran%2520scaffold%26jtitle%3DJ.%2520Pharm.%2520Pharmacol.%26date%3D2020%26volume%3D72%26spage%3D236%26epage%3D248%26doi%3D10.1111%2Fjphp.13196" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref114"><div class="reference"><strong class="refLabel"><a href="#ref114" class="rightTabRefNumLink">114</a></strong><div class="NLM_citation" id="rightTab-cit114"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kokornaczyk, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schepmann, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamaguchi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Itami, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laurini, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fermeglia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pricl, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wünsch, B.</span></span> <span> </span><span class="NLM_article-title">Thiazole-Based σ(1) Receptor Ligands: Diversity by Late-Stage C-H Arylation of Thiazoles, Structure-Affinity and Selectivity Relationships, and Molecular Interactions</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">1070</span>– <span class="NLM_lpage">1080</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201700166</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1002%2Fcmdc.201700166" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=28544475" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtVarsL3K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2017&pages=1070-1080&author=A.+K.+Kokornaczykauthor=D.+Schepmannauthor=J.+Yamaguchiauthor=K.+Itamiauthor=E.+Lauriniauthor=M.+Fermegliaauthor=S.+Priclauthor=B.+W%C3%BCnsch&title=Thiazole-Based+%CF%83%281%29+Receptor+Ligands%3A+Diversity+by+Late-Stage+C-H+Arylation+of+Thiazoles%2C+Structure-Affinity+and+Selectivity+Relationships%2C+and+Molecular+Interactions&doi=10.1002%2Fcmdc.201700166"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit114R"><div class="casContent"><span class="casTitleNuber">114</span><div class="casTitle"><span class="NLM_cas:atitle">Thiazole-Based σ1 Receptor Ligands: Diversity by Late-Stage C-H Arylation of Thiazoles, Structure-Affinity and Selectivity Relationships, and Mol. Interactions</span></div><div class="casAuthors">Kokornaczyk, Artur K.; Schepmann, Dirk; Yamaguchi, Junichiro; Itami, Kenichiro; Laurini, Erik; Fermeglia, Maurizio; Pricl, Sabrina; Wuensch, Bernhard</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1070-1080</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Spirocyclic thiophene derivs. represent promising σ1 ligands with high σ1 affinity and selectivity over the σ2 subtype.  To increase ligand efficiency, the thiophene ring was replaced bioisosterically by a thiazole ring, and the pyran ring was opened.  Late-stage diversification by regioselective C-H arylation of thiazoles 9 a-c resulted in a set of 53 compds. with high diversity.  This set of compds. was analyzed with respect to σ1 affinity, σ1/σ2 selectivity, lipophilicity (logD7.4), lipophilicity-cor. ligand efficiency (LELP), and mol. target interactions.  The most promising candidates were pyridyl-substituted thiazole derivs. 33 c (2-(1-benzyl-4-ethoxypiperidin-4-yl)-5-(pyridin-3-yl)thiazole) and 34 c (2-(1-benzyl-4-ethoxypiperidin-4-yl)-5-(pyridin-4-yl)thiazole), possessing low-nanomolar σ1 affinity (Ki=1.3 and 1.9 nM), high σ1/σ2 selectivity (>1500-fold), low lipophilicity (logD7.4=1.8) and very good ligand efficiency (LELP=5.5), indicating promising pharmacodynamics and pharmacokinetics.  Mol. simulation studies, including docking and deconvolution of the free binding energy into its major components, led to decreased hydrophobic stabilization of pyridyl derivs. 33 c and 34 c, which was compensated by lower desolvation energy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpH1KP3Hivs9rVg90H21EOLACvtfcHk0lgvxWiavKQ2iw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtVarsL3K&md5=5317bdafd4f74079cf90fc4d86d751fa</span></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201700166&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201700166%26sid%3Dliteratum%253Aachs%26aulast%3DKokornaczyk%26aufirst%3DA.%2BK.%26aulast%3DSchepmann%26aufirst%3DD.%26aulast%3DYamaguchi%26aufirst%3DJ.%26aulast%3DItami%26aufirst%3DK.%26aulast%3DLaurini%26aufirst%3DE.%26aulast%3DFermeglia%26aufirst%3DM.%26aulast%3DPricl%26aufirst%3DS.%26aulast%3DW%25C3%25BCnsch%26aufirst%3DB.%26atitle%3DThiazole-Based%2520%25CF%2583%25281%2529%2520Receptor%2520Ligands%253A%2520Diversity%2520by%2520Late-Stage%2520C-H%2520Arylation%2520of%2520Thiazoles%252C%2520Structure-Affinity%2520and%2520Selectivity%2520Relationships%252C%2520and%2520Molecular%2520Interactions%26jtitle%3DChemMedChem%26date%3D2017%26volume%3D12%26spage%3D1070%26epage%3D1080%26doi%3D10.1002%2Fcmdc.201700166" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref115"><div class="reference"><strong class="refLabel"><a href="#ref115" class="rightTabRefNumLink">115</a></strong><div class="NLM_citation" id="rightTab-cit115"><span><span class="NLM_contrib-group"><span class="NLM_string-name">de Costa, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowen, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hellewell, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">George, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rothman, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reid, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobson, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rice, K. C.</span></span> <span> </span><span class="NLM_article-title">Alterations in the stereochemistry of the kappa-selective opioid agonist U50,488 result in high-affinity sigma ligands</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1989</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">1996</span>– <span class="NLM_lpage">2002</span>, <span class="refDoi"> DOI: 10.1021/jm00128a050</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00128a050" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADyaL1MXkvFOjsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=1989&pages=1996-2002&author=B.+R.+de+Costaauthor=W.+D.+Bowenauthor=S.+B.+Hellewellauthor=C.+Georgeauthor=R.+B.+Rothmanauthor=A.+A.+Reidauthor=J.+M.+Walkerauthor=A.+E.+Jacobsonauthor=K.+C.+Rice&title=Alterations+in+the+stereochemistry+of+the+kappa-selective+opioid+agonist+U50%2C488+result+in+high-affinity+sigma+ligands&doi=10.1021%2Fjm00128a050"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit115R"><div class="casContent"><span class="casTitleNuber">115</span><div class="casTitle"><span class="NLM_cas:atitle">Alterations in the stereochemistry of the κ-selective opioid agonist U50,488 result in high-affinity σ ligands</span></div><div class="casAuthors">De Costa, Brian R.; Bowen, Wayne D.; Hellewell, Susan B.; George, Clifford; Rothman, Richard B.; Reid, Audrey A.; Walker, J. Michael; Jacobson, Arthur E.; Rice, Kenner C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1989</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1996-2002</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    </div><div class="casAbstract">The prepn. and in vitro σ receptor activity of (1R,2S)- (I) (R = 3,4-Cl2C6H3CH2CO throughout) and (1S,2R)-cis-3,4-dichloro-N-methyl-N-(2-pyrrolidinocyclohexyl)phenylacetamide (II) are described.  I and II are prepd. from (±)-trans-2-(methylamino)cyclohexanol (III).  III is converted to (±)-cis-2-pyrrolidino-N-methylcycohexylamine [(±)-IV] in 5 steps.  ±-IV is resolved with mandelic acid and the individual enantiomers coupled with ROH to give I and II.  I, II and their corresponding optically pure trans diastereomers V and VI were compared for their binding affinities at κ opioid, σ, D2-dopamine, and phencyclidine receptors in competitive binding assays.  V shows the highest affinity for κ receptors, and moderate affinity for σ receptors.  VI has low affinity for both receptors.  In contrast, I and II show high affinity for σ receptors and negligible affinity for κ opioid receptors.  V and VI lack affinity for D2-dopamine receptors.  I and II bind only weakly to these receptors.  All the compds. lack affinity for phencyclidine receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDId1AOnJ0Z7Vg90H21EOLACvtfcHk0lgvxWiavKQ2iw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL1MXkvFOjsLY%253D&md5=1cebf875652a80a4407737d52a9a43f9</span></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.1021%2Fjm00128a050&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00128a050%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BCosta%26aufirst%3DB.%2BR.%26aulast%3DBowen%26aufirst%3DW.%2BD.%26aulast%3DHellewell%26aufirst%3DS.%2BB.%26aulast%3DGeorge%26aufirst%3DC.%26aulast%3DRothman%26aufirst%3DR.%2BB.%26aulast%3DReid%26aufirst%3DA.%2BA.%26aulast%3DWalker%26aufirst%3DJ.%2BM.%26aulast%3DJacobson%26aufirst%3DA.%2BE.%26aulast%3DRice%26aufirst%3DK.%2BC.%26atitle%3DAlterations%2520in%2520the%2520stereochemistry%2520of%2520the%2520kappa-selective%2520opioid%2520agonist%2520U50%252C488%2520result%2520in%2520high-affinity%2520sigma%2520ligands%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1989%26volume%3D32%26spage%3D1996%26epage%3D2002%26doi%3D10.1021%2Fjm00128a050" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref116"><div class="reference"><strong class="refLabel"><a href="#ref116" class="rightTabRefNumLink">116</a></strong><div class="NLM_citation" id="rightTab-cit116"><span><span class="NLM_contrib-group"><span class="NLM_string-name">de Costa, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rice, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowen, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thurkauf, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rothman, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Band, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobson, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Radesca, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Contreras, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daly, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iyengar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finn, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vazirani, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, J. M.</span></span> <span> </span><span class="NLM_article-title">Synthesis and evaluation of N-substituted cis-N-methyl-2-(1-pyrrolidinyl)cyclohexylamines as high affinity sigma receptor ligands. Identification of a new class of highly potent and selective sigma receptor probes</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1990</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">3100</span>– <span class="NLM_lpage">3110</span>, <span class="refDoi"> DOI: 10.1021/jm00173a030</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00173a030" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref116/cit116&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADyaK3MXitlOgtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=1990&pages=3100-3110&author=B.+R.+de+Costaauthor=K.+C.+Riceauthor=W.+D.+Bowenauthor=A.+Thurkaufauthor=R.+B.+Rothmanauthor=L.+Bandauthor=A.+E.+Jacobsonauthor=L.+Radescaauthor=P.+C.+Contrerasauthor=N.+M.+Grayauthor=I.+Dalyauthor=S.+Iyengarauthor=D.+T.+Finnauthor=S.+Vaziraniauthor=J.+M.+Walker&title=Synthesis+and+evaluation+of+N-substituted+cis-N-methyl-2-%281-pyrrolidinyl%29cyclohexylamines+as+high+affinity+sigma+receptor+ligands.+Identification+of+a+new+class+of+highly+potent+and+selective+sigma+receptor+probes&doi=10.1021%2Fjm00173a030"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit116R"><div class="casContent"><span class="casTitleNuber">116</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and evaluation of N-substituted cis-N-methyl-2-(1-pyrrolidinyl)cyclohexylamines as high affinity σ receptor ligands.  Identification of a new class of highly potent and selective σ receptor probes</span></div><div class="casAuthors">De Costa, Brian R.; Bowen, Wayne D.; Thurkauf, Andrew; Finn, Daniel T.; Vazirani, Sondra; Rothman, Richard B.; Band, Linda; Contreras, Patricia C.; Gray, Nancy M.; et al.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3100-10</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    </div><div class="casAbstract">N-Substituted cis-2-(1-pyrrolidinyl)-N-methylcyclohexylamines, were synthesized and their structure-activity requirements detd.  The compds. were synthesized by starting with the previously reported (±)-, 1S,2R-(+), and 1R,2S-(-)-cis-2-(1-pyrrolidinyl)-N-methylcyclohexylamines.  Anal. of σ ([3H](+)-PPP), κ ([3H]bremazocine and [3H]U69,593), dopamine-d2 ([3H]sulpiride), and phencyclidine (PCP) ([3H]TCP) receptor binding in guinea pig brain revealed a no. of highly potent and selective σ receptor ligands.  Notably, 1S,2R-cis-(-)-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]-2-naphthaleneacetamide (I), (±)-cis-2-amino-4,5-dichloro-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]benzeneacetamide, 1S,2R-(-)-cis-N-methyl-N-[2-(3,4-dichlorophenyl)ethyl]-N-[2-(1-pyrrolidinyl)cyclohexyl]amine, and 1R,2S-(+)-cis-N-methyl-N-[2-(3,4-dichlorophenyl)ethyl]-N-[2-(1-pyrrolidinyl)cyclohexyl]amine exhibited very high affinity at σ receptors, by displacement of [3H]-(+)-3-(3-hydroxyphenyl)-N-(1-propyl)piperidine ([3H](+)-3-PPP).  These compds. showed insignificant affinity for κ, dopamine, or PCP receptors, making them valuable tools for the study of σ receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo38ckLuefHc7Vg90H21EOLACvtfcHk0lg3ylV-eZzldA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXitlOgtg%253D%253D&md5=3b87eb15b278f3eaaf769d0620b58b6d</span></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=10.1021%2Fjm00173a030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00173a030%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BCosta%26aufirst%3DB.%2BR.%26aulast%3DRice%26aufirst%3DK.%2BC.%26aulast%3DBowen%26aufirst%3DW.%2BD.%26aulast%3DThurkauf%26aufirst%3DA.%26aulast%3DRothman%26aufirst%3DR.%2BB.%26aulast%3DBand%26aufirst%3DL.%26aulast%3DJacobson%26aufirst%3DA.%2BE.%26aulast%3DRadesca%26aufirst%3DL.%26aulast%3DContreras%26aufirst%3DP.%2BC.%26aulast%3DGray%26aufirst%3DN.%2BM.%26aulast%3DDaly%26aufirst%3DI.%26aulast%3DIyengar%26aufirst%3DS.%26aulast%3DFinn%26aufirst%3DD.%2BT.%26aulast%3DVazirani%26aufirst%3DS.%26aulast%3DWalker%26aufirst%3DJ.%2BM.%26atitle%3DSynthesis%2520and%2520evaluation%2520of%2520N-substituted%2520cis-N-methyl-2-%25281-pyrrolidinyl%2529cyclohexylamines%2520as%2520high%2520affinity%2520sigma%2520receptor%2520ligands.%2520Identification%2520of%2520a%2520new%2520class%2520of%2520highly%2520potent%2520and%2520selective%2520sigma%2520receptor%2520probes%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1990%26volume%3D33%26spage%3D3100%26epage%3D3110%26doi%3D10.1021%2Fjm00173a030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref117"><div class="reference"><strong class="refLabel"><a href="#ref117" class="rightTabRefNumLink">117</a></strong><div class="NLM_citation" id="rightTab-cit117"><span><span class="NLM_contrib-group"><span class="NLM_string-name">de Costa, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Radesca, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Paolo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowen, W. D.</span></span> <span> </span><span class="NLM_article-title">Synthesis, characterization, and biological evaluation of a novel class of N-(arylethyl)-N-alkyl-2-(1-pyrrolidinyl)ethylamines: structural requirements and binding affinity at the sigma receptor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1992</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">38</span>– <span class="NLM_lpage">47</span>, <span class="refDoi"> DOI: 10.1021/jm00079a004</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00079a004" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADyaK38Xkt1KhsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=1992&pages=38-47&author=B.+R.+de+Costaauthor=L.+Radescaauthor=L.+Di+Paoloauthor=W.+D.+Bowen&title=Synthesis%2C+characterization%2C+and+biological+evaluation+of+a+novel+class+of+N-%28arylethyl%29-N-alkyl-2-%281-pyrrolidinyl%29ethylamines%3A+structural+requirements+and+binding+affinity+at+the+sigma+receptor&doi=10.1021%2Fjm00079a004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit117R"><div class="casContent"><span class="casTitleNuber">117</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis, characterization, and biological evaluation of a novel class of N-(arylethyl)-N-alkyl-2-(1-pyrrolidinyl)ethylamines:  structural requirements and binding affinity at the σ receptor</span></div><div class="casAuthors">De Costa, Brian R.; Radesca, Lilian; Di Paolo, Lisa; Bowen, Wayne D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">38-47</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    </div><div class="casAbstract">Title compds., e.g. I (R = H, Me, Et, Pr, allyl, Bu, R1 = R2 = Cl; R = Me, R1, R2 = H, Cl; R1R2 = benzo), were prepd. and their binding affinity for σ-, phencyclidine, kappa opiate, and dopamine D2 receptors was measured.  Thus, pyrrolidine II (R3 = Cl) was aminated with H2NR to give II (R3 = NHR) which reacted with 3,4-dichlorophenylacetic acid and was reduced with AlH3/THF to give I (R = H, Me, Et, Pr, allyl, Bu, R1 = R2 = Cl).  When I (R = Me, R1 = R2 = Cl) was tested for its capacity to displace [3H]-(+)-3-PPP (PPP = 1-n-propyl-3-(3-hydroxyphenyl)piperidine) from guinea pig brain membranes, it exhibited a Ki of 0.34 nM.  Structure activity relationships were also examd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMksg4R4UY9LVg90H21EOLACvtfcHk0lg3ylV-eZzldA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK38Xkt1KhsLo%253D&md5=47f25860bff66bed7175f73cc44012a9</span></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.1021%2Fjm00079a004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00079a004%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BCosta%26aufirst%3DB.%2BR.%26aulast%3DRadesca%26aufirst%3DL.%26aulast%3DDi%2BPaolo%26aufirst%3DL.%26aulast%3DBowen%26aufirst%3DW.%2BD.%26atitle%3DSynthesis%252C%2520characterization%252C%2520and%2520biological%2520evaluation%2520of%2520a%2520novel%2520class%2520of%2520N-%2528arylethyl%2529-N-alkyl-2-%25281-pyrrolidinyl%2529ethylamines%253A%2520structural%2520requirements%2520and%2520binding%2520affinity%2520at%2520the%2520sigma%2520receptor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1992%26volume%3D35%26spage%3D38%26epage%3D47%26doi%3D10.1021%2Fjm00079a004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref118"><div class="reference"><strong class="refLabel"><a href="#ref118" class="rightTabRefNumLink">118</a></strong><div class="NLM_citation" id="rightTab-cit118"><span><span class="NLM_contrib-group"><span class="NLM_string-name">de Costa, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dominguez, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, X. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Radesca, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowen, W.</span></span> <span> </span><span class="NLM_article-title">Synthesis and biological evaluation of conformationally restricted 2-(1-pyrrolidinyl)-N-[2-(3,4-dichlorophenyl)ethyl]-N-methylethylenediam ines as sigma receptor ligands. 1. Pyrrolidine, piperidine, homopiperidine, and tetrahydroisoquinoline classes</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1992</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">4334</span>– <span class="NLM_lpage">4343</span>, <span class="refDoi"> DOI: 10.1021/jm00101a011</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00101a011" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref118/cit118&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADyaK38Xmtlekt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=1992&pages=4334-4343&author=B.+R.+de+Costaauthor=C.+Dominguezauthor=X.+S.+Heauthor=W.+Williamsauthor=L.+Radescaauthor=W.+Bowen&title=Synthesis+and+biological+evaluation+of+conformationally+restricted+2-%281-pyrrolidinyl%29-N-%5B2-%283%2C4-dichlorophenyl%29ethyl%5D-N-methylethylenediam+ines+as+sigma+receptor+ligands.+1.+Pyrrolidine%2C+piperidine%2C+homopiperidine%2C+and+tetrahydroisoquinoline+classes&doi=10.1021%2Fjm00101a011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit118R"><div class="casContent"><span class="casTitleNuber">118</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and biological evaluation of conformationally restricted 2-(1-pyrrolidinyl)-N-[2-(3,4-dichlorophenyl)ethyl]-N-methylethylenediamines as σ receptor ligands.  1.  Pyrrolidine, piperidine, homopiperidine, and tetrahydroisoquinoline classes</span></div><div class="casAuthors">De Costa, Brian R.; Dominguez, Celia; He, Xiao Shu; Williams, Wanda; Radesca, Lilian; Bowen, Wayne</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">4334-43</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    </div><div class="casAbstract">The synthesis and σ receptor affinity of a series of conformationally restricted derivs. of 2-(1-pyrrolidinyl)-N-[2-(3,4-dichlorophenyl)ethyl]-N-methylethylenediamine (1) are described.  The pyrrolidinyl (or N,N-dialkyl), ethylenediamine, N-alkyl, and phenylethyl portions of this σ receptor pharmacophore were restricted by its incorporation into 1,2-cyclohexanediamine-, pyrrolidine-, piperidine-, homopiperidine-, and tetrahydroisoquinoline-contg. ligands.  The σ receptor binding affinities of these compds. were detd. using [3H](+)-pentazocine in guinea pig brain homogenates.  The synthesis of all but one class was achieved by acylation and alane redn. of the appropriate diamine precursors whose synthesis is also reported.  The σ receptor affinities ranged from 1.34 nM for 6,7-dichloro-2-[2-(1-pyrrolidinyl)ethyl]tetrahydroisoquinoline to 455 nM for (1R,2R)-trans-N-[2-(3,4-dichlorophenyl)ethyl]-N-methyl-2-(1-pyrrolidinyl) cyclohexylamine.  In this displacement assay, (+)-pentazocine exhibited a Ki of 3.1 nM while DTG and haloperidol showed Ki values of 27.7 and 3.7 nM, resp.  The conformationally free parent compd. 1 exhibited a Ki value of 2.1 nM.  Comparison of both the σ receptor affinities and nitrogen atom geometry of the compds. revealed that a gauche relation of the N atoms of cis-1,2-cyclohexanediamines is not imperative for high affinity as previously thought.  It is highly likely that nitrogen lone pair orientations and steric factors on the aliph. portions of these ligands play a major role in the σ receptor binding of this pharmacophore.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHFiRFsAl737Vg90H21EOLACvtfcHk0liCxOASeQM3qg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK38Xmtlekt7c%253D&md5=3a971359707bd29bdecd4ea1e8de23b7</span></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=10.1021%2Fjm00101a011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00101a011%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BCosta%26aufirst%3DB.%2BR.%26aulast%3DDominguez%26aufirst%3DC.%26aulast%3DHe%26aufirst%3DX.%2BS.%26aulast%3DWilliams%26aufirst%3DW.%26aulast%3DRadesca%26aufirst%3DL.%26aulast%3DBowen%26aufirst%3DW.%26atitle%3DSynthesis%2520and%2520biological%2520evaluation%2520of%2520conformationally%2520restricted%25202-%25281-pyrrolidinyl%2529-N-%255B2-%25283%252C4-dichlorophenyl%2529ethyl%255D-N-methylethylenediam%2520ines%2520as%2520sigma%2520receptor%2520ligands.%25201.%2520Pyrrolidine%252C%2520piperidine%252C%2520homopiperidine%252C%2520and%2520tetrahydroisoquinoline%2520classes%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1992%26volume%3D35%26spage%3D4334%26epage%3D4343%26doi%3D10.1021%2Fjm00101a011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref119"><div class="reference"><strong class="refLabel"><a href="#ref119" class="rightTabRefNumLink">119</a></strong><div class="NLM_citation" id="rightTab-cit119"><span><span class="NLM_contrib-group"><span class="NLM_string-name">de Costa, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, X. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Linders, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dominguez, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, Z. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowen, W. D.</span></span> <span> </span><span class="NLM_article-title">Synthesis and evaluation of conformationally restricted N-[2-(3,4-dichlorophenyl)ethyl]-N-methyl-2-(1-pyrrolidinyl)ethylamines at sigma receptors. 2. Piperazines, bicyclic amines, bridged bicyclic amines, and miscellaneous compounds</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">2311</span>– <span class="NLM_lpage">2320</span>, <span class="refDoi"> DOI: 10.1021/jm00068a007</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00068a007" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref119/cit119&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADyaK2cXhtVKqsro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=1993&pages=2311-2320&author=B.+R.+de+Costaauthor=X.+S.+Heauthor=J.+T.+Lindersauthor=C.+Dominguezauthor=Z.+Q.+Guauthor=W.+Williamsauthor=W.+D.+Bowen&title=Synthesis+and+evaluation+of+conformationally+restricted+N-%5B2-%283%2C4-dichlorophenyl%29ethyl%5D-N-methyl-2-%281-pyrrolidinyl%29ethylamines+at+sigma+receptors.+2.+Piperazines%2C+bicyclic+amines%2C+bridged+bicyclic+amines%2C+and+miscellaneous+compounds&doi=10.1021%2Fjm00068a007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit119R"><div class="casContent"><span class="casTitleNuber">119</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and evaluation of conformationally restricted N-[2-(3,4-dichlorophenyl)ethyl]-N-methyl-2-(1-pyrrolidinyl)ethylamines at σ receptors. 2. Piperazines, bicyclic amines, bridged bicyclic amines, and miscellaneous compounds</span></div><div class="casAuthors">de Costa, Brian R.; He, Xiaoshu; Linders, Joannes T. M.; Dominguez, Celia; Gu, Zi Qiang; Williams, Wanda; Bowen, Wayne</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">2311-20</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    </div><div class="casAbstract">As a continuation of an earlier study (J. Med. Chem. 1992, 35, 4334-4343) the σ-receptor ligand was conformationally restricted in 2-(1-pyrrolidinyl)-N-[2-(3,4-dichlorophenyl)ethyl]-N-methylethylamine (I) by incorporating it into homologous piperazines and homopiperazines, diazabicyclononanes and decanes, bridgehead bicyclooctanes and nonanes as well as other misc. compds.  σ-Receptor binding affinities were obtained using [3H](+)-pentazocine in guinea pig brain membranes.  Probably the N lone pair orientation found in the piperazines affords the strongest binding interaction.  Other N lone pair orientations or compds. representing unlikely staggered conformations of I [as in 4-[2-(3,4-dichlorophenyl)ethyl]-1,4-diazabicyclo[3.2.2]nonane] show very weak σ interaction.  Comparison of the binding data of different N-substituted homologs of I with those of the 1-[2-(3,4-dichlorophenyl)ethyl]-4-alkylpiperazines suggests that the 2 N atoms of I are working in opposition to one another in terms of their sensitivity to steric bulk.  The high binding affinity of 1,4-diazabicyclo[4.3.0]nonanes suggests that these may approx. the Me and pyrrolidine ring conformations found in I when it is bound to the σ receptor.  Binding data suggest that the conformation of I favors strong binding interaction at σ-receptors.  σ-Receptor Ki's was 0.55 nM for 1-[2-(3,4-dichlorophenyl)ethyl]-4-n-butylpiperazine.  Overall comparison of the results indicate that I is subject to considerable conformational freedom and suggests that the σ receptor is not subject to rigid stereochem. restraints with I.  These results corroborate an earlier study where I was restrained using simple monocyclic heterocycles.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqyOzXD549F2bVg90H21EOLACvtfcHk0liCxOASeQM3qg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXhtVKqsro%253D&md5=f09774edf56b0d4fe631332167d67480</span></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=10.1021%2Fjm00068a007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00068a007%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BCosta%26aufirst%3DB.%2BR.%26aulast%3DHe%26aufirst%3DX.%2BS.%26aulast%3DLinders%26aufirst%3DJ.%2BT.%26aulast%3DDominguez%26aufirst%3DC.%26aulast%3DGu%26aufirst%3DZ.%2BQ.%26aulast%3DWilliams%26aufirst%3DW.%26aulast%3DBowen%26aufirst%3DW.%2BD.%26atitle%3DSynthesis%2520and%2520evaluation%2520of%2520conformationally%2520restricted%2520N-%255B2-%25283%252C4-dichlorophenyl%2529ethyl%255D-N-methyl-2-%25281-pyrrolidinyl%2529ethylamines%2520at%2520sigma%2520receptors.%25202.%2520Piperazines%252C%2520bicyclic%2520amines%252C%2520bridged%2520bicyclic%2520amines%252C%2520and%2520miscellaneous%2520compounds%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1993%26volume%3D36%26spage%3D2311%26epage%3D2320%26doi%3D10.1021%2Fjm00068a007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref120"><div class="reference"><strong class="refLabel"><a href="#ref120" class="rightTabRefNumLink">120</a></strong><div class="NLM_citation" id="rightTab-cit120"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torrence-Campbell, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowen, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rice, K. C.</span></span> <span> </span><span class="NLM_article-title">Characterization of novel N,N’-disubstituted piperazines as sigma receptor ligands</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">4950</span>– <span class="NLM_lpage">4957</span>, <span class="refDoi"> DOI: 10.1021/jm980143k</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm980143k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref120/cit120&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADyaK1cXnt1Cltb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=1998&pages=4950-4957&author=Y.+Zhangauthor=W.+Williamsauthor=C.+Torrence-Campbellauthor=W.+D.+Bowenauthor=K.+C.+Rice&title=Characterization+of+novel+N%2CN%E2%80%99-disubstituted+piperazines+as+sigma+receptor+ligands&doi=10.1021%2Fjm980143k"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit120R"><div class="casContent"><span class="casTitleNuber">120</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of Novel N,N'-Disubstituted Piperazines as σ Receptor Ligands</span></div><div class="casAuthors">Zhang, Ying; Williams, Wanda; Torrence-Campbell, Cheryl; Bowen, Wayne D.; Rice, Kenner C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">4950-4957</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">σ Receptors have been the focus of extensive studies because of their potential functional role in several important physiol. and biochem. processes.  To further evaluate the properties of σ receptors, esp. σ-1 and σ-2 subtypes, we have synthesized a series of 32 N,N'-disubstituted piperazine compds.  The design of these compds. was based upon the early structure-activity relationship (SAR) studies of the min. structural requirements of a mol. necessary to elicit σ receptor binding activity.  In the N-(3-phenylpropyl)piperazine series, compds. with the ethylenediamine moiety showed 6-20-fold higher affinity for σ-1 and 2-40-fold higher affinity for σ-2 relative to their corresponding amides.  The (m-nitrophenethyl)piperazine exhibits a subnanomolar affinity for the σ-1 site, whereas the corresponding o-nitro compd. shows the highest affinity for the σ-2 site (Ki = 4.9 nM).  Compds. with a free amino terminus were designed as precursors for use as bioconjugated affinity compds.  Some of these compds. displayed high affinity for σ-1 and moderate affinity for σ-2 sites and are currently used for the purifn. and characterization of the receptor subtypes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGra76qaE-298bVg90H21EOLACvtfcHk0liCxOASeQM3qg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXnt1Cltb4%253D&md5=ef77cf7c7f695dbfe771f3acb90d62e1</span></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=10.1021%2Fjm980143k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm980143k%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DWilliams%26aufirst%3DW.%26aulast%3DTorrence-Campbell%26aufirst%3DC.%26aulast%3DBowen%26aufirst%3DW.%2BD.%26aulast%3DRice%26aufirst%3DK.%2BC.%26atitle%3DCharacterization%2520of%2520novel%2520N%252CN%25E2%2580%2599-disubstituted%2520piperazines%2520as%2520sigma%2520receptor%2520ligands%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1998%26volume%3D41%26spage%3D4950%26epage%3D4957%26doi%3D10.1021%2Fjm980143k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref121"><div class="reference"><strong class="refLabel"><a href="#ref121" class="rightTabRefNumLink">121</a></strong><div class="NLM_citation" id="rightTab-cit121"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Foster, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowen, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsumoto, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coop, A.</span></span> <span> </span><span class="NLM_article-title">1,4-dibenzylpiperazines possess anticocaine activity</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">749</span>– <span class="NLM_lpage">751</span>, <span class="refDoi"> DOI: 10.1016/S0960-894X(02)01034-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1016%2FS0960-894X%2802%2901034-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=12639573" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref121/cit121&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BD3sXhvV2gt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2003&pages=749-751&author=A.+Fosterauthor=H.+Wuauthor=W.+Chenauthor=W.+Williamsauthor=W.+D.+Bowenauthor=R.+R.+Matsumotoauthor=A.+Coop&title=1%2C4-dibenzylpiperazines+possess+anticocaine+activity&doi=10.1016%2FS0960-894X%2802%2901034-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit121R"><div class="casContent"><span class="casTitleNuber">121</span><div class="casTitle"><span class="NLM_cas:atitle">1,4-Dibenzylpiperazines possess anticocaine activity</span></div><div class="casAuthors">Foster, Abby; Wu, Huifang; Chen, Weibin; Williams, Wanda; Bowen, Wayne D.; Matsumoto, Rae R.; Coop, Andrew</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">749-751</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">N,N-Dibenzylpiperazines have high affinity for sigma receptors, and we aimed to increase their anticocaine activity by introducing substituents known to enhance such activity in other sigma ligands.  Ligands with high affinity for sigma-1 receptors resulted, but their activity in attenuating cocaine-induced convulsions did not correlate with sigma-1 binding affinity, and may be more closely related to their sigma-2 binding affinities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrsKsFVsWiEebVg90H21EOLACvtfcHk0ljIW9MionPT8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXhvV2gt7o%253D&md5=3ed59384169b385501f8c6761e8bb476</span></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2802%2901034-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252802%252901034-X%26sid%3Dliteratum%253Aachs%26aulast%3DFoster%26aufirst%3DA.%26aulast%3DWu%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DW.%26aulast%3DWilliams%26aufirst%3DW.%26aulast%3DBowen%26aufirst%3DW.%2BD.%26aulast%3DMatsumoto%26aufirst%3DR.%2BR.%26aulast%3DCoop%26aufirst%3DA.%26atitle%3D1%252C4-dibenzylpiperazines%2520possess%2520anticocaine%2520activity%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2003%26volume%3D13%26spage%3D749%26epage%3D751%26doi%3D10.1016%2FS0960-894X%2802%2901034-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref122"><div class="reference"><strong class="refLabel"><a href="#ref122" class="rightTabRefNumLink">122</a></strong><div class="NLM_citation" id="rightTab-cit122"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bedürftig, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wünsch, B.</span></span> <span> </span><span class="NLM_article-title">Chiral, nonracemic (piperazin-2-yl)methanol derivatives with sigma-receptor affinity</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">3299</span>– <span class="NLM_lpage">3311</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2004.03.059</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1016%2Fj.bmc.2004.03.059" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref122/cit122&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=15158798" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2004&pages=3299-3311&author=S.+Bed%C3%BCrftigauthor=B.+W%C3%BCnsch&title=Chiral%2C+nonracemic+%28piperazin-2-yl%29methanol+derivatives+with+sigma-receptor+affinity&doi=10.1016%2Fj.bmc.2004.03.059"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2004.03.059&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2004.03.059%26sid%3Dliteratum%253Aachs%26aulast%3DBed%25C3%25BCrftig%26aufirst%3DS.%26aulast%3DW%25C3%25BCnsch%26aufirst%3DB.%26atitle%3DChiral%252C%2520nonracemic%2520%2528piperazin-2-yl%2529methanol%2520derivatives%2520with%2520sigma-receptor%2520affinity%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2004%26volume%3D12%26spage%3D3299%26epage%3D3311%26doi%3D10.1016%2Fj.bmc.2004.03.059" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref123"><div class="reference"><strong class="refLabel"><a href="#ref123" class="rightTabRefNumLink">123</a></strong><div class="NLM_citation" id="rightTab-cit123"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Holl, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schepmann, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wunsch, B.</span></span> <span> </span><span class="NLM_article-title">Homologous piperazine-alcanols: chiral pool synthesis and pharmacological evaluation</span>. <i>MedChemComm</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">673</span>, <span class="refDoi"> DOI: 10.1039/c2md20070h</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1039%2Fc2md20070h" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref123/cit123&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BC38XnvVyhsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=673&author=R.+Hollauthor=D.+Schepmannauthor=B.+Wunsch&title=Homologous+piperazine-alcanols%3A+chiral+pool+synthesis+and+pharmacological+evaluation&doi=10.1039%2Fc2md20070h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit123R"><div class="casContent"><span class="casTitleNuber">123</span><div class="casTitle"><span class="NLM_cas:atitle">Homologous piperazine-alkanols: chiral pool synthesis and pharmacological evaluation</span></div><div class="casAuthors">Holl, Ralph; Schepmann, Dirk; Wuensch, Bernhard</div><div class="citationInfo"><span class="NLM_cas:title">MedChemComm</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">673-679</span>CODEN:
                <span class="NLM_cas:coden">MCCEAY</span>;
        ISSN:<span class="NLM_cas:issn">2040-2503</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Starting with proteinogenic amino acids (S)-aspartate and (S)-glutamate, homologous piperazine-2-alkanol derivs. were prepd. by a five step synthesis.  Diversity was introduced by N-1 alkylation of the piperazinedione derivs. with various alkyl halides and subsequent LiAlH4 redn. of dioxopiperazine esters provided alc. derivs.  These ethanol derivs. show similar σ1-receptor affinity [σ-non-opioid intracellular receptor, σ-receptor 1] as other methanol derivs., but increased selectivity over the σ2 subtype [σ-non-opioid intracellular receptor, σ-receptor 2].  Corresponding propanol derivs. are considerably less potent.  A benzyl or dimethylallyl residue at N-1 appears to be optimal for high σ1 affinity (structure-activity relationship).  The synthesis of the target compds. was achieved using L-aspartic acid-derived piperazine ketone and L-glutamic acid derived piperazine ketone derivs. and amines as starting materials.  The title compds. thus formed included a piperazine-2-ethanol deriv. (I) and a piperazine-2-propanol deriv. (II) and related substances.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGosjCHrjfOiRrVg90H21EOLACvtfcHk0ljIW9MionPT8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XnvVyhsb8%253D&md5=68fa5af26634a8b1958be8bc8eab8b3f</span></div><a href="/servlet/linkout?suffix=cit123&amp;dbid=16384&amp;doi=10.1039%2Fc2md20070h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc2md20070h%26sid%3Dliteratum%253Aachs%26aulast%3DHoll%26aufirst%3DR.%26aulast%3DSchepmann%26aufirst%3DD.%26aulast%3DWunsch%26aufirst%3DB.%26atitle%3DHomologous%2520piperazine-alcanols%253A%2520chiral%2520pool%2520synthesis%2520and%2520pharmacological%2520evaluation%26jtitle%3DMedChemComm%26date%3D2012%26volume%3D3%26spage%3D673%26doi%3D10.1039%2Fc2md20070h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref124"><div class="reference"><strong class="refLabel"><a href="#ref124" class="rightTabRefNumLink">124</a></strong><div class="NLM_citation" id="rightTab-cit124"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Weigl, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bedürftig, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maier, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wünsch, B.</span></span> <span> </span><span class="NLM_article-title">Conformationally constrained ethylenediamines: synthesis and receptor binding of 6,8-diazabicyclo[3.2.2]nonanes</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">2245</span>– <span class="NLM_lpage">2257</span>, <span class="refDoi"> DOI: 10.1016/S0968-0896(02)00043-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1016%2FS0968-0896%2802%2900043-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=11983522" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref124/cit124&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BD38Xjt1Cqsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2002&pages=2245-2257&author=M.+Weiglauthor=S.+Bed%C3%BCrftigauthor=C.+A.+Maierauthor=B.+W%C3%BCnsch&title=Conformationally+constrained+ethylenediamines%3A+synthesis+and+receptor+binding+of+6%2C8-diazabicyclo%5B3.2.2%5Dnonanes&doi=10.1016%2FS0968-0896%2802%2900043-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit124R"><div class="casContent"><span class="casTitleNuber">124</span><div class="casTitle"><span class="NLM_cas:atitle">Conformationally constrained ethylenediamines: synthesis and receptor binding of 6,8-Diazabicyclo[3.2.2]nonanes</span></div><div class="casAuthors">Weigl, Manuela; Bedurftig, Stephan; Maier, Christoph A.; Wunsch, Bernhard</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2245-2257</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">Both (R)- and (S)-enantiomers of 6,8-diazabicyclo[3.2.2]nonanes I (R1 = R2 = Me; R1 = H, R2 = 3,4-Cl2C6H3CH2CO) representing conformationally constrained ethylenediamines were synthesized, and their receptor affinity was studied.  The Dieckmann-type cyclization of the (piperazinyl)propionate II followed by trapping of the product with Me3SiCl provided the bicyclononane III.  III was further stereoselectively transformed into I, which were investigated in competition expts. with radioligands for their σ1-, σ2-, κ-, and μ-receptor affinities.  The (2R)-I (R1 = R2 = Me) showed promising σ1-receptor affinity (Ki=23.8 nM) and selectivity, whereas the (2S)-I (R1 = H, R2 = 3,4-Cl2C6H3CH2CO) displayed a σ-receptor binding profile (σ1: Ki=184 nM; σ2: Ki=263 nM) very similar to the binding profile of the atypical antipsychotic BMY-14802.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEq7HgmkI3g7Vg90H21EOLACvtfcHk0ljIW9MionPT8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xjt1Cqsbc%253D&md5=240dccb500c528c6018cda8ed02be479</span></div><a href="/servlet/linkout?suffix=cit124&amp;dbid=16384&amp;doi=10.1016%2FS0968-0896%2802%2900043-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0968-0896%252802%252900043-3%26sid%3Dliteratum%253Aachs%26aulast%3DWeigl%26aufirst%3DM.%26aulast%3DBed%25C3%25BCrftig%26aufirst%3DS.%26aulast%3DMaier%26aufirst%3DC.%2BA.%26aulast%3DW%25C3%25BCnsch%26aufirst%3DB.%26atitle%3DConformationally%2520constrained%2520ethylenediamines%253A%2520synthesis%2520and%2520receptor%2520binding%2520of%25206%252C8-diazabicyclo%255B3.2.2%255Dnonanes%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2002%26volume%3D10%26spage%3D2245%26epage%3D2257%26doi%3D10.1016%2FS0968-0896%2802%2900043-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref125"><div class="reference"><strong class="refLabel"><a href="#ref125" class="rightTabRefNumLink">125</a></strong><div class="NLM_citation" id="rightTab-cit125"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Weigl, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wünsch, B.</span></span> <span> </span><span class="NLM_article-title">Synthesis of bridged piperazines with sigma receptor affinity</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">1247</span>– <span class="NLM_lpage">1262</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2007.02.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1016%2Fj.ejmech.2007.02.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=17420073" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref125/cit125&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtFOjtrjM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2007&pages=1247-1262&author=M.+Weiglauthor=B.+W%C3%BCnsch&title=Synthesis+of+bridged+piperazines+with+sigma+receptor+affinity&doi=10.1016%2Fj.ejmech.2007.02.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit125R"><div class="casContent"><span class="casTitleNuber">125</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of bridged piperazines with σ receptor affinity</span></div><div class="casAuthors">Weigl, Manuela; Wuensch, Bernhard</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1247-1262</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Bridged piperazines I (R1 = Me, n-Bu, PhCH2CH2; R2 = H, R3 = HO, MeO, PhCH2O; R2 = R3 = MeO) were designed as conformationally restricted piperazine σ receptor ligands.  The chiral pool synthesis started from (S)-glutamate, which was transformed in five reaction steps into the piperazinediones bearing a propionic acid ester side chain.  Subsequent two-step Dieckmann cyclization provided the bicyclic ketones II as key intermediates.  The redn. of II with LiAlH4 followed by NaBH4 redn., Williamson ether synthesis and LiAlH4 redn. led to the Me and benzyl ethers I (R2 = H; R3 = MeO, PhCH2O).  High σ1 affinity is attained when one large substituent is introduced either at N-8 or O-2.  The most potent σ1 ligand in this series of compds. is I (R1 = n-Bu; R2 = H; R3 = MeO) (Ki = 13.2 nM, selectivity σ2:σ1 = 16).  Moreover, the N-Me derivs. I (R1 = Me; R2 = H; R3 = PhCH2O) (σ2: Ki = 30.4 nM) and I (R1 = Me; R2 = H; R3 = MeO) (σ2 preference) represent promising starting points for the development of potent and selective σ2 ligands.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqEahVlnmz8r7Vg90H21EOLACvtfcHk0lihnbV3EFpZhQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtFOjtrjM&md5=297e903f5741aae37fa81f16df51a6e2</span></div><a href="/servlet/linkout?suffix=cit125&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2007.02.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2007.02.005%26sid%3Dliteratum%253Aachs%26aulast%3DWeigl%26aufirst%3DM.%26aulast%3DW%25C3%25BCnsch%26aufirst%3DB.%26atitle%3DSynthesis%2520of%2520bridged%2520piperazines%2520with%2520sigma%2520receptor%2520affinity%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2007%26volume%3D42%26spage%3D1247%26epage%3D1262%26doi%3D10.1016%2Fj.ejmech.2007.02.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref126"><div class="reference"><strong class="refLabel"><a href="#ref126" class="rightTabRefNumLink">126</a></strong><div class="NLM_citation" id="rightTab-cit126"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Holl, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schepmann, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fröhlich, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grünert, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bednarski, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wünsch, B.</span></span> <span> </span><span class="NLM_article-title">Dancing of the second aromatic residue around the 6,8-diazabicyclo[3.2.2]nonane framework: influence on sigma receptor affinity and cytotoxicity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">2126</span>– <span class="NLM_lpage">2137</span>, <span class="refDoi"> DOI: 10.1021/jm801522j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm801522j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref126/cit126&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BD1MXisVCjtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=2126-2137&author=R.+Hollauthor=D.+Schepmannauthor=R.+Fr%C3%B6hlichauthor=R.+Gr%C3%BCnertauthor=P.+J.+Bednarskiauthor=B.+W%C3%BCnsch&title=Dancing+of+the+second+aromatic+residue+around+the+6%2C8-diazabicyclo%5B3.2.2%5Dnonane+framework%3A+influence+on+sigma+receptor+affinity+and+cytotoxicity&doi=10.1021%2Fjm801522j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit126R"><div class="casContent"><span class="casTitleNuber">126</span><div class="casTitle"><span class="NLM_cas:atitle">Dancing of the Second Aromatic Residue around the 6,8-Diazabicyclo[3.2.2]nonane Framework: Influence on σ Receptor Affinity and Cytotoxicity</span></div><div class="casAuthors">Holl, Ralph; Schepmann, Dirk; Froehlich, Roland; Grunert, Renate; Bednarski, Patrick J.; Wunsch, Bernhard</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2126-2137</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of 6,8-diazabicyclo[3.2.2]nonane derivs. bearing two arom. moieties was prepd., the affinity toward σ1 and σ2 receptors was investigated, and the growth inhibition of six human tumor cell lines was detd.  The enantiopure bicyclic ketones 5a ((+)-(1S,5S)-6-allyl-8-(4-methoxybenzyl)-6,8-diazabicyclo[3.2.2]nonane-2,7,9-trione) and 5b ((+)-(1S,5S)-6-allyl-8-(2,4-dimethoxybenzyl)-6,8-diazabicyclo[3.2.2]nonane-2,7,9-trione) as well as their enantiomers ent-5a and ent-5b served as chiral building blocks, which were derived from (S)- and (R)-glutamate, resp.  Structure-affinity relationships revealed that 11a (Ki = 154 nM), ent-11a (Ki = 91 nM), and ent-17a (Ki = 104 nM) are the most potent σ1 ligands.  High σ2 affinity was achieved with 17b (Ki = 159 nM) and 8b (Ki = 400 nM).  The bicyclic σ ligands showed a selective growth inhibition of the small cell lung cancer cell line A-427 with the benzyl ethers 11 and the benzylidene derivs. 17 being the most potent compds.  11A has a cytotoxic potency (IC50 = 0.92 μM), which exceeds the activity of cisplatin and interacts considerably with both σ1 and σ2 receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMiz2RmGxA4bVg90H21EOLACvtfcHk0lihnbV3EFpZhQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXisVCjtL8%253D&md5=e7ba5fd031757e3ed8dcf0fd86bb0721</span></div><a href="/servlet/linkout?suffix=cit126&amp;dbid=16384&amp;doi=10.1021%2Fjm801522j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm801522j%26sid%3Dliteratum%253Aachs%26aulast%3DHoll%26aufirst%3DR.%26aulast%3DSchepmann%26aufirst%3DD.%26aulast%3DFr%25C3%25B6hlich%26aufirst%3DR.%26aulast%3DGr%25C3%25BCnert%26aufirst%3DR.%26aulast%3DBednarski%26aufirst%3DP.%2BJ.%26aulast%3DW%25C3%25BCnsch%26aufirst%3DB.%26atitle%3DDancing%2520of%2520the%2520second%2520aromatic%2520residue%2520around%2520the%25206%252C8-diazabicyclo%255B3.2.2%255Dnonane%2520framework%253A%2520influence%2520on%2520sigma%2520receptor%2520affinity%2520and%2520cytotoxicity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D2126%26epage%3D2137%26doi%3D10.1021%2Fjm801522j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref127"><div class="reference"><strong class="refLabel"><a href="#ref127" class="rightTabRefNumLink">127</a></strong><div class="NLM_citation" id="rightTab-cit127"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Holl, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schepmann, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grünert, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bednarski, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wünsch, B.</span></span> <span> </span><span class="NLM_article-title">Relationships between the structure of 6-allyl-6,8-diazabicyclo[3.2.2]nonane derivatives and their sigma receptor affinity and cytotoxic activity</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">777</span>– <span class="NLM_lpage">793</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2008.11.043</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1016%2Fj.bmc.2008.11.043" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=19081725" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref127/cit127&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtFeqsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2009&pages=777-793&author=R.+Hollauthor=D.+Schepmannauthor=R.+Gr%C3%BCnertauthor=P.+J.+Bednarskiauthor=B.+W%C3%BCnsch&title=Relationships+between+the+structure+of+6-allyl-6%2C8-diazabicyclo%5B3.2.2%5Dnonane+derivatives+and+their+sigma+receptor+affinity+and+cytotoxic+activity&doi=10.1016%2Fj.bmc.2008.11.043"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit127R"><div class="casContent"><span class="casTitleNuber">127</span><div class="casTitle"><span class="NLM_cas:atitle">Relationships between the structure of 6-allyl-6,8-diazabicyclo[3.2.2]nonane derivatives and their σ receptor affinity and cytotoxic activity</span></div><div class="casAuthors">Holl, Ralph; Schepmann, Dirk; Gruenert, Renate; Bednarski, Patrick J.; Wuensch, Bernhard</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">777-793</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A series of bridged piperazine derivs. was prepd. and the affinity toward σ1 and σ2 receptors by means of radioligand binding assays as well as the inhibition of the growth of six human tumor cell lines was investigated.  All possible stereoisomers of the 2-hydroxy, 2-methoxy, 2,2-dimethoxy, 2-oxo, and 2-unsubstituted 6,8-diazabicyclo[3.2.2]nonanes were prepd. in a chiral pool synthesis starting with (S)- and (R)-glutamate.  A Dieckmann analogous cyclization was the key step in the synthesis of the bicyclic framework.  The configuration in position 2 was established by a diastereoselective LiBH4 redn. and subsequent Mitsunobu inversion.  Structure-affinity relationships demonstrate that substituents in position 2 decrease σ1 receptor affinity which might be due to unfavorable interactions with the σ1 receptor protein.  Without a substituent in position 2 high σ1 affinity was obtained (23a ((+)-(1S,5S)-6-allyl-8-(4-methoxybenzyl)-6,8-diazabicyclo[3.2.2]nonane): K i = 11 nM).  Expts. with six human tumor cell lines showed a weak but selective growth inhibition of the human small cell lung cancer cell line A-427 by the Me ethers ent-16b (IC50 = 18.9 μM), 21a (IC50 = 16.4 μM), ent-21a (IC50 = 20.4 μM), and 21b (IC50 = 27.1 μM) and the unsubstituted compds. 23a and 23b (42% inhibition at 20 μM).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEBsQOc45My7Vg90H21EOLACvtfcHk0lihnbV3EFpZhQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtFeqsrY%253D&md5=e69818a3ef5def6300dc8ce5bc959797</span></div><a href="/servlet/linkout?suffix=cit127&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2008.11.043&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2008.11.043%26sid%3Dliteratum%253Aachs%26aulast%3DHoll%26aufirst%3DR.%26aulast%3DSchepmann%26aufirst%3DD.%26aulast%3DGr%25C3%25BCnert%26aufirst%3DR.%26aulast%3DBednarski%26aufirst%3DP.%2BJ.%26aulast%3DW%25C3%25BCnsch%26aufirst%3DB.%26atitle%3DRelationships%2520between%2520the%2520structure%2520of%25206-allyl-6%252C8-diazabicyclo%255B3.2.2%255Dnonane%2520derivatives%2520and%2520their%2520sigma%2520receptor%2520affinity%2520and%2520cytotoxic%2520activity%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2009%26volume%3D17%26spage%3D777%26epage%3D793%26doi%3D10.1016%2Fj.bmc.2008.11.043" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref128"><div class="reference"><strong class="refLabel"><a href="#ref128" class="rightTabRefNumLink">128</a></strong><div class="NLM_citation" id="rightTab-cit128"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Holl, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schepmann, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bednarski, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grünert, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wünsch, B.</span></span> <span> </span><span class="NLM_article-title">Relationships between the structure of 6-substituted 6,8-diazabicyclo[3.2.2]nonan-2-ones and their sigma receptor affinity and cytotoxic activity</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">1445</span>– <span class="NLM_lpage">1455</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2009.01.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1016%2Fj.bmc.2009.01.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=19196515" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref128/cit128&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BD1MXitVyisL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2009&pages=1445-1455&author=R.+Hollauthor=D.+Schepmannauthor=P.+J.+Bednarskiauthor=R.+Gr%C3%BCnertauthor=B.+W%C3%BCnsch&title=Relationships+between+the+structure+of+6-substituted+6%2C8-diazabicyclo%5B3.2.2%5Dnonan-2-ones+and+their+sigma+receptor+affinity+and+cytotoxic+activity&doi=10.1016%2Fj.bmc.2009.01.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit128R"><div class="casContent"><span class="casTitleNuber">128</span><div class="casTitle"><span class="NLM_cas:atitle">Relationships between the structure of 6-substituted 6,8-diazabicyclo[3.2.2]nonan-2-ones and their σ receptor affinity and cytotoxic activity</span></div><div class="casAuthors">Holl, Ralph; Schepmann, Dirk; Bednarski, Patrick J.; Gruenert, Renate; Wuensch, Bernhard</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1445-1455</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A series of 2-oxo-6,8-diazabicyclo[3.2.2]nonane derivs. was prepd. and the affinity towards σ1 and σ2 receptors was investigated by means of radioligand binding assays as well as their inhibition of the growth of six human tumor cell lines was studied.  Starting from the enantiopure bicyclic ketones 3 and ent-3 bridged piperazines with different residues in position 6 were synthesized.  The N-6 allyl protective group was removed by a RhCl3 catalyzed double bond isomerization and subsequent hydrolysis of the resulting enamide 8.  After acetalization the secondary amide 10 was alkylated and arylated.  Structure affinity relationships show that a relatively large substituent, which has not necessarily to be an arom. one, is required in position 6 for high σ1 receptor affinity (e.g., 12 and ent-12 with a dimethylallyl residue: K i = 20 nM and 17 nM).  Furthermore, it was shown that substituents that reduce the basicity of N-6 led to a severe decrease in σ1 affinity.  Growth inhibition expts. with six human tumor cell lines revealed that the allyl and benzyl substituted 6,8-diazabicyclo[3.2.2]nonan-2-one derivs. 5, ent-5 and ent-14 are able to selectively inhibit the growth of the bladder cancer cell line 5637.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFTT1u_7JzY7Vg90H21EOLACvtfcHk0lihnbV3EFpZhQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXitVyisL8%253D&md5=daf4343250a2cd50481485a248b73d8b</span></div><a href="/servlet/linkout?suffix=cit128&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2009.01.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2009.01.012%26sid%3Dliteratum%253Aachs%26aulast%3DHoll%26aufirst%3DR.%26aulast%3DSchepmann%26aufirst%3DD.%26aulast%3DBednarski%26aufirst%3DP.%2BJ.%26aulast%3DGr%25C3%25BCnert%26aufirst%3DR.%26aulast%3DW%25C3%25BCnsch%26aufirst%3DB.%26atitle%3DRelationships%2520between%2520the%2520structure%2520of%25206-substituted%25206%252C8-diazabicyclo%255B3.2.2%255Dnonan-2-ones%2520and%2520their%2520sigma%2520receptor%2520affinity%2520and%2520cytotoxic%2520activity%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2009%26volume%3D17%26spage%3D1445%26epage%3D1455%26doi%3D10.1016%2Fj.bmc.2009.01.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref129"><div class="reference"><strong class="refLabel"><a href="#ref129" class="rightTabRefNumLink">129</a></strong><div class="NLM_citation" id="rightTab-cit129"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sunnam, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schepmann, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wibbeling, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wünsch, B.</span></span> <span> </span><span class="NLM_article-title">Bicyclic sigma receptor ligands by stereoselective Dieckmann analogous cyclization of piperazinebutyrate</span>. <i>Org. Biomol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">3715</span>– <span class="NLM_lpage">3722</span>, <span class="refDoi"> DOI: 10.1039/c003878d</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1039%2Fc003878d" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=20556273" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref129/cit129&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpsFeqsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2010&pages=3715-3722&author=S.+K.+Sunnamauthor=D.+Schepmannauthor=B.+Wibbelingauthor=B.+W%C3%BCnsch&title=Bicyclic+sigma+receptor+ligands+by+stereoselective+Dieckmann+analogous+cyclization+of+piperazinebutyrate&doi=10.1039%2Fc003878d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit129R"><div class="casContent"><span class="casTitleNuber">129</span><div class="casTitle"><span class="NLM_cas:atitle">Bicyclic σ receptor ligands by stereoselective Dieckmann analogous cyclization of piperazinebutyrate</span></div><div class="casAuthors">Sunnam, Sunil Kumar; Schepmann, Dirk; Wibbeling, Birgit; Wuensch, Bernhard</div><div class="citationInfo"><span class="NLM_cas:title">Organic & Biomolecular Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">3715-3722</span>CODEN:
                <span class="NLM_cas:coden">OBCRAK</span>;
        ISSN:<span class="NLM_cas:issn">1477-0520</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Starting from racemic 2-aminoadipic acid the piperazinedione I with a butyrate side chain was synthesized in four reaction steps.  The four-carbon bridge was established upon deprotonation of I with LHMDS and subsequent trapping of the lithium alcoholate with Me3SiCl to give diastereoselectively the mixed Me silyl ketal II in 94% yield.  The relative configuration of the new center of chirality was detd. by X-ray crystal structure anal. of II.  The high diastereoselectivity during the conversion of the butyrate I into the mixed Me silyl ketal II supports the formation of the lithium alcoholate as central intermediate.  Stereoselective redn. of the ketone with LiBH4 led to the alc., which was benzylated and reduced to provide the final bicyclic products III (R = H, Bn).  Whereas the alc. III (R = H) shows only moderate affinity to both σ receptor subtypes, the benzyl ether III (R = Bn) represents a potent and selective σ1 receptor ligand (Ki = 47 nM).  Comparison of the σ receptor affinities of III (R = H, Bn) with the smaller homologues IV (R = H, Me) clearly indicates that the size of the bridge and the O-substituent dets. subtype selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8zdqYzoKvQLVg90H21EOLACvtfcHk0lj6A_lnWO0M_Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpsFeqsL8%253D&md5=598c2048ff25585ff4ce098b43c117fd</span></div><a href="/servlet/linkout?suffix=cit129&amp;dbid=16384&amp;doi=10.1039%2Fc003878d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc003878d%26sid%3Dliteratum%253Aachs%26aulast%3DSunnam%26aufirst%3DS.%2BK.%26aulast%3DSchepmann%26aufirst%3DD.%26aulast%3DWibbeling%26aufirst%3DB.%26aulast%3DW%25C3%25BCnsch%26aufirst%3DB.%26atitle%3DBicyclic%2520sigma%2520receptor%2520ligands%2520by%2520stereoselective%2520Dieckmann%2520analogous%2520cyclization%2520of%2520piperazinebutyrate%26jtitle%3DOrg.%2520Biomol.%2520Chem.%26date%3D2010%26volume%3D8%26spage%3D3715%26epage%3D3722%26doi%3D10.1039%2Fc003878d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref130"><div class="reference"><strong class="refLabel"><a href="#ref130" class="rightTabRefNumLink">130</a></strong><div class="NLM_citation" id="rightTab-cit130"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Geiger, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zelenka, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weigl, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fröhlich, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wibbeling, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lehmkuhl, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schepmann, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grünert, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bednarski, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wünsch, B.</span></span> <span> </span><span class="NLM_article-title">Synthesis of bicyclic sigma receptor ligands with cytotoxic activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">6144</span>– <span class="NLM_lpage">6153</span>, <span class="refDoi"> DOI: 10.1021/jm070620b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm070620b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref130/cit130&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BD2sXht1CrurnM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=6144-6153&author=C.+Geigerauthor=C.+Zelenkaauthor=M.+Weiglauthor=R.+Fr%C3%B6hlichauthor=B.+Wibbelingauthor=K.+Lehmkuhlauthor=D.+Schepmannauthor=R.+Gr%C3%BCnertauthor=P.+J.+Bednarskiauthor=B.+W%C3%BCnsch&title=Synthesis+of+bicyclic+sigma+receptor+ligands+with+cytotoxic+activity&doi=10.1021%2Fjm070620b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit130R"><div class="casContent"><span class="casTitleNuber">130</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of Bicyclic σ Receptor Ligands with Cytotoxic Activity</span></div><div class="casAuthors">Geiger, Christian; Zelenka, Christel; Weigl, Manuela; Froehlich, Roland; Wibbeling, Birgit; Lehmkuhl, Kirstin; Schepmann, Dirk; Gruenert, Renate; Bednarski, Patrick J.; Wuensch, Bernhard</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">6144-6153</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">All possible stereoisomeric alcs. (6-benzyl-8-(4-methoxybenzyl)-6,8-diazabicyclo[3.2.2]nonan-2-ol) and Me ethers (6-benzyl-2-methoxy-8-(4-methoxybenzyl)-6,8-diazabicyclo[3.2.2]nonane) are prepd. from (R)- and (S)-glutamate.  A Dieckmann analogous cyclization, which makes use of trapping the primary cyclization product with Me3SiCl, generates the bicyclic framework.  Stereoselective LiBH4 redn. and Mitsunobu inversion establish the configuration in position 2.  Enantiomeric alcs. I (1S,2S,5R) and ent-I (1R,2R,5S) as well as diastereomeric Me ethers II (1R,2R,5S) and III (1R,2S,5S) display high σ1 receptor affinity.  Cell growth inhibition of the stereoisomeric alcs. and Me ethers against five human tumor cell lines is investigated.  In particular, at a concn. of 20 μM the four Me ethers stop completely the cell growth of the small cell lung cancer cell line A-427, indicating a specific target in this cell line.  The IC50-values of Me ethers II and III are in the range of the antitumor drugs cisplatin and oxaliplatin.  Binding assays show that the investigated tumor cell lines express considerable amts. of σ1 and σ2 receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpu13hI5qstBrVg90H21EOLACvtfcHk0lj6A_lnWO0M_Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXht1CrurnM&md5=4b4723f550d614d2b1c26cfc4266aa3e</span></div><a href="/servlet/linkout?suffix=cit130&amp;dbid=16384&amp;doi=10.1021%2Fjm070620b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm070620b%26sid%3Dliteratum%253Aachs%26aulast%3DGeiger%26aufirst%3DC.%26aulast%3DZelenka%26aufirst%3DC.%26aulast%3DWeigl%26aufirst%3DM.%26aulast%3DFr%25C3%25B6hlich%26aufirst%3DR.%26aulast%3DWibbeling%26aufirst%3DB.%26aulast%3DLehmkuhl%26aufirst%3DK.%26aulast%3DSchepmann%26aufirst%3DD.%26aulast%3DGr%25C3%25BCnert%26aufirst%3DR.%26aulast%3DBednarski%26aufirst%3DP.%2BJ.%26aulast%3DW%25C3%25BCnsch%26aufirst%3DB.%26atitle%3DSynthesis%2520of%2520bicyclic%2520sigma%2520receptor%2520ligands%2520with%2520cytotoxic%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26spage%3D6144%26epage%3D6153%26doi%3D10.1021%2Fjm070620b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref131"><div class="reference"><strong class="refLabel"><a href="#ref131" class="rightTabRefNumLink">131</a></strong><div class="NLM_citation" id="rightTab-cit131"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sunnam, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schepmann, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rack, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fröhlich, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korpis, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bednarski, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wünsch, B.</span></span> <span> </span><span class="NLM_article-title">Synthesis and biological evaluation of conformationally restricted σ(1) receptor ligands with 7,9-diazabicyclo[4.2.2]decane scaffold</span>. <i>Org. Biomol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">5525</span>– <span class="NLM_lpage">5540</span>, <span class="refDoi"> DOI: 10.1039/c0ob00402b</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1039%2Fc0ob00402b" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=20953473" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref131/cit131&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVOrs73O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2010&pages=5525-5540&author=S.+K.+Sunnamauthor=D.+Schepmannauthor=E.+Rackauthor=R.+Fr%C3%B6hlichauthor=K.+Korpisauthor=P.+J.+Bednarskiauthor=B.+W%C3%BCnsch&title=Synthesis+and+biological+evaluation+of+conformationally+restricted+%CF%83%281%29+receptor+ligands+with+7%2C9-diazabicyclo%5B4.2.2%5Ddecane+scaffold&doi=10.1039%2Fc0ob00402b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit131R"><div class="casContent"><span class="casTitleNuber">131</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and biological evaluation of conformationally restricted σ1 receptor ligands with 7,9-diazabicyclo[4.2.2]decane scaffold</span></div><div class="casAuthors">Sunnam, Sunil K.; Schepmann, Dirk; Rack, Elisabeth; Froehlich, Roland; Korpis, Katharina; Bednarski, Patrick J.; Wuensch, Bernhard</div><div class="citationInfo"><span class="NLM_cas:title">Organic & Biomolecular Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">5525-5540</span>CODEN:
                <span class="NLM_cas:coden">OBCRAK</span>;
        ISSN:<span class="NLM_cas:issn">1477-0520</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">The key step in the synthesis of the 7,9-diazabicyclo[4.2.2]decane system was a modified Dieckmann condensation of piperazinebutyrate I, which made use of trapping the first cyclized intermediate with TMS-Cl to provide bicyclic ketone II.  Compd. II was then used to prep. various derivs.  The σ1 and σ2 receptor affinities of these derivs. were investigated in receptor binding studies with radioligands.  All test compds. showed a lower σ1 affinity than the corresponding bicyclic derivs. with a three-membered bridge.  The reduced σ1 receptor affinity was attributed to the larger four-membered bridge.  This hypothesis was supported by alkene III, which represented the most potent σ1 ligand of this series (Ki = 7.5 nM).  In alkene III the size and flexibility of the bridge is considerably reduced by the double bond.  Compd. III and two other analogs revealed moderate inhibition of the growth of the human tumor cell lines A-427, 5637 and MCF-7.  Again, these compds. were less potent than the analogs with a three-membered bridge.  The IC50-value of III against the small cell lung cancer cell line A-427 (IC50 = 10 μM) should be emphasized, since this cell line is particularly sensitive to homologs with a three-carbon bridge.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJ-d3GvdXU4rVg90H21EOLACvtfcHk0lj6A_lnWO0M_Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVOrs73O&md5=2e53b17fa9ab6ccae159aa987d718859</span></div><a href="/servlet/linkout?suffix=cit131&amp;dbid=16384&amp;doi=10.1039%2Fc0ob00402b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc0ob00402b%26sid%3Dliteratum%253Aachs%26aulast%3DSunnam%26aufirst%3DS.%2BK.%26aulast%3DSchepmann%26aufirst%3DD.%26aulast%3DRack%26aufirst%3DE.%26aulast%3DFr%25C3%25B6hlich%26aufirst%3DR.%26aulast%3DKorpis%26aufirst%3DK.%26aulast%3DBednarski%26aufirst%3DP.%2BJ.%26aulast%3DW%25C3%25BCnsch%26aufirst%3DB.%26atitle%3DSynthesis%2520and%2520biological%2520evaluation%2520of%2520conformationally%2520restricted%2520%25CF%2583%25281%2529%2520receptor%2520ligands%2520with%25207%252C9-diazabicyclo%255B4.2.2%255Ddecane%2520scaffold%26jtitle%3DOrg.%2520Biomol.%2520Chem.%26date%3D2010%26volume%3D8%26spage%3D5525%26epage%3D5540%26doi%3D10.1039%2Fc0ob00402b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref132"><div class="reference"><strong class="refLabel"><a href="#ref132" class="rightTabRefNumLink">132</a></strong><div class="NLM_citation" id="rightTab-cit132"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Weber, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brune, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Börgel, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lange, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korpis, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bednarski, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Laurini, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fermeglia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pricl, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schepmann, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wünsch, B.</span></span> <span> </span><span class="NLM_article-title">Rigidity versus Flexibility: Is This an Issue in σ1 Receptor Ligand Affinity and Activity?</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">5505</span>– <span class="NLM_lpage">5519</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00585</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00585" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref132/cit132&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BC28XnsVyitr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=5505-5519&author=F.+Weberauthor=S.+Bruneauthor=F.+B%C3%B6rgelauthor=C.+Langeauthor=K.+Korpisauthor=P.+J.+Bednarskiauthor=E.+Lauriniauthor=M.+Fermegliaauthor=S.+Priclauthor=D.+Schepmannauthor=B.+W%C3%BCnsch&title=Rigidity+versus+Flexibility%3A+Is+This+an+Issue+in+%CF%831+Receptor+Ligand+Affinity+and+Activity%3F&doi=10.1021%2Facs.jmedchem.6b00585"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit132R"><div class="casContent"><span class="casTitleNuber">132</span><div class="casTitle"><span class="NLM_cas:atitle">Rigidity versus Flexibility: Is This an Issue in σ1 Receptor Ligand Affinity and Activity?</span></div><div class="casAuthors">Weber, Frauke; Brune, Stefanie; Boergel, Frederik; Lange, Carsten; Korpis, Katharina; Bednarski, Patrick J.; Laurini, Erik; Fermeglia, Maurizio; Pricl, Sabrina; Schepmann, Dirk; Wuensch, Bernhard</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">5505-5519</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Stereoisomeric 2,5-diazabicyclo[2.2.2]octanes 14 and 15 were prepd. in a chiral-pool synthesis starting from (S)- or (R)-aspartate.  The key step in the synthesis was a Dieckmann-analogous cyclization of (dioxopiperazinyl)acetates 8, which involved trapping of the intermediate hemiketal anion with Me3SiCl.  The σ1 affinity was tested using membrane prepns. from animal (guinea pig) and human origin.  The binding of bicyclic compds. was analyzed by mol. dynamics simulations based on a 3D homol. model of the σ1 receptor.  The good correlation between Ki values obsd. in the σ1 assays and calcd. free binding energy, coupled with the identification of four crucial ligand/receptor interactions, allowed the formulation of structure-affinity relationships.  In an in vitro antitumor assay with seven human tumor cell lines, the bicyclic compds. inhibited selectively the growth of the cell line A427, which is due to induction of apoptosis.  In this assay, the compds. behave like the known σ1 receptor antagonist haloperidol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMpZXtybW1V7Vg90H21EOLACvtfcHk0lgYk0HFyV7I1w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XnsVyitr0%253D&md5=d5fc4600fcd605c8b191a921bddf5e56</span></div><a href="/servlet/linkout?suffix=cit132&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00585&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00585%26sid%3Dliteratum%253Aachs%26aulast%3DWeber%26aufirst%3DF.%26aulast%3DBrune%26aufirst%3DS.%26aulast%3DB%25C3%25B6rgel%26aufirst%3DF.%26aulast%3DLange%26aufirst%3DC.%26aulast%3DKorpis%26aufirst%3DK.%26aulast%3DBednarski%26aufirst%3DP.%2BJ.%26aulast%3DLaurini%26aufirst%3DE.%26aulast%3DFermeglia%26aufirst%3DM.%26aulast%3DPricl%26aufirst%3DS.%26aulast%3DSchepmann%26aufirst%3DD.%26aulast%3DW%25C3%25BCnsch%26aufirst%3DB.%26atitle%3DRigidity%2520versus%2520Flexibility%253A%2520Is%2520This%2520an%2520Issue%2520in%2520%25CF%25831%2520Receptor%2520Ligand%2520Affinity%2520and%2520Activity%253F%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D5505%26epage%3D5519%26doi%3D10.1021%2Facs.jmedchem.6b00585" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref133"><div class="reference"><strong class="refLabel"><a href="#ref133" class="rightTabRefNumLink">133</a></strong><div class="NLM_citation" id="rightTab-cit133"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Perregaard, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moltzen, E. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meier, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sánchez, C.</span></span> <span> </span><span class="NLM_article-title">Sigma ligands with subnanomolar affinity and preference for the sigma 2 binding site. 1. 3-(omega-aminoalkyl)-1H-indoles</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">1998</span>– <span class="NLM_lpage">2008</span>, <span class="refDoi"> DOI: 10.1021/jm00011a019</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm00011a019" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref133/cit133&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADyaK2MXls1yqt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=1995&pages=1998-2008&author=J.+Perregaardauthor=E.+K.+Moltzenauthor=E.+Meierauthor=C.+S%C3%A1nchez&title=Sigma+ligands+with+subnanomolar+affinity+and+preference+for+the+sigma+2+binding+site.+1.+3-%28omega-aminoalkyl%29-1H-indoles&doi=10.1021%2Fjm00011a019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit133R"><div class="casContent"><span class="casTitleNuber">133</span><div class="casTitle"><span class="NLM_cas:atitle">σ Ligands with Subnanomolar Affinity and Preference for the σ2 Binding Site. 1. 3-(ω-Aminoalkyl)-1H-indoles</span></div><div class="casAuthors">Perregaard, Jens; Moltzen, Ejner K.; Meier, Eddi; Sanchez, Connie</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1998-2008</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of 4-(1H-indol-3-yl)-1-butyl-substituted 4-phenylpiperidines, 4-phenyl-1,2,3,6-tetrahydropyridines, and 4-phenylpiperazines was synthesized.  The Ph group was optionally substituted with 4-fluoro or 2-methoxy substituents.  High affinity for both σ1 and σ2 binding sites was achieved with these compds.  Addnl., these compds. had relatively high affinity for serotonin 5-HT1A and 5-HT2A, dopamine D2, and adrenergic α1 receptors.  Introduction of a 4-fluorophenyl substituent at the indole nitrogen atom rendered very selective σ2 ligands with subnanomolar affinity for the σ2 binding site.  The prototype of such a compd. was I.  This compd. had the following binding affinities: IC50 (σ1) = 16 nM, IC50 (σ2) = 0.27 nM, IC50 (5-HT1A) = 22 000 nM, IC50 (5-HT2A) = 270 nM, IC50 (D2) = 4200 nM, IC50 (α1) = 220 nM.  Spiro-joining of the Ph and the piperidine rings into a spiro[isobenzofuran-1(3H),4'-piperidine] ring system resulted in even more selective compds.  Variations of the 1-substituent at the indole and of the chain length of the alkylene spacer group were studied.  The optimal compd. was the spiro analog of I.  This compd. (II) had the binding affinities: IC50 (σ1) = 17 nM, IC50 (σ2) = 0.12 nM, IC50 (5-HT1A) = 21 000 nM, IC50 (5-HT2A) = 2000 nM, IC50 (D2) = 800 nM, IC50 (α1) = 330 nM.  However, the most selective σ2 vs. σ1 ligand was the tropane deriv. (III).  This compd. had the following binding affinities: IC50 (σ1) = 1200 nM, IC50 (σ2) = 2.5 nM.  Potent anxiolytic activity in the black/white box exploration test in rats was found with the two most prominent σ2 ligands Lu 29-253 and Lu 28-179.  Good penetration into the CNS was documented both after s.c. and peroral administration of Lu 28-179 by ex vivo binding studies.  Long duration of action was demonstrated both in ex vivo binding (T1/2 ∼ 20 h) and in the black/white box exploration test.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGraJL4h7Q5nXbVg90H21EOLACvtfcHk0lgYk0HFyV7I1w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXls1yqt7w%253D&md5=c7856739a0cfdd0615e1a6428d759445</span></div><a href="/servlet/linkout?suffix=cit133&amp;dbid=16384&amp;doi=10.1021%2Fjm00011a019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00011a019%26sid%3Dliteratum%253Aachs%26aulast%3DPerregaard%26aufirst%3DJ.%26aulast%3DMoltzen%26aufirst%3DE.%2BK.%26aulast%3DMeier%26aufirst%3DE.%26aulast%3DS%25C3%25A1nchez%26aufirst%3DC.%26atitle%3DSigma%2520ligands%2520with%2520subnanomolar%2520affinity%2520and%2520preference%2520for%2520the%2520sigma%25202%2520binding%2520site.%25201.%25203-%2528omega-aminoalkyl%2529-1H-indoles%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1995%26volume%3D38%26spage%3D1998%26epage%3D2008%26doi%3D10.1021%2Fjm00011a019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref134"><div class="reference"><strong class="refLabel"><a href="#ref134" class="rightTabRefNumLink">134</a></strong><div class="NLM_citation" id="rightTab-cit134"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Berardi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferorelli, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abate, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colabufo, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Contino, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perrone, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tortorella, V.</span></span> <span> </span><span class="NLM_article-title">4-(tetralin-1-yl)- and 4-(naphthalen-1-yl)alkyl derivatives of 1-cyclohexylpiperazine as sigma receptor ligands with agonist sigma2 activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">2308</span>– <span class="NLM_lpage">2317</span>, <span class="refDoi"> DOI: 10.1021/jm031026e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm031026e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref134/cit134&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BD2cXis1Whs7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=2308-2317&author=F.+Berardiauthor=S.+Ferorelliauthor=C.+Abateauthor=N.+A.+Colabufoauthor=M.+Continoauthor=R.+Perroneauthor=V.+Tortorella&title=4-%28tetralin-1-yl%29-+and+4-%28naphthalen-1-yl%29alkyl+derivatives+of+1-cyclohexylpiperazine+as+sigma+receptor+ligands+with+agonist+sigma2+activity&doi=10.1021%2Fjm031026e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit134R"><div class="casContent"><span class="casTitleNuber">134</span><div class="casTitle"><span class="NLM_cas:atitle">4-(Tetralin-1-yl)- and 4-(Naphthalen-1-yl)alkyl Derivatives of 1-Cyclohexylpiperazine as σ Receptor Ligands with Agonist σ2 Activity</span></div><div class="casAuthors">Berardi, Francesco; Ferorelli, Savina; Abate, Carmen; Colabufo, Nicola Antonio; Contino, Marialessandra; Perrone, Roberto; Tortorella, Vincenzo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2308-2317</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Several 1-cyclohexylpiperazine derivs. related to σ2 receptor ligand 1-cyclohexyl-4-[3-(5-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)propyl]piperazine (I, Ki = 0.34 nM) were synthesized and tested in radioligand binding assays, to attempt a structure-affinity relationship study.  Intermediate alkyl chain length and methoxyl group position on the tetralin nucleus were varied.  A few naphthalene analogs were also prepd.  High affinities were found in σ2 receptor binding for almost all compds., some of which displayed Ki values in subnanomolar range, but low σ2/σ1 selectivities were found.  The highest σ2 affinities were displayed by compds. with an intermediate alkyl chain of three or five methylenes.  Quite high σ1 receptor affinity was found for compds. with a four-methylene chain.  Moreover, homologs of compd. I displayed also satisfactory selectivities over dopamine D2-like, serotonin 5-HT3, and adrenergic α1 receptors.  These compds. and a few others were tested in the inhibition of the elec. evoked contractions in guinea pig bladder and were demonstrated to be full σ2 agonists.  The activity values correlated well to the affinity scale (EC50 in μM range).  I and related compds. are proposed as a class of potential antineoplastic and PET diagnosis agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFYmaM73BtBLVg90H21EOLACvtfcHk0lgYk0HFyV7I1w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXis1Whs7k%253D&md5=d49b636ae09bd42fdfbc65404737767e</span></div><a href="/servlet/linkout?suffix=cit134&amp;dbid=16384&amp;doi=10.1021%2Fjm031026e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm031026e%26sid%3Dliteratum%253Aachs%26aulast%3DBerardi%26aufirst%3DF.%26aulast%3DFerorelli%26aufirst%3DS.%26aulast%3DAbate%26aufirst%3DC.%26aulast%3DColabufo%26aufirst%3DN.%2BA.%26aulast%3DContino%26aufirst%3DM.%26aulast%3DPerrone%26aufirst%3DR.%26aulast%3DTortorella%26aufirst%3DV.%26atitle%3D4-%2528tetralin-1-yl%2529-%2520and%25204-%2528naphthalen-1-yl%2529alkyl%2520derivatives%2520of%25201-cyclohexylpiperazine%2520as%2520sigma%2520receptor%2520ligands%2520with%2520agonist%2520sigma2%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26spage%3D2308%26epage%3D2317%26doi%3D10.1021%2Fjm031026e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref135"><div class="reference"><strong class="refLabel"><a href="#ref135" class="rightTabRefNumLink">135</a></strong><div class="NLM_citation" id="rightTab-cit135"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Intagliata, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alsharif, W. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mesangeau, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fazio, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seminerio, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsumoto, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCurdy, C. R.</span></span> <span> </span><span class="NLM_article-title">Benzimidazolone-based selective σ(2) receptor ligands: Synthesis and pharmacological evaluation</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>165</i></span>,  <span class="NLM_fpage">250</span>– <span class="NLM_lpage">257</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2019.01.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1016%2Fj.ejmech.2019.01.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=30685525" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref135/cit135&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvFKks7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=165&publication_year=2019&pages=250-257&author=S.+Intagliataauthor=W.+F.+Alsharifauthor=C.+Mesangeauauthor=N.+Fazioauthor=M.+Seminerioauthor=Y.+T.+Xuauthor=R.+R.+Matsumotoauthor=C.+R.+McCurdy&title=Benzimidazolone-based+selective+%CF%83%282%29+receptor+ligands%3A+Synthesis+and+pharmacological+evaluation&doi=10.1016%2Fj.ejmech.2019.01.019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit135R"><div class="casContent"><span class="casTitleNuber">135</span><div class="casTitle"><span class="NLM_cas:atitle">Benzimidazolone-based selective σ2 receptor ligands: Synthesis and pharmacological evaluation</span></div><div class="casAuthors">Intagliata, Sebastiano; Alsharif, Walid F.; Mesangeau, Christophe; Fazio, Nicola; Seminerio, Michael; Xu, Yan-Tong; Matsumoto, Rae R.; McCurdy, Christopher R.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">165</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">250-257</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Sigma receptors (σRs) are considered to be a significant and valid target for developing new medications to address several diseases.  Their potential involvement in numerous central nervous system disorders, neuropathic pain, addiction, and cancer has been extensively reported.  In particular, the σ2R has been identified as potential target for the development of pharmaceutical agents intended to treat the neg. effects assocd. with drugs of abuse.  As a continuation of our previous efforts to develop new selective σ2R ligands, a series of benzimidazolone derivs. I (R1 = H, COCH3; R2 = H, CH3, C3H7, C5H11, C10H21; R3 = cyclohexyl, 4-FC6H4) was designed, synthesized, and characterized.  The newly synthesized ligands were evaluated through in vitro radioligand binding assays to det. their affinity and selectivity towards both σ1 and σ2 receptors.  Several derivs. displayed high affinity for the σ2R (Ki = 0.66-68.5 nM) and varied from preferring to selective values, compared to σ1R (σ1/σ2 = 5.8-1139).  Among them, compd. I (R1 = H; R2 = C3H7; R3 = 4-FC6H4) displayed the ability to produce a dose-dependent redn. in the convulsive effects of cocaine in a rodent model after injecting 10 mg/kg (i.p.).  These preliminary results support the use of selective σ2R ligands in the development of useful pharmacol. tools or potential pharmacotherapies for cocaine toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_xm6l0yxuALVg90H21EOLACvtfcHk0ljmuZEwz3UzAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvFKks7o%253D&md5=38af6fa85bd035ad2dc497d21de12357</span></div><a href="/servlet/linkout?suffix=cit135&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2019.01.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2019.01.019%26sid%3Dliteratum%253Aachs%26aulast%3DIntagliata%26aufirst%3DS.%26aulast%3DAlsharif%26aufirst%3DW.%2BF.%26aulast%3DMesangeau%26aufirst%3DC.%26aulast%3DFazio%26aufirst%3DN.%26aulast%3DSeminerio%26aufirst%3DM.%26aulast%3DXu%26aufirst%3DY.%2BT.%26aulast%3DMatsumoto%26aufirst%3DR.%2BR.%26aulast%3DMcCurdy%26aufirst%3DC.%2BR.%26atitle%3DBenzimidazolone-based%2520selective%2520%25CF%2583%25282%2529%2520receptor%2520ligands%253A%2520Synthesis%2520and%2520pharmacological%2520evaluation%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2019%26volume%3D165%26spage%3D250%26epage%3D257%26doi%3D10.1016%2Fj.ejmech.2019.01.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref136"><div class="reference"><strong class="refLabel"><a href="#ref136" class="rightTabRefNumLink">136</a></strong><div class="NLM_citation" id="rightTab-cit136"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lever, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lever, S. Z.</span></span> <span> </span><span class="NLM_article-title">Synthesis and in vitro evaluation of tetrahydroisoquinolinyl benzamides as ligands for sigma receptors</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">2594</span>– <span class="NLM_lpage">2597</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2007.02.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1016%2Fj.bmcl.2007.02.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=17317173" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref136/cit136&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BD2sXktVentbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2007&pages=2594-2597&author=R.+Xuauthor=J.+R.+Leverauthor=S.+Z.+Lever&title=Synthesis+and+in+vitro+evaluation+of+tetrahydroisoquinolinyl+benzamides+as+ligands+for+sigma+receptors&doi=10.1016%2Fj.bmcl.2007.02.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit136R"><div class="casContent"><span class="casTitleNuber">136</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and in vitro evaluation of tetrahydroisoquinolinyl benzamides as ligands for σ receptors</span></div><div class="casAuthors">Xu, Rong; Lever, John R.; Lever, Susan Z.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2594-2597</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">5-Bromo-N-[4-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-butyl]-2,3-dimethoxy-benzamide (I) is one of the most potent and selective σ 2 receptor ligands reported to date.  Previous structure-activity relationship studies of such tetrahydroisoquinolinyl benzamides have focused on the linker that connects the ring systems and the effects of benzamide ring substituents.  The present study explores the effects of fusing methylene-, ethylene-, and propylenedioxy rings onto the tetrahydroisoquinoline in place of the two methoxy groups.  These modifications decreased σ2 affinity by 8- to 12-fold, with no major differences noted with ring size.  By contrast, the methylenedioxy analog showed a 10-fold greater σ1 affinity than I, and progressively lower σ1 affinities were then noted with increasing ring size.  The tetrahydroisoquinoline ring of I was opened to study the effects of greater conformational fluidity on σ receptor binding.  The σ2 affinity of the open-ring compd. decreased by 1700-fold, while σ1 affinity was not changed.  Thus, a constrained tetrahydroisoquinoline ring system is key to the exceptional σ2 receptor binding affinity and selectivity of this active series.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqakEVagD56yrVg90H21EOLACvtfcHk0ljmuZEwz3UzAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXktVentbY%253D&md5=31e997afa809148182c5701dd201fadd</span></div><a href="/servlet/linkout?suffix=cit136&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2007.02.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2007.02.005%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DR.%26aulast%3DLever%26aufirst%3DJ.%2BR.%26aulast%3DLever%26aufirst%3DS.%2BZ.%26atitle%3DSynthesis%2520and%2520in%2520vitro%2520evaluation%2520of%2520tetrahydroisoquinolinyl%2520benzamides%2520as%2520ligands%2520for%2520sigma%2520receptors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2007%26volume%3D17%26spage%3D2594%26epage%3D2597%26doi%3D10.1016%2Fj.bmcl.2007.02.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref137"><div class="reference"><strong class="refLabel"><a href="#ref137" class="rightTabRefNumLink">137</a></strong><div class="NLM_citation" id="rightTab-cit137"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rothfuss, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vangveravong, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hotchkiss, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mach, R. H.</span></span> <span> </span><span class="NLM_article-title">Sigma-2 ligands induce tumour cell death by multiple signalling pathways</span>. <i>Br. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>106</i></span>,  <span class="NLM_fpage">693</span>– <span class="NLM_lpage">701</span>, <span class="refDoi"> DOI: 10.1038/bjc.2011.602</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1038%2Fbjc.2011.602" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=22251921" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref137/cit137&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BC38XisVGqtLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2012&pages=693-701&author=C.+Zengauthor=J.+Rothfussauthor=J.+Zhangauthor=W.+Chuauthor=S.+Vangveravongauthor=Z.+Tuauthor=F.+Panauthor=K.+C.+Changauthor=R.+Hotchkissauthor=R.+H.+Mach&title=Sigma-2+ligands+induce+tumour+cell+death+by+multiple+signalling+pathways&doi=10.1038%2Fbjc.2011.602"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit137R"><div class="casContent"><span class="casTitleNuber">137</span><div class="casTitle"><span class="NLM_cas:atitle">Sigma-2 ligands induce tumour cell death by multiple signalling pathways</span></div><div class="casAuthors">Zeng, C.; Rothfuss, J.; Zhang, J.; Chu, W.; Vangveravong, S.; Tu, Z.; Pan, F.; Chang, K. C.; Hotchkiss, R.; Mach, R. H.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">693-701</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The sigma-2 receptor has been identified as a biomarker of proliferating cells in solid tumors.  In the present study, we studied the mechanisms of sigma-2 ligand-induced cell death in the mouse breast cancer cell line EMT-6 and the human melanoma cell line MDA-MB-435.  EMT-6 and MDA-MB-435 cells were treated with sigma-2 ligands.  The modulation of multiple signaling pathways of cell death was evaluated.  Three sigma-2 ligands (WC-26, SV119 and RHM-138) induced DNA fragmentation, caspase-3 activation and PARP-1 cleavage.  The caspase inhibitor Z-VAD-FMK partially blocked DNA fragmentation and cytotoxicity caused by these compds.  These data suggest that sigma-2 ligand-induced apoptosis and caspase activation are partially responsible for the cell death.  WC-26 and siramesine induced formation of vacuoles in the cells.  WC-26, SV119, RHM-138 and siramesine increased the synthesis and processing of microtubule-assocd. protein light chain 3, an autophagosome marker, and decreased the expression levels of the downstream effectors of mammalian target of rapamycin (mTOR), p70S6K and 4EBP1, suggesting that sigma-2 ligands induce autophagy, probably by inhibition of the mTOR pathway.  All four sigma-2 ligands decreased the expression of cyclin D1 in a time-dependent manner.  In addn., WC-26 and SV119 mainly decreased cyclin B1, E2 and phosphorylation of retinoblastoma protein (pRb); RHM-138 mainly decreased cyclin E2; and 10 μ siramesine mainly decreased cyclin B1 and pRb.  These data suggest that sigma-2 ligands also impair cell-cycle progression in multiple phases of the cell cycle.  Sigma-2 ligands induce cell death by multiple signalling pathways.  British Journal of Cancer (2012) 106, 693-701; doi:10.1038/bjc.2011.602 www.bjcancer.com Published online 17 Jan. 2012.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrD3JJVld4hWbVg90H21EOLACvtfcHk0lhnxwk3QBBHlg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XisVGqtLc%253D&md5=2869df85c11d9213eafe6d7082bde86e</span></div><a href="/servlet/linkout?suffix=cit137&amp;dbid=16384&amp;doi=10.1038%2Fbjc.2011.602&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbjc.2011.602%26sid%3Dliteratum%253Aachs%26aulast%3DZeng%26aufirst%3DC.%26aulast%3DRothfuss%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DChu%26aufirst%3DW.%26aulast%3DVangveravong%26aufirst%3DS.%26aulast%3DTu%26aufirst%3DZ.%26aulast%3DPan%26aufirst%3DF.%26aulast%3DChang%26aufirst%3DK.%2BC.%26aulast%3DHotchkiss%26aufirst%3DR.%26aulast%3DMach%26aufirst%3DR.%2BH.%26atitle%3DSigma-2%2520ligands%2520induce%2520tumour%2520cell%2520death%2520by%2520multiple%2520signalling%2520pathways%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2012%26volume%3D106%26spage%3D693%26epage%3D701%26doi%3D10.1038%2Fbjc.2011.602" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref138"><div class="reference"><strong class="refLabel"><a href="#ref138" class="rightTabRefNumLink">138</a></strong><div class="NLM_citation" id="rightTab-cit138"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wheeler, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mach, R. H.</span></span> <span> </span><span class="NLM_article-title">New N-substituted 9-azabicyclo[3.3.1]nonan-3alpha-yl phenylcarbamate analogs as sigma2 receptor ligands: synthesis, in vitro characterization, and evaluation as PET imaging and chemosensitization agents</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">1222</span>– <span class="NLM_lpage">1231</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2008.12.025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1016%2Fj.bmc.2008.12.025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=19119012" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref138/cit138&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtlOht7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2009&pages=1222-1231&author=W.+Chuauthor=J.+Xuauthor=D.+Zhouauthor=F.+Zhangauthor=L.+A.+Jonesauthor=K.+T.+Wheelerauthor=R.+H.+Mach&title=New+N-substituted+9-azabicyclo%5B3.3.1%5Dnonan-3alpha-yl+phenylcarbamate+analogs+as+sigma2+receptor+ligands%3A+synthesis%2C+in+vitro+characterization%2C+and+evaluation+as+PET+imaging+and+chemosensitization+agents&doi=10.1016%2Fj.bmc.2008.12.025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit138R"><div class="casContent"><span class="casTitleNuber">138</span><div class="casTitle"><span class="NLM_cas:atitle">New N-substituted 9-azabicyclo[3.3.1]nonan-3α-yl phenylcarbamate analogs as σ2 receptor ligands: Synthesis, in vitro characterization, and evaluation as PET imaging and chemosensitization agents</span></div><div class="casAuthors">Chu, Wenhua; Xu, Jinbin; Zhou, Dong; Zhang, Fanjie; Jones, Lynne A.; Wheeler, Kenneth T.; Mach, Robert H.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1222-1231</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A series of N-substituted 9-azabicyclo[3.3.1]nonan-3α-yl phenylcarbamate analogs were synthesized.  Among them, WC-26 and WC-59 were identified as the most potent σ2 receptor ligands (Ki = 2.58 and 0.82 nM, resp.) with high selectivity against σ1 (Ki of σ1/σ2 ratio = 557 and 2087, resp.). [18F]WC-59 was radiolabeled via a nucleophilic substitution of a mesylate precursor by [18F]fluoride, and in vitro direct binding studies of [18F]WC-59 were conducted using membrane prepns. from murine EMT-6 solid breast tumors.  The results indicate that [18F]WC-59 binds specifically to σ2 receptors in vitro (Kd = ∼2 nM).  Biodistribution studies of [18F]WC-59 in EMT-6 tumor-bearing mice indicated that the tracer was a less suitable candidate for clin. imaging studies than existing F-18 labeled σ2 receptor ligands.  The ability of WC-26 to enhance the cytotoxic effects of the chemotherapy drug, doxorubicin, was evaluated in cell culture using the mouse breast tumor EMT-6 and the human tumor MDA-MB435.  WC-26 greatly increased the ability of doxorubicin to kill these two tumor cell lines in vitro.  These results indicate that WC-26 is potentially a useful chemosensitizer for the treatment of cancer when combined with conventional chemotherapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqcNkdxZdeDmbVg90H21EOLACvtfcHk0lhnxwk3QBBHlg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtlOht7o%253D&md5=164a5c8a7e81d14338e3981d317d417b</span></div><a href="/servlet/linkout?suffix=cit138&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2008.12.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2008.12.025%26sid%3Dliteratum%253Aachs%26aulast%3DChu%26aufirst%3DW.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DZhou%26aufirst%3DD.%26aulast%3DZhang%26aufirst%3DF.%26aulast%3DJones%26aufirst%3DL.%2BA.%26aulast%3DWheeler%26aufirst%3DK.%2BT.%26aulast%3DMach%26aufirst%3DR.%2BH.%26atitle%3DNew%2520N-substituted%25209-azabicyclo%255B3.3.1%255Dnonan-3alpha-yl%2520phenylcarbamate%2520analogs%2520as%2520sigma2%2520receptor%2520ligands%253A%2520synthesis%252C%2520in%2520vitro%2520characterization%252C%2520and%2520evaluation%2520as%2520PET%2520imaging%2520and%2520chemosensitization%2520agents%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2009%26volume%3D17%26spage%3D1222%26epage%3D1231%26doi%3D10.1016%2Fj.bmc.2008.12.025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref139"><div class="reference"><strong class="refLabel"><a href="#ref139" class="rightTabRefNumLink">139</a></strong><div class="NLM_citation" id="rightTab-cit139"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Azzariti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colabufo, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berardi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porcelli, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niso, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simone, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perrone, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paradiso, A.</span></span> <span> </span><span class="NLM_article-title">Cyclohexylpiperazine derivative PB28, a sigma2 agonist and sigma1 antagonist receptor, inhibits cell growth, modulates P-glycoprotein, and synergizes with anthracyclines in breast cancer</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">1807</span>– <span class="NLM_lpage">1816</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-05-0402</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1158%2F1535-7163.MCT-05-0402" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=16891467" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref139/cit139&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BD28XnslWksbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2006&pages=1807-1816&author=A.+Azzaritiauthor=N.+A.+Colabufoauthor=F.+Berardiauthor=L.+Porcelliauthor=M.+Nisoauthor=G.+M.+Simoneauthor=R.+Perroneauthor=A.+Paradiso&title=Cyclohexylpiperazine+derivative+PB28%2C+a+sigma2+agonist+and+sigma1+antagonist+receptor%2C+inhibits+cell+growth%2C+modulates+P-glycoprotein%2C+and+synergizes+with+anthracyclines+in+breast+cancer&doi=10.1158%2F1535-7163.MCT-05-0402"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit139R"><div class="casContent"><span class="casTitleNuber">139</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclohexylpiperazine derivative PB28, a σ2 agonist and σ1 antagonist receptor, inhibits cell growth, modulates P-glycoprotein, and synergizes with anthracyclines in breast cancer</span></div><div class="casAuthors">Azzariti, Amalia; Colabufo, Nicola A.; Berardi, Francesco; Porcelli, Letizia; Niso, Mauro; Simone, Grazia M.; Perrone, Roberto; Paradiso, Angelo</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1807-1816</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">σ Ligands have recently been shown to have cytotoxic activity, to induce ceramide-dependent/caspase-independent apoptosis, and to down-regulate P-glycoprotein (P-gp) mRNA levels in some mouse and human models.  In this study, we verified whether a mixed σ2 agonist/σ1 antagonist, PB28, was able to have antitumor activity and to enhance anthracycline efficacy in two human breast cancer cell lines, MCF7 and MCF7 ADR, both characterized by significant σ2 receptor expression, by high and low σ1 receptor expression, and low and high P-gp expression, resp.  In both cell lines, PB28 showed high σ2 receptor affinity and low σ1 receptor affinity; furthermore, it inhibited cell growth with a clear effect at 48 h (IC50 in nanomolar range), a consistent time exposure-independent increase of G0-G1-phase fraction (of ∼20% of both cell lines) and caspase-independent apoptosis (15% increased after 1-day drug exposure).  PB28 also reduced P-gp expression in a concn.- and time-dependent manner (∼60% in MCF7 and 90% in MCF7 ADR).  We showed also a strong synergism between PB28 and doxorubicin by adopting either simultaneous or sequential schedules of the two drugs.  We suggest that this synergism could depend on PB28-induced increase of intracellular accumulation of doxorubicin (∼50% in MCF7 and 75% in MCF7 ADR by flow cytometry anal.).  In conclusion, we suggest that the σ2 agonist PB28 could be an interesting antitumor agent either in monotherapy or in combination with conventional drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPbEQT82-rDrVg90H21EOLACvtfcHk0lhnxwk3QBBHlg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XnslWksbo%253D&md5=a0581c8aec111a6474b1b041d916bcf5</span></div><a href="/servlet/linkout?suffix=cit139&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-05-0402&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-05-0402%26sid%3Dliteratum%253Aachs%26aulast%3DAzzariti%26aufirst%3DA.%26aulast%3DColabufo%26aufirst%3DN.%2BA.%26aulast%3DBerardi%26aufirst%3DF.%26aulast%3DPorcelli%26aufirst%3DL.%26aulast%3DNiso%26aufirst%3DM.%26aulast%3DSimone%26aufirst%3DG.%2BM.%26aulast%3DPerrone%26aufirst%3DR.%26aulast%3DParadiso%26aufirst%3DA.%26atitle%3DCyclohexylpiperazine%2520derivative%2520PB28%252C%2520a%2520sigma2%2520agonist%2520and%2520sigma1%2520antagonist%2520receptor%252C%2520inhibits%2520cell%2520growth%252C%2520modulates%2520P-glycoprotein%252C%2520and%2520synergizes%2520with%2520anthracyclines%2520in%2520breast%2520cancer%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2006%26volume%3D5%26spage%3D1807%26epage%3D1816%26doi%3D10.1158%2F1535-7163.MCT-05-0402" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref140"><div class="reference"><strong class="refLabel"><a href="#ref140" class="rightTabRefNumLink">140</a></strong><div class="NLM_citation" id="rightTab-cit140"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dence, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ponde, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wheeler, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Welch, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mach, R. H.</span></span> <span> </span><span class="NLM_article-title">Carbon-11 labeled sigma2 receptor ligands for imaging breast cancer</span>. <i>Nucl. Med. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">423</span>– <span class="NLM_lpage">430</span>, <span class="refDoi"> DOI: 10.1016/j.nucmedbio.2005.03.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1016%2Fj.nucmedbio.2005.03.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=15982571" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref140/cit140&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BD2MXlvVWmtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2005&pages=423-430&author=Z.+Tuauthor=C.+S.+Denceauthor=D.+E.+Pondeauthor=L.+Jonesauthor=K.+T.+Wheelerauthor=M.+J.+Welchauthor=R.+H.+Mach&title=Carbon-11+labeled+sigma2+receptor+ligands+for+imaging+breast+cancer&doi=10.1016%2Fj.nucmedbio.2005.03.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit140R"><div class="casContent"><span class="casTitleNuber">140</span><div class="casTitle"><span class="NLM_cas:atitle">Carbon-11 labeled σ2 receptor ligands for imaging breast cancer</span></div><div class="casAuthors">Tu, Zhude; Dence, Carmen S.; Ponde, Datta E.; Jones, Lynne; Wheeler, Kenneth T.; Welch, Michael J.; Mach, Robert H.</div><div class="citationInfo"><span class="NLM_cas:title">Nuclear Medicine and Biology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">423-430</span>CODEN:
                <span class="NLM_cas:coden">NMBIEO</span>;
        ISSN:<span class="NLM_cas:issn">0969-8051</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Four conformationally flexible benzamide analogs having a high affinity and outstanding selectivity for σ 2 vs. σ 1 receptors were synthesized and radiolabeled with carbon-11 by reaction with [11C]methyl iodide.  The four 11C-labeled radiotracers were evaluated for their potential to image the proliferative status of breast tumors with positron emission tomog. (PET).  In vivo studies in female BALB/C mice bearing EMT-6 breast tumors showed that one radiotracer, (2-methoxy-11C)-N-(4-(3,4-dihydro-6,7-dimethoxy-isoquinolin-2(1H)-yl)butyl)-5-methylbenzamide ([11C]2), had a high tumor uptake and suitable tumor/background ratio for imaging purposes.  Blocking studies were consistent with the labeling of σ 2 receptors in vivo.  A study comparing the in vivo properties of [11C]2 and 18F-3'-fluoro-3'-deoxy-L-thymidine ([18F]FLT) indicated that [11C]2 had either similar (lung, fat) or better (blood, muscle) tumor/organ ratios than [18F]FLT in the tissues that are important for breast tumor imaging.  Consequently, [11C]2 is a potential radiotracer for imaging the proliferative status of breast tumors in vivo with PET.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkQua1-WPjULVg90H21EOLACvtfcHk0lifb_64LYj1aA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXlvVWmtbw%253D&md5=2dc5b04da294d92bef1f5511d6e5054c</span></div><a href="/servlet/linkout?suffix=cit140&amp;dbid=16384&amp;doi=10.1016%2Fj.nucmedbio.2005.03.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.nucmedbio.2005.03.008%26sid%3Dliteratum%253Aachs%26aulast%3DTu%26aufirst%3DZ.%26aulast%3DDence%26aufirst%3DC.%2BS.%26aulast%3DPonde%26aufirst%3DD.%2BE.%26aulast%3DJones%26aufirst%3DL.%26aulast%3DWheeler%26aufirst%3DK.%2BT.%26aulast%3DWelch%26aufirst%3DM.%2BJ.%26aulast%3DMach%26aufirst%3DR.%2BH.%26atitle%3DCarbon-11%2520labeled%2520sigma2%2520receptor%2520ligands%2520for%2520imaging%2520breast%2520cancer%26jtitle%3DNucl.%2520Med.%2520Biol.%26date%3D2005%26volume%3D32%26spage%3D423%26epage%3D430%26doi%3D10.1016%2Fj.nucmedbio.2005.03.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref141"><div class="reference"><strong class="refLabel"><a href="#ref141" class="rightTabRefNumLink">141</a></strong><div class="NLM_citation" id="rightTab-cit141"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Matsumoto, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lerner, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Howard, E. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brackett, D. J.</span></span> <span> </span><span class="NLM_article-title">Sigma receptors: potential medications development target for anti-cocaine agents</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>469</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">12</span>, <span class="refDoi"> DOI: 10.1016/S0014-2999(03)01723-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1016%2FS0014-2999%2803%2901723-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=12782179" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref141/cit141&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BD3sXktFGltLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=469&publication_year=2003&pages=1-12&author=R.+R.+Matsumotoauthor=Y.+Liuauthor=M.+Lernerauthor=E.+W.+Howardauthor=D.+J.+Brackett&title=Sigma+receptors%3A+potential+medications+development+target+for+anti-cocaine+agents&doi=10.1016%2FS0014-2999%2803%2901723-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit141R"><div class="casContent"><span class="casTitleNuber">141</span><div class="casTitle"><span class="NLM_cas:atitle">σ Receptors: potential medications development target for anti-cocaine agents</span></div><div class="casAuthors">Matsumoto, Rae R.; Liu, Yun; Lerner, Megan; Howard, Eric W.; Brackett, Daniel J.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">469</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">1-12</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">A review.  The ability of cocaine to interact with σ receptors suggests a viable target for medications development.  Recently, numerous novel compds. and antisense oligodeoxynucleotides targeting σ receptors have been synthesized and shown to prevent the behavioral toxicity and psychomotor stimulant effects of cocaine in animals.  Protective doses of σ receptor antagonists have also been shown to prevent changes in gene expression that are induced by cocaine.  Together, the studies provide insight and promising future directions for the development of potential medications for the treatment of cocaine addiction and overdose.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoyVIAeqL1jAbVg90H21EOLACvtfcHk0lj2L5zKOJ0m5w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXktFGltLk%253D&md5=cda4068319c69e00726295a4b19f00fa</span></div><a href="/servlet/linkout?suffix=cit141&amp;dbid=16384&amp;doi=10.1016%2FS0014-2999%2803%2901723-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0014-2999%252803%252901723-0%26sid%3Dliteratum%253Aachs%26aulast%3DMatsumoto%26aufirst%3DR.%2BR.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DLerner%26aufirst%3DM.%26aulast%3DHoward%26aufirst%3DE.%2BW.%26aulast%3DBrackett%26aufirst%3DD.%2BJ.%26atitle%3DSigma%2520receptors%253A%2520potential%2520medications%2520development%2520target%2520for%2520anti-cocaine%2520agents%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2003%26volume%3D469%26spage%3D1%26epage%3D12%26doi%3D10.1016%2FS0014-2999%2803%2901723-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref142"><div class="reference"><strong class="refLabel"><a href="#ref142" class="rightTabRefNumLink">142</a></strong><div class="NLM_citation" id="rightTab-cit142"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mach, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">West, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whirrett, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Childers, S. R.</span></span> <span> </span><span class="NLM_article-title">The analgesic tropane analogue (±)-SM 21 has a high affinity for sigma2 receptors</span>. <i>Life Sci.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">PL131</span>– <span class="NLM_lpage">7</span>, <span class="refDoi"> DOI: 10.1016/S0024-3205(99)00014-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1016%2FS0024-3205%2899%2900014-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref142/cit142&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10096443" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=1999&pages=PL131-7&author=R.+H.+Machauthor=L.+Wuauthor=T.+Westauthor=B.+R.+Whirrettauthor=S.+R.+Childers&title=The+analgesic+tropane+analogue+%28%C2%B1%29-SM+21+has+a+high+affinity+for+sigma2+receptors&doi=10.1016%2FS0024-3205%2899%2900014-4"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit142&amp;dbid=16384&amp;doi=10.1016%2FS0024-3205%2899%2900014-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0024-3205%252899%252900014-4%26sid%3Dliteratum%253Aachs%26aulast%3DMach%26aufirst%3DR.%2BH.%26aulast%3DWu%26aufirst%3DL.%26aulast%3DWest%26aufirst%3DT.%26aulast%3DWhirrett%26aufirst%3DB.%2BR.%26aulast%3DChilders%26aufirst%3DS.%2BR.%26atitle%3DThe%2520analgesic%2520tropane%2520analogue%2520%2528%25C2%25B1%2529-SM%252021%2520has%2520a%2520high%2520affinity%2520for%2520sigma2%2520receptors%26jtitle%3DLife%2520Sci.%26date%3D1999%26volume%3D64%26spage%3DPL131%26epage%3D7%26doi%3D10.1016%2FS0024-3205%2899%2900014-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref143"><div class="reference"><strong class="refLabel"><a href="#ref143" class="rightTabRefNumLink">143</a></strong><div class="NLM_citation" id="rightTab-cit143"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vangveravong, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mach, R. H.</span></span> <span> </span><span class="NLM_article-title">Synthesis of N-substituted 9-azabicyclo[3.3.1]nonan-3alpha-yl carbamate analogs as sigma2 receptor ligands</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">6988</span>– <span class="NLM_lpage">6997</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2006.06.028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1016%2Fj.bmc.2006.06.028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=16837201" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref143/cit143&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BD28XptFSksb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2006&pages=6988-6997&author=S.+Vangveravongauthor=J.+Xuauthor=C.+Zengauthor=R.+H.+Mach&title=Synthesis+of+N-substituted+9-azabicyclo%5B3.3.1%5Dnonan-3alpha-yl+carbamate+analogs+as+sigma2+receptor+ligands&doi=10.1016%2Fj.bmc.2006.06.028"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit143R"><div class="casContent"><span class="casTitleNuber">143</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of N-substituted 9-azabicyclo[3.3.1]nonan-3α-yl carbamate analogs as σ2 receptor ligands</span></div><div class="casAuthors">Vangveravong, Suwanna; Xu, Jinbin; Zeng, Chenbo; Mach, Robert H.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">6988-6997</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A series of N-substituted 9-azabicyclo[3.3.1]nonan-3α-yl phenylcarbamates was prepd. and their affinities for sigma (σ1 and σ2) receptors were measured in vitro.  The results of their structure-activity relationship study identified two new compds., N-(9-(4-aminobutyl)-9-azabicyclo[3.3.1]nonan-3α-yl)-N'-(2-methoxy-5-methylphenyl)carbamate and N-(9-(6-aminohexyl)-9-azabicyclo[3.3.1]nonan-3α-yl)-N'-(2-methoxy-5-methylphenyl)carbamate, having a high affinity and selectivity for σ2 vs. σ1 receptors.  These compds. were also used in the prepn. of biotinylated and fluorescent probes of the σ2 receptor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqXF8zYVhnm77Vg90H21EOLACvtfcHk0lj2L5zKOJ0m5w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XptFSksb4%253D&md5=47e29a60b0fcac2e986cec05be628ef8</span></div><a href="/servlet/linkout?suffix=cit143&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2006.06.028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2006.06.028%26sid%3Dliteratum%253Aachs%26aulast%3DVangveravong%26aufirst%3DS.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DZeng%26aufirst%3DC.%26aulast%3DMach%26aufirst%3DR.%2BH.%26atitle%3DSynthesis%2520of%2520N-substituted%25209-azabicyclo%255B3.3.1%255Dnonan-3alpha-yl%2520carbamate%2520analogs%2520as%2520sigma2%2520receptor%2520ligands%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2006%26volume%3D14%26spage%3D6988%26epage%3D6997%26doi%3D10.1016%2Fj.bmc.2006.06.028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref144"><div class="reference"><strong class="refLabel"><a href="#ref144" class="rightTabRefNumLink">144</a></strong><div class="NLM_citation" id="rightTab-cit144"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hornick, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vangveravong, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitchem, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spitzer, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goedegebuure, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mach, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hawkins, W. G.</span></span> <span> </span><span class="NLM_article-title">The novel sigma-2 receptor ligand SW43 stabilizes pancreas cancer progression in combination with gemcitabine</span>. <i>Mol. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">298</span>, <span class="refDoi"> DOI: 10.1186/1476-4598-9-298</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1186%2F1476-4598-9-298" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=21092190" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref144/cit144&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsF2hs7vL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=298&author=J.+R.+Hornickauthor=J.+Xuauthor=S.+Vangveravongauthor=Z.+Tuauthor=J.+B.+Mitchemauthor=D.+Spitzerauthor=P.+Goedegebuureauthor=R.+H.+Machauthor=W.+G.+Hawkins&title=The+novel+sigma-2+receptor+ligand+SW43+stabilizes+pancreas+cancer+progression+in+combination+with+gemcitabine&doi=10.1186%2F1476-4598-9-298"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit144R"><div class="casContent"><span class="casTitleNuber">144</span><div class="casTitle"><span class="NLM_cas:atitle">The novel sigma-2 receptor ligand SW43 stabilizes pancreas cancer progression in combination with gemcitabine</span></div><div class="casAuthors">Hornick, John R.; Xu, Jinbin; Vangveravong, Suwanna; Tu, Zhude; Mitchem, Jonathan B.; Spitzer, Dirk; Goedegebuure, Peter; Mach, Robert H.; Hawkins, William G.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">298</span>CODEN:
                <span class="NLM_cas:coden">MCOACG</span>;
        ISSN:<span class="NLM_cas:issn">1476-4598</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Background: Sigma-2 receptors are over-expressed in proliferating cancer cells, making an attractive target for the targeted treatment of pancreatic cancer.  In this study, we investigated the role of the novel sigma-2 receptor ligand SW43 to induce apoptosis and augment std. chemotherapy.  Results: The binding affinity for sigma-2 ligands is high in pancreas cancer, and they induce apoptosis with a rank order of SV119 < SW43 < SRM in vitro.  Combining these compds. with gemcitabine further increased apoptosis and decreased viability.  Our in vivo model showed that sigma-2 ligand treatment decreased tumor vol. to the same extent as gemcitabine.  However, SW43 combination treatment with gemcitabine was superior to the other compds. and resulted in stabilization of tumor vol. during treatment, with minimal toxicities.  Conclusions: This study shows that the sigma-2 ligand SW43 has the greatest capacity to augment gemcitabine in a pre-clin. model of pancreas cancer and has provided us with the rationale to move this compd. forward with clin. investigations for patients with pancreatic cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7apBSRKE1DrVg90H21EOLACvtfcHk0lhFSSAO5AMphQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsF2hs7vL&md5=ff30e331ee6e3d4890f5b1fa01f86251</span></div><a href="/servlet/linkout?suffix=cit144&amp;dbid=16384&amp;doi=10.1186%2F1476-4598-9-298&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1476-4598-9-298%26sid%3Dliteratum%253Aachs%26aulast%3DHornick%26aufirst%3DJ.%2BR.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DVangveravong%26aufirst%3DS.%26aulast%3DTu%26aufirst%3DZ.%26aulast%3DMitchem%26aufirst%3DJ.%2BB.%26aulast%3DSpitzer%26aufirst%3DD.%26aulast%3DGoedegebuure%26aufirst%3DP.%26aulast%3DMach%26aufirst%3DR.%2BH.%26aulast%3DHawkins%26aufirst%3DW.%2BG.%26atitle%3DThe%2520novel%2520sigma-2%2520receptor%2520ligand%2520SW43%2520stabilizes%2520pancreas%2520cancer%2520progression%2520in%2520combination%2520with%2520gemcitabine%26jtitle%3DMol.%2520Cancer%26date%3D2010%26volume%3D9%26spage%3D298%26doi%3D10.1186%2F1476-4598-9-298" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref145"><div class="reference"><strong class="refLabel"><a href="#ref145" class="rightTabRefNumLink">145</a></strong><div class="NLM_citation" id="rightTab-cit145"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vangveravong, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hyrc, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, K. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rothfuss, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldberg, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hotchkiss, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mach, R. H.</span></span> <span> </span><span class="NLM_article-title">Characterization and evaluation of two novel fluorescent sigma-2 receptor ligands as proliferation probes</span>. <i>Mol. Imaging</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">420</span>– <span class="NLM_lpage">433</span>, <span class="refDoi"> DOI: 10.2310/7290.2011.00009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.2310%2F7290.2011.00009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=22201533" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref145/cit145&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BC38XitlGnsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=420-433&author=C.+Zengauthor=S.+Vangveravongauthor=L.+A.+Jonesauthor=K.+Hyrcauthor=K.+C.+Changauthor=J.+Xuauthor=J.+M.+Rothfussauthor=M.+P.+Goldbergauthor=R.+S.+Hotchkissauthor=R.+H.+Mach&title=Characterization+and+evaluation+of+two+novel+fluorescent+sigma-2+receptor+ligands+as+proliferation+probes&doi=10.2310%2F7290.2011.00009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit145R"><div class="casContent"><span class="casTitleNuber">145</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization and evaluation of two novel fluorescent sigma-2 receptor ligands as proliferation probes</span></div><div class="casAuthors">Zeng, Chenbo; Vangveravong, Suwanna; Jones, Lynne A.; Hyrc, Krzystof; Chang, Katherine C.; Xu, Jinbin; Rothfuss, Justin M.; Goldberg, Mark P.; Hotchkiss, Richard S.; Mach, Robert H.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Imaging</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">420-433</span>CODEN:
                <span class="NLM_cas:coden">MIOMBP</span>;
        ISSN:<span class="NLM_cas:issn">1535-3508</span>.
    
            (<span class="NLM_cas:orgname">Decker Publishing</span>)
        </div><div class="casAbstract">We synthesized and characterized two novel fluorescent sigma-2 receptor selective ligands, SW120 and SW116, and evaluated these ligands as potential probes for imaging cell proliferation.  Both ligands are highly selective for sigma-2 receptors vs. sigma-1 receptors.  SW120 and SW116 were internalized into MDA-MB-435 cells, and 50% of the max. fluorescent intensity was reached in 11 and 24 min, resp.  In vitro studies showed that 50% of SW120 or SW116 washed out of cells in 1 h.  The internalization of SW120 was reduced ≈30% by phenylarsine oxide, an inhibitor of endocytosis, suggesting that sigma-2 ligands are internalized, in part, by an endocytotic pathway.  Subcellular localization studies using confocal and two-photon microscopy showed that SW120 and SW116 partially colocalized with fluorescent markers of mitochondria, endoplasmic reticulum, lysosomes, and the plasma membrane, suggesting that sigma-2 receptors localized to the cytoplasmic organelles and plasma membrane.  SW120 did not colocalize with the nuclear dye 4',6-diamidino-2-phenylindole.  In vivo studies showed that the uptake of SW120 in solid tumors and peripheral blood mononuclear cells of mice pos. correlated with the expression level of the cell proliferation marker Ki-67, suggesting that sigma-2 fluorescent probes may be used to image cell proliferation in mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpP5AnDOdYA4rVg90H21EOLACvtfcHk0lhFSSAO5AMphQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XitlGnsr8%253D&md5=4887fd2cbf00e42c7c4fb719ca4f4192</span></div><a href="/servlet/linkout?suffix=cit145&amp;dbid=16384&amp;doi=10.2310%2F7290.2011.00009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2310%252F7290.2011.00009%26sid%3Dliteratum%253Aachs%26aulast%3DZeng%26aufirst%3DC.%26aulast%3DVangveravong%26aufirst%3DS.%26aulast%3DJones%26aufirst%3DL.%2BA.%26aulast%3DHyrc%26aufirst%3DK.%26aulast%3DChang%26aufirst%3DK.%2BC.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DRothfuss%26aufirst%3DJ.%2BM.%26aulast%3DGoldberg%26aufirst%3DM.%2BP.%26aulast%3DHotchkiss%26aufirst%3DR.%2BS.%26aulast%3DMach%26aufirst%3DR.%2BH.%26atitle%3DCharacterization%2520and%2520evaluation%2520of%2520two%2520novel%2520fluorescent%2520sigma-2%2520receptor%2520ligands%2520as%2520proliferation%2520probes%26jtitle%3DMol.%2520Imaging%26date%3D2011%26volume%3D10%26spage%3D420%26epage%3D433%26doi%3D10.2310%2F7290.2011.00009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref146"><div class="reference"><strong class="refLabel"><a href="#ref146" class="rightTabRefNumLink">146</a></strong><div class="NLM_citation" id="rightTab-cit146"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vangveravong, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDunn, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hawkins, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mach, R. H.</span></span> <span> </span><span class="NLM_article-title">Sigma-2 receptor ligand as a novel method for delivering a SMAC mimetic drug for treating ovarian cancer</span>. <i>Br. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>109</i></span>,  <span class="NLM_fpage">2368</span>– <span class="NLM_lpage">2377</span>, <span class="refDoi"> DOI: 10.1038/bjc.2013.593</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1038%2Fbjc.2013.593" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=24104966" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref146/cit146&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsFyntbfK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2013&pages=2368-2377&author=C.+Zengauthor=S.+Vangveravongauthor=J.+E.+McDunnauthor=W.+G.+Hawkinsauthor=R.+H.+Mach&title=Sigma-2+receptor+ligand+as+a+novel+method+for+delivering+a+SMAC+mimetic+drug+for+treating+ovarian+cancer&doi=10.1038%2Fbjc.2013.593"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit146R"><div class="casContent"><span class="casTitleNuber">146</span><div class="casTitle"><span class="NLM_cas:atitle">Sigma-2 receptor ligand as a novel method for delivering a SMAC mimetic drug for treating ovarian cancer</span></div><div class="casAuthors">Zeng, C.; Vangveravong, S.; McDunn, J. E.; Hawkins, W. G.; Mach, R. H.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2368-2377</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Background: The sigma-2 receptor has been validated as a biomarker for proliferating tumors.  Second mitochondria-derived activator of caspase (Smac) is a protein released from mitochondria into the cytosol, leading to apoptosis.  In this study, we investigated a sigma-2 ligand as a tumor-targeting drug delivery agent for treating ovarian cancer.  Methods: A sigma-2 ligand, SW 43, was conjugated with a Smac mimetic compd. (SMC), SW IV-52s, to form SW III-123.  The delivery function of the sigma-2 moiety and cell killing mechanisms of SW III-123 were examd. in human ovarian cancer cell lines.  Results: SW III-123 internalization into ovarian cancer cells was mediated by sigma-2 receptors.  SW III-123, but not SW IV-52s or SW 43, exhibited potent cytotoxicity in human ovarian cancer cell lines SKOV-3, CaOV-3 and BG-1 after 24-h treatment, suggesting that the sigma-2 ligand successfully delivered SMC into ovarian cancer cells.  SW III-123 induced rapid degrdn. of inhibitor of apoptosis proteins (cIAP1 and cIAP2), accumulation of NF-κB-inducing kinase (NIK) and phosphorylation of NF-κB p65, suggesting that SW III-123 activated both canonical and noncanonical NF-κB pathways in SKOV-3 cells.  SW III-123 cleaved caspase-8, -9 and -3.  Tumor necrosis factor alpha (TNFα) antibody markedly blocked SW III-123-induced cell death and caspase-3 activity in SKOV-3 cells, indicating that SW III-123 activated both intrinsic and extrinsic apoptotic pathways and induced TNFα-dependent cell death in SKOV-3 cells.  Conclusion: Sigma-2 ligands are a promising tumor-targeting drug delivery agent.  Sigma-2-conjugated SMC exemplifies a novel class of therapeutic drugs for treating ovarian cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrvRumJqiAfb7Vg90H21EOLACvtfcHk0lhFSSAO5AMphQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsFyntbfK&md5=d2f329d307adab71704872279f034320</span></div><a href="/servlet/linkout?suffix=cit146&amp;dbid=16384&amp;doi=10.1038%2Fbjc.2013.593&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbjc.2013.593%26sid%3Dliteratum%253Aachs%26aulast%3DZeng%26aufirst%3DC.%26aulast%3DVangveravong%26aufirst%3DS.%26aulast%3DMcDunn%26aufirst%3DJ.%2BE.%26aulast%3DHawkins%26aufirst%3DW.%2BG.%26aulast%3DMach%26aufirst%3DR.%2BH.%26atitle%3DSigma-2%2520receptor%2520ligand%2520as%2520a%2520novel%2520method%2520for%2520delivering%2520a%2520SMAC%2520mimetic%2520drug%2520for%2520treating%2520ovarian%2520cancer%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2013%26volume%3D109%26spage%3D2368%26epage%3D2377%26doi%3D10.1038%2Fbjc.2013.593" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref147"><div class="reference"><strong class="refLabel"><a href="#ref147" class="rightTabRefNumLink">147</a></strong><div class="NLM_citation" id="rightTab-cit147"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Banister, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoo, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chua, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mach, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kassiou, M.</span></span> <span> </span><span class="NLM_article-title">N-Arylalkyl-2-azaadamantanes as cage-expanded polycarbocyclic sigma (σ) receptor ligands</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">5289</span>– <span class="NLM_lpage">5292</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2011.07.028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1016%2Fj.bmcl.2011.07.028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=21788137" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref147/cit147&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtVKisrfK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=5289-5292&author=S.+D.+Banisterauthor=D.+T.+Yooauthor=S.+W.+Chuaauthor=J.+Cuiauthor=R.+H.+Machauthor=M.+Kassiou&title=N-Arylalkyl-2-azaadamantanes+as+cage-expanded+polycarbocyclic+sigma+%28%CF%83%29+receptor+ligands&doi=10.1016%2Fj.bmcl.2011.07.028"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit147R"><div class="casContent"><span class="casTitleNuber">147</span><div class="casTitle"><span class="NLM_cas:atitle">N-Arylalkyl-2-azaadamantanes as cage-expanded polycarbocyclic sigma (σ) receptor ligands</span></div><div class="casAuthors">Banister, Samuel D.; Yoo, David T.; Chua, Sook Wern; Cui, Jinquan; Mach, Robert H.; Kassiou, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">5289-5292</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A series of racemic N-arylalkyl-2-azaadamantan-1-ols and the corresponding deoxygenated, achiral N-arylalkyl-2-azaadamantanes were synthesized and screened in competition binding assays against a panel of CNS targets.  Adamantyl hemiaminals (i.e., N-arylalkyl-2-azaadamantan-1-ols) displayed generally low affinity for both σ1 (Ki values = 294-1950 nM) and σ2 receptors (Ki values = 201-1020 nM), and negligible affinity for 42 other CNS proteins.  Deoxygenation of N-arylalkyl-2-azaadamantan-1-ols to give the corresponding achiral azaadamantanes N-arylalkyl-2-azaadamantanes greatly improved affinity for σ1 (Ki values = 8.3-239 nM) and σ2 receptors (Ki values = 34-312 nM).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTyzjKlJvqgLVg90H21EOLACvtfcHk0liIUxMLMSEJVQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtVKisrfK&md5=74c53cfd1870fbcc72d6345367ad26de</span></div><a href="/servlet/linkout?suffix=cit147&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2011.07.028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2011.07.028%26sid%3Dliteratum%253Aachs%26aulast%3DBanister%26aufirst%3DS.%2BD.%26aulast%3DYoo%26aufirst%3DD.%2BT.%26aulast%3DChua%26aufirst%3DS.%2BW.%26aulast%3DCui%26aufirst%3DJ.%26aulast%3DMach%26aufirst%3DR.%2BH.%26aulast%3DKassiou%26aufirst%3DM.%26atitle%3DN-Arylalkyl-2-azaadamantanes%2520as%2520cage-expanded%2520polycarbocyclic%2520sigma%2520%2528%25CF%2583%2529%2520receptor%2520ligands%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D21%26spage%3D5289%26epage%3D5292%26doi%3D10.1016%2Fj.bmcl.2011.07.028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref148"><div class="reference"><strong class="refLabel"><a href="#ref148" class="rightTabRefNumLink">148</a></strong><div class="NLM_citation" id="rightTab-cit148"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Peeters, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romieu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maurice, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maloteaux, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hermans, E.</span></span> <span> </span><span class="NLM_article-title">Involvement of the sigma 1 receptor in the modulation of dopaminergic transmission by amantadine</span>. <i>Eur. J. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">2212</span>– <span class="NLM_lpage">2220</span>, <span class="refDoi"> DOI: 10.1111/j.0953-816X.2004.03297.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1111%2Fj.0953-816X.2004.03297.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=15090047" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref148/cit148&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A280%3ADC%252BD2c7ps1Crsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2004&pages=2212-2220&author=M.+Peetersauthor=P.+Romieuauthor=T.+Mauriceauthor=T.+P.+Suauthor=J.+M.+Maloteauxauthor=E.+Hermans&title=Involvement+of+the+sigma+1+receptor+in+the+modulation+of+dopaminergic+transmission+by+amantadine&doi=10.1111%2Fj.0953-816X.2004.03297.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit148R"><div class="casContent"><span class="casTitleNuber">148</span><div class="casTitle"><span class="NLM_cas:atitle">Involvement of the sigma 1 receptor in the modulation of dopaminergic transmission by amantadine</span></div><div class="casAuthors">Peeters Magali; Romieu Pascal; Maurice Tangui; Su Tsung-Ping; Maloteaux Jean-Marie; Hermans Emmanuel</div><div class="citationInfo"><span class="NLM_cas:title">The European journal of neuroscience</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2212-20</span>
        ISSN:<span class="NLM_cas:issn">0953-816X</span>.
    </div><div class="casAbstract">Pharmacological effects of amantadine on dopaminergic transmission are proposed to result from an uncompetitive antagonism at glutamate N-methyl-D-aspartate (NMDA) receptors.  However, our previous studies examining amantadine-mediated dopamine receptor regulation in the rat striatum revealed a discrepancy from a direct interference with glutamate transmission.  Preliminary in vitro binding data from the literature suggested the interaction of amantadine with the sigma1 receptor.  Therefore, we have now further characterized the pharmacological properties of amantadine and memantine at this receptor and investigated its involvement in the modulation of striatal dopaminergic transmission.  Our binding studies using [3H]-(+)SKF-10,047 indicated that amantadine and memantine behave as ligands of the sigma(1) receptor in rat forebrain homogenates (Ki values of 7.44 +/- 0.82 and 2.60 +/- 0.62 microm, respectively).  In NG108-15 neuroblastoma cells, both drugs (amantadine (100 microm) and memantine (10 microm)) potentiated the bradykinin-induced mobilization of intracellular Ca2+, mimicking the effect of the sigma1 receptor agonist PRE-084 (1 microm).  Finally, we previously showed that in striatal membranes from amantadine-treated rats, the functional coupling of dopamine receptors with G-proteins was enhanced.  Similarly, PRE-084 dose-dependently increased the [35S]GTPgammaS binding induced by dopamine (Emax 28 and 26% of basal, 0.3 and 1 mg/kg PRE-084, respectively).  By contrast, BD1047, which is without effect on its own, antagonized the effects of amantadine and PRE-084.  Together, these data demonstrate that aminoadamantanes behave as sigma1 receptor agonists, and confirm an involvement of this receptor in modulating dopamine receptors exerted by therapeutically relevant concentrations of amantadine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR6D1GR30Lj8xpyrDyM_m9cfW6udTcc2eb5YQIGPJlD4bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2c7ps1Crsg%253D%253D&md5=d616f11a3001addf47ace0c12fa9884a</span></div><a href="/servlet/linkout?suffix=cit148&amp;dbid=16384&amp;doi=10.1111%2Fj.0953-816X.2004.03297.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.0953-816X.2004.03297.x%26sid%3Dliteratum%253Aachs%26aulast%3DPeeters%26aufirst%3DM.%26aulast%3DRomieu%26aufirst%3DP.%26aulast%3DMaurice%26aufirst%3DT.%26aulast%3DSu%26aufirst%3DT.%2BP.%26aulast%3DMaloteaux%26aufirst%3DJ.%2BM.%26aulast%3DHermans%26aufirst%3DE.%26atitle%3DInvolvement%2520of%2520the%2520sigma%25201%2520receptor%2520in%2520the%2520modulation%2520of%2520dopaminergic%2520transmission%2520by%2520amantadine%26jtitle%3DEur.%2520J.%2520Neurosci.%26date%3D2004%26volume%3D19%26spage%3D2212%26epage%3D2220%26doi%3D10.1111%2Fj.0953-816X.2004.03297.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref149"><div class="reference"><strong class="refLabel"><a href="#ref149" class="rightTabRefNumLink">149</a></strong><div class="NLM_citation" id="rightTab-cit149"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marrazzo, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prezzavento, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pappalardo, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bousquet, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iadanza, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pike, V. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ronsisvalle, G.</span></span> <span> </span><span class="NLM_article-title">Synthesis of (+)- and (−)-cis-2-[(1-adamantylamino)-methyl]-1-phenylcyclopropane derivatives as high affinity probes for sigma1 and sigma2 binding sites</span>. <i>Farmaco</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">45</span>– <span class="NLM_lpage">53</span>, <span class="refDoi"> DOI: 10.1016/S0014-827X(01)01170-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1016%2FS0014-827X%2801%2901170-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=11902645" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref149/cit149&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BD38XhtF2isrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2002&pages=45-53&author=A.+Marrazzoauthor=O.+Prezzaventoauthor=M.+S.+Pappalardoauthor=E.+Bousquetauthor=M.+Iadanzaauthor=V.+W.+Pikeauthor=G.+Ronsisvalle&title=Synthesis+of+%28%2B%29-+and+%28%E2%88%92%29-cis-2-%5B%281-adamantylamino%29-methyl%5D-1-phenylcyclopropane+derivatives+as+high+affinity+probes+for+sigma1+and+sigma2+binding+sites&doi=10.1016%2FS0014-827X%2801%2901170-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit149R"><div class="casContent"><span class="casTitleNuber">149</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of (+)- and (-)-cis-2-[(1-adamantylamino)-methyl]-1-phenylcyclopropane derivatives as high affinity probes for σ1 and σ2 binding sites</span></div><div class="casAuthors">Marrazzo, Agostino; Prezzavento, Orazio; Pappalardo, Maria S.; Bousquet, Ennio; Iadanza, Manuela; Pike, Victor W.; Ronsisvalle, Giuseppe</div><div class="citationInfo"><span class="NLM_cas:title">Farmaco</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">45-53</span>CODEN:
                <span class="NLM_cas:coden">FRMCE8</span>;
        ISSN:<span class="NLM_cas:issn">0014-827X</span>.
    
            (<span class="NLM_cas:orgname">Editions Scientifiques et Medicales Elsevier</span>)
        </div><div class="casAbstract">Selective ligands for either sigma1 (σ1) or σ2 binding sites are potentially useful for gaining a better understanding of the physiol. functions of these proteins.  Moreover, potent and selective homochiral σ1 and σ2 binding site ligands represent leads to potential radioligands for tumor imaging with positron emission tomog. (PET).  On the basis of their structural similarity to previous leads, new (+)- and (-)-cis-2-[(1-adamantylamino)-methyl]-1-phenylcyclopropane derivs. were synthesized and their binding affinities for σ1 and σ2 binding sites were detd.  Each enantiomer showed high affinity for both σ1 and σ2 binding sites, but only (-)-cis-methyl-2-{[1-adamantyl(methyl)amino]methyl}-1-phenylcyclopropane-carboxylate, (-)-4, showed appreciable selectivity for binding to σ1 vs. σ2 sites.  The enantiomers of cis-(2-{[1-adamantyl(methyl)amino]methyl}-1-phenylcyclopropyl)methanol, 6, expressed the highest affinity for σ1 and σ2 binding sites.  Ligands (-)-4, (+)-6 and (-)-6 might be rapidly labeled in their N-Me groups by methylation of the N-desmethyl analogs with [11C]iodomethane to provide prospective radioligands for PET.  The N-desmethyl analogs, which are also high affinity ligands, were prepd. and shown to undergo satisfactory methylation with iodomethane.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpT3_FB3c2S_rVg90H21EOLACvtfcHk0ljpx4v6DS5U1A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XhtF2isrg%253D&md5=0f3a1115c3c8f7bd0a305d26cb234d35</span></div><a href="/servlet/linkout?suffix=cit149&amp;dbid=16384&amp;doi=10.1016%2FS0014-827X%2801%2901170-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0014-827X%252801%252901170-3%26sid%3Dliteratum%253Aachs%26aulast%3DMarrazzo%26aufirst%3DA.%26aulast%3DPrezzavento%26aufirst%3DO.%26aulast%3DPappalardo%26aufirst%3DM.%2BS.%26aulast%3DBousquet%26aufirst%3DE.%26aulast%3DIadanza%26aufirst%3DM.%26aulast%3DPike%26aufirst%3DV.%2BW.%26aulast%3DRonsisvalle%26aufirst%3DG.%26atitle%3DSynthesis%2520of%2520%2528%252B%2529-%2520and%2520%2528%25E2%2588%2592%2529-cis-2-%255B%25281-adamantylamino%2529-methyl%255D-1-phenylcyclopropane%2520derivatives%2520as%2520high%2520affinity%2520probes%2520for%2520sigma1%2520and%2520sigma2%2520binding%2520sites%26jtitle%3DFarmaco%26date%3D2002%26volume%3D57%26spage%3D45%26epage%3D53%26doi%3D10.1016%2FS0014-827X%2801%2901170-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref150"><div class="reference"><strong class="refLabel"><a href="#ref150" class="rightTabRefNumLink">150</a></strong><div class="NLM_citation" id="rightTab-cit150"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Intagliata, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agha, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kopajtic, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katz, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamble, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avery, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCurdy, C. R.</span></span> <span> </span><span class="NLM_article-title">Exploring 1-adamantanamine as an alternative amine moiety for metabolically labile azepane ring in newly synthesized benzo[d]thiazol-2(3H)one σ receptor ligands</span>. <i>Med. Chem. Res.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">1697</span>– <span class="NLM_lpage">1706</span>, <span class="refDoi"> DOI: 10.1007/s00044-020-02597-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1007%2Fs00044-020-02597-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=33584084" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref150/cit150&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhtlCqtb%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2020&pages=1697-1706&author=S.+Intagliataauthor=H.+Aghaauthor=T.+A.+Kopajticauthor=J.+L.+Katzauthor=S.+H.+Kambleauthor=A.+Sharmaauthor=B.+A.+Averyauthor=C.+R.+McCurdy&title=Exploring+1-adamantanamine+as+an+alternative+amine+moiety+for+metabolically+labile+azepane+ring+in+newly+synthesized+benzo%5Bd%5Dthiazol-2%283H%29one+%CF%83+receptor+ligands&doi=10.1007%2Fs00044-020-02597-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit150R"><div class="casContent"><span class="casTitleNuber">150</span><div class="casTitle"><span class="NLM_cas:atitle">Exploring 1-adamantanamine as an alternative amine moiety for metabolically labile azepane ring in newly synthesized benzo[d]thiazol-2(3H)one σ receptor ligands</span></div><div class="casAuthors">Intagliata, Sebastiano; Agha, Hebaalla; Kopajtic, Theresa A.; Katz, Jonathan L.; Kamble, Shyam H.; Sharma, Abhisheak; Avery, Bonnie A.; McCurdy, Christopher R.</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Chemistry Research</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1697-1706</span>CODEN:
                <span class="NLM_cas:coden">MCREEB</span>;
        ISSN:<span class="NLM_cas:issn">1054-2523</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Abstr.: In this work we report the structure-affinity relationships, binding properties, and metabolic stability studies of a series of benzo[d]thiazol-2(3H)one as sigma receptor (σR) ligands.  Specifically, to improve the metabolic stability of the cyclic amine fragment of our lead compd. (SN56), the metabolically unstable azepane ring was replaced with a 1-adatamantamine moiety.  Within the synthesized analogs, compd. 12(I) had low nanomolar affinity for the σ1R (Ki = 7.2 nM) and moderate preference (61-fold) over the σ2R.  In vitro metabolic stability studies showed a slight improvement of the metabolic stability for 7-12, even though an extensive metab. in rat liver microsomes is being obsd.  Furthermore, metabolic soft spot identification of 12 suggested that the N-Me group of the adamantyl moiety is a major site of metab.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgLzdtkl59-bVg90H21EOLACvtfcHk0lie0ZdY3uWV3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhtlCqtb%252FJ&md5=fa088b90e24345ad3b559684f8e94d8e</span></div><a href="/servlet/linkout?suffix=cit150&amp;dbid=16384&amp;doi=10.1007%2Fs00044-020-02597-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00044-020-02597-2%26sid%3Dliteratum%253Aachs%26aulast%3DIntagliata%26aufirst%3DS.%26aulast%3DAgha%26aufirst%3DH.%26aulast%3DKopajtic%26aufirst%3DT.%2BA.%26aulast%3DKatz%26aufirst%3DJ.%2BL.%26aulast%3DKamble%26aufirst%3DS.%2BH.%26aulast%3DSharma%26aufirst%3DA.%26aulast%3DAvery%26aufirst%3DB.%2BA.%26aulast%3DMcCurdy%26aufirst%3DC.%2BR.%26atitle%3DExploring%25201-adamantanamine%2520as%2520an%2520alternative%2520amine%2520moiety%2520for%2520metabolically%2520labile%2520azepane%2520ring%2520in%2520newly%2520synthesized%2520benzo%255Bd%255Dthiazol-2%25283H%2529one%2520%25CF%2583%2520receptor%2520ligands%26jtitle%3DMed.%2520Chem.%2520Res.%26date%3D2020%26volume%3D29%26spage%3D1697%26epage%3D1706%26doi%3D10.1007%2Fs00044-020-02597-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref151"><div class="reference"><strong class="refLabel"><a href="#ref151" class="rightTabRefNumLink">151</a></strong><div class="NLM_citation" id="rightTab-cit151"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Groth-Pedersen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ostenfeld, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Høyer-Hansen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nylandsted, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jäättelä, M.</span></span> <span> </span><span class="NLM_article-title">Vincristine induces dramatic lysosomal changes and sensitizes cancer cells to lysosome-destabilizing siramesine</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>67</i></span>,  <span class="NLM_fpage">2217</span>– <span class="NLM_lpage">2225</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-06-3520</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1158%2F0008-5472.CAN-06-3520" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=17332352" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref151/cit151&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BD2sXitlSjs7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2007&pages=2217-2225&author=L.+Groth-Pedersenauthor=M.+S.+Ostenfeldauthor=M.+H%C3%B8yer-Hansenauthor=J.+Nylandstedauthor=M.+J%C3%A4%C3%A4ttel%C3%A4&title=Vincristine+induces+dramatic+lysosomal+changes+and+sensitizes+cancer+cells+to+lysosome-destabilizing+siramesine&doi=10.1158%2F0008-5472.CAN-06-3520"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit151R"><div class="casContent"><span class="casTitleNuber">151</span><div class="casTitle"><span class="NLM_cas:atitle">Vincristine Induces Dramatic Lysosomal Changes and Sensitizes Cancer Cells to Lysosome-Destabilizing Siramesine</span></div><div class="casAuthors">Groth-Pedersen, Line; Ostenfeld, Marie Stampe; Hoyer-Hansen, Maria; Nylandsted, Jesper; Jaeaettelae, Marja</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">2217-2225</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Vincristine is a microtubule-destabilizing antimitotic drug that has been used in cancer therapy for over 40 years.  However, the knowledge on vincristine-induced cell death pathways is still sparse.  Here, we show that vincristine induces dramatic changes in the lysosomal compartment and sensitizes cells to lysosomal membrane permeabilization.  In HeLa cervix carcinoma cells, vincristine induced mitotic arrest and massive cell death assocd. with an early increase in the lysosomal vol. and lysosomal leakage followed by the activation of the intrinsic apoptosis program.  In contrast, the majority of vincristine-treated MCF-7 breast carcinoma cells resisted apoptosis.  Instead, they adapted to the spindle assembly checkpoint and escaped the mitotic arrest as micronucleated and senescent cells with an increase in the vol. and the activity of their lysosomal compartment.  Consistent with its substantial effects on the lysosomes, vincristine greatly sensitized cultured cancer cells as well as orthotopic breast cancer xenografts in mice to the cytotoxicity induced by siramesine, a sigma-2 receptor ligand that kills cancer cells by destabilizing their lysosomes.  Importantly, the combination of nontoxic concns. of vincristine and siramesine resulted in massive cell death even in MCF-7 cells that were capable of escaping vincristine-induced spindle assembly checkpoint and cell death.  Similar synergism was obsd. when siramesine was combined with a semisynthetic vincristine analog, vinorelbine, or with microtubule-stabilizing paclitaxel.  These data strongly suggest that combination therapies consisting of microtubule-disturbing and lysosome-destabilizing drugs may prove useful in the treatment of otherwise therapy-resistant human cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrvI_uHH5FhrLVg90H21EOLACvtfcHk0lie0ZdY3uWV3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXitlSjs7s%253D&md5=f5de3130e9fe376a8079ded0a3df9411</span></div><a href="/servlet/linkout?suffix=cit151&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-06-3520&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-06-3520%26sid%3Dliteratum%253Aachs%26aulast%3DGroth-Pedersen%26aufirst%3DL.%26aulast%3DOstenfeld%26aufirst%3DM.%2BS.%26aulast%3DH%25C3%25B8yer-Hansen%26aufirst%3DM.%26aulast%3DNylandsted%26aufirst%3DJ.%26aulast%3DJ%25C3%25A4%25C3%25A4ttel%25C3%25A4%26aufirst%3DM.%26atitle%3DVincristine%2520induces%2520dramatic%2520lysosomal%2520changes%2520and%2520sensitizes%2520cancer%2520cells%2520to%2520lysosome-destabilizing%2520siramesine%26jtitle%3DCancer%2520Res.%26date%3D2007%26volume%3D67%26spage%3D2217%26epage%3D2225%26doi%3D10.1158%2F0008-5472.CAN-06-3520" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref152"><div class="reference"><strong class="refLabel"><a href="#ref152" class="rightTabRefNumLink">152</a></strong><div class="NLM_citation" id="rightTab-cit152"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ostenfeld, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Høyer-Hansen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bastholm, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fehrenbacher, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olsen, O. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Groth-Pedersen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puustinen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirkegaard-Sørensen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nylandsted, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Farkas, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jäättelä, M.</span></span> <span> </span><span class="NLM_article-title">Anti-cancer agent siramesine is a lysosomotropic detergent that induces cytoprotective autophagosome accumulation</span>. <i>Autophagy</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">487</span>– <span class="NLM_lpage">499</span>, <span class="refDoi"> DOI: 10.4161/auto.5774</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.4161%2Fauto.5774" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=18305408" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref152/cit152&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BD1cXntFynurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2008&pages=487-499&author=M.+S.+Ostenfeldauthor=M.+H%C3%B8yer-Hansenauthor=L.+Bastholmauthor=N.+Fehrenbacherauthor=O.+D.+Olsenauthor=L.+Groth-Pedersenauthor=P.+Puustinenauthor=T.+Kirkegaard-S%C3%B8rensenauthor=J.+Nylandstedauthor=T.+Farkasauthor=M.+J%C3%A4%C3%A4ttel%C3%A4&title=Anti-cancer+agent+siramesine+is+a+lysosomotropic+detergent+that+induces+cytoprotective+autophagosome+accumulation&doi=10.4161%2Fauto.5774"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit152R"><div class="casContent"><span class="casTitleNuber">152</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-cancer agent siramesine is a lysosomotropic detergent that induces cytoprotective autophagosome accumulation</span></div><div class="casAuthors">Ostenfeld, Marie Stampe; Hoeyer-Hansen, Maria; Bastholm, Lone; Fehrenbacher, Nicole; Olsen, Ole Dines; Groth-Pedersen, Line; Puustinen, Pietri; Kirkegaard-Soerensen, Thomas; Nylandsted, Jesper; Farkas, Thomas; Jaattela, Marja</div><div class="citationInfo"><span class="NLM_cas:title">Autophagy</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">487-499</span>CODEN:
                <span class="NLM_cas:coden">AUTOC9</span>;
        ISSN:<span class="NLM_cas:issn">1554-8627</span>.
    
            (<span class="NLM_cas:orgname">Landes Bioscience</span>)
        </div><div class="casAbstract">A σ-2 receptor ligand siramesine induces lysosomal leakage and cathepsin-dependent death of cancer cells in vitro and displays potent anti-cancer activity in vivo.  The mechanism by which siramesine destabilizes lysosomes is, however, unknown.  Here, we show that siramesine induces a rapid rise in the lysosomal pH that is followed by lysosomal leakage and dysfunction.  The rapid accumulation of siramesine into cancer cell lysosomes, its ability to destabilize isolated lysosomes, and its chem. structure as an amphiphilic amine indicate that it is a lysosomotropic detergent.  Notably, siramesine triggers also a substantial Atg6- and Atg7-dependent accumulation of autophagosomes that is assocd. with a rapid and sustained inhibition of mammalian target of rapamycin complex 1 (mTORC1; an inhibitor of autophagy).  Siramesine fails, however, to increase the degrdn. rate of long-lived proteins.  Thus, the massive accumulation of autophagosomes is likely to be due to a combined effect of activation of autophagy signaling and decreased autophagosome turnover.  Importantly, pharmacol. and RNA interference-based inhibition of autophagosome formation further sensitizes cancer cells to siramesine-induced cytotoxicity.  These data identify siramesine as a lysosomotropic detergent that triggers cell death via a direct destabilization of lysosomes and cytoprotection by inducing the accumulation of autophagosomes.  Therefore, the combination of siramesine with inhibitors of autophagosome formation appears as a promising approach for future cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpJb0mggS39urVg90H21EOLACvtfcHk0lgnkzoZyHfloQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXntFynurk%253D&md5=9b3d02ef1cf41e1b3b433ca637e38cc2</span></div><a href="/servlet/linkout?suffix=cit152&amp;dbid=16384&amp;doi=10.4161%2Fauto.5774&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fauto.5774%26sid%3Dliteratum%253Aachs%26aulast%3DOstenfeld%26aufirst%3DM.%2BS.%26aulast%3DH%25C3%25B8yer-Hansen%26aufirst%3DM.%26aulast%3DBastholm%26aufirst%3DL.%26aulast%3DFehrenbacher%26aufirst%3DN.%26aulast%3DOlsen%26aufirst%3DO.%2BD.%26aulast%3DGroth-Pedersen%26aufirst%3DL.%26aulast%3DPuustinen%26aufirst%3DP.%26aulast%3DKirkegaard-S%25C3%25B8rensen%26aufirst%3DT.%26aulast%3DNylandsted%26aufirst%3DJ.%26aulast%3DFarkas%26aufirst%3DT.%26aulast%3DJ%25C3%25A4%25C3%25A4ttel%25C3%25A4%26aufirst%3DM.%26atitle%3DAnti-cancer%2520agent%2520siramesine%2520is%2520a%2520lysosomotropic%2520detergent%2520that%2520induces%2520cytoprotective%2520autophagosome%2520accumulation%26jtitle%3DAutophagy%26date%3D2008%26volume%3D4%26spage%3D487%26epage%3D499%26doi%3D10.4161%2Fauto.5774" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref153"><div class="reference"><strong class="refLabel"><a href="#ref153" class="rightTabRefNumLink">153</a></strong><div class="NLM_citation" id="rightTab-cit153"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Parry, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alakoskela, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khandelia, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jäättelä, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mahalka, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinnunen, P. K.</span></span> <span> </span><span class="NLM_article-title">High-affinity small molecule-phospholipid complex formation: binding of siramesine to phosphatidic acid</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>130</i></span>,  <span class="NLM_fpage">12953</span>– <span class="NLM_lpage">12960</span>, <span class="refDoi"> DOI: 10.1021/ja800516w</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja800516w" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref153/cit153&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtVymtLjN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=130&publication_year=2008&pages=12953-12960&author=M.+J.+Parryauthor=J.+M.+Alakoskelaauthor=H.+Khandeliaauthor=S.+A.+Kumarauthor=M.+J%C3%A4%C3%A4ttel%C3%A4author=A.+K.+Mahalkaauthor=P.+K.+Kinnunen&title=High-affinity+small+molecule-phospholipid+complex+formation%3A+binding+of+siramesine+to+phosphatidic+acid&doi=10.1021%2Fja800516w"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit153R"><div class="casContent"><span class="casTitleNuber">153</span><div class="casTitle"><span class="NLM_cas:atitle">High-Affinity Small Molecule-Phospholipid Complex Formation: Binding of Siramesine to Phosphatidic Acid</span></div><div class="casAuthors">Parry, Mikko J.; Alakoskela, Juha-Matti I.; Khandelia, Himanshu; Kumar, Subramanian Arun; Jaattela, Marja; Mahalka, Ajay K.; Kinnunen, Paavo K. J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">130</span>
        (<span class="NLM_cas:issue">39</span>),
    <span class="NLM_cas:pages">12953-12960</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Siramesine (SRM) is a σ-2 receptor agonist which has been recently shown to inhibit growth of cancer cells.  Fluorescence spectroscopy expts. revealed two distinct binding sites for this drug in phospholipid membranes.  More specifically, acidic phospholipids retain siramesine on the bilayer surface due to a high-affinity interaction, reaching satn. at an apparent 1:1 drug-acidic phospholipid stoichiometry, where after the drug penetrates into the hydrocarbon core of the membrane.  This behavior was confirmed using Langmuir films.  Of the anionic phospholipids, the highest affinity, comparable to the affinities for the binding of small mol. ligands to proteins, was measured for phosphatidic acid (PA, mole fraction of XPA = 0.2 in phosphatidylcholine vesicles), yielding a mol. partition coeff. of 240 ± 80 × 106.  An MD simulation on the siramesine:PA interaction was in agreement with the above data.  Taking into account the key role of PA as a signaling mol. promoting cell growth our results suggest a new paradigm for the development of anticancer drugs, viz.  Design of small mols. specifically scavenging phospholipids involved in the signaling cascades controlling cell behavior.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGohibvMcWOby7Vg90H21EOLACvtfcHk0lgnkzoZyHfloQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtVymtLjN&md5=d45a6fd73bc046be4774db13fa8ee3e5</span></div><a href="/servlet/linkout?suffix=cit153&amp;dbid=16384&amp;doi=10.1021%2Fja800516w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja800516w%26sid%3Dliteratum%253Aachs%26aulast%3DParry%26aufirst%3DM.%2BJ.%26aulast%3DAlakoskela%26aufirst%3DJ.%2BM.%26aulast%3DKhandelia%26aufirst%3DH.%26aulast%3DKumar%26aufirst%3DS.%2BA.%26aulast%3DJ%25C3%25A4%25C3%25A4ttel%25C3%25A4%26aufirst%3DM.%26aulast%3DMahalka%26aufirst%3DA.%2BK.%26aulast%3DKinnunen%26aufirst%3DP.%2BK.%26atitle%3DHigh-affinity%2520small%2520molecule-phospholipid%2520complex%2520formation%253A%2520binding%2520of%2520siramesine%2520to%2520phosphatidic%2520acid%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2008%26volume%3D130%26spage%3D12953%26epage%3D12960%26doi%3D10.1021%2Fja800516w" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref154"><div class="reference"><strong class="refLabel"><a href="#ref154" class="rightTabRefNumLink">154</a></strong><div class="NLM_citation" id="rightTab-cit154"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jonhede, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petersen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zetterberg, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karlsson, J. O.</span></span> <span> </span><span class="NLM_article-title">Acute effects of the sigma-2 receptor agonist siramesine on lysosomal and extra-lysosomal proteolytic systems in lens epithelial cells</span>. <i>Mol. Vision</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">819</span>– <span class="NLM_lpage">827</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=20461150" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref154/cit154&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BC3cXmtl2gsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2010&pages=819-827&author=S.+Jonhedeauthor=A.+Petersenauthor=M.+Zetterbergauthor=J.+O.+Karlsson&title=Acute+effects+of+the+sigma-2+receptor+agonist+siramesine+on+lysosomal+and+extra-lysosomal+proteolytic+systems+in+lens+epithelial+cells"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit154R"><div class="casContent"><span class="casTitleNuber">154</span><div class="casTitle"><span class="NLM_cas:atitle">Acute effects of the sigma-2 receptor agonist siramesine on lysosomal and extra-lysosomal proteolytic systems in lens epithelial cells</span></div><div class="casAuthors">Jonhede, S.; Petersen, A.; Zetterberg, M.; Karlsson, J.-O.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Vision</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">819-827</span>CODEN:
                <span class="NLM_cas:coden">MVEPFB</span>;
        ISSN:<span class="NLM_cas:issn">1090-0535</span>.
    
            (<span class="NLM_cas:orgname">Molecular Vision</span>)
        </div><div class="casAbstract">Purpose: The aim of the present study was to examine the effects of the sigma-2 receptor agonist, siramesine, on morphol., growth, cell death, lysosomal function, and effects on extra-lysosomal proteolytic systems in human lens epithelial cells.  Methods: Human lens epithelial cells in culture were exposed to siramesine and examd. for morphol. changes using Nomarski optics or calcein.  Lysosomes were evaluated using acridine orange and Magic Red (RR-cresyl violet).  Nuclear morphol. was studied using Hoechst 33342 and propidium iodide.  Enzymic activities in living cells or cell lysates were studied using fluorogenic substrates.  Results: Siramesine at low concns. increased the cytoplasmic proteolytic activity of the proteasome and the calpain system.  Effects were also obsd. with respect to lysosomal morphol., acidity and function.  In addn., activation of caspase-3 and the appearance of nuclei with an apoptotic morphol. was found.  Conclusions: Siramesine at low concns. affects lens epithelial cells with perturbations of the major proteolytic systems and lysosomal morphol., resulting in caspase activation and cell death.  Siramesine may be a possible substance for the treatment or prevention of posterior capsular opacification (PCO).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr8GZEyfaEcYLVg90H21EOLACvtfcHk0liZfhWE0uscNQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXmtl2gsLo%253D&md5=6cfdd2882ba59fb5c39c268ad876233e</span></div><a href="/servlet/linkout?suffix=cit154&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJonhede%26aufirst%3DS.%26aulast%3DPetersen%26aufirst%3DA.%26aulast%3DZetterberg%26aufirst%3DM.%26aulast%3DKarlsson%26aufirst%3DJ.%2BO.%26atitle%3DAcute%2520effects%2520of%2520the%2520sigma-2%2520receptor%2520agonist%2520siramesine%2520on%2520lysosomal%2520and%2520extra-lysosomal%2520proteolytic%2520systems%2520in%2520lens%2520epithelial%2520cells%26jtitle%3DMol.%2520Vision%26date%3D2010%26volume%3D16%26spage%3D819%26epage%3D827" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref155"><div class="reference"><strong class="refLabel"><a href="#ref155" class="rightTabRefNumLink">155</a></strong><div class="NLM_citation" id="rightTab-cit155"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rothfuss, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vangveravong, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mach, R. H.</span></span> <span> </span><span class="NLM_article-title">Functional assays to define agonists and antagonists of the sigma-2 receptor</span>. <i>Anal. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>448</i></span>,  <span class="NLM_fpage">68</span>– <span class="NLM_lpage">74</span>, <span class="refDoi"> DOI: 10.1016/j.ab.2013.12.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1016%2Fj.ab.2013.12.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=24333652" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref155/cit155&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitleltbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=448&publication_year=2014&pages=68-74&author=C.+Zengauthor=J.+M.+Rothfussauthor=J.+Zhangauthor=S.+Vangveravongauthor=W.+Chuauthor=S.+Liauthor=Z.+Tuauthor=J.+Xuauthor=R.+H.+Mach&title=Functional+assays+to+define+agonists+and+antagonists+of+the+sigma-2+receptor&doi=10.1016%2Fj.ab.2013.12.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit155R"><div class="casContent"><span class="casTitleNuber">155</span><div class="casTitle"><span class="NLM_cas:atitle">Functional assays to define agonists and antagonists of the sigma-2 receptor</span></div><div class="casAuthors">Zeng, Chenbo; Rothfuss, Justin M.; Zhang, Jun; Vangveravong, Suwanna; Chu, Wenhua; Li, Shihong; Tu, Zhude; Xu, Jinbin; Mach, Robert H.</div><div class="citationInfo"><span class="NLM_cas:title">Analytical Biochemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">448</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">68-74</span>CODEN:
                <span class="NLM_cas:coden">ANBCA2</span>;
        ISSN:<span class="NLM_cas:issn">0003-2697</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The sigma-2 receptor has been identified as a biomarker in proliferating tumors.  To date there is no well-established functional assay for defining sigma-2 agonists and antagonists.  Many sigma-2 ligands with diverse structures have been shown to induce cell death in a variety of cancer cells by triggering caspase-dependent and independent apoptosis.  Therefore, in the current study, we used the cell viability assay and the caspase-3 activity assay to det. sigma-2 agonists and antagonists.  Three classes of sigma-2 ligands developed in our lab. were evaluated for their potency to induce cell death in two tumor cell lines, mouse breast cancer cell line EMT-6 and human melanoma cell line MDA-MB-435.  The data showed that the EC50 values of the sigma-2 ligands using the cell viability assay ranged from 11.4 μM to >200 μM, which were comparable with the EC50 values obtained using the caspase-3 assay.  Based on the cytotoxicity of a sigma-2 ligand relative to that of siramesine, a commonly accepted sigma-2 agonist, we have categorized our sigma-2 ligands into agonists, partial agonists, and antagonists.  The establishment of functional assays for defining sigma-2 agonists and antagonists will facilitate functional characterization of sigma-2 receptor ligands and sigma-2 receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqFM0mxQ6ge67Vg90H21EOLACvtfcHk0liZfhWE0uscNQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitleltbw%253D&md5=4f50b1c949dfd9ffaf07b539e109d741</span></div><a href="/servlet/linkout?suffix=cit155&amp;dbid=16384&amp;doi=10.1016%2Fj.ab.2013.12.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ab.2013.12.008%26sid%3Dliteratum%253Aachs%26aulast%3DZeng%26aufirst%3DC.%26aulast%3DRothfuss%26aufirst%3DJ.%2BM.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DVangveravong%26aufirst%3DS.%26aulast%3DChu%26aufirst%3DW.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DTu%26aufirst%3DZ.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DMach%26aufirst%3DR.%2BH.%26atitle%3DFunctional%2520assays%2520to%2520define%2520agonists%2520and%2520antagonists%2520of%2520the%2520sigma-2%2520receptor%26jtitle%3DAnal.%2520Biochem.%26date%3D2014%26volume%3D448%26spage%3D68%26epage%3D74%26doi%3D10.1016%2Fj.ab.2013.12.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref156"><div class="reference"><strong class="refLabel"><a href="#ref156" class="rightTabRefNumLink">156</a></strong><div class="NLM_citation" id="rightTab-cit156"><span><span class="NLM_contrib-group"><span class="NLM_string-name">C̆esen, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Repnik, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turk, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turk, B.</span></span> <span> </span><span class="NLM_article-title">Siramesine triggers cell death through destabilisation of mitochondria, but not lysosomes</span>. <i>Cell Death Dis.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>4</i></span>, <span class="NLM_elocation-id">e818</span> <span class="refDoi"> DOI: 10.1038/cddis.2013.361</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1038%2Fcddis.2013.361" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref156/cit156&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=24091661" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&author=M.+H.+C%CC%86esenauthor=U.+Repnikauthor=V.+Turkauthor=B.+Turk&title=Siramesine+triggers+cell+death+through+destabilisation+of+mitochondria%2C+but+not+lysosomes&doi=10.1038%2Fcddis.2013.361"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit156&amp;dbid=16384&amp;doi=10.1038%2Fcddis.2013.361&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fcddis.2013.361%26sid%3Dliteratum%253Aachs%26aulast%3DC%25CC%2586esen%26aufirst%3DM.%2BH.%26aulast%3DRepnik%26aufirst%3DU.%26aulast%3DTurk%26aufirst%3DV.%26aulast%3DTurk%26aufirst%3DB.%26atitle%3DSiramesine%2520triggers%2520cell%2520death%2520through%2520destabilisation%2520of%2520mitochondria%252C%2520but%2520not%2520lysosomes%26jtitle%3DCell%2520Death%2520Dis.%26date%3D2013%26volume%3D4%26doi%3D10.1038%2Fcddis.2013.361" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref157"><div class="reference"><strong class="refLabel"><a href="#ref157" class="rightTabRefNumLink">157</a></strong><div class="NLM_citation" id="rightTab-cit157"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ma, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dielschneider, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henson, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choquette, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blankstein, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibson, S. B.</span></span> <span> </span><span class="NLM_article-title">Ferroptosis and autophagy induced cell death occur independently after siramesine and lapatinib treatment in breast cancer cells</span>. <i>PLoS One</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>12</i></span>, <span class="NLM_elocation-id">e0182921</span> <span class="refDoi"> DOI: 10.1371/journal.pone.0182921</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1371%2Fjournal.pone.0182921" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=28827805" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref157/cit157&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BC1cXps1Gltw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2017&author=S.+Maauthor=R.+F.+Dielschneiderauthor=E.+S.+Hensonauthor=W.+Xiaoauthor=T.+R.+Choquetteauthor=A.+R.+Blanksteinauthor=Y.+Chenauthor=S.+B.+Gibson&title=Ferroptosis+and+autophagy+induced+cell+death+occur+independently+after+siramesine+and+lapatinib+treatment+in+breast+cancer+cells&doi=10.1371%2Fjournal.pone.0182921"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit157R"><div class="casContent"><span class="casTitleNuber">157</span><div class="casTitle"><span class="NLM_cas:atitle">Ferroptosis and autophagy induced cell death occur independently after siramesine and lapatinib treatment in breast cancer cells</span></div><div class="casAuthors">Ma, Shumei; Dielschneider, Rebecca F.; Henson, Elizabeth S.; Xiao, Wenyan; Choquette, Tricia R.; Blankstein, Anna R.; Chen, Yongqiang; Gibson, Spencer B.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">e0182921/1-e0182921/14</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Ferroptosis is a cell death pathway characterized by iron-dependent accumulation of reactive oxygen species (ROS) within the cell.  The combination of siramesine, a lysosome disruptor, and lapatinib, a dual tyrosine kinase inhibitor, has been shown to synergistically induce cell death in breast cancer cells mediated by ferroptosis.  These treatments also induce autophagy but its role in this synergistic cell death is unclear.  In this study, we detd. that siramesine and lapatinib initially induced ferroptosis but changes to an autophagy induced cell death after 24 h.  Furthermore, we found that intracellular iron level increased in a time dependent manner following treatment accompanied by an increase in ROS.  Using the iron chelator deferoxamine (DFO) or the ROS scavenger alpha-tocopherol decreased both autophagy flux and cell death.  We further discovered that decreased expression of the iron storage protein, ferritin was partially dependent upon autophagy degrdn.  In contrast, the expression of transferrin, which is responsible for the transport of iron into cells, is increased following treatment with lapatinib alone or in combination with siramesine.  This indicates that ferroptosis and autophagy induced cell death occur independently but both are mediated by iron dependent ROS generation in breast cancer cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXjALGki64VbVg90H21EOLACvtfcHk0lhfvc6IfNGCDA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXps1Gltw%253D%253D&md5=a8da6a20f81c76164abdf2a9dd55337b</span></div><a href="/servlet/linkout?suffix=cit157&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0182921&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0182921%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DS.%26aulast%3DDielschneider%26aufirst%3DR.%2BF.%26aulast%3DHenson%26aufirst%3DE.%2BS.%26aulast%3DXiao%26aufirst%3DW.%26aulast%3DChoquette%26aufirst%3DT.%2BR.%26aulast%3DBlankstein%26aufirst%3DA.%2BR.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DGibson%26aufirst%3DS.%2BB.%26atitle%3DFerroptosis%2520and%2520autophagy%2520induced%2520cell%2520death%2520occur%2520independently%2520after%2520siramesine%2520and%2520lapatinib%2520treatment%2520in%2520breast%2520cancer%2520cells%26jtitle%3DPLoS%2520One%26date%3D2017%26volume%3D12%26doi%3D10.1371%2Fjournal.pone.0182921" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref158"><div class="reference"><strong class="refLabel"><a href="#ref158" class="rightTabRefNumLink">158</a></strong><div class="NLM_citation" id="rightTab-cit158"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Niso, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abate, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Contino, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferorelli, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Azzariti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perrone, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colabufo, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berardi, F.</span></span> <span> </span><span class="NLM_article-title">Sigma-2 receptor agonists as possible antitumor agents in resistant tumors: hints for collateral sensitivity</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">2026</span>– <span class="NLM_lpage">2035</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201300291</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1002%2Fcmdc.201300291" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=24106081" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref158/cit158&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsFOlt7vE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=2026-2035&author=M.+Nisoauthor=C.+Abateauthor=M.+Continoauthor=S.+Ferorelliauthor=A.+Azzaritiauthor=R.+Perroneauthor=N.+A.+Colabufoauthor=F.+Berardi&title=Sigma-2+receptor+agonists+as+possible+antitumor+agents+in+resistant+tumors%3A+hints+for+collateral+sensitivity&doi=10.1002%2Fcmdc.201300291"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit158R"><div class="casContent"><span class="casTitleNuber">158</span><div class="casTitle"><span class="NLM_cas:atitle">Sigma-2 Receptor Agonists as Possible Antitumor Agents in Resistant Tumors: Hints for Collateral Sensitivity</span></div><div class="casAuthors">Niso, Mauro; Abate, Carmen; Contino, Marialessandra; Ferorelli, Savina; Azzariti, Amalia; Perrone, Roberto; Colabufo, Nicola Antonio; Berardi, Francesco</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2026-2035</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">With the aim of contributing to the development of novel antitumor agents, high-affinity σ2 receptor agonists were developed, with 6,7-dimethoxy-2-[4-[1-(4-fluorophenyl)-1H-indol-3-yl]butyl]-1,2,3,4-tetrahydroisoquinoline (15) and 9-[4-(6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolin-2-yl)butyl]-9H-carbazole (25) showing exceptional selectivity for the σ2 subtype.  Most of the compds. displayed notable antiproliferative activity in human MCF7 breast adenocarcinoma cells, with similar activity in the corresponding doxorubicin-resistant MCF7adr cell line.  Surprisingly, a few compds., including 25, displayed enhanced activity in MCF7adr cells over parent cells, recalling the phenomenon of collateral sensitivity, which is under study for the treatment of drug-resistant tumors.  All of the compds. showed interaction with P-glycoprotein (P-gp), and 15 and 25, with the greatest activity, were able to revert P-gp-mediated resistance and reestablish the antitumor effect of doxorubicin in MCF7adr cells.  The authors therefore identified a series of σ2 receptor agonists endowed with intriguing antitumor properties; these compds. deserve further investigation for the development of alternate strategies against multidrug-resistant cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGrW9r580YjbVg90H21EOLACvtfcHk0lhfvc6IfNGCDA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsFOlt7vE&md5=cd4926ffa90d3fd1c2761bfe2cbe777c</span></div><a href="/servlet/linkout?suffix=cit158&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201300291&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201300291%26sid%3Dliteratum%253Aachs%26aulast%3DNiso%26aufirst%3DM.%26aulast%3DAbate%26aufirst%3DC.%26aulast%3DContino%26aufirst%3DM.%26aulast%3DFerorelli%26aufirst%3DS.%26aulast%3DAzzariti%26aufirst%3DA.%26aulast%3DPerrone%26aufirst%3DR.%26aulast%3DColabufo%26aufirst%3DN.%2BA.%26aulast%3DBerardi%26aufirst%3DF.%26atitle%3DSigma-2%2520receptor%2520agonists%2520as%2520possible%2520antitumor%2520agents%2520in%2520resistant%2520tumors%253A%2520hints%2520for%2520collateral%2520sensitivity%26jtitle%3DChemMedChem%26date%3D2013%26volume%3D8%26spage%3D2026%26epage%3D2035%26doi%3D10.1002%2Fcmdc.201300291" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref159"><div class="reference"><strong class="refLabel"><a href="#ref159" class="rightTabRefNumLink">159</a></strong><div class="NLM_citation" id="rightTab-cit159"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xie, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kniess, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neuber, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deuther-Conrad, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mamat, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lieberman, B. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mach, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brust, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinbach, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pietzsch, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, H.</span></span> <span> </span><span class="NLM_article-title">Novel indole-based sigma-2 receptor ligands: synthesis, structure-affinity relationship and antiproliferative activity</span>. <i>MedChemComm</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">1093</span>– <span class="NLM_lpage">1103</span>, <span class="refDoi"> DOI: 10.1039/C5MD00079C</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1039%2FC5MD00079C" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref159/cit159&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BC2MXmslGgtbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&pages=1093-1103&author=F.+Xieauthor=T.+Kniessauthor=C.+Neuberauthor=W.+Deuther-Conradauthor=C.+Mamatauthor=B.+P.+Liebermanauthor=B.+Liuauthor=R.+H.+Machauthor=P.+Brustauthor=J.+Steinbachauthor=J.+Pietzschauthor=H.+Jia&title=Novel+indole-based+sigma-2+receptor+ligands%3A+synthesis%2C+structure-affinity+relationship+and+antiproliferative+activity&doi=10.1039%2FC5MD00079C"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit159R"><div class="casContent"><span class="casTitleNuber">159</span><div class="casTitle"><span class="NLM_cas:atitle">Novel indole-based sigma-2 receptor ligands: synthesis, structure-affinity relationship and antiproliferative activity</span></div><div class="casAuthors">Xie, Fang; Kniess, Torsten; Neuber, Christin; Deuther-Conrad, Winnie; Mamat, Constantin; Lieberman, Brian P.; Liu, Boli; Mach, Robert H.; Brust, Peter; Steinbach, Jorg; Pietzsch, Jens; Jia, Hongmei</div><div class="citationInfo"><span class="NLM_cas:title">MedChemComm</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1093-1103</span>CODEN:
                <span class="NLM_cas:coden">MCCEAY</span>;
        ISSN:<span class="NLM_cas:issn">2040-2503</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">The synthesis and biol. evaluation of a series of indole-based σ2 receptor ligands I [R = 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolinyl, 5,6-dimethoxyisoindolinyl, 4-phenylpiperidinyl-4-carbonitrile, etc.] derived from siramesine was reported.  In vitro competition binding assays showed that these analogs possessed high to moderate affinity and selectivity for σ2 receptors.  Structure-affinity relationship analyses of these indole-based σ2 receptor ligands were performed.  In the 3-(4,5-dimethythiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, I [R = 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolinyl, 5,6-dimethoxyisoindolinyl] displayed significant and comparable antiproliferative activity in DU145, MCF7 and C6 cells to siramesine.  In cell cycle analyses, compds. I [R = 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolinyl, 5,6-dimethoxyisoindolinyl] and siramesine were found to induce a G1 phase cell cycle arrest in DU145 cells using flow cytometry.  The combination of 5,6-dimethoxyisoindoline scaffold and N-(4-fluorophenyl)indole moiety was identified as a new σ2 receptor ligand deserving further investigation as an antitumor agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqtDXWI6Q_fILVg90H21EOLACvtfcHk0ljpfc169NqMIQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXmslGgtbk%253D&md5=766f04340f2e6ec6f64c7dcd3790334b</span></div><a href="/servlet/linkout?suffix=cit159&amp;dbid=16384&amp;doi=10.1039%2FC5MD00079C&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC5MD00079C%26sid%3Dliteratum%253Aachs%26aulast%3DXie%26aufirst%3DF.%26aulast%3DKniess%26aufirst%3DT.%26aulast%3DNeuber%26aufirst%3DC.%26aulast%3DDeuther-Conrad%26aufirst%3DW.%26aulast%3DMamat%26aufirst%3DC.%26aulast%3DLieberman%26aufirst%3DB.%2BP.%26aulast%3DLiu%26aufirst%3DB.%26aulast%3DMach%26aufirst%3DR.%2BH.%26aulast%3DBrust%26aufirst%3DP.%26aulast%3DSteinbach%26aufirst%3DJ.%26aulast%3DPietzsch%26aufirst%3DJ.%26aulast%3DJia%26aufirst%3DH.%26atitle%3DNovel%2520indole-based%2520sigma-2%2520receptor%2520ligands%253A%2520synthesis%252C%2520structure-affinity%2520relationship%2520and%2520antiproliferative%2520activity%26jtitle%3DMedChemComm%26date%3D2015%26volume%3D6%26spage%3D1093%26epage%3D1103%26doi%3D10.1039%2FC5MD00079C" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref160"><div class="reference"><strong class="refLabel"><a href="#ref160" class="rightTabRefNumLink">160</a></strong><div class="NLM_citation" id="rightTab-cit160"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Abate, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niso, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abatematteo, F. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Contino, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colabufo, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berardi, F.</span></span> <span> </span><span class="NLM_article-title">PB28, the Sigma-1 and Sigma-2 Receptors Modulator With Potent Anti-SARS-CoV-2 Activity: A Review About Its Pharmacological Properties and Structure Affinity Relationships</span>. <i>Front. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">589810</span>, <span class="refDoi"> DOI: 10.3389/fphar.2020.589810</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.3389%2Ffphar.2020.589810" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=33364961" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref160/cit160&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BB3MXjs1Squ7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2020&pages=589810&author=C.+Abateauthor=M.+Nisoauthor=F.+S.+Abatematteoauthor=M.+Continoauthor=N.+A.+Colabufoauthor=F.+Berardi&title=PB28%2C+the+Sigma-1+and+Sigma-2+Receptors+Modulator+With+Potent+Anti-SARS-CoV-2+Activity%3A+A+Review+About+Its+Pharmacological+Properties+and+Structure+Affinity+Relationships&doi=10.3389%2Ffphar.2020.589810"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit160R"><div class="casContent"><span class="casTitleNuber">160</span><div class="casTitle"><span class="NLM_cas:atitle">PB28, the Sigma-1 and Sigma-2 receptors modulator with potent anti-SARS-CoV-2 activity: a review about its pharmacological properties and structure affinity relationships</span></div><div class="casAuthors">Abate, Carmen; Niso, Mauro; Abatematteo, Francesca Serena; Contino, Marialessandra; Colabufo, Nicola Antonio; Berardi, Francesco</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Pharmacology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">589810</span>CODEN:
                <span class="NLM_cas:coden">FPRHAU</span>;
        ISSN:<span class="NLM_cas:issn">1663-9812</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">A review.  These un precedented times have forced the scientific community to gather to face the COVID -19 pandemic.  Efforts in diverse direction s have been made.  A multi-university team has focused on the identification of the host (human) proteins interacting with SAR S-CoV-2 viral proteins, with the aim of hampering these interactions that may cause severe COVI D- 19 symptoms.  Sigma-1 and sigma-2 receptors surprisingly belong to the ''druggable'' host proteins found, with the pan-sigma receptor modulator PB28 displaying the most potent anti- SARS- CoV-2 activity in in vitro assays.  Being 20-fold more active than hydroxychloroquine, without cardiac side effects, PB 28 is a promising antiviral candidate worthy of further investigation .  Our research group developed PB28 in 1996 and have thoroughly characterized its biol. properties since then.  Structure-affinity relationship (SAfiR) studies at the sigma receptor subtypes were also undertaken with PB28 as the lead compd.  We herein report our knowledge of PB 28 to share information that may help to gain insight into the antiviral action of this compd. and sigma receptors, while providing structural hints that may speed up the translation into therapeutics of this class of ligands.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqk1RpLTKAzz7Vg90H21EOLACvtfcHk0ljpfc169NqMIQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3MXjs1Squ7s%253D&md5=e2462870af8b9f38306c795248658775</span></div><a href="/servlet/linkout?suffix=cit160&amp;dbid=16384&amp;doi=10.3389%2Ffphar.2020.589810&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffphar.2020.589810%26sid%3Dliteratum%253Aachs%26aulast%3DAbate%26aufirst%3DC.%26aulast%3DNiso%26aufirst%3DM.%26aulast%3DAbatematteo%26aufirst%3DF.%2BS.%26aulast%3DContino%26aufirst%3DM.%26aulast%3DColabufo%26aufirst%3DN.%2BA.%26aulast%3DBerardi%26aufirst%3DF.%26atitle%3DPB28%252C%2520the%2520Sigma-1%2520and%2520Sigma-2%2520Receptors%2520Modulator%2520With%2520Potent%2520Anti-SARS-CoV-2%2520Activity%253A%2520A%2520Review%2520About%2520Its%2520Pharmacological%2520Properties%2520and%2520Structure%2520Affinity%2520Relationships%26jtitle%3DFront.%2520Pharmacol.%26date%3D2020%26volume%3D11%26spage%3D589810%26doi%3D10.3389%2Ffphar.2020.589810" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref161"><div class="reference"><strong class="refLabel"><a href="#ref161" class="rightTabRefNumLink">161</a></strong><div class="NLM_citation" id="rightTab-cit161"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Colabufo, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leopoldo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferorelli, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abate, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Contino, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perrone, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niso, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perrone, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berardi, F.</span></span> <span> </span><span class="NLM_article-title">Why PB28 Could Be a Covid 2019 Game Changer?</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">2048</span>– <span class="NLM_lpage">2050</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.0c00271</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.0c00271" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref161/cit161&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhs1Sku7zK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2020&pages=2048-2050&author=N.+A.+Colabufoauthor=M.+Leopoldoauthor=S.+Ferorelliauthor=C.+Abateauthor=M.+Continoauthor=M.+G.+Perroneauthor=M.+Nisoauthor=R.+Perroneauthor=F.+Berardi&title=Why+PB28+Could+Be+a+Covid+2019+Game+Changer%3F&doi=10.1021%2Facsmedchemlett.0c00271"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit161R"><div class="casContent"><span class="casTitleNuber">161</span><div class="casTitle"><span class="NLM_cas:atitle">Why PB28 Could Be a Covid 2019 Game Changer?</span></div><div class="casAuthors">Colabufo, Nicola Antonio; Leopoldo, Marcello; Ferorelli, Savina; Abate, Carmen; Contino, Marialessandra; Perrone, Maria Grazia; Niso, Mauro; Perrone, Roberto; Berardi, Francesco</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2048-2050</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">PB28, a cyclohexylpiperazine deriv., could be a potential strategy for Covid 19 because in a recent study it has been found more active than hydroxychloroquine without interaction with cardiac proteins.  PB28 has been designed, developed, and biol. evaluated in the past decade in our research group.  A possible mechanism to explain its surprising anti-COVID-19 activity is suggested..</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbkFHE-HKT8LVg90H21EOLACvtfcHk0ljBIMD5DEWItw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhs1Sku7zK&md5=fb909aba5c7e289f25ef382edc290db2</span></div><a href="/servlet/linkout?suffix=cit161&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.0c00271&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.0c00271%26sid%3Dliteratum%253Aachs%26aulast%3DColabufo%26aufirst%3DN.%2BA.%26aulast%3DLeopoldo%26aufirst%3DM.%26aulast%3DFerorelli%26aufirst%3DS.%26aulast%3DAbate%26aufirst%3DC.%26aulast%3DContino%26aufirst%3DM.%26aulast%3DPerrone%26aufirst%3DM.%2BG.%26aulast%3DNiso%26aufirst%3DM.%26aulast%3DPerrone%26aufirst%3DR.%26aulast%3DBerardi%26aufirst%3DF.%26atitle%3DWhy%2520PB28%2520Could%2520Be%2520a%2520Covid%25202019%2520Game%2520Changer%253F%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2020%26volume%3D11%26spage%3D2048%26epage%3D2050%26doi%3D10.1021%2Facsmedchemlett.0c00271" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref162"><div class="reference"><strong class="refLabel"><a href="#ref162" class="rightTabRefNumLink">162</a></strong><div class="NLM_citation" id="rightTab-cit162"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Riganti, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giampietro, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kopecka, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costamagna, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abatematteo, F. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Contino, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abate, C.</span></span> <span> </span><span class="NLM_article-title">MRP1-Collateral Sensitizers as a Novel Therapeutic Approach in Resistant Cancer Therapy: An In Vitro and In Vivo Study in Lung Resistant Tumor</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">3333</span>, <span class="refDoi"> DOI: 10.3390/ijms21093333</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.3390%2Fijms21093333" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref162/cit162&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhvVOjtr7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2020&pages=3333&author=C.+Rigantiauthor=R.+Giampietroauthor=J.+Kopeckaauthor=C.+Costamagnaauthor=F.+S.+Abatematteoauthor=M.+Continoauthor=C.+Abate&title=MRP1-Collateral+Sensitizers+as+a+Novel+Therapeutic+Approach+in+Resistant+Cancer+Therapy%3A+An+In+Vitro+and+In+Vivo+Study+in+Lung+Resistant+Tumor&doi=10.3390%2Fijms21093333"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit162R"><div class="casContent"><span class="casTitleNuber">162</span><div class="casTitle"><span class="NLM_cas:atitle">MRP1-collateral sensitizers as a novel therapeutic approach in resistant cancer therapy: an in vitro and in vivo study in lung resistant tumor</span></div><div class="casAuthors">Riganti, Chiara; Giampietro, Roberta; Kopecka, Joanna; Costamagna, Costanzo; Abatematteo, Francesca Serena; Contino, Marialessandra; Abate, Carmen</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3333</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Multidrug resistance (MDR) is the main obstacle to current chemotherapy and it is mainly due to the overexpression of some efflux transporters such as MRP1.  One of the most studied strategies to overcome MDR has been the inhibition of MDR pumps through small mols., but its translation into the clinic unfortunately failed.  Recently, a phenomenon called collateral sensitivity (CS) emerged as a new strategy to hamper MDR acting as a synthetic lethality, where the genetic changes developed upon the acquisition of resistance towards a specific agent are followed by the development of hypersensitivity towards a second agent.  Among our library of sigma ligands acting as MDR modulators, we identified three compds., F397, F400, and F421, acting as CS-promoting agents.  We deepened their CS mechanisms in the "pure" model of MRP1-expressing cells (MDCK-MRP1) and in MRP1-expressing/drug resistant non-small cell lung cancer cells (A549/DX).  The in vitro results demonstrated that (i) the three ligands are highly cytotoxic for MRP1-expressing cells; (ii) their effect is MRP1-mediated; (iii) they increase the cytotoxicity induced by cis-Pt, the therapeutic agent commonly used in the treatment of lung tumors; and (iv) their effect is ROS-mediated.  Moreover, a preclin. in vivo study performed in lung tumor xenografts confirms the in vitro findings, making the three CS-promoting agents candidates for a novel therapeutic approach in lung resistant tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr2NdF_JUOCXbVg90H21EOLACvtfcHk0ljBIMD5DEWItw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhvVOjtr7E&md5=cb2dfd75f3f115dcd7bc0c92c65b5c8e</span></div><a href="/servlet/linkout?suffix=cit162&amp;dbid=16384&amp;doi=10.3390%2Fijms21093333&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms21093333%26sid%3Dliteratum%253Aachs%26aulast%3DRiganti%26aufirst%3DC.%26aulast%3DGiampietro%26aufirst%3DR.%26aulast%3DKopecka%26aufirst%3DJ.%26aulast%3DCostamagna%26aufirst%3DC.%26aulast%3DAbatematteo%26aufirst%3DF.%2BS.%26aulast%3DContino%26aufirst%3DM.%26aulast%3DAbate%26aufirst%3DC.%26atitle%3DMRP1-Collateral%2520Sensitizers%2520as%2520a%2520Novel%2520Therapeutic%2520Approach%2520in%2520Resistant%2520Cancer%2520Therapy%253A%2520An%2520In%2520Vitro%2520and%2520In%2520Vivo%2520Study%2520in%2520Lung%2520Resistant%2520Tumor%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2020%26volume%3D21%26spage%3D3333%26doi%3D10.3390%2Fijms21093333" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref163"><div class="reference"><strong class="refLabel"><a href="#ref163" class="rightTabRefNumLink">163</a></strong><div class="NLM_citation" id="rightTab-cit163"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Abate, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elenewski, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niso, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berardi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colabufo, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Azzariti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perrone, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glennon, R. A.</span></span> <span> </span><span class="NLM_article-title">Interaction of the sigma(2) receptor ligand PB28 with the human nucleosome: computational and experimental probes of interaction with the H2A/H2B dimer</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">268</span>– <span class="NLM_lpage">273</span>, <span class="refDoi"> DOI: 10.1002/cmdc.200900402</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1002%2Fcmdc.200900402" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=20077462" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref163/cit163&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtl2ntr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2010&pages=268-273&author=C.+Abateauthor=J.+Elenewskiauthor=M.+Nisoauthor=F.+Berardiauthor=N.+A.+Colabufoauthor=A.+Azzaritiauthor=R.+Perroneauthor=R.+A.+Glennon&title=Interaction+of+the+sigma%282%29+receptor+ligand+PB28+with+the+human+nucleosome%3A+computational+and+experimental+probes+of+interaction+with+the+H2A%2FH2B+dimer&doi=10.1002%2Fcmdc.200900402"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit163R"><div class="casContent"><span class="casTitleNuber">163</span><div class="casTitle"><span class="NLM_cas:atitle">Interaction of the σ2 Receptor Ligand PB28 with the Human Nucleosome: Computational and Experimental Probes of Interaction with the H2A/H2B Dimer</span></div><div class="casAuthors">Abate, Carmen; Elenewski, Justin; Niso, Mauro; Berardi, Francesco; Colabufo, Nicola Antonio; Azzariti, Amalia; Perrone, Roberto; Glennon, Richard A.</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">268-273</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Sigma-2 (σ2) binding sites are an emerging target for anti-neoplastic agents due to the strong apoptotic effect exhibited by σ2 agonists in vitro and the overexpression of these sites in tumor cells.  Nonetheless, no σ2 receptor protein has been identified.  Affinity chromatog. using the high-affinity σ2 ligand PB28 and human SK-N-SH neuroblastoma cells was previously utilized to identify σ2 ligand binding proteins, specifically histones H1, H2A, H2B, and H3.3a.  To rationalize this finding, homol. modeling and automated docking studies were employed to probe intermol. interactions between PB28 and human nucleosomal proteins.  These studies predicted interaction of PB28 with the H2A/H2B dimer at a series of sites previously implicated in chromatin compaction and nucleosomal assembly.  To exptl. verify this prediction, a competitive binding assay was performed on the reconstituted H2A/H2B dimer using [3H]PB28 as radioligand, and an IC50 value of 0.50 nM was detd. for PB28 binding.  In addn., [3H]PB28 was found to accumulate with up to a fivefold excess in nuclear fractions over cytosolic fractions of SK-N-SH and MCF7 cells, indicating that PB28 is capable of entering the nucleus to interact with histone proteins.  In conjunction with computational results, these data suggest that PB28 may exert its cytotoxic effect through direct interaction with nuclear material.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkk6FOeqP6z7Vg90H21EOLACvtfcHk0lhcfGKNmuWswA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtl2ntr4%253D&md5=34320626eb0e20f03b814697c5ee59b0</span></div><a href="/servlet/linkout?suffix=cit163&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.200900402&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.200900402%26sid%3Dliteratum%253Aachs%26aulast%3DAbate%26aufirst%3DC.%26aulast%3DElenewski%26aufirst%3DJ.%26aulast%3DNiso%26aufirst%3DM.%26aulast%3DBerardi%26aufirst%3DF.%26aulast%3DColabufo%26aufirst%3DN.%2BA.%26aulast%3DAzzariti%26aufirst%3DA.%26aulast%3DPerrone%26aufirst%3DR.%26aulast%3DGlennon%26aufirst%3DR.%2BA.%26atitle%3DInteraction%2520of%2520the%2520sigma%25282%2529%2520receptor%2520ligand%2520PB28%2520with%2520the%2520human%2520nucleosome%253A%2520computational%2520and%2520experimental%2520probes%2520of%2520interaction%2520with%2520the%2520H2A%252FH2B%2520dimer%26jtitle%3DChemMedChem%26date%3D2010%26volume%3D5%26spage%3D268%26epage%3D273%26doi%3D10.1002%2Fcmdc.200900402" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref164"><div class="reference"><strong class="refLabel"><a href="#ref164" class="rightTabRefNumLink">164</a></strong><div class="NLM_citation" id="rightTab-cit164"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Abate, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niso, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berardi, F.</span></span> <span> </span><span class="NLM_article-title">Sigma-2 receptor: past, present and perspectives on multiple therapeutic exploitations</span>. <i>Future Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1997</span>– <span class="NLM_lpage">2018</span>, <span class="refDoi"> DOI: 10.4155/fmc-2018-0072</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.4155%2Ffmc-2018-0072" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=29966437" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref164/cit164&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsFagtr%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2018&pages=1997-2018&author=C.+Abateauthor=M.+Nisoauthor=F.+Berardi&title=Sigma-2+receptor%3A+past%2C+present+and+perspectives+on+multiple+therapeutic+exploitations&doi=10.4155%2Ffmc-2018-0072"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit164R"><div class="casContent"><span class="casTitleNuber">164</span><div class="casTitle"><span class="NLM_cas:atitle">Sigma-2 receptor: past, present and perspectives on multiple therapeutic exploitations</span></div><div class="casAuthors">Abate, Carmen; Niso, Mauro; Berardi, Francesco</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">1997-2018</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">Identification of sigma-2 receptor (sig-2R) has been controversial.  Nevertheless, interest in sig-2R is high for its overexpression in tumors and potentials in oncol.  Addnl., sig-2R antagonists inhibit Aβ binding at neurons, blocking the cognitive impairments of Alzheimer's disease.  The most representative classes of sig-2R ligands are herein treated with focus on compds. that served to study sig-2R biol. and to produce sig-2R: fluorescent ligands; multifunctional anticancer agents; and targeting nanoparticles.  Although fluorescent ligands serve as 'green' pharmacol. tools, sig-2R-multifunctional conjugates and sig-2R-targeted nanoparticles show how sig-2R targeting increases the activity of anticancer drugs in tumors with reduced toxicity.  Altogether, this review draws a picture of the multiple approaches of sig-2R ligands in cancer therapy and as Alzheimer's disease modifying disease agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpld3SYZuyx8bVg90H21EOLACvtfcHk0li5FO9Q6NtBag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsFagtr%252FP&md5=f0024b9581e1a7804165f215f99c15ac</span></div><a href="/servlet/linkout?suffix=cit164&amp;dbid=16384&amp;doi=10.4155%2Ffmc-2018-0072&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc-2018-0072%26sid%3Dliteratum%253Aachs%26aulast%3DAbate%26aufirst%3DC.%26aulast%3DNiso%26aufirst%3DM.%26aulast%3DBerardi%26aufirst%3DF.%26atitle%3DSigma-2%2520receptor%253A%2520past%252C%2520present%2520and%2520perspectives%2520on%2520multiple%2520therapeutic%2520exploitations%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2018%26volume%3D10%26spage%3D1997%26epage%3D2018%26doi%3D10.4155%2Ffmc-2018-0072" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref165"><div class="reference"><strong class="refLabel"><a href="#ref165" class="rightTabRefNumLink">165</a></strong><div class="NLM_citation" id="rightTab-cit165"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Berardi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abate, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferorelli, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Uricchio, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colabufo, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niso, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perrone, R.</span></span> <span> </span><span class="NLM_article-title">Exploring the importance of piperazine N-atoms for sigma(2) receptor affinity and activity in a series of analogs of 1-cyclohexyl-4-[3-(5-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)propyl]piperazine (PB28)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">7817</span>– <span class="NLM_lpage">7828</span>, <span class="refDoi"> DOI: 10.1021/jm9007505</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm9007505" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref165/cit165&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht12iu7bP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=7817-7828&author=F.+Berardiauthor=C.+Abateauthor=S.+Ferorelliauthor=V.+Uricchioauthor=N.+A.+Colabufoauthor=M.+Nisoauthor=R.+Perrone&title=Exploring+the+importance+of+piperazine+N-atoms+for+sigma%282%29+receptor+affinity+and+activity+in+a+series+of+analogs+of+1-cyclohexyl-4-%5B3-%285-methoxy-1%2C2%2C3%2C4-tetrahydronaphthalen-1-yl%29propyl%5Dpiperazine+%28PB28%29&doi=10.1021%2Fjm9007505"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit165R"><div class="casContent"><span class="casTitleNuber">165</span><div class="casTitle"><span class="NLM_cas:atitle">Exploring the Importance of Piperazine N-Atoms for σ2 Receptor Affinity and Activity in a Series of Analogs of 1-Cyclohexyl-4-[3-(5-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)propyl]piperazine (PB28)</span></div><div class="casAuthors">Berardi, Francesco; Abate, Carmen; Ferorelli, Savina; Uricchio, Vincenzo; Colabufo, Nicola A.; Niso, Mauro; Perrone, Roberto</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">7817-7828</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">σ2-Agonist 1-cyclohexyl-4-[3-(5-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)propyl]piperazine (7, PB 28), which proved to revert doxorubicin resistance in breast cancer cells, was taken as a template to prep. new analogs.  One of the two basic N-atoms was alternatively replaced by a methine or converted into an amide or ammonium function, with the aim of finding out which of them was essential for σ2 receptor affinity and activity.  Some simply 4-substituted 1-cyclohexylpiperazines were also investigated.  None of the compds. was as high-affinity as 7 (σ2Ki = 0.68, σ1Ki = 0.38 nM), proving that both basic N-atoms ensure better σ2 receptor binding.  Amide 36 emerged as high-affinity (Ki = 0.11 nM) and noteworthy selective (1627-fold) σ1 ligand.  Small N-cyclohexylpiperazine 59 displayed the highest σ2 affinity (Ki = 4.70 nM).  The σ2/σ1 selectivities were generally low.  Antiproliferative assay in SK-N-SH cells revealed piperidines 24 and 15 as putative σ2 agonists (EC50s 1.40 and 3.64 μM resp.) more potent than 7.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5IKlpVJCy1LVg90H21EOLACvtfcHk0ljmfkWbYnyIiw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht12iu7bP&md5=5f58080ebd8d153b325e005024babd88</span></div><a href="/servlet/linkout?suffix=cit165&amp;dbid=16384&amp;doi=10.1021%2Fjm9007505&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm9007505%26sid%3Dliteratum%253Aachs%26aulast%3DBerardi%26aufirst%3DF.%26aulast%3DAbate%26aufirst%3DC.%26aulast%3DFerorelli%26aufirst%3DS.%26aulast%3DUricchio%26aufirst%3DV.%26aulast%3DColabufo%26aufirst%3DN.%2BA.%26aulast%3DNiso%26aufirst%3DM.%26aulast%3DPerrone%26aufirst%3DR.%26atitle%3DExploring%2520the%2520importance%2520of%2520piperazine%2520N-atoms%2520for%2520sigma%25282%2529%2520receptor%2520affinity%2520and%2520activity%2520in%2520a%2520series%2520of%2520analogs%2520of%25201-cyclohexyl-4-%255B3-%25285-methoxy-1%252C2%252C3%252C4-tetrahydronaphthalen-1-yl%2529propyl%255Dpiperazine%2520%2528PB28%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D7817%26epage%3D7828%26doi%3D10.1021%2Fjm9007505" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref166"><div class="reference"><strong class="refLabel"><a href="#ref166" class="rightTabRefNumLink">166</a></strong><div class="NLM_citation" id="rightTab-cit166"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nicholson, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Comeau, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mesangeau, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCurdy, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowen, W. D.</span></span> <span> </span><span class="NLM_article-title">Characterization of CM572, a Selective Irreversible Partial Agonist of the Sigma-2 Receptor with Antitumor Activity</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>354</i></span>,  <span class="NLM_fpage">203</span>– <span class="NLM_lpage">212</span>, <span class="refDoi"> DOI: 10.1124/jpet.115.224105</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1124%2Fjpet.115.224105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=26034081" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref166/cit166&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFyltL%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=354&publication_year=2015&pages=203-212&author=H.+Nicholsonauthor=A.+Comeauauthor=C.+Mesangeauauthor=C.+R.+McCurdyauthor=W.+D.+Bowen&title=Characterization+of+CM572%2C+a+Selective+Irreversible+Partial+Agonist+of+the+Sigma-2+Receptor+with+Antitumor+Activity&doi=10.1124%2Fjpet.115.224105"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit166R"><div class="casContent"><span class="casTitleNuber">166</span><div class="casTitle"><span class="NLM_cas:atitle">Characterization of CM572, a selective irreversible partial agonist of the sigma-2 receptor with antitumor activity</span></div><div class="casAuthors">Nicholson, Hilary; Comeau, Anthony; Mesangeau, Christophe; McCurdy, Christopher R.; Bowen, Wayne D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">354</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">203-212</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The sigma-2 receptors are promising therapeutic targets due to significant upregulation in tumor cells compared to normal tissue.  Here we characterize CM572 (3-(4-(4-(4-fluorophenyl)piperazin-1-yl)butyl)-6-isothiocyanatobenzo[d]oxazol-2(3H)-one) (sigma-1 Ki ≥ 10 μM, sigma-2 Ki = 14.6±6.9 nM), a novel isothiocyanate deriv. of the putative sigma-2 antagonist, SN79 (6-acetyl-3-(4-(4-(4-fluorophenyl)piperazin-1-yl)butyl)benzo[d]oxazol-2(3H)-one).  CM572 binds irreversibly to sigma-2 receptors by virtue of the isothiocyanate moiety, but not to sigma-1.  Studies in human SK-N-SH neuroblastoma cells revealed that CM572 induced an immediate, dose-dependent rise in cytosolic calcium concn.  A 24 h treatment of SK-N-SH cells with CM572 induced dose-dependent cell death, with an EC50 =7.6±1.7 μM.  This effect was sustained over 24 h even after a 60 min pretreatment with CM572, followed by extensive washing to remove ligand, indicating an irreversible effect consistent with the irreversible binding data.  Western blot anal. revealed that CM572 also induced cleavage activation of pro-apoptotic Bid.  These data suggest irreversible agonist-like activity.  Low concns. of CM572 that were minimally effective were able to significantly attenuate the calcium signal and cell death induced by the sigma-2 agonist CB-64D ((+)-1R,5R-(E)-8-benzylidene-5-(3-hydroxyphenyl)-2-methylmorphan-7-one).  CM572 was also cytotoxic against PANC-1 pancreatic and MCF-7 breast cancer cell lines.  The cytotoxic activity of CM572 was selective for cancer cells over normal cells, being much less potent against primary human melanocytes and human mammary epithelial cells.  Taken together, these data show that CM572 is a selective, irreversible sigma-2 receptor partial agonist.  This novel irreversible ligand may further our understanding of the endogenous role of this receptor, in addn. to having potential use in targeted cancer diagnosis and therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrP_-A6OU9fyrVg90H21EOLACvtfcHk0ljmfkWbYnyIiw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFyltL%252FO&md5=35573ea29dcf6dbc6544f4c20c4f69d6</span></div><a href="/servlet/linkout?suffix=cit166&amp;dbid=16384&amp;doi=10.1124%2Fjpet.115.224105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.115.224105%26sid%3Dliteratum%253Aachs%26aulast%3DNicholson%26aufirst%3DH.%26aulast%3DComeau%26aufirst%3DA.%26aulast%3DMesangeau%26aufirst%3DC.%26aulast%3DMcCurdy%26aufirst%3DC.%2BR.%26aulast%3DBowen%26aufirst%3DW.%2BD.%26atitle%3DCharacterization%2520of%2520CM572%252C%2520a%2520Selective%2520Irreversible%2520Partial%2520Agonist%2520of%2520the%2520Sigma-2%2520Receptor%2520with%2520Antitumor%2520Activity%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2015%26volume%3D354%26spage%3D203%26epage%3D212%26doi%3D10.1124%2Fjpet.115.224105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref167"><div class="reference"><strong class="refLabel"><a href="#ref167" class="rightTabRefNumLink">167</a></strong><div class="NLM_citation" id="rightTab-cit167"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nicholson, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alsharif, W. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Comeau, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mesangeau, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Intagliata, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mottinelli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCurdy, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowen, W. D.</span></span> <span> </span><span class="NLM_article-title">Divergent Cytotoxic and Metabolically Stimulative Functions of Sigma-2 Receptors: Structure-Activity Relationships of 6-Acetyl-3-(4-(4-(4-fluorophenyl)piperazin-1-yl)butyl)benzo[d]oxazol-2(3H)-one (SN79) Derivatives</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>368</i></span>,  <span class="NLM_fpage">272</span>– <span class="NLM_lpage">281</span>, <span class="refDoi"> DOI: 10.1124/jpet.118.253484</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1124%2Fjpet.118.253484" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=30530624" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref167/cit167&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BC1MXns1Wjs78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=368&publication_year=2019&pages=272-281&author=H.+E.+Nicholsonauthor=W.+F.+Alsharifauthor=A.+B.+Comeauauthor=C.+Mesangeauauthor=S.+Intagliataauthor=M.+Mottinelliauthor=C.+R.+McCurdyauthor=W.+D.+Bowen&title=Divergent+Cytotoxic+and+Metabolically+Stimulative+Functions+of+Sigma-2+Receptors%3A+Structure-Activity+Relationships+of+6-Acetyl-3-%284-%284-%284-fluorophenyl%29piperazin-1-yl%29butyl%29benzo%5Bd%5Doxazol-2%283H%29-one+%28SN79%29+Derivatives&doi=10.1124%2Fjpet.118.253484"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit167R"><div class="casContent"><span class="casTitleNuber">167</span><div class="casTitle"><span class="NLM_cas:atitle">Divergent cytotoxic and metabolically stimulative functions of sigma-2 receptors: structure-activity relationships of 6-Acetyl-3- (4-(4-(4-fluorophenyl)piperazin-1-yl)butyl)benzo[d]oxazol-2(3H)-one (SN79) derivativess</span></div><div class="casAuthors">Nicholson, Hilary E.; Alsharif, Walid F.; Comeau, Anthony B.; Mesangeau, Christophe; Intagliata, Sebastiano; Mottinelli, Marco; McCurdy, Christopher R.; Bowen, Wayne D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">368</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">272-281, 1-9</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Here we investigate a series of 6-substituted SN79 analogs to assess the structural determinants governing these divergent effects.  Substitutions on the benzoxazolone ring of the core SN79 structure resulted in high-affinity sigma-2 receptor ligands (Ki = 0.56-17.9 nM), with replacement of the heterocyclic oxygen by N-Me (producing N-methylbenzimidazolones) generally decreasing sigma-1 affinity and a sulfur substitution (producing benzothiazolones) imparting high affinity at both subtypes, lowering subtype selectivity.  Substitution at the 6-position with COCH3, NO2, NH2, or F resulted in ligands that were not cytotoxic.  Five of these ligands induced an increase in metabolic activity, as measured by increased redn. of MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) in human SK-N-SH neuroblastoma cells, further supporting a role for sigma-2 receptors in metab.  Substitutionwith 6-isothiocyanate resulted in ligands that were sigma-2 selective and that irreversibly bound to the sigma-2 receptor, but not to the sigma-1 receptor.  These ligands induced cell death upon both acute and continuous treatment (EC50 = 7.6-32.8 muM), suggesting that irreversible receptor binding plays a role in cytotoxicity.  These ligands will be useful for further study of these divergent roles of sigma-2 receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCm9hpQzXLhLVg90H21EOLACvtfcHk0ljjlRQXfKehJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXns1Wjs78%253D&md5=daa90a75b164799d819e46fa246d3370</span></div><a href="/servlet/linkout?suffix=cit167&amp;dbid=16384&amp;doi=10.1124%2Fjpet.118.253484&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.118.253484%26sid%3Dliteratum%253Aachs%26aulast%3DNicholson%26aufirst%3DH.%2BE.%26aulast%3DAlsharif%26aufirst%3DW.%2BF.%26aulast%3DComeau%26aufirst%3DA.%2BB.%26aulast%3DMesangeau%26aufirst%3DC.%26aulast%3DIntagliata%26aufirst%3DS.%26aulast%3DMottinelli%26aufirst%3DM.%26aulast%3DMcCurdy%26aufirst%3DC.%2BR.%26aulast%3DBowen%26aufirst%3DW.%2BD.%26atitle%3DDivergent%2520Cytotoxic%2520and%2520Metabolically%2520Stimulative%2520Functions%2520of%2520Sigma-2%2520Receptors%253A%2520Structure-Activity%2520Relationships%2520of%25206-Acetyl-3-%25284-%25284-%25284-fluorophenyl%2529piperazin-1-yl%2529butyl%2529benzo%255Bd%255Doxazol-2%25283H%2529-one%2520%2528SN79%2529%2520Derivatives%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2019%26volume%3D368%26spage%3D272%26epage%3D281%26doi%3D10.1124%2Fjpet.118.253484" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref168"><div class="reference"><strong class="refLabel"><a href="#ref168" class="rightTabRefNumLink">168</a></strong><div class="NLM_citation" id="rightTab-cit168"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mach, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freeman, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vangveravong, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luedtke, R. R.</span></span> <span> </span><span class="NLM_article-title">Conformationally-flexible benzamide analogues as dopamine D3 and sigma 2 receptor ligands</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">195</span>– <span class="NLM_lpage">202</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2003.09.083</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1016%2Fj.bmcl.2003.09.083" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=14684327" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref168/cit168&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BD3sXpvVWntbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2004&pages=195-202&author=R.+H.+Machauthor=Y.+Huangauthor=R.+A.+Freemanauthor=L.+Wuauthor=S.+Vangveravongauthor=R.+R.+Luedtke&title=Conformationally-flexible+benzamide+analogues+as+dopamine+D3+and+sigma+2+receptor+ligands&doi=10.1016%2Fj.bmcl.2003.09.083"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit168R"><div class="casContent"><span class="casTitleNuber">168</span><div class="casTitle"><span class="NLM_cas:atitle">Conformationally-flexible benzamide analogues as dopamine D3 and σ2 receptor ligands</span></div><div class="casAuthors">Mach, Robert H.; Huang, Yunsheng; Freeman, Rebekah A.; Wu, Li; Vangveravong, Suwanna; Luedtke, Robert R.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">195-202</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">A series of conformationally-flexible analogs was prepd. and their affinities for D2-like dopamine (D2, D3 and D4) were detd. using in vitro radioligand binding assays.  The results of this structure-activity relationship study identified one compd. that bound with high affinity (Ki value=2 nM) and moderate selectivity (30-fold) for D3 compared to D2 receptors.  In addn., this series of compds. were also tested for affinity at σ1 and σ2 receptors.  We evaluated the affinity of these dopaminergic compds. at sigma receptors because (a) several antipsychotic drugs, which are high affinity antagonists at dopamine D2-like receptors, also bind to sigma receptors and (b) sigma receptors are expressed ubiquitously and at high levels (picomoles per mg proteins).  It was obsd. that a no. of analogs displayed high affinity and excellent selectivity for σ2 vs. σ1 receptors.  Consequently, these novel compds. may be useful for characterizing the functional role of σ2 receptors and for imaging the σ2 receptor status of tumors in vivo with PET.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTCz3LVM_ZorVg90H21EOLACvtfcHk0ljjlRQXfKehJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXpvVWntbk%253D&md5=2fae22514cbeaa1ff88eecec09de31ec</span></div><a href="/servlet/linkout?suffix=cit168&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2003.09.083&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2003.09.083%26sid%3Dliteratum%253Aachs%26aulast%3DMach%26aufirst%3DR.%2BH.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DFreeman%26aufirst%3DR.%2BA.%26aulast%3DWu%26aufirst%3DL.%26aulast%3DVangveravong%26aufirst%3DS.%26aulast%3DLuedtke%26aufirst%3DR.%2BR.%26atitle%3DConformationally-flexible%2520benzamide%2520analogues%2520as%2520dopamine%2520D3%2520and%2520sigma%25202%2520receptor%2520ligands%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2004%26volume%3D14%26spage%3D195%26epage%3D202%26doi%3D10.1016%2Fj.bmcl.2003.09.083" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref169"><div class="reference"><strong class="refLabel"><a href="#ref169" class="rightTabRefNumLink">169</a></strong><div class="NLM_citation" id="rightTab-cit169"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mach, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wheeler, K. T.</span></span> <span> </span><span class="NLM_article-title">Development of molecular probes for imaging sigma-2 receptors in vitro and in vivo</span>. <i>Cent. Nerv. Syst. Agents Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">230</span>– <span class="NLM_lpage">245</span>, <span class="refDoi"> DOI: 10.2174/1871524910909030230</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.2174%2F1871524910909030230" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=20021357" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref169/cit169&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtVWnt7rJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2009&pages=230-245&author=R.+H.+Machauthor=K.+T.+Wheeler&title=Development+of+molecular+probes+for+imaging+sigma-2+receptors+in+vitro+and+in+vivo&doi=10.2174%2F1871524910909030230"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit169R"><div class="casContent"><span class="casTitleNuber">169</span><div class="casTitle"><span class="NLM_cas:atitle">Development of molecular probes for imaging sigma-2 receptors in vitro and in vivo</span></div><div class="casAuthors">Mach, Robert Henry; Wheeler, Kenneth Theodore</div><div class="citationInfo"><span class="NLM_cas:title">Central Nervous System Agents in Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">230-245</span>CODEN:
                <span class="NLM_cas:coden">CNSAC3</span>;
        ISSN:<span class="NLM_cas:issn">1871-5249</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The sigma-2 (σ2) receptor is proving to be an important protein in the field of cancer biol.  The observations that σ2 receptors have a 10-fold higher d. in proliferating tumor cells than in quiescent tumor cells, and that σ2 receptor agonists are capable of killing tumor cells via apoptotic and non-apoptotic mechanisms, indicate that this receptor is an important mol. target for the development of radiotracers for imaging tumors using techniques such as Positron Emission Tomog. (PET) and Single Photon Emission Computed Tomog. (SPECT) and for the development of cancer chemotherapeutic agents.  In spite of recent promising results towards achieving these goals, research in this field has been hampered by the fact that the mol. identity of the protein sequence of the σ2 receptor is currently not known.  Consequently, most of what is known about this protein has been obtained using either radiolabeled or fluorescent probes for this receptor, or biochem. anal. of the effect of σ2 selective ligands on cells growing under tissue culture conditions.  This article provides a review of the development and use of σ2 receptor ligands, and how these ligands have been used with a variety of in vitro and in vivo models to gain a greater understanding of the role this receptor plays in cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpC9Mm5Pn8dtbVg90H21EOLACvtfcHk0ljjlRQXfKehJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtVWnt7rJ&md5=1babf73dd3a6dcf8eb3eb8b29702360e</span></div><a href="/servlet/linkout?suffix=cit169&amp;dbid=16384&amp;doi=10.2174%2F1871524910909030230&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1871524910909030230%26sid%3Dliteratum%253Aachs%26aulast%3DMach%26aufirst%3DR.%2BH.%26aulast%3DWheeler%26aufirst%3DK.%2BT.%26atitle%3DDevelopment%2520of%2520molecular%2520probes%2520for%2520imaging%2520sigma-2%2520receptors%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DCent.%2520Nerv.%2520Syst.%2520Agents%2520Med.%2520Chem.%26date%3D2009%26volume%3D9%26spage%3D230%26epage%3D245%26doi%3D10.2174%2F1871524910909030230" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref170"><div class="reference"><strong class="refLabel"><a href="#ref170" class="rightTabRefNumLink">170</a></strong><div class="NLM_citation" id="rightTab-cit170"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, G. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, X. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mach, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y. S.</span></span> <span> </span><span class="NLM_article-title">Synthesis and pharmacological evaluation of 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline derivatives as sigma-2 receptor ligands</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>147</i></span>,  <span class="NLM_fpage">227</span>– <span class="NLM_lpage">237</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2017.11.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1016%2Fj.ejmech.2017.11.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=29438891" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref170/cit170&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BC1cXis1SmtLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=147&publication_year=2018&pages=227-237&author=Y.+T.+Sunauthor=G.+F.+Wangauthor=Y.+Q.+Yangauthor=F.+Jinauthor=Y.+Wangauthor=X.+Y.+Xieauthor=R.+H.+Machauthor=Y.+S.+Huang&title=Synthesis+and+pharmacological+evaluation+of+6%2C7-dimethoxy-1%2C2%2C3%2C4-tetrahydroisoquinoline+derivatives+as+sigma-2+receptor+ligands&doi=10.1016%2Fj.ejmech.2017.11.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit170R"><div class="casContent"><span class="casTitleNuber">170</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and pharmacological evaluation of 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline derivatives as sigma-2 receptor ligands</span></div><div class="casAuthors">Sun, Yu-Tong; Wang, Gui-Fei; Yang, Yi-Qiu; Jin, Fujun; Wang, Yifei; Xie, Xiao-Yang; Mach, Robert H.; Huang, Yun-Sheng</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">147</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">227-237</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">The compds. 6,7-Dimethoxy-1,2,3,4-tetrahydroisoquinolinylalkyl benzamides I (R = 4-methoxy-2-methylphenyl, 2,4-dimethoxyphenyl, 2-hydroxy-3,4,5-trimethoxy-6-methylphenyl; n = 1, 2, 4), II (R1 = 4-methoxy-2-methylphenyl, 2,4-dimethoxyphenyl; n = 1, 2, 4) and III [R2 = 6,7-(MeO2), 6-NO2-7-Cl; X = CH2, (CH2)2, (CH2)3] are among a few categories of structures that have demonstrated high affinities and selectivities for sigma-2 receptor and been used extensively as study tools in various tumor imaging and therapy.  As a continuous effort, a new series of 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline derivs. I, II and III was synthesized and evaluated for their affinities for both sigma-1 and sigma-2 receptors.  Most of these newly developed analogs showed good to excellent binding affinities for sigma-2 receptor with no or low affinities for sigma-1 receptor.  In particular, compds. I (R = 4-methoxy-2-methylphenyl, 2,4-dimethoxyphenyl; n = 4) and II (R1 = 4-methoxy-2-methylphenyl, 2,4-dimethoxyphenyl; x = 4) demonstrated Ki values of 5-6 nM affinities and excellent selectivities for sigma-2 receptor.  In addn., these analogs also demonstrated moderate anticancer activities against human liver Huh-7 tumor cells and human esophagus KYSE-140 cancer cells.  But their cytotoxicities seem not to be correlated with their sigma-2 receptor affinities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGplR07xXaNwMrVg90H21EOLACvtfcHk0lg7DAHTGA9C8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXis1SmtLw%253D&md5=c55a4c98ed32db97e8aeb14bf2bcf782</span></div><a href="/servlet/linkout?suffix=cit170&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2017.11.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2017.11.016%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DY.%2BT.%26aulast%3DWang%26aufirst%3DG.%2BF.%26aulast%3DYang%26aufirst%3DY.%2BQ.%26aulast%3DJin%26aufirst%3DF.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DXie%26aufirst%3DX.%2BY.%26aulast%3DMach%26aufirst%3DR.%2BH.%26aulast%3DHuang%26aufirst%3DY.%2BS.%26atitle%3DSynthesis%2520and%2520pharmacological%2520evaluation%2520of%25206%252C7-dimethoxy-1%252C2%252C3%252C4-tetrahydroisoquinoline%2520derivatives%2520as%2520sigma-2%2520receptor%2520ligands%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D147%26spage%3D227%26epage%3D237%26doi%3D10.1016%2Fj.ejmech.2017.11.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref171"><div class="reference"><strong class="refLabel"><a href="#ref171" class="rightTabRefNumLink">171</a></strong><div class="NLM_citation" id="rightTab-cit171"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xie, X. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riad, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mach, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y. S.</span></span> <span> </span><span class="NLM_article-title">Synthesis, binding, and functional properties of tetrahydroisoquinolino-2-alkyl phenones as selective σ(2)R/TMEM97 ligands</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2021</span>,  <span class="NLM_volume"><i>209</i></span>,  <span class="NLM_fpage">112906</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2020.112906</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1016%2Fj.ejmech.2020.112906" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=33049607" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref171/cit171&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BB3cXitVOrtb7N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=209&publication_year=2021&pages=112906&author=X.+Y.+Xieauthor=Y.+Y.+Liauthor=W.+H.+Maauthor=A.+F.+Chenauthor=Y.+T.+Sunauthor=J.+Y.+Leeauthor=A.+Riadauthor=D.+H.+Xuauthor=R.+H.+Machauthor=Y.+S.+Huang&title=Synthesis%2C+binding%2C+and+functional+properties+of+tetrahydroisoquinolino-2-alkyl+phenones+as+selective+%CF%83%282%29R%2FTMEM97+ligands&doi=10.1016%2Fj.ejmech.2020.112906"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit171R"><div class="casContent"><span class="casTitleNuber">171</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis, binding and functional properties of tetrahydroisoquinolino-2-alkyl phenones as selective σ2R/TMEM97 ligands</span></div><div class="casAuthors">Xie, Xiao-Yang; Li, Yu-Yun; Ma, Wen-Hui; Chen, Ai-Fang; Sun, Yu-Tong; Lee, Ji Youn; Riad, Aladdin; Xu, Dao-Hua; Mach, Robert H.; Huang, Yun-Sheng</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2021</span>),
    <span class="NLM_cas:volume">209</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">112906</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A series of tetrahydroisoquinolino-2-alkyl phenones I [R1 = H, OMe; R2 = H, OMe; n = 2, 3, 4, 5, 6] was synthesized and identified as selective σ2R/TMEM97 ligands.  Among the synthesized compds., four analogs I [R1 = R2 = H, n = 3, 4, 5, 6] demonstrated the best affinity with Ki values of 5.1, 3.0, 0.38 and 1.33 nM, resp., for σ2R/TMEM97 and selectivity ratios of >196, 53, >2631 and > 751, resp., for σ2R/TMEM97 over σ1R.  Functional assays indicated that these four most potent analogs I [R1 = R2 = H, n = 3, 4, 5, 6] had no effects on intracellular calcium concn. and were classified as putative σ2R/TMEM97 antagonists according to current understanding.  The σ2R/TMEM97 was suggested to play important roles in the central nervous system.  Based on published pharmacol. and clin. results from several regarded σ2R/TMEM97 antagonists, these analogs I may potentially be useful for the treatment of various neurodegenerative diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpN7ViTUty9tbVg90H21EOLACvtfcHk0lg7DAHTGA9C8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXitVOrtb7N&md5=b3f0363b6da78d49b62f8ca635d0171f</span></div><a href="/servlet/linkout?suffix=cit171&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2020.112906&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2020.112906%26sid%3Dliteratum%253Aachs%26aulast%3DXie%26aufirst%3DX.%2BY.%26aulast%3DLi%26aufirst%3DY.%2BY.%26aulast%3DMa%26aufirst%3DW.%2BH.%26aulast%3DChen%26aufirst%3DA.%2BF.%26aulast%3DSun%26aufirst%3DY.%2BT.%26aulast%3DLee%26aufirst%3DJ.%2BY.%26aulast%3DRiad%26aufirst%3DA.%26aulast%3DXu%26aufirst%3DD.%2BH.%26aulast%3DMach%26aufirst%3DR.%2BH.%26aulast%3DHuang%26aufirst%3DY.%2BS.%26atitle%3DSynthesis%252C%2520binding%252C%2520and%2520functional%2520properties%2520of%2520tetrahydroisoquinolino-2-alkyl%2520phenones%2520as%2520selective%2520%25CF%2583%25282%2529R%252FTMEM97%2520ligands%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2021%26volume%3D209%26spage%3D112906%26doi%3D10.1016%2Fj.ejmech.2020.112906" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref172"><div class="reference"><strong class="refLabel"><a href="#ref172" class="rightTabRefNumLink">172</a></strong><div class="NLM_citation" id="rightTab-cit172"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Abate, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferorelli, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Contino, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marottoli, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colabufo, N. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perrone, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berardi, F.</span></span> <span> </span><span class="NLM_article-title">Arylamides hybrids of two high-affinity σ2 receptor ligands as tools for the development of PET radiotracers</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">4733</span>– <span class="NLM_lpage">4741</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2011.05.057</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1016%2Fj.ejmech.2011.05.057" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=21684636" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref172/cit172&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtV2rtbnN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2011&pages=4733-4741&author=C.+Abateauthor=S.+Ferorelliauthor=M.+Continoauthor=R.+Marottoliauthor=N.+A.+Colabufoauthor=R.+Perroneauthor=F.+Berardi&title=Arylamides+hybrids+of+two+high-affinity+%CF%832+receptor+ligands+as+tools+for+the+development+of+PET+radiotracers&doi=10.1016%2Fj.ejmech.2011.05.057"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit172R"><div class="casContent"><span class="casTitleNuber">172</span><div class="casTitle"><span class="NLM_cas:atitle">Arylamides hybrids of two high-affinity σ2 receptor ligands as tools for the development of PET radiotracers</span></div><div class="casAuthors">Abate, Carmen; Ferorelli, Savina; Contino, Marialessandra; Marottoli, Roberta; Colabufo, Nicola Antonio; Perrone, Roberto; Berardi, Francesco</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4733-4741</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">1-Cyclohexyl-4-[3-(5-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)propyl]piperazine 1 (PB28) and 2-Methoxy-5-methyl-N-[4-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)butyl]benzamide 2 (RHM-1) represent leads for tumor diagnosis, given their high affinity at σ2 receptors.  With the purpose of obtaining good candidates for σ2 PET tracers development, hybrid structures between 1 and 2 were designed.  Excellent σ1/σ2 selectivities were reached when 6,7-dimethoxytetrahydroisoquinoline was linked to an o-methoxy substituted arylamide (11a, 12a, 15a), and for these benzamides an intramol. H-bond in the active conformation at the σ sites, was hypothesized.  However these excellent σ2 ligands were accompanied by interaction with P-gp, which may limit their use as σ2 receptor PET agents when tumors overexpress P-gp.  Compd. 15a whose P-gp interaction was just moderate represents an interesting tool for the development of σ2 PET tracers useful in tumors overexpressing P-gp.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrlYNVyEcnCB7Vg90H21EOLACvtfcHk0lg7DAHTGA9C8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtV2rtbnN&md5=a01159535eddfd4206a80b173da9e51e</span></div><a href="/servlet/linkout?suffix=cit172&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2011.05.057&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2011.05.057%26sid%3Dliteratum%253Aachs%26aulast%3DAbate%26aufirst%3DC.%26aulast%3DFerorelli%26aufirst%3DS.%26aulast%3DContino%26aufirst%3DM.%26aulast%3DMarottoli%26aufirst%3DR.%26aulast%3DColabufo%26aufirst%3DN.%2BA.%26aulast%3DPerrone%26aufirst%3DR.%26aulast%3DBerardi%26aufirst%3DF.%26atitle%3DArylamides%2520hybrids%2520of%2520two%2520high-affinity%2520%25CF%25832%2520receptor%2520ligands%2520as%2520tools%2520for%2520the%2520development%2520of%2520PET%2520radiotracers%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2011%26volume%3D46%26spage%3D4733%26epage%3D4741%26doi%3D10.1016%2Fj.ejmech.2011.05.057" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref173"><div class="reference"><strong class="refLabel"><a href="#ref173" class="rightTabRefNumLink">173</a></strong><div class="NLM_citation" id="rightTab-cit173"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Niso, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mosier, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marottoli, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferorelli, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cassano, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gasparre, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leopoldo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berardi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abate, C.</span></span> <span> </span><span class="NLM_article-title">High-affinity sigma-1 (σ(1)) receptor ligands based on the σ(1) antagonist PB212</span>. <i>Future Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">2547</span>– <span class="NLM_lpage">2562</span>, <span class="refDoi"> DOI: 10.4155/fmc-2019-0042</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.4155%2Ffmc-2019-0042" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=31633399" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref173/cit173&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvF2hu77F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2019&pages=2547-2562&author=M.+Nisoauthor=P.+D.+Mosierauthor=R.+Marottoliauthor=S.+Ferorelliauthor=G.+Cassanoauthor=G.+Gasparreauthor=M.+Leopoldoauthor=F.+Berardiauthor=C.+Abate&title=High-affinity+sigma-1+%28%CF%83%281%29%29+receptor+ligands+based+on+the+%CF%83%281%29+antagonist+PB212&doi=10.4155%2Ffmc-2019-0042"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit173R"><div class="casContent"><span class="casTitleNuber">173</span><div class="casTitle"><span class="NLM_cas:atitle">High-affinity sigma-1 (σ1) receptor ligands based on the σ1 antagonist PB212</span></div><div class="casAuthors">Niso, Mauro; Mosier, Philip D.; Marottoli, Roberta; Ferorelli, Savina; Cassano, Giuseppe; Gasparre, Giuseppe; Leopoldo, Marcello; Berardi, Francesco; Abate, Carmen</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">2547-2562</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">The σ1 receptor is a druggable target involved in many physiol. processes and diseases.  To clarify its physiol. and derive therapeutic benefit, nine analogs based on the σ1 antagonist PB212 were synthesized replacing the 4-methylpiperidine with basic moieties of varying size and degree of conformational freedom.  A 3-Phenylpyrrolidine, 4-phenylpiperidine or granatane derivs. displayed the highest affinity (Ki.#x00A0; = 0.12, 0.31 or 1.03 nM).  Calcium flux assays in MCF7s1 cells indicated that the highest σ1 receptor affinity are σ1 antagonists.  Mol. models provided a structural basis for understanding the σ1 affinity and functional activity of the analogs and incorporated Glennon's σ1 pharmacophore model.  Herein, we identify new compds. exploitable as therapeutic drug leads or as tools to study σ1 receptor physiol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNdKWlbfMVGbVg90H21EOLACvtfcHk0liVDHvUV8HN_Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvF2hu77F&md5=7aeacec7b3775acb3dffc268b4cd81be</span></div><a href="/servlet/linkout?suffix=cit173&amp;dbid=16384&amp;doi=10.4155%2Ffmc-2019-0042&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc-2019-0042%26sid%3Dliteratum%253Aachs%26aulast%3DNiso%26aufirst%3DM.%26aulast%3DMosier%26aufirst%3DP.%2BD.%26aulast%3DMarottoli%26aufirst%3DR.%26aulast%3DFerorelli%26aufirst%3DS.%26aulast%3DCassano%26aufirst%3DG.%26aulast%3DGasparre%26aufirst%3DG.%26aulast%3DLeopoldo%26aufirst%3DM.%26aulast%3DBerardi%26aufirst%3DF.%26aulast%3DAbate%26aufirst%3DC.%26atitle%3DHigh-affinity%2520sigma-1%2520%2528%25CF%2583%25281%2529%2529%2520receptor%2520ligands%2520based%2520on%2520the%2520%25CF%2583%25281%2529%2520antagonist%2520PB212%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2019%26volume%3D11%26spage%3D2547%26epage%3D2562%26doi%3D10.4155%2Ffmc-2019-0042" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref174"><div class="reference"><strong class="refLabel"><a href="#ref174" class="rightTabRefNumLink">174</a></strong><div class="NLM_citation" id="rightTab-cit174"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Niso, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pati, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berardi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abate, C.</span></span> <span> </span><span class="NLM_article-title">Rigid versus flexible anilines or anilides confirm the bicyclic ring as the hydrophobic portion for optimal σ2 receptor binding and provide novel tools for the development of future σ2 receptor PET radiotracers</span>. <i>RSC Adv.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">88508</span>– <span class="NLM_lpage">88518</span>, <span class="refDoi"> DOI: 10.1039/C6RA15783A</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1039%2FC6RA15783A" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref174/cit174&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsV2hurvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2016&pages=88508-88518&author=M.+Nisoauthor=M.+L.+Patiauthor=F.+Berardiauthor=C.+Abate&title=Rigid+versus+flexible+anilines+or+anilides+confirm+the+bicyclic+ring+as+the+hydrophobic+portion+for+optimal+%CF%832+receptor+binding+and+provide+novel+tools+for+the+development+of+future+%CF%832+receptor+PET+radiotracers&doi=10.1039%2FC6RA15783A"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit174R"><div class="casContent"><span class="casTitleNuber">174</span><div class="casTitle"><span class="NLM_cas:atitle">Rigid versus flexible anilines or anilides confirm the bicyclic ring as the hydrophobic portion for optimal σ2 receptor binding and provide novel tools for the development of future σ2 receptor PET radiotracers</span></div><div class="casAuthors">Niso, Mauro; Pati, Maria Laura; Berardi, Francesco; Abate, Carmen</div><div class="citationInfo"><span class="NLM_cas:title">RSC Advances</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">91</span>),
    <span class="NLM_cas:pages">88508-88518</span>CODEN:
                <span class="NLM_cas:coden">RSCACL</span>;
        ISSN:<span class="NLM_cas:issn">2046-2069</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Despite their uncertain identification, σ2 receptors are promising targets for the development of diagnostics and therapeutics for tumor diseases.  Among the σ2 ligands developed, the class of the flexible benzamides furnished an optimal pharmacophore for σ2 receptor high affinity ligands.  Herein, the bicyclic-preferred conformation for σ2 binding was confirmed through the development of 3,4-dihydroquinolin-(1H)2-one isomeric derivs., 1,2,3,4-tetrahydroquinolines and the corresponding flexible anilides and anilines, all linked to the 6,7-dimethoxytetrahydroisoquinoline as a basic moiety. 3,4-Dihydroisoquinolin-(1H)2-one (10a) and 1,2,3,4-tetrahydroisoquinoline (11b) emerged for high σ2 affinity combined to an excellent σ2vs. σ1 selectivity.  In particular, compd. 11b with its low nanomolar σ2 affinity and impressive 2807-fold σ2vs. σ1 selectivity largely exceeded the biol. profile of the best 3,4-dihydroisoquinolin-(2H)1-one ref. compds. (1).  Because of the absence of a cytotoxic effect, the modest interaction with the P-gp, an appropriate lipophilicity and the presence of easily radiolabeling functions, 11b deserves further investigation for the imaging of σ2 receptors via PET in tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpS9WsRZfp-sLVg90H21EOLACvtfcHk0liVDHvUV8HN_Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsV2hurvI&md5=81a4e20ee40dd8b3dbf753caa0f0c528</span></div><a href="/servlet/linkout?suffix=cit174&amp;dbid=16384&amp;doi=10.1039%2FC6RA15783A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC6RA15783A%26sid%3Dliteratum%253Aachs%26aulast%3DNiso%26aufirst%3DM.%26aulast%3DPati%26aufirst%3DM.%2BL.%26aulast%3DBerardi%26aufirst%3DF.%26aulast%3DAbate%26aufirst%3DC.%26atitle%3DRigid%2520versus%2520flexible%2520anilines%2520or%2520anilides%2520confirm%2520the%2520bicyclic%2520ring%2520as%2520the%2520hydrophobic%2520portion%2520for%2520optimal%2520%25CF%25832%2520receptor%2520binding%2520and%2520provide%2520novel%2520tools%2520for%2520the%2520development%2520of%2520future%2520%25CF%25832%2520receptor%2520PET%2520radiotracers%26jtitle%3DRSC%2520Adv.%26date%3D2016%26volume%3D6%26spage%3D88508%26epage%3D88518%26doi%3D10.1039%2FC6RA15783A" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref175"><div class="reference"><strong class="refLabel"><a href="#ref175" class="rightTabRefNumLink">175</a></strong><div class="NLM_citation" id="rightTab-cit175"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Abate, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Selivanova, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krämer, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schibli, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marottoli, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perrone, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berardi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niso, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ametamey, S. M.</span></span> <span> </span><span class="NLM_article-title">Development of 3,4-dihydroisoquinolin-1(2H)-one derivatives for the Positron Emission Tomography (PET) imaging of σ<sub>2</sub> receptors</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>69</i></span>,  <span class="NLM_fpage">920</span>– <span class="NLM_lpage">930</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2013.09.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1016%2Fj.ejmech.2013.09.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=24161678" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref175/cit175&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhslarur%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2013&pages=920-930&author=C.+Abateauthor=S.+V.+Selivanovaauthor=A.+M%C3%BCllerauthor=S.+D.+Kr%C3%A4merauthor=R.+Schibliauthor=R.+Marottoliauthor=R.+Perroneauthor=F.+Berardiauthor=M.+Nisoauthor=S.+M.+Ametamey&title=Development+of+3%2C4-dihydroisoquinolin-1%282H%29-one+derivatives+for+the+Positron+Emission+Tomography+%28PET%29+imaging+of+%CF%832+receptors&doi=10.1016%2Fj.ejmech.2013.09.018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit175R"><div class="casContent"><span class="casTitleNuber">175</span><div class="casTitle"><span class="NLM_cas:atitle">Development of 3,4-dihydroisoquinolin-1(2H)-one derivatives for the Positron Emission Tomography (PET) imaging of σ2 receptors</span></div><div class="casAuthors">Abate, Carmen; Selivanova, Svetlana V.; Muller, Adrienne; Kramer, Stefanie D.; Schibli, Roger; Marottoli, Roberta; Perrone, Roberto; Berardi, Francesco; Niso, Mauro; Ametamey, Simon M.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">920-930</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">σ2 Receptors are promising biomarkers for cancer diagnosis given the relationship between the proliferative status of tumors and their d.  With the aim of contributing to the research of σ2 receptor Positron Emission Tomog. (PET) probes, we developed 2-[3-[6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl]propyl]-3,4-dihydroisoquinolin-1(2H)-one (3), with optimal σ2 pharmacol. properties and appropriate lipophilicity.  Hence, 3 served as the lead compd. for the development of a series of dihydroisoquinolinones amenable to radiolabeling.  Radiosynthesis for compd. 26, which displayed the most appropriate σ2 profile, was developed and σ2 specific binding for the corresponding [18F]-26 was confirmed by in vitro autoradiog. on rat brain slices.  Despite the excellent in vitro properties, [18F]-26 could not successfully image σ2 receptors in the rat brain in vivo, maybe because of its interaction with P-gp.  Nevertheless, [18F]-26 may still be worthy of further investigation for the imaging of σ2 receptors in peripheral tumors devoid of P-gp overexpression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrW5YBLkmnQ9rVg90H21EOLACvtfcHk0liVDHvUV8HN_Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhslarur%252FE&md5=ffff00424b23e5a01c49ce26fa9c9736</span></div><a href="/servlet/linkout?suffix=cit175&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2013.09.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2013.09.018%26sid%3Dliteratum%253Aachs%26aulast%3DAbate%26aufirst%3DC.%26aulast%3DSelivanova%26aufirst%3DS.%2BV.%26aulast%3DM%25C3%25BCller%26aufirst%3DA.%26aulast%3DKr%25C3%25A4mer%26aufirst%3DS.%2BD.%26aulast%3DSchibli%26aufirst%3DR.%26aulast%3DMarottoli%26aufirst%3DR.%26aulast%3DPerrone%26aufirst%3DR.%26aulast%3DBerardi%26aufirst%3DF.%26aulast%3DNiso%26aufirst%3DM.%26aulast%3DAmetamey%26aufirst%3DS.%2BM.%26atitle%3DDevelopment%2520of%25203%252C4-dihydroisoquinolin-1%25282H%2529-one%2520derivatives%2520for%2520the%2520Positron%2520Emission%2520Tomography%2520%2528PET%2529%2520imaging%2520of%2520%25CF%25832%2520receptors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2013%26volume%3D69%26spage%3D920%26epage%3D930%26doi%3D10.1016%2Fj.ejmech.2013.09.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref176"><div class="reference"><strong class="refLabel"><a href="#ref176" class="rightTabRefNumLink">176</a></strong><div class="NLM_citation" id="rightTab-cit176"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shi, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunosewoyo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, L.</span></span> <span> </span><span class="NLM_article-title">Synthesis and pharmacological evaluation of σ2 receptor ligands based on a 3-alkoxyisoxazole scaffold: potential antitumor effects against osteosarcoma</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2021</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">524</span>– <span class="NLM_lpage">536</span>, <span class="refDoi"> DOI: 10.1002/cmdc.202000461</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1002%2Fcmdc.202000461" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=32964625" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref176/cit176&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BB3cXitFynu73M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2021&pages=524-536&author=J.+J.+Shiauthor=K.+H.+Jiaauthor=H.+Sunauthor=H.+Gunosewoyoauthor=F.+Yangauthor=J.+Tangauthor=J.+Luoauthor=L.+Yu&title=Synthesis+and+pharmacological+evaluation+of+%CF%832+receptor+ligands+based+on+a+3-alkoxyisoxazole+scaffold%3A+potential+antitumor+effects+against+osteosarcoma&doi=10.1002%2Fcmdc.202000461"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit176R"><div class="casContent"><span class="casTitleNuber">176</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Pharmacological Evaluation of σ2 Receptor Ligands Based on a 3-Alkoxyisoxazole Scaffold: Potential Antitumor Effects against Osteosarcoma</span></div><div class="casAuthors">Shi, Jun-Jie; Jia, Kun-Hang; Sun, Hao; Gunosewoyo, Hendra; Yang, Fan; Tang, Jie; Luo, Jian; Yu, Li-Fang</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2021</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">524-536</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Since its initial discovery as the basis for nicotinic acetylcholine receptor ligands, the 3-alkoxyisoxazole scaffold has been shown to be a versatile platform for the development of potent σ1 and σ2 receptor ligands.  Herein we report a further SAR exploration of the 3-alkoxyisoxazole scaffold with the aim of obtaining potent σ2 receptor ligands.  Various substitutions on the benzene ring and at the basic amino regions resulted in a total of 21 compds. that were tested for their binding affinities for the σ2 receptor.  In particular, compd. 51 [(2S)-1-(4-ammoniobutyl)-2-(((5-((3,4-dichlorophenoxy)methyl)isoxazol-3-yl)oxy)methyl)pyrrolidin-1-ium chloride] was identified as one of the most potent σ2 ligands within the series, with a Ki value of 7.9 nM.  It demonstrated potent antiproliferative effects on both osteosarcoma cell lines 143B and MOS-J (IC50 values of 0.89 and 0.71 μM, resp.), relative to siramesine (IC50 values of 1.81 and 2.01 μM).  Moreover, compd. 51 inhibited clonal formation of osteosarcoma 143B cells at 1 μM, corresponding to half the dose required of siramesine for similar effects.  The general cytotoxicity profile of compd. 51 was assessed in a no. of normal cell lines, including HaCaT, HAF, and LO2 cells.  Furthermore, FACS anal. showed that compd. 51 likely inhibits osteosarcoma cell growth by disruption of the cell cycle and promotion of apoptosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVKnzjY_scVLVg90H21EOLACvtfcHk0lgr6gJ741-22Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXitFynu73M&md5=290203492ee0e5d70c002b6a595737e8</span></div><a href="/servlet/linkout?suffix=cit176&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.202000461&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.202000461%26sid%3Dliteratum%253Aachs%26aulast%3DShi%26aufirst%3DJ.%2BJ.%26aulast%3DJia%26aufirst%3DK.%2BH.%26aulast%3DSun%26aufirst%3DH.%26aulast%3DGunosewoyo%26aufirst%3DH.%26aulast%3DYang%26aufirst%3DF.%26aulast%3DTang%26aufirst%3DJ.%26aulast%3DLuo%26aufirst%3DJ.%26aulast%3DYu%26aufirst%3DL.%26atitle%3DSynthesis%2520and%2520pharmacological%2520evaluation%2520of%2520%25CF%25832%2520receptor%2520ligands%2520based%2520on%2520a%25203-alkoxyisoxazole%2520scaffold%253A%2520potential%2520antitumor%2520effects%2520against%2520osteosarcoma%26jtitle%3DChemMedChem%26date%3D2021%26volume%3D16%26spage%3D524%26epage%3D536%26doi%3D10.1002%2Fcmdc.202000461" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref177"><div class="reference"><strong class="refLabel"><a href="#ref177" class="rightTabRefNumLink">177</a></strong><div class="NLM_citation" id="rightTab-cit177"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yu, L. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunosewoyo, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kozikowski, A. P.</span></span> <span> </span><span class="NLM_article-title">From α4β2 Nicotinic Ligands to the Discovery of σ1 Receptor Ligands: Pharmacophore Analysis and Rational Design</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">1054</span>– <span class="NLM_lpage">1058</span>, <span class="refDoi"> DOI: 10.1021/ml3002715</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml3002715" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref177/cit177&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFamtr3K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=1054-1058&author=L.+F.+Yuauthor=H.+K.+Zhangauthor=H.+Gunosewoyoauthor=A.+P.+Kozikowski&title=From+%CE%B14%CE%B22+Nicotinic+Ligands+to+the+Discovery+of+%CF%831+Receptor+Ligands%3A+Pharmacophore+Analysis+and+Rational+Design&doi=10.1021%2Fml3002715"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit177R"><div class="casContent"><span class="casTitleNuber">177</span><div class="casTitle"><span class="NLM_cas:atitle">From α4β2 Nicotinic Ligands to the Discovery of σ1 Receptor Ligands: Pharmacophore Analysis and Rational Design</span></div><div class="casAuthors">Yu, Li-Fang; Zhang, Han-Kun; Gunosewoyo, Hendra; Kozikowski, Alan P.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1054-1058</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Comparative analyses of the pharmacophoric elements required for σ1 and nicotinic ligands led to the identification of a potent and selective σ1 ligand (15, I).  Compd. 15 displayed high selectivity for the σ1 receptor (Ki, σ1 = 4.1 nM; Ki, σ2 = 1312 nM) with moderate binding affinity for the DAT (Ki = 373 nM) and NET (Ki = 203 nM) in the PDSP broad screening panel of common CNS neurotransmitter transporters and receptors.  The key finding in this present work is that a subtle structural modification could be used as a tool to switch a ligand's selectivity between nAChRs and sigma receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp00SphSwYKLrVg90H21EOLACvtfcHk0lgr6gJ741-22Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFamtr3K&md5=908dc6a13498beb6e751249b33d35e71</span></div><a href="/servlet/linkout?suffix=cit177&amp;dbid=16384&amp;doi=10.1021%2Fml3002715&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml3002715%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DL.%2BF.%26aulast%3DZhang%26aufirst%3DH.%2BK.%26aulast%3DGunosewoyo%26aufirst%3DH.%26aulast%3DKozikowski%26aufirst%3DA.%2BP.%26atitle%3DFrom%2520%25CE%25B14%25CE%25B22%2520Nicotinic%2520Ligands%2520to%2520the%2520Discovery%2520of%2520%25CF%25831%2520Receptor%2520Ligands%253A%2520Pharmacophore%2520Analysis%2520and%2520Rational%2520Design%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D3%26spage%3D1054%26epage%3D1058%26doi%3D10.1021%2Fml3002715" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref178"><div class="reference"><strong class="refLabel"><a href="#ref178" class="rightTabRefNumLink">178</a></strong><div class="NLM_citation" id="rightTab-cit178"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neue, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schepmann, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yanagisawa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamaguchi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Würthwein, E. U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Itami, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wünsch, B.</span></span> <span> </span><span class="NLM_article-title">Improvement of σ1 receptor affinity by late-stage C-H-bond arylation of spirocyclic lactones</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">1844</span>– <span class="NLM_lpage">1856</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2013.01.038</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1016%2Fj.bmc.2013.01.038" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=23462714" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref178/cit178&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BC3sXivF2rur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2013&pages=1844-1856&author=C.+Meyerauthor=B.+Neueauthor=D.+Schepmannauthor=S.+Yanagisawaauthor=J.+Yamaguchiauthor=E.+U.+W%C3%BCrthweinauthor=K.+Itamiauthor=B.+W%C3%BCnsch&title=Improvement+of+%CF%831+receptor+affinity+by+late-stage+C-H-bond+arylation+of+spirocyclic+lactones&doi=10.1016%2Fj.bmc.2013.01.038"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit178R"><div class="casContent"><span class="casTitleNuber">178</span><div class="casTitle"><span class="NLM_cas:atitle">Improvement of σ1 receptor affinity by late-stage C-H-bond arylation of spirocyclic lactones</span></div><div class="casAuthors">Meyer, Christina; Neue, Benedikt; Schepmann, Dirk; Yanagisawa, Shuichi; Yamaguchi, Junichiro; Wuerthwein, Ernst-Ulrich; Itami, Kenichiro; Wuensch, Bernhard</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1844-1856</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The direct C-H-bond arylation of the complex spirocyclic lactones 13 (I), 14 (II), and 18 (III) allows the introduction of diverse aryl moieties in the last step of the synthesis.  A selective α-arylation of the thiophene moiety was performed with the catalytic system PdCl2/2,2'-bipyridyl/Ag2CO3, whereas the β-position of the thiophene ring was addressed by using the alternative catalytic system PdCl2/P[OCH(CF3)2]3/Ag2CO3.  Due to electronic and steric reasons the arylation of the five-membered lactone 18 occurred in both α-positions providing 4'-mono-, 6'-mono- and 4',6'-diarylated thiophenes 22-26a-c.  Compds. with an addnl. aryl moiety at the 'upper left (top)' position (1'-position of 13, 3'-position of 14, 4'-position of 18) showed increased σ1 affinity compared to the non-arylated parent compds.  A Ph moiety at the 'left' position (2'-position in 20a) also increased the σ1 affinity but to a lower extent.  A considerable redn. of σ1 affinity was obsd. after introducing an aryl moiety in 6'-position of 18, which might result from shielding the tertiary amine, which is crucial for interaction with the σ1 receptor.  The discussion of the exptl. results is supported by high-level quantum chem. DFT-calcns. of the NBO-charges of 13 and 18 and the relative energies of the related arylated products.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpyzGVeovUWVbVg90H21EOLACvtfcHk0lgr6gJ741-22Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXivF2rur4%253D&md5=80f77a4c4e526bf9b34d4def3ed81b92</span></div><a href="/servlet/linkout?suffix=cit178&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2013.01.038&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2013.01.038%26sid%3Dliteratum%253Aachs%26aulast%3DMeyer%26aufirst%3DC.%26aulast%3DNeue%26aufirst%3DB.%26aulast%3DSchepmann%26aufirst%3DD.%26aulast%3DYanagisawa%26aufirst%3DS.%26aulast%3DYamaguchi%26aufirst%3DJ.%26aulast%3DW%25C3%25BCrthwein%26aufirst%3DE.%2BU.%26aulast%3DItami%26aufirst%3DK.%26aulast%3DW%25C3%25BCnsch%26aufirst%3DB.%26atitle%3DImprovement%2520of%2520%25CF%25831%2520receptor%2520affinity%2520by%2520late-stage%2520C-H-bond%2520arylation%2520of%2520spirocyclic%2520lactones%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2013%26volume%3D21%26spage%3D1844%26epage%3D1856%26doi%3D10.1016%2Fj.bmc.2013.01.038" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref179"><div class="reference"><strong class="refLabel"><a href="#ref179" class="rightTabRefNumLink">179</a></strong><div class="NLM_citation" id="rightTab-cit179"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pluchino, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hall, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldsborough, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Callaghan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gottesman, M. M.</span></span> <span> </span><span class="NLM_article-title">Collateral sensitivity as a strategy against cancer multidrug resistance</span>. <i>Drug Resist. Updates</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">98</span>– <span class="NLM_lpage">105</span>, <span class="refDoi"> DOI: 10.1016/j.drup.2012.03.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1016%2Fj.drup.2012.03.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=22483810" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref179/cit179&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BC38XmslynsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2012&pages=98-105&author=K.+M.+Pluchinoauthor=M.+D.+Hallauthor=A.+S.+Goldsboroughauthor=R.+Callaghanauthor=M.+M.+Gottesman&title=Collateral+sensitivity+as+a+strategy+against+cancer+multidrug+resistance&doi=10.1016%2Fj.drup.2012.03.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit179R"><div class="casContent"><span class="casTitleNuber">179</span><div class="casTitle"><span class="NLM_cas:atitle">Collateral sensitivity as a strategy against cancer multidrug resistance</span></div><div class="casAuthors">Pluchino, Kristen M.; Hall, Matthew D.; Goldsborough, Andrew S.; Callaghan, Richard; Gottesman, Michael M.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Resistance Updates</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">98-105</span>CODEN:
                <span class="NLM_cas:coden">DRUPFW</span>;
        ISSN:<span class="NLM_cas:issn">1368-7646</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  While chemotherapy remains the most effective treatment for disseminated tumors, acquired or intrinsic drug resistance accounts for approx. 90% of treatment failure.  Multidrug resistance (MDR), the simultaneous resistance to drugs that differ both structurally and mechanistically, often results from drug efflux pumps in the cell membrane that reduce intracellular drug levels to less than therapeutic concns.  Expression of the MDR transporter P-glycoprotein (P-gp, MDR1, ABCB1) has been shown to correlate with overall poor chemotherapy response and prognosis.  This review will focus on collateral sensitivity (CS), the ability of compds. to kill MDR cells selectively over the parental cells from which they were derived.  Insights into CS may offer an alternative strategy for the clin. resoln. of MDR, as highly selective and potent CS agents may lead to drugs that are effective at MDR cell killing and tumor resensitization.  Four main mechanistic hypotheses for CS will be reviewed, followed by a discussion on quant. and exptl. evaluation of CS.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGox5FqYWa-hS7Vg90H21EOLACvtfcHk0lgr6gJ741-22Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmslynsLg%253D&md5=237f7f798703a7f9c45e75796e0b5d2d</span></div><a href="/servlet/linkout?suffix=cit179&amp;dbid=16384&amp;doi=10.1016%2Fj.drup.2012.03.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drup.2012.03.002%26sid%3Dliteratum%253Aachs%26aulast%3DPluchino%26aufirst%3DK.%2BM.%26aulast%3DHall%26aufirst%3DM.%2BD.%26aulast%3DGoldsborough%26aufirst%3DA.%2BS.%26aulast%3DCallaghan%26aufirst%3DR.%26aulast%3DGottesman%26aufirst%3DM.%2BM.%26atitle%3DCollateral%2520sensitivity%2520as%2520a%2520strategy%2520against%2520cancer%2520multidrug%2520resistance%26jtitle%3DDrug%2520Resist.%2520Updates%26date%3D2012%26volume%3D15%26spage%3D98%26epage%3D105%26doi%3D10.1016%2Fj.drup.2012.03.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref180"><div class="reference"><strong class="refLabel"><a href="#ref180" class="rightTabRefNumLink">180</a></strong><div class="NLM_citation" id="rightTab-cit180"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maher, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haas, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Longen, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oyer, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, F. J.</span></span> <span> </span><span class="NLM_article-title">Small-Molecule Sigma1Modulator Induces Autophagic Degradation of PD-L1</span>. <i>Mol. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">243</span>– <span class="NLM_lpage">255</span>, <span class="refDoi"> DOI: 10.1158/1541-7786.MCR-17-0166</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1158%2F1541-7786.MCR-17-0166" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=29117944" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref180/cit180&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitVeiurc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2018&pages=243-255&author=C.+M.+Maherauthor=J.+D.+Thomasauthor=D.+A.+Haasauthor=C.+G.+Longenauthor=H.+M.+Oyerauthor=J.+Y.+Tongauthor=F.+J.+Kim&title=Small-Molecule+Sigma1Modulator+Induces+Autophagic+Degradation+of+PD-L1&doi=10.1158%2F1541-7786.MCR-17-0166"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit180R"><div class="casContent"><span class="casTitleNuber">180</span><div class="casTitle"><span class="NLM_cas:atitle">Small-Molecule Sigma1 Modulator Induces Autophagic Degradation of PD-L1</span></div><div class="casAuthors">Maher, Christina M.; Thomas, Jeffrey D.; Haas, Derick A.; Longen, Charles G.; Oyer, Halley M.; Tong, Jane Y.; Kim, Felix J.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">243-255</span>CODEN:
                <span class="NLM_cas:coden">MCROC5</span>;
        ISSN:<span class="NLM_cas:issn">1541-7786</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Emerging evidence suggests that Sigma1 (SIGMAR1, also known as sigma-1 receptor) is a unique ligand-regulated integral membrane scaffolding protein that contributes to cellular protein and lipid homeostasis.  Previously, we demonstrated that some small-mol. modulators of Sigma1 alter endoplasmic reticulum (ER)-assocd. protein homeostasis pathways in cancer cells, including the unfolded protein response and autophagy.  Programmed death-ligand 1 (PD-L1) is a type I integral membrane glycoprotein that is cotranslationally inserted into the ER and is processed and transported through the secretory pathway.  Once at the surface of cancer cells, PD-L1 acts as a T-cell inhibitory checkpoint mol. and suppresses antitumor immunity.  Here, we demonstrate that in Sigma1-expressing triple-neg. breast and androgen-independent prostate cancer cells, PD-L1 protein levels were suppressed by RNAi knockdown of Sigma1 and by small-mol. inhibition of Sigma1.  Sigma1-mediated action was confirmed by pharmacol. competition between Sigma1-selective inhibitor and activator ligands.  When administered alone, the Sigma1 inhibitor decreased cell surface PD-L1 expression and suppressed functional interaction of PD-1 and PD-L1 in a coculture of T cells and cancer cells.  Conversely, the Sigma1 activator increased PD-L1 cell surface expression, demonstrating the ability to pos. and neg. modulate Sigma1 assocd. PD-L1 processing.  We discovered that the Sigma1 inhibitor induced degrdn. of PD-L1 via autophagy, by a mechanism distinct from bulk macroautophagy or general ER stress-assocd. autophagy.  Finally, the Sigma1 inhibitor suppressed IFNγ-induced PD-L1.  Our data demonstrate that small-mol. Sigma1 modulators can be used to regulate PD-L1 in cancer cells and trigger its degrdn. by selective autophagy.  Implications: Sigma1 modulators sequester and eliminate PD-L1 by autophagy, thus preventing functional PD-L1 expression at the cell surface.  This posits Sigma1 modulators as novel therapeutic agents in PD-L1/PD-1 blockade strategies that regulate the tumor immune microenvironment.  Visual Overview: http//mcr.accrjournals.org/content/molcanres/16/02/243/F1.large.jpg.  Mol Cancer Res; 16(2); 243-55. ©2017 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPoBdyWoswA7Vg90H21EOLACvtfcHk0liKCda1HcA8Dw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitVeiurc%253D&md5=84f9aee84ada0bb2b7ce13f2d210b52b</span></div><a href="/servlet/linkout?suffix=cit180&amp;dbid=16384&amp;doi=10.1158%2F1541-7786.MCR-17-0166&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1541-7786.MCR-17-0166%26sid%3Dliteratum%253Aachs%26aulast%3DMaher%26aufirst%3DC.%2BM.%26aulast%3DThomas%26aufirst%3DJ.%2BD.%26aulast%3DHaas%26aufirst%3DD.%2BA.%26aulast%3DLongen%26aufirst%3DC.%2BG.%26aulast%3DOyer%26aufirst%3DH.%2BM.%26aulast%3DTong%26aufirst%3DJ.%2BY.%26aulast%3DKim%26aufirst%3DF.%2BJ.%26atitle%3DSmall-Molecule%2520Sigma1Modulator%2520Induces%2520Autophagic%2520Degradation%2520of%2520PD-L1%26jtitle%3DMol.%2520Cancer%2520Res.%26date%3D2018%26volume%3D16%26spage%3D243%26epage%3D255%26doi%3D10.1158%2F1541-7786.MCR-17-0166" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref181"><div class="reference"><strong class="refLabel"><a href="#ref181" class="rightTabRefNumLink">181</a></strong><div class="NLM_citation" id="rightTab-cit181"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, S. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xia, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuo, C. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khoo, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cha, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsu, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsu, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamaguchi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sahin, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allison, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hortobagyi, G. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hung, M. C.</span></span> <span> </span><span class="NLM_article-title">Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">12632</span>, <span class="refDoi"> DOI: 10.1038/ncomms12632</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=10.1038%2Fncomms12632" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=27572267" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref181/cit181&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVKjsbnJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=12632&author=C.+W.+Liauthor=S.+O.+Limauthor=W.+Xiaauthor=H.+H.+Leeauthor=L.+C.+Chanauthor=C.+W.+Kuoauthor=K.+H.+Khooauthor=S.+S.+Changauthor=J.+H.+Chaauthor=T.+Kimauthor=J.+L.+Hsuauthor=Y.+Wuauthor=J.+M.+Hsuauthor=H.+Yamaguchiauthor=Q.+Dingauthor=Y.+Wangauthor=J.+Yaoauthor=C.+C.+Leeauthor=H.+J.+Wuauthor=A.+A.+Sahinauthor=J.+P.+Allisonauthor=D.+Yuauthor=G.+N.+Hortobagyiauthor=M.+C.+Hung&title=Glycosylation+and+stabilization+of+programmed+death+ligand-1+suppresses+T-cell+activity&doi=10.1038%2Fncomms12632"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit181R"><div class="casContent"><span class="casTitleNuber">181</span><div class="casTitle"><span class="NLM_cas:atitle">Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity</span></div><div class="casAuthors">Li, Chia-Wei; Lim, Seung-Oe; Xia, Weiya; Lee, Heng-Huan; Chan, Li-Chuan; Kuo, Chu-Wei; Khoo, Kay-Hooi; Chang, Shih-Shin; Cha, Jong-Ho; Kim, Taewan; Hsu, Jennifer L.; Wu, Yun; Hsu, Jung-Mao; Yamaguchi, Hirohito; Ding, Qingqing; Wang, Yan; Yao, Jun; Lee, Cheng-Chung; Wu, Hsing-Ju; Sahin, Aysegul A.; Allison, James P.; Yu, Dihua; Hortobagyi, Gabriel N.; Hung, Mien-Chie</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">12632</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Extracellular interaction between programmed death ligand-1 (PD-L1) and programmed cell death protein-1 (PD-1) leads to tumor-assocd. immune escape.  Here we show that the immunosuppression activity of PD-L1 is stringently modulated by ubiquitination and N-glycosylation.  We show that glycogen synthase kinase 3β (GSK3β) interacts with PD-L1 and induces phosphorylation-dependent proteasome degrdn. of PD-L1 by β-TrCP.  In-depth anal. of PD-L1 N192, N200 and N219 glycosylation suggests that glycosylation antagonizes GSK3β binding.  In this regard, only non-glycosylated PD-L1 forms a complex with GSK3β and β-TrCP.  We also demonstrate that epidermal growth factor (EGF) stabilizes PD-L1 via GSK3β inactivation in basal-like breast cancer.  Inhibition of EGF signalling by gefitinib destabilizes PD-L1, enhances antitumor T-cell immunity and therapeutic efficacy of PD-1 blockade in syngeneic mouse models.  Together, our results link ubiquitination and glycosylation pathways to the stringent regulation of PD-L1, which could lead to potential therapeutic strategies to enhance cancer immune therapy efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrQnyTgbFXcD7Vg90H21EOLACvtfcHk0liKCda1HcA8Dw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVKjsbnJ&md5=35cab8a1af28193769fe685c0e1f37b7</span></div><a href="/servlet/linkout?suffix=cit181&amp;dbid=16384&amp;doi=10.1038%2Fncomms12632&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms12632%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DC.%2BW.%26aulast%3DLim%26aufirst%3DS.%2BO.%26aulast%3DXia%26aufirst%3DW.%26aulast%3DLee%26aufirst%3DH.%2BH.%26aulast%3DChan%26aufirst%3DL.%2BC.%26aulast%3DKuo%26aufirst%3DC.%2BW.%26aulast%3DKhoo%26aufirst%3DK.%2BH.%26aulast%3DChang%26aufirst%3DS.%2BS.%26aulast%3DCha%26aufirst%3DJ.%2BH.%26aulast%3DKim%26aufirst%3DT.%26aulast%3DHsu%26aufirst%3DJ.%2BL.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DHsu%26aufirst%3DJ.%2BM.%26aulast%3DYamaguchi%26aufirst%3DH.%26aulast%3DDing%26aufirst%3DQ.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DYao%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DC.%2BC.%26aulast%3DWu%26aufirst%3DH.%2BJ.%26aulast%3DSahin%26aufirst%3DA.%2BA.%26aulast%3DAllison%26aufirst%3DJ.%2BP.%26aulast%3DYu%26aufirst%3DD.%26aulast%3DHortobagyi%26aufirst%3DG.%2BN.%26aulast%3DHung%26aufirst%3DM.%2BC.%26atitle%3DGlycosylation%2520and%2520stabilization%2520of%2520programmed%2520death%2520ligand-1%2520suppresses%2520T-cell%2520activity%26jtitle%3DNat.%2520Commun.%26date%3D2016%26volume%3D7%26spage%3D12632%26doi%3D10.1038%2Fncomms12632" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref182"><div class="reference"><strong class="refLabel"><a href="#ref182" class="rightTabRefNumLink">182</a></strong><div class="NLM_citation" id="rightTab-cit182"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Proschak, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stark, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merk, D.</span></span> <span> </span><span class="NLM_article-title">Polypharmacology by Design: A Medicinal Chemist’s Perspective on Multitargeting Compounds</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">420</span>– <span class="NLM_lpage">444</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00760</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00760" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref182/cit182&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlKms7fE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=420-444&author=E.+Proschakauthor=H.+Starkauthor=D.+Merk&title=Polypharmacology+by+Design%3A+A+Medicinal+Chemist%E2%80%99s+Perspective+on+Multitargeting+Compounds&doi=10.1021%2Facs.jmedchem.8b00760"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit182R"><div class="casContent"><span class="casTitleNuber">182</span><div class="casTitle"><span class="NLM_cas:atitle">Polypharmacology by Design: A Medicinal Chemist's Perspective on Multitargeting Compounds</span></div><div class="casAuthors">Proschak, Ewgenij; Stark, Holger; Merk, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">420-444</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Multitargeting compds. comprising activity on more than a single biol. target have gained remarkable relevance in drug discovery owing to the complexity of multifactorial diseases such as cancer, inflammation, or the metabolic syndrome.  Polypharmacol. drug profiles can produce additive or synergistic effects while reducing side effects and significantly contribute to the high therapeutic success of indispensable drugs such as aspirin.  While their identification has long been the result of serendipity, medicinal chem. now tends to design polypharmacol.  Modern in vitro pharmacol. methods and chem. probes allow a systematic search for rational target combinations and recent innovations in computational technologies, crystallog., or fragment-based design equip multitarget compd. development with valuable tools.  In this Perspective, we analyze the relevance of multiple ligands in drug discovery and the versatile toolbox to design polypharmacol.  We conclude that despite some characteristic challenges remaining unresolved, designed polypharmacol. holds enormous potential to secure future therapeutic innovation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOEwJSxWw3vbVg90H21EOLACvtfcHk0liKCda1HcA8Dw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlKms7fE&md5=6dc4b8e1c4777372396626140a302663</span></div><a href="/servlet/linkout?suffix=cit182&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00760%26sid%3Dliteratum%253Aachs%26aulast%3DProschak%26aufirst%3DE.%26aulast%3DStark%26aufirst%3DH.%26aulast%3DMerk%26aufirst%3DD.%26atitle%3DPolypharmacology%2520by%2520Design%253A%2520A%2520Medicinal%2520Chemist%25E2%2580%2599s%2520Perspective%2520on%2520Multitargeting%2520Compounds%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D420%26epage%3D444%26doi%3D10.1021%2Facs.jmedchem.8b00760" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref183"><div class="reference"><strong class="refLabel"><a href="#ref183" class="rightTabRefNumLink">183</a></strong><div class="NLM_citation" id="rightTab-cit183"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H.</span></span> <span> </span><span class="NLM_article-title">Rational Design of Multitarget-Directed Ligands: Strategies and Emerging Paradigms</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">8881</span>– <span class="NLM_lpage">8914</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00017</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00017" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref183/cit183&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BC1MXptlKrt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=8881-8914&author=J.+Zhouauthor=X.+Jiangauthor=S.+Heauthor=H.+Jiangauthor=F.+Fengauthor=W.+Liuauthor=W.+Quauthor=H.+Sun&title=Rational+Design+of+Multitarget-Directed+Ligands%3A+Strategies+and+Emerging+Paradigms&doi=10.1021%2Facs.jmedchem.9b00017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit183R"><div class="casContent"><span class="casTitleNuber">183</span><div class="casTitle"><span class="NLM_cas:atitle">Rational Design of Multitarget-Directed Ligands: Strategies and Emerging Paradigms</span></div><div class="casAuthors">Zhou, Junting; Jiang, Xueyang; He, Siyu; Jiang, Hongli; Feng, Feng; Liu, Wenyuan; Qu, Wei; Sun, Haopeng</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">8881-8914</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Due to the complexity of multifactorial diseases, single-target drugs do not always exhibit satisfactory efficacy.  Recently, increasing evidence indicates that simultaneous modulation of multiple targets may improve both therapeutic safety and efficacy, compared with single-target drugs.  However, few multitarget drugs are on market or in clin. trials, despite the best efforts of medicinal chemists.  This article discusses the systematic establishment of target combination, lead generation, and optimization of multitarget-directed ligands (MTDLs).  Moreover, we analyze some MTDLs research cases for several complex diseases in recent years and the physicochem. properties of 117 clin. multitarget drugs, with the aim to reveal the trends and insights of the potential use of MTDLs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGraLqk7hMZnoLVg90H21EOLACvtfcHk0liss4qt860HyQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXptlKrt7k%253D&md5=37adb9bc31802e62fd7f8d0d6e7697e3</span></div><a href="/servlet/linkout?suffix=cit183&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00017%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DJ.%26aulast%3DJiang%26aufirst%3DX.%26aulast%3DHe%26aufirst%3DS.%26aulast%3DJiang%26aufirst%3DH.%26aulast%3DFeng%26aufirst%3DF.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DQu%26aufirst%3DW.%26aulast%3DSun%26aufirst%3DH.%26atitle%3DRational%2520Design%2520of%2520Multitarget-Directed%2520Ligands%253A%2520Strategies%2520and%2520Emerging%2520Paradigms%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D8881%26epage%3D8914%26doi%3D10.1021%2Facs.jmedchem.9b00017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref184"><div class="reference"><strong class="refLabel"><a href="#ref184" class="rightTabRefNumLink">184</a></strong><div class="NLM_citation" id="rightTab-cit184"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mangiatordi, G. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Intranuovo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delre, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abatematteo, F. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abate, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niso, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Creanza, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ancona, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stefanachi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Contino, M.</span></span> <span> </span><span class="NLM_article-title">Cannabinoid Receptor Subtype 2 (CB2R) in a Multitarget Approach: Perspective of an Innovative Strategy in Cancer and Neurodegeneration</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">14448</span>– <span class="NLM_lpage">14469</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.0c01357</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.0c01357" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref184/cit184&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;key=1%3ACAS%3A528%3ADC%252BB3cXitFagtLbI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=14448-14469&author=G.+F.+Mangiatordiauthor=F.+Intranuovoauthor=P.+Delreauthor=F.+S.+Abatematteoauthor=C.+Abateauthor=M.+Nisoauthor=T.+M.+Creanzaauthor=N.+Anconaauthor=A.+Stefanachiauthor=M.+Contino&title=Cannabinoid+Receptor+Subtype+2+%28CB2R%29+in+a+Multitarget+Approach%3A+Perspective+of+an+Innovative+Strategy+in+Cancer+and+Neurodegeneration&doi=10.1021%2Facs.jmedchem.0c01357"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit184R"><div class="casContent"><span class="casTitleNuber">184</span><div class="casTitle"><span class="NLM_cas:atitle">Cannabinoid Receptor Subtype 2 (CB2R) in a Multitarget Approach: Perspective of an Innovative Strategy in Cancer and Neurodegeneration</span></div><div class="casAuthors">Mangiatordi, Giuseppe Felice; Intranuovo, Francesca; Delre, Pietro; Abatematteo, Francesca Serena; Abate, Carmen; Niso, Mauro; Creanza, Teresa Maria; Ancona, Nicola; Stefanachi, Angela; Contino, Marialessandra</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">14448-14469</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The cannabinoid receptor subtype 2 (CB2R) represents an interesting and new therapeutic target for its involvement in the first steps of neurodegeneration as well as in cancer onset and progression.  Several studies, focused on different types of tumors, report a promising anticancer activity induced by CB2R agonists due to their ability to reduce inflammation and cell proliferation.  Moreover, in neuroinflammation, the stimulation of CB2R, overexpressed in microglial cells, exerts beneficial effects in neurodegenerative disorders.  With the aim to overcome current treatment limitations, new drugs can be developed by specifically modulating, together with CB2R, other targets involved in such multifactorial disorders.  Building on successful case studies of already developed multitarget strategies involving CB2R, in this Perspective we aim at prompting the scientific community to consider new promising target assocns. involving HDACs (histone deacetylases) and σ receptors by employing modern approaches based on mol. hybridization, computational polypharmacol., and machine learning algorithms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTiSamPzU_wLVg90H21EOLACvtfcHk0liss4qt860HyQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXitFagtLbI&md5=bd76a9dd2196d6362df55b79f25ecdc2</span></div><a href="/servlet/linkout?suffix=cit184&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.0c01357&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.0c01357%26sid%3Dliteratum%253Aachs%26aulast%3DMangiatordi%26aufirst%3DG.%2BF.%26aulast%3DIntranuovo%26aufirst%3DF.%26aulast%3DDelre%26aufirst%3DP.%26aulast%3DAbatematteo%26aufirst%3DF.%2BS.%26aulast%3DAbate%26aufirst%3DC.%26aulast%3DNiso%26aufirst%3DM.%26aulast%3DCreanza%26aufirst%3DT.%2BM.%26aulast%3DAncona%26aufirst%3DN.%26aulast%3DStefanachi%26aufirst%3DA.%26aulast%3DContino%26aufirst%3DM.%26atitle%3DCannabinoid%2520Receptor%2520Subtype%25202%2520%2528CB2R%2529%2520in%2520a%2520Multitarget%2520Approach%253A%2520Perspective%2520of%2520an%2520Innovative%2520Strategy%2520in%2520Cancer%2520and%2520Neurodegeneration%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D14448%26epage%3D14469%26doi%3D10.1021%2Facs.jmedchem.0c01357" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5HK1" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5HK1','PDB','5HK1'); return false;">PDB: 5HK1</a></li></ul></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.0c02265&amp;pbContext=%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.0c02265%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2021.64.issue-12%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.0c02265" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                7MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"67994b18595022c0","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
